CN1680441A - 新型化合物 - Google Patents
新型化合物Info
- Publication number
- CN1680441A CN1680441A CNA2005100624133A CN200510062413A CN1680441A CN 1680441 A CN1680441 A CN 1680441A CN A2005100624133 A CNA2005100624133 A CN A2005100624133A CN 200510062413 A CN200510062413 A CN 200510062413A CN 1680441 A CN1680441 A CN 1680441A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- polynucleotides
- sequence
- cell
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 243
- 229920001184 polypeptide Polymers 0.000 claims abstract description 199
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 195
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 178
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 154
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 154
- 239000002157 polynucleotide Substances 0.000 claims abstract description 154
- 238000000034 method Methods 0.000 claims abstract description 77
- 238000000926 separation method Methods 0.000 claims description 33
- 239000013604 expression vector Substances 0.000 claims 3
- 238000003556 assay Methods 0.000 abstract description 2
- 238000010188 recombinant method Methods 0.000 abstract description 2
- 210000004072 lung Anatomy 0.000 description 636
- 210000004556 brain Anatomy 0.000 description 343
- 208000029742 colonic neoplasm Diseases 0.000 description 215
- 208000020816 lung neoplasm Diseases 0.000 description 215
- 208000026310 Breast neoplasm Diseases 0.000 description 214
- 208000006673 asthma Diseases 0.000 description 210
- 210000001258 synovial membrane Anatomy 0.000 description 208
- 239000000523 sample Substances 0.000 description 178
- 210000004027 cell Anatomy 0.000 description 168
- 210000001072 colon Anatomy 0.000 description 150
- 210000000481 breast Anatomy 0.000 description 136
- 210000000988 bone and bone Anatomy 0.000 description 103
- 210000002889 endothelial cell Anatomy 0.000 description 103
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 93
- 201000010099 disease Diseases 0.000 description 92
- 210000000845 cartilage Anatomy 0.000 description 84
- 210000000265 leukocyte Anatomy 0.000 description 82
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 80
- 230000014509 gene expression Effects 0.000 description 80
- 206010006187 Breast cancer Diseases 0.000 description 77
- 229920002477 rna polymer Polymers 0.000 description 58
- 230000000694 effects Effects 0.000 description 55
- 206010028980 Neoplasm Diseases 0.000 description 54
- 108020004999 messenger RNA Proteins 0.000 description 54
- 241000725303 Human immunodeficiency virus Species 0.000 description 53
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 49
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 49
- 238000002360 preparation method Methods 0.000 description 49
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 47
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 46
- 210000001519 tissue Anatomy 0.000 description 44
- 210000004185 liver Anatomy 0.000 description 42
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 40
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 40
- 210000001744 T-lymphocyte Anatomy 0.000 description 40
- 210000003719 b-lymphocyte Anatomy 0.000 description 39
- 210000003979 eosinophil Anatomy 0.000 description 39
- 210000004493 neutrocyte Anatomy 0.000 description 38
- 210000000496 pancreas Anatomy 0.000 description 38
- 102000004169 proteins and genes Human genes 0.000 description 38
- 210000003321 cartilage cell Anatomy 0.000 description 37
- 125000003729 nucleotide group Chemical group 0.000 description 37
- 235000018102 proteins Nutrition 0.000 description 37
- 239000002773 nucleotide Substances 0.000 description 36
- 241000321096 Adenoides Species 0.000 description 35
- 210000002534 adenoid Anatomy 0.000 description 35
- 210000004443 dendritic cell Anatomy 0.000 description 34
- 210000004003 subcutaneous fat Anatomy 0.000 description 34
- 210000001616 monocyte Anatomy 0.000 description 32
- 108020004463 18S ribosomal RNA Proteins 0.000 description 31
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 31
- 239000008103 glucose Substances 0.000 description 31
- 241000282414 Homo sapiens Species 0.000 description 30
- 210000003734 kidney Anatomy 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 28
- 238000013459 approach Methods 0.000 description 27
- 239000002299 complementary DNA Substances 0.000 description 27
- 238000005516 engineering process Methods 0.000 description 26
- 201000011510 cancer Diseases 0.000 description 25
- 239000012634 fragment Substances 0.000 description 23
- 210000002784 stomach Anatomy 0.000 description 22
- 210000001550 testis Anatomy 0.000 description 22
- 238000011282 treatment Methods 0.000 description 22
- 210000004291 uterus Anatomy 0.000 description 22
- 230000008859 change Effects 0.000 description 21
- 210000005075 mammary gland Anatomy 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 20
- 230000000302 ischemic effect Effects 0.000 description 20
- 210000002027 skeletal muscle Anatomy 0.000 description 20
- 210000001541 thymus gland Anatomy 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 19
- 210000001638 cerebellum Anatomy 0.000 description 19
- 210000004696 endometrium Anatomy 0.000 description 19
- 230000013011 mating Effects 0.000 description 19
- 210000003016 hypothalamus Anatomy 0.000 description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 210000001672 ovary Anatomy 0.000 description 18
- 210000002826 placenta Anatomy 0.000 description 18
- 210000002307 prostate Anatomy 0.000 description 18
- 210000000664 rectum Anatomy 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 18
- 210000000952 spleen Anatomy 0.000 description 18
- 210000001685 thyroid gland Anatomy 0.000 description 18
- 102000038624 GSKs Human genes 0.000 description 17
- 125000003275 alpha amino acid group Chemical group 0.000 description 17
- 210000001630 jejunum Anatomy 0.000 description 17
- 210000000568 mesometrium Anatomy 0.000 description 17
- 210000003681 parotid gland Anatomy 0.000 description 17
- 238000011160 research Methods 0.000 description 17
- 210000003079 salivary gland Anatomy 0.000 description 17
- 238000012216 screening Methods 0.000 description 17
- 230000003248 secreting effect Effects 0.000 description 17
- 210000000813 small intestine Anatomy 0.000 description 17
- 210000003932 urinary bladder Anatomy 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 210000004100 adrenal gland Anatomy 0.000 description 16
- 210000003679 cervix uteri Anatomy 0.000 description 16
- 210000003128 head Anatomy 0.000 description 16
- 210000003405 ileum Anatomy 0.000 description 16
- 230000004072 osteoblast differentiation Effects 0.000 description 16
- 210000004881 tumor cell Anatomy 0.000 description 16
- 239000011734 sodium Substances 0.000 description 15
- 230000029663 wound healing Effects 0.000 description 15
- 206010061218 Inflammation Diseases 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 14
- 208000023275 Autoimmune disease Diseases 0.000 description 13
- 108020003264 Cotransporters Proteins 0.000 description 13
- 102000034534 Cotransporters Human genes 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 208000014951 hematologic disease Diseases 0.000 description 13
- 208000018706 hematopoietic system disease Diseases 0.000 description 13
- 239000005557 antagonist Substances 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 108091092562 ribozyme Proteins 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 10
- 239000012190 activator Substances 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 201000005202 lung cancer Diseases 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 201000008482 osteoarthritis Diseases 0.000 description 10
- 206010009944 Colon cancer Diseases 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 230000004060 metabolic process Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 8
- 108091058545 Secretory proteins Proteins 0.000 description 8
- 102000040739 Secretory proteins Human genes 0.000 description 8
- 241000700584 Simplexvirus Species 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 7
- 230000003143 atherosclerotic effect Effects 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 210000000936 intestine Anatomy 0.000 description 7
- 239000011574 phosphorus Substances 0.000 description 7
- 229910052698 phosphorus Inorganic materials 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 102000039026 CRISP family Human genes 0.000 description 6
- 108091065563 CRISP family Proteins 0.000 description 6
- 108010053085 Complement Factor H Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 101000577115 Homo sapiens Monocarboxylate transporter 2 Proteins 0.000 description 6
- 101000577126 Homo sapiens Monocarboxylate transporter 4 Proteins 0.000 description 6
- 206010025476 Malabsorption Diseases 0.000 description 6
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 102100025272 Monocarboxylate transporter 2 Human genes 0.000 description 6
- 108010046644 Polymeric Immunoglobulin Receptors Proteins 0.000 description 6
- 102100035187 Polymeric immunoglobulin receptor Human genes 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- -1 cell factor Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000010353 genetic engineering Methods 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 230000004807 localization Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000000414 obstructive effect Effects 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 230000009261 transgenic effect Effects 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 101710186708 Agglutinin Proteins 0.000 description 5
- 241001635598 Enicostema Species 0.000 description 5
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 5
- 101001125858 Homo sapiens Peptidase inhibitor 15 Proteins 0.000 description 5
- 101710146024 Horcolin Proteins 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 241000758789 Juglans Species 0.000 description 5
- 235000009496 Juglans regia Nutrition 0.000 description 5
- 101710189395 Lectin Proteins 0.000 description 5
- 101710179758 Mannose-specific lectin Proteins 0.000 description 5
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 5
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 5
- 102100029323 Peptidase inhibitor 15 Human genes 0.000 description 5
- 239000000910 agglutinin Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 230000008034 disappearance Effects 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 238000013537 high throughput screening Methods 0.000 description 5
- 235000010335 lysozyme Nutrition 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 230000003252 repetitive effect Effects 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 235000020234 walnut Nutrition 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- 108010049777 Ankyrins Proteins 0.000 description 4
- 102000008102 Ankyrins Human genes 0.000 description 4
- 102100028681 C-type lectin domain family 4 member K Human genes 0.000 description 4
- 101710183165 C-type lectin domain family 4 member K Proteins 0.000 description 4
- 102000016550 Complement Factor H Human genes 0.000 description 4
- 241000699802 Cricetulus griseus Species 0.000 description 4
- 102000004860 Dipeptidases Human genes 0.000 description 4
- 108090001081 Dipeptidases Proteins 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 101000577121 Homo sapiens Monocarboxylate transporter 3 Proteins 0.000 description 4
- 101001038300 Homo sapiens Protein ERGIC-53 Proteins 0.000 description 4
- 208000013016 Hypoglycemia Diseases 0.000 description 4
- 102100025276 Monocarboxylate transporter 4 Human genes 0.000 description 4
- 108010014251 Muramidase Proteins 0.000 description 4
- 102000016943 Muramidase Human genes 0.000 description 4
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 4
- 206010029164 Nephrotic syndrome Diseases 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 102100040252 Protein ERGIC-53 Human genes 0.000 description 4
- 108090000088 Symporters Proteins 0.000 description 4
- 102000003673 Symporters Human genes 0.000 description 4
- 108060008245 Thrombospondin Proteins 0.000 description 4
- 102000002938 Thrombospondin Human genes 0.000 description 4
- 238000011319 anticancer therapy Methods 0.000 description 4
- 230000008827 biological function Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 208000035269 cancer or benign tumor Diseases 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 230000006377 glucose transport Effects 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 230000008676 import Effects 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 208000009928 nephrosis Diseases 0.000 description 4
- 231100001027 nephrosis Toxicity 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000004481 post-translational protein modification Effects 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 4
- 229940107700 pyruvic acid Drugs 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 3
- 102100035432 Complement factor H Human genes 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 206010066786 Diabetic keratopathy Diseases 0.000 description 3
- 102100039632 Glioma pathogenesis-related protein 1 Human genes 0.000 description 3
- 206010018473 Glycosuria Diseases 0.000 description 3
- 101000777314 Homo sapiens Choline kinase alpha Proteins 0.000 description 3
- 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 description 3
- 101001056234 Homo sapiens Sperm mitochondrial-associated cysteine-rich protein Proteins 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- 101710157838 Lysozyme g Proteins 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- 108090000315 Protein Kinase C Proteins 0.000 description 3
- 108091006277 SLC5A1 Proteins 0.000 description 3
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 description 3
- 102100026503 Sperm mitochondrial-associated cysteine-rich protein Human genes 0.000 description 3
- 108010023197 Streptokinase Proteins 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 102000004357 Transferases Human genes 0.000 description 3
- 108090000992 Transferases Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 230000007177 brain activity Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 239000005482 chemotactic factor Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 210000000695 crystalline len Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 206010061311 nervous system neoplasm Diseases 0.000 description 3
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 230000005730 ADP ribosylation Effects 0.000 description 2
- 102000011690 Adiponectin Human genes 0.000 description 2
- 108010076365 Adiponectin Proteins 0.000 description 2
- 108010053754 Aldehyde reductase Proteins 0.000 description 2
- 102100027265 Aldo-keto reductase family 1 member B1 Human genes 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 description 2
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 description 2
- XXAXVMUWHZHZMJ-UHFFFAOYSA-N Chymopapain Chemical compound OC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O XXAXVMUWHZHZMJ-UHFFFAOYSA-N 0.000 description 2
- 108090001069 Chymopapain Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 208000001819 Crigler-Najjar Syndrome Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 102000010170 Death domains Human genes 0.000 description 2
- 108050001718 Death domains Proteins 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 2
- 102100030072 Doublesex- and mab-3-related transcription factor 3 Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 2
- 108010027279 Facilitative Glucose Transport Proteins Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 208000009139 Gilbert Disease Diseases 0.000 description 2
- 208000022412 Gilbert syndrome Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000797917 Homo sapiens 1,5-anhydro-D-fructose reductase Proteins 0.000 description 2
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 2
- 101000864825 Homo sapiens Doublesex- and mab-3-related transcription factor 3 Proteins 0.000 description 2
- 101000888759 Homo sapiens Glioma pathogenesis-related protein 1 Proteins 0.000 description 2
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 101100315984 Macaca fascicularis UGT2B23 gene Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108700022034 Opsonin Proteins Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 208000005155 Picornaviridae Infections Diseases 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108091006296 SLC2A1 Proteins 0.000 description 2
- 108091006307 SLC2A10 Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 description 2
- 102100039667 Solute carrier family 2, facilitated glucose transporter member 11 Human genes 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 102100036034 Thrombospondin-1 Human genes 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 208000026062 Tissue disease Diseases 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 101001051101 Xenopus laevis Low-density lipoprotein receptor 1 Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000010523 cascade reaction Methods 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000003200 chromosome mapping Methods 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 230000002057 chronotropic effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000005002 female reproductive tract Anatomy 0.000 description 2
- 210000000497 foam cell Anatomy 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000000020 growth cone Anatomy 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 102000047612 human CCN2 Human genes 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000002919 insect venom Substances 0.000 description 2
- 210000001821 langerhans cell Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000011682 nervous system cancer Diseases 0.000 description 2
- 230000008271 nervous system development Effects 0.000 description 2
- 230000007472 neurodevelopment Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 210000001915 nurse cell Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 108091008695 photoreceptors Proteins 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000003334 potential effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000009145 protein modification Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 208000013076 thyroid tumor Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- LQIPDFIUPOYMPR-BKYURJJWSA-N (2e,4e)-n-[2-[[(2r,3r,4r,5r,6s)-2-[(1s)-1,2-dihydroxyethyl]-4,5-dihydroxy-6-(7h-purin-6-ylamino)oxan-3-yl]amino]-2-oxoethyl]tetradeca-2,4-dienamide Chemical compound O1[C@@H]([C@@H](O)CO)[C@H](NC(=O)CNC(=O)/C=C/C=C/CCCCCCCCC)[C@@H](O)[C@@H](O)[C@H]1NC1=NC=NC2=C1NC=N2 LQIPDFIUPOYMPR-BKYURJJWSA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- UKUVVAMSXXBMRX-UHFFFAOYSA-N 2,4,5-trithia-1,3-diarsabicyclo[1.1.1]pentane Chemical compound S1[As]2S[As]1S2 UKUVVAMSXXBMRX-UHFFFAOYSA-N 0.000 description 1
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 101710133359 Agglutinin receptor Proteins 0.000 description 1
- 102100034668 Alpha-lactalbumin Human genes 0.000 description 1
- 102100039173 Ankyrin repeat domain-containing protein 50 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010004716 Binge eating Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 101100180402 Caenorhabditis elegans jun-1 gene Proteins 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000700112 Chinchilla Species 0.000 description 1
- 241000700113 Chinchilla chinchilla Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 1
- 108010007718 Chromogranins Proteins 0.000 description 1
- 102000007345 Chromogranins Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010061045 Colon neoplasm Diseases 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 102100030386 Granzyme A Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000946384 Homo sapiens Alpha-lactalbumin Proteins 0.000 description 1
- 101000889453 Homo sapiens Ankyrin repeat domain-containing protein 50 Proteins 0.000 description 1
- 101100392605 Homo sapiens GLIPR1 gene Proteins 0.000 description 1
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 description 1
- 101000941866 Homo sapiens Leucine-rich repeat neuronal protein 2 Proteins 0.000 description 1
- 101001038314 Homo sapiens Protein ERGIC-53-like Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000009066 Hyaluronoglucosaminidase Human genes 0.000 description 1
- DGABKXLVXPYZII-UHFFFAOYSA-N Hyodeoxycholic acid Natural products C1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DGABKXLVXPYZII-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 1
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102100034870 Kallikrein-8 Human genes 0.000 description 1
- 101710176225 Kallikrein-8 Proteins 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100032655 Leucine-rich repeat neuronal protein 1 Human genes 0.000 description 1
- 101710164331 Leucine-rich repeat neuronal protein 1 Proteins 0.000 description 1
- 102100032653 Leucine-rich repeat neuronal protein 2 Human genes 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 241000258118 Lytechinus variegatus Species 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000002568 Multienzyme Complexes Human genes 0.000 description 1
- 108010093369 Multienzyme Complexes Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 1
- 102100022437 Myotonin-protein kinase Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 241000256259 Noctuidae Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000036830 Normal foetus Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- KUIFHYPNNRVEKZ-VIJRYAKMSA-N O-(N-acetyl-alpha-D-galactosaminyl)-L-threonine Chemical compound OC(=O)[C@@H](N)[C@@H](C)O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O KUIFHYPNNRVEKZ-VIJRYAKMSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710131039 Opsin-5 Proteins 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 102100025386 Oxidized low-density lipoprotein receptor 1 Human genes 0.000 description 1
- 101710199789 Oxidized low-density lipoprotein receptor 1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 101710118982 Pathogen-related protein Proteins 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100040251 Protein ERGIC-53-like Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 description 1
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical group CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Chemical group 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- FMYKJLXRRQTBOR-BZSNNMDCSA-N acetylleucyl-leucyl-norleucinal Chemical compound CCCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O FMYKJLXRRQTBOR-BZSNNMDCSA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010060162 alglucerase Proteins 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 108010006523 asialoglycoprotein receptor Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000021617 central nervous system development Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002976 chymopapain Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 201000011024 colonic benign neoplasm Diseases 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000037020 contractile activity Effects 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 108010067396 dornase alfa Proteins 0.000 description 1
- 238000012912 drug discovery process Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- YTVGSCZIHGRVAV-UHFFFAOYSA-N ganoderic acid c1 Chemical compound CC12CCC(=O)C(C)(C)C1CC(O)C1=C2C(=O)CC2(C)C(C(CC(=O)CC(C)C(O)=O)C)CC(=O)C21C YTVGSCZIHGRVAV-UHFFFAOYSA-N 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 108010026195 glycanase Proteins 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 101150097574 gsk gene Proteins 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- DGABKXLVXPYZII-SIBKNCMHSA-N hyodeoxycholic acid Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-N 0.000 description 1
- 239000000864 hyperglycemic agent Substances 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- 230000006122 isoprenylation Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000005857 malignant hypertension Diseases 0.000 description 1
- 230000000566 mammotropic effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000001501 megacaryocyte Anatomy 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000036630 mental development Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940051921 muramidase Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 230000001452 natriuretic effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 229940107568 pulmozyme Drugs 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 101150057603 putP gene Proteins 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000009774 resonance method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000001324 spliceosome Anatomy 0.000 description 1
- 210000001543 spongioblast Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000005400 testing for adjacent nuclei with gyration operator Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000005866 tritylation reaction Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了表I中所列基因的多肽和多核苷酸,以及用重组技术制备所述多肽的方法。本发明还公开了在诊断试验中利用表I所列基因的多肽和多核苷酸的方法。
Description
本申请是2001年9月13日提交的发明名称为“新型化合物”即中国专利申请01818830.3的分案申请。
发明领域
本发明涉及新鉴定的多肽及编码所述多肽的多核苷酸,它们在诊断中的应用,以及它们在鉴定可能作为在治疗有潜在作用的激动剂和拮抗剂的化合物中的用途,本发明还涉及所述多肽和多核苷酸的制备。本发明所述的多核苷酸及多肽还涉及具有信号序列的蛋白,该信号序列可使所述蛋白分泌于胞外或者与膜结合(下文往往统称为分泌蛋白或分泌多肽)。
发明背景
药物发现方法由于涉及“功能基因组”学,即以基因组或基因为基础的高流通量(high throughput)生物学,而正经历一场重大变革。这种方法作为将基因和基因产物鉴定为治疗靶标的手段,迅速取代了原来以“定位克隆”为基础的方法。生物功能或遗传疾病的表型得到鉴定,接着可根据其遗传图谱位置回溯到负责基因(responsible gene)。
功能基因组学在很大程度上依赖于高流通量DNA测序技术和各种生物信息学工具,以便从现有多种分子生物学数据库中鉴定出有潜在价值的基因序列。一直需要鉴定和定性其它基因及有关蛋白/多肽,这是药物发现的靶标。
那些天然分泌到血液、淋巴或其它体液中,或者分泌到细胞膜上的蛋白及多肽是研发药物的首要目标。原因在于可以相对容易地将蛋白治疗靶向它们的作用位置(体液或细胞膜)。真核细胞和原核细胞将蛋白质分泌入胞外区间的天然通道分别为内质网和内膜(Palade,1975,Science,189,347;Milstein,Brownlee,Harrison,and Mathews,1972,Nature New Biol.,239,117;Blobel,and Dobberstein,1975,J.Cell.Biol.,67,835)。反之,现在还没有发现一条将蛋白质由细胞外输入细胞质的天然通道(除了胞吐作用,即蛇毒液中毒素侵入细胞的机制外)。因此,将蛋白治疗物靶入细胞面临着巨大困难。
分泌型及膜结合型蛋白包括但不限于所有肽激素及其受体(包括但不限于胰岛素、生长激素、趋化因子、细胞因子、神经肽、整联蛋白、激肽释放酶、核纤层蛋白、黑色素、利尿钠激素、neuropsin,神经营养蛋白,垂体激素、多效蛋白(pleiotropins),前列腺素、分泌粒蛋白、选择蛋白、血小板球蛋白、胸腺素),乳腺癌及结肠癌基因产物、苗条蛋白(leptin)、肥胖基因蛋白及其受体、血清白蛋白、超过氧化物歧化酶、剪接体蛋白、7TM(跨膜)蛋白也称为G-蛋白偶联型受体、免疫球蛋白、丝氨酸蛋白酶的几个家族(包括但不限于血液凝固级联反应的蛋白、消化酶)、脱氧核糖核酸酶I等。
FDA或外国机构批准基于分泌型蛋白或膜结合蛋白的治疗物包括但不限于胰岛素、胰高血糖素、生长激素、绒毛膜促性腺素、促卵泡激素、促黄体素释放激素(luteinizing hormone)、降钙素、促肾上腺皮质激素(ACTH)、血管升压素、白细胞介素、干扰素、免疫球蛋白、乳铁传递蛋白(有多家公司销售的不同产品)、组织型纤溶酶原激活物(Alteplase,Genentech)、hyaulorindase(Wydase,Wyeth-Ayerst),α链道酶(Pulmozyme\,Genentech),Chymodiactin(chymopapain,Knoll),糖脑苷酶(Ceredase,Genzyme),链激酶(Kabikinase,Pharmacia)(Streptase,Astra)等。这表明分泌型及膜结合型蛋白质作为治疗靶标已有确证的历史。显然,需要对其它能够预防、减缓或纠正功能紊乱或疾病的分泌型及膜结合型蛋白质进行鉴定及定性,所述功能紊乱或疾病包括但不限于糖尿病、乳腺癌、前列腺癌、结肠癌及其它恶性肿瘤、高血压及低血压、肥胖症、过食症、厌食症、生长畸形、哮喘、燥狂抑郁病、痴呆、精神狂乱、智力低下、亨廷顿氏病、图雷特氏(Tourette)综合征、精神分裂症、生长发育障碍、精神发育障碍或性发育障碍、以及血液级联反应系统功能紊乱(包括导致中风(stroke)的那些功能紊乱)。本发明中含信号序列的蛋白还可以用来进一步阐明目前还未完全理解的蛋白输送机制,因而可以用作研究工具。
发明概述
本发明涉及表I中列出基因的具体多肽及多核苷酸,包括用于制备它们的重组材料和方法。这类多肽和多核苷酸与治疗特定疾病的方法相关,所述疾病包括但不限于表III和V所列疾病,下文称作“本发明所述疾病”。另一方面,本发明涉及用本发明提供的材料鉴别激动剂和拮抗剂(例如,抑制剂)的方法,以及用鉴别出的化合物治疗与表I所列基因的多肽和/或多核苷酸失衡相关的病症的方法。另一方面,本发明还涉及用来检测与表I所列基因活性或水平异常有关的疾病的诊断试验。本发明另一方面涉及多肽以及多核苷酸,所述多核苷酸包括序列表中所列的任何核苷酸序列,所述多肽包括上述多核苷酸编码的多肽。另一方面,本发明还涉及包括序列表所列任一多肽序列的多肽及其制备所用的重组材料和方法。本发明另一方面还涉及使用所述多肽和多核苷酸的方法。所述使用包括治疗因本发明所述基因的表达、产量、功能和、或代谢的异常而引发的疾病、异常及紊乱(这些情况下文统称疾病),本领域技术人员能够很容易地从公开的每个所附序列与其它蛋白的同源性方面理解这些疾病。另一方面,本发明涉及用本发明提供的材料鉴定激动剂和拮抗剂的方法,以及治疗与鉴定出的化合物失衡相关的疾病的方法。本发明另一方面还涉及检测与本发明所述分泌型蛋白的活性或水平异常有关的疾病的诊断试验。
发明详述
第一方面,本发明涉及表I中所列基因的多肽。所述多肽包括:(a)由包括序列表中所列的一种序列的多核苷酸编码的分离的多肽,本发明中提到序列表中所列多核苷酸或多肽时,在序列表部分的序列列表中有相应参照;(b)一种分离的多肽,该多肽包括与序列表中的一种多肽序列具有至少95%,96%,97%,98%,或99%同一性的多肽序列;(c)一种分离的多肽,该多肽包括序列表中所列的多肽序列;(d)一种分离多肽,该多肽与序列表中列出的多肽序列之间具有至少95%,96%,97%,98%,或99%的同一性;(e)序列表中列出的一种多肽序列;以及(f)一种分离的多肽,该多肽具有或包括与序列表所列的多肽序列之间的同一性指数(Indentity Index)为0.95,0.96,0.97,0.98,或0.99的多肽序列;(g)(a)~(f)中所述多肽的片段及变体。
本发明多肽据信是表II中基因家族的成员。因此根据表III和V中所列的理由,它们具有治疗和诊断的价值。表I中基因的多肽及多核苷酸的生物学特性在本发明中称为表I中基因的多肽及多核苷酸的“生物学活性”。优选地,本发明多肽具有表I中基因的至少一种生物学活性。
本发明多肽还包括上述多肽的变体,其中包括所有的等位形式及剪接变体。所述多肽可以是从参考多肽通过保守或非保守的插入、缺失及取代,或其任何组合变化而来。具体优选的变体是那些以任意组合插入、取代或缺失了数个(如50~30、30~20、20~10、10~5、5~3、3~2、2~1个或1个)氨基酸的变体。
本发明多肽的优选片段包括这样的分离的多肽,该分离的多肽包括一种氨基酸序列,该序列具有来自序列表所列的一种氨基酸序列的至少30、50或100个连续氨基酸,或者该序列具有将序列表所列的一种氨基酸序列中截短或缺失至少30、50或100个连续氨基酸所得的氨基酸序列。优选片段是能介导表I中基因的多肽和多核苷酸的生物学活性的生物活性片段,包括那些具有近似活性或改良活性的片段,或者是不良活性降低的片段。还优选在动物体,尤其是人体中具有抗原性或免疫原性的片段。
可以通过肽合成技术利用本发明多肽的片段制备相应的全长多肽;因此,这些变体可以当作制备本发明全长多肽的中间体。本发明中的多肽可以是“成熟”蛋白的形式,也可以是如前体或融合蛋白等更大蛋白的一部分。通常,包括一段额外的氨基酸序列是有利的,其中所述氨基酸序列含有分泌或前导序列、前序列,有助于纯化的序列,例如多组氨酸残基,或者在重组生产过程中用来保持稳定的一段额外的氨基酸序列。
本发明多肽可以以任何适当的方式制备,例如可以从天然来源分离,从含表达系统(见下文)的基因工程宿主细胞分离,或者例如使用自动肽合成仪化学合成,或者上述方法的组合。制备所述多肽的方法为本领域技术人员所熟知。
另一方面,本发明涉及表I中所列基因的多核苷酸。这些多核苷酸包括:(a)一种分离的多核苷酸,其中包含与序列表中一种多核苷酸序列之间具有至少95%,96%,97%,98%,或99%同一性的多核苷酸序列;(b)一种分离多核苷酸,其中包含序列表中所列的一种多核苷酸;(c)一种分离的多核苷酸,该多核苷酸与序列表中列出的一种多核苷酸之间具有至少95%,96%,97%,98%,或99%的同一性;(d)序列表中列出的一种分离的多核苷酸;(e)一种分离的多核苷酸,其中包含编码如下多肽序列的多核苷酸序列:所述多肽序列与序列表中的一种多肽序列之间具有至少95%,96%,97%,98%,或99%的同一性;(f)一种分离的多核苷酸,其中包含编码序列表中一种多肽的多核苷酸序列;(g)一种分离的多核苷酸,其具有如下多核苷酸序列:所述序列编码的多肽与序列表中一种多肽序列之间具有至少95%,96%,97%,98%,或99%的同一性;(h)一种分离的多核苷酸,该多核苷酸编码序列表中的一种多肽;(i)一种分离的多核苷酸,该多核苷酸具有或包含与序列表所列的一种多核苷酸序列之间的同一性指数为0.95,0.96,0.97,0.98,或0.99的多核苷酸序列;(j)一种分离的多核苷酸,其具有或包含编码如下多肽序列的多核苷酸序列:所述多肽序列与序列表中所列的一种多肽序列之间的同一性指数为0.95,0.96,0.97,0.98,或0.99;以及上述多核苷酸的片段或变体,或者上述多核苷酸全长序列的互补多核苷酸。
本发明所述多核苷酸的优选片段包括一种分离的多核苷酸,该分离的多核苷酸含有如下核苷酸序列:所述核苷酸序列具有来自序列表中所列的一种序列的至少15、30、50或100个连续核苷酸;或者所述多核苷酸序列具有从序列表的一种序列中截短或缺失了至少30、50或100个连续核苷酸所得的序列。
本发明所述多核苷酸的优选变体包括剪接变体、等位变体以及多态性,包括其有1个或多个单核苷酸多态性(SNP)的多核苷酸。
本发明所述多核苷酸还包括编码符合下述条件的多肽变体的多核苷酸:即所述多肽变体包含序列表中的一种氨基酸序列,并且该氨基酸序列中以任意组合取代、缺失或添加了50-30、30-20、20-10、10-5、5-3、3-2、2-1或1个氨基酸残基。
另一方面,本发明提供了作为本发明所述DNA序列的RNA转录物的多核苷酸。因此,本发明提供了下述RNA多核苷酸以及与其互补的RNA多核苷酸:(a)其包括编码序列表中一种多肽的DNA序列的RNA转录物;(b)其本身为编码序列表中一种多肽的DNA序列的RNA转录物;(c)其包括序列表中一种DNA序列的RNA转录物;或者(d)其本身是序列表中一种DNA序列的RNA转录物。
序列表中多核苷酸序列与表II中多核苷酸序列之间具有同源性。序列表中多核苷酸序列是编码序列表中多肽的cDNA序列。编码序列表中多肽的多核苷酸序列可以与序列表中多肽的编码序列相同,或者它也可以是序列表所列序列之外的序列,但由于遗传密码的丰余性(简并性),它也可以编码序列表中的多肽。序列表中所列序列的多肽与表II中基因家族的其它蛋白相关,与表II中多肽之间具有同源性和/或结构类似性。本发明所述的优选多肽及多核苷酸预计与它们的同源多肽及多核苷酸之间具有类似的生物功能/特性。另外,本发明优选的多肽及多核苷酸具有表I中所列基因的至少1种活性。
本发明所述多核苷酸可以用标准克隆及筛选技术从cDNA文库中得到,该cDNA文库源自表IV中组织的mRNA(参见,例如,Sambrook等,分子克隆:实验指南,第二版,Cold Spring Harbor Laboratory Press,Cold SpringHarbor,N.Y.(1989))。本发明所述多核苷酸还可以从天然来源获得,例如基因组DNA文库,或者可以用公知的和商业化的技术合成。
当将本发明所述多核苷酸用于重组生产本发明多肽时,所述多核苷酸可以包括:成熟多肽的编码序列本身,或者与其它编码序列位于同一阅读框的成熟多肽的编码序列,所述其它序列例如编码前导或分泌序列、前-、或原-、或前原-蛋白序列、或其它融合肽部分的序列。例如,可以编码有助于融合多肽纯化的标记序列。在本发明该方面的特定优选实施例中,所述标记序列为六组氨酸肽,如pQE载体(Qiagen,Inc.)中提供的,以及见Gentz等,ProcNatl Acad Sci USA(1989)86:821-824一文中的描述,或者为HA标签。多核苷酸也可以包括非编码的5′及3′序列,例如转录、非翻译序列,剪接及多腺苷酸化信号,核糖体结合位点及稳定mRNA的序列。
与序列表中多核苷酸序列相同或者具有足够同一性的多核苷酸可以用作cDNA及基因组DNA的杂交探针,或者作为核酸扩增反应(例如,PCR)的引物。所述探针可以用来分离编码本发明多肽的全长cDNA及基因组克隆,以及可以用来分离与序列表中序列间有高度序列相似性(通常至少为95%的同一性)的其它基因(包括编码人源平行进化同系物(paralogs)的基因以及其它物种来源的直向同系物(orthologs)及平行进化同系物的基因)的cDNA及基因组克隆。优选的探针及引物通常包括至少15个核苷酸,优选至少30个核苷酸,如果不是至少100个核苷酸,也可以为至少50个。特别优选的探针为30-50个核苷酸。特别优选的引物为20-25个核苷酸。
编码本发明多肽的多核苷酸,包括来自其它物种的同系物,可以通过包括下述步骤的方法来获得:用具有序列表中序列或其片段的标记探针(优选至少15个核苷酸)在严谨条件下筛选文库,分离出含序列表中多核苷酸序列的全长cDNA及基因组克隆。所述杂交技术为本领域技术人员所熟知。优选的严谨杂交条件包括42℃下在含下列成分的溶液中温育过夜:50%甲酰胺,5xSSC(150mM NaCI,15mM柠檬酸三钠)、50mM磷酸钠(pH 7.6),5xDenhardt′s溶液、10%葡聚糖硫酸酯、以及20μg/ml变性剪切后的鲑鱼精DNA;然后在约65℃用0.1x SSC洗涤滤膜。因此,本发明还包括在严谨条件下用标记探针筛选文库获得的分离的多核苷酸,优选地,该多核苷酸具有至少100个核苷酸,所述探针为序列表中序列或其片段,优选至少15个核苷酸。
本领域技术人员应该理解,很多情况下,分离的cDNA序列是不完整的,其编码多肽的区域不会一直延伸至5’末端。这是反转录酶所造成的结果,该酶本身具有低“持续合成能力”(聚合反应过程中该酶保持与模板结合的能力的一个指标),因而在第一链cDNA合成过程中不能合成mRNA模板的完整DNA拷贝。
现有数种本领域技术人员熟知的方法可以得到全长cDNA,或者延伸短cDNA,例如以cDNA末端快速扩增法(RACE)为基础的方法(参见,例如,Frohman et al.,Proc Nat Acad Sci USA 85,8998-9002,1988)。近来该技术有一些改进,以Marathon(商标名)技术(Clontech Laboratories Inc.)为代表,例如已大大简化了较长cDNA的筛选。在Marathon(商标名)技术中,从选定组织提取mRNA,从中制备cDNA,并且在每个末端都连接“衔接头(adaptor)”序列。然后,联合使用基因特异性引物和衔接头特异性寡核苷酸引物,通过核酸扩增(PCR)来扩增“丢失的”cDNA 5’末端。然后用“嵌套”引物重复PCR反应,所述嵌套引物是经设计而在扩增产物内部退火的引物(通常,一个为与衔接头序列的更偏3′侧退火的衔接头特异性引物,另一引物为与已知基因序列的更偏5′侧退火的基因特异性引物)。然后,通过DNA测序分析该反应产物,通过下述方法构建全长cDNA:将产物与现有cDNA直接连接得到全长序列,或者利用新的序列信息设计5′引物进行单独的全长PCR扩增。
本发明所述重组多肽可以用本领域技术人员熟知的方法从含表达系统的遗传工程构建的宿主细胞中制备得到。因此,另一方面,本发明涉及含本发明所述一个或多个多核苷酸的表达系统,涉及用所述表达系统通过遗传工程手段构建的宿主细胞,以及涉及用重组技术制备本发明多肽。还可以以用源自本发明所述DNA构建体的RNA利用无细胞翻译系统来制备所述蛋白。
就重组制备而言,可以用遗传工程手段构建宿主细胞以导入本发明所述多核苷酸的表达系统或者其部分。可以用多种常规实验指南中描述的方法将多核苷酸引入宿主细胞,例如Davis等,Basic Methods in Molecular Biology(1986)和Sambrook等(同上)。将多核苷酸导入宿主细胞的优选方法包括,例如,磷酸钙转染、DEAE-葡聚糖介导的转染、转位(transvection)、显微注射、阳离子脂质-介导的转染、电穿孔、转导、刮擦上样(scrape loading)、弹道导入(ballistic introduction)或感染。
合适宿主的代表性实例包括细菌细胞,例如链球菌、葡萄球菌、大肠杆菌、链霉菌及枯草芽孢杆菌细胞;真菌细胞,例如酵母细胞和曲霉菌细胞;昆虫细胞例如果蝇S2和夜蛾(spodoptera)Sf9细胞;动物细胞例如CHO、COS、HeLa、C127、3T3、BHK、HEK293和Bowes黑色素瘤细胞;以及植物细胞。
有多种表达系统都可以使用,例如,染色体、附加体及病毒来源的系统,例如,源自下述的载体:细菌质粒、噬菌体、转座子、酵母附加体、插入元件、酵母染色体元件、病毒如杆状病毒、乳多空病毒、如SV40、痘苗病毒、腺病毒、禽痘病毒、伪狂犬病毒及反转录病毒,及来源于其组合的载体,例如源自质粒及噬菌体遗传元件的载体,例如粘粒及噬菌粒。所述表达系统可以包含调控及实施表达的控制区。通常,任一能够在宿主细胞中维持、增殖或表达多核苷酸以生成多肽的系统或载体都可以使用。合适的多核苷酸序列可以通过多种熟知及常规技术中的任一种插入到表达系统,所述技术例如,Sambrook et al.,(如上)一书中描述的方法。可以将合适的分泌信号导入目的多肽从而使得翻译后的蛋白能够分泌到内质网腔、周质间隙或胞外环境。这些信号相对于所述多肽可以是内源性的,也可以是异源性信号。
如果本发明多肽的表达是为了用于筛选实验,那么通常优选在细胞表面制备所述多肽。这种情况下,可以在用于筛选实验前收获细胞。如果多肽分泌入培养基中,那么可回收培养基以回收及纯化所述多肽。如果在胞内生成,那么在回收多肽之前必须首先裂解细胞。
可以采用本领域熟知的方法从重组细胞培养物中回收和纯化本发明多肽,其中包括硫酸铵或乙醇沉淀、酸抽提、阴离子或阳离子交换层析、磷酸纤维素层析、疏水作用层析、亲和层析、羟基磷灰石层析以及凝集素层析。最优选地,用高效液相色谱来纯化。当多肽在胞内合成、分离和/或纯化过程中变性时,可以使用本领域熟知的蛋白重折叠技术重新生成活性构象。
本发明多肽可以用作诊断试剂,检测相关基因中的突变。对突变形式的基因的检测,其特征在于cDNA或基因组序列中列于序列表中的多核苷酸,且其与功能紊乱相关。本发明将提供一诊断工具,该诊断工具可以辅助诊断或明确诊断疾病或疾病易感性,所述疾病是由基因的低表达、过表达或表达在空间或时间上的变化引起。带有基因突变的个体可以通过多种本领域熟知的技术在DNA水平上检测。
用于诊断的核酸可以从受试者细胞中获得,例如从血液、尿液、唾液、组织活检或尸检材料中获得。基因组DNA可以直接用于检测,或者在分析前用PCR,优选用RT-PCR,或者用其它扩增技术进行酶性扩增。RNA或cDNA也可以以类似的方式应用。通过扩增产物与正常基因型相比大小上的变化来检测缺失和插入。通过将扩增的DNA与标记后的表1中基因的核苷酸序列杂交可检测点突变。用RNA酶消化或解链温度的差异可将错配的双螺旋体与完美匹配的序列区分。还可以以DNA片段在有或无变性试剂存在的情况下,在凝胶中电泳迁移率的改变,或者通过直接DNA测序(参见,例如,Myers et al.,Science(1985)230:1242)来检测DNA序列的差异。还可以用核酸酶保护试验或者化学切割方法检测出特定位点上的序列变化,所述保护例如RNA酶及S1保护(见,Cotton et al.,Proc Natl Acad Sci USA(1985)85:4397-4401)。
可以构建包含表I中基因的多核苷酸序列或其片段的寡核苷酸探针阵列以实施高效筛选,例如对基因突变的高效筛选。所述阵列优选为高密度阵列或载网(grids)。阵列技术的方法为本领域熟知,具有广泛用途,并且可以用来研究分子遗传学中的多种问题,包括基因表达、基因连锁及基因变异性,参见,例如,M.Chee et al.,Science,274,610-613(1996)以及本发明引述的其它文献。
也可以通过检测多肽或mRNA表达的异常减少或增加来诊断或测定受试者对本发明所述疾病的易感性。表达的减少或增加可以用本领域熟知的任一检测多核苷酸量的方法在RNA水平上测量出来,所述方法例如,核酸扩增、如PCR、RT-PCR、RNA酶保护、Northern印迹法及其它杂交方法。用于测定蛋白,如本发明多肽在来自宿主的标本中的水平的分析技术已为本领域技术人员所熟知。所述分析方法包括放射免疫测定、竞争结合试验、Western印迹分析及ELISA试验。
因此另一方面,本发明涉及一种诊断试剂盒,其包括:(a)本发明所述多核苷酸,优选序列表中的核苷酸序列,或者其片段或RNA转录体;(b)与(a)中多核苷酸互补的核苷酸序列;(c)本发明所述多肽,优选序列表中的多肽或其片段;或者(d)抗本发明多肽的抗体,优选抗序列表中的多肽的抗体。
可以理解的是,在任一所述试剂盒中,(a),(b),(c)或(d)中都包含一种基本组分。该试剂盒可以用来诊断疾病或对疾病的易感性,尤其是本发明所述疾病。
本发明所述多核苷酸序列对于染色体定位研究很有价值。序列表中的序列特异性地靶向单个人源染色体的特定位点并可与该位点杂交。在本发明的染色体上对相关序列作图是使这些序列和基因相关疾病间建立关联的重要的第一步。一旦将序列定位到确切的染色体位置,就可以将染色体上该序列的物理位置与遗传图谱资料间建立相关关系。所述资料见于,例如,V.McKusick,Mendelian Inheritance in Man(available online through JohnsHopkins University Welch Medical Library)。然后,通过连锁分析(物理邻接基因的共遗传),鉴定出已定位到同一染色体区域中的基因与疾病间的相关关系。基因组序列(基因片段等)的确切人染色体定位可以用放射杂交(RH)作图方法确定(Walter,M.Spillett,D.,Thomas,P.,Weissenbach,J.,and Goodfellow,P.,(1994)一种构建全基因组放射杂交图谱的方法,Nature Genetics 7,22-28)。大量的RH试验板(panel)获自Research Genetics(Huntsville,AL,USA)例如GeneBridge4 RH板(Hum Mol Genet 1996 Mar;5(3):339-46 A radiationhybrid map of the human genome.Gyapay G,Schmitt K,Fizames C,Jones H,Vega-Czarny N,Spillett D,Muselet D,Proud′homme JF,Dib C,Auffray C,Morissette J,Weissenbach J,Goodfellow PN)。为了用所述试验板确定基因的染色体定位,使用根据RH DNA上的目的基因设计的引物进行93次PCR反应。这些DNA中的每一个都包括维持在仓鼠背景(人/仓鼠杂交细胞系)中的随机人基因组片段。这些PCR反应得到93个分值,它们指示目的基因的PCR产物的存在与否。将这些分值与用已知位点基因组序列的PCR产物得到的分值进行比较。所述比较在该网址上进行,即http://www.genome.wi.mit.edu/。
本发明所述多核苷酸序列还是进行组织表达研究的有效工具。所述研究导致能确定本发明所述多核苷酸的表达模式,从而通过检测编码所述多肽的mRNA来指示组织中所编码的多肽的表达模式。所用的技术为本领域熟知,包括对排列在载网上的克隆进行原位杂交技术,例如cDNA微阵列杂交(Schena et al,Science,270,467-470,1995 and Shalon et al,Genome Res,6,639-645,1996)以及核苷酸扩增技术如PCR。优选的方法使用Perkin Elmer公司提供的TAQMAN(商标名)技术。这些研究的结果可以为所述多肽在生物体内的正常功能提供指示。此外,mRNA的正常表达模式与同一基因的替代形式(例如,多肽编码能力有变或具有调节性突变的那些)所编码的mRNA的表达模式间的对比研究,可以为本发明多肽的作用提供有价值的发现,或者对其在疾病中的不适当表达所起的作用提供有价值的发现。这些不适当表达可以是时间、空间或单纯量上的特性。
本发明另一方面还涉及抗体。本发明多肽或其片段,或表达它们的细胞,都可以用作免疫原,以制备针对本发明多肽具有免疫特异性的抗体。“免疫特异性”一词是指所述抗体与本发明多肽间的亲和力明显大于其与现有技术中其它相关多肽间的亲和力。
抗本发明多肽的抗体可以通过常规方法向动物,优选非人动物,施用所述多肽或含表位的片段、或细胞而获得。就制备单克隆抗体而言,任一能够通过连续细胞系培养获得抗体的技术都可以使用。实例包括杂交瘤技术(Kohler,G and Milstein,C.,Nature(1975)256:495-497)、trioma技术、人B-细胞杂交瘤技术(Kozbor et al.,Immunology Today(1983)4:72)以及EBV-杂交瘤技术(Cole et al.,Monoclonal Antibodies and Cancer Therapy,77-96,Alan R.Liss,Inc.,1985)。
用于制备单链抗体的技术,例如序列号为No.4,946,778的美国专利中描述的,也可以调整后用来制备抗本发明多肽的单链抗体。另外,转基因小鼠,或其它生物,包括其它哺乳动物,也可以用于表达人源化抗体。
上述抗体可以用于分离或鉴定表达所述多肽的克隆,或者通过亲和层析纯化所述多肽。抗本发明多肽的抗体也可以用来治疗本发明所述疾病。
本发明多肽及多核苷酸还可以用作疫苗。因此,另一方面,本发明涉及一种激发哺乳动物免疫应答的方法,该方法包括用足够量的本发明多肽接种哺乳动物,使所述哺乳动物产生抗体和/或T细胞免疫应答,包括,例如,产细胞因子的T细胞或细胞毒性T细胞,以使所述动物抗御疾病,而无论疾病是否已在个体中存在。哺乳动物体内的免疫应答还可以通过这样的方法来激发,该方法包括通过能指导多核苷酸表达并且能在体内编码所述多肽的载体运载本发明多肽,诱导免疫应答,产生抗体,保护所述动物免遭本发明所述疾病。上述载体施用的一种方法是将其包裹颗粒或将其它物质,使其加速进入目的细胞。所述核酸载体包括DNA、RNA、修饰后的核酸、或DNA/RNA杂合体。就用作疫苗而言,多肽或核酸载体通常以疫苗制剂(组合物)的形式提供。所述制剂可以进一步包括适当的载体。由于多肽可能在胃中被降解,所以优选通过非胃肠道途径给药(例如,皮下、肌内、静脉内、或皮内注射)。适于非胃肠道给药的制剂包括含水及不含水的无菌注射液,其中可含有抗氧化剂、缓冲液、抑菌剂以及能使制剂与受体血液等渗(instonic)的溶质;以及含水及不含水无菌悬液,其中可包括悬浮剂或增稠剂。所述制剂可以配制成单位剂量或多剂量包装,例如,密封安瓿和小瓶,以及可以冻干方式保存,只需在使用前临时加入无菌液态载体。所述疫苗制剂还可包括佐剂系统用来增强制剂的免疫原性,例如水包油系统以及其它本领域已知系统。剂量取决于疫苗的比活性,可根据常规经验容易地确定。
本发明多肽具有与1种或多种病理状态有关的1种或多种生物功能,所述病理状态具体为本发明所述疾病。因此,鉴定出能够刺激或抑制所述多肽的功能或水平的化合物是有用的。因此,另一方面,本发明提供了一种筛选能够刺激或抑制所述多肽功能或水平的化合物的方法。上述方法能够鉴定出可用于治疗及预防本发明所述疾病的激动剂或拮抗剂。可从如下多种来源鉴定上述化合物,例如,细胞、无细胞制剂、化学文库、化合物集合、以及天然产物混合物。如此鉴定出的激动剂或拮抗剂可以为天然或修饰后的所述多肽的底物、配体、受体、酶等(依情况而定);其结构或功能的模拟体(参见,Coligan et al.,Current Protocols in Immunology 1(2):Chapter 5(1991))或小分子。所述小分子优选分子量低于2,000道尔顿,更优选为300~1,000道尔顿,最优选400~700道尔顿。优选这些小分子为有机分子。
该筛选方法通过与候选化合物直接或间接连接的标记物,可以简便地检测出候选化合物与多肽、与带有所述多肽的细胞或细胞膜、或与其融合蛋白的结合。或者,所述筛选方法可以包括检测(定性或定量)候选化合物与多肽同标记竞争物(例如激动剂或拮抗剂)之间的竞争结合。另外,这些筛选方法可以使用适于带有该多肽的细胞的检测系统,测试候选化合物是否能引发由所述多肽被激发或被抑制所产生的信号。通常在有已知激动剂的情况下测定对激活作用的抑制剂,此时可观察候选化合物存在时该激动剂的活化效果。另外,筛选方法可以简单地包括将候选化合物与含本发明多肽的溶液混合,形成混合物,测量混合物中表I所列基因的活性,并且将表I所列基因的混合物的活性与不含候选化合物的对照混合物进行比较。
本发明多肽可以用于常规低容量筛选方法以及还可用于高流通量筛选(high-throughput screening)(HTS)方式。所述HTS方式不仅可以使用成熟的96孔微量滴定板,还可以使用最近出现的384孔微量滴定板,而且还可用新出现的方法,例如Schullek et al,Anal Biochem.,246,20-29,(1997)一书描述的毫微孔(nanowell)方法。
融合蛋白,例如由Fc部分和如上所述的表I中基因的多肽形成的融合蛋白,也可用于高流通量筛选试验,来鉴定本发明多肽的拮抗剂(见D.Bennettet al.,J Mol Recognition,8:52-58(1995);and K.Johanson et al.,J Biol Chem,270(16):9459-9471(1995))。
本发明所述的多核苷酸、多肽及抗该多肽的抗体也可以用于设计筛选方法,来检测所加入的化合物对细胞中mRNA及多肽的生产的影响。例如,可构建ELISA试验,用本领域常规方法使用单克隆及多克隆抗体测定分泌型多肽及细胞结合型多肽的水平。用该方法能从适当操作后的细胞或组织中发现可抑或增加多肽的生产的试剂(也分别称为拮抗剂或激动剂)。
通过本领域已知的常规受体结合技术,可用本发明多肽鉴定膜结合受体或可溶性受体。这些技术包括,但不限于,配体结合及交联试验,其中所述多肽被放射性同位素(例如,125I)标记、化学修饰(例如,生物素化)、或融合到适于检测或纯化的肽序列上,然后与推定受体的来源物(细胞、细胞膜、细胞上清液、组织提取物、体液)孵育。其它方法包括生物物理学技术如表面胞质基因组共振及光谱学方法。这些筛选方法还可用于鉴定能够与多肽竞争性结合多肽受体的激动剂及拮抗剂。完成所述试验的常规技术为本领域熟知。
本发明多肽的拮抗剂的实例包括抗体或者,在某些情况下,与配体紧密相关的寡核苷酸或蛋白,所述多肽的底物,受体,酶等,例如配体、底物、受体、酶的片段等;或者可与本发明多肽结合但不能激发应答的小分子,该多肽的活性从而受到抑制。
筛选方法还涉及使用转基因技术及表I中的基因。构建转基因动物的技术已很成熟。例如,可将表I中的基因通过显微注射导入受精卵的雄性原核,通过反转录病毒转移入植入前或植入后的胚胎,或者将遗传工程修饰后的胚胎干细胞例如通过电穿孔注射入宿主胚泡。特别有用的转基因动物是所谓的“敲入(knock-in)”动物,其中该动物基因组中的动物基因被人源的等同基因所取代。敲入转基因动物可用于药物发现过程,用作靶标确认,其中所述化合物对于人靶标是特异性的。其它有用的转基因动物有所谓的“敲除(knock-out)”动物,其中与本发明多肽相应且被细胞中内源DNA序列编码的动物直向进化同系物的表达被部分或完全废除。基因敲除可以靶向特异细胞或组织,由于技术局限可能只发生在某些细胞或组织中,或者可以发生在全部,或基本上全部动物细胞中。转基因动物技术还提供了一种完整动物表达-克隆系统,其中导入的基因被表达,生成大量本发明多肽。
可用于上述方法的筛选试剂盒构成本发明的另一方面。所述筛选试剂盒包括:(a)本发明所述多肽;(b)表达本发明多肽的重组细胞;(c)表达本发明多肽的细胞膜;或者(d)抗本发明多肽的抗体;所述多肽优选是序列表中所列多肽。
应该理解的是,任一种所述试剂盒中,(a),(b),(c)或(d)可以包括一基本组分。
术语表
提供下列定义以便更好地理解本发明中经常出现的术语。
本发明中的“抗体”包括多克隆及单克隆抗体,嵌合、单链、及人源化抗体,以及Fab片段,包括Fab的产物或其它免疫球蛋白表达文库的产物。
“分离的”是指通过人工改变了其天然状态,即如果其是天然生成的,那么已将其从原初的环境中改变或移取出来,或者这两种情况都同时发生。例如,生物活体中天然存在的多核苷酸或多肽不是“分离的”,但是从其天然状态下的共存物中分离出来的同样的多核苷酸或多肽就是“分离的”。本发明中使用的该术语就是这个含义。另外,通过转化、基因操作或其它任一重组方法导入到生物体中的多核苷酸或多肽都是“分离的”,即使其仍存在于该生物体中,所述生物体可以是存活的或死亡的。
“分泌型蛋白的活性或者分泌型多肽的活性”或者“分泌型蛋白的生物活性或者分泌型多肽的生物活性”是指所述分泌型蛋白的代谢或生理功能,包括近似的活性或增强的活性或者减小了不需要的副作用的活性。另外还包括所述分泌蛋白的抗原活性及免疫原活性。
“分泌蛋白的基因”是指包含了所附任一核苷酸序列的多核苷酸或其等位变体和/或其互补体。
“多核苷酸”通常是指任一多核糖核酸(RNA)或多脱氧核糖核酸(DNA),可以是修饰后的或者未经修饰的RNA或DNA。“多核苷酸”包括,但不限于,单链及双链DNA,单链和双链区混合体的DNA,单链及双链RNA,以及单链和双链区混合的RNA,包含DNA和RNA的杂合分子,所述DNA和RNA可以是单链或更通常为双链或者单链与双链区的混合体。此外,“多核苷酸”还指三链区,包含RNA或DNA或者同时包含二者。术语“多核苷酸”还包括含1个或多个已修饰的碱基的DNA或RNA以及为稳定或其它原因对骨架修饰后的DNA或RNA。“修饰的”碱基包括,例如三苯甲基化的(tritylated)碱基以及肌苷等非常见碱基。可对DNA及RNA作多种修饰;因此“多核苷酸”包括自然界中常见的多核苷酸的化学、酶促或代谢修饰形式,以及病毒及细胞特有的化学形式DNA及RNA。“多核苷酸″还包括相对短的多核苷酸,通常称为寡核苷酸。
“多肽″是指含2个或多个通过肽键或修饰后的肽键彼此相连的氨基酸的任一多肽(即肽等排物(isostere))。“多肽”既可以指短链多肽,也可以指长链多肽。短链多肽通常称为肽、寡肽或寡聚体,长链多肽通常称为蛋白质。多肽可以包括除20种由基因编码的氨基酸以外的氨基酸。“多肽”包括经天然加工如翻译后加工或者经本领域熟知的化学修饰技术加工后的氨基酸序列。所述修饰在基础课本和更详尽的专著以及大量研究文献中都有详细的描述。修饰可以发生在多肽的任一位置,包括肽骨架、氨基酸侧链以及氨基或羧基末端。应该理解的是相同的修饰可以以同等程度或不同程度出现在给定多肽的数个位点。另外,给定的多肽可以包括多种类型的修饰。多肽可以是分支状的(遍在化的结果),可以是环形的,有或无分支。环形、分支状及分支环形多肽可以得自翻译后的天然加工或者可用合成方法来制备。修饰包括乙酰化、酰化、ADP-核糖基化、酰胺化、生物素化、共价连接黄素、共价连接亚铁血红素部分、共价连接核苷酸或核苷酸衍生物、共价连接脂类或脂类衍生物、共价连接磷脂酰肌醇(phosphotidylinositol)、交联、环化、形成二硫键、去甲基化、形成共价交联、生成胱氨酸、生成焦谷氨酸、甲酰化、γ-羧基化、糖基化、GPI锚定形成、羟基化、碘化、甲基化、豆蔻酰化、氧化、蛋白裂解性加工、磷酸化、异戊二烯化、外消旋化、硒代化(selenoylation)、磺化、借助转运-RNA向蛋白添加氨基酸如精氨酸化,以及遍在化(参见,例如,蛋白结构及分子特性,2nd Ed.,T.E.Creighton,W.H.Freeman and Company,New York,1993;Wold,F.,Post-translational Protein Modifications:Perspectives and Prospects,1-12,in Post-translational Covalent Modification ofProteins,B.C.Johnson,Ed.,Academic Press,New York,1983;Seifter et al.,“Analysis for protein modifications and nonprotein cofactors″,Meth Enzymol,182,626-646,1990,and Rattan etal.,“Protein Synthesis:PosttranslationalModifications and Aging″,Ann NY Acad Sci,663,48-62,1992)。
多肽序列的“片段″是指比参考序列短但是基本保留了与参考多肽相同的生物功能或活性的多肽序列。多核苷酸序列的“片段″是指比序列表中所列参考序列短的多核苷酸序列。
“变体″是指这样的多肽或多核苷酸序列,它们不同于参考多核苷酸或参考多肽,但是保留了参考多核苷酸或参考多肽的基本特性。多核苷酸的常见变体在核苷酸序列上不同于参考多核苷酸。该变体的核苷酸序列的改变可能改变或不改变由所述参考多核苷酸编码的多肽的氨基酸序列。核苷酸改变导致参考序列编码的多肽中氨基酸取代、添加、缺失、融合及截短,讨论见下文。多肽的常见变体在氨基酸序列上不同于参考多肽。通常,改变是有限的,从而使参考多肽的序列与该变体的序列在整体上是十分近似的,并且多个区域是相同的。变体和参考多肽之间可因1个或多个取代、插入、缺失的任意组合而在氨基酸序列上不同。取代或插入的氨基酸残基可以由或不由遗传密码子编码。常见的保守取代包括Gly,Ala;Val,Ile,Leu;Asp,Glu;Asn,Gln;Ser,Thr;Lys,Arg;以及Phe和Tyr。多核苷酸或多肽的变体可以是天然生成的,如等位基因,或者也可以是不知道能天然生成的变体。多核苷酸及多肽的非天然生成的变体可用诱变技术制备或直接合成。另外还包括的变体是具有1个或多个翻译后修饰的多肽,例如糖基化、磷酸化、甲基化、ADP核糖基化等。实施方案包括N-末端氨基酸的甲基化、丝氨酸及苏氨酸的磷酸化以及C-末端甘氨酸的修饰。
“等位基因″是指基因组特定座位上一个基因的2个或多个备选形式中的一种。
“多态性″是指一群体内基因组特定位置上核苷酸序列(以及编码的多肽序列,如果相关)的不同。
“单核苷酸多态性”(SNP)是指一群体内基因组的单个核苷酸位置上出现核苷酸变化。SNP可发生于基因组的一个基因内或多个基因间区域中。SNP可以用等位基因特异性扩增(ASA)来分析。这项操作需要至少3个引物。其中用到一种共同引物,它与待分析的多态性反向互补。该共同引物从多态性碱基起为50-1500bp。另外两个(或多个)引物是彼此基本相同的,但最后的3’碱基有所变动,以便与构成多态性的2个(或多个)等位基因之一匹配。然后在标本DNA上进行两个(或多个)PCR反应,每个PCR反应都使用上述共同引物和其中一种等位特异性引物。
本发明中的“剪接变体”是指来自相同的基因组DNA序列,但经历了不同的RNA剪接的的RNA分子。不同的RNA剪接发生在对初始RNA转录物进行剪接时,通常是为了除去内含子,它们导致制备出不只一种mRNA分子,其中的每一种都编码不同的氨基酸序列。剪接变体一词也指上述cDNA分子编码的蛋白质。
“同一性”是指通过序列对比测定出的两个或多个多肽序列或者是两个或多个多核苷酸序列之间的关系。通常,同一性是指在所比较的序列长度内两多肽序列之间氨基酸与氨基酸的对应性,或两多核苷酸序列之间核苷酸与核苷酸的对应性。
“%同一性”-对于不完全对应的序列,可以测定“%同一性”。通常将两种要进行比较的序列对应排列,以便得到序列间的最大相关程度。这包括为提高对应排列程度,在其中的1或两个序列中插入“间隙”。可以就每一参与比较的序列的全长来测定%同一性(称为整体对应排列),这特别适用于长度相等或非常近似的序列,或者也可以就指定长度的较短序列进行测定(称为局部对应排列),这更适用于长度不等的多个序列。
“相似性”是对两种多肽序列间相关程度作进一步更精确的测量。通常,“相似性”意指两多肽链的氨基酸间的对比,是在残基逐一对比水平上的对比,不仅涉及残基对之间的确切对应(如同一性的计算),也涉及并非确切对应的残基对,其中所述确切对应的残基对是指,其中每一残基来自参与对比的不同序列,所述并非确切对应的残基对是指,在进化的基础上,一残基可能要取代另一残基。这种可能性有一相关“分值”,可从中测算出两序列间的“%相似性”。
比较两或多序列间同一性及相似性的方法为本领域所熟知。因此例如,Wisconsin Sequence Analysis Package,版本9.1(Devereux J et al,NucleicAcids Res,12,387-395,1984,可得自Genetics Computer Group,Madison,Wisconsin,USA)中的程序,例如程序BESTFIT和GAP,可用来测定两种多核苷酸序列间的%同一性以及两种多肽序列间的%同一性和%相似性。BESTFIT使用Smith和Waterman的“局部同源性″算法(J Mol Biol,147,195-197,1981,Advances in Applied Mathematics,2,482-489,1981),找出两序列间最相似的单个区域。BESTFIT更适于比较长度上不近似的两种多核苷酸或两种多肽序列,该程序将较短序列假定为较长序列的一部分。比较过程中,GAP将两序列对应排列,根据Neddleman和Wunsch的算法(J Mol Biol,48,443-453,1970),找出“最大相似性”。GAP更适于比较近似等长的序列,期望对全长序列进行对应排列。优选地,每个程序中使用的参数“间隙权值″和“长度权值″对于多核苷酸序列分别为50和3,对于多肽序列则分别为12和4。优选地,在将待比的两序列最佳对应排列时测定%同一性和相似性。
用于测定序列间同一性和/或相似性的其它程序也为本领域所已知,例如BLAST程序家族(Altschul S F等,J Mol Biol,215,403-410,1990,AltschulS F等,Nucleic Acids Res.,25:389-3402,1997,可得自National Center forBiotechnology Information(NCBI),Bethesda,Maryland,USA,也可以从NCBI在www.ncbi.nlm.nih.Gov的主页获得)和FASTA(Pearson W R,Methods inEnzymology,183,63-99,1990;Pearson W R and Lipman D J,Proc Nat AcadSci USA,85,2444-2448,1988,是Wisconsin Sequence Analysis软件包的一部分)。
优选地,使用BLOSUM62氨基酸取代矩阵(Henikoff S and Henikoff J G.Proc.Nat.Acad Sci.USA,89,10915-10919,1992)进行多肽序列对比,其中包括在对比前首先将核苷酸序列翻译为氨基酸序列。
优选地,使用BESTFIT程序测定待测多核苷酸或多肽序列与作为参考的多核苷酸或多肽序列之间的%同一性,其中将所述待测序列与所述参考序列最进行最佳对应排列,并将程序的参数设为如上所述的缺省值。
“同一性指数”是序列相关程度的度量,其可用来比较候选序列(多核苷酸或多肽)和参考序列。因此,例如,与参考多核苷酸序列之间的同一性指数为0.95的候选多核苷酸序列可认为与参考序列是相同的,只是相对于参考序列的每100个核苷酸,在候选多核苷酸序列上有平均最多达5处差异。所述差异选自至少1个核苷酸缺失、取代、包括转换和颠换、或插入。这些差异可出现在参考多核苷酸序列5′或3′末端或者两末端之间的任一位置,可以单个地散布在参考序列的核苷酸之间,或者也可以以1个或多个连续集团的方式散布在参考序列内。换句话说,为了得到与参考多核苷酸序列间同一性指数为0.95的多核苷酸序列,可以使参考序列的每100个核苷酸中有平均最多达5个缺失、取代或插入,或其任一组合,如上文所述。必要时对其它同一性指数,例如0.96,0.97,0.98和0.99的情况也可以照此办理。
类似地,就多肽而言,与参考多肽序列之间的同一性指数为0.95的候选多肽序列可认为与参考序列是相同的,只是相对于参考序列的每100个氨基酸,在候选多肽序列上有平均最多达5处差异。所述差异选自至少1个氨基酸缺失、取代、包括保守和非保守、或插入。这些差异可出现在参考多肽序列的氨基末端或羧基末端或者两末端之间的任一位置,可以单个地散布在参考序列的氨基酸之间,或者也可以以1个或多个连续集团的方式散布在参考序列内。换句话说,为了得到与参考序列间同一性指数为0.95的多肽序列,可以使参考序列的每100个氨基酸中有平均最多达5个缺失、取代或插入,或其任一组合,如上文所述。必要时对其它同一性指数,例如0.96,0.97,0.98和0.99的情况也可以照此办理。
核苷酸或氨基酸差异数与同一性指数之间的关系可以表述为:
na≤Xa-(Xa·I)
其中,na为核苷酸或氨基酸差异的数目,
xa为序列表中所列序列的核苷酸或氨基酸的总数,
I为同一性指数,
·为乘法运算符,且
其中当xa和I的乘积为非整数时,要将其下舍为最接近的整数,然后再被xa减。
“同系物″是本领域的一个广义词汇,意指与参考序列间有很高的序列相关程度的多核苷酸或多肽序列。所述的相关程度可通过如上述测定两种序列之间的同一性和/或相似性的程度来定量。属于这一广义词汇范畴内的有“直向进化同系物″及“平行进化同系物″。“直向进化同系物″是指与另一物种中的多核苷酸或多肽功能等价的多核苷酸或多肽。“平行进化同系物″是指同一物种中功能类似的多核苷酸或多肽。
“融合蛋白″是指由两个,通常为互不相关的两个,融合基因或其片段编码的蛋白质。在一个举例中,EP-A-0 464 533-A公开了包括免疫球蛋白分子恒定区的不同部分和另一种人蛋白质或其部分的融合蛋白质。多数情况下,用免疫球蛋白Fc区域作为融合蛋白质的一部分有助于用于治疗和诊断,可以提高药物动力学特性[参见,例如,EP-A 0232 262]。另一方面,在某些用途时,在融合蛋白表达、检测及纯化后,需将Fc部分去掉。
所有出版物及参考文献,包括但不限于该说明书中引用的专利和专利申请,作为一个整体在此引入作为参考,如同每一单篇出版物或参考文献专门单独地引入作为参考。本申请请求优先权的任一专利申请也被完整引入作为参考,方式同上述出版物及参考文献。
表I
基因名称 | GSK基因ID | 核酸序列号 | 相应的蛋白序列号 |
sbg960509cbrecpt | 960509 | SEQ ID NO:1 | SEQ ID NO:45 |
sbg614126complfH | 614126 | SEQ ID NO:2SEQ ID NO:3 | SEQ ID NO:46SEQ ID NO:47 |
sbg120703RNase | 120703 | SEQ ID NO:4 | SEQ ID NO:48 |
sbg98530TS | 98530 | SEQ ID NO:5SEQ ID NO:6 | SEQ ID NO:49SEQ ID NO:50 |
sbg563917RDP | 63917 | SEQ ID NO:7SEQ ID NO:8 | SEQ ID NO:51SEQ ID NO:52 |
sbg618069LRR | 618069 | SEQ ID NO:9SEQ ID NO:10 | SEQ ID NO:53SEQ ID NO:54 |
sbg934114Relaxin | 934114 | SEQ ID NO:11 | SEQ ID NO:55 |
sbg99174LOX-like | 99174 | SEQ ID NO:12 | SEQ ID NO:56 |
sbg995002PIGR | 995002 | SEQ ID NO:13 | SEQ ID NO:57 |
sbg1033026C1q | 1033026 | SEQ ID NO:14SEQ ID NO:15 | SEQ ID NO:58SEQ ID NO:59 |
sbg1003675RNase | 1003675 | SEQ ID NO:16 | SEQ ID NO:60 |
sbg1015258PLM | 1015258 | SEQ ID NO:17 | SEQ ID NO:61 |
sbg1003328IG | 1003328 | SEQ ID NO:18SEQ ID NO:19 | SEQ ID NO:62SEQ ID NO:63 |
sbg1020829SGLT | 1020829 | SEQ ID NO:20 | SEQ ID NO:64 |
sb1005450UDPGT | 1005450 | SEQ ID NO:21SEQ ID NO:22 | SEQ ID NO:65SEQ ID NO:66 |
sbg1002620TIa | 1002620 | SEQ ID NO:23SEQ ID NO:24 | SEQ ID NO:67SEQ ID NO:68 |
sbg1002620TIb | 1002620 | SEQ ID NO:25 | SEQ ID NO:69 |
sbg102200MCTa | 102200 | SEQ ID NO:26SEQ ID NO:27 | SEQ ID NO:70SEQ ID NO:71 |
sbg102200MCTb | 102200 | SEQ ID NO:28 | SEQ ID NO:72 |
sbg1020380LYG | 1020380 | SEQ ID NO:29SEQ ID NO:30 | SEQ ID NO:73SEQ ID NO:74 |
sbg1007026SGLT | 1007026 | SEQ ID NO:31 | SEQ ID NO:75 |
sbg1012732GLUT | 1012732 | SEQ ID NO:32SEQ ID NO:33 | SEQ ID NO:76SEQ ID NO:77 |
sbg1012732GLUTb | 1012732 | SEQ ID NO:34 | SEQ ID NO:78 |
sbg1018172CSP | 1018172 | SEQ ID NO:35SEQ ID NO:36 | SEQ ID NO:79SEQ ID NO:80 |
sbg1004570ERGIC | 1004570 | SEQ ID NO:37SEQ ID NO:38 | SEQ ID NO:81SEQ ID NO:82 |
sbg1016995IGBrecpt | 1016995 | SEQ ID NO:39SEQ ID NO:40 | SEQ ID NO:83SEQ ID NO:84 |
sbg1151bSREC | 1151 | SEQ ID NO:41SEQ ID NO:42 | SEQ ID NO:85SEQ ID NO:86 |
sbg1399854ANK | 1399854 | SEQ ID NO:43SEQ ID NO:44 | SEQ ID NO:87SEQ ID NO:88 |
表II
基因名称 | 基因家族 | 同源性最接近的多核苷酸 | 同源性最接近的多肽 | 细胞定位(根据同源性) |
sbg960509cbrecpt | 糖结合受体 | GB:AC007395直接提交(1999年4月25日)Genome SequencingCenter,Washington University School of Medicine,4444 Forest Park Parkway,St.Louis,MO 63108,USA | 小鼠Kupffer细胞C型凝集素受体,gi:7949066(1996年10月25日)提交到DDBJ/EMBL/GenBank数据库。 | 膜结合型 |
sbg614126complfH | 补体因子H | SC:AL353809(2001年1月20日)由Sanger Centre,Hinxton,Cambridgeshire,CB10 1SA,UK.提交 | 人H因子类似物1,gi:11321587 Estaller,C.,Koistmen,V.,Schwaeble,W.,Dierich,M.P.,and Weiss,E.H.J.ImmunoL146,3190-3196(1991) | 分泌型 |
sbg120703RNase | RNA酶 | GB:AL157687(2000年5月24日)直接提交到EMBL/GenBank/DDBJ databases by Genoscope。 | 人角质细胞来源的RNA酶样蛋白geneseqp:Y44192由INNOGENETICS NV提交申请号和申请日:EP-943679-A1,22-SEP-99 | 分泌型 |
sbg98530TS | I型血小板反应蛋白 | GB:AC027307提交(2000年5月30日)Production SequencingFacility,DOE Joint Genome Institute,2800 MitchellDrive,Walnut Creek,CA 94598,USA | 小鼠RIKEN cDNA 2010109H09基因,gi:13385092The RIKEN Genome Exploration Research Group Phase IITeam and FANTOM Consortium.Nature 409,685-690(2001) | 分泌型 |
sbg563917RDP | 肾二肽酶 | GB:AC009077(1999年8月3日)由Production Sequencing Facility,DOE Joint Genome Institute,2800 Mitchell Drive,Walnut Creek,CA 94598,USA直接提交 | 推定的人金属肽酶(M19家族)gi:11641273 Chen,J.M,Fortunato,M.和Barrett,A.J提交(2000年11月2日)Chen J.M.,MRC MolecularEnzymology Laboratory,The Babraham Institute,Babraham,Cambridge,CB2 4AT,UK | 分泌型 |
表II(续)
基因名称 | 基因家族 | 同源性最接近的多核苷酸 | 同源性最接近的多肽 | 细胞定位(根据同源性) |
sbg618069LRR | 富含亮氨酸的重复蛋白 | GB:AL589765(2001年3月16日)由Sanger Centre,Hinxton,Cambridgeshire,CB10 1SA,UK提交。 | Macaca束状脑蛋白(fascicularis brain protein),gi:9651088(2000年7月28日)提交到DDBJ/EMBL/GenBank databases.KatsuyukiHashimoto,National Institute of Infectious Diseases,Division ofGenetic Resources;23-1,Toyama 1-chome,Shinjuku-ku,Tokyo162-8640,Japan | 膜结合型 |
sbg934114Relaxin | 胰岛素 | JGI:CIT978SKB_55O6Joint Genome Institute发现DoE/LLNL/LBNL/LANL. | 小鼠胰岛素样肽(松弛素/胰岛素样蛋白),gi:7387805Conklin D,Lofton-Day CE,Haldeman BA,Ching A,Whitmore TE,Lok S,Jaspers S.1999.基因组的s60:50-56. | 分泌型 |
sbg99174LOX-like | C型凝集素 | GB:AL137062直接提交(2000年8月9日)Sanger Centre,Hinxton,Cambridgeshire,CB10 1SA,UK. | 推定的小鼠蛋白,gi:12855891 The RIKEN Genome ExplorationResearch Group Phase II Team and FANTOM Consortium.Nature409,685-690(2001) | 膜结合型 |
sbg995002PIGR | 聚免疫球蛋白受体(PIGR) | GB:AC027192直接提交(2000年3月28日)Whitehead Institute/MITCenter for Genome Research,320 Charles Street,Cambridge,MA 02141,USA. | 人TANGO 354蛋白,geneseqp:B66271由(MILL-)MILLENNIUM PHARM INC提交申请号和申请日:WO200100673-A1,04-JAN-01 | 膜结合型 |
sb1033026C1q | C1q | GB:AL359736直接提交(22-AUG-2000)Sanger Centre,Hinxton,Cambridgeshire,CB10 1SA,UK. | 人脂肪细胞特异性分泌蛋白,gi:4757760Maeda,K.,Okubo,K,Shimomura,I.,Funahashi,T.,Matsuzawa,Y.和Matsubara,K.Biochem.Biophys.Res.Commun.221(2),286-289(1996) | 分泌型 |
表II(续)
基因名称 | 基因家族 | 同源性最接近的多核苷酸 | 同源性最接近的多肽 | 细胞定位(根据同源性) |
sbg1003675RNase | RNA酶 | EMBL:CNS01RIHEuropean Molecular Biology Laboratory发现 | 短尾毛丝鼠(Chinchilla brevicaudata)胰核糖核酸酶,gi:133205 Van Den Berg A,Van Den Hende-TimmerL,Beintema JJ.1976.Biochim Biophys Acta453:400-9. | 分泌型 |
sbg1015258PLM | 磷肌纤维蛋白(Phospholemman)(PLM) | GB:AL022345(1999年12月10日)由Sanger Centre,Hinxton,Cambridgeshire,CB10 1SA,UK直接提交 | 人磷肌纤维蛋白样蛋白,geneseqp:W51104由(HUMA-)HUMAN GENOME SCI INC提交申请号和申请日:WO9839448-A2,11-SEP-98 | 膜结合型 |
sbg1003328IG | 免疫球蛋白 | EMBL:HSBA536C5European Molecular Biology Laboratory发现 | 人免疫系统分子,geneseqp:B15536由(INCY-)INCYTE PHARM INC提交申请号和申请日:WO200060080-A2,12-OCT-00 | 膜结合型 |
sbg1020829SGLT | Na+/葡萄糖协同转运蛋白 | GB:AJ009617(1998年7月17日)由MPIMG,Abt.Lehrach,Max PlanckInstitut fuer Molekulare Genetik,Ihnestrasse 73,Berlin,14195,Germany直接提交 | 穴兔(Oryctolagus cuniculus)Na/葡萄糖协同转运蛋白,gi:520469 Pajor,A.M.1994 Biochim.BiophysActa 1194(2),349-51. | 膜结合型 |
sbg1005450UDPGT | UDP-葡糖苷酸转移酶(UDPGT) | GB:AC016612提交(1999年12月4日)Production Sequencing Facility,DOE Joint Genome Institute,2800 Mitchell Drive,WalnutCreek,CA 94598,USA | 人PRO1780蛋白,geneseqp:B24025由GENENTECH INC提交申请号和申请日:WO200053750-A1,14-SEP-00 | 膜结合型 |
sbg1002620TIa | 富含半胱氨酸的分泌蛋白(CRISP)胰蛋白酶抑制物 | GB:AC025280(2000年3月8日)由Production Sequencing Facility,DOEJoint Genome Institute,2800 Mitchell Drive,Walnut Creek,CA94598,USA提交 | 人假拟蛋白(human hypothetical protein)DKFZp434B044,gi:13899332 Wiemann,S.,Weil,B.et al.Genome Res.11(3),422-435(2001) | 分泌型 |
表II(续)
基因名称 | 基因家族 | 同源性最接近的多核苷酸 | 同源性最接近的多肽 | 细胞定位(根据同源性) |
sbg1002620TIb | 富含半胱氨酸的分泌蛋白(CRISP)胰蛋白酶抑制物 | GB:AC025280(2000年3月8日)由Production Sequencing Facility,DOE Joint Genome Institute,2800 Mitchell Drive,WalnutCreek,CA 94598,USA直接提交 | 大鼠晚期妊娠肺蛋白1,gi:4324682Kaplan,F.,Ledoux,P.,Kassamali,F.Q.,Gagnon,S.,Post,M.,Koehler,D.,Deimling,J and Sweezey,N.B.Am.J.Physiol.276(6),L1027-L1036(1999) | 分泌型 |
sbg102200MCTa | 单羧酸酯协同转运蛋白(MCT1) | GB:AC015918(1999年11月17日)由Whitehead Institute/MIT Centerfor Genome Research,320 Charles Street,Cambridge,MA 02141,USA.直接提交 | 未命名的小鼠蛋白产物,gi:7670446(2000年4月12日)提交到DDBJ/EMBL/GenBank databases by KatsuyukiHashimoto,National Institute of Infectious Diseases,Division of Genetic Resources;23-1,Toyama 1-chome,Shinjuku-ku,Tokyo 162-8640,Japan | 膜结合型 |
sbg102200MCTb | 单羧酸酯协同转运蛋白(MCT1) | GB:AC015918(1999年11月17日)由Whitehead Institute/MIT Centerfor Gcnome Research,320 Charles Street,Cambridge,MA 02141,USA.直接提交 | 人溶质载体16(单羧酸协同转运蛋白),成员8,gi:13655082(2001年4月27日)由National Center forBiotechnology Information,NIH,Bethesda,MD 20894,USA提交 | 膜结合型 |
sbg1020380LYG | 性病肉芽肿型溶菌酶(Goose-typelysozyme)G | GB:AC023965(2000年2月20日)由Whitehead Institute/MIT Centerfor Genome Research,320 Charles Street,Cambridge,MA 02141,USA直接提交 | 溶菌酶G(1,4-β-N-乙酰胞壁质酶E)(性病肉芽肿型溶菌酶)gi:126634 Schoentgen,F.,Jolles,J.and Jolles,P.Eur.J.Biochem.123(3),489-497(1982) | 分泌型 |
sbg1007026SGLT | 钠-葡萄糖协同转运蛋白 | GB:AC046167直接提交(2000年4月13日)Whitehead Institute/MITCenter for Genome Research,320 Charles Street,Cambridge,MA02141. | 人转运蛋白TPPT-13,geneseqp:B60093由INCYTE基因组的SINC提交申请号和申请日:WO200078953-A2,28-DEC-00 | 膜结合型 |
表II(续)
基因名称 | 基因家族 | 同源性最接近的多核苷酸 | 同源性最接近的多肽 | 细胞定位(根据同源性) |
sbg1012732GLUT | 葡萄糖转运蛋白 | GB:AP000350(1999年6月10日)提交到DDBJ/EMBL/GenBankdatabases.Nobuyoshi Shimizu,Keio university,school ofmedicine,Molecular Biology;35 Shinanomachi,Shinjuku-ku,Tokyo 160-0016,Japan. | 人葡萄糖转运蛋白GLUT10,gi:13540598提交(2000年2月10日)Joost H.G.,Institute of Pharmacology and Toxicology,MedicalFaculty,Technical University of Aachen,Wendlingweg2,Aache,D-52057,GERMANY | 膜结合型 |
sbg1012732GLUTb | 葡萄糖转运蛋白 | GB:AP000350(1999年6月10日)提交到DDBJ/EMBL/GenBankdatabases.Nobuyoshi Shimizu,Keio university,school ofmedicine,Molecular Biology;35 Shinanomachi,Shinjuku-ku,Tokyo 160-0016,Japan. | 人葡萄糖转运蛋白GLUT10,gi:13540598提交(2000年2月10日)Joost H.G.,Institute of Pharmacology andToxicology,Medical Faculty,Technical University ofAachen,Wendlingweg 2,Aachen,D-52057,GERMANY | 膜结合型 |
sbg1018172CSP | 硫酸软骨素蛋白聚糖 | EMBL:AL354819,和SC:AL590007.提交(2001年4月30日和2001年5月4日)由Sanger Centre,Hinxton,Cambridgeshire,CB10 1SA,UK.EMBL:AC017111,Submitted(09-DEC-1999)Genome Sequencing Center,Washington University School of Medicine,4444 ForestPark Parkway,St.Louis,MO 63108,USA提交 | 杂色松海胆胚胎囊胚腔胞外基质蛋白(Lytechinusvariegatus embryonic blastocoelar extracellular matrixprotein),gi:9837426提交(2000年7月14日)Biological Sciences,Carnegie Mellon University,4400Fifth Ave,Pittsburgh,PA 15213,USA | 分泌型 |
sbg1004570ERGIC | ER-Golgi中间室蛋白(intermediatecompartmentprotein) | GB:AC020705提交(2000年1月8日)Genome Sequencing Center,Washington University School of Medicine,4444 ForestPark Parkway,St.Louis,MO 63108,USA | 人ERGL蛋白,gi:11141891提交(2000年9月6日)Laboratory of Molecular Biology,NCI,NIH,37Convent Dr.,Bldg.37,Rm.4B20,Betgesda,MD 20892,USA | 膜结合型 |
表II(续)
基因名称 | 基因家族 | 同源性最接近的多核苷酸 | 同源性最接近的多肽 | 细胞定位(根据同源性) |
sbg1016995IGBrecpt | 免疫球蛋白受体 | GB:AL353721提交(2001年7月7日)Sanger Centre,Hinxton,Cambgeshire,CB101SA,UK. | 人免疫球蛋白超家族受体转运相关型1,gi:14550416 Hatzivassiliou,G.,Miller,I.J.,Takizawa,J.,et al.Immumty 14(3),277-289(2001) | 膜结合型 |
sbg1151bSREC | EGF-样LDL受体蛋白 | GB:AC005500Chen,F.,D,L.,Do,T.,Dumanski,J.P.和Roe,B.A.直接提交(01年5月31日)Department Of Chemistry and Biochemistry,The University OfOklahoma,620 Parrington Oval,Room 208,Norman,OK 73019,USA | 人抚育细胞受体(Human nurse cellreceptor)B6TNC#10b,geneseqp:B60395由(SHIO)SHIONOGI& COLTD提交,申请号和申请日:JP2000308492-A,07-NOV-00 | 膜结合型 |
sbg1399854ANK | 锚蛋白重复家族 | GB:AC020658直接提交(2000年1月8日)Multimegabase Sequencing Center,University of Washington,PO BOX 357730,Seattle,WA 98195,USA | 人KIAA1223蛋白,gi:6330617NagaseT,IshikawaK,Kikuno R,Hirosawa M,Nomura N,and OharaO;1999 DNA Res 6:337-45. | 胞质型 |
表III
基因名称 | 用途 | 相关疾病 |
Sbg960509cbrecpt | 本发明的一个实施方案是Sbg960509cbrecpt在治疗或诊断癌症方面的用途。与Sbg960509cbrecpt接近的一个同系物是Langerin。Langerin是II型Ca2+依赖型凝集素,它是一种内吞受体,由朗格汉斯细胞(LC)表达。将Langerin的cDNA转染到成纤维细胞中可产生具有Birbeck颗粒(BG)典型特征的膜结构的致密网状物。这提示对BG的诱导是Langerin捕捉抗原的功能的结果,其开辟了进入这些细胞器的途径,提供了进入非传统抗原呈递途径的通路(Valladeau J,RavelO,Dezutter-Dambuyant C,Moore K,Kleijmeer M,Liu Y,Duvert-Frances V,Vincent C,Schmitt D,Davoust J,Caux C,Lebecque S,Saeland S.2000.Immunity Jan;12(1):71-81)。在正常和转化的人肝细胞中,第二种脱唾液酸糖蛋白受体多肽H2的不同剪接的转录物之间可发现明显的不一致(Paietta E,Stockert RJ,Racevskis J.1992.Hepatology Mar;15(3):395-402)。已证明人的巨噬细胞表面C型凝集素可识别Tn抗原,一种公知的人的癌相关表位(Suzuki N,Yamamoto K,Toyoshima S,Osawa T,Irimura T.1996.J Immunol Jan 1;156(1):128-35)。 | 自身免疫性疾病和癌 |
Sbg614126complfH | 本发明的一个实施方案是Sbg614126complfH在癌,阿尔茨海默氏病,和/或肿瘤细胞逃逸的诊断或治疗方面的用途。与Sbg614126complfH接近的一个同系物是人补体因子H。人补体因子H可用AM34抗体在阿尔茨海默氏病患者的脑脊液中检测到。近来发现,AM34能使衰老斑的染色呈阳性,因子H与人脑中衰老斑有关(Honda S,Itoh F,YoshimotoM,Ohno S,Hinoda Y,Imai K.2000.J Gerontol A Biol Sci Med Sci.May;55(5):M265-9)。此外还提示,人H2成胶质细胞瘤细胞对补体介导的杀伤的特殊抗性可归因于因子H和因子H样蛋白1的产生和结合(Junnikkala S,Jokiranta TS,Friese MA,Jarva H,Zipfel PF,Meri S.2000.J Immunol.Jun 1;164(11):6075-81)。而且,因子H显示可结合骨涎蛋白和骨桥蛋白,并可使肿瘤细胞逃逸补体介导的攻击(Fedarko NS,Fohr B,Robey PG,Young MF,Fisher LW.2000.J BiolChem.Jun 2;275(22):16666-72)。最后,补体因子H基因的突变与常染色体隐性非典型性溶血性尿毒症综合征(autosomal recessive atypical hemolytic uremic syndrome)相关(Ying L,Katz Y,Schlesinger M,Carmi R,Shalev H,Haider | 阿尔茨海默氏病,癌,肿瘤转移和常染色体隐性非典型性溶血性尿毒症综合征 |
N,Beck G,Sheffield VC,Landau D.1999.Am J Hum Genet Dec;65(6):1538-46)。 | ||
Sbg120703RNase | 本发明一个实施方案是将Sbg120703RNase用作抗癌治疗和凋亡相关疾病治疗的工具。已显示基因改造后的胰腺RNA酶对小鼠和人肿瘤细胞有细胞毒作用,但对人和小鼠的正常细胞无任何可检测到的毒性。这种人胰腺RNA酶的变体选择性地使来源于人甲状腺肿瘤的细胞对凋亡性死亡敏感。因为其对肿瘤细胞的选择性并且因为其来源于人,该蛋白被认为代表抗癌治疗的一种有希望的工具(Piccoli R,Di Gaetano S,De Lorenzo C,Grauso M,Monaco C,Spalletti-Cernia D,Laccetti P,Cinatl J,Matousek J,D’alessio G.1999.Proc Natl Acad Sci USA 96:7768-73)。另外,RNA酶本身也可以用于治疗RNA病毒感染,其拮抗剂可用于治疗与凋亡有关的疾病。 | 癌和感染 |
Sbg98530TS | 本发明的一个实施方案是Sbg98530TS在伤口愈合过程,神经系统发育,和影响细胞迁移,存活或血管发生方面的用途。月Sbg98530TS接近的一个同系物是血小板反应蛋白。血小板反应蛋白是一个蛋白家族,广泛存在于胚胎的细胞外基质,多种血小板反应蛋白的表达模式和体外特性提示,其对细胞和生长锥迁移,尤其在神经系统发育期间细胞和生长锥的迁移可能有指导作用(Adams JC,2000.Tucker RP Dev Dyn 218:280-99)。细胞与细胞外基质的相互作用对在细胞转化和肿瘤发生过程中所产生的病理变化是重要的。已提示血小板反应蛋白-1可通过影响细胞的迁移,存活或血管发生来调节肿瘤的表型(Liaw L,Crawford HC.1999.Braz J Med Bio Res 32:805-12)。另外,血小板反应蛋白-1也是在组织发育和修复过程中细胞外基质的瞬时成分(Adams JC.1997.Int J Biochem Cell Biol 29:861-5)。 | 癌,伤口愈合性疾病 |
Sbg563917RDP | 本发明的一个实施方案是Sbg563917RDP在治疗或诊断慢性肾衰竭和老化的眼晶状体和白内障方面的用途。与Sbg563917RDP接近的同系物是肾脏和晶状体二肽酶。已报道肾脏二肽酶活性在慢性肾衰竭组中明显下降(FukumuraY,Kera Y,Oshitam S,Ushijima Y,Kobayashi I,LiuZ,Watanabe T,Yamada R,Kikuchi H,Kawazu S and Yabuuchi M.1999 Ann Clin Biochem Mar;36(Pt2):221-5)。相反,在老化和白内障中检测到晶状体二肽酶的活性增强(Sulochana KN,Ramakrishnan S and Punitham R.1999 Br J Ophthalmol Jul;83(7):885)。 | 肾脏疾病,老化,白内障,癌和阿尔茨海默氏病 |
Sbg618069LRR | 本发明的一个实施方案是Sbg618069LRR在治疗或诊断神经发育和成年神经系统疾病方面的用途。与Sbg618069LRR | 触角相关疾病,与胃肠 |
接近的一个同系物是富含亮氨酸的重复蛋白。富含亮氨酸的重复蛋白,这种无刺触芒足(spineless-aristapedia)已显示与触角(tango)bHLH-PAS蛋白相互作用,以控制果蝇中触角和跗节的发育(Emmons RB,Duncan D,Estes PA,Kiefel P,Mosher JT,Sonnenfeld M,Ward MP,Duncan I and Crews ST.1999.Development Sep;126(17):3937-45)。在小鼠,神经元中富亮氨酸重复的NLRR-1和NLRR-2mRNA主要在中枢神经系统表达,且在神经元发育和成人神经系统中发挥明显但不同的作用(Taguchi A,Wanaka A,Mori T,Matsumoto K,Imai Y,Tagaki T and Tohyama M.1996.Brain Rea MolBrain Res Jan;35(1-2):31-40)。而且,富含亮氨酸的重复蛋白超家族的新成员GAC1可在恶性神经胶质瘤中得到扩增和过表达(Almeida A,Zhu XX,Vogt N,Tyagi R,Muleris M,Dutrillaux AM,Dutrillaux B,Ross D,Malfoy B and HanashS.1998.Oncogene Jun 11;16(23):2997-3002)。 | 粘膜的保存和维持以及急性和慢性粘膜损伤修复有关的疾病,帕金森氏病,阿尔茨海默氏病,ALS,神经病,癌,伤口愈合和组织修复 | |
Sbg934114Relaxin | 本发明的一个实施方案是Sbg934114Relaxin在治疗或诊断胶原重建,乳腺癌,和子宫收缩性疾病方面的用途。Sbg934114Relaxin接近的一个同系物是松弛素。松弛素有各种生物学活性,包括诱导胶原重建和随后在分娩过程中使产道组织软化,抑制子宫收缩活性和刺激乳腺的生长和分化(Bani D.1997.GenPharmacol 28:13-22)。松弛素属于胰岛素超家族,主要由妊娠和非妊娠女性的黄体产生。在男性体内,松弛素在前列腺中合成并被释放到精液中(GoldsmithLT,Weiss G,Steinetz BG.1995.0Endocrinol Metab Clin North Am 24:171-86)。已进一步证明,松弛素可调节培养的乳腺癌细胞的生长和分化,促进多种器官,包括子宫,乳腺,肺脏和心脏中血管的扩张,对心脏有变时作用(chronotropicaction),抑制肥大细胞释放组胺,抑制血小板聚集和巨核细胞释放血小板,影响脑垂体的激素分泌(Bani D.1997.GenPharmacol 28:13-22)。另外,一些报道显示松弛素对减少全身性硬皮病中皮肤的累及是有效的(Furst DE 1998.CurrOpin Rheumotol 10:123-8)。 | 癌,类风湿性疾病,心脏疾病,全身性硬皮病和早产 |
Sbg99174LOX-like | 本发明的一个实施方案是Sbg99174LOX-like在治疗或诊断内皮细胞功能或动脉粥样硬化中的用途。Sbg99174LOX-like接近的一个同系物是氧化的低密度脂蛋白受体1。Sbg99174LOX-like和氧化的低密度脂蛋白受体1,包含C型凝集素功能域(CTL)(Colonna M,Samaridis J,Angman L.2000.Eur J Immunol 30:697-704)。有证据提示氧 | 心血管疾病(例如动脉粥样硬化,高血压,发作综合征(stroke)) |
化的低密度脂蛋白(OxLDL)在内皮细胞功能改变中起关键作用。凝集素样OxLDL受体1(LOX-1)是主要的内皮细胞OxLDL受体。内皮细胞功能改变可见于动脉粥样硬化发病的最早期阶段(Aoyama T,Sawanmura T,Furutani Y,Matsuoka R,Yoshida MC,Fujiwara H,Masaki T.Biochem J.1999 339(Pt1):177-84)。 | ||
Sbg995002PIGR | 本发明的一个实施方案是Sbg995002PIGR将IgA和IgM主动转运到上皮细胞顶端表面(apical surface)的用途。Sbg995002PIGR接近的一个同系物是多聚免疫球蛋白受体。多聚免疫球蛋白受体结合上皮细胞基底外侧表面的多聚IgA和IgM。PIGR敲除小鼠完全缺失主动的外部IgA和IgM的转运,但仍保持正常,并有生育能力(fertile)(JohansenFE,Pekna M,Norderhaug IN,Haneberg B,Hietala MA,Krajci P,Betsholtz C,Brandtzaeg P.1999.J Exp Med190:915-22)。另外,已有报道,PIGR能被肿瘤坏死因子(TNF)-α上调(Takenouchi-Ohkubo N,Takahashi T,Tsuchiya M,Mestecky J,Moldoveanu Z,Moro I;2000.Immunogenetics 51:289-95)。 | 感染和炎症(如炎症性肠疾病,麸质敏感型肠病和尿道感染) |
Sbg1033026C1q | 本发明的一个实施方案是Sbg1033026C1q调节中枢神经系统功能的用途。与Sbg1033026C1q接近的一个同系物是C1q相关因子。C1q是活化血清补体系统的C1酶复合物的一种亚单位。已显示人的C1q相关因子(CRF)转录物在脑中,尤其在脑干中表达的水平最高。类似的,在小鼠脑中,CRF的转录物在参与运动功能的神经系统区域最丰富(Berube NG,Swanson XH,Bertram MJ,Kittle JD,Didenko V,Baskin DS,Smith JR,and Pereira-Smith OM.,1999,BrainRes.Mol.BrainRes.63:233-240)。而且,ACRP30在结构上类似于补体因子C1q,其形成大的同型寡聚体,执行一系列的翻译后修饰。ACRP30蛋白可能是参与与食物摄入,糖分解代谢和脂肪分解代谢有关的能量守恒的复合物平衡系统的因子(Scheer PE,Williams S,Fogliano M,Baldini G,Lodish HF;1995;J Biol Chem 270:26746-9)。 | 中枢神经系统疾病 |
Sbg1003675RNase | 本发明的一个实施方案是Sbg1003675RNase作为一种有前途的工具,用于抗癌治疗和凋亡相关疾病的用途。与Sbg1003675RNase接近的一个同系物是RNA酶。已显示,基因工程改造后的胰腺RNA酶对小鼠和人肿瘤细胞有细胞毒作用,但对人和小鼠正常细胞没有任何可检测到的毒性。这种人胰腺RNA酶的变体选择性地使来源于人甲状腺肿瘤的细胞对凋亡性死亡敏感。因为其对肿瘤细胞的选择性并且因为它来源于人,该蛋白被认为代表抗癌治疗的一 | 病毒感染和肿瘤 |
种有希望的工具(Piccoli R,Di Gaetano S,De Lorenzo C,Grauso M,Monaco C,Spalletti-Cernia D,Laccetti P,Cinatl J,Matousek J,D’Alessio G.1999 Proc Natl Acad Sci USA96:7768-73)。另外,RNA酶本身也可以用于治疗RNA病毒感染,其拮抗剂可用于治疗与凋亡有关的疾病。 | ||
Sbg1015258PLM | 本发明的一个实施方案是Sbg1015258PLM调节骨骼肌和心肌疾病方面的用途。与Sbg1015258PLM接近的一个同系物是磷肌纤维蛋白。磷肌纤维蛋白(PLM)在骨骼肌和心脏中含量丰富,且是对胰岛素和肾上腺素能刺激发生应答而被磷酸化的主要底物。所有磷肌纤维蛋白都是具有单一跨膜区的小蛋白(Chen LS,O1 CF,Numann R,Cuddy M.1997.Genomics 41:435-4)。磷肌纤维蛋白可被蛋白激酶A和蛋白激酶C磷酸化以诱导被超极化作用活化的氯电流,从而在肌肉收缩中起作用。近来显示磷肌纤维蛋白是肌强直性营养不良蛋白激酶的底物,并因此与该疾病有关,所述疾病是对骨骼肌和心肌有明显作用的常染色体显性遗传疾病(Mounsey JP,John JE 3rd,Helmke SM,Bush EW,Gilbert J,Roses AD,Perryman MB,Jones LR,Moorman JR,Moorman JR.2000.J Bio Chem;275:23362-7)。 | 肌强直性肌营养不良 |
Sbg1003328IG | 本发明的一个实施方案是Sbg1003328IG产生免疫抑制剂以抑制免疫应答的用途。与Sbg1003328IG接近的一个同系物是V7,一种人白细胞表面蛋白(Stockinger H,Gadd SJ,Eher R,Majdic O,Schreiber W,Kasinrerk W,Strass B,SchnablE,Knapp W.1990.J Immunol 145:3889-97)。Sbg1003328IG是一种免疫球蛋白(Ig)样膜蛋白,包含三个潜在的Ig区,且其总体上与V7有很强的序列相似性。 | 癌,感染,自身免疫性疾病,造血性疾病,伤口愈合性疾病和炎症 |
Sbg1020829SGLT | 本发明的一个实施方案是Sbg1020829SGLT调节Na(+)-依赖性葡萄糖转运的用途。与Sbg1020829SGLT接近的一个同系物是Na(+)/葡萄糖协同转运蛋白。人肠Na(+)/葡萄糖协同转运蛋白(SGLT1)已被克隆和测序。已发现人和兔的肠Na(+)/葡萄糖协同转运蛋白之间有接近的同源性,这些蛋白和大肠杆菌Na(+)/脯氨酸协同转运蛋白(putP)有明显的同源性,这提示哺乳动物Na(+)/葡萄糖协同转运蛋白和原核生物Na(+)/脯氨酸协同转运蛋白有共同的祖先基因(HedigerMA,Turk E,Wright EM.1989 Proc Natl Acad Sci USA Aug;86(15):5748-52)。另外,对葡萄糖/半乳糖吸收障碍(GCM)的患者进行肠组织活检发现,刷状缘中Na(+)-依赖性葡萄糖吸收有特异性缺陷。在从患GGM的家族成员的基因组 | 癌,感染,自身免疫性疾病,造血性疾病,伤口愈合性疾病,炎症和葡萄糖/半乳糖吸收障碍 |
DNA扩增得到的SGLT1中发现有单个错义突变。该突变的SGLT1与GGM表型共分离,并在注射了这种互补RNA的非洲爪蟾卵母细胞中导致Na(+)-依赖性葡萄糖转运的完全丧失(Turk E,Zabel B,Mundlos S,Dyer J,Wright EM.1991 Nature Mar 28;350(6316):354-6)。 | ||
sbg1005450UDPGT | 本发明的一个实施方案是sbg1005450UDPGT调节外周类固醇靶组织中雌激素和雄激素分解代谢的用途。与sbg1005450UDPGT接近的一个同系物是UDP-葡糖苷酸转移酶(UDPGT)基因。已发现在由肝胆红素UDPGT活性下降导致II型Crigler-Najjar综合征的7名患者中,UDP-葡糖苷酸转移酶(UDPGT)基因的启动子和编码区有突变(Yamamoto K,Soeda Y,Kamisako T,Hosaka H,Fukano M,Sato H,Fujiyama Y,Adachi Y,Satoh Y,Bamba T.1998.JHum Genet 43(2):111-4)。另报道了一例由胆红素UDPGT基因的纯合错义突变所致的Gilbert综合征(Maruo Y,Sato H,Yamano T,Doida Y,Shimada M.1998.J Pediatr Jun;132(6):1045-7)。另外,已克隆出猴子UDPGTUGT1A9,其mRNA在肝外雌激素应答型组织中得到表达,这提示其在雌激素代谢中潜在的作用(Albert C,Vallee M,Beaudry G,BelangerA,Hum DW.1999.Endocrinology Jul;140(7):3292-302)。人UDPGTUGT2B23转录物也在肝外组织包括前列腺,乳腺,附睾,睾丸和卵巢中得到表达。UGT2B23的活性可用62种潜在的内源性底物检测,证明该活性对6种类固醇和胆汁酸,猪脱氧胆酸是起作用的,这提示UGT2B23可能在外周类固醇靶组织中雌激素和雄激素的分解代谢方面起重要作用(Barbier O,Levesque E,Belanger A,Hum DW.1999.Endocrinology Dec;140(12):5538-48)。 | 癌,感染,自身免疫性疾病,造血性疾病,伤口愈合性疾病,炎症,Gilbert综合征,II型Crigler-Najjar综合征(CN)和类固醇激素分解代谢机能障碍 |
sbg1002620TIa | 本发明一个实施方案是sbg1002620TIa调节人肿瘤细胞的用途。与sbg1002620TIa接近的一个同系物是人假拟蛋白DKFZp434B044。该基因也类似于在其N末端区包含Sc7家族的胞外区的胰蛋白酶抑制蛋白(Genome Res.11(3),422-435(2001))。胰蛋白酶抑制蛋白P25TI序列与CRISP家族蛋白有相似性,所述CRISP家族蛋白包含昆虫毒液过敏原,哺乳动物睾丸特异性蛋白和植物致病性相关蛋白。编码P25TI和另外两种神经胶质瘤致病性相关蛋白GliPR和RTVP-1(它们也显示在结构上与CRISP家族蛋白类似)的mRNA,在人肿瘤组织中频繁表达,但在正常人组织细胞系中未检测到(Yamakawa T,Miyata S,Ogawa N,Koshikawa N,Yasumitsu H,Kanamori T,Miyazaki K 1998.Biochim | 癌,感染,自身免疫性疾病,造血性疾病,伤口愈合性疾病,炎症,血液凝固性疾病,细胞粘附性疾病,胰腺炎,休克,多器官衰竭和胃 |
Biophys Acta Jan 21;1395(2):202-8.,Murphy EV,Zhang Y,Zhu W,Biggs J.1995.Gene Jun 14;159(1):131-5.,Rich T,Chen P,Furman F,Huynh N,Israel MA.1996.Gene Nov 21;180(1-2):125-30)。 | 肠溃疡 | |
sbg1002620TIb | 本发明的一个实施方案是sbg1002620TIb作为一些神经系统肿瘤的标志物的用途,和调节人神经母细胞瘤和成胶质细胞瘤的表达的用途。与sbg1002620TIb接近的一个同系物是妊娠晚期肺1(LGLI)蛋白。妊娠晚期肺1(LGLI)蛋白与P25TI,这种纯化自人成胶质细胞瘤细胞培养基的胰蛋白酶抑制蛋白显示81%的同源性(Kaplan F,Ledoux P,KassamaliFQ,Gagnon S,Post M,Koehler D,Deimling J,Sweezey NB.1999.Am J Physiol Jun;276(6 Pt 1):L1027-36;KoshikawaN,Nakamura T,Tsuchiya N,Isaji M,Yasumitsu H,Umeda M,Miyazaki K.1996.J Biochem(Tokyo)Feb;119(2):334-9)。分离编码P25TI的cDNA,该序列与CRISP家族蛋白有相似性,所述CRISP家族蛋白包括昆虫毒液过敏原,哺乳动物睾丸特异性蛋白和植物致病性相关蛋白。P25TI mRNA通常在人神经母细胞瘤和成胶质细胞瘤中表达,但未在正常人组织细胞系中检测到(Yamakawa T,Miyata S,Ogawa N,Koshikawa N,Yasumitsu H,KanamoriT,Miyazaki K 1998.Biochim Biophys Acta Jan 21;1395(2):202-8)。另外两种神经胶质瘤致病相关蛋白GliPR和RTVP-1也显示在结构上与CRISP家族蛋白类似。GLIPR在人脑肿瘤,多形成胶质细胞瘤/星形细胞瘤中高表达,但在正常胎儿和成年脑组织中不表达,在神经系统其它肿瘤中也不表达(Murphy EV,Zhang Y,Zhu W,Biggs J.1995.Gene Jun 14;159(1):131-5)。多种RTVP-1 mRNA在一组起源自胶质的神经系统肿瘤的细胞系中高表达,但这些RNA在非胶质来源的神经系统肿瘤细胞系中低表达或不表达(Rich T,Chen P,Furman F,Huynh N,Israel MA 1996.GeneNov 21;180(1-2):125-30). | 肿瘤,感染,自身免疫性疾病,造血性疾病,伤口愈合性疾病,炎症,血液凝固性疾病,细胞粘附性疾病,胰腺炎,休克,多器官衰竭和胃肠溃疡 |
sbg102200MCTa | 本发明的一个实施方案是sbg102200MCTa调节包括造血细胞系,Burkitt′s淋巴瘤和实体肿瘤的细胞在内的癌细胞的用途。与sbg102200MCTa接近的一个同系物是来自中国仓鼠和小鼠的MCT1。从Ehrlich Lettre肿瘤细胞中已克隆到小鼠H+-单羧酸协同转运蛋白(MCT1)并进行了测序,发现该MCT1的序列与来自中国仓鼠和人的MCT1序列分别有93%和87%的同源性。N-聚糖酶(glycanase)-F治疗和体外翻译实验证明糖基化对MCT1的功能不是必需的(Carpenter | 癌,感染,自身免疫性疾病,造血性疾病,伤口愈合性疾病和炎症 |
L,Poole RC,Halestrap AP.1996.Biochim Biophys Acta Mar 13;1279(2):157-63)。已发现,从视网膜色素上皮(RPE)cDNA文库中克隆到的小鸡单羧酸协同转运蛋白MCT3仅在RPE细胞中表达。用pCl-neo/MCT3转染的大鼠甲状腺上皮细胞系FRTL显示丙酮酸的摄取增强,这提示MCT3可调节眼内光感受器间隙(interphotoreceptor space)中的乳酸水平(Yoon H,Fanelli A,Grollman EF,Philp NJ.1997 Biochem Biophys Res Commun May 8;234(1):90-4)。在人类,MCT2被视为人体内主要的丙酮酸转运蛋白。在各种人肿瘤细胞系中发现MCT1和MCT2的mRNA是共表达的,所述肿瘤细胞系中包括造血细胞系HL60,K562,MOLT-4,Burkitt’s淋巴瘤Raji和实体肿瘤细胞如SW480,A549和G361。这些发现提示人MCT1和MCT2可能有不同的的生物学作用(LinRY,Vera JC,Chaganti RS,Golde DW.1998.J Biol Chem Oct 30;273(44):28959-65)。 | ||
sbg102200MCTb | 本发明的一个实施方案是sbg102200MCTb调节癌细胞,包括造血细胞系,Burkitt’s淋巴瘤和实体肿瘤的细胞的用途。与sbg102200MCTb接近同系物是来自中国仓鼠和小鼠的MCT1。从Ehrlich Lettre肿瘤细胞中已克隆到小鼠H+-单羧化物协同转运蛋白(MCT1)并进行了测序,发现该MCT1的序列与来自中国仓鼠和人的MCT1序列分别有93%和87%的同源性。N-聚糖酶-F治疗和体外翻译实验证明糖基化对MCT1的功能不是必需的(Carpenter L,Poole RC,HalestrapAP.1996.Biochim Biophys Acta Mar 13;1279(2):157-63)。已发现,从视网膜色素上皮细胞(RPE)cDNA文库中克隆到的小鸡单羧酸协同转运蛋白MCT3仅在RPE细胞中表达。用pCl-neo/MCT3转染的大鼠甲状腺上皮细胞系FRTL显示丙酮酸的摄取增强,这提示MCT3可调节眼内光感受器间隙中的乳酸水平(Yoon H,Fanelli A,Grollman EF,PhilpNJ.1997.Biochem Biophys Res Commun May 8;234(1):90-4)。在人类,MCT2被视为人体内主要的丙酮酸转运蛋白。在各种人肿瘤细胞系中发现MCT1和MCT2的mRNA共表达,所述肿瘤细胞系中包括造血细胞系HL60,K562,MOLT-4,Burkitt’s淋巴瘤Raii和实体肿瘤细胞如SW480,A549和G361。这些发现提示人MCT1和MCT2可能有不同的的生物学作用(Lin RY,Vera JC,Chaganti RS,Golde DW.1998.J Biol Chem Oct 30;273(44):28959-65)。 | 癌,感染,自身免疫性疾病,造血性疾病,伤口愈合性疾病和炎症 |
Sbg1020380LYG | 本发明的一个实施方案是Sbg1020380LYG在免疫系统和提高免疫制剂的活性方面的用途,且其可充当牙周组织疾病 | 癌,感染,自身免疫性 |
活动性的生物标志物。与Sbg1020380LYG接近的一个同系物是溶菌酶。溶菌酶是使细菌裂解的防御性物质,并且已被改造以起消化作用(Qasba PK,Kumar S,1997,Crit Rev Biochem Mol Biol 32:255-306)。在组织和体液中的那些溶菌酶参与免疫系统,并可提高免疫制剂的活性。溶菌酶也可作为来源于炎症细胞的牙周组织疾病活动性的生物标志物(Eley BM,and Cox SW,1998,Br Dent J 184:323-8)。 | 疾病,造血性疾病,伤口愈合性疾病和炎症 | |
Sbg1007026SGLT | 本发明的一个实施方案是Sbg1007026SGLT,这种人钠-萄萄糖协同转运蛋白在调节葡萄糖/半乳糖吸收障碍(GGM),家族性肾糖尿和糖尿病性肾脏疾病方面的用途。与Sbg1007026SGLT接近的一个同系物是来自人和兔的其它钠-葡萄糖协同转运蛋白。人钠-葡萄糖协同转运蛋白是造成细胞中葡萄糖的主动积聚的原因(Hediger MA,Turk E,Wright EM.1989.Proc Natl Acad Sci USA 86:5748-52)。肾脏钠-葡萄糖协同转运蛋白可能与肾脏疾病如家族性肾糖尿和糖尿病性肾脏疾病的病理生理学有关(Kanai Y,Lee WS,You G,Brown D,Hediger MA.1994.J Clin Invest 93:397-404)。另外,对葡萄糖/半乳糖吸收障碍(GGM)患者的研究揭示,在刷状缘中葡萄糖的钠依赖性吸收方面有特异性缺陷,由葡萄糖/半乳糖吸收障碍所引起的严重腹泻和脱水通常是致命性的,除非将这些糖从食物中除去(Turk E,Zabel B,Mundlos S,Dyer J,Wright EM.1991 Nature 350:354-6)。 | 葡萄糖/半乳糖吸收障碍(GGM),家族性肾糖尿和糖尿病性肾脏疾病 |
Sbg1012732GLUT | 本发明的一个实施方案是Sbg1012732GLUT在维持细胞的稳态和代谢方面的用途。Yu Sbg1012732GLUT接近的一个同系物是跨膜葡萄糖转运蛋白(gluts)。葡萄糖的摄取通过跨膜葡萄糖转运蛋白(gluts)实现,且葡萄糖跨越浆膜的转运对维持细胞的稳态和代谢是重要的。葡萄糖被细胞摄取,经磷酸化变成葡萄糖-6磷酸。癌细胞对葡萄糖的利用与正常组织相比极大提高。肿瘤组织常与葡萄糖转运蛋白,尤其是glut1的异常和/或过表达有关(Smith TA.1999.Br JBiomed Sci 56:285-92)。在肾小球细胞中葡萄糖利用的增加引起醛糖还原酶,蛋白激酶C和TGF-β的表达和活性增强,它们在糖尿病性肾病中被认为在细胞外基质中过度积聚(Z Katedy i Zakladu Patofizjologii,Akaemii Medycznej wPoznaniu.1999.Przegl Lek 56:793-9)。内皮细胞葡萄糖转运方面的改变以及脑屏障和视网膜中GLUT1过多可能严重影响葡萄糖运输到这些组织中,且是两种主要的糖尿病并发症,胰岛素诱导的低血糖和胰岛素性肾病发生的主要信 | 肿瘤,糖尿病性肾病和胰岛素诱导的低血糖。 |
号(Kumagai AK.1999.Diabetes Metab ResRev 15:261-73)。 | ||
Sbg1012732GLUTb | 本发明的一个实施方案是Sbg1012732GLUTb在维持细胞的稳态和代谢方面的用途。与Sbg1012732GLUT接近的一个同系物是跨膜葡萄糖转运蛋白(gluts)。葡萄糖的摄取通过跨膜葡萄糖转运蛋白(gluts)实现,且葡萄糖跨越浆膜的转运对维持细胞的稳态和代谢是重要的。葡萄糖被细胞摄取,经磷酸化变成葡萄糖-6磷酸。癌细胞对葡萄糖的利用与正常组织相比极大提高。肿瘤组织常与葡萄糖转运蛋白,尤其是glut1的异常和/或过表达有关(Smith TA.1999.Br JBiomed Sci 56:285-92)。在肾小球细胞中葡萄糖利用的增加引起醛糖还原酶,蛋白激酶C和TGF-β的表达和活性增强,它们在糖尿病性肾病中被认为在细胞外基质中过度积聚(Z Katedry i Zakladu Patofizjologii,Akaemii Medycznej wPoznaniu.1999.Przegl Lek 56:793-9)。内皮细胞葡萄糖转运方面的改变以及脑屏障和视网膜中GLUT1过多可能严重影响葡萄糖运输到这些组织中,且是两种主要的糖尿病并发症,胰岛素诱导的低血糖和胰岛素性肾病发生的主要信号(Kumagai AK.1999.Diabetes Metab Res Rev 15:261-73)。 | 肿瘤,糖尿病性肾病和胰岛素诱导的低血糖。 |
Sbg1018172CSP | 本发明的一个实施方案是Sbg1018172CSP在调节黑色素瘤,自身免疫性疾病,造血性疾病,伤口愈合和炎症方面的用途。与Sbg1018172CSP接近的一个同系物是黑色素瘤相关的硫酸软骨素蛋白聚糖(MCSP)核心蛋白NG2。MCSP核心蛋白NG2可以用作共同受体,用于在黑色素瘤细胞中传播和形成与α4β1整合素有关的局部接触(Iida J,MeijneAM,Spiro RC,Roos E,Furcht LT,McCarthy JB.1995.Cancer Res Mar 15;55(10):2177-85)。由mAb9.2.27识别的MCSP经过克隆显示,所述核心蛋白包含2322个氨基酸的开放阅读框架,其中包含大的细胞外区,疏水性跨膜区和相对短的胞内尾。在人黑色素瘤细胞系,以及从黑色素瘤皮肤转移灶制备的活检组织(但不是在人其它肿瘤细胞中或各种人胚胎和成年组织中)已检测到MCSP RNA(Pluschke G,Vanek M,Evans A,Dittmar T,Schmid P,Itin P,FilardoEJ,Reisfeld RA.1996.Proc Natl Acad Sci USA Sep 3;93(18):9710-5)。 | 黑色素瘤,感染,自身免疫性疾病,造血性疾病,伤口愈合和炎症 |
Sbg1004570ERGIC | 本发明的一个实施方案是Sbg1004570ERGIC作为探针用于研究分泌途径中蛋白的运输的用途,所述蛋白的运输对于根除和治疗许多先天和后天的疾病,如囊性纤维变性,阿尔茨海默氏病和病毒感染,黑色素瘤的调节,自身免疫性 | 癌,感染,自身免疫性疾病,造血性疾病,伤 |
疾病,造血性疾病,伤口愈合和炎症是至关重要的。与Sbg1004570ERGIC接近的一个同系物是ERGIC-53,一种ER-高尔基体间隔室蛋白(ERGIC)。一种ERGIC蛋白在耐受抗肿瘤药物KRN5500的HT-29结肠腺癌细胞中高出2倍以上。结合其它信息表明,细胞的分泌途径是对KRN550敏感的主要决定因素(Kamishohara M,Kenney S,Domergue R,Vistica DT,Sausville EA 2000 Exp Cell Res May 1;256(2):468-79)。ERGIC-53中的突变显示可引起凝血因子V和VIII的联合缺陷,并提示ERGIC-53可起到分泌蛋白特定亚类从ER向高尔基体转运的分子伴侣的作用,所述分泌蛋白的特定亚类包括凝血因子V和VII(Nichols WC,Seligsohn U,Zivelin A,Terry VH,Hertel CE,Wheatley MA,Moussalli MJ,Hauri HP,Ciavarella N,Kaufman RJ,Ginsburg D.1998.Cell Apr 3;93(1):61-70)。另外,可将ERGIC-53视作一种颇有吸引力的探针,用于研究分泌途径中蛋白运输的许多方面,而这对根除和治疗多种先天和后天疾病,如囊性纤维变性,阿尔茨海默氏病和病毒感染是至关重要的(Hauri HP,Kappeler F,Andersson H,Appenzeller C.2000 J Cell SciFeb;113(Pt4):587-96)。 | 口愈合性疾病,炎症和阿尔茨海默氏病 | |
Sbg1016995IGBrecpt | 本发明的一个实施方案是Sbg1016995IGBrecpt清除循环的自身抗体和免疫复合物的用途。与Sbg1016995IGBrecpt接近的一个同系物是豚鼠免疫球蛋白Fc受体(Tominaga M,Sakata A,Ohmura T,Yamashita T,Koyama J,Onoue K,1990.Biochem Biophys Res Commun Apr 30;168(2):683-9)。近来已有报道,在患归伯二氏综合征(guillain-Barresyndrome)的患者体内存在IgG Fc受体的多态性,这提示IgG Fc受体在清除循环的自身抗体和免疫复合物方面起作用(Vedeler CA,Raknes G,Myhr KM,Nyland H.2000 Neurology Sep 12;55(5):705-7)。 | 自身免疫性疾病,过敏和归伯二氏综合征 |
sbg1151bSREC | 本发明的一个实施方案是,sbg1151bSREC,这种清除受体(scavenger receptor)在调节动脉粥样硬化的致病和动脉粥样硬化损伤中泡沫细胞的形成方面的用途。与sbg1151bSREC接近的一个同系物是清除受体A类I型和II型。大多数清除受体与数种结构不同的配体相互作用,所述配体如氧化的低密度脂蛋白(Ox-LDL)和乙酰LDL。多个研究显示Ox-LDL参与动脉粥样硬化的致病(Steinbrecher UP.1999 Biochim Biophys Acta Jan 4;1436(3):279-98)。在没有动脉粥样硬化损伤的动脉壁中分散的巨噬细胞中,可微量但持续检测到清除受体A类I型和II型(SRA)。相反,在动脉粥 | 动脉粥样硬化性疾病 |
样硬化损伤中,核心区周围的巨噬细胞显示与SRA的强免疫反应性,这提示SRA参与动脉粥样硬化损伤中泡沫细胞的形成(Nakata A,Nakagawa Y,Nishida M,Nozaki S,Miyagawa J,Nakagawa T,Tamura R,Matsumoto K,Kameda-Takemura K,Yamashita S and Matsuzawa Y.Arterioscler Thromb Vasc Biol 1999 May;19(5):1333-9). | ||
sbg1399854ANK | 本发明的一个实施方案是sbg1399854ANK在蛋白-蛋白之间相互作用方面的用途,且其可通过抑制细胞周期蛋白依赖型激酶的蛋白来起作用。本发明既包含死亡结构域又包含锚蛋白重复区。死亡结构域参与细胞死亡的信号传递过程(Cleveland J.and Ihle J.N.1995.Cell 81:479-482)。锚蛋白重复(ANK)是大约33个氨基酸的串联重复模块。已知许多锚蛋白重复区参与蛋白与蛋白之间的相互作用(Svetlana Gorina and Nikola P.Pavletich;1996 Science274:1001-1005)。 | 癌,感染,自身免疫性疾病,造血性疾病,伤口愈合性疾病和炎症 |
表IV.用SybrMan检测mRNA的组织特异性的定量表达
用SYBR-Green定量PCR(Applied Biosystems,Foster City,CA;参见Schmittgen T.D.et al.,Analytical Biochemistry 285:194-204,2000)以及从各种人组织中制备的人cDNA测定所述基因的mRNA的组织特异性定量表达模式。使用序列表中每个基因的第一种核酸序列设计基因特异性PCR引物。域循环(Ct)定义为部分循环数,在该循环数的情况下通过剪切探针生成的报告分子荧光达到10倍于背景的域值。在序列检测系统软件预测到一个以上的PCR产物的情况下,可用Taqman进行特定的PCR扩增(如在特定基因情况下所提示的那样)。
在每种基因的第一个表中,显示了对各种人组织中身份鉴别基因(geneofidentification(GOI))mRNA的两次平行检测的结果(第3列和第4列)。表中显示了每种组织RNA的两次平行检测的平均GOI mRNA拷贝数(第5列)。检测了来自每种组织RNA的18S rRNA的平均值(第6列)并用以标准化。为使每种组织具有相同的18S rRNA量(50ng),用50ng除以所测每种组织的18SrRNA的量(第6列),计算出标准化系数(第7列)。每个GOI标准化系数乘以平均mRNA拷贝数即可得到每50ng总RNA中mRNA的拷贝数(第8列)。
倍数变化显示在每种基因的第二个表中,其仅对有对照物的疾病组织进行了计算。没有对照物的所有标本在倍数变化列中显示空白。另外,倍数变化的数值是疾病标本和正常标本相比较的倍数变化。所以,任何正常标本的后面没有倍数变化数值。对于有成对肿瘤的患者(结肠,肺和乳腺),每种肿瘤与其特定的正常对照物相比较。如果不存在与患者相匹配的正常/疾病对,那么每种疾病标本要与同一组织类型的所有正常标本的平均值相比较。例如,不能应用来自提供阿尔茨海默(Alzheimer)脑的同一患者中的正常脑。在进行倍数变化的检测中,应用3个正常脑标本和4个阿尔茨海默脑标本。取3个正常标本的平均值,再将每个阿尔茨海默标本与该平均值进行比较。
缩写:
ALZ:阿尔茨海默氏病
CT:CLONTECH(1020 East Meadow Circle Palo Alto,CA 94303-4230,USA)
KC:由GSK研究者制备的标本
COPD:慢性阻塞性肺病
Endo:内皮细胞的
VEGF:血管内皮细胞生长因子
bFGF:碱性成纤维细胞生长因子
BM:骨髓
Osteo:成骨细胞
OA:骨关节炎
RA:类风湿性关节炎
PBL:外周血淋巴细胞
PBMNC:外周血单核细胞
HIV:人类免疫缺陷病毒
HSV:单纯疱疹病毒
HPV:人乳头瘤病毒
基因名称sbg960509cbrecpt
在正常和疾病标本中总体表达最低。在全脑,胚胎肝脏和子宫中有最高的正常表达。在2份肺肿瘤标本,一份乳腺肿瘤标本和一份正常乳腺标本中有最高的疾病表达。在4份结肠肿瘤的一份中下调提示其与结肠癌有关。在4份AD脑标本的2份中下调和在全脑中的高表达,提示其参与阿尔茨海默氏病。在3份COPD肺标本中都下调,和在4份哮喘肺标本中都下调,提示在COPD和哮喘中存在该基因。在3份心脏标本的2份中上调,提示其在非阻塞性和阻塞性DCM中的作用。由于Cts>35,上述模式很难解释。免疫细胞中有中度到低度的表达。在OA和RA滑膜中有中度表达。
标本sbg960509cbrecpt | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18S rRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 40,40 | 0 | 0 | 0.00 | 3.06 | 16.34 | 0.00 |
皮下脂肪Zenbio | 40,40 | 0 | 0 | 0.00 | 0.96 | 52.36 | 0.00 |
肾上腺Clontech | 40,40 | 0 | 0 | 0.00 | 0.61 | 81.97 | 0.00 |
全脑Clontech | 33.26,32.07 | 24.63 | 48.4 | 36.52 | 7.24 | 6.91 | 252.18 |
胎脑clontech | 40,40 | 0 | 0 | 0.00 | 0.48 | 103.95 | 0.00 |
Clontech | |||||||
小脑Clontech | 40,40 | 0 | 0 | 0.00 | 2.17 | 23.04 | 0.00 |
子宫颈 | 40,40 | 0 | 0 | 0.00 | 2.42 | 20.66 | 0.00 |
结肠 | 40,40 | 0 | 0 | 0.00 | 2.71 | 18.45 | 0.00 |
子宫内膜 | 40,40 | 0.81 | 0 | 0.41 | 0.73 | 68.21 | 27.63 |
食管 | 40,40 | 0 | 0 | 0.00 | 1.37 | 36.50 | 0.00 |
心脏Clontech | 40,40 | 0 | 0 | 0.00 | 1.32 | 37.88 | 0.00 |
下丘脑 | 40,40 | 0 | 0 | 0.00 | 0.32 | 155.28 | 0.00 |
回肠 | 40,40 | 0 | 0 | 0.00 | 2.58 | 19.38 | 0.00 |
空肠 | 35.56,34.42 | 6.66 | 12.71 | 9.69 | 6.60 | 7.58 | 73.37 |
肾脏 | 40,40 | 0 | 0 | 0.00 | 2.12 | 23.58 | 0.00 |
肝脏 | 40,40 | 0 | 0 | 0.00 | 1.50 | 33.33 | 0.00 |
胚胎肝脏Clontech | 33.46,34.83 | 14.95 | 27.51 | 21.23 | 10.40 | 4.81 | 102.07 |
肺 | 40,40 | 0 | 0 | 0.00 | 2.57 | 19.46 | 0.00 |
乳腺Clontech | 40,40 | 21.94 | 10.06 | 16.00 | 13.00 | 3.85 | 61.54 |
子宫肌层 | 40,40 | 0 | 0 | 0.00 | 2.34 | 21.37 | 0.00 |
网膜 | 40,40 | 0 | 0 | 0.00 | 3.94 | 12.69 | 0.00 |
卵巢 | 40,40 | 0 | 0 | 0.00 | 4.34 | 11.52 | 0.00 |
胰腺 | 40,40 | 0 | 0 | 0.00 | 0.81 | 61.80 | 0.00 |
胰头 | 40,40 | 0 | 0 | 0.00 | 1.57 | 31.85 | 0.00 |
腮腺 | 40,40 | 0 | 0 | 0.00 | 5.48 | 9.12 | 0.00 |
胎盘Clontech | 40,40 | 0.39 | 0 | 0.20 | 5.26 | 9.51 | 1.85 |
前列腺 | 40,40 | 0 | 0 | 0.00 | 3.00 | 16.67 | 0.00 |
直肠 | 40,40 | 0 | 0 | 0.00 | 1.23 | 40.65 | 0.00 |
唾液腺Clontech | 34.79,40 | 10.31 | 0 | 5.16 | 7.31 | 6.84 | 35.26 |
骨骼肌Clontech | 40,40 | 0 | 0 | 0.00 | 1.26 | 39.68 | 0.00 |
皮肤 | 40,40 | 0 | 0 | 0.00 | 1.21 | 41.32 | 0.00 |
小肠Clontech | 40,40 | 0 | 0 | 0.00 | 0.98 | 51.07 | 0.00 |
脾脏 | 40,40 | 0 | 0 | 0.00 | 4.92 | 10.16 | 0.00 |
胃 | 35.8,38.29 | 5.82 | 1.41 | 3.62 | 2.73 | 18.32 | 66.21 |
睾丸Clontech | 40,40 | 0 | 0 | 0.00 | 0.57 | 87.87 | 0.00 |
胸腺Clontech | 35.13,35.08 | 8.48 | 8.75 | 8.62 | 9.89 | 5.06 | 43.55 |
甲状腺 | 40,40 | 0 | 0 | 0.00 | 2.77 | 18.05 | 0.00 |
气管Clontech | 35.26,ND | 7.9 | ND | 7.90 | 9.71 | 5.15 | 40.68 |
膀胱 | 40,ND | 0 | ND | 0.00 | 5.47 | 9.14 | 0.00 |
子宫 | 35.09,33.87 | 8.67 | 17.4 | 13.04 | 5.34 | 9.36 | 122.05 |
基因组 | 26.62 | 1067.33 | |||||
b-肌动蛋白 | 27.44 | 670.43 | |||||
1.00E+05 | 19.22 | 100000 | |||||
1.00E+05 | 19.38 | 100000 | |||||
1.00E+04 | 22.78 | 10000 | |||||
1.00E+04 | 20.52 | 10000 | |||||
1.00E+03 | 26.45 | 1000 | |||||
1.00E+03 | 27.03 | 1000 | |||||
1.00E+02 | 30.99 | 100 | |||||
1.00E+02 | 31.26 | 100 | |||||
1.00E+01 | 40 | 0 | |||||
1.00E+01 | 40 | 0 | |||||
1.00E-00 | 40 | 0 | |||||
1.00E-00 | 40 | 0 | |||||
NTC | 40 | 0 | |||||
NTC | 40 | 0 |
标本sbg960509cbrecpt | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 29.42 | 332.32 | 正常结肠 | ||
结肠肿瘤GW98-166 | 21940 | 30.95 | 66.31 | 132.62 | 结肠肿瘤 | -2.51 |
正常结肠GW98-178 | 22080 | 31.32 | 53.01 | 106.02 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 30.57 | 83.1 | 166.20 | 结肠肿瘤 | 1.57 |
正常结肠GW98-561 | 23514 | 31.44 | 49.16 | 98.32 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 31.81 | 39.47 | 78.94 | 结肠肿瘤 | -1.25 |
正常结肠GW98-894 | 24691 | 29.44 | 164.69 | 329.38 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 34.42 | 8.18 | 16.36 | 结肠肿瘤 | -20.13 |
正常肺GW98-3 | 20742 | 28.04 | 383.11 | 766.22 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 34.22 | 9.19 | 18.38 | 肺肿瘤 | -41.69 |
正常肺GW97-179 | 20677 | 30.93 | 66.74 | 133.48 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 27.11 | 667.61 | 1335.22 | 肺肿瘤 | 10.00 |
正常肺GW98-165 | 21922 | 28.31 | 323.99 | 647.98 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 30.92 | 67.22 | 134.44 | 肺肿瘤 | -4.82 |
正常肺GW98-282 | 22584 | 31.76 | 40.67 | 81.34 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 29.61 | 148.67 | 297.34 | 肺肿瘤 | 3.66 |
正常乳腺GW00-392 | 28750 | 27.64 | 487.44 | 487.44 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 27.47 | 539.99 | 1079.98 | 乳腺肿瘤 | 2.22 |
正常乳腺GW00-413 | 28798 | 33.36 | 15.44 | 15.44 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 30.88 | 68.84 | 137.68 | 乳腺肿瘤 | 8.92 |
正常乳腺GW00-235:238 | 27592-95 | 34.74 | 6.73 | 6.73 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 33.73 | 12.41 | 12.41 | 乳腺肿瘤 | 1.84 |
正常乳腺GW98-621 | 23656 | 27.7 | 469.27 | 938.54 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 33.1 | 18.13 | 36.26 | 乳腺肿瘤 | -25.88 |
正常大脑BB-99-542 | 25507 | 31.46 | 48.61 | 97.22 | 正常大脑 | |
正常大脑BB-99-406 | 25509 | 34.17 | 9.52 | 19.04 | 正常大脑 | |
正常大脑BB-99-904 | 25546 | 35.69 | 3.79 | 7.58 | 正常大脑 | |
大脑期5ALZ BB99-874 | 25502 | 40 | 0 | 0.00 | 大脑期5-ALZ | -41.28 |
大脑期5ALZ BB99-887 | 25503 | 34.96 | 5.91 | 11.82 | 大脑期5-ALZ | -3.49 |
大脑期5ALZ BB99-862 | 25504 | 33.13 | 17.82 | 35.64 | 大脑期5-ALZ | -1.16 |
大脑期5ALZ BB99-927 | 25542 | 40 | 0 | 0.00 | 大脑期5-ALZ | -41.28 |
CT肺KC | normal | 29.53 | 155.88 | 311.76 | CT肺 |
肺26KC | normal | 肺26 | ||||
肺27KC | normal | 39.2 | 0.46 | 0.46 | 肺27 | |
肺24KC | COPD | 40 | 0 | 0.00 | 肺24 | -104.07 |
肺28KC | COPD | 40 | 0 | 0.00 | 肺28 | -104.07 |
肺23KC | COPD | 34.81 | 6.44 | 6.44 | 肺23 | -16.16 |
肺25KC | normal | 40 | 0 | 0.00 | 肺25 | |
哮喘肺ODO3112 | 29321 | 38.99 | 0.52 | 0.52 | 哮喘肺 | -200.14 |
哮喘肺ODO3433 | 29323 | 33.69 | 12.65 | 25.30 | 哮喘肺 | -4.11 |
哮喘肺ODO3397 | 29322 | 33.53 | 13.98 | 27.96 | 哮喘肺 | -3.72 |
哮喘肺ODO4928 | 29325 | 34.27 | 8.96 | 17.92 | 哮喘肺 | -5.81 |
内皮细胞KC | control | 40 | 0 | 0.00 | 内皮细胞 | |
内皮细胞VEGFKC | 40 | 0 | 0.00 | 内皮细胞VEGF | 0.00 | |
内皮细胞bFGF KC | 40 | 0 | 0.00 | 内皮细胞bFGF | 0.00 | |
心脏Clontech | normal | 35.53 | 4.19 | 8.38 | 心脏 | |
心脏(T-1)缺血 | 29417 | 34 | 10.5 | 21.00 | 心脏T-1 | 2.51 |
心脏(T-14)非阻塞性DCM | 29422 | 31.16 | 58.24 | 116.48 | 心脏T-14 | 13.90 |
心脏(T-3399)DCM | 29426 | 28.35 | 317.67 | 635.34 | 心脏T-3399 | 75.82 |
腺样增殖体GW99-269 | 26162 | 31.52 | 46.93 | 93.86 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 30.82 | 71.35 | 142.70 | 扁桃体 | |
T细胞PC00314 | 28453 | 34.36 | 8.47 | 16.94 | T细胞 | |
PBMNC | 40 | 0 | 0.00 | PBMNC | ||
单核细胞 | 40 | 0 | 0.00 | 单核细胞 | ||
B细胞PC00665 | 28455 | 40 | 0 | 0.00 | B细胞 | |
树突细胞28441 | 31.52 | 47.02 | 94.04 | 树突细胞 | ||
中性粒细胞 | 28440 | 36.13 | 2.91 | 2.91 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 40 | 0 | 0.00 | 嗜酸性粒细胞 | |
BM unstim | 40 | 0 | 0.00 | BM未刺激的 |
BM stim | 40 | 0 | 0.00 | BM刺激的 | 0.00 | |
osteo dif | 40 | 0 | 0.00 | 成骨细胞分化 | 0.00 | |
osteo undif | 40 | 0 | 0.00 | 成骨细胞未分化 | ||
软骨细胞 | 40 | 0 | 0.00 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 32.08 | 33.47 | 33.47 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 31.43 | 49.5 | 99.00 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 30.42 | 91.04 | 182.08 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 32.11 | 32.84 | 65.68 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 31.07 | 61.51 | 123.02 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 36.21 | 2.78 | 5.56 | RA滑膜 | |
OA骨(biobank) | 29217 | 31.49 | 47.85 | 47.85 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 30.11 | 109.44 | 218.88 | OA骨 | |
OA骨标本2 | J.Emory | 32.6 | 24.52 | 49.04 | OA骨 | |
软骨(库) | Normal | 32.09 | 33.26 | 66.52 | 软骨(库) | |
软骨(库) | OA | 33.1 | 18.07 | 36.14 | 软骨(库) | -1.84 |
PBL未感染的 | 28441 | 27.68 | 474.91 | 949.82 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 31.76 | 40.5 | 81.00 | PBL HIV IIIB | -11.73 |
MRC5未感染的(100%) | 29158 | 40 | 0 | 0.00 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 34.15 | 9.61 | 19.22 | MRC5 HSV株F | 19.22 |
W12细胞 | 29179 | 40 | 0 | 0.00 | W12细胞 | |
角质细胞 | 29180 | 38.16 | 0.85 | 1.70 | 角质细胞 | |
B-肌动蛋白对照 | 27.02 | 707.5 | ||||
基因组 | 26.1 | 1232.73 | ||||
1.00E+05 | 18.64 | 100000 | ||||
1.00E+05 | 18.95 | 100000 | ||||
1.00E+04 | 22.4 | 10000 |
1.00E+04 | 22.17 | 10000 | ||||
1.00E+03 | 26.34 | 1000 | ||||
1.00E+03 | 25.94 | 1000 | ||||
1.00E+02 | 31.03 | 100 | ||||
1.00E+02 | 32.83 | 100 | ||||
1.00E+01 | 33.21 | 10 | ||||
1.00E+01 | 32.93 | 10 | ||||
1.00E-00 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
NTC | 40 | 0 |
基因名称sbg960509cbrecpt
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | -2.51 |
结肠肿瘤 | 1.57 |
结肠肿瘤 | -1.25 |
结肠肿瘤 | -20.13 |
肺肿瘤 | -41.69 |
肺肿瘤 | 10.00 |
肺肿瘤 | -4.82 |
肺肿瘤 | 3.66 |
乳腺肿瘤 | 2.22 |
乳腺肿瘤 | 8.92 |
乳腺肿瘤 | 1.84 |
乳腺肿瘤 | -25.88 |
大脑期5ALZ | -41.28 |
大脑期5ALZ | -3.49 |
大脑期5ALZ | -1.16 |
大脑期5ALZ | -41.28 |
肺24 | -104.07 |
肺28 | -104.07 |
肺23 | -16.16 |
哮喘肺 | -200.14 |
哮喘肺 | -4.11 |
哮喘肺 | -3.72 |
哮喘肺 | -5.81 |
内皮细胞VEGF | 0.00 |
内皮细胞bFGF | 0.00 |
心脏T-1 | 2.51 |
心脏T-14 | 13.90 |
心脏T-3399 | 75.82 |
BM刺激的 | 0.00 |
Osteo未分化的 | 0.00 |
软骨(库) | -1.84 |
PBL HIV IIIB | -11.73 |
MRC5 HSV 株F | 19.22 |
基因名称sbg614126complfH
在正常和疾病标本中,有中度到低度的总体表达。在肝脏和胚胎肝脏中有最高的正常表达。在全脑,卵巢和子宫中可见较低(但仍然是明显的)表达。在2份乳腺肿瘤样品,一份正常脑标本,一份正常肺标本,多份OA滑膜标本的一份中以及在HSV感染的MRC5细胞中有最高的疾病表达。在4份结肠肿瘤的一份中上调提示其在结肠肿瘤中的作用。在4份肺肿瘤的2份中下调,在4份乳腺肿瘤的1份中上调提示其在肺和乳腺癌中的作用。在全部3份COPD肺标本中下调和全部4份哮喘肺中下调提示其参与慢性阻塞性肺疾病和哮喘。在3份心脏标本的一份中上调提示其在DCM中的作用。在HSV中上调提示其作为潜在的宿主因子与单纯疱疹病毒有关。在免疫细胞,RA和OA滑膜骨和软骨有中度到低度的表达。
标本sbg614126complfH | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18S rRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 40.40 | 0 | 0 | 0.00 | 3.06 | 16.34 | 0.00 |
皮下脂肪Zenbio | 40,40 | 0 | 0 | 0.00 | 0.96 | 52.36 | 0.00 |
肾上腺Clontech | 40,40 | 0 | 0 | 0.00 | 0.61 | 81.97 | 0.00 |
全脑Clontech | 32.34,31.88 | 46.5 | 61.71 | 54.11 | 7.24 | 6.91 | 373.65 |
胎脑clontech | 40,40 | 0 | 0 | 0.00 | 0.48 | 103.95 | 0.00 |
小脑Clontech | 40,40 | 0 | 0 | 0.00 | 2.17 | 23.04 | 0.00 |
子宫颈 | 40,35.04 | 0 | 8.88 | 4.44 | 2.42 | 20.66 | 91.74 |
结肠 | 40,40 | 0 | 0 | 0.00 | 2.71 | 18.45 | 0.00 |
子宫内膜 | 40,40 | 0 | 0 | 0.00 | 0.73 | 68.21 | 0.00 |
食管 | 40,40 | 0 | 0 | 0.00 | 1.37 | 36.50 | 0.00 |
心脏Clontech | 40,40 | 0 | 0 | 0.00 | 1.32 | 37.88 | 0.00 |
下丘脑 | 40,39.79 | 0 | 0.48 | 0.24 | 0.32 | 155.28 | 37.27 |
回肠 | 40,36.32 | 0 | 4.04 | 2.02 | 2.58 | 19.38 | 39.15 |
空肠 | 33.25,34.19 | 26.6 | 14.98 | 20.79 | 6.60 | 7.58 | 157.50 |
肾脏 | 40,40 | 0 | 0 | 0.00 | 2.12 | 23.58 | 0.00 |
肝脏 | 28.77,28.81 | 417.4 | 407.38 | 412.39 | 1.50 | 33.33 | 13746.33 |
胚胎肝Clontech | 29.63,29.5 | 246.38 | 266.67 | 256.53 | 10.40 | 4.81 | 1233.29 |
肺 | 40,40 | 0 | 0 | 0.00 | 2.57 | 19.46 | 0.00 |
乳腺Clontech | 34.19,40 | 14.9 | 0 | 7.45 | 13.00 | 3.85 | 28.65 |
子宫肌层 | 35.76,40 | 5.7 | 0 | 2.85 | 2.34 | 21.37 | 60.90 |
网膜 | 36.04,33.62 | 4.81 | 21.16 | 12.99 | 3.94 | 12.69 | 164.78 |
卵巢 | 34.29,32.95 | 14.02 | 31.93 | 22.98 | 4.34 | 11.52 | 264.69 |
胰腺 | 40,40 | 0 | 0 | 0.00 | 0.81 | 61.80 | 0.00 |
胰头 | 38.98,35.35 | 0.79 | 7.32 | 4.06 | 1.57 | 31.85 | 129.14 |
腮腺 | 34.58,33.83 | 11.74 | 18.68 | 15.21 | 5.48 | 9.12 | 138.78 |
胎盘Clontech | 35.73,35.66 | 5.82 | 6.06 | 5.94 | 5.26 | 9.51 | 56.46 |
前列腺 | 40,40 | 0 | 0 | 0.00 | 3.00 | 16.67 | 0.00 |
直肠 | 40,40 | 0.38 | 0 | 0.19 | 1.23 | 40.65 | 7.72 |
唾液腺Clontech | 40,40 | 0.3 | 0 | 0.15 | 7.31 | 6.84 | 1.03 |
骨骼肌Clontech | 40,40 | 0 | 0.28 | 0.14 | 1.26 | 39.68 | 5.56 |
皮肤 | 40,40 | 0 | 0.33 | 0.17 | 1.21 | 41.32 | 6.82 |
小肠Clontech | 40,40 | 0 | 0 | 0.00 | 0.98 | 51.07 | 0.00 |
脾脏 | 40,40 | 0 | 0 | 0.00 | 4.92 | 10.16 | 0.00 |
胃 | 40,36 | 0 | 4.92 | 2.46 | 2.73 | 18.32 | 45.05 |
睾丸Clontech | 40,40 | 0 | 0 | 0.00 | 0.57 | 87.87 | 0.00 |
胸腺Clontech | 40,37.06 | 0 | 2.56 | 1.28 | 9.89 | 5.06 | 6.47 |
甲状腺 | 40,40 | 0 | 0.31 | 0.16 | 2.77 | 18.05 | 2.80 |
气管Clontech | 40,40 | 0.28 | 0 | 0.14 | 9.71 | 5.15 | 0.72 |
膀胱 | 40,34.13 | 0 | 15.53 | 7.77 | 5.47 | 9.14 | 70.98 |
子宫 | 33.21,32.79 | 27.27 | 35.32 | 31.30 | 5.34 | 9.36 | 293.02 |
基因组 | 26.93 | 1288.98 | |||||
b-肌动蛋白 | 27.55 | 878.74 | |||||
1.00E+05 | 20.07 | 100000 | |||||
1.00E+05 | 20.14 | 100000 | |||||
1.00E+04 | 23.43 | 10000 | |||||
1.00E+04 | 23.34 | 10000 | |||||
1.00E+03 | 26.84 | 1000 | |||||
1.00E+03 | 27.02 | 1000 | |||||
1.00E+02 | 31.72 | 100 | |||||
1.00E+02 | 31.32 | 100 | |||||
1.00E+01 | 33.78 | 10 | |||||
1.00E+01 | 35.79 | 10 | |||||
1.00E-00 | 40 | 0 | |||||
1.00E-00 | 40 | 0 | |||||
NTC | 40 | 0 | |||||
NTC | 40 | 0 |
标本sbg614126complfH | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 34.6 | 13.63 | 27.26 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 35.71 | 7.35 | 14.70 | 结肠肿瘤 | -1.85 |
正常结肠GW98-178 | 22080 | 40 | 0 | 0.00 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 39.81 | 0.75 | 1.50 | 结肠肿瘤 | 1.50 |
正常结肠GW98-561 | 23514 | 38.61 | 1.45 | 2.90 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 34.84 | 11.95 | 23.90 | 结肠肿瘤 | 8.24 |
正常结肠GW98-894 | 24691 | 39.05 | 1.14 | 2.28 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 40 | 0 | 0.00 | 结肠肿瘤 | -2.28 |
正常肺GW98-3 | 20742 | 35.78 | 7.04 | 14.08 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 40 | 0 | 0.00 | 肺肿瘤 | -14.08 |
正常肺GW97-179 | 20677 | 33.99 | 19.21 | 38.42 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 40 | 0.49 | 0.98 | 肺肿瘤 | -39.20 |
正常肺GW98-165 | 21922 | 39.63 | 0.82 | 1.64 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 38.89 | 1.24 | 2.48 | 肺肿瘤 | 1.51 |
正常肺GW98-282 | 22584 | 40 | 0 | 0.00 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 40 | 0 | 0.00 | 肺肿瘤 | 0.00 |
正常乳腺GW00-392 | 28750 | 32.71 | 39.28 | 39.28 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 31.65 | 70.89 | 141.78 | 乳腺肿瘤 | 3.61 |
正常乳腺GW00-413 | 28798 | 35.83 | 6.88 | 6.88 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 33.17 | 30.3 | 60.60 | 乳腺肿瘤 | 8.81 |
正常乳腺GW00-235:238 | 27592-95 | 36.73 | 4.16 | 4.16 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 35.98 | 6.33 | 6.33 | 乳腺肿瘤 | 1.52 |
正常乳腺GW98-621 | 23656 | 37.38 | 2.89 | 5.78 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 34.95 | 11.23 | 22.46 | 乳腺肿瘤 | 3.89 |
正常大脑BB99-542 | 25507 | 32.26 | 50.34 | 100.68 | 正常大脑 | |
正常大脑BB99-406 | 25509 | 40 | 0.57 | 1.14 | 正常大脑 | |
正常大脑BB99-904 | 25546 | 34.68 | 13.04 | 26.08 | 正常大脑 | |
大脑期5ALZBB99-874 | 25502 | 40 | 0 | 0.00 | 大脑期5-ALZ | -42.63 |
大脑期5ALZBB99-887 | 25503 | 35.87 | 6.73 | 13.46 | 大脑期5-ALZ | -3.17 |
大脑期5ALZBB99-862 | 25504 | 39.2 | 1.05 | 2.10 | 大脑期5-ALZ | -20.30 |
大脑期5ALZBB99-927 | 25542 | 40 | 0 | 0.00 | 大脑期5-ALZ | -42.63 |
CT肺KC | normal | 39.4 | 0.93 | 1.86 | CT肺 | |
肺26KC | normal | 肺26 | ||||
肺27KC | normal | 40 | 0 | 0.00 | 肺27 | |
肺24KC | COPD | 40 | 0 | 0.00 | 肺24 | -0.62 |
肺28KC | COPD | 40 | 0 | 0.00 | 肺28 | -0.62 |
肺23KC | COPD | 40 | 0 | 0.00 | 肺23 | -0.62 |
肺25KC | normal | 40 | 0 | 0.00 | 肺25 | |
哮喘肺ODO3112 | 29321 | 36.52 | 4.68 | 4.68 | 哮喘肺 | 7.55 |
哮喘肺ODO3433 | 29323 | 40 | 0 | 0.00 | 哮喘肺 | -0.62 |
哮喘肺ODO3397 | 29322 | 40 | 0 | 0.00 | 哮喘肺 | -0.62 |
哮喘肺ODO4928 | 29325 | 38.18 | 1.85 | 3.70 | 哮喘肺 | 5.97 |
内皮细胞KC | control | 40 | 0 | 0.00 | 内皮细胞 | |
内皮细胞VEGFKC | 40 | 0 | 0.00 | 内皮细胞VEGF | 0.00 | |
内皮细胞bFGF KC | 40 | 0 | 0.00 | 内皮细胞bFGF | 0.00 | |
心脏Clontech | normal | 40 | 0 | 0.00 | 心脏 | |
心脏(T-1)缺血 | 29417 | 40 | 0 | 0.00 | 心脏T-1 | 0.00 |
心脏(T-14)非阻塞性DCM | 29422 | 40 | 0 | 0.00 | 心脏T-14 | 0.00 |
心脏(T-3399)DCM | 29426 | 36.03 | 6.13 | 12.26 | 心脏T-3399 | 12.26 |
腺样增殖体GW99-269 | 26162 | 34.08 | 18.19 | 36.38 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 37.46 | 2.77 | 5.54 | 扁桃体 | |
T细胞PC00314 | 28453 | 40 | 0 | 0.00 | T细胞 | |
PBMNC | 40 | 0 | 0.00 | PBMNC | ||
单核细胞 | 40 | 0 | 0.00 | 单核细胞 | ||
B细胞PC00665 | 28455 | 34.56 | 13.99 | 27.98 | B细胞 | |
树突细胞28441 | 40 | 0 | 0.00 | 树突细胞 | ||
中性粒细胞 | 28440 | 33.76 | 21.85 | 21.85 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 40 | 0 | 0.00 | 嗜酸性粒细胞 | |
BM unstim | 40 | 0 | 0.00 | BM未刺激的 | ||
BM stim | 40 | 0 | 0.00 | BM刺激的 | 0.00 | |
osteo dif | 40 | 0 | 0.00 | 成骨细胞分化 | 0.00 | |
osteo undif | 40 | 0 | 0.00 | 成骨细胞未分化 | ||
软骨细胞 | 34.25 | 16.55 | 41.38 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 40 | 0 | 0.00 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 40 | 0 | 0.00 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 33.1 | 31.54 | 63.08 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 40 | 0 | 0.00 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 40 | 0 | 0.00 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 40 | 0 | 0.00 | RA滑膜 | |
OA骨(biobank) | 29217 | 40 | 0 | 0.00 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 40 | 0 | 0.00 | OA骨 | |
OA骨标本2 | J.Emory | 40 | 0 | 0.00 | OA骨 | |
软骨(库) | Normal | 40 | 0 | 0.00 | 软骨(库) | |
软骨(库) | OA | 40 | 0 | 0.00 | 软骨(库) | 0.00 |
PBL未感染的 | 28441 | 36.12 | 5.84 | 110.68 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 36.1 | 5.9 | 11.80 | PBL HIV IIIB | 1.01 |
MRC5未感染的 | 29158 | 40 | 0 | 0.00 | MRC5未感染的 |
(100%) | (100%) | |||||
MRC5 HSV株F | 29178 | 31.83 | 64.08 | 128.16 | MRC5 HSV株F | 128.16 |
W12细胞 | 29179 | 40 | 0 | 0.00 | W12细胞 | |
角质细胞 | 29180 | 40 | 0 | 0.00 | 角质细胞 | |
B-肌动蛋白对照 | 27.26 | 820.77 | ||||
基因组 | 26.18 | 1496.25 | ||||
1.00E+05 | 19.13 | 100000 | ||||
1.00E+05 | 19.38 | 100000 | ||||
1.00E+04 | 22.56 | 10000 | ||||
1.00E+04 | 22.67 | 10000 | ||||
1.00E+03 | 26.01 | 1000 | ||||
1.00E+03 | 26.44 | 1000 | ||||
1.00E+02 | 30.93 | 100 | ||||
1.00E+02 | 30.1 | 100 | ||||
1.00E+01 | 38.59 | 10 | ||||
1.00E+01 | 33.26 | 10 | ||||
1.00E-00 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
NTC | 40 | 0 |
基因名称sbg614126complfH
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | -1.85 |
结肠肿瘤 | 1.50 |
结肠肿瘤 | 8.24 |
结肠肿瘤 | -2.28 |
肺肿瘤 | -14.08 |
肺肿瘤 | -39.20 |
肺肿瘤 | 1.51 |
肺肿瘤 | 0.00 |
乳腺肿瘤 | 3.61 |
乳腺肿瘤 | 8.81 |
乳腺肿瘤 | 1.52 |
乳腺肿瘤 | 3.89 |
大脑期5ALZ | -42.63 |
大脑期5ALZ | -3.17 |
大脑期5ALZ | -20.30 |
大脑期5ALZ | -42.63 |
肺24 | -0.62 |
肺28 | -0.62 |
肺23 | -0.62 |
哮喘肺 | 7.55 |
哮喘肺 | -0.62 |
哮喘肺 | -0.62 |
哮喘肺 | 5.97 |
内皮细胞VEGF | 0.00 |
内皮细胞bFGF | 0.00 |
心脏T-1 | 0.00 |
心脏T-14 | 0.00 |
心脏T-3399 | 12.26 |
BM刺激的 | 0.00 |
Osteo未分化的 | 0.00 |
软骨(库) | 0.00 |
PBL HIV IIIB | 1.01 |
MRC5 HSV株F | 128.16 |
基因名称sbg120703RNase
在正常和疾病标本中有中度到低度的总体表达。在全脑和唾液腺中有最高水平的正常表达。在胚胎肝脏和胸腺中有中度表达。在2份正常的肺标本,一份肺肿瘤标本,正常软骨库和HSV感染的MRC5细胞中有最高的疾病表达。在4份结肠肿瘤的一份中上调提示其在结肠癌中的作用。在4份肺肿瘤标本的2份中下调提示其可能与肺癌有关。在4份乳腺肿瘤的2份中上调提示其参与乳腺癌。在所有3份COPD肺标本中都下调提示其参与COPD。在所有3份心脏标本中都上调提示在心脏疾病,如DCM和缺血中有该基因。在OA和RA的滑膜和OA的骨标本中高表达提示其可能参与骨关节炎和类风湿性关节炎。在HSV中上调提示该基因作为潜在的宿主因子与单纯疱疹病毒有关。在免疫细胞中有中度到低度的表达。
标本sbg120703RNase | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 40,36.24 | 0 | 2.54 | 1.27 | 3.06 | 16.34 | 20.75 |
皮下脂肪Zenbio | 36.58,40 | 2.07 | 0 | 1.04 | 0.96 | 52.36 | 54.19 |
肾上腺Clontech | 40,40 | 0.22 | 0 | 0.11 | 0.61 | 81.97 | 9.02 |
全脑Clontech | 28.62,28.6 | 245.21 | 247.41 | 246.31 | 7.24 | 6.91 | 1701.04 |
胎脑clontech | 40,40 | 0.3 | 0 | 0.15 | 0.48 | 103.95 | 15.59 |
小脑Clontech | 40,40 | 0.29 | 0 | 0.15 | 2.17 | 23.04 | 3.34 |
子宫颈 | 35.3,40 | 4.45 | 0 | 2.23 | 2.42 | 20.66 | 45.97 |
结肠 | 40,40 | 0.26 | 0 | 0.13 | 2.71 | 18.45 | 2.40 |
子宫内膜 | 40,38.38 | 0 | 0.7 | 0.35 | 0.73 | 68.21 | 23.87 |
食管 | 36.11,37.01 | 2.74 | 1.6 | 2.17 | 1.37 | 36.50 | 79.20 |
心脏Clontech | 40,40 | 0 | 0 | 0.00 | 1.32 | 37.88 | 0.00 |
下丘脑 | 40,40 | 0 | 0 | 0.00 | 0.32 | 155.28 | 0.00 |
回肠 | 39.31,36.07 | 0.4 | 2.8 | 1.60 | 2.58 | 19.38 | 31.01 |
空肠 | 34.13,39.51 | 8.98 | 0.36 | 4.67 | 6.60 | 7.58 | 35.38 |
肾脏 | 40,40 | 0.48 | 0 | 0.24 | 2.12 | 23.58 | 5.66 |
肝脏 | 34.4,36.04 | 7.64 | 2.86 | 5.25 | 1.50 | 33.33 | 175.00 |
胚胎肝Clontech | 31.46,31.39 | 44.65 | 46.4 | 45.53 | 10.40 | 4.81 | 218.87 |
肺 | 34.21,35.61 | 8.59 | 3.71 | 6.15 | 2.57 | 19.46 | 119.65 |
乳腺Clontech | 34.9,35.65 | 5.67 | 3.6 | 4.64 | 13.00 | 3.85 | 17.83 |
子宫肌层 | 40,38.99 | 0 | 0.49 | 0.25 | 2.34 | 21.37 | 5.24 |
网膜 | 38.39,34.35 | 0.7 | 7.89 | 4.30 | 3.94 | 12.69 | 54.51 |
卵巢 | 35,33.21 | 5.34 | 15.64 | 10.49 | 4.34 | 11.52 | 120.85 |
胰腺 | 40 | 0 | 0 | 0.00 | 0.81 | 61.80 | 0.00 |
胰头 | 40 | 0 | 0 | 0.00 | 1.57 | 31.85 | 0.00 |
腮腺 | 32.22,33.49 | 28.28 | 13.18 | 20.73 | 5.48 | 9.12 | 189.14 |
胎盘Clontech | 37,39.59 | 1.6 | 0.34 | 0.97 | 5.26 | 9.51 | 9.22 |
前列腺 | 35.03,35.75 | 5.23 | 3.4 | 4.32 | 3.00 | 16.67 | 71.92 |
直肠 | 38.25,40 | 0.76 | 0.21 | 0.49 | 1.23 | 40.65 | 19.72 |
唾液腺Clontech | 30.01,29.73 | 106.25 | 125.78 | 116.02 | 7.31 | 6.84 | 793.54 |
骨骼肌Clontech | 40,39.16 | 0.41 | 0.44 | 0.43 | 1.26 | 39.68 | 16.87 |
皮肤 | 37.21,35.01 | 1.42 | 5.31 | 3.37 | 1.21 | 41.32 | 139.05 |
小肠Clontech | 40,40 | 0 | 0.19 | 0.10 | 0.98 | 51.07 | 4.85 |
脾脏 | 35.4,35.9 | 4.2 | 3.11 | 3.66 | 4.92 | 10.16 | 37.14 |
胃 | 36.12,40 | 2.73 | 0.21 | 1.47 | 2.73 | 18.32 | 26.92 |
睾丸Clontech | 40,40 | 0 | 0 | 0.00 | 0.57 | 87.87 | 0.00 |
胸腺Clontech | 31.88,31.42 | 34.61 | 45.62 | 40.12 | 9.89 | 5.06 | 202.81 |
甲状腺 | 40,35.22 | 0 | 4.67 | 2.34 | 2.77 | 18.05 | 42.15 |
气管Clontech | 35.38,37.52 | 4.26 | 1.17 | 2.72 | 9.71 | 5.15 | 13.98 |
膀胱 | 38.77,40 | 0.56 | 0.31 | 0.44 | 5.47 | 9.14 | 3.98 |
子宫 | 33.66,37.55 | 11.93 | 1.16 | 6.55 | 5.34 | 9.36 | 61.28 |
基因组 | 25.78 | 1342.66 | |||||
b-肌动蛋白 | 27.27 | 551.42 | |||||
1.00E+05 | 19.03 | 100000 | |||||
1.00E+05 | 19.08 | 100000 | |||||
1.00E+04 | 22.28 | 10000 | |||||
1.00E+04 | 22.27 | 10000 | |||||
1.00E+03 | 25.85 | 1000 |
1.00E+03 | 25.6 | 1000 | |||||
1.00E+02 | 30.44 | 100 | |||||
1.00E+02 | 29.33 | 100 | |||||
1.00E+01 | 34.4 | 10 | |||||
1.00E+01 | 34.48 | 10 | |||||
1.00E-00 | |||||||
1.00E-00 | |||||||
NTC | 40 | -1 | |||||
NTC | 40 | 0 |
标本sbg120703RNase | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 29.03 | 142.85 | 285.70 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 28.31 | 226.87 | 453.74 | 结肠肿瘤 | 1.59 |
正常结肠GW98-178 | 22080 | 33.08 | 10.78 | 21.56 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 29.33 | 118.09 | 236.18 | 结肠肿瘤 | 10.95 |
正常结肠GW98-561 | 23514 | 30.02 | 76.09 | 152.18 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 30.42 | 58.89 | 117.78 | 结肠肿瘤 | -1.29 |
正常结肠GW98-894 | 24691 | 29.07 | 139.29 | 278.58 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 30.3 | 63.5 | 127.00 | 结肠肿瘤 | -2.19 |
正常肺GW98-3 | 20742 | 26.86 | 574.4 | 1148.80 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 30.07 | 73.89 | 147.78 | 肺肿瘤 | -7.77 |
正常肺GW97-179 | 20677 | 29.74 | 90.79 | 181.58 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 27.63 | 351.24 | 702.48 | 肺肿瘤 | 3.87 |
正常肺GW98-165 | 21922 | 26.63 | 663.94 | 1327.88 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 29.38 | 114.52 | 229.04 | 肺肿瘤 | -5.80 |
正常肺GW98-282 | 22584 | 30 | 77.02 | 154.04 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 29.64 | 97.04 | 194.08 | 肺肿瘤 | 1.26 |
正常乳腺GW00-392 | 28750 | 29.08 | 138.57 | 138.57 | 正常乳腺 |
乳腺肿瘤GW00-391 | 28746 | 28.77 | 169.53 | 339.06 | 乳腺肿瘤 | 2.45 |
正常乳腺GW00-413 | 28798 | 32.72 | 13.55 | 13.55 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 31.01 | 40.4 | 80.80 | 乳腺肿瘤 | 5.96 |
正常乳腺GW00-235:238 | 27592-95 | 34.39 | 4.68 | 4.68 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 31.4 | 31.48 | 31.48 | 乳腺肿瘤 | 6.73 |
正常乳腺GW98-621 | 23656 | 28.54 | 195.6 | 391.20 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 30.37 | 60.84 | 121.68 | 乳腺肿瘤 | -3.21 |
正常大脑BB99-542 | 25507 | 32.94 | 11.79 | 23.58 | 正常大脑 | |
正常大脑BB99-406 | 25509 | 32.22 | 18.66 | 37.32 | 正常大脑 | |
正常大脑BB99-904 | 25546 | 32.3 | 17.71 | 35.42 | 正常大脑 | |
大脑期5ALZ BB99-874 | 25502 | 32.82 | 12.76 | 25.52 | 大脑期5-ALZ | -1.26 |
大脑期5ALZ BB99-887 | 25503 | 30.31 | 63.18 | 126.36 | 大脑期5-ALZ | 3.94 |
大脑期5ALZ BB99-862 | 25504 | 31.42 | 31.08 | 62.16 | 大脑期5-ALZ | 1.94 |
大脑期5ALZ BB99-927 | 25542 | 33.35 | 9.08 | 18.16 | 大脑期5-ALZ | -1.77 |
CT肺KC | normal | 30.41 | 59.49 | 118.98 | CT肺 | |
肺26KC | normal | 肺26 | ||||
肺27KC | normal | 37.69 | 0.57 | 0.57 | 肺27 | |
肺24KC | COPD | 40 | 0 | 0.00 | 肺24 | -40.17 |
肺28KC | COPD | 40 | 0 | 0.00 | 肺28 | -40.17 |
肺23KC | COPD | 40 | 0 | 0.00 | 肺23 | -40.17 |
肺25KC | normal | 36.86 | 0.97 | 0.97 | 肺25 | |
哮喘肺ODO3112 | 29321 | 33.08 | 10.79 | 10.79 | 哮喘肺 | -3.72 |
哮喘肺ODO3433 | 29323 | 29.94 | 80.31 | 160.62 | 哮喘肺 | 4.00 |
哮喘肺ODO3397 | 29322 | 29.79 | 87.94 | 175.88 | 哮喘肺 | 4.38 |
哮喘肺ODO4928 | 29325 | 30.08 | 73.39 | 146.78 | 哮喘肺 | 3.65 |
内皮细胞KC | control | 40 | 0.13 | 0.13 | 内皮细胞 | |
内皮细胞VEGF KC | 40 | 0 | 0.00 | 内皮细胞VEGF | -0.13 | |
内皮细胞bFGF KC | 40 | 0.12 | 0.12 | 内皮细胞bFGF | -1.08 | |
心脏Clontech | normal | 34.66 | 3.95 | 7.90 | 心脏 | |
心脏(T-1)缺血 | 29417 | 30.43 | 58.48 | 116.96 | 心脏T-1 | 14.81 |
心脏(T-14)非阻塞性DCM | 29422 | 30.3 | 63.76 | 127.52 | 心脏T-14 | 16.14 |
心脏(T-3399)DCM | 29426 | 31.14 | 37.27 | 74.54 | 心脏T-3399 | 9.44 |
腺样增殖体GW99-269 | 26162 | 33.15 | 10.31 | 20.62 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 30.26 | 65.22 | 130.44 | 扁桃体 | |
T细胞PC00314 | 28453 | 33.29 | 9.45 | 18.90 | T细胞 | |
PBMNC | 40 | 0 | 0.00 | PBMNC | ||
单核细胞 | 40 | 0 | 0.00 | 单核细胞 | ||
B细胞PC00665 | 28455 | 32.25 | 18.35 | 36.70 | B细胞 | |
树突细胞28441 | 30.52 | 55.34 | 110.68 | 树突细胞 | ||
中性粒细胞 | 28440 | 31.61 | 27.61 | 27.61 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 33.2 | 10.01 | 20.02 | 嗜酸性粒细胞 | |
BM unstim | 40 | 0 | 0.00 | BM未刺激的 | ||
BM stim | 40 | 0 | 0.00 | BM刺激的 | 0.00 | |
osteo dif | 40 | 0 | 0.00 | 成骨细胞分化 | 0.00 | |
osteo undif | 40 | 0 | 0.00 | 成骨细胞未分化 | ||
软骨细胞 | 29.65 | 96.25 | 240.63 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 28.59 | 190.09 | 190.09 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 29.06 | 140.66 | 281.32 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 28.38 | 216.61 | 433.22 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 29.43 | 111 | 222.00 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 28.35 | 220.48 | 440.96 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 28.7 | 176.79 | 353.58 | RA滑膜 | |
OA骨(biobank) | 29217 | 30.6 | 52.6 | 52.60 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 29.64 | 97.1 | 194.20 | OA骨 | |
OA骨标本2 | J.Emory | 30.85 | 44.71 | 89.42 | OA骨 | |
软骨(库) | Normal | 28.07 | 264.86 | 529.72 | 软骨(库) | |
软骨(库) | OA | 30.47 | 56.97 | 113.94 | 软骨(库) | -4.65 |
PBL未感染的 | 28441 | 33.41 | 8.73 | 17.46 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 32.1 | 20.17 | 40.34 | PBL HIV IIIB | 2.31 |
MRC5未感染的(100%) | 29158 | 31.09 | 38.5 | 77.00 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 28.24 | 237.46 | 474.92 | MRC5 HSV株F | 6.17 |
W12细胞 | 29179 | 28.83 | 162.45 | 324.90 | W12细胞 | |
角质细胞 | 29180 | 29.21 | 127.89 | 255.78 | 角质细胞 | |
B-肌动蛋白对照 | 26.99 | 528.52 | ||||
基因组 | 25.66 | 1229.15 | ||||
1.00E+05 | 18.76 | 100000 | ||||
1.00E+05 | 19.03 | 100000 | ||||
1.00E+04 | 22.01 | 10000 | ||||
1.00E+04 | 22.05 | 10000 | ||||
1.00E+03 | 26.01 | 1000 | ||||
1.00E+03 | 25.68 | 1000 | ||||
1.00E+02 | 30.57 | 100 | ||||
1.00E+02 | 30.32 | 100 | ||||
1.00E+01 | 32.24 | 10 | ||||
1.00E+01 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
NTC | 40 | 0 |
基因名称sbg120703RNase
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | 1.59 |
结肠肿瘤 | 10.95 |
结肠肿瘤 | -1.29 |
结肠肿瘤 | -2.19 |
肺肿瘤 | -7.77 |
肺肿瘤 | 3.87 |
肺肿瘤 | -5.80 |
肺肿瘤 | 1.26 |
乳腺肿瘤 | 2.45 |
乳腺肿瘤 | 5.96 |
乳腺肿瘤 | 6.73 |
乳腺肿瘤 | -3.21 |
大脑期5ALZ | -1.26 |
大脑期5ALZ | 3.94 |
大脑期5ALZ | 1.94 |
大脑期5ALZ | -1.77 |
肺24 | -40.17 |
肺28 | -40.17 |
肺23 | -40.17 |
哮喘肺 | -3.72 |
哮喘肺 | 4.00 |
哮喘肺 | 4.38 |
哮喘肺 | 3.65 |
内皮细胞VEGF | -0.13 |
内皮细胞bFGF | -1.08 |
心脏T-1 | 14.81 |
心脏T-14 | 16.14 |
心脏T-3399 | 9.44 |
BM刺激的 | 0.00 |
Osteo未分化的 | 0.00 |
软骨(库) | -4.65 |
PBL HIV IIIB | 2.31 |
MRC5 HSV株F | 6.17 |
基因名称sbg98530TS
在正常和疾病标本中有中度的总体表达。在全脑,子宫内膜和睾丸中有最高的正常表达。在正常心脏,骨骼肌和食管中有中度表达。在大部分胃肠道标本和女性生殖道标本中显示表达。在一份结肠肿瘤标本,所有3份心脏标本,和软骨细胞中有最高的疾病表达。数据突出显示肌肉特异性表达模时。在4份结肠肿瘤的一份中上调,在4份乳腺肿瘤的2份中上调提示其参与结肠肿癌和乳腺癌。在所有3份COPD标本中下调提示其在慢性阻塞性肺病中的作用。在HSV中下调提示其作为潜在的宿主因子与单纯疱疹病毒有关。在免疫细胞中有中度到低度的总体表达。在软骨细胞和OA和RA的滑膜中高表达提示其可能参与骨关节炎和类风湿性关节炎。
标本sbg98530TS | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 40,36.35 | 0 | 4.22 | 2.11 | 3.06 | 16.34 | 34.48 |
皮下脂肪Zenbio | 35.78,40 | 5.89 | 0 | 2.95 | 0.96 | 52.36 | 154.19 |
肾上腺Clontech | 40,40 | 0 | 0 | 0.00 | 0.61 | 81.97 | 0.00 |
全脑Clontech | 26.63,26.42 | 1253.02 | 1414.2 | 1333.61 | 7.24 | 6.91 | 9210.01 |
胎脑clontech | 40,37.33 | 0 | 2.38 | 1.19 | 0.48 | 103.95 | 123.70 |
小脑Clontech | 35.9,40 | 5.5 | 0 | 2.75 | 2.17 | 23.04 | 63.36 |
子宫颈 | 33.47,34.27 | 22.86 | 14.26 | 18.56 | 2.42 | 20.66 | 383.47 |
结肠 | 34.49,34.05 | 12.58 | 16.28 | 14.43 | 2.71 | 18.45 | 266.24 |
子宫内膜 | 33.28,32.94 | 25.41 | 31.15 | 28.28 | 0.73 | 68.21 | 1929.06 |
食管 | 33.61,32.9 | 21.02 | 31.85 | 26.44 | 1.37 | 36.50 | 964.78 |
心脏Clontech | 33.32,33.03 | 24.91 | 29.42 | 27.17 | 1.32 | 37.88 | 1028.98 |
下丘脑 | 40,40 | 0 | 0 | 0.00 | 0.32 | 155.28 | 0.00 |
回肠 | 35.89,33.37 | 5.53 | 24.14 | 14.84 | 2.58 | 19.38 | 287.50 |
空肠 | 31.55,31.42 | 70.2 | 75.71 | 72.96 | 6.60 | 7.58 | 552.69 |
肾脏 | 40,35.5 | 0 | 6.96 | 3.48 | 2.12 | 23.58 | 82.08 |
肝脏 | 34.29,33.63 | 14.07 | 20.78 | 17.43 | 1.50 | 33.33 | 580.83 |
胚胎肝Clontech | 32.16,32.92 | 49.02 | 31.52 | 40.27 | 10.40 | 4.81 | 193.61 |
肺 | 40,35.78 | 0 | 2.95 | 2.57 | 19.46 | 57.30 | |
乳腺Clontech | 31.42,32.08 | 75.62 | 51.54 | 63.58 | 13.00 | 3.85 | 244.54 |
子宫肌层 | 32.93,32.03 | 31.21 | 52.84 | 42.03 | 2.34 | 21.37 | 897.97 |
网膜 | 35.21,40 | 8.23 | 0 | 4.12 | 3.94 | 12.69 | 52.22 |
卵巢 | 35.36,35.51 | 7.53 | 6.89 | 7.21 | 4.34 | 11.52 | 83.06 |
胰腺 | 40,40 | 0 | 0 | 0.00 | 0.81 | 61.80 | 0.00 |
胰头 | 40,37.54 | 0 | 2.11 | 1.06 | 1.57 | 31.85 | 33.60 |
腮腺 | 31.67,31.01 | 65.33 | 96.46 | 80.90 | 5.48 | 9.12 | 738.09 |
胎盘Clontech | 33.13,32.05 | 27.88 | 52.3 | 40.09 | 5.26 | 9.51 | 381.08 |
前列腺 | 35.03,40 | 9.13 | 5.22 | 7.18 | 3.00 | 16.67 | 119.58 |
直肠 | 40,35.19 | 0 | 8.32 | 4.16 | 1.23 | 40.65 | 169.11 |
唾液腺Clontech | 32.41,34.06 | 42.32 | 16.15 | 29.24 | 7.31 | 6.84 | 199.97 |
骨骼肌Clontech | 33.93,33.76 | 17.41 | 19.28 | 18.35 | 1.26 | 39.68 | 727.98 |
皮肤 | 40,40 | 0 | 0 | 0.00 | 1.21 | 41.32 | 0.00 |
小肠Clontech | 34.11 | 11.73 | 15.7 | 13.72 | 0.98 | 51.07 | 700.46 |
脾脏 | 36.08,40 | 4.94 | 0.37 | 2.66 | 4.92 | 10.16 | 26.98 |
胃 | 40,40 | 0 | 0 | 0.00 | 2.73 | 18.32 | 0.00 |
睾丸Clontech | 35.54,33.26 | 6.79 | 25.83 | 16.31 | 0.57 | 87.87 | 1433.22 |
胸腺Clontech | 33.66,34.12 | 20.35 | 15.62 | 17.99 | 9.89 | 5.06 | 90.93 |
甲状腺 | 40,35.46 | 0 | 7.12 | 3.56 | 2.77 | 18.05 | 64.26 |
气管Clontech | 32.08,31.84 | 51.54 | 59.21 | 55.38 | 9.71 | 5.15 | 285.14 |
膀胱 | 34.75,36.99 | 10.8 | 2.91 | 6.86 | 5.47 | 9.14 | 62.66 |
子宫 | 31.79,32.2 | 60.97 | 47.95 | 54.46 | 5.34 | 9.36 | 509.93 |
基因组 | 26.8 | 1133.17 | |||||
b-肌动蛋白 | 27.6 | 706.62 | |||||
1.00E+05 | 19.53 | 100000 | |||||
1.00E+05 | 19.54 | 100000 | |||||
1.00E+04 | 22.8 | 10000 |
1.00E+04 | 23.02 | 10000 | |||||
1.00E+03 | 26.14 | 1000 | |||||
1.00E+03 | 26.59 | 1000 | |||||
1.00E+02 | 31.41 | 100 | |||||
1.00E+02 | 30.97 | 100 | |||||
1.00E+01 | 40 | 0 | |||||
1.00E+01 | 35.24 | 10 | |||||
1.00E-00 | 40 | 0 | |||||
1.00E-00 | 40 | 0 | |||||
NTC | 40 | 0 | |||||
NTC | 40 | 0 |
标本sbg98530TS | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 26.26 | 1792.89 | 3585.78 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 26.2 | 1856.22 | 3712.44 | 结肠肿瘤 | 1.04 |
正常结肠GW98-178 | 22080 | 27.25 | 986.8 | 1973.60 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 26.7 | 1369.12 | 2738.24 | 结肠肿瘤 | 1.39 |
正常结肠GW98-561 | 23514 | 27.55 | 821.35 | 1642.70 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 24.64 | 4748.96 | 9497.92 | 结肠肿瘤 | 5.78 |
正常结肠GW98-894 | 24691 | 27.27 | 971.87 | 1943.74 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 25.35 | 3093.47 | 6186.94 | 结肠肿瘤 | 3.18 |
正常肺GW98-3 | 20742 | 27.02 | 1133.68 | 2267.36 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 27.26 | 981.94 | 1963.88 | 肺肿瘤 | -1.15 |
正常肺GW97-179 | 20677 | 29.14 | 315.07 | 630.14 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 28.15 | 571.76 | 1143.52 | 肺肿瘤 | 1.81 |
正常肺GW98-165 | 21922 | 27.86 | 682.2 | 1364.40 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 27.45 | 871.19 | 1742.38 | 肺肿瘤 | 1.28 |
正常肺GW98-282 | 22584 | 28.12 | 581.74 | 1163.48 | 正常肺 |
肺肿瘤GW98-281 | 22583 | 29.32 | 283.71 | 567.42 | 肺肿瘤 | -2.05 |
正常乳腺GW00-392 | 28750 | 27.85 | 687.38 | 687.38 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 26.61 | 1444.19 | 2888.38 | 乳腺肿瘤 | 4.20 |
正常乳腺GW00-413 | 28798 | 28.43 | 483.03 | 483.03 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 25.49 | 2836.66 | 5673.32 | 乳腺肿瘤 | 11.75 |
正常乳腺GW00-235:238 | 27592-95 | 32.26 | 48.29 | 48.29 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 29.07 | 328.46 | 328.46 | 乳腺肿瘤 | 6.80 |
正常乳腺GW98-621 | 23656 | 26.82 | 1279.07 | 2558.14 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 26.8 | 1289.27 | 2578.54 | 乳腺肿瘤 | 1.01 |
正常大脑BB-99-542 | 25507 | 29.03 | 337.63 | 675.26 | 正常大脑 | |
正常大脑BB-99-406 | 25509 | 29.19 | 305.6 | 611.20 | 正常大脑 | |
正常大脑BB-99-904 | 25546 | 30.44 | 144.55 | 289.10 | 正常大脑 | |
大脑期5ALZ BB99-874 | 25502 | 28.47 | 471.8 | 943.60 | 大脑期5-ALZ | 1.80 |
大脑期5ALZ BB99-887 | 25503 | 27.3 | 955.52 | 1911.04 | 大脑期5-ALZ | 3.64 |
大脑期5ALZ BB99-862 | 25504 | 27.42 | 891.77 | 1783.54 | 大脑期5-ALZ | 3.40 |
大脑期5ALZ BB99-927 | 25542 | 29.31 | 285.16 | 570.32 | 大脑期5-ALZ | 1.09 |
CT肺KC | normal | 27.96 | 643.88 | 1287.76 | CT肺 | |
肺26KC | normal | 35.82 | 5.66 | 5.66 | 肺26 | |
肺27KC | normal | 40 | 0 | 0.00 | 肺27 | |
肺24KC | COPD | 40 | 0 | 0.00 | 肺24 | -325.52 |
肺28KC | COPD | 35.3 | 7.73 | 7.73 | 肺28 | -42.11 |
肺23KC | COPD | 36.67 | 3.39 | 3.39 | 肺23 | -96.02 |
肺25KC | normal | 35.11 | 8.67 | 8.67 | 肺25 | |
哮喘肺ODO3112 | 29321 | 31.01 | 102.08 | 102.08 | 哮喘肺 | -3.19 |
哮喘肺ODO3433 | 29323 | 29.76 | 216.81 | 433.62 | 哮喘肺 | 1.33 |
哮喘肺ODO3397 | 29322 | 29.83 | 208.08 | 416.16 | 哮喘肺 | 1.28 |
哮喘肺ODO4928 | 29325 | 30.37 | 150.17 | 300.34 | 哮喘肺 | -1.08 |
内皮细胞KC | control | 37.54 | 2 | 2.00 | 内皮细胞 | |
内皮细胞VEGF KC | 35.77 | 5.83 | 5.83 | 内皮细胞VEGF | 2.92 | |
内皮细胞bFGF KC | 40 | 0 | 0.00 | 内皮细胞bFGF | -2.00 |
心脏Clontech | normal | 26.09 | 1982.44 | 3964.88 | 心脏 | |
心脏(T-1)缺血 | 29417 | 24 | 6956.27 | 13912.54 | 心脏T-1 | 3.51 |
心脏(T-14)非阻塞性DCM心脏 | 29422 | 24.55 | 5010.03 | 10020.06 | 心脏T-14 | 2.53 |
心脏(T-3399)DCM | 29426 | 24.05 | 6766.57 | 13533.14 | 心脏T-3399 | 3.41 |
腺样增殖体GW99-269 | 26162 | 30.56 | 134.11 | 268.22 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 27.94 | 651.01 | 1302.02 | 扁桃体 | |
T细胞PC00314 | 28453 | 29.8 | 212.45 | 424.90 | T细胞 | |
PBMNC | 33.01 | 30.69 | 30.69 | PBMNC | ||
单核细胞 | 33.42 | 23.9 | 47.80 | 单核细胞 | ||
B细胞PC00665 | 28455 | 33.52 | 22.59 | 45.18 | B细胞 | |
树突细胞28441 | 29.07 | 329.58 | 659.16 | 树突细胞 | ||
中性粒细胞 | 28440 | 30.39 | 149 | 149.00 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 35.41 | 7.25 | 14.50 | 嗜酸性粒细胞 | |
BM unstim | 34.24 | 14.65 | 14.65 | BM未刺激的 | ||
BM stim | 36.61 | 3.51 | 3.51 | BM刺激的 | -4.17 | |
成骨细胞(osteo)分化的KC | 30.55 | 135.33 | 135.23 | 成骨细胞分化 | 3.02 | |
osteo undif | 32.38 | 44.88 | 44.88 | 成骨细胞未分化 | ||
软骨细胞 | 25.35 | 3089.54 | 7723.85 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 28.75 | 398.53 | 398.53 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 27.04 | 1119.77 | 2239.54 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 28.85 | 375.92 | 751.84 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 28.14 | 574.66 | 1149.32 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 27.58 | 806.11 | 1612.22 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 28.04 | 611.1 | 1222.20 | RA滑膜 | |
OA骨(biobank) | 29217 | 30.25 | 161.3 | 161.30 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 31.24 | 89.29 | 178.58 | OA骨 | |
OA骨标本2 | J.Emory | 30.98 | 104.34 | 208.68 | OA骨 |
软骨(库(pool)) | Normal | 29.86 | 204.47 | 408.94 | 软骨(库) | |
软骨(库) | OA | 29.37 | 275.09 | 550.18 | 软骨(库) | 1.35 |
PBL未感染的 | 28441 | 26.45 | 1598.39 | 3196.78 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 27.57 | 814.58 | 1629.16 | PBL HIV IIIB | -1.96 |
MRC5未感染的(100%) | 29158 | 25.13 | 3539.95 | 7079.90 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 30.49 | 139.89 | 279.78 | MRC5 HSV株F | -25.31 |
W12细胞 | 29179 | 26.72 | 1359.04 | 2718.08 | W12细胞 | |
角质细胞 | 29180 | 26.41 | 1633.77 | 3267.54 | 角质细胞 | |
B-肌动蛋白对照 | 27.87 | 678.8 | ||||
基因组 | 26.9 | 1214.71 | ||||
1.00E+05 | 19.86 | 100000 | ||||
1.00E+05 | 19.82 | 100000 | ||||
1.00E+04 | 23.15 | 10000 | ||||
1.00E+04 | 23.21 | 10000 | ||||
1.00E+03 | 26.62 | 1000 | ||||
1.00E+03 | 26.79 | 1000 | ||||
1.00E+02 | 31.2 | 100 | ||||
1.00E+02 | 32.2 | 100 | ||||
1.00E+01 | 40 | 0 | ||||
1.00E+01 | 34.53 | 10 | ||||
1.00E-00 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
NTC | 40 | 0 |
基因名称sbg98530TS
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | 1.04 |
结肠肿瘤 | 1.39 |
结肠肿瘤 | 5.78 |
结肠肿瘤 | 3.18 |
肺肿瘤 | -1.15 |
肺肿瘤 | 1.81 |
肺肿瘤 | 1.28 |
肺肿瘤 | -2.05 |
乳腺肿瘤 | 4.20 |
乳腺肿瘤 | 11.75 |
乳腺肿瘤 | 6.80 |
乳腺肿瘤 | 1.01 |
大脑期5ALZ | 1.80 |
大脑期5ALZ | 3.64 |
大脑期5ALZ | 3.40 |
大脑期5ALZ | 1.09 |
肺24 | -325.52 |
肺28 | -42.11 |
肺23 | -96.02 |
哮喘肺 | -3.19 |
哮喘肺 | 1.33 |
哮喘肺 | 1.28 |
哮喘肺 | -1.08 |
内皮细胞VEGF | 2.92 |
内皮细胞bFGF | -2.00 |
心脏T-1 | 3.51 |
心脏T-14 | 2.53 |
心脏T-3399 | 3.41 |
BM stim | -4.17 |
Osteo undif | 3.02 |
软骨(库) | 1.35 |
PBL HIV IIIB | -1.96 |
MRC5 HSV株F | -25.31 |
基因名称sbg563917RDP
在正常和疾病标本中有中度到低度的总体表达。在睾丸,肝脏,气管和全脑中有最高的正常表达。在大多数胃肠道标本中显示良好表达。在T细胞,B细胞,中性粒细胞和嗜酸性粒细胞中有最高的疾病表达。在4份乳腺肿瘤的1份中上调提示其参与乳腺癌。在所有3份COPD肺中下调提示其参与慢性阻塞性肺病。在在缺血性心脏标本中下调提示在缺血性心脏疾病中涉及该基因。在VEGF和bFGF治疗的内皮细胞中下调提示其在血管生成的作用。在HSV中上调提示其作为潜在的宿主因子与单纯疱疹病毒有关。
标本sbg563917RDP | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 35.34,40 | 3.66 | 0 | 1.83 | 3.06 | 16.34 | 29.90 |
皮下脂肪Zenbio | 40,40 | 0 | 0.00 | 0.96 | 52.36 | 0.00 | |
肾上腺Clontech | 40,40 | 0 | 0 | 0.00 | 0.61 | 81.97 | 0.00 |
全脑Clontech | 30.09,30.01 | 91.85 | 96.8 | 94.33 | 7.24 | 6.91 | 651.42 |
胎脑clontech | 40,40 | 0 | 0 | 0.00 | 0.48 | 103.95 | 0.00 |
小脑Clontech | 35.19,40 | 4.03 | 0 | 2.02 | 2.17 | 23.04 | 46.43 |
子宫颈 | 36.08,40 | 2.33 | 0 | 1.17 | 2.42 | 20.66 | 24.07 |
结肠 | 36.07,35.1 | 2.35 | 4.24 | 3.30 | 2.71 | 18.45 | 60.79 |
子宫内膜 | 35.01,40 | 4.49 | 0 | 2.25 | 0.73 | 68.21 | 153.14 |
食管 | 34.94,40 | 4.68 | 0 | 2.34 | 1.37 | 36.50 | 85.40 |
心脏Clontech | 40,40 | 0 | 0 | 0.00 | 1.32 | 37.88 | 0.00 |
下丘脑 | 40,40 | 0 | 0 | 0.00 | 0.32 | 155.28 | 0.00 |
回肠 | 35.24,40 | 3.89 | 0 | 1.95 | 2.58 | 19.38 | 37.69 |
空肠 | 35.37,33.35 | 3.6 | 12.44 | 8.02 | 6.60 | 7.58 | 60.76 |
肾脏 | 40,34.97 | 0 | 4.6 | 2.30 | 2.12 | 23.58 | 54.25 |
肝脏 | 33.51,34.6 | 11.25 | 5.78 | 8.52 | 1.50 | 33.33 | 283.83 |
胚胎肝Clontech | 33.19,35.54 | 13.75 | 3.25 | 8.50 | 10.40 | 4.81 | 40.87 |
肺 | 34.32 | 6.84 | 2.28 | 4.56 | 2.57 | 19.46 | 88.72 |
乳腺Clontech | 40,35.14 | 0 | 4.15 | 2.08 | 13.00 | 3.85 | 7.98 |
子宫肌层 | 40,40 | 0 | 0.09 | 0.05 | 2.34 | 21.37 | 0.96 |
网膜 | 36.17,33.01 | 2.2 | 15.32 | 8.76 | 3.94 | 12.69 | 111.17 |
卵巢 | 40,40 | 0 | 0 | 0.00 | 4.34 | 11.52 | 0.00 |
胰腺 | 40,40 | 0 | 0 | 0.00 | 0.81 | 61.80 | 0.00 |
胰头 | 40,40 | 0 | 0 | 0.00 | 1.57 | 31.85 | 0.00 |
腮腺 | 35.43,39.81 | 3.46 | 0.24 | 1.85 | 5.48 | 9.12 | 16.88 |
胎盘Clontech | 33.7,35.45 | 10.02 | 3.42 | 6.72 | 5.26 | 9.51 | 63.88 |
前列腺 | 40,40 | 0 | 0 | 0.00 | 3.00 | 16.67 | 0.00 |
直肠 | 40,40 | 0 | 0 | 0.00 | 1.23 | 40.65 | 0.00 |
唾液腺Clontech | 34.89,40 | 4.83 | 0 | 2.42 | 7.31 | 6.84 | 16.52 |
骨骼肌Clontech | 40,40 | 0 | 0 | 0.00 | 1.26 | 39.68 | 0.00 |
皮肤 | 40,40 | 0 | 0 | 0.00 | 1.21 | 41.32 | 0.00 |
小肠Clontech | 40,40 | 0 | 0 | 0.00 | 0.98 | 51.07 | 0.00 |
脾脏 | 35.01,33.36 | 4.48 | 12.38 | 8.43 | 4.92 | 10.16 | 85.67 |
胃 | 33.38,34.18 | 12.18 | 7.48 | 9.83 | 2.73 | 18.32 | 180.04 |
睾丸Clontech | 34.25,32.86 | 7.17 | 16.84 | 12.01 | 0.57 | 87.87 | 1054.92 |
胸腺Clontech | 32.14,33.25 | 26.17 | 13.24 | 19.71 | 9.89 | 5.06 | 99.62 |
甲状腺 | 40,40 | 0 | 0.09 | 0.05 | 2.77 | 18.05 | 0.81 |
气管Clontech | 31.41,31 | 41.04 | 52.65 | 46.85 | 9.71 | 5.15 | 241.22 |
膀胱 | 40,35.05 | 0 | 4.38 | 2.19 | 5.47 | 9.14 | 20.02 |
子宫 | 33.77,33.41 | 9.62 | 12 | 10.81 | 5.34 | 9.36 | 101.22 |
基因组 | 26.54 | 813.56 | |||||
b-肌动蛋白 | 27.39 | 481.34 | |||||
1.00E+05 | 18.71 | 100000 | |||||
1.00E+05 | 18.92 | 100000 | |||||
1.00E+04 | 22.44 | 10000 |
1.00E+04 | 22.11 | 10000 | |||||
1.00E+03 | 26.05 | 1000 | |||||
1.00E+03 | 26.11 | 1000 | |||||
1.00E+02 | 30.4 | 100 | |||||
1.00E+02 | 30.17 | 100 | |||||
1.00E+01 | 33.87 | 10 | |||||
1.00E+01 | 33.26 | 10 | |||||
1.00E-00 | 40 | 0 | |||||
1.00E-00 | 40 | 0 | |||||
NTC | 40 | 0 | |||||
NTC | 40 | 0 |
标本sbg563917RDP | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 30.39 | 148.35 | 296.70 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 30.93 | 110.14 | 220.28 | 结肠肿瘤 | -1.35 |
正常结肠GW98-178 | 22080 | 32.93 | 36.71 | 73.42 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 34.8 | 13.09 | 26.18 | 结肠肿瘤 | -2.80 |
正常结肠GW98-561 | 23514 | 31.41 | 84.68 | 169.36 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 32.09 | 58.33 | 116.66 | 结肠肿瘤 | -1.45 |
正常结肠GW98-894 | 24691 | 30.02 | 182.15 | 364.30 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 31.12 | 99.26 | 198.52 | 结肠肿瘤 | -1.84 |
正常肺GW98-3 | 20742 | 28.4 | 443.99 | 887.98 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 33.59 | 25.44 | 50.88 | 肺肿瘤 | -17.45 |
正常肺GW97-179 | 20677 | 28.63 | 391.85 | 783.70 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 29.16 | 292.08 | 584.16 | 肺肿瘤 | -1.34 |
正常肺GW98-165 | 21922 | 29.13 | 296.8 | 593.60 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 30.22 | 163.43 | 326.86 | 肺肿瘤 | -1.82 |
正常肺GW98-282 | 22584 | 31.71 | 71.72 | 143.44 | 正常肺 |
肺肿瘤GW98-281 | 22583 | 31.74 | 70.77 | 141.54 | 肺肿瘤 | -1.01 |
正常乳腺GW00-392 | 28750 | 31.49 | 81.02 | 81.02 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 33.58 | 25.62 | 51.24 | 乳腺肿瘤 | -1.58 |
正常乳腺GW00-413 | 28798 | 35.07 | 11.31 | 11.31 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 31.99 | 61.52 | 123.04 | 乳腺肿瘤 | 10.88 |
正常乳腺GW00-235:238 | 27592-95 | 35.63 | 8.3 | 8.30 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 34.33 | 16.97 | 16.97 | 乳腺肿瘤 | 2.04 |
正常乳腺GW98-621 | 23656 | 32.07 | 58.95 | 117.90 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 32.71 | 41.33 | 82.66 | 乳腺肿瘤 | -1.43 |
正常大脑BB-99-542 | 25507 | 30.16 | 168.86 | 337.72 | 正常大脑 | |
正常大脑BB-99-406 | 25509 | 31.12 | 99.35 | 198.70 | 正常大脑 | |
正常大脑BB-99-904 | 25546 | 31.14 | 98.44 | 196.88 | 正常大脑 | |
大脑期5ALZ BB99-874 | 25502 | 33.16 | 32.39 | 64.78 | 大脑期5-ALZ | -3.77 |
大脑期5ALZ BB99-887 | 25503 | 29.32 | 267.28 | 534.56 | 大脑期5-ALZ | 2.19 |
大脑期5ALZ BB99-862 | 25504 | 30.36 | 150.72 | 301.44 | 大脑期5-ALZ | 1.23 |
大脑期5ALZ BB99-927 | 25542 | 30.1 | 174.01 | 348.02 | 大脑期5-ALZ | 1.42 |
CT肺KC | normal | 31.06 | 102.88 | 205.76 | CT肺 | |
肺26KC | normal | 32.15 | 56.21 | 56.21 | 肺26 | |
肺27KC | normal | 35.96 | 6.92 | 6.92 | 肺27 | |
肺24KC | COPD | 40 | 0 | 0.00 | 肺24 | -70.34 |
肺28KC | COPD | 36.21 | 6.05 | 6.05 | 肺28 | -11.63 |
肺23KC | COPD | 34.83 | 12.87 | 12.87 | 肺23 | -5.47 |
肺25KC | normal | 34.89 | 12.45 | 12.45 | 肺25 | |
哮喘肺ODO3112 | 29321 | 32.57 | 44.76 | 44.76 | 哮喘肺 | -1.57 |
哮喘肺ODO3433 | 29323 | 32.4 | 49.04 | 98.08 | 哮喘肺 | 1.39 |
哮喘肺ODO3397 | 29322 | 31.79 | 68.64 | 137.28 | 哮喘肺 | 1.95 |
哮喘肺ODO4928 | 29325 | 31.34 | 88.11 | 176.22 | 哮喘肺 | 2.51 |
内皮细胞KC | control | 35.77 | 7.68 | 7.68 | 内皮细胞 | |
内皮细胞VEGF KC | 40 | 0 | 0.00 | 内皮细胞VEGF | -7.68 | |
内皮细胞bFGF KC | 40 | 0 | 0.00 | 内皮细胞bFGF | -7.68 |
心脏Clontech | normal | 31.09 | 100.75 | 201.50 | 心脏 | |
心脏(T-1)缺血 | 29417 | 34.75 | 13.46 | 26.92 | 心脏T-1 | -7.49 |
心脏(T-14)非阻塞性DCM | 29422 | 33.69 | 24.17 | 48.34 | 心脏T-14 | -4.17 |
心脏(T-3399)DCM | 29426 | 33.48 | 27.16 | 54.32 | 心脏T-3399 | -3.71 |
腺样增殖体GW99-269 | 26162 | 30.49 | 140.7 | 281.40 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 30.07 | 177.32 | 354.64 | 扁桃体 | |
T细胞PC00314 | 28453 | 27.79 | 622.1 | 1244.20 | T细胞 | |
PBMNC | 36.19 | 6.11 | 6.11 | PBMNC | ||
单核细胞 | 33.24 | 30.91 | 61.82 | 单核细胞 | ||
B细胞PC00665 | 28455 | 26.37 | 1355.2 | 2710.40 | B细胞 | |
树突细胞28441 | 28.69 | 378.62 | 757.24 | 树突细胞 | ||
中性粒细胞 | 28440 | 23.28 | 7420.47 | 7420.47 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 25.33 | 2408.94 | 4817.88 | 嗜酸性粒细胞 | |
BM unstim | 32.24 | 53.57 | 53.57 | BM未刺激的 | ||
BM stim | 31.92 | 64.05 | 64.05 | BM刺激的 | 1.20 | |
osteo dif | 40 | 0 | 0.00 | 成骨细胞分化 | 0.00 | |
osteo undif | 40 | 0 | 0.00 | 成骨细胞未分化 | ||
软骨细胞 | 37.59 | 2.82 | 7.05 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 31.77 | 69.48 | 69.48 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 31.16 | 96.93 | 193.86 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 30.84 | 115.69 | 231.38 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 30.96 | 108.37 | 216.74 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 29.2 | 285.91 | 571.82 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 29.87 | 198.12 | 396.24 | RA滑膜 | |
OA骨(biobank) | 29217 | 29.67 | 220.64 | 220.64 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 30.54 | 136.41 | 272.82 | OA骨 | |
OA骨标本2 | J.Emory | 29.38 | 259.07 | 518.14 | OA骨 | |
软骨(库) | Normal | 31.34 | 87.88 | 175.76 | 软骨(库) |
软骨(库) | OA | 32.9 | 37.23 | 74.46 | 软骨(库) | -2.36 |
PBL未感染的 | 28441 | 30.55 | 135.85 | 271.70 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 31.02 | 104.8 | 209.60 | PBL HIV IIIB | -1.30 |
MRC5未感染的(100%) | 29158 | 35.11 | 11.06 | 22.12 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 29.63 | 226.14 | 452.28 | MRC5 HSV株F | 20.45 |
W12细胞 | 29179 | 37.87 | 2.42 | 4.84 | W12细胞 | |
角质细胞 | 29180 | 36.14 | 6.26 | 12.52 | 角质细胞 | |
B-肌动蛋白对照 | 27.14 | 887.42 | ||||
基因组 | 26.16 | 1520.17 | ||||
1.00E+05 | 19.22 | 100000 | ||||
1.00E+05 | 19.2 | 100000 | ||||
1.00E+04 | 22.49 | 10000 | ||||
1.00E+04 | 22.62 | 10000 | ||||
1.00E+03 | 26.23 | 1000 | ||||
1.00E+03 | 26.05 | 1000 | ||||
1.00E+02 | 30.26 | 100 | ||||
1.00E+02 | 31.03 | 100 | ||||
1.00E+01 | 38.68 | 10 | ||||
1.00E+01 | 33.47 | 10 | ||||
1.00E-00 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
NTC | 40 | 0 |
基因名称sbg563917RDP
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | -1.35 |
结肠肿瘤 | -2.80 |
结肠肿瘤 | -1.45 |
结肠肿瘤 | -1.84 |
肺肿瘤 | -17.45 |
肺肿瘤 | -1.34 |
肺肿瘤 | -1.82 |
肺肿瘤 | -1.01 |
乳腺肿瘤 | -1.58 |
乳腺肿瘤 | 10.88 |
乳腺肿瘤 | 2.04 |
乳腺肿瘤 | -1.43 |
大脑期5ALZ | -3.77 |
大脑期5ALZ | 2.19 |
大脑期5ALZ | 1.23 |
大脑期5ALZ | 1.42 |
肺24 | -70.34 |
肺28 | -11.63 |
肺23 | -5.47 |
哮喘肺 | -1.57 |
哮喘肺 | 1 .39 |
哮喘肺 | 1.95 |
哮喘肺 | 2.51 |
内皮细胞VEGF | -7.68 |
内皮细胞bFGF | -7.68 |
心脏T-1 | -7.49 |
心脏T-14 | -4.17 |
心脏T-3399 | -3.71 |
BM stim | 1.20 |
Osteo undif | 0.00 |
软骨(库) | -2.36 |
PBL HIV IIIB | -1.30 |
MRC5 HSV株F | 20.45 |
基因名称sbg618069LRR
在正常和疾病标本中有低的总体表达。在全脑,胎脑,小脑和胸腺中有最高的正常表达。在1份结肠肿瘤标本,1份肺肿瘤标本,和未感染的PBL细胞中有最高的疾病表达。在4份结肠肿瘤的2份中下调提示其在结肠癌中的作用。在4份肺肿瘤的一份中上调和4份乳腺肿瘤的2份中上调提示其在肺癌和乳腺癌中的作用。在所有3份COPD肺标本中下调提示该基因在COPD中的作用。其在受到刺激的骨髓中上调。在HIV感染的细胞系中下调,和在免疫细胞中的中度表达提示其与HIV有关。在HSV中上调提示其作为潜在的宿主因子与单纯疱疹病毒有关。
标本sbg618069LRR | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 35.24,34.33 | 4.38 | 7.65 | 6.02 | 3.06 | 16.34 | 98.28 |
皮下脂肪Zenbio | 40,40 | 0 | 0.08 | 0.04 | 0.96 | 52.36 | 2.09 |
肾上腺Clontech | 39.9,38.74 | 0.13 | 0.51 | 0.32 | 0.61 | 81.97 | 26.23 |
全脑Clontech | 27.02,26.51 | 673.36 | 916.93 | 795.15 | 7.24 | 6.91 | 5491.33 |
胎脑clontech | 40,40 | 0.13 | 6.01 | 3.07 | 0.48 | 103.95 | 319.13 |
小脑Clontech | 32.15,32.13 | 28.98 | 29.44 | 29.21 | 2.17 | 23.04 | 673.04 |
子宫颈 | 40,40 | 0 | 0 | 0.00 | 2.42 | 20.66 | 0.00 |
结肠 | 36.53,39.88 | 1.98 | 0.25 | 1.12 | 2.71 | 18.45 | 20.57 |
子宫内膜 | 37.98,40 | 0.82 | 0.19 | 0.51 | 0.73 | 68.21 | 34.45 |
食管 | 38.86,40 | 0.48 | 0.15 | 0.32 | 1.37 | 36.50 | 11.50 |
心脏Clontech | 34.17,34.72 | 8.41 | 6.03 | 7.22 | 1.32 | 37.88 | 273.48 |
下丘脑 | 40,40 | 0 | 0.07 | 0.04 | 0.32 | 155.28 | 5.43 |
回肠 | 40,40 | 0.17 | 0.11 | 0.14 | 2.58 | 19.38 | 2.71 |
空肠 | 33.07,34.34 | 16.52 | 7.58 | 12.05 | 6.60 | 7.58 | 91.29 |
肾脏 | 36.05,40 | 2.67 | 0.21 | 1.44 | 2.12 | 23.58 | 33.96 |
肝脏 | 38.72,40 | 0.52 | 0.61 | 0.57 | 1.50 | 33.33 | 18.83 |
胚胎肝Clontech | 33.28,36.35 | 14.52 | 2.22 | 8.37 | 10.40 | 4.81 | 40.24 |
肺 | 40,40 | 0.13 | 0.08 | 0.11 | 2.57 | 19.46 | 2.04 |
乳腺Clontech | 40,34.19 | 0 | 8.33 | 4.17 | 13.00 | 3.85 | 16.02 |
子宫肌层 | 40,40 | 0.28 | 0 | 0.14 | 2.34 | 21.37 | 2.99 |
网膜 | 35.01,35.36 | 5.04 | 4.07 | 4.56 | 3.94 | 12.69 | 57.80 |
卵巢 | 34.24,40 | 8.07 | 0.26 | 4.17 | 4.34 | 11.52 | 47.98 |
胰腺 | 40,40 | 0.11 | 0.13 | 0.12 | 0.81 | 61.80 | 7.42 |
胰头 | 40,40 | 0 | 0 | 0.00 | 1.57 | 31.85 | 0.00 |
腮腺 | 34.01,34.28 | 9.31 | 7.9 | 8.61 | 5.48 | 9.12 | 78.51 |
胎盘Clontech | 40,40 | 0 | 0.07 | 0.04 | 5.26 | 9.51 | 0.33 |
前列腺 | 40,39.13 | 0.15 | 0.4 | 0.28 | 3.00 | 16.67 | 4.58 |
直肠 | 40,39.55 | 0.21 | 0.31 | 0.26 | 1.23 | 40.65 | 10.57 |
唾液腺Clontech | 32.35,33.08 | 25.74 | 16.45 | 21.10 | 7.31 | 6.84 | 144.29 |
骨骼肌Clontech | 34.78,40 | 5.81 | 0.27 | 3.04 | 1.26 | 39.68 | 120.63 |
皮肤 | 40,40 | 0 | 0 | 0.00 | 1.21 | 41.32 | 0.00 |
小肠Clontech | 40,40 | 0.16 | 0 | 0.08 | 0.98 | 51.07 | 4.09 |
脾脏 | 35.59,40 | 3.53 | 0.59 | 2.06 | 4.92 | 10.16 | 20.93 |
胃 | 36.73,40 | 1.76 | 0.11 | 0.94 | 2.73 | 18.32 | 17.12 |
睾丸Clontech | 37.91,40 | 0.86 | 0.1 | 0.48 | 0.57 | 87.87 | 42.18 |
胸腺Clontech | 30.22,29.94 | 94.88 | 112.23 | 103.56 | 9.89 | 5.06 | 523.53 |
甲状腺 | 35.15,40 | 4.62 | 0 | 2.31 | 2.77 | 18.05 | 41.70 |
气管Clontech | 33.49,34.21 | 12.75 | 8.22 | 10.49 | 9.71 | 5.15 | 53.99 |
膀胱 | 40,40 | 0.09 | 0.08 | 0.09 | 5.47 | 9.14 | 0.78 |
子宫 | 35.26,33.03 | 4.31 | 16.97 | 10.64 | 5.34 | 9.36 | 99.63 |
基因组 | 26.04 | 1229.54 | |||||
b-肌动蛋白 | 27.25 | 584.19 | |||||
1.00E+05 | 19.09 | 100000 | |||||
1.00E+05 | 19.04 | 100000 | |||||
1.00E+04 | 22.35 | 10000 |
1.00E+04 | 22.35 | 10000 | |||||
1.00E+03 | 26.07 | 1000 | |||||
1.00E+03 | 26.26 | 1000 | |||||
1.00E+02 | 30.64 | 100 | |||||
1.00E+02 | 30.38 | 100 | |||||
1.00E+01 | 34.04 | 10 | |||||
1.00E+01 | 33.52 | 10 | |||||
1.00E-00 | 40 | 0 | |||||
1.00E-00 | 40 | 0 | |||||
NTC | 40 | 0 | |||||
NTC | 40 | 0 |
标本sbg618069LRR | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 29.52 | 176.51 | 353.02 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 33.45 | 18.5 | 37.00 | 结肠肿瘤 | -9.54 |
正常结肠GW98-178 | 22080 | 31.82 | 47.14 | 94.28 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 29.68 | 160.67 | 321.34 | 结肠肿瘤 | 3.41 |
正常结肠GW98-561 | 23514 | 30.33 | 110.78 | 221.56 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 33.11 | 22.39 | 44.78 | 结肠肿瘤 | -4.95 |
正常结肠GW98-894 | 24691 | 28.1 | 396.95 | 793.90 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 26.93 | 779.99 | 1559.98 | 结肠肿瘤 | 1.96 |
正常肺GW98-3 | 20742 | 30.41 | 105.78 | 211.56 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 26.28 | 1128.28 | 2256.56 | 肺肿瘤 | 10.67 |
正常肺GW97-179 | 20677 | 29.28 | 201.91 | 403.82 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 28.35 | 345.36 | 690.72 | 肺肿瘤 | 1.71 |
正常肺GW98-165 | 21922 | 28.42 | 331.95 | 663.90 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 30.98 | 76.05 | 152.10 | 肺肿瘤 | -4.36 |
正常肺GW98-282 | 22584 | 34.15 | 12.36 | 24.72 | 正常肺 |
肺肿瘤GW98-281 | 22583 | 32.08 | 40.6 | 81.20 | 肺肿瘤 | 3.28 |
正常乳腺GW00-392 | 28750 | 29.67 | 161.68 | 161.68 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 28.98 | 239.65 | 479.30 | 乳腺肿瘤 | 2.96 |
正常乳腺GW00-413 | 28798 | 31.78 | 48.04 | 48.04 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 29.69 | 159.55 | 319.10 | 乳腺肿瘤 | 6.64 |
正常乳腺GW00-235:238 | 27592-95 | 34.18 | 12.14 | 12.14 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 29.2 | 211.28 | 211.28 | 乳腺肿瘤 | 17.40 |
正常乳腺GW98-621 | 23656 | 29.72 | 157.4 | 314.80 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 31.12 | 70.17 | 140.34 | 乳腺肿瘤 | -2.24 |
正常大脑BB-99-542 | 25507 | 30.81 | 83.89 | 167.78 | 正常大脑 | |
正常大脑BB-99-406 | 25509 | 31.02 | 74.28 | 148.56 | 正常大脑 | |
正常大脑BB-99-904 | 25546 | 31.39 | 60.08 | 120.16 | 正常大脑 | |
大脑期5ALZBB99-874 | 25502 | 32.54 | 31.07 | 62.14 | 大脑期5-ALZ | -2.34 |
大脑期5ALZBB99-887 | 25503 | 30.65 | 92.1 | 184.20 | 大脑期5-ALZ | 1.27 |
大脑期5ALZBB99-862 | 25504 | 31.68 | 50.92 | 101.84 | 大脑期5-ALZ | -1.43 |
大脑期5ALZBB99-927 | 25542 | 31.39 | 60.36 | 120.72 | 大脑期5-ALZ | -1.21 |
CT肺KC | normal | 30.47 | 101.87 | 203.74 | CT肺 | |
肺26KC | normal | 肺26 | ||||
肺27KC | normal | 39.27 | 0.65 | 0.65 | 肺27 | |
肺24KC | COPD | 40 | 0 | 0.00 | 肺24 | -68.13 |
肺28KC | COPD | 37.38 | 1.93 | 1.93 | 肺28 | -35.30 |
肺23KC | COPD | 34.28 | 11.47 | 11.47 | 肺23 | -5.94 |
肺25KC | normal | 40 | 0 | 0.00 | 肺25 | |
哮喘肺ODO3112 | 29321 | 33.17 | 21.73 | 21.73 | 哮喘肺 | -3.14 |
哮喘肺ODO3433 | 29323 | 32.35 | 34.64 | 69.28 | 哮喘肺 | 1.02 |
哮喘肺ODO3397 | 29322 | 30.83 | 83.1 | 166.20 | 哮喘肺 | 2.44 |
哮喘肺ODO4928 | 29325 | 30.94 | 77.99 | 155.98 | 哮喘肺 | 2.29 |
内皮细胞KC | control | 40 | 0 | 0.00 | 内皮细胞 | |
内皮细胞VEGFKC | 40 | 0 | 0.00 | 内皮细胞VEGF | 0.00 | |
内皮细胞bFGF KC | 40 | 0 | 0.00 | 内皮细胞bFGF | 0.00 | |
心脏Clontech | normal | 30.52 | 99.45 | 198.90 | 心脏 | |
心脏(T-1)缺血 | 29417 | 28.78 | 270.18 | 540.36 | 心脏T-1 | 2.72 |
心脏(T-14)非阻塞性DCM | 29422 | 29.62 | 166.76 | 333.52 | 心脏T-14 | 1.68 |
心脏(T-3399)DCM | 29426 | 30.05 | 129.76 | 259.52 | 心脏T-3399 | 1.30 |
腺样增殖体GW99-269 | 26162 | 29.05 | 230.93 | 461.86 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 29.77 | 152.22 | 304.44 | 扁桃体 | |
T细胞PC00314 | 28453 | 31.6 | 53.48 | 106.96 | T细胞 | |
PBMNC | 39.8 | 0.48 | 0.48 | PBMNC | ||
单核细胞 | 40 | 0 | 0.00 | 单核细胞 | ||
B细胞PC00665 | 28455 | 31.56 | 54.77 | 109.54 | B细胞 | |
树突细胞28441 | 34.09 | 12.8 | 25.60 | 树突细胞 | ||
中性粒细胞 | 28440 | 34.03 | 13.21 | 13.21 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 40 | 0 | 0.00 | 嗜酸性粒细胞 | |
BM unstim | 40 | 0 | 0.00 | BM未刺激的 | ||
BM stim | 35.71 | 5.04 | 5.04 | BM刺激的 | 5.04 | |
osteo dif | 40 | 0 | 0.00 | 成骨细胞分化 | 0.00 | |
osteo undif | 40 | 0 | 0.00 | 成骨细胞未分化 | ||
软骨细胞 | 33.5 | 17.89 | 44.73 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 32.24 | 37.02 | 37.02 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 27.95 | 434.95 | 869.90 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 30.9 | 79.82 | 159.64 | OA滑膜 |
RA滑膜NP03/01 | 28466 | 31.79 | 47.9 | 95.80 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 33.06 | 23.05 | 46.10 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 32.76 | 27.41 | 54.82 | RA滑膜 | |
OA骨(biobank) | 29217 | 32.02 | 42.02 | 42.02 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 31.32 | 62.63 | 125.26 | OA骨 | |
OA骨标本2 | J.Emory | 33.13 | 22.24 | 44.48 | OA骨 | |
软骨(库) | Normal | 30.76 | 86.51 | 173.02 | 软骨(库) | |
软骨(库) | OA | 33.13 | 22.15 | 44.30 | 软骨(库) | -3.91 |
PBL未感染的 | 28441 | 26.78 | 847.01 | 1694.02 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 28.21 | 374.26 | 748.52 | PBL HIV IIIB | -2.26 |
MRC5未感染的(100%) | 29158 | 40 | 0 | 0.00 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 31.26 | 64.96 | 129.92 | MRC5 HSV株F | 129.92 |
W12细胞 | 29179 | 40 | 0 | 0.00 | W12细胞 | |
角质细胞 | 29180 | 39.77 | 0.49 | 0.98 | 角质细胞 | |
B-肌动蛋白对照 | 27.18 | 675.17 | ||||
基因组 | 25.96 | 1358.6 | ||||
1.00E+05 | 18.58 | 100000 | ||||
1.00E+05 | 18.53 | 100000 | ||||
1.00E+04 | 22.04 | 10000 | ||||
1.00E+04 | 22.1 | 10000 | ||||
1.00E+03 | 25.85 | 1000 | ||||
1.00E+03 | 26.11 | 1000 | ||||
1.00E+02 | 34.02 | 100 | ||||
1.00E+02 | 30.53 | 100 | ||||
1.00E+01 | 32.98 | 10 | ||||
1.00E+01 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
1.00E-00 | 38.21 | 1 | ||||
NTC | 40 | 0 |
基因名称sbg618069LRR
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | -9.54 |
结肠肿瘤 | 3.41 |
结肠肿瘤 | -4.95 |
结肠肿瘤 | 1.96 |
肺肿瘤 | 10.67 |
肺肿瘤 | 1.71 |
肺肿瘤 | -4.36 |
肺肿瘤 | 3.28 |
乳腺肿瘤 | 2.96 |
乳腺肿瘤 | 6.64 |
乳腺肿瘤 | 17.40 |
乳腺肿瘤 | -2.24 |
大脑期5ALZ | -2.34 |
大脑期5ALZ | 1.27 |
大脑期5ALZ | -1.43 |
大脑期5ALZ | -1.21 |
肺24 | -68.13 |
肺28 | -35.30 |
肺23 | -5.94 |
哮喘肺 | -3.14 |
哮喘肺 | 1.02 |
哮喘肺 | 2.44 |
哮喘肺 | 2.29 |
内皮细胞VEGF | 0.00 |
内皮细胞bFGF | 0.00 |
心脏T-1 | 2.72 |
心脏T-14 | 1.68 |
心脏T-3399 | 1.30 |
BM stim | 5.04 |
Osteo undif | 0.00 |
软骨(库) | -3.91 |
PBL HIV IIIB | -2.26 |
MRC5 HSV株F | 129.92 |
基因名称sbg934114Relaxin
在正常和疾病标本中有低的总体表达。在睾丸,肝脏和全脑中有最高的正常表达。在3份正常肺标本,一份正常肿瘤标本中,HSV感染的MRC5细胞中,腺样增殖体(adenoid)中和T细胞中有最高的疾病表达。在2份正常肺标本中,1份肺肿瘤标本中,1份正常乳腺标本中,1份乳腺肿瘤标本中和未感染的PBL标本中有最高的疾病表达。在4份结肠肿瘤的1份中下调,在4份肺肿瘤的2份中下调提示其在结肠癌和肺癌中的作用。在所有3份COPD肺标本中下调,和4份哮喘肺标本的3份中上调提示COPD和哮喘涉及该基因。在3份心脏标本的2份中上调提示其在肺阻塞性和阻塞性DCM中的作用。在OA软骨库中下调,在RA和OA滑膜,OA骨,和软骨细胞中低表达提示其参与骨关节炎和类风湿性关节炎。在HIV感染的原代细胞系中下调提示其与HIV有关。在HSV中上调提示其作为潜在的宿主因子与单纯疱疹病毒有关。
标本sbg934114Relaxin | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 37.4,40 | 5.41 | 0 | 2.71 | 3.06 | 16.34 | 44.20 |
皮下脂肪Zenbio | 40,40 | 0.73 | 0 | 0.37 | 0.96 | 52.36 | 19.11 |
肾上腺Clontech | 40,40 | 0.73 | 0.69 | 0.71 | 0.61 | 81.97 | 58.20 |
全脑Clontech | 33.52,34.72 | 47.76 | 24.26 | 36.01 | 7.24 | 6.91 | 248.69 |
胎脑clontech | 39.51,40 | 1.65 | 0.86 | 1.26 | 0.48 | 103.95 | 130.46 |
小脑Clontech | 40,39.84 | 0.99 | 1.37 | 1.18 | 2.17 | 23.04 | 27.19 |
子宫颈 | 40,40 | 1.05 | 0 | 0.53 | 2.42 | 20.66 | 10.85 |
结肠 | 40,37.31 | 0 | 5.7 | 2.85 | 2.71 | 18.45 | 52.58 |
子宫内膜 | 40,40 | 0 | 0 | 0.00 | 0.73 | 68.21 | 0.00 |
食管 | 40,40 | 0 | 0 | 0.00 | 1.37 | 36.50 | 0.00 |
心脏Clontech | 38.11,40 | 3.63 | 1.31 | 2.47 | 1.32 | 37.88 | 93.56 |
下丘脑 | 40,40 | 0 | 1.06 | 0.53 | 0.32 | 155.28 | 82.30 |
回肠 | 40,36.79 | 0 | 7.62 | 3.81 | 2.58 | 19.38 | 73.84 |
空肠 | 35.14,35.9 | 19.25 | 12.54 | 15.90 | 6.60 | 7.58 | 120.42 |
肾脏 | 40,40 | 0 | 0 | 0.00 | 2.12 | 23.58 | 0.00 |
肝脏 | 37.25,35.17 | 5.88 | 18.92 | 12.40 | 1.50 | 33.33 | 413.33 |
胚胎肝Clontech | 40,37.38 | 0.73 | 5.47 | 3.10 | 10.40 | 4.81 | 14.90 |
肺 | 37.07,40 | 6.52 | 0 | 3.26 | 2.57 | 19.46 | 63.42 |
乳腺Clontech | 40,40 | 0 | 0 | 0.00 | 13.00 | 3.85 | 0.00 |
子宫肌层 | 37.95,40 | 3.98 | 0 | 1.99 | 2.34 | 21.37 | 42.52 |
网膜 | 36.24,37.04 | 10.39 | 6.63 | 8.51 | 3.94 | 12.69 | 107.99 |
卵巢 | 35.29,36.26 | 17.66 | 10.28 | 13.97 | 4.34 | 11.52 | 160.94 |
胰腺 | 39.48,40 | 1.69 | 0 | 0.85 | 0.81 | 61.80 | 52.22 |
胰头 | 36.17,39.82 | 10.79 | 1.39 | 6.09 | 1.57 | 31.85 | 193.95 |
腮腺 | 40,38.66 | 0 | 2.67 | 1.34 | 5.48 | 9.12 | 12.18 |
胎盘Clontech | 40,36.57 | 0 | 8.63 | 4.32 | 5.26 | 9.51 | 41.02 |
前列腺 | 36.91,40 | 7.14 | 0 | 3.57 | 3.00 | 16.67 | 59.50 |
直肠 | 40,37.34 | 0 | 5.61 | 2.81 | 1.23 | 40.65 | 114.02 |
唾液腺Clontech | 40,40 | 0 | 0 | 0.00 | 7.31 | 6.84 | 0.00 |
骨骼肌Clontech | 40,39.45 | 0 | 1.71 | 0.86 | 1.26 | 39.68 | 33.93 |
皮肤 | 39.2,40 | 1.98 | 0 | 0.99 | 1.21 | 41.32 | 40.91 |
小肠Clontech | 40,40 | 0 | 0 | 0.00 | 0.98 | 51.07 | 0.00 |
脾脏 | 36,40 | 11.84 | 0 | 5.92 | 4.92 | 10.16 | 60.16 |
胃 | 35.48,39.19 | 15.9 | 1.98 | 8.94 | 2.73 | 18.32 | 163.74 |
睾丸Clontech | 40,36.09 | 0 | 11.27 | 5.64 | 0.57 | 87.87 | 495.17 |
胸腺Clontech | 34.34,36.66 | 30.03 | 8.2 | 19.12 | 9.89 | 5.06 | 96.64 |
甲状腺 | 40,40 | 0 | 0 | 0.00 | 2.77 | 18.05 | 0.00 |
气管Clontech | 40,37.8 | 0 | 4.33 | 2.17 | 9.71 | 5.15 | 11.15 |
膀胱 | 40,40 | 0 | 0 | 0.00 | 5.47 | 9.14 | 0.00 |
子宫 | 37.11,35.16 | 6.36 | 18.96 | 12.66 | 5.34 | 9.36 | 118.54 |
基因组 | 27.61 | 1307.98 | |||||
b-肌动蛋白 | 27.15 | 1697.68 | |||||
1.00E+05 | 19.88 | 100000 | |||||
1.00E+05 | 20.05 | 100000 | |||||
1.00E+04 | 24.01 | 10000 | |||||
1.00E+04 | 23.92 | 10000 | |||||
1.00E+03 | 27.98 | 1000 | |||||
1.00E+03 | 27.6 | 1000 | |||||
1.00E+02 | 32.89 | 100 | |||||
1.00E+02 | 32.2 | 100 | |||||
1.00E+01 | 36.1 | 10 | |||||
1.00E+01 | |||||||
1.00E-00 | |||||||
1.00E-00 | |||||||
NTC | 40 | 0 | |||||
NTC | 40 | 0 |
标本sbg934114Relaxin | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 36.1 | 22.33 | 44.66 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 36.47 | 18.37 | 36.74 | 结肠肿瘤 | -1.22 |
正常结肠GW98-178 | 22080 | 35.7 | 27.58 | 55.16 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 38.05 | 7.98 | 15.96 | 结肠肿瘤 | -3.46 |
正常结肠GW98-561 | 23514 | 33.57 | 84.85 | 169.70 | 正常结肠 |
结肠肿瘤GW98-560 | 23513 | 37.66 | 9.8 | 19.60 | 结肠肿瘤 | -8.66 |
正常结肠GW98-894 | 24691 | 36.39 | 19.09 | 38.18 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 36.43 | 18.74 | 37.48 | 结肠肿瘤 | -1.02 |
正常肺GW98-3 | 20742 | 32.48 | 150.6 | 301.20 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 36.65 | 16.64 | 33.28 | 肺肿瘤 | -9.05 |
正常肺GW97-179 | 20677 | 33.22 | 102.07 | 204.14 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 32.31 | 164.63 | 329.26 | 肺肿瘤 | 1.61 |
正常肺GW98-165 | 21922 | 32.08 | 185.96 | 371.92 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 35.14 | 37.09 | 74.18 | 肺肿瘤 | -5.01 |
正常肺GW98-282 | 22584 | 36.41 | 18.93 | 37.86 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 35.24 | 35.13 | 70.26 | 肺肿瘤 | 1.86 |
正常乳腺GW00-392 | 28750 | 34.04 | 66.25 | 66.25 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 37.9 | 8.61 | 17.22 | 乳腺肿瘤 | -3.85 |
正常乳腺GW00-413 | 28798 | 36.36 | 19.44 | 19.44 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 36.79 | 15.49 | 30.98 | 乳腺肿瘤 | 1.59 |
正常乳腺GW00-235:238 | 27592-95 | 36.91 | 14.52 | 14.52 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 35.43 | 31.71 | 31.71 | 乳腺肿瘤 | 2.18 |
正常乳腺GW98-621 | 23656 | 36.26 | 20.51 | 41.02 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 35.76 | 26.68 | 53.36 | 乳腺肿瘤 | 1.30 |
正常大脑BB-99-542 | 25507 | 37.99 | 8.21 | 16.42 | 正常大脑 | |
正常大脑BB-99-406 | 25509 | 40 | 1.41 | 2.82 | 正常大脑 | |
正常大脑BB-99-904 | 25546 | 40 | 0 | 0.00 | 正常大脑 | |
大脑期5ALZBB99-874 | 25502 | 38.65 | 5.82 | 11.64 | 大脑期5-ALZ | 1.81 |
大脑期5ALZBB99-887 | 25503 | 37 | 13.9 | 27.80 | 大脑期5-ALZ | 4.33 |
大脑期5ALZBB99-862 | 25504 | 37.4 | 11.24 | 22.48 | 大脑期5-ALZ | 3.51 |
大脑期5ALZBB99-927 | 25542 | 38 | 8.19 | 16.38 | 大脑期5-ALZ | 2.55 |
CT肺KC | normal | 35.32 | 33.59 | 67.18 | CT肺 | |
肺26KC | normal | 37.02 | 13.72 | 13.72 | 肺26 | |
肺27KC | normal | 40 | 0 | 0.00 | 肺27 | |
肺24KC | COPD | 39.97 | 2.78 | 2.78 | 肺24 | -7.81 |
肺28KC | COPD | 40 | 0 | 0.00 | 肺28 | -21.71 |
肺23KC | COPD | 39.06 | 4.67 | 4.67 | 肺23 | -4.65 |
肺25KC | normal | 38.61 | 5.92 | 5.92 | 肺25 | |
哮喘肺ODO3112 | 29321 | 36.02 | 23.31 | 23.31 | 哮喘肺 | 1.07 |
哮喘肺ODO3433 | 29323 | 34.12 | 63.36 | 126.72 | 哮喘肺 | 5.84 |
哮喘肺ODO3397 | 29322 | 33.99 | 68.06 | 136.12 | 哮喘肺 | 6.27 |
哮喘肺ODO4928 | 29325 | 33.77 | 76.08 | 152.16 | 哮喘肺 | 7.01 |
内皮细胞KC | control | 40 | 0 | 0.00 | 内皮细胞 | |
内皮细胞VEGF KC | 40 | 0 | 0.00 | 内皮细胞VEGF | 0.00 | |
内皮细胞bFGF KC | 38.16 | 7.54 | 7.54 | 内皮细胞bFGF | 7.54 | |
心脏Clontech | normal | 40 | 0 | 0.00 | 心脏 | |
心脏(T-1)缺血 | 29417 | 40 | 1.36 | 2.72 | 心脏T-1 | 2.72 |
心脏(T-14)非阻塞性DCM | 29422 | 36.31 | 20.01 | 40.02 | 心脏T-14 | 40.02 |
心脏(T-3399)DCM | 29426 | 37.17 | 12.7 | 25.40 | 心脏T-3399 | 25.40 |
腺样增殖体GW99-269 | 26162 | 33.33 | 96.07 | 192.14 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 34.86 | 42.85 | 85.70 | 扁桃体 | |
T细胞PC00314 | 28453 | 33.48 | 88.65 | 177.30 | T细胞 | |
PBMNC | 40 | 0 | 0.00 | PBMNC | ||
单核细胞 | 40 | 0 | 0.00 | 单核细胞 | ||
B细胞PC00665 | 28455 | 32.44 | 153.68 | 307.36 | B细胞 | |
树突细胞28441 | 35.78 | 26.47 | 52.94 | 树突细胞 | ||
中性粒细胞 | 28440 | 36.18 | 21.43 | 21.43 | 中性粒细胞 |
嗜酸性粒细胞 | 28446 | 39.2 | 4.34 | 8.68 | 嗜酸性粒细胞 | |
BM unstim | 39.56 | 3.6 | 3.60 | BM未刺激的 | ||
BM stim | 40 | 1.34 | 1.34 | BM刺激的 | -2.69 | |
osteo dif | 40 | 0 | 0.00 | 成骨细胞分化 | 0.00 | |
osteo undif | 40 | 0 | 0.00 | 成骨细胞未分化 | ||
软骨细胞 | 36.64 | 16.79 | 41.98 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 34.75 | 45.45 | 45.45 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 36.02 | 23.28 | 46.56 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 34.24 | 59.37 | 118.74 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 37.88 | 8.71 | 17.42 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 36.02 | 23.22 | 46.44 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 34.9 | 41.9 | 83.80 | RA滑膜 | |
OA骨(biobank) | 29217 | 33.59 | 83.75 | 83.75 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 37.31 | 11.8 | 23.60 | OA骨 | |
OA骨标本2 | J.Emory | 37.47 | 10.81 | 21.62 | OA骨 | |
软骨(库) | Normal | 34.61 | 49.07 | 98.14 | 软骨(库) | |
软骨(库) | OA | 40 | 0 | 0.00 | 软骨(库) | -98.14 |
PBL未感染的 | 28441 | 33.86 | 72.8 | 145.60 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 37.08 | 13.28 | 26.56 | PBL HIV IIIB | -5.48 |
MRC5未感染的(100%) | 29158 | 39.01 | 4.81 | 9.62 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 31.5 | 252.68 | 505.36 | MRC5 HSV株F | 52.53 |
W12细胞 | 29179 | 39.84 | 3.1 | 6.20 | W12细胞 | |
角质细胞 | 29180 | 39.07 | 4.64 | 9.28 | 角质细胞 | |
B-肌动蛋白对照 | 27.9 | 1683.49 | ||||
基因组 | 28.13 | 1492.71 | ||||
1.00E+05 | 20.5 | 100000 | ||||
1.00E+05 | 20.61 | 100000 | ||||
1.00E+04 | 24.56 | 10000 | ||||
1.00E+04 | 24.17 | 10000 |
1.00E+03 | 28.14 | 1000 | ||||
1.00E+03 | 28.32 | 1000 | ||||
1.00E+02 | 34.26 | 100 | ||||
1.00E+02 | 32.76 | 100 | ||||
1.00E+01 | 38.07 | 10 | ||||
1.00E+01 | 37.53 | 10 | ||||
1.00E-00 | 40 | 0 | ||||
1.00E-00 | 40 | 1 | ||||
NTC | 38.42 | -1 |
基因名称sbg934114Relaxin
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | -1.22 |
结肠肿瘤 | -3.46 |
结肠肿瘤 | -8.66 |
结肠肿瘤 | -1.02 |
肺肿瘤 | -9.05 |
肺肿瘤 | 1.61 |
肺肿瘤 | -5.01 |
肺肿瘤 | 1.86 |
乳腺肿瘤 | -3.85 |
乳腺肿瘤 | 1.59 |
乳腺肿瘤 | 2.18 |
乳腺肿瘤 | 1.30 |
大脑期5ALZ | 1.81 |
大脑期5ALZ | 4.33 |
大脑期5ALZ | 3.51 |
大脑期5ALZ | 2.55 |
肺24 | -7.81 |
肺28 | -21.71 |
肺23 | -4.65 |
哮喘肺 | 1.07 |
哮喘肺 | 5.84 |
哮喘肺 | 6.27 |
哮喘肺 | 7.01 |
内皮细胞VEGF | 0.00 |
内皮细胞bFGF | 7.54 |
心脏T-1 | 2.72 |
心脏T-14 | 40.02 |
心脏T-3399 | 25.40 |
BM stim | -2.69 |
Osteo undif | 0.00 |
软骨(库) | -98.14 |
PBL HIV IIIB | -5.48 |
MRC5 HSV株F | 52.53 |
基因名称sbg99174LOX-like
在正常和疾病标本中中度的总体表达。在全脑,肝脏,皮肤,脾脏,睾丸有最高的正常表达。在女性生殖道标本中和胃肠道标本中有相对好的表达。在一份正常肺标本中,一份哮喘肺标本中,中性粒细胞,嗜酸性粒细胞,2份RA滑膜标本中和一份OA骨标本中有最高的疾病表达。在4份肺肿瘤标本的1份中下调提示其可能参与肺癌。在4份乳腺肿瘤的2份中上调提示其参与乳腺癌。在4份AD脑的1份中下调和在脑中观察到的高表达提示其参与阿尔茨海默氏病。在3份COPD肺标本的2份中下调提示其参与慢性阻塞性肺病。在4份哮喘肺标本的1份中上调提示其在哮喘中的作用。在OA的软骨中下调和在OA和RA的滑膜中高表达提示其可能参与骨关节炎和类风湿性关节炎。在T细胞中证实高表达为其在RA/OA中的作用提供了补充的证据。在其它免疫细胞中为中度表达。
标本sbg99174LOX-like | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 39.67,34.48 | 0.53 | 11.91 | 6.22 | 3.06 | 16.34 | 101.63 |
皮下脂肪Zenbio | 40,39.75 | 0.39 | 0.51 | 0.45 | 0.96 | 52.36 | 23.56 |
肾上腺Clontech | 38.61,37.69 | 1 | 1.75 | 1.38 | 0.61 | 81.97 | 112.70 |
全脑Clontech | 30.59,31.07 | 122.95 | 92.57 | 107.76 | 7.24 | 6.91 | 744.20 |
胎脑clontech | 40,40 | 0 | 0.29 | 0.15 | 0.48 | 103.95 | 15.07 |
小脑Clontech | 40,40 | 0.4 | 0.4 | 0.40 | 2.17 | 23.04 | 9.22 |
子宫颈 | 35.77,40 | 5.52 | 0.62 | 3.07 | 2.42 | 20.66 | 63.43 |
结肠 | 40,39.41 | 0.34 | 0.62 | 0.48 | 2.71 | 18.45 | 8.86 |
子宫内膜 | 40,38.65 | 0 | 0.98 | 0.49 | 0.73 | 68.21 | 33.42 |
食管 | 40,40 | 0.35 | 0.41 | 0.38 | 1.37 | 36.50 | 13.87 |
心脏Clontech | 39.33,40 | 0.65 | 0 | 0.33 | 1.32 | 37.88 | 12.31 |
下丘脑 | 40,39.54 | 0 | 0.58 | 0.29 | 0.32 | 155.28 | 45.03 |
回肠 | 35.42,35.76 | 6.79 | 5.55 | 6.17 | 2.58 | 19.38 | 119.57 |
空肠 | 34.13,33.4 | 14.77 | 22.9 | 18.84 | 6.60 | 7.58 | 142.69 |
肾脏 | 40,37.22 | 0.68 | 2.32 | 1.50 | 2.12 | 23.58 | 35.38 |
肝脏 | 33.5,33.86 | 21.47 | 17.3 | 19.39 | 1.50 | 33.33 | 646.17 |
胚胎肝Clontech | 32.78,33.23 | 33.08 | 25.33 | 29.21 | 10.40 | 4.81 | 140.41 |
肺 | 33.96,34.44 | 16.33 | 12.25 | 14.29 | 2.57 | 19.46 | 278.02 |
乳腺Clontech | 35.05,36.02 | 8.51 | 4.76 | 6.64 | 13.00 | 3.85 | 25.52 |
子宫肌层 | 35.08,35.49 | 8.34 | 6.52 | 7.43 | 2.34 | 21.37 | 158.76 |
网膜 | 37.6,35.05 | 1.83 | 8.49 | 5.16 | 3.94 | 12.69 | 65.48 |
卵巢 | 35.57,32.76 | 6.21 | 33.46 | 19.84 | 4.34 | 11.52 | 228.51 |
胰腺 | 40,40 | 0 | 0.42 | 0.21 | 0.81 | 61.80 | 12.98 |
胰头 | 40,38.65 | 0.56 | 0.98 | 0.77 | 1.57 | 31.85 | 24.52 |
腮腺 | 35.28,40 | 7.4 | 0.64 | 4.02 | 5.48 | 9.12 | 36.68 |
胎盘Clontech | 40,39.17 | 0.32 | 0.72 | 0.52 | 5.26 | 9.51 | 4.94 |
前列腺 | 40,35.34 | 0 | 7.15 | 3.58 | 3.00 | 16.67 | 59.58 |
直肠 | 37.29,39.02 | 2.22 | 0.78 | 1.50 | 1.23 | 40.65 | 60.98 |
唾液腺Clontech | 40,38.15 | 0.27 | 1.32 | 0.80 | 7.31 | 6.84 | 5.44 |
骨骼肌Clontech | 40,38.56 | 0.56 | 1.03 | 0.80 | 1.26 | 39.68 | 31.55 |
皮肤 | 35.1,34.19 | 8.22 | 14.22 | 11.22 | 1.21 | 41.32 | 463.64 |
小肠Clontech | 40,40 | 0 | 0.85 | 0.43 | 0.98 | 51.07 | 21.71 |
脾脏 | 32.2,32.08 | 46.76 | 50.49 | 48.63 | 4.92 | 10.16 | 494.16 |
胃 | 34.28,34.07 | 13.5 | 15.3 | 14.40 | 2.73 | 18.32 | 263.74 |
睾丸Clontech | 34.05,32.7 | 15.46 | 34.82 | 25.14 | 0.57 | 87.87 | 2209.14 |
胸腺Clontech | 33.85,32.4 | 17.44 | 41.71 | 29.58 | 9.89 | 5.06 | 149.52 |
甲状腺 | 34.22,34.29 | 13.93 | 13.37 | 13.65 | 2.77 | 18.05 | 246.39 |
气管Clontech | 32.51,32.4 | 38.89 | 41.53 | 40.21 | 9.71 | 5.15 | 207.05 |
膀胱 | 35.47,40 | 6.6 | 0 | 3.30 | 5.47 | 9.14 | 30.16 |
子宫 | 33.8,33.6 | 18.01 | 20.22 | 19.12 | 5.34 | 9.36 | 178.98 |
基因组 | 26.31 | 1603.29 | |||||
b-肌动蛋白 | 27.35 | 860.96 | |||||
1.00E+05 | 19.71 | 100000 | |||||
1.00E+05 | 19.88 | 100000 | |||||
1.00E+04 | 22.98 | 10000 | |||||
1.00E+04 | 23.01 | 10000 | |||||
1.00E+03 | 26.44 | 1000 | |||||
1.00E+03 | 26.54 | 1000 | |||||
1.00E+02 | 31.28 | 100 | |||||
1.00E+02 | 31.29 | 100 | |||||
1.00E+01 | 35.79 | 10 | |||||
1.00E+01 | 34.36 | 10 | |||||
1.00E-00 | 38.32 | 1 | |||||
1.00E-00 | 40 | 1 | |||||
NTC | 40 | 0 | |||||
NTC | 40 | 0 |
标本sbg99174LOX-like | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 29.81 | 184.31 | 368.62 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 29.25 | 254.48 | 508.96 | 结肠肿瘤 | 1.38 |
正常结肠GW98-178 | 22080 | 32.06 | 50.31 | 100.62 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 31.77 | 59.28 | 118.56 | 结肠肿瘤 | 1.18 |
正常结肠GW98-561 | 23514 | 33.21 | 25.83 | 51.66 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 31.74 | 60.51 | 121.02 | 结肠肿瘤 | 2.34 |
正常结肠GW98-894 | 24691 | 30.17 | 149.84 | 299.68 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 29.41 | 232.23 | 464.46 | 结肠肿瘤 | 1.55 |
正常肺GW98-3 | 20742 | 25.76 | 1914.72 | 3829.44 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 30.12 | 154.63 | 309.26 | 肺肿瘤 | -12.38 |
正常肺GW97-179 | 20677 | 29.59 | 209.5 | 419.00 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 27.2 | 835.04 | 1670.08 | 肺肿瘤 | 3.99 |
正常肺GW98-165 | 21922 | 28.22 | 462.22 | 924.44 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 29.27 | 251.87 | 503.74 | 肺肿瘤 | -1.84 |
正常肺GW98-282 | 22584 | 30.18 | 149.17 | 298.34 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 28.47 | 399.41 | 798.82 | 肺肿瘤 | 2.68 |
正常乳腺GW00-392 | 28750 | 30.24 | 143.58 | 143.58 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 30.16 | 151.08 | 302.16 | 乳腺肿瘤 | 2.10 |
正常乳腺GW00-413 | 28798 | 31.51 | 68.87 | 68.87 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 28.91 | 310.66 | 621.32 | 乳腺肿瘤 | 9.02 |
正常乳腺GW00-235:238 | 27592-95 | 40 | 0 | 0.00 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 33.55 | 21.28 | 21.28 | 乳腺肿瘤 | 21.28 |
正常乳腺GW98-621 | 23656 | 31.57 | 66.56 | 133.12 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 31.15 | 84.8 | 169.60 | 乳腺肿瘤 | 1.27 |
正常大脑BB-99-542 | 25507 | 29.55 | 214.38 | 428.76 | 正常大脑 | |
正常大脑BB-99-406 | 25509 | 29.15 | 270.89 | 541.78 | 正常大脑 | |
正常大脑BB-99-904 | 25546 | 30.48 | 124.98 | 249.96 | 正常大脑 | |
大脑期5ALZBB99-874 | 25502 | 33.57 | 20.99 | 41.98 | 大脑期5-ALZ | -9.69 |
大脑期5ALZBB99-887 | 25503 | 29.89 | 176.42 | 352.84 | 大脑期5-ALZ | -1.15 |
大脑期5ALZBB99-862 | 25504 | 31.65 | 63.83 | 127.66 | 大脑期5-ALZ | -3.19 |
大脑期5ALZBB99-927 | 25542 | 31.04 | 90.73 | 181.46 | 大脑期5-ALZ | -2.24 |
CT肺KC | normal | 29.94 | 170.8 | 341.60 | CT肺 | |
肺26KC | normal | 30.63 | 115.04 | 115.04 | 肺26 | |
肺27KC | normal | 32.22 | 45.83 | 45.83 | 肺27 | |
肺24KC | COPD | 34.16 | 14.91 | 14.91 | 肺24 | -9.21 |
肺28KC | COPD | 33.51 | 21.7 | 21.70 | 肺28 | -6.33 |
肺23KC | COPD | 32.51 | 38.67 | 38.67 | 肺23 | -3.55 |
肺25KC | normal | 32.18 | 46.79 | 46.79 | 肺25 | |
哮喘肺ODO3112 | 29321 | 31.84 | 56.95 | 56.95 | 哮喘肺 | -2.41 |
哮喘肺ODO3433 | 29323 | 31.12 | 86.42 | 172.84 | 哮喘肺 | 1.26 |
哮喘肺ODO3397 | 29322 | 27.13 | 867.31 | 1734.62 | 哮喘肺 | 12.63 |
哮喘肺ODO4928 | 29325 | 30.25 | 142.92 | 285.84 | 哮喘肺 | 2.08 |
内皮细胞KC | control | 31.23 | 81.05 | 81.05 | 内皮细胞 | |
内皮细胞VEGFKC | 31.87 | 56.15 | 56.15 | endo VEGF | -1.44 | |
内皮细胞bFGFKC | 32.64 | 35.97 | 35.97 | endo bFGF | -2.25 | |
心脏Clontech | normal | 35.46 | 7.06 | 14.12 | 心脏 | |
心脏(T-1)缺血 | 29417 | 35.73 | 6.03 | 12.06 | 心脏T-1 | -1.17 |
心脏(T-14)非阻塞性DCM | 29422 | 34.34 | 13.49 | 26.98 | 心脏T-14 | 1.91 |
心脏(T-3399)DCM | 29426 | 33.65 | 20.01 | 40.02 | 心脏T-3399 | 2.83 |
腺样增殖体GW99-269 | 26162 | 31.2 | 82.69 | 165.38 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 30.8 | 103.96 | 207.92 | 扁桃体 | |
T细胞PC00314 | 28453 | 28.16 | 480.4 | 960.80 | T细胞 | |
PBMNC | 30.25 | 143.11 | 143.11 | PBMNC | ||
单核细胞 | 30.05 | 160.68 | 321.36 | 单核细胞 | ||
B细胞PC00665 | 28455 | 30.75 | 107.02 | 214.04 | B细胞 | |
树突细胞28441 | 30.32 | 137.17 | 274.34 | 树突细胞 | ||
中性粒细胞 | 28440 | 26.32 | 1390.87 | 1390.87 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 25.07 | 2854.44 | 5708.88 | 嗜酸性粒细胞 | |
BM unstim | 30.72 | 109.05 | 109.05 | BM未刺激的 | ||
BM stim | 28.61 | 369.2 | 369.20 | BM刺激的 | 3.39 | |
osteo dif | 40 | 0 | 0.00 | 成骨细胞分化 | -0.28 | |
osteo undif | 40 | 0.28 | 0.28 | 成骨细胞未分化 | ||
软骨细胞 | 34.3 | 13.76 | 34.40 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 27.56 | 676.63 | 676.63 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 31.41 | 73.19 | 146.38 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 28.02 | 518.05 | 1036.10 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 27.03 | 921.88 | 1843.76 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 27.04 | 914.02 | 1828.04 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 29.06 | 285.08 | 570.16 | RA滑膜 | |
OA骨(biobank) | 29217 | 26.78 | 1065.84 | 1065.84 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 30.27 | 141.07 | 282.14 | OA骨 | |
OA骨标本2 | J.Emory | 27.04 | 917.04 | 1834.08 | OA骨 | |
软骨(库) | Normal | 28.23 | 461.21 | 922.42 | 软骨(库) | |
软骨(库) | OA | 33.16 | 26.65 | 53.30 | 软骨(库) | -17.31 |
PBL未感染的 | 28441 | 28.72 | 346.97 | 693.94 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 28.54 | 384.02 | 768.04 | PBL HIV IIIB | 1.11 |
MRC5 未感染的(100%) | 29158 | 31.64 | 64.07 | 128.14 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 31.53 | 68.31 | 136.62 | MRC5 HSV株F | 1.07 |
W12细胞 | 29179 | 34.44 | 12.72 | 25.44 | W12细胞 | |
角质细胞 | 29180 | 36.02 | 5.1 | 10.20 | 角质细胞 | |
B-肌动蛋白对照 | 27.2 | 835.98 | ||||
基因组 | 26.76 | 1073.72 | ||||
1.00E+05 | 19.13 | 100000 | ||||
1.00E+05 | 19.61 | 100000 | ||||
1.00E+04 | 22.79 | 10000 | ||||
1.00E+04 | 22.5 | 10000 | ||||
1.00E+03 | 26.36 | 1000 | ||||
1.00E+03 | 26.23 | 1000 | ||||
1.00E+02 | 31.25 | 100 | ||||
1.00E+02 | 30.82 | 100 | ||||
1.00E+01 | 35.02 | 10 | ||||
1.00E+01 | 35.15 | 10 | ||||
1.00E-00 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
NTC | 40 | 0 |
基因名称sbg99174LOX-like
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | 1.38 |
结肠肿瘤 | 1.18 |
结肠肿瘤 | 2.34 |
结肠肿瘤 | 1.55 |
肺肿瘤 | -12.38 |
肺肿瘤 | 3.99 |
肺肿瘤 | -1.84 |
肺肿瘤 | 2.68 |
乳腺肿瘤 | 2.10 |
乳腺肿瘤 | 9.02 |
乳腺肿瘤 | 21.28 |
乳腺肿瘤 | 1.27 |
大脑期5ALZ | -9.69 |
大脑期5ALZ | -1.15 |
大脑期5ALZ | -3.19 |
大脑期5ALZ | -2.24 |
肺24 | -9.21 |
肺28 | -6.33 |
肺23 | -3.55 |
哮喘肺 | -2.41 |
哮喘肺 | 1.26 |
哮喘肺 | 12.63 |
哮喘肺 | 2.08 |
内皮细胞VEGF | -1.44 |
内皮细胞bFGF | -2.25 |
心脏T-1 | -1.17 |
心脏T-14 | 1.91 |
心脏T-3399 | 2.83 |
BM stim | 3.39 |
Osteo undif | -0.28 |
软骨(库) | -17.31 |
PBL HIV IIIB | 1.11 |
MRC5 HSV株F | 1.07 |
基因名称sbg995002PIGR(Taqman)
在正常和疾病标本中有极低的总体表达。在结肠和腮腺中有最高的正常表达。在一份肺肿瘤标本中和一份结肠肿瘤标本中有最高的疾病表达。在4份结肠肿瘤的1份中和4份肺肿瘤的1份中上调提示其在结肠癌和肺癌中的作用。在4份AD脑标本的3份中下调和在全脑中高表达提示其参与阿尔茨海默氏病。在所有3份COPD肺标本中下调提示该基因与COPD有关。在缺血性和非阻塞性DCM心脏标本中下调提示该基因在心血管疾病中的作用。其在受到刺激的骨髓标本中上调。在HSV中上调提示其作为潜在的宿主因子与单纯疱疹病毒有关。其在中性粒细胞和嗜酸性粒细胞中高表达。
标本sbg995002PIGR | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 40,40 | 0 | 0 | 0.00 | 3.06 | 16.34 | 0.00 |
皮下脂肪Zenbio | 40,40 | 0 | 0 | 0.00 | 0.96 | 52.36 | 0.00 |
肾上腺Clontech | 40,40 | 0 | 0 | 0.00 | 0.61 | 81.97 | 0.00 |
全脑Clontech | 36.78,40 | 11.16 | 0 | 5.58 | 7.24 | 6.91 | 38.54 |
胎脑clontech | 40,40 | 0 | 0 | 0.00 | 0.48 | 103.95 | 0.00 |
小脑Clontech | 40,40 | 0 | 0 | 0.00 | 2.17 | 23.04 | 0.00 |
子宫颈 | 40,40 | 0 | 0 | 0.00 | 2.42 | 20.66 | 0.00 |
结肠 | 37.16,37.12 | 8.81 | 9.05 | 8.93 | 2.71 | 18.45 | 164.76 |
子宫内膜 | 40,40 | 0 | 0 | 0.00 | 0.73 | 68.21 | 0.00 |
食管 | 40,40 | 0 | 0 | 0.00 | 1.37 | 36.50 | 0.00 |
心脏Clontech | 40,40 | 0 | 0 | 0.00 | 1.32 | 37.88 | 0.00 |
下丘脑 | 40,40 | 0 | 0 | 0.00 | 0.32 | 155.28 | 0.00 |
回肠 | 40,40 | 0 | 0 | 0.00 | 2.58 | 19.38 | 0.00 |
空肠 | 40,40 | 0 | 0 | 0.00 | 6.60 | 7.58 | 0.00 |
肾脏 | 40,40 | 0 | 0 | 0.00 | 2.12 | 23.58 | 0.00 |
肝脏 | 40,39.16 | 0 | 2.58 | 1.29 | 1.50 | 33.33 | 43.00 |
胚胎肝Clontech | 40,40 | 0 | 0 | 0.00 | 10.40 | 4.81 | 0.00 |
肺 | 40,40 | 0 | 0 | 0.00 | 2.57 | 19.46 | 0.00 |
乳腺Clontech | 40,39.18 | 0 | 2.55 | 1.28 | 13.00 | 3.85 | 4.90 |
子宫肌层 | 40,40 | 0 | 0 | 0.00 | 2.34 | 21.37 | 0.00 |
网膜 | 40,38.04 | 0 | 5.15 | 2.58 | 3.94 | 12.69 | 32.68 |
卵巢 | 39.29,40 | 2.37 | 0 | 1.19 | 4.34 | 11.52 | 13.65 |
胰腺 | 40,40 | 0 | 0 | 0.00 | 0.81 | 61.80 | 0.00 |
胰头 | 40,40 | 0 | 0 | 0.00 | 1.57 | 31.85 | 0.00 |
腮腺 | 36.7,37.94 | 11.72 | 5.46 | 8.59 | 5.48 | 9.12 | 78.38 |
胎盘Clontech | 40,40 | 0 | 0 | 0.00 | 5.26 | 9.51 | 0.00 |
前列腺 | 40,40 | 0 | 0 | 0.00 | 3.00 | 16.67 | 0.00 |
直肠 | 40,40 | 0 | 0 | 0.00 | 1.23 | 40.65 | 0.00 |
唾液腺Clontech | 37.23,39.21 | 8.45 | 2.5 | 5.48 | 7.31 | 6.84 | 37.45 |
骨骼肌Clontech | 40,40 | 0 | 0 | 0.00 | 1.26 | 39.68 | 0.00 |
皮肤 | 40,40 | 0 | 0 | 0.00 | 1.21 | 41.32 | 0.00 |
小肠Clontech | 40,40 | 0 | 0 | 0.00 | 0.98 | 51.07 | 0.00 |
脾脏 | 40,38.76 | 1.25 | 3.3 | 2.28 | 4.92 | 10.16 | 23.12 |
胃 | 40,39.25 | 1.25 | 2.43 | 1.84 | 2.73 | 18.32 | 33.70 |
睾丸Clontech | 40,40 | 0 | 0 | 0.00 | 0.57 | 87.87 | 0.00 |
胸腺Clontech | 37.82,40 | 5.88 | 0 | 2.94 | 9.89 | 5.06 | 14.86 |
甲状腺 | 40,40 | 0 | 0 | 0.00 | 2.77 | 18.05 | 0.00 |
气管Clontech | 40,40 | 0 | 0 | 0.00 | 9.71 | 5.15 | 0.00 |
膀胱 | 40,40 | 0 | 0 | 0.00 | 5.47 | 9.14 | 0.00 |
子宫 | 38.34,40 | 4.27 | 0 | 2.14 | 5.34 | 9.36 | 19.99 |
基因组 | 29.66 | 888.99 | |||||
b-肌动蛋白 | 30.72 | 462.87 | |||||
1.00E+05 | 22.2 | 100000 | |||||
1.00E+05 | 22.14 | 100000 | |||||
1.00E+04 | 25.72 | 10000 | |||||
1.00E+04 | 25.66 | 10000 | |||||
1.00E+03 | 29.16 | 1000 | |||||
1.00E+03 | 29.07 | 1000 | |||||
1.00E+02 | 32.37 | 100 | |||||
1.00E+02 | 34.12 | 100 | |||||
1.00E+01 | 37.12 | 10 |
1.00E+01 | 37.11 | 10 | |||||
1.00E-00 | 40 | 0 | |||||
1.00E-00 | 40 | 0 | |||||
NTC | 40 | 0 | |||||
NTC | 38.03 | -1 |
标本sbg995002PIGR | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 33.43 | 149.84 | 299.68 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 32.49 | 274.64 | 549.28 | 结肠肿瘤 | 1.83 |
正常结肠GW98-178 | 22080 | 40 | 0 | 0.00 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 31.11 | 675.8 | 1351.60 | 结肠肿瘤 | 1351.60 |
正常结肠GW98-561 | 23514 | 37.74 | 9.09 | 18.18 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 35.81 | 31.94 | 63.88 | 结肠肿瘤 | 3.51 |
正常结肠GW98-894 | 24691 | 33.17 | 177.11 | 354.22 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 31.61 | 488.49 | 976.98 | 结肠肿瘤 | 2.76 |
正常肺GW98-3 | 20742 | 35.48 | 39.55 | 79.10 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 28.32 | 4121.56 | 8243.12 | 肺肿瘤 | 104.21 |
正常肺GW97-179 | 20677 | 36.47 | 20.69 | 41.38 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 37.24 | 12.59 | 25.18 | 肺肿瘤 | -1.64 |
正常肺GW98-165 | 21922 | 37.32 | 11.96 | 23.92 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 36.07 | 26.9 | 53.80 | 肺肿瘤 | 2.25 |
正常肺GW98-282 | 22584 | 38.49 | 5.58 | 11.16 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 37.89 | 8.24 | 16.48 | 肺肿瘤 | 1.48 |
正常乳腺GW00-392 | 28750 | 39.03 | 3.93 | 3.93 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 38.01 | 7.65 | 15.30 | 乳腺肿瘤 | 3.89 |
正常乳腺GW00-413 | 28798 | 40 | 0 | 0.00 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 38.67 | 4.98 | 9.96 | 乳腺肿瘤 | 9.96 |
正常乳腺GW00-235:238 | 27592-95 | 40 | 0 | 0.00 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 40 | 0 | 0.00 | 乳腺肿瘤 | 0.00 |
正常乳腺GW98-621 | 23656 | 36.12 | 26.13 | 52.26 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 40 | 0 | 0.00 | 乳腺肿瘤 | -52.26 |
正常大脑BB-99-542 | 25507 | 37.14 | 13.43 | 26.86 | 正常大脑 | |
正常大脑BB-99-406 | 25509 | 40 | 0 | 0.00 | 正常大脑 | |
正常大脑BB-99-904 | 25546 | 40 | 0 | 0.00 | 正常大脑 | |
大脑期5ALZ BB99-874 | 25502 | 40 | 0 | 0.00 | 大脑期5-ALZ | -8.95 |
大脑期5ALZ BB99-887 | 25503 | 40 | 0.51 | 1.02 | 大脑期5-ALZ | -8.78 |
大脑期5ALZ BB99-862 | 25504 | 40 | 0.88 | 1.76 | 大脑期5-ALZ | -5.09 |
大脑期5ALZ BB99-927 | 25542 | 40 | 1.9 | 3.80 | 大脑期5-ALZ | -2.36 |
CT肺KC | normal | 36.59 | 19.23 | 38.46 | CT肺 | |
肺26KC | normal | 40 | 0 | 0.00 | 肺26 | |
肺27KC | normal | 40 | 0 | 0.00 | 肺27 | |
肺24KC | COPD | 40 | 0 | 0.00 | 肺24 | -9.62 |
肺28KC | COPD | 40 | 0 | 0.00 | 肺28 | -9.62 |
肺23KC | COPD | 40 | 0 | 0.00 | 肺23 | -9.62 |
肺25KC | normal | 40 | 0 | 0.00 | 肺25 | |
哮喘肺ODO3112 | 29321 | 40 | 0 | 0.00 | 哮喘肺 | -9.62 |
哮喘肺ODO3433 | 29323 | 38.36 | 6.1 | 12.20 | 哮喘肺 | 1.27 |
哮喘肺ODO3397 | 29322 | 37.29 | 12.16 | 24.32 | 哮喘肺 | 2.53 |
哮喘肺ODO4928 | 29325 | 38.01 | 7.64 | 15.28 | 哮喘肺 | 1.59 |
内皮细胞KC | control | 40 | 0 | 0.00 | 内皮细胞 | |
内皮细胞VEGFKC | 40 | 0 | 0.00 | endo VEGF | 0.00 | |
内皮细胞bFGF KC | 40 | 0 | 0.00 | endo bFGF | 0.00 | |
心脏Clontech | normal | 37.85 | 8.49 | 16.98 | 心脏 | |
心脏(T-1)缺血 | 29417 | 40 | 0 | 0.00 | 心脏T-1 | -16.98 |
心脏(T-14)非阻塞性DCM | 29422 | 40 | 0 | 0.00 | 心脏T-14 | -16.98 |
心脏(T-3399)DCM | 29426 | 39.5 | 2.9 | 5.80 | 心脏T-3399 | -2.93 |
腺样增殖体GW99-269 | 26162 | 40 | 0 | 0.00 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 36.35 | 22.46 | 44.92 | 扁桃体 | |
T细胞PC00314 | 28453 | 36.17 | 25.23 | 50.46 | T细胞 | |
PBMNC | 40 | 0 | 0.00 | PBMNC | ||
单核细胞 | 40 | 0.45 | 0.90 | 单核细胞 | ||
B细胞PC00665 | 28455 | 40 | 0.6 | 1.20 | B细胞 | |
树突细胞28441 | 38.07 | 7.37 | 14.74 | 树突细胞 | ||
中性粒细胞 | 28440 | 32.73 | 236.09 | 236.09 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 33.68 | 126.65 | 253.30 | 嗜酸性粒细胞 | |
BM unstim | 40 | 0 | 0.00 | BM未刺激的 | ||
BM stim | 36.52 | 20.1 | 20.10 | BM刺激的 | 20.10 | |
osteo dif | 40 | 0 | 0.00 | 成骨细胞分化 | 0.00 | |
osteo undif | 40 | 0 | 0.00 | 成骨细胞未分化 | ||
软骨细胞 | 39.61 | 2.7 | 6.75 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 39.91 | 1.59 | 1.59 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 38.98 | 4.07 | 8.14 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 36.29 | 23.27 | 46.54 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 35.81 | 31.94 | 63.88 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 34.79 | 61.79 | 123.58 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 35.08 | 51.15 | 102.30 | RA滑膜 | |
OA骨(biobank) | 29217 | 40 | 1.12 | 1.12 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 36.8 | 16.77 | 33.54 | OA骨 | |
OA骨标本2 | J.Emory | 34.72 | 64.74 | 129.48 | OA骨 | |
软骨(库) | Normal | 37.46 | 10.93 | 21.86 | 软骨(库) | |
软骨(库) | OA | 40 | 0 | 0.00 | 软骨(库) | -21.86 |
PBL未感染的 | 28441 | 35.05 | 52.27 | 104.54 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 37.31 | 12.04 | 24.08 | PBL HIV IIIB | -4.34 |
MRC5未感染的(100%) | 29158 | 40 | 0 | 0.00 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 38.19 | 6.8 | 13.60 | MRC5 HSV株F | 13.60 |
W12细胞 | 29179 | 40 | 0 | 0.00 | W12细胞 | |
角质细胞 | 29180 | 40 | 0 | 0.00 | 角质细胞 | |
B-肌动蛋白对照 | 29.77 | 1604.25 | ||||
基因组 | 30.5 | 1001.61 | ||||
1.00E+05 | 22.95 | 100000 | ||||
1.00E+05 | 22.91 | 100000 | ||||
1.00E+04 | 26.49 | 10000 | ||||
1.00E+04 | 26.66 | 10000 | ||||
1.00E+03 | 30.62 | 1000 | ||||
1.00E+03 | 30.43 | 1000 | ||||
1.00E+02 | 36.12 | 100 | ||||
1.00E+02 | 34.73 | 100 | ||||
1.00E+01 | 38.58 | 10 | ||||
1.00E+01 | 38.82 | 10 | ||||
1.00E-00 | 40 | 0 | ||||
1.00E-00 | 37.86 | 1 | ||||
NTC | 40 | 0 |
基因名称sbg995002PIGR
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | 1.83 |
结肠肿瘤 | 1351.60 |
结肠肿瘤 | 3.51 |
结肠肿瘤 | 2.76 |
肺肿瘤 | 104.21 |
肺肿瘤 | -1.64 |
肺肿瘤 | 2.25 |
肺肿瘤 | 1.48 |
乳腺肿瘤 | 3.89 |
乳腺肿瘤 | 9.96 |
乳腺肿瘤 | 0.00 |
乳腺肿瘤 | -52.26 |
大脑期5ALZ | -8.95 |
大脑期5ALZ | -8.78 |
大脑期5ALZ | -5.09 |
大脑期5ALZ | -2.36 |
肺24 | -9.62 |
肺28 | -9.62 |
肺23 | -9.62 |
哮喘肺 | -9.62 |
哮喘肺 | 1.27 |
哮喘肺 | 2.53 |
哮喘肺 | 1.59 |
内皮细胞VEGF | 0.00 |
内皮细胞bFGF | 0.00 |
心脏T-1 | -16.98 |
心脏T-14 | -16.98 |
心脏T-3399 | -2.93 |
BM stim | 20.10 |
Osteo undif | 0.00 |
软骨(库) | -21.86 |
PBL HIV IIIB | -4.34 |
MRC5 HSV株F | 13.60 |
基因名称sbg1033026C1q
在正常和疾病标本中有低度到中度的总体表达。在皮下脂肪组织,皮下脂肪,全脑和心脏中有最高的正常表达。在3份心脏标本中有最高的疾病表达。在4份肺肿瘤标本的1份中下调和在4份乳腺肿瘤标本的2份中上调提示该基因在肺癌和乳腺癌中的作用。在4份AD脑标本的2份中上调提示其参与阿尔茨海默氏病。在所有3份心脏标本中上调提示参与心血管疾病,例如非阻塞性和阻塞性DCM和缺血。其在所有免疫细胞中低表达。在OA的滑膜和骨标本中和在RA的滑膜标本中为低度到中度表达。
标本sbg1033026C1q | Ct(标本1标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 32.32,31.18 | 11.99 | 24.91 | 18.45 | 3.06 | 16.34 | 301.47 |
皮下脂肪Zenbio | 34.95,33.78 | 2.2 | 4.69 | 3.45 | 0.96 | 52.36 | 180.37 |
肾上腺Clontech | 40,40 | 0 | 0 | 0.00 | 0.61 | 81.97 | 0.00 |
全脑Clontech | 28.5,28.04 | 140.11 | 187.98 | 164.05 | 7.24 | 6.91 | 1132.91 |
胎脑clontech | 40,40 | 0 | 0 | 0.00 | 0.48 | 103.95 | 0.00 |
小脑Clontech | 40,40 | 0 | 0 | 0.00 | 2.17 | 23.04 | 0.00 |
子宫颈 | 40,40 | 0 | 0 | 0.00 | 2.42 | 20.66 | 0.00 |
结肠 | 34.82,3 8.44 | 2.39 | 0.23 | 1.31 | 2.71 | 18.45 | 24.17 |
子宫内膜 | 40,35.09 | 0 | 2.01 | 1.01 | 0.73 | 68.21 | 68.55 |
食管 | 40,40 | 0 | 0 | 0.00 | 1.37 | 36.50 | 0.00 |
心脏Clontech | 32.53,34.31 | 10.45 | 3.32 | 6.89 | 1.32 | 37.88 | 260.80 |
下丘脑 | 40,40 | 0 | 0 | 0.00 | 0.32 | 155.28 | 0.00 |
回肠 | 40,34.55 | 0 | 2.85 | 1.43 | 2.58 | 19.38 | 27.62 |
空肠 | 33.04,34.86 | 7.51 | 2.33 | 4.92 | 6.60 | 7.58 | 37.27 |
肾脏 | 40,40 | 0 | 0 | 0.00 | 2.12 | 23.58 | 0.00 |
肝脏 | 35.81,33.92 | 1.26 | 4.28 | 2.77 | 1.50 | 33.33 | 92.33 |
胚胎肝Clontech | 32.05,40 | 14.25 | 0 | 7.13 | 10.40 | 4.81 | 34.25 |
肺 | 40,33.51 | 0 | 5.58 | 2.79 | 2.57 | 19.46 | 54.28 |
乳腺Clontech | 31.05,30.69 | 27.02 | 34.2 | 30.61 | 13.00 | 3.85 | 117.73 |
子宫肌层 | 33.29,35.1 | 6.42 | 2 | 4.21 | 2.34 | 21.37 | 89.96 |
网膜 | 34.44,40 | 3.07 | 0 | 1.54 | 3.94 | 12.69 | 19.48 |
卵巢 | 32.59,35.04 | 10.03 | 2.07 | 6.05 | 4.34 | 11.52 | 69.70 |
胰腺 | 40,40 | 0 | 0 | 0.00 | 0.81 | 61.80 | 0.00 |
胰头 | 40,40 | 0 | 0 | 0.00 | 1.57 | 31.85 | 0.00 |
腮腺 | 34.63,33.09 | 2.71 | 7.29 | 5.00 | 5.48 | 9.12 | 45.62 |
胎盘Clontech | 32.77,33.01 | 8.94 | 7.7 | 8.32 | 5.26 | 9.51 | 79.09 |
前列腺 | 40,40 | 0 | 0 | 0.00 | 3.00 | 16.67 | 0.00 |
直肠 | 40,34.44 | 0 | 3.06 | 1.53 | 1.23 | 40.65 | 62.20 |
唾液腺Clontech | 32.96,40 | 7.94 | 0 | 3.97 | 7.31 | 6.84 | 27.15 |
骨骼肌Clontech | 40,40 | 0 | 0 | 0.00 | 1.26 | 39.68 | 0.00 |
皮肤 | 40,33.46 | 0.6 | 5.75 | 3.18 | 1.21 | 41.32 | 131.20 |
小肠Clontech | 40,40 | 0 | 0 | 0.00 | 0.98 | 51.07 | 0.00 |
脾脏 | 35.65,35 | 1.4 | 2.13 | 1.77 | 4.92 | 10.16 | 17.94 |
胃 | 40,34.73 | 0 | 2.54 | 1.27 | 2.73 | 18.32 | 23.26 |
睾丸Clontech | 40,35.12 | 0 | 1.98 | 0.99 | 0.57 | 87.87 | 86.99 |
胸腺Clontech | 32.44,31.57 | 11.11 | 19.37 | 15.24 | 9.89 | 5.06 | 77.05 |
甲状腺 | 40,40 | 0 | 0 | 0.00 | 2.77 | 18.05 | 0.00 |
气管Clontech | 34.58,33.56 | 2.79 | 5.4 | 4.10 | 9.71 | 5.15 | 21.09 |
膀胱 | 33.45,33.34 | 5.8 | 6.21 | 6.01 | 5.47 | 9.14 | 54.89 |
子宫 | 33.19,32.41 | 6.82 | 11.32 | 9.07 | 5.34 | 9.36 | 84.93 |
基因组 | 25.47 | 981.57 | |||||
b-肌动蛋白 | 26.87 | 398.61 | |||||
1.00E+05 | 18.24 | 100000 | |||||
1.00E+05 | 18.35 | 100000 | |||||
1.00E+04 | 21.53 | 10000 | |||||
1.00E+04 | 21.62 | 10000 | |||||
1.00E+03 | 25.17 | 1000 | |||||
1.00E+03 | 25.03 | 1000 | |||||
1.00E+02 | 30.53 | 100 | |||||
1.00E+02 | 30.49 | 100 | |||||
1.00E+01 | 30.85 | 10 | |||||
1.00E+01 | 40 | 10 |
1.00E-00 | 40 | 0 | |||||
1.00E-00 | 40 | 0 | |||||
NTC | 40 | 0 | |||||
NTC | 40 | 0 |
标本sbg1033026C1q | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 27.03 | 397.15 | 794.30 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 29.53 | 91.39 | 182.78 | 结肠肿瘤 | -4.35 |
正常结肠GW98-178 | 22080 | 30.3 | 57.81 | 115.62 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 29.31 | 103.84 | 207.68 | 结肠肿瘤 | 1.80 |
正常结肠GW98-561 | 23514 | 28.79 | 140.64 | 281.28 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 30.18 | 62.18 | 124.36 | 结肠肿瘤 | -2.26 |
正常结肠GW98-894 | 24691 | 28.31 | 187.28 | 374.56 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 28.75 | 143.93 | 287.86 | 结肠肿瘤 | -1.30 |
正常肺GW98-3 | 20742 | 28.18 | 201.78 | 403.56 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 32.35 | 17.41 | 34.82 | 肺肿瘤 | -11.59 |
正常肺GW97-179 | 20677 | 29.94 | 71.52 | 143.04 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 28.76 | 143.36 | 286.72 | 肺肿瘤 | 2.00 |
正常肺GW98-165 | 21922 | 28.69 | 149.49 | 298.98 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 31.28 | 32.63 | 65.26 | 肺肿瘤 | -4.58 |
正常肺GW98-282 | 22584 | 31.42 | 30.07 | 60.14 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 30.33 | 56.83 | 113.66 | 肺肿瘤 | 1.89 |
正常乳腺GW00-392 | 28750 | 28.72 | 146.7 | 146.70 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 27.02 | 398.56 | 797.12 | 乳腺肿瘤 | 5.43 |
正常乳腺GW00-413 | 28798 | 30.95 | 39.63 | 39.63 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 30.58 | 49.03 | 98.06 | 乳腺肿瘤 | 2.47 |
正常乳腺GW00-235:238 | 27592-95 | 32.53 | 15.6 | 15.60 | 正常乳腺 |
乳腺肿瘤GW00-231:234 | 27588-91 | 29.58 | 88.49 | 88.49 | 乳腺肿瘤 | 5.67 |
正常乳腺GW98-621 | 23656 | 27.5 | 300.39 | 600.78 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 29.28 | 105.43 | 210.86 | 乳腺肿瘤 | -2.85 |
正常大脑BB-99-542 | 25507 | 30.67 | 46.59 | 93.18 | 正常大脑 | |
正常大脑BB-99-406 | 25509 | 29.54 | 90.66 | 181.32 | 正常大脑 | |
正常大脑BB-99-904 | 25546 | 31.13 | 35.58 | 71.16 | 正常大脑 | |
大脑期5ALZBB99-874 | 25502 | 31.4 | 30.36 | 60.72 | 大脑期5-ALZ | -1.90 |
大脑期5ALZBB99-887 | 25503 | 28.39 | 177.94 | 355.88 | 大脑期5-ALZ | 3.09 |
大脑期5ALZBB99-862 | 25504 | 28.92 | 130.19 | 260.38 | 大脑期5-ALZ | 2.26 |
大脑期5ALZBB99-927 | 25542 | 28.2 | 198.98 | 397.96 | 大脑期5-ALZ | 3.45 |
CT肺KC | normal | 31.24 | 33.37 | 66.74 | CT肺 | |
肺26KC | normal | 33.59 | 8.37 | 8.37 | 肺26 | |
肺27KC | normal | 37.8 | 0.7 | 0.70 | 肺27 | |
肺24KC | COPD | 34.56 | 4.73 | 4.73 | 肺24 | -4.39 |
肺28KC | COPD | 35.39 | 2.91 | 2.91 | 肺28 | -7.13 |
肺23KC | COPD | 34.74 | 4.26 | 4.26 | 肺23 | -4.87 |
肺25KC | normal | 33.85 | 7.19 | 7.19 | 肺25 | |
哮喘肺ODO3112 | 29321 | 35.04 | 3.57 | 3.57 | 哮喘肺 | -5.81 |
哮喘肺ODO3433 | 29323 | 32.44 | 16.48 | 32.96 | 哮喘肺 | 1.59 |
哮喘肺ODO3397 | 29322 | 29.4 | 98.44 | 196.88 | 哮喘肺 | 9.49 |
哮喘肺ODO4928 | 29325 | 31.1 | 36.23 | 72.46 | 哮喘肺 | 3.49 |
内皮细胞KC | control | 40 | 0 | 0.00 | 内皮细胞 | |
endo VEGF KC | 40 | 0 | 0.00 | endo VEGF | 0.00 | |
endo bFGF KC | 35.4 | 2.89 | 2.89 | endo bFGF | 2.89 | |
心脏Clontech | normal | 29.05 | 120.78 | 241.56 | 心脏 |
心脏(T-1)缺血 | 29417 | 26.23 | 633.79 | 1267.58 | 心脏T-1 | 5.25 |
心脏(T-14)非阻塞性DCM | 29422 | 25.74 | 847.85 | 1695.70 | 心脏T-14 | 7.02 |
心脏(T-3399)DCM | 29426 | 25.03 | 1289.37 | 2578.74 | 心脏T-3399 | 10.68 |
腺样增殖体GW99-269 | 26162 | 35.24 | 3.17 | 6.34 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 31 | 38.35 | 76.70 | 扁桃体 | |
T细胞PC00314 | 28453 | 31.75 | 24.69 | 49.38 | T细胞 | |
PBMNC | 40 | 0 | 0.00 | PBMNC | ||
单核细胞 | 40 | 0 | 0.00 | 单核细胞 | ||
B细胞PC00665 | 28455 | 31.35 | 31.31 | 62.62 | B细胞 | |
树突细胞28441 | 32.81 | 13.25 | 26.50 | 树突细胞 | ||
中性粒细胞 | 28440 | 31.76 | 24.51 | 24.51 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 33.08 | 11.29 | 22.58 | 嗜酸性粒细胞 | |
BM unstim | 36.9 | 1.19 | 1.19 | BM未刺激的 | ||
BM stim | 38.86 | 0.38 | 0.38 | BM刺激的 | -3.13 | |
osteo dif | 37.77 | 0.72 | 0.72 | 成骨细胞分化 | 0.72 | |
osteo undif | 40 | 0 | 0.00 | 成骨细胞未分化 | ||
软骨细胞 | 33.14 | 10.88 | 27.20 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 30.61 | 48.28 | 48.28 | OA滑膜 | |
OA骨膜NP10/01 | 29461 | 27.5 | 300.97 | 601.94 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 29.28 | 105.55 | 211.10 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 30.18 | 62.3 | 124.60 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 29.22 | 109.5 | 219.00 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 30.06 | 66.71 | 133.42 | RA滑膜 | |
OA骨(biobank) | 29217 | 32.6 | 14.99 | 14.99 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 30.48 | 52.25 | 104.50 | OA骨 | |
OA骨标本2 | J.Emory | 32.31 | 17.76 | 35.52 | OA骨 | |
软骨(库) | Normal | 30.45 | 53.05 | 106.10 | 软骨(库) | |
软骨(库) | OA | 30.81 | 43.01 | 86.02 | 软骨(库) | -1.23 |
PBL未感染的 | 28441 | 30.19 | 61.92 | 123.84 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 31.19 | 34.35 | 68.70 | PBL HIV IIIB | -1.80 |
MRC5未感染的(100%) | 29158 | 30.19 | 62.02 | 124.04 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 31.13 | 35.48 | 70.96 | MRC5 HSV株F | -1.75 |
W12细胞 | 29179 | 32 | 21.32 | 42.64 | W12细胞 | |
角质细胞 | 29180 | 33.3 | 9.92 | 19.84 | 角质细胞 | |
B肌动蛋白对照 | 26.66 | 492.23 | ||||
基因组 | 24.83 | 1443.91 | ||||
1.00E+05 | 18.12 | 100000 | ||||
1.00E+05 | 18.12 | 100000 | ||||
1.00E+04 | 21.28 | 10000 | ||||
1.00E+04 | 21.31 | 10000 | ||||
1.00E+03 | 24.92 | 1000 | ||||
1.00E+03 | 24.9 | 1000 | ||||
1.00E+02 | 29.22 | 100 | ||||
1.00E+02 | 29.26 | 100 | ||||
1.00E+01 | 33.13 | 10 | ||||
1.00E+01 | 34.32 | 10 | ||||
1.00E-00 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
NTC | 40 | 0 |
基因名称sbg1033026C1q
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | -4.35 |
结肠肿瘤 | 1.80 |
结肠肿瘤 | -2.26 |
结肠肿瘤 | -1.30 |
肺肿瘤 | -11.59 |
肺肿瘤 | 2.00 |
肺肿瘤 | -4.58 |
肺肿瘤 | 1.89 |
乳腺肿瘤 | 5.43 |
乳腺肿瘤 | 2.47 |
乳腺肿瘤 | 5.67 |
乳腺肿瘤 | -2.85 |
大脑期5ALZ | -1.90 |
大脑期5ALZ | 3.09 |
大脑期5ALZ | 2.26 |
大脑期5ALZ | 3.45 |
肺24 | -4.39 |
肺28 | -7.13 |
肺23 | -4.87 |
哮喘肺 | -5.81 |
哮喘肺 | 1.59 |
哮喘肺 | 9.49 |
哮喘肺 | 3.49 |
内皮细胞VEGF | 0.00 |
内皮细胞bFGF | 2.89 |
心脏T-1 | 5.25 |
心脏T-14 | 7.02 |
心脏T-3399 | 10.68 |
BM stim | -3.13 |
Osteo undif | 0.72 |
软骨(库) | -1.23 |
PBL HIV IIIB | -1.80 |
MRC50 HSV株F | -1.75 |
基因名称sbg1003675Rnase
失败
基因名称sbg1015258PLM
在正常和疾病标本中有低的总体表达。在子宫内膜,下丘脑,肝脏小肠和睾丸中有最高的正常表达。在一份乳腺正常/肿瘤对中,一份正常的脑标本中,二份阿尔茨海默氏病脑标本中,B细胞和HSV感染的MRC5细胞中有最高的疾病表达。在4份肺肿瘤标本的1份中下调,足以认定其在肺癌中的作用。在4份乳腺肿瘤标本的2份中上调提示其参与乳腺癌。在3份COPD标本的2份中下调和在4份哮喘肺标本的2份中下调提示其在慢性阻塞性肺病和哮喘中的作用。在阻塞性DCM心脏标本中上调提示其在心血管疾病中有潜在的作用。在受到刺激的骨髓标本中下调。在OA的软骨库中下调提示在骨关节炎中涉及该基因。在HSV感染的MRC5细胞中上调提示该基因可能是HSV中的宿主因子。在所有免疫细胞(除B细胞外)中低表达,在B细胞中中度表达。
标本sbg1015258PLM | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 39.96,39.32 | 0.39 | 0.73 | 0.56 | 3.06 | 16.34 | 9.15 |
皮下脂肪Zenbio | 39.61,37.77 | 0.62 | 1.84 | 1.23 | 0.96 | 52.36 | 64.40 |
肾上腺Clontech | 36.89,37.65 | 3.12 | 1.98 | 2.55 | 0.61 | 81.97 | 209.02 |
全脑Clontech | 32.77,33.06 | 36.18 | 30.37 | 33.28 | 7.24 | 6.91 | 229.80 |
胎脑clontech | 38.01,37.52 | 1.6 | 2.14 | 1.87 | 0.48 | 103.95 | 194.39 |
小脑Clontech | 38.34,37.8 | 1.31 | 1.81 | 1.56 | 2.17 | 23.04 | 35.94 |
子宫颈 | 36.9,37.17 | 3.1 | 2.64 | 2.87 | 2.42 | 20.66 | 59.30 |
结肠 | 35.93,37.95 | 5.51 | 1.66 | 3.59 | 2.71 | 18.45 | 66.14 |
子宫内膜 | 34.62,37.51 | 12.02 | 2.15 | 7.09 | 0.73 | 68.21 | 483.29 |
食管 | 35.76,37.39 | 6.1 | 2.31 | 4.21 | 1.37 | 36.50 | 153.47 |
心脏Clontech | 36.78,38.53 | 3.33 | 1.17 | 2.25 | 1.32 | 37.88 | 85.23 |
下丘脑 | 37.12,36.52 | 2.71 | 3.87 | 3.29 | 0.32 | 155.28 | 510.87 |
回肠 | 36.15,36.19 | 4.84 | 4.72 | 4.78 | 2.58 | 19.38 | 92.64 |
空肠 | 34.6,33.48 | 12.14 | 23.65 | 17.90 | 6.60 | 7.58 | 135.57 |
肾脏 | 37.16,37.9 | 2.65 | 1.7 | 2.18 | 2.12 | 23.58 | 51.30 |
肝脏 | 34.6,36.06 | 12.13 | 5.11 | 8.62 | 1.50 | 33.33 | 287.33 |
胚胎肝Clontech | 34.32,36.91 | 14.35 | 3.07 | 8.71 | 10.40 | 4.81 | 41.88 |
肺 | 36.94,35.31 | 3.02 | 7.98 | 5.50 | 2.57 | 19.46 | 107.00 |
乳腺Clontech | 38.03,36.89 | 1.58 | 3.11 | 2.35 | 13.00 | 3.85 | 9.02 |
子宫肌层 | 38.44,38 | 1.24 | 1.6 | 1.42 | 2.34 | 21.37 | 30.34 |
网膜 | 35.41,35.38 | 7.51 | 7.64 | 7.58 | 3.94 | 12.69 | 96.13 |
卵巢 | |||||||
胰腺 | 34.32,34.36 | 14.4 | 14.07 | 14.24 | 4.34 | 11.52 | 164.00 |
胰头 | 36.44,36.82 | 4.07 | 3.25 | 3.66 | 0.81 | 61.80 | 226.21 |
腮腺 | 37.54,36.96 | 2.11 | 2.98 | 2.55 | 1.57 | 31.85 | 81.05 |
胎盘Clontech | 37.1,35.46 | 2.75 | 7.29 | 5.02 | 5.48 | 9.12 | 45.80 |
前列腺 | 36.07,35.36 | 5.08 | 7.74 | 6.41 | 5.26 | 9.51 | 60.93 |
直肠 | 37.4,37.82 | 2.3 | 1.79 | 2.05 | 3.00 | 16.67 | 34.08 |
唾液腺Clontech | 36.65,37.39 | 3.59 | 2.32 | 2.96 | 1.23 | 40.65 | 120.12 |
骨骼肌Clontech | 38.55,39.31 | 1.16 | 0.74 | 0.95 | 7.31 | 6.84 | 6.50 |
皮肤 | 37.59,36.87 | 2.06 | 3.15 | 2.61 | 1.26 | 39.68 | 103.37 |
小肠Clontech | 38.36,36.33 | 1.3 | 4.34 | 2.82 | 1.21 | 41.32 | 116.53 |
脾脏 | 36.05,36.76 | 5.14 | 3.37 | 4.26 | 0.98 | 51.07 | 217.31 |
胃 | 37.62,35.34 | 2.02 | 7.83 | 4.93 | 4.92 | 10.16 | 50.05 |
睾丸Clontech | 35.8,35.15 | 5.95 | 8.76 | 7.36 | 2.73 | 18.32 | 134.71 |
胸腺Clontech | 35.14,37.08 | 8.82 | 2.77 | 5.80 | 0.57 | 87.87 | 509.23 |
甲状腺 | 35.89,35.06 | 5.65 | 9.22 | 7.44 | 9.89 | 5.06 | 37.59 |
气管Clontech | 37.59,37.2 | 2.06 | 2.59 | 2.33 | 2.77 | 18.05 | 41.97 |
膀胱 | 37.52,37.95 | 2.14 | 1.66 | 1.90 | 9.71 | 5.15 | 9.78 |
子宫 | 37.47,35.44 | 2.2 | 7.38 | 4.79 | 5.47 | 9.14 | 43.78 |
皮下脂肪细胞Zenbio | 34.17,34.12 | 15.66 | 16.17 | 15.92 | 5.34 | 9.36 | 149.02 |
基因组 | 27.03 | 1097.52 | |||||
b-肌动蛋白 | 27.23 | 974.77 | |||||
1.00E+05 | 19.25 | 100000 | |||||
1.00E+05 | 19.2 | 100000 | |||||
1.00E+04 | 22.99 | 10000 | |||||
1.00E+04 | 22.94 | 10000 | |||||
1.00E+03 | 27.09 | 1000 | |||||
1.00E+03 | 27.28 | 1000 | |||||
1.00E+02 | 31.49 | 100 | |||||
1.00E+02 | 31.46 | 100 | |||||
1.00E+01 | 37.86 | 10 | |||||
1.00E+01 | 35.45 | 10 | |||||
1.00E-00 | 37.08 | 1 | |||||
1.00E-00 | 37.4 | 1 | |||||
NTC | 36.45 | -1 | |||||
NTC | 36.15 | -1 |
标本sbg1015258PLM | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 35.4 | 9.91 | 19.82 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 35.13 | 11.61 | 23.22 | 结肠肿瘤 | 1.17 |
正常结肠GW98-178 | 22080 | 34.84 | 13.83 | 27.66 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 35 | 12.59 | 25.18 | 结肠肿瘤 | -1.10 |
正常结肠GW98-561 | 23514 | 35.48 | 9.4 | 18.80 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 36.2 | 6.14 | 12.28 | 结肠肿瘤 | -1.53 |
正常结肠GW98-894 | 24691 | 34.53 | 16.62 | 33.24 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 34.29 | 19.25 | 38.50 | 结肠肿瘤 | 1.16 |
正常肺GW98-3 | 20742 | 34.53 | 16.69 | 33.38 | 正常肺 |
肺肿瘤GW98-2 | 20741 | 37.87 | 2.25 | 4.50 | 肺肿瘤 | -7.42 |
正常肺GW97-179 | 20677 | 34.59 | 16.02 | 32.04 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 34.45 | 17.43 | 34.86 | 肺肿瘤 | 1.09 |
正常肺GW98-165 | 21922 | 33.89 | 24.39 | 48.78 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 35.48 | 9.43 | 18.86 | 肺肿瘤 | -2.59 |
正常肺GW98-282 | 22584 | 36.67 | 4.62 | 9.24 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 37.87 | 2.26 | 4.52 | 肺肿瘤 | -2.04 |
正常乳腺GW00-392 | 28750 | 34.17 | 20.64 | 20.64 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 33.54 | 30.09 | 60.18 | 乳腺肿瘤 | 2.92 |
正常乳腺GW00-413 | 28798 | 39.05 | 1.11 | 1.11 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 35.01 | 12.46 | 24.92 | 乳腺肿瘤 | 22.45 |
正常乳腺GW00-235:238 | 27592-95 | 40 | 0.55 | 0.55 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 35.07 | 12.02 | 12.02 | 乳腺肿瘤 | 21.85 |
正常乳腺GW98-621 | 23656 | 33 | 41.58 | 83.16 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 33.05 | 40.47 | 80.94 | 乳腺肿瘤 | -1.03 |
正常大脑BB-99-542 | 25507 | 32.73 | 48.93 | 97.86 | 正常大脑 | |
正常大脑BB-99-406 | 25509 | 33.97 | 23.34 | 46.68 | 正常大脑 | |
正常大脑BB-99-904 | 25546 | 37.88 | 2.24 | 4.48 | 正常大脑 | |
大脑期5ALZ BB99-874 | 25502 | 35.92 | 7.25 | 14.50 | 大脑期5ALZ | -3.43 |
大脑期5ALZ BB99-887 | 25503 | 31.57 | 97.99 | 195.98 | 大脑期5ALZ | 3.95 |
大脑期5ALZ BB99-862 | 25504 | 36.08 | 6.57 | 13.14 | 大脑期5ALZ | -3.78 |
大脑期5ALZ BB99-927 | 25542 | 32.66 | 50.98 | 101.96 | 大脑期5ALZ | 2.05 |
CT肺KC | normal | 37.37 | 3.04 | 6.08 | CT肺 | |
肺26KC | normal | 肺26 | ||||
肺27KC | normal | 38.52 | 1.52 | 1.52 | 肺27 | |
肺24KC | COPD | 40 | 0 | 0.00 | 肺24 | -3.07 |
肺28KC | COPD | 37.4 | 2.99 | 2.99 | 肺28 | -1.03 |
肺23KC | COPD | 39.56 | 0.82 | 0.82 | 肺23 | -3.74 |
肺25KC | normal | 38.43 | 1.61 | 1.61 | 肺25 | |
哮喘肺ODO3112 | 29321 | 39.45 | 0.88 | 0.88 | 哮喘肺 | -3.49 |
哮喘肺ODO3433 | 29323 | 36.48 | 5.19 | 10.38 | 哮喘肺 | 3.38 |
哮喘肺ODO3397 | 29322 | 35.56 | 8.99 | 17.98 | 哮喘肺 | 5.86 |
哮喘肺ODO4928 | 29325 | 37.06 | 3.66 | 7.32 | 哮喘肺 | 2.38 |
内皮细胞KC | control | 39.29 | 0.96 | 0.96 | 内皮细胞 | |
endo VEGFKC | 37.65 | 2.57 | 2.57 | endo VEGF | 2.68 | |
endo bFGFKC | 40 | 0.48 | 0.48 | endo bFGF | -2.00 | |
心脏Clontech | nomal | 40 | 0.68 | 1.36 | 心脏 | |
心脏(T-1)缺血 | 29417 | 39.29 | 0.96 | 1.92 | 心脏T-1 | 1.41 |
心脏(T-14)非阻塞性DCM | 29422 | 38.21 | 1.84 | 3.68 | 心脏T-14 | 2.71 |
心脏(T-3399)DCM | 29426 | 35.49 | 9.35 | 18.70 | 心脏T-3399 | 13.75 |
腺样增殖体GW99-269 | 26162 | 39.63 | 0.78 | 1.56 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 34.5 | 16.92 | 33.84 | 扁桃体 | |
T细胞PC00314 | 28453 | 34.57 | 16.25 | 32.50 | T细胞 | |
PBMNC | 37.32 | 3.13 | 3.13 | PBMNC | ||
单核细胞 | 37.74 | 2.44 | 4.88 | 单核细胞 | ||
B细胞PC00665 | 28455 | 33.32 | 34.36 | 68.72 | B细胞 | |
树突细胞28441 | 37.29 | 3.19 | 6.38 | 树突细胞 | ||
中性粒细胞 | 28440 | 36.01 | 6.85 | 6.85 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 35.38 | 9.98 | 19.96 | 嗜酸性粒细胞 | |
BM unstim | 37.44 | 2.91 | 2.91 | BM未刺激的 | ||
BM stim | 40 | 0.53 | 0.53 | BM刺激的 | -5.49 | |
osteo dif | 38.15 | 1.91 | 1.91 | 成骨细胞分化 | -1.38 | |
osteo undif | 37.6 | 2.64 | 2.64 | 成骨细胞未分化 | ||
软骨细胞 | 36.1 | 6.51 | 16.28 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 35.58 | 8.86 | 8.86 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 35.46 | 9.54 | 19.08 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 34.05 | 22.23 | 44.46 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 37.92 | 2.19 | 4.38 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 35.39 | 9.92 | 19.84 | RA滑膜 |
RA滑膜NP45/00 | 28475 | 35.03 | 12.37 | 24.74 | RA滑膜 | |
OA骨(biobank) | 29217 | 39.98 | 0.67 | 0.67 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 36.06 | 6.68 | 13.36 | OA骨 | |
OA骨标本2 | J.Emory | 39.89 | 0.67 | 1.34 | OA骨 | |
软骨(库) | Normal | 35.57 | 8.92 | 17.84 | 软骨(库) | |
软骨(库) | OA | 39.5 | 0.85 | 1.70 | 软骨(库) | -10.49 |
PBL未感染的 | 28441 | 36.65 | 4.67 | 9.34 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 36.94 | 3.92 | 7.84 | PBL HIV IIIB | -1.19 |
MRC5未感染的(100%) | 29158 | 37.54 | 2.74 | 5.48 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 33.19 | 37.18 | 74.36 | MRC5 HSV株F | 13.57 |
W12细胞 | 29179 | 37.23 | 3.3 | 6.60 | W12细胞 | |
角质细胞 | 29180 | 37.18 | 3.4 | 6.80 | 角质细胞 | |
B-肌动蛋白对照 | 27.26 | 1296.87 | ||||
基因组 | 27.2 | 1345.34 | ||||
1.00E+05 | 19.44 | 100000 | ||||
1.00E+05 | 19.81 | 100000 | ||||
1.00E+04 | 23.63 | 10000 | ||||
1.00E+04 | 23.41 | 10000 | ||||
1.00E+03 | 27.77 | 1000 | ||||
1.00E+03 | 27.89 | 1000 | ||||
1.00E+02 | 32.32 | 100 | ||||
1.00E+02 | 32.3 | 100 | ||||
1.00E+01 | 36.77 | 10 | ||||
1.00E+01 | 36.39 | 10 | ||||
1.00E-00 | 38.06 | 1 | ||||
1.00E-00 | 37.56 | 1 | ||||
NTC | 38.18 | -1 |
基因名称sbg1015258PLM
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | 1.17 |
结肠肿瘤 | -1.10 |
结肠肿瘤 | -1.53 |
结肠肿瘤 | 1.16 |
肺肿瘤 | -7.42 |
肺肿瘤 | 1.09 |
肺肿瘤 | -2.59 |
肺肿瘤 | -2.04 |
乳腺肿瘤 | 2.92 |
乳腺肿瘤 | 22.45 |
乳腺肿瘤 | 21.85 |
乳腺肿瘤 | -1.03 |
大脑期5ALZ | -3.43 |
大脑期5ALZ | 3.95 |
大脑期5ALZ | -3.78 |
大脑期5ALZ | 2.05 |
肺24 | -3.07 |
肺28 | -1.03 |
肺23 | -3.74 |
哮喘肺 | -3.49 |
哮喘肺 | 3.38 |
哮喘肺 | 5.86 |
哮喘肺 | 2.38 |
endo VEGF | 2.68 |
endo bFGF | -2.00 |
心脏T-1 | 1.41 |
心脏T-14 | 2.71 |
心脏T-3399 | 13.75 |
BM stim | -5.49 |
Osteo undif | -1.38 |
软骨(库) | -10.49 |
PBL HIV IIIB | -1.19 |
MRC5 HSV株F | 13.57 |
基因名称sbg1003328IG(Taqman)
中度的总体表达。在全脑,胎脑和小脑中有最高的正常表达,在结肠和乳腺中其表达水平略低。在结肠和肺肿瘤对,以及在正常和阿尔茨海默氏病脑中有最高的疾病表达。在4份乳腺肿瘤标本的2份中明显上调,在4份乳腺肿瘤标本的1份中轻微上调提示在乳腺癌中涉及该基因。在所有3份COPD标本中下调可能提示与慢性阻塞性肺病有关。在4份哮喘标本的1份中下调提示其在哮喘中该基因的潜在作用。在HSV感染的MRC5细胞中下调提示该基因可能在HSV中起作用。在所有3份OA的滑膜标本中,所有3份RA滑膜标本中,所有2份OA骨标本中高表达,以及在T细胞和B细胞中确定的高表达提示在骨关节炎和类风湿性关节炎中涉及该基因。
标本sbg1003328IG | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 32.35,32.1 | 109.15 | 127.12 | 118.14 | 3.06 | 16.34 | 1930.31 |
皮下脂肪Zenbio | 37.92,40 | 3.84 | 0 | 1.92 | 0.96 | 52.36 | 100.52 |
肾上腺Clontech | 38.07,35.73 | 3.5 | 14.32 | 8.91 | 0.61 | 81.97 | 730.33 |
全脑Clontech | 22.72,23.09 | 35640.5 | 28576.52 | 32108.51 | 7.24 | 6.91 | 221743.85 |
胎脑clontech | 33.39,34.06 | 58.43 | 39.04 | 48.74 | 0.48 | 103.95 | 5066.01 |
小脑Clontech | 31.32,31.02 | 202.49 | 242.95 | 222.72 | 2.17 | 23.04 | 5131.80 |
子宫颈 | 36.36,35.6 | 9.78 | 15.49 | 12.64 | 2.42 | 20.66 | 261.05 |
结肠 | 30.74,32.11 | 286.9 | 125.78 | 206.34 | 2.71 | 18.45 | 3807.01 |
子宫内膜 | 34.58,36.01 | 28.47 | 12.11 | 20.29 | 0.73 | 68.21 | 1384.04 |
食管 | 37.54,36.05 | 4.82 | 11.78 | 8.30 | 1.37 | 36.50 | 302.92 |
心脏Clontech | 36.23,36.85 | 10.56 | 7.3 | 8.93 | 1.32 | 37.88 | 338.26 |
下丘脑 | 40,36.96 | 0 | 6.81 | 3.41 | 0.32 | 155.28 | 528.73 |
回肠 | 34.79,34.48 | 25.09 | 30.4 | 27.75 | 2.58 | 19.38 | 537.69 |
空肠 | 30.14,31.02 | 412.72 | 242.47 | 327.60 | 6.60 | 7.58 | 2481.78 |
肾脏 | 33.94,34.61 | 41.89 | 28.12 | 35.01 | 2.12 | 23.58 | 825.59 |
肝脏 | 36.11,35.38 | 11.41 | 17.61 | 14.51 | 1.50 | 33.33 | 483.67 |
胚胎肝Clontech | 30.24,30.27 | 388.12 | 381.28 | 384.70 | 10.40 | 4.81 | 1849.52 |
肺 | 35.59,35.09 | 15.59 | 20.98 | 18.29 | 2.57 | 19.46 | 355.74 |
乳腺Clontech | 29.21,28.52 | 718.74 | 1090.18 | 904.46 | 13.00 | 3.85 | 3478.69 |
子宫肌层 | 33.7,34.11 | 48.42 | 37.85 | 43.14 | 2.34 | 21.37 | 921.69 |
网膜 | 33.83,33.57 | 44.75 | 52.27 | 48.51 | 3.94 | 12.69 | 615.61 |
卵巢 | 32.47,32.34 | 101.42 | 109.96 | 105.69 | 4.34 | 11.52 | 1217.63 |
胰腺 | 38.16,40 | 3.31 | 0 | 1.66 | 0.81 | 61.80 | 102.29 |
胰头 | 40,36.68 | 0 | 8.07 | 4.04 | 1.57 | 31.85 | 128.50 |
腮腺 | 31.68,31.03 | 162.92 | 241.11 | 202.02 | 5.48 | 9.12 | 1843.20 |
胎盘Clontech | 30.48,30.82 | 335.37 | 274.53 | 304.95 | 5.26 | 9.51 | 2898.76 |
前列腺 | 33.39,32.15 | 58.39 | 122.82 | 90.61 | 3.00 | 16.67 | 1510.08 |
直肠 | 35.95,35.32 | 12.5 | 18.32 | 15.41 | 1.23 | 40.65 | 626.42 |
唾液腺Clontech | 31.25,30.65 | 211.88 | 303.2 | 257.54 | 7.31 | 6.84 | 1761.56 |
骨骼肌Clontech | 36.61,37.62 | 8.44 | 4.6 | 6.52 | 1.26 | 39.68 | 258.73 |
皮肤 | 36.37,36.08 | 9.71 | 11.56 | 10.64 | 1.21 | 41.32 | 439.46 |
小肠Clontech | 36.74,34.51 | 7.79 | 29.79 | 18.79 | 0.98 | 51.07 | 959.65 |
脾脏 | 34.78,35.63 | 25.25 | 15.18 | 20.22 | 4.92 | 10.16 | 205.44 |
胃 | 40,35.13 | 0.88 | 20.56 | 10.72 | 2.73 | 18.32 | 196.34 |
睾丸Clontech | 35.01,39.68 | 22.07 | 1.33 | 11.70 | 0.57 | 87.87 | 1028.12 |
胸腺Clontech | 29.15,29.2 | 749.23 | 724.61 | 736.92 | 9.89 | 5.06 | 3725.58 |
甲状腺 | 32.02,32.14 | 133.23 | 123.77 | 128.50 | 2.77 | 18.05 | 2319.49 |
气管Clontech | 31.28,30.17 | 207.67 | 405.04 | 306.36 | 9.71 | 5.15 | 1577.52 |
膀胱 | 33.07,32.91 | 70.6 | 78.07 | 74.34 | 5.47 | 9.14 | 679.48 |
子宫 | 33.01,33.15 | 73.56 | 67.48 | 70.52 | 5.34 | 9.36 | 660.30 |
基因组 | 29.15 | 746.77 | |||||
b-肌动蛋白 | 30.2 | 397.52 | |||||
1.00E+05 | 21.06 | 100000 | |||||
1.00E+05 | 20.94 | 100000 | |||||
1.00E+04 | 25.06 | 10000 | |||||
1.00E+04 | 24.54 | 10000 | |||||
1.00E+03 | 28.32 | 1000 | |||||
1.00E+03 | 28.77 | 1000 | |||||
1.00E+02 | 33 | 100 | |||||
1.00E+02 | 32.74 | 100 | |||||
1.00E+01 | 35.9 | 10 | |||||
1.00E+01 | 40 | 0 | |||||
1.00E-00 | 40 | 0 | |||||
1.00E-00 | 40 | 0 | |||||
NTC | 40 | 0 | |||||
NTC | 40 | 0 |
标本sbg1003328IG | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 24.26 | 15509.01 | 31018.02 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 24.5 | 13727.44 | 27454.88 | 结肠肿瘤 | -1.13 |
正常结肠GW98-178 | 22080 | 28.01 | 2276.97 | 4553.94 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 27.11 | 3618.2 | 7236.40 | 结肠肿瘤 | 1.59 |
正常结肠GW98-561 | 23514 | 24.47 | 13993.67 | 27987.34 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 25.32 | 9040.47 | 18080.94 | 结肠肿瘤 | -1.55 |
正常结肠GW98-894 | 24691 | 24.17 | 16251.61 | 32503.22 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 25.15 | 9872.46 | 19744.92 | 结肠肿瘤 | -1.65 |
正常肺GW98-3 | 20742 | 24.4 | 14498.52 | 28997.04 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 24.66 | 12640.32 | 25280.64 | 肺肿瘤 | -1.15 |
正常肺GW97-179 | 20677 | 24.12 | 16680.84 | 33361.68 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 24.69 | 12468.91 | 24937.82 | 肺肿瘤 | -1.34 |
正常肺GW98-165 | 21922 | 25.09 | 10168.18 | 20336.36 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 25.49 | 8296.37 | 16592.74 | 肺肿瘤 | -1.23 |
正常肺GW98-282 | 22584 | 26.85 | 4131.52 | 8263.04 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 26.59 | 4702 | 9404.00 | 肺肿瘤 | 1.14 |
正常乳腺GW00-392 | 28750 | 25.9 | 6719.98 | 6719.98 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 25.04 | 10402.11 | 20804.22 | 乳腺肿瘤 | 3.10 |
正常乳腺GW00-413 | 28798 | 32.51 | 226.94 | 226.94 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 26.37 | 5261.73 | 10523.46 | 乳腺肿瘤 | 46.37 |
正常乳腺GW00-235:238 | 27592-95 | 34.58 | 78.63 | 78.63 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 28.45 | 1812.86 | 1812.86 | 乳腺肿瘤 | 23.06 |
正常乳腺GW98-621 | 23656 | 25.26 | 9289.36 | 18578.72 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 25.66 | 7579.13 | 15158.26 | 乳腺肿瘤 | -1.23 |
正常大脑BB-99-542 | 25507 | 22.52 | 37845.47 | 75690.94 | 正常大脑 | |
正常大脑BB-99-406 | 25509 | 23.07 | 28574.8 | 57149.60 | 正常大脑 | |
正常大脑BB-99-904 | 25546 | 23.85 | 19214.49 | 38428.98 | 正常大脑 | |
大脑期5ALZBB99-874 | 25502 | 25.98 | 6442.51 | 12885.02 | 大脑期5-ALZ | -4.43 |
大脑期5ALZBB99-887 | 25503 | 23.19 | 26936.06 | 53872.12 | 大脑期5-ALZ | -1.06 |
大脑期5ALZBB99-862 | 25504 | 23.42 | 23948.83 | 47897.66 | 大脑期5-ALZ | -1.19 |
大脑期5ALZBB99-927 | 25542 | 24.15 | 16419.33 | 32838.66 | 大脑期5-ALZ | -1.74 |
CT肺KC | normal | 25.63 | 7714.35 | 15428.70 | CT肺 |
肺26KC | normal | 32.34 | 247.99 | 247.99 | 肺26 | |
肺27KC | normal | 33.71 | 122.77 | 122.77 | 肺27 | |
肺24KC | COPD | 32.47 | 231.47 | 231.47 | 肺24 | -17.21 |
肺28KC | COPD | 32.63 | 213.14 | 213.14 | 肺28 | -18.70 |
肺23KC | COPD | 31.2 | 444.95 | 444.95 | 肺23 | -8.96 |
肺25KC | normal | 33.46 | 139.4 | 139.40 | 肺25 | |
哮喘肺ODO3112 | 29321 | 31.6 | 360.95 | 360.95 | 哮喘肺 | -11.04 |
哮喘肺ODO3433 | 29323 | 28.66 | 1634.71 | 3269.42 | 哮喘肺 | -1.22 |
哮喘肺ODO3397 | 29322 | 26.36 | 5294.26 | 10588.52 | 哮喘肺 | 2.66 |
哮喘肺ODO4928 | 29325 | 28.23 | 2033.93 | 4067.86 | 哮喘肺 | 1.02 |
内皮细胞KC | control | 30.68 | 580.47 | 580.47 | 内皮细胞 | |
内皮细胞VEGFKC | 31.08 | 471.26 | 471.26 | 内皮细胞VEGF | -1.23 | |
内皮细胞bFGF KC | 32.25 | 259.04 | 259.04 | 内皮细胞bFGF | -2.24 | |
心脏Clontech | normal | 27.28 | 3312.82 | 6625.64 | 心脏 | |
心脏(T-1)缺血 | 29417 | 27.48 | 2979.22 | 5958.44 | 心脏T-1 | -1.11 |
心脏(T-14)非阻塞性DCM心脏 | 29422 | 27.74 | 2613.8 | 5227.60 | 心脏T-14 | -1.27 |
心脏(T-399)DCM | 29426 | 26.66 | 4541.38 | 9082.76 | 心脏T-3399 | 1.37 |
腺样增殖体GW99-269 | 26162 | 27.83 | 2493.31 | 4986.62 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 25.68 | 7506.04 | 15012.08 | 扁桃体 | |
T细胞PC00314 | 28453 | 27.18 | 3487.61 | 6975.22 | T细胞 | |
PBMNC | 32.6 | 216.73 | 216.73 | PBMNC | ||
单核细胞 | 32.27 | 256.89 | 513.78 | 单核细胞 | ||
B细胞PC00665 | 28455 | 27.83 | 2492.12 | 4984.24 | B细胞 | |
树突细胞28441 | 26.67 | 4528.97 | 9057.94 | 树突细胞 | ||
中性粒细胞 | 28440 | 28.4 | 1862.35 | 1862.35 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 31.69 | 344.59 | 689.18 | 嗜酸性粒细胞 | |
BM unstim | 32.04 | 289.03 | 289.03 | BM未刺激的 |
BM stim | 30.59 | 607.18 | 607.18 | BM刺激的 | 2.10 | |
osteo dif | 28.43 | 1831.57 | 1831.57 | 成骨细胞分化 | 3.42 | |
osteo undif | 30.83 | 536 | 536.00 | 成骨细胞未分化 | ||
软骨细胞 | 26.74 | 4368.46 | 10921.15 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 27.91 | 2391.03 | 2391.03 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 27.4 | 3109.93 | 6219.86 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 27.05 | 3729.47 | 7458.94 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 25.53 | 8116.96 | 16233.92 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 26.06 | 6167.42 | 12334.84 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 25.35 | 8888.66 | 17777.32 | RA滑膜 | |
OA骨(biobank) | 29217 | 30.23 | 729.87 | 729.87 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 27.65 | 2743.38 | 5486.76 | OA骨 | |
OA骨标本2 | J.Emory | 28.02 | 2258.96 | 4517.92 | OA骨 | |
软骨(库) | Normal | 25.82 | 7006.64 | 14013.28 | 软骨(库) | |
软骨(库) | OA | 27.22 | 3408.61 | 6817.22 | 软骨(库) | -2.06 |
PBL未感染的 | 28441 | 24.24 | 15680.49 | 31360.98 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 25.43 | 8521.98 | 17043.96 | PBL HIV IIIB | -1.84 |
MRC5未感染的(100%) | 29158 | 25.58 | 7922.19 | 15844.38 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 32.02 | 291.12 | 582.24 | MRC5 HSV株F | -27.21 |
W12细胞 | 29179 | 26.03 | 6269.24 | 12538.48 | W12细胞 | |
角质细胞 | 29180 | 25.43 | 8538.15 | 17076.30 | 角质细胞 | |
B-肌动蛋白对照 | 29.74 | 938.61 | ||||
基因组 | 28.79 | 1522.16 | ||||
1.00E+05 | 20.84 | 100000 | ||||
1.00E+05 | 21.4 | 100000 | ||||
1.00E+04 | 24.5 | 10000 | ||||
1.00E+04 | 25.2 | 10000 | ||||
1.00E+03 | 28.45 | 1000 | ||||
1.00E+03 | 29.25 | 1000 |
1.00E+02 | 35.34 | 100 | ||||
1.00E+02 | 33.61 | 100 | ||||
1.00E+01 | 38.95 | 10 | ||||
1.00E+01 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
NTC | 40 | 0 |
基因名称sbg1003328IG
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | -1.13 |
结肠肿瘤 | 1.59 |
结肠肿瘤 | -1.55 |
结肠肿瘤 | -1.65 |
肺肿瘤 | -1.15 |
肺肿瘤 | -1.34 |
肺肿瘤 | -1.23 |
肺肿瘤 | 1.14 |
乳腺肿瘤 | 3.10 |
乳腺肿瘤 | 46.37 |
乳腺肿瘤 | 23.06 |
乳腺肿瘤 | -1.23 |
大脑期5ALZ | -4.43 |
大脑期5ALZ | -1.06 |
大脑期5ALZ | -1.19 |
大脑期5ALZ | -1.74 |
肺24 | -17.21 |
肺28 | -18.70 |
肺23 | -8.96 |
哮喘肺 | -11.04 |
哮喘肺 | -1.22 |
哮喘肺 | 2.66 |
哮喘肺 | 1.02 |
内皮细胞VEGF | -1.23 |
内皮细胞bFGF | -2.24 |
心脏T-1 | -1.11 |
心脏T-14 | -1.27 |
心脏T-3399 | 1.37 |
BM刺激的 | 2.10 |
Osteo未分化的 | 3.42 |
软骨(库) | -2.06 |
PBL HIV IIIB | -1.84 |
MRC5 HSV株F | -27.21 |
基因名称sbg1020829SGLT
在正常和疾病标本中有低的总体表达。在全脑,肾脏和胸腺中有最高的正常表达。在腺样增殖体,扁桃体,T细胞,B细胞和嗜酸性粒细胞中有最高的疾病表达。其有极高的免疫细胞特异性。在4份肺肿瘤标本的1份中下调和4份乳腺肿瘤标本的1份中上调提示其参与肺和乳腺肿瘤。在4份AD脑标本的3份中上调提示其参与阿尔茨海默氏病。在所有3份COPD标本中下调提示其在慢性阻塞性肺病中的作用。在受到刺激的骨髓中下调。在HSV感染的MRC5细胞中上调提示该基因可能是HSV中的宿主因子。在OA和RA标本中中度到高度的表达提示其在骨关节炎和类风湿性关节炎中的潜在作用。
标本sbg1020829SGLT | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 37.07,40 | 7.33 | 0 | 3.67 | 3.06 | 16.34 | 59.89 |
皮下脂肪Zenbio | 40,40 | 0 | 0 | 0.00 | 0.96 | 52.36 | 0.00 |
肾上腺Clontech | 40,40 | 0 | 0 | 0.00 | 0.61 | 81.97 | 0.00 |
全脑Clontech | 32.13,32.38 | 138.5 | 119.48 | 128.99 | 7.24 | 6.91 | 890.81 |
胎脑clontech | 40,40 | 0 | 0 | 0.00 | 0.48 | 103.95 | 0.00 |
小脑Clontech | 40,40 | 0 | 0 | 0.00 | 2.17 | 23.04 | 0.00 |
子宫颈 | 36.13,40 | 12.82 | 0 | 6.41 | 2.42 | 20.66 | 132.44 |
结肠 | 36.93,36.84 | 7.97 | 8.41 | 8.19 | 2.71 | 18.45 | 151.11 |
子宫内膜 | 37.45,37.41 | 5.84 | 5.98 | 5.91 | 0.73 | 68.21 | 403.14 |
食管 | 40,40 | 0 | 0 | 0.00 | 1.37 | 36.50 | 0.00 |
心脏Clontech | 40,40 | 0 | 0 | 0.00 | 1.32 | 37.88 | 0.00 |
下丘脑 | 40,40 | 0 | 0 | 0.00 | 0.32 | 155.28 | 0.00 |
回肠 | 36.53,35.17 | 10.09 | 22.67 | 16.38 | 2.58 | 19.38 | 317.44 |
空肠 | 40,35.73 | 0 | 16.2 | 8.10 | 6.60 | 7.58 | 61.36 |
肾脏 | 31.93,31.01 | 155.27 | 269.39 | 212.33 | 2.12 | 23.58 | 5007.78 |
肝脏 | 36.1,35.88 | 13.05 | 14.82 | 13.94 | 1.50 | 33.33 | 464.50 |
胚胎肝Clontech | 35.06,34.36 | 24.26 | 36.78 | 30.52 | 10.40 | 4.81 | 146.73 |
肺 | 37.24,40 | 6.63 | 0 | 3.32 | 2.57 | 19.46 | 64.49 |
乳腺Clontech | 34.25,34.21 | 39.27 | 40.17 | 39.72 | 13.00 | 3.85 | 152.77 |
子宫肌层 | 38.48,35.31 | 3.16 | 20.87 | 12.02 | 2.34 | 21.37 | 256.73 |
网膜 | 40,38.91 | 0 | 2.45 | 1.23 | 3.94 | 12.69 | 15.55 |
卵巢 | 37.87,37.06 | 4.56 | 7.37 | 5.97 | 4.34 | 11.52 | 68.72 |
胰腺 | 40,40 | 0 | 0 | 0.00 | 0.81 | 61.80 | 0.00 |
胰头 | 40,40 | 0 | 0 | 0.00 | 1.57 | 31.85 | 0.00 |
腮腺 | 36.06,37.07 | 13.32 | 7.31 | 10.32 | 5.48 | 9.12 | 94.11 |
胎盘Clontech | 35.98,38.73 | 13.96 | 2.72 | 8.34 | 5.26 | 9.51 | 79.28 |
前列腺 | 40,40 | 0 | 0 | 0.00 | 3.00 | 16.67 | 0.00 |
直肠 | 40,40 | 0 | 0 | 0.00 | 1.23 | 40.65 | 0.00 |
唾液腺Clontech | 37.05,37.06 | 7.4 | 7.36 | 7.38 | 7.31 | 6.84 | 50.48 |
骨骼肌Clontech | 40,40 | 0 | 0 | 0.00 | 1.26 | 39.68 | 0.00 |
皮肤 | 40,40 | 0 | 0 | 0.00 | 1.21 | 41.32 | 0.00 |
小肠Clontech | 40,40 | 0 | 0 | 0.00 | 0.98 | 51.07 | 0.00 |
脾脏 | 35.62,35.72 | 17.34 | 16.35 | 16.85 | 4.92 | 10.16 | 171.19 |
胃 | 40,40 | 0 | 1.61 | 0.81 | 2.73 | 18.32 | 14.74 |
睾丸Clontech | 40,40 | 0 | 0 | 0.00 | 0.57 | 87.87 | 0.00 |
胸腺Clontech | 31.3,31.09 | 226.24 | 257.15 | 241.70 | 9.89 | 5.06 | 1221.92 |
甲状腺 | 40,40 | 0 | 0 | 0.00 | 2.77 | 18.05 | 0.00 |
气管Clontech | 36.6,36.64 | 9.68 | 9.44 | 9.56 | 9.71 | 5.15 | 49.23 |
膀胱 | 40,40 | 0 | 0 | 0.00 | 5.47 | 9.14 | 0.00 |
子宫 | 34.64,36.65 | 31.06 | 9.41 | 20.24 | 5.34 | 9.36 | 189.47 |
基因组 | 29.07 | 853.08 | |||||
b-肌动蛋白 | 27.08 | 2793.5 | |||||
1.00E+05 | 20.85 | 100000 | |||||
1.00E+05 | 21.11 | 100000 | |||||
1.00E+04 | 24.81 | 10000 | |||||
1.00E+04 | 24.95 | 10000 | |||||
1.00E+03 | 28.39 | 1000 | |||||
1.00E+03 | 28.9 | 1000 | |||||
1.00E+02 | 34.1 | 100 | |||||
1.00E+02 | 32.86 | 100 | |||||
1.00E+01 | 35.52 | 10 | |||||
1.00E+01 | 40 | 0 | |||||
1.00E-00 | 40 | 0 | |||||
1.00E-00 | 40 | 0 | |||||
NTC | 40 | 0 | |||||
NTC | 40 | 0 |
标本sbg1020829SGLT | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 31.06 | 206.55 | 413.10 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 31.18 | 193.59 | 387.18 | 结肠肿瘤 | -1.07 |
正常结肠GW98-178 | 22080 | 30.74 | 244.37 | 488.74 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 30.37 | 299.28 | 598.56 | 结肠肿瘤 | 1.22 |
正常结肠GW98-561 | 23514 | 29.31 | 527.04 | 1054.08 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 31.86 | 134.48 | 268.96 | 结肠肿瘤 | -3.92 |
正常结肠GW98-894 | 24691 | 31.84 | 135.33 | 270.66 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 31.9 | 131.57 | 263.14 | 结肠肿瘤 | -1.03 |
正常肺GW98-3 | 20742 | 28.81 | 689.14 | 1378.28 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 31.91 | 130.71 | 261.42 | 肺肿瘤 | -5.27 |
正常肺GW97-179 | 20677 | 30.04 | 356.26 | 712.52 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 29.05 | 605.73 | 1211.46 | 肺肿瘤 | 1.70 |
正常肺GW98-165 | 21922 | 28.42 | 852.41 | 1704.82 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 30.51 | 277.13 | 554.26 | 肺肿瘤 | -3.08 |
正常肺GW98-282 | 22584 | 31.23 | 188.34 | 376.68 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 30.46 | 285 | 570.00 | 肺肿瘤 | 1.51 |
正常乳腺GW00-392 | 28750 | 31.14 | 197.15 | 197.15 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 32.15 | 114.65 | 229.30 | 乳腺肿瘤 | 1.16 |
正常乳腺GW00-413 | 28798 | 34.87 | 26.64 | 26.64 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 31.83 | 136.42 | 272.84 | 乳腺肿瘤 | 10.24 |
正常乳腺GW00-235:238 | 27592-95 | 36.34 | 12.09 | 12.09 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 33.48 | 56.11 | 56.11 | 乳腺肿瘤 | 4.64 |
正常乳腺GW98-621 | 23656 | 32.39 | 100.78 | 201.56 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 31.4 | 171.82 | 343.64 | 乳腺肿瘤 | 1.70 |
正常大脑BB99-542 | 25507 | 34.49 | 32.75 | 65.50 | 正常大脑 | |
正常大脑BB99-406 | 25509 | 34.01 | 42.2 | 84.40 | 正常大脑 | |
正常大脑BB99-904 | 25546 | 36.17 | 13.3 | 26.60 | 正常大脑 | |
大脑期5ALZ BB99-874 | 25502 | 31.16 | 195.23 | 390.46 | 大脑期5-ALZ | 6.64 |
大脑期5ALZ BB99-887 | 25503 | 31.56 | 157.33 | 314.66 | 大脑期5-ALZ | 5.35 |
大脑期5ALZ BB99-862 | 25504 | 32.62 | 89.2 | 178.40 | 大脑期5-ALZ | 3.03 |
大脑期5ALZ BB99-927 | 25542 | 33.26 | 63.43 | 126.86 | 大脑期5-ALZ | 2.16 |
CT肺KC | normal | 30.82 | 234.88 | 469.76 | CT肺 | |
肺26KC | normal | 30.21 | 325.42 | 325.42 | 肺26 | |
肺27KC | normal | 36.89 | 9 | 9.00 | 肺27 | |
肺24KC | COPD | 36.17 | 13.24 | 13.24 | 肺24 | -15.84 |
肺28KC | COPD | 38.38 | 4.06 | 4.06 | 肺28 | -51.66 |
肺23KC | COPD | 35.53 | 18.67 | 18.67 | 肺23 | -11.23 |
肺25KC | normal | 34.37 | 34.83 | 34.83 | 肺25 | |
哮喘肺ODO3112 | 29321 | 33.65 | 51.41 | 51.41 | 哮喘肺 | -4.08 |
哮喘肺ODO3433 | 29323 | 30.62 | 260.95 | 521.90 | 哮喘肺 | 2.49 |
哮喘肺ODO3397 | 29322 | 31.31 | 180.14 | 360.28 | 哮喘肺 | 1.72 |
哮喘肺ODO4928 | 29325 | 31.14 | 197.09 | 394.18 | 哮喘肺 | 1.88 |
内皮细胞KC | control | 32.56 | 92.23 | 92.23 | 内皮细胞 | |
内皮细胞VEGF KC | 33.29 | 62.39 | 62.39 | 内皮细胞VEGF | -1.48 | |
内皮细胞bFGF KC | 32.55 | 92.65 | 92.65 | 内皮细胞bFGF | 1.00 | |
心脏Clontech | normal | 33.17 | 66.25 | 132.50 | 心脏 | |
心脏(T-1)缺血 | 29417 | 33.07 | 70.16 | 140.32 | 心脏T-1 | 1.06 |
心脏(T-14)非阻塞性DCM | 29422 | 34.64 | 30.13 | 60.26 | 心脏T-14 | -2.20 |
心脏(T-3399)DCM | 29426 | 32.53 | 93.63 | 187.26 | 心脏T-3399 | 1.41 |
腺样增殖体GW99-269 | 26162 | 28.92 | 650.55 | 1301.10 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 27.11 | 1719.42 | 3438.84 | 扁桃体 | |
T细胞PC00314 | 28453 | 28.05 | 1037.04 | 2074.08 | T细胞 | |
PBMNC | 36.57 | 10.71 | 10.71 | PBMNC | ||
单核细胞 | 33.22 | 64.68 | 129.36 | 单核细胞 | ||
B细胞PC00665 | 28455 | 27.07 | 1757.79 | 3515.58 | B细胞 | |
树突细胞28441 | 33.77 | 48.05 | 96.10 | 树突细胞 | ||
中性粒细胞 | 28440 | 30.71 | 248.56 | 248.56 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 27.3 | 1549.7 | 3099.40 | 嗜酸性粒细胞 |
BM unstim | 30.06 | 352.26 | 352.26 | BM未刺激的 | ||
BM stim | 34.14 | 39.39 | 39.39 | BM刺激的 | -8.94 | |
osteo dif | 36.29 | 12.42 | 12.42 | 成骨细胞分化 | 12.42 | |
osteo undif | 40 | 0 | 0.00 | 成骨细胞未分化 | ||
软骨细胞 | 32.11 | 117.39 | 293.48 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 30.17 | 331.7 | 331.70 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 32.05 | 120.98 | 241.96 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 30.13 | 339.03 | 678.06 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 31.28 | 182.96 | 365.92 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 29.81 | 402.34 | 804.68 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 30.22 | 324.14 | 648.28 | RA滑膜 | |
OA骨(biobank) | 29217 | 28.45 | 837.78 | 837.78 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 30.21 | 325.03 | 650.06 | OA骨 | |
OA骨标本2 | J.Emory | 29.8 | 406 | 812.00 | OA骨 | |
软骨(库) | Normal | 31.09 | 203.28 | 406.56 | 软骨(库) | |
软骨(库) | OA | 32.18 | 112.77 | 225.54 | 软骨(库) | -1.80 |
PBL未感染的 | 28441 | 29.17 | 567.22 | 1134.44 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 30.73 | 246.69 | 493.38 | PBL HIV IIIB | -2.30 |
MRC5未感染的(100%) | 29158 | 35.54 | 18.61 | 37.22 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 30.54 | 272.3 | 544.60 | MRC5 HSV株F | 14.63 |
W12细胞 | 29179 | 32.28 | 107.25 | 214.50 | W12细胞 | |
角质细胞 | 29180 | 34.27 | 36.84 | 73.68 | 角质细胞 | |
B-肌动蛋白对照 | 27.03 | 1793.92 | ||||
基因组 | 27.77 | 1204.8 | ||||
1.00E+05 | 19.84 | 100000 | ||||
1.00E+05 | 19.86 | 100000 | ||||
1.00E+04 | 23.46 | 10000 | ||||
1.00E+04 | 23.8 | 10000 | ||||
1.00E+03 | 27.45 | 1000 |
1.00E+03 | 27.94 | 1000 | ||||
1.00E+02 | 33.86 | 100 | ||||
1.00E+02 | 31.41 | 100 | ||||
1.00E+01 | 40 | 0 | ||||
1.00E+01 | 36.88 | 10 | ||||
1.00E-00 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
NTC | 40 | 0 |
基因名称sbg1020829SGLT
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | -1.07 |
结肠肿瘤 | 1.22 |
结肠肿瘤 | -3.92 |
结肠肿瘤 | -1.03 |
肺肿瘤 | -5.27 |
肺肿瘤 | 1.70 |
肺肿瘤 | -3.08 |
肺肿瘤 | 1.51 |
乳腺肿瘤 | 1.16 |
乳腺肿瘤 | 10.24 |
乳腺肿瘤 | 4.64 |
乳腺肿瘤 | 1.70 |
大脑期5ALZ | 6.64 |
大脑期5ALZ | 5.35 |
大脑期5ALZ | 3.03 |
大脑期5ALZ | 2.16 |
肺24 | -15.84 |
肺28 | -51.66 |
肺23 | -11.23 |
哮喘肺 | -4.08 |
哮喘肺 | 2.49 |
哮喘肺 | 1.72 |
哮喘肺 | 1.88 |
内皮细胞VEGF | -1.48 |
内皮细胞bFGF | 1.00 |
心脏T-1 | 1.06 |
心脏T-14 | -2.20 |
心脏T-3399 | 1.41 |
BM刺激的 | -8.94 |
Osteo未分化的 | 12.42 |
软骨(库) | -1.80 |
PBL HIV IIIB | -2.30 |
MRC5 HSV株F | 14.63 |
基因名称sbg1005450UDPGT
其有低度到中度的总体表达。在子宫内膜,食管和脾脏有最高的正常表达,在小脑,下丘脑,直肠和子宫有较低的表达水平。在一份OA滑膜标本中有最高的疾病表达。在4份结肠肿瘤标本的1份中下调可足以作出有关结肠癌的疾病断言。在4份肺肿瘤标本的1份中上调提示该基因在肺癌中潜在的作用。在4份AD脑标本的2份中下调提示其参与阿尔茨海默氏病。在所有3份COPD肺标本中和所有4份哮喘肺标本中下调提示其参与慢性阻塞性肺病和哮喘。在HSV感染的MRC5细胞中上调提示该基因可能是HSV中的宿主因子。该基因在B细胞和树突细胞中中度表达。
标本sbg1005450UDPGT | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 40,40 | 0.15 | 0.17 | 0.16 | 3.06 | 16.34 | 2.61 |
皮下脂肪Zenbio | 40,40 | 0 | 0 | 0.00 | 0.96 | 52.36 | 0.00 |
肾上腺Clontech | 40,40 | 0 | 0.14 | 0.07 | 0.61 | 81.97 | 5.74 |
全脑Clontech | 33.74,40 | 12.07 | 0 | 6.04 | 7.24 | 6.91 | 41.68 |
胎脑clontech | 40,40 | 0 | 0 | 0.00 | 0.48 | 103.95 | 0.00 |
小脑Clontech | 32.07,33.2 | 32.85 | 16.64 | 24.75 | 2.17 | 23.04 | 570.16 |
子宫颈 | 40,40 | 0 | 0 | 0.00 | 2.42 | 20.66 | 0.00 |
结肠 | 40,35.16 | 0 | 5.12 | 2.56 | 2.71 | 18.45 | 47.23 |
子宫内膜 | 32.73,31.85 | 22.19 | 37.5 | 29.85 | 0.73 | 68.21 | 2035.81 |
食管 | 32.67,29.39 | 22.91 | 165.34 | 94.13 | 1.37 | 36.50 | 3435.22 |
心脏Clontech | 37.12,35.03 | 1.58 | 5.55 | 3.57 | 1.32 | 37.88 | 135.04 |
下丘脑 | 34.08,40 | 9.84 | 0 | 4.92 | 0.32 | 155.28 | 763.98 |
回肠 | 34.35 | 8.33 | 8.33 | 2.58 | 19.38 | 161.43 | |
空肠 | 40,40 | 0 | 0 | 0.00 | 6.60 | 7.58 | 0.00 |
肾脏 | 38.89,40 | 0.54 | 0 | 0.27 | 2.12 | 23.58 | 6.37 |
肝脏 | 36.32,40 | 2.55 | 0 | 1.28 | 1.50 | 33.33 | 42.50 |
胚胎肝Clontech | 36.96 | 1.74 | 1.74 | 10.40 | 4.81 | 8.37 | |
肺 | 40,40 | 0 | 0 | 0.00 | 2.57 | 19.46 | 0.00 |
乳腺Clontech | 40,40 | 0 | 0 | 0.00 | 13.00 | 3.85 | 0.00 |
子宫肌层 | 40,38.22 | 0 | 0.82 | 0.41 | 2.34 | 21.37 | 8.76 |
网膜 | 36.17,40 | 2.8 | 0 | 1.40 | 3.94 | 12.69 | 17.77 |
卵巢 | 40,40 | 0 | 0 | 0.00 | 4.34 | 11.52 | 0.00 |
胰腺 | 40,40 | 0 | 0 | 0.00 | 0.81 | 61.80 | 0.00 |
胰头 | 40,38.35 | 0 | 0.75 | 0.38 | 1.57 | 31.85 | 11.94 |
腮腺 | 40,40 | 0 | 0 | 0.00 | 5.48 | 9.12 | 0.00 |
胎盘Clontech | 39.06,35.49 | 0.49 | 4.22 | 2.36 | 5.26 | 9.51 | 22.39 |
前列腺 | 38.81,40 | 0.57 | 0 | 0.29 | 3.00 | 16.67 | 4.75 |
直肠 | 35.22,33.25 | 4.94 | 16.2 | 10.57 | 1.23 | 40.65 | 429.67 |
唾液腺Clontech | 32.56,34.56 | 24.55 | 7.36 | 15.96 | 7.31 | 6.84 | 109.13 |
骨骼肌Clontech | 40,40 | 0 | 0 | 0.00 | 1.26 | 39.68 | 0.00 |
皮肤 | 34.26,40 | 8.8 | 0 | 4.40 | 1.21 | 41.32 | 181.82 |
小肠Clontech | 40 | 0 | 6.23 | 3.12 | 0.98 | 51.07 | 159.09 |
脾脏 | 40,27.36 | 0 | 560.92 | 280.46 | 4.92 | 10.16 | 2850.20 |
胃 | 33.49,39.12 | 13.98 | 0.47 | 7.23 | 2.73 | 18.32 | 132.33 |
睾丸Clontech | 40,40 | 0 | 0 | 0.00 | 0.57 | 87.87 | 0.00 |
胸腺Clontech | 40,35.33 | 0 | 4.64 | 2.32 | 9.89 | 5.06 | 11.73 |
甲状腺 | 37.18,35.52 | 1.53 | 4.13 | 2.83 | 2.77 | 18.05 | 51.08 |
气管Clontech | 40,40 | 0 | 0 | 0.00 | 9.71 | 5.15 | 0.00 |
膀胱 | 40,40 | 0 | 0.16 | 0.08 | 5.47 | 9.14 | 0.73 |
子宫 | 30.11 | 106.94 | 0 | 53.47 | 5.34 | 9.36 | 500.66 |
基因组 | 35.81 | 3.47 | |||||
b-肌动蛋白 | 26.86 | 757.01 | |||||
1.00E+05 | 18.99 | 100000 | |||||
1.00E+05 | 19.13 | 100000 | |||||
1.00E+04 | 22.43 | 10000 | |||||
1.00E+04 | 22.31 | 10000 | |||||
1.00E+03 | 25.74 | 1000 | |||||
1.00E+03 | 25.99 | 1000 | |||||
1.00E+02 | 31.47 | 100 | |||||
1.00E+02 | 29.82 | 100 | |||||
1.00E+01 | 40 | 0 | |||||
1.00E+01 | 40 | 0 | |||||
1.00E-00 | 40 | 0 | |||||
1.00E-00 | 40 | 0 | |||||
NTC | 26.02 | -1 | |||||
NTC | 40 | 0 |
标本sbg1005450UDPGT | 登记号(GSK标识符r) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 40 | 0.17 | 0.34 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 39.88 | 0.29 | 0.58 | 结肠肿瘤 | 1.71 |
正常结肠GW98-178 | 22080 | 40 | 0 | 0.00 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 40 | 0 | 0.00 | 结肠肿瘤 | 0.00 |
正常结肠GW98-561 | 23514 | 40 | 0 | 0.00 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 40 | 0 | 0.00 | 结肠肿瘤 | 0.00 |
正常结肠GW98-894 | 24691 | 33.84 | 10.47 | 20.94 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 40 | 0 | 0.00 | 结肠肿瘤 | -20.94 |
正常肺GW98-3 | 20742 | 40 | 0 | 0.00 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 40 | 0 | 0.00 | 肺肿瘤 | 0.00 |
正常肺GW97-179 | 20677 | 31.67 | 37.94 | 75.88 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 33.08 | 16.47 | 32.94 | 肺肿瘤 | -2.30 |
正常肺GW98-165 | 21922 | 40 | 0 | 0.00 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 40 | 0 | 0.00 | 肺肿瘤 | 0.00 |
正常肺GW98-282 | 22584 | 40 | 0 | 0.00 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 35.03 | 5.16 | 10.32 | 肺肿瘤 | 10.32 |
正常乳腺GW00-392 | 28750 | 32.64 | 21.38 | 21.38 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 31.67 | 37.98 | 75.96 | 乳腺肿瘤 | 3.55 |
正常乳腺GW00-413 | 28798 | 32.54 | 22.63 | 22.63 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 29.23 | 161.71 | 323.42 | 乳腺肿瘤 | 14.29 |
正常乳腺GW00-235:238 | 27592-95 | 37.05 | 1.55 | 1.55 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 35.03 | 5.17 | 5.17 | 乳腺肿瘤 | 3.34 |
正常乳腺GW98-621 | 23656 | 34.12 | 8.87 | 17.74 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 40 | 0 | 0.00 | 乳腺肿瘤 | -17.74 |
正常大脑BB-99-542 | 25507 | 34.28 | 8.05 | 16.10 | 正常大脑 | |
正常大脑BB-99-406 | 25509 | 40 | 0 | 0.00 | 正常大脑 | |
正常大脑BB-99-904 | 25546 | 40 | 0 | 0.00 | 正常大脑 | |
大脑期5ALZ BB99-874 | 25502 | 38.8 | 0.55 | 1.10 | 大脑期5-ALZ | -4.88 |
大脑期5ALZ BB99-887 | 25503 | 40 | 0 | 0.00 | 大脑期5-ALZ | -5.37 |
大脑期5ALZ BB99-862 | 25504 | 36.16 | 2.64 | 5.28 | 大脑期5-ALZ | -1.02 |
大脑期5ALZ BB99-927 | 25542 | 40 | 0 | 0.00 | 大脑期5-ALZ | -5.37 |
CT肺KC | normal | 36.61 | 2.02 | 4.04 | CT肺 | |
肺26KC | normal | 肺26 | ||||
肺27KC | normal | 40 | 0 | 0.00 | 肺27 | |
肺24KC | COPD | 40 | 0 | 0.00 | 肺24 | -1.35 |
肺28KC | COPD | 40 | 0 | 0.00 | 肺28 | -1.35 |
肺23KC | COPD | 40 | 0 | 0.00 | 肺23 | -1.35 |
肺25KC | normal | 40 | 0 | 0.00 | 肺25 | |
哮喘肺ODO3112 | 29321 | 38.19 | 0.79 | 0.79 | 哮喘肺 | -1.70 |
哮喘肺ODO3433 | 29323 | 36.09 | 2.76 | 5.52 | 哮喘肺 | 4.10 |
哮喘肺ODO3397 | 29322 | 40 | 0 | 0.00 | 哮喘肺 | -1.35 |
哮喘肺ODO4928 | 29325 | 40 | 0 | 0.00 | 哮喘肺 | -1.35 |
内皮细胞KC | control | 40 | 0 | 0.00 | 内皮细胞 | |
内皮细胞VEGF KC | 40 | 0 | 0.00 | 内皮细胞VEGF | 0.00 | |
内皮细胞bFGF KC | 40 | 0 | 0.00 | 内皮细胞bFGF | 0.00 | |
心脏Clontech | normal | 40 | 0 | 0.00 | 心脏 | |
心脏(T-1)缺血 | 29417 | 38.36 | 0.71 | 1.42 | 心脏T-1 | 1.42 |
心脏(T-14)非阻塞性DCM心脏 | 29422 | 40 | 0 | 0.00 | 心脏T-14 | 0.00 |
心脏(T-3399)DCM | 29426 | 40 | 0 | 0.00 | 心脏T-3399 | 0.00 |
腺样增殖体GW99-269 | 26162 | 38.96 | 0.5 | 1.00 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 35.44 | 4.04 | 8.08 | 扁桃体 | |
T细胞PC00314 | 28453 | 38.83 | 0.54 | 1.08 | T细胞 | |
PBMNC | 40 | 0 | 0.00 | PBMNC | ||
单核细胞 | 35.1 | 4.94 | 9.88 | 单核细胞 | ||
B细胞PC00665 | 28455 | 33.32 | 14.31 | 28.62 | B细胞 | |
树突细胞28441 | 32.53 | 22.85 | 45.70 | 树突细胞 | ||
中性粒细胞 | 28440 | 34.43 | 7.39 | 7.39 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 40 | 0 | 0.00 | 嗜酸性粒细胞 |
BM unstim | 40 | 0 | 0.00 | BM未刺激的 | ||
BM stim | 34.12 | 8.87 | 8.87 | BM刺激的 | 8.87 | |
成骨细胞(osteo)分化的KC | 40 | 0 | 0.00 | 成骨细胞分化 | 0.00 | |
osteo undif | 40 | 0 | 0.00 | 成骨细胞未分化 | ||
软骨细胞 | 34.51 | 7.05 | 17.63 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 40 | 0 | 0.00 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 27.21 | 538.51 | 1077.02 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 33.5 | 12.85 | 25.70 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 39.09 | 0.46 | 0.92 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 40 | 0 | 0.00 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 40 | 0 | 0.00 | RA滑膜 | |
OA骨(biobank) | 29217 | 40 | 0 | 0.00 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 35.23 | 4.59 | 9.18 | OA骨 | |
OA骨标本2 | J.Emory | 37.1 | 1.51 | 3.02 | OA骨 | |
软骨(库(pool)) | Normal | 35.45 | 4.01 | 8.02 | 软骨(库) | |
软骨(库) | OA | 40 | 0 | 0.00 | 软骨(库) | -8.02 |
PBL未感染的 | 28441 | 40 | 0 | 0.00 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 40 | 0 | 0.00 | PBL HIV IIIB | 0.00 |
MRC5未感染的(100%) | 29158 | 40 | 0.17 | 0.34 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 30.15 | 93.76 | 187.52 | MRC5 HSV株F | 551.53 |
W12细胞 | 29179 | 40 | 0 | 0.00 | W12细胞 | |
角质细胞 | 29180 | 35.72 | 3.44 | 6.88 | 角质细胞 | |
B-肌动蛋白对照 | 26.57 | 788.4 | ||||
基因组 | 25.69 | 1326.94 | ||||
1.00E+05 | 18.72 | 100000 | ||||
1.00E+05 | 18.74 | 100000 | ||||
1.00E+04 | 22.11 | 10000 |
1.00E+04 | 22.15 | 10000 | ||||
1.00E+03 | 25.57 | 1000 | ||||
1.00E+03 | 25.54 | 1000 | ||||
1.00E+02 | 31.37 | 100 | ||||
1.00E+02 | 29.65 | 100 | ||||
1.00E+01 | 40 | 0 | ||||
1.00E+01 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
NTC | 40 | 0 |
基因名称sbg1005450UDPGT
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | 1.71 |
结肠肿瘤 | 0.00 |
结肠肿瘤 | 0.00 |
结肠肿瘤 | -20.94 |
肺肿瘤 | 0.00 |
肺肿瘤 | -2.30 |
肺肿瘤 | 0.00 |
肺肿瘤 | 10.32 |
乳腺肿瘤 | 3.55 |
乳腺肿瘤 | 14.29 |
乳腺肿瘤 | 3.34 |
乳腺肿瘤 | -17.74 |
大脑期5ALZ | -4.88 |
大脑期5ALZ | -5.37 |
大脑期5ALZ | -1.02 |
大脑期5ALZ | -5.37 |
肺24 | -1.35 |
肺28 | -1.35 |
肺23 | -1.35 |
哮喘肺 | -1.70 |
哮喘肺 | 4.10 |
哮喘肺 | -1.35 |
哮喘肺 | -1.35 |
内皮细胞VEGF | 0.00 |
内皮细胞bFGF | 0.00 |
心脏T-1 | 1.42 |
心脏T-14 | 0.00 |
心脏T-3399 | 0.00 |
BM刺激的 | 8.87 |
Osteo未分化的 | 0.00 |
软骨(库) | -8.02 |
PBL HIV IIIB | 0.00 |
MRC5 HSV株F | 551.53 |
基因名称sbg1002620Tia
有中度总体表达。在全脑,子宫内膜,子宫肌层,胎盘和直肠中有最高的正常表达。在一份结肠正常/肿瘤对中,正常肺标本中,一份哮喘肺标本中,中性粒细胞,嗜酸性粒细胞,一份RA滑膜标本中有最高的疾病表达。在代表胃肠道的所有标本中的高水平表达提示该基因在IBS,IBD和Crohn’s病中的潜在作用。在3份COPD肺标本的1份中下调提示其参与慢性阻塞性肺病。在4份哮喘肺标本的1份中上调提示其在哮喘中的作用。在OA的滑膜和骨标本中和在RA滑膜标本中高表达。在软骨细胞中也高表达。在免疫细胞中有不同水平的表达,其中在中性粒细胞和嗜酸性粒细胞中有最高的表达,在树突细胞中有最低的表达。在B细胞和T细胞中以及OA的标本中确定的高表达表明,该基因与骨关节炎和类风湿性关节炎有关。
标本sbg1002620TIa | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 35.04,34.4 | 201.66 | 274.43 | 238.05 | 3.06 | 16.34 | 3889.62 |
皮下脂肪Zenbio | 38.03,38.45 | 48.67 | 39.85 | 44.26 | 0.96 | 52.36 | 2317.28 |
肾上腺Clontech | 38.71,38.14 | 35.25 | 46.23 | 40.74 | 0.61 | 81.97 | 3339.34 |
全脑Clontech | 29.27,29.32 | 3152.23 | 3071.49 | 3111.86 | 7.24 | 6.91 | 21490.75 |
胎脑clontech | 40,37.57 | 0 | 60.7 | 30.35 | 0.48 | 103.95 | 3154.89 |
小脑Clontech | 39.37,39.14 | 25.78 | 28.75 | 27.27 | 2.17 | 23.04 | 628.23 |
子宫颈 | 34.05,34.32 | 323.57 | 285.02 | 304.30 | 2.42 | 20.66 | 6287.09 |
结肠 | 32.64,32.98 | 633.12 | 537.54 | 585.33 | 2.71 | 18.45 | 10799.45 |
子宫内膜 | 34.44,33.84 | 269.09 | 357.16 | 313.13 | 0.73 | 68.21 | 21359.14 |
食管 | 35.48,35.21 | 163.52 | 186.15 | 174.84 | 1.37 | 36.50 | 6380.84 |
心脏Clontech | 38.67,39.08 | 35.94 | 29.52 | 32.73 | 1.32 | 37.88 | 1239.77 |
下丘脑 | 40,40 | 0 | 0 | 0.00 | 0.32 | 155.28 | 0.00 |
回肠 | 33.07,32.9 | 516.19 | 559.94 | 538.07 | 2.58 | 19.38 | 10427.62 |
空肠 | 30.58,30.66 | 1688.39 | 1625.61 | 1657.00 | 6.60 | 7.58 | 12553.03 |
肾脏 | 34.9,33.68 | 216.07 | 385.19 | 300.63 | 2.12 | 23.58 | 7090.33 |
肝脏 | 37.17,36.49 | 73.4 | 101.31 | 87.36 | 1.50 | 33.33 | 2911.83 |
胚胎肝Clontech | 33.99,34.79 | 332.15 | 227.82 | 279.99 | 10.40 | 4.81 | 1346.08 |
肺 | 34.67,34.06 | 240.47 | 321.54 | 281.01 | 2.57 | 19.46 | 5467.02 |
乳腺Clontech | 29.3,29.19 | 3098.36 | 3272.39 | 3185.38 | 13.00 | 3.85 | 12251.44 |
子宫肌层 | 32.45,31.79 | 692.54 | 946.75 | 819.65 | 2.34 | 21.37 | 17513.78 |
网膜 | 32.88,33.43 | 563.23 | 434.44 | 498.84 | 3.94 | 12.69 | 6330.39 |
卵巢 | 33.02,32.92 | 528.43 | 553.26 | 540.85 | 4.34 | 11.52 | 6230.93 |
胰腺 | 37.31,39.81 | 68.49 | 20.84 | 44.67 | 0.81 | 61.80 | 2760.51 |
胰头 | 38.5,39.16 | 38.99 | 28.45 | 33.72 | 1.57 | 31.85 | 1073.89 |
腮腺 | 34.48,34.22 | 263.15 | 298.49 | 280.82 | 5.48 | 9.12 | 2562.23 |
胎盘Clontech | 31.16,30.91 | 1280.82 | 1442.99 | 1361.91 | 5.26 | 9.51 | 12945.87 |
前列腺 | 33.5,33.11 | 420.13 | 506.76 | 463.45 | 3.00 | 16.67 | 7724.08 |
直肠 | 34.48,33.88 | 263.61 | 350.22 | 306.92 | 1.23 | 40.65 | 12476.22 |
唾液腺Clontech | 34.48,34.32 | 263.4 | 284.18 | 273.79 | 7.31 | 6.84 | 1872.71 |
骨骼肌Clontech | 40,39.37 | 0 | 25.73 | 12.87 | 1.26 | 39.68 | 510.52 |
皮肤 | 35.52,35.13 | 160.58 | 193.62 | 177.10 | 1.21 | 41.32 | 7318.18 |
小肠Clontech | 36.79,36.59 | 87.74 | 96.5 | 92.12 | 0.98 | 51.07 | 4704.80 |
脾脏 | 34.45,34.51 | 267.45 | 260 | 263.73 | 4.92 | 10.16 | 2680.13 |
胃 | 35.16,33.89 | 191.03 | 348.48 | 269.76 | 2.73 | 18.32 | 4940.57 |
睾丸Clontech | 38.19,37.07 | 45.22 | 76.91 | 61.07 | 0.57 | 87.87 | 5365.99 |
胸腺Clontech | 33.74,33.57 | 374.59 | 406.79 | 390.69 | 9.89 | 5.06 | 1975.18 |
甲状腺 | 34.18,33.46 | 304.38 | 427.57 | 365.98 | 2.77 | 18.05 | 6606.05 |
气管Clontech | 32.67,31.27 | 623.94 | 1213.65 | 918.80 | 9.71 | 5.15 | 4731.18 |
膀胱 | 32.07,31.34 | 830.04 | 1176.15 | 1003.10 | 5.47 | 9.14 | 9169.06 |
子宫 | 31.75,31.37 | 968.5 | 1157.09 | 1062.80 | 5.34 | 9.36 | 9951.26 |
基因组 | 31.33 | 1181.44 | |||||
b-肌动蛋白 | 28.56 | 4411.32 | |||||
1.00E+05 | 22.12 | 100000 | |||||
1.00E+05 | 22.12 | 100000 | |||||
1.00E+04 | 26.72 | 10000 | |||||
1.00E+04 | 26.91 | 10000 | |||||
1.00E+03 | 31.28 | 1000 | |||||
1.00E+03 | 31.5 | 1000 | |||||
1.00E+02 | 36.35 | 100 | |||||
1.00E+02 | 37.09 | 100 | |||||
1.00E+01 | 40 | 10 | |||||
1.00E+01 | 40 | 10 | |||||
1.00E-00 | 40 | 1 | |||||
1.00E-00 | 40 | 0 | |||||
NTC | 40 | 0 | |||||
NTC | 40 | 0 |
标本sbg1002620TIa | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 24.54 | 22693.01 | 45386.02 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 24.18 | 26862.61 | 53725.22 | 结肠肿瘤 | 1.18 |
正常结肠GW98-178 | 22080 | 27.08 | 6895.34 | 13790.68 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 28.41 | 3692.19 | 7384.38 | 结肠肿瘤 | -1.87 |
正常结肠GW98-561 | 23514 | 26.58 | 8698.68 | 17397.36 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 27.85 | 4799.22 | 9598.44 | 结肠肿瘤 | -1.81 |
正常结肠GW98-894 | 24691 | 25.9 | 11972.57 | 23945.14 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 28.04 | 4396.4 | 8792.80 | 结肠肿瘤 | -2.72 |
正常肺GW98-3 | 20742 | 24.25 | 26016.9 | 52033.80 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 27.64 | 5300.37 | 10600.74 | 肺肿瘤 | -4.91 |
正常肺GW97-179 | 20677 | 25.1 | 17476.66 | 34953.32 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 25.53 | 14274.54 | 28549.08 | 肺肿瘤 | -1.22 |
正常肺GW98-165 | 21922 | 24.62 | 21917.37 | 43834.74 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 25.64 | 13526.49 | 27052.98 | 肺肿瘤 | -1.62 |
正常肺GW98-282 | 22584 | 27.08 | 6884.03 | 13768.06 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 25.37 | 15385.8 | 30771.60 | 肺肿瘤 | 2.23 |
正常乳腺GW00-392 | 28750 | 26.07 | 11065.25 | 11065.25 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 26.87 | 7611.48 | 15222.96 | 乳腺肿瘤 | 1.38 |
正常乳腺GW00-413 | 28798 | 28.65 | 3294.68 | 3294.68 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 28.52 | 3496.94 | 6993.88 | 乳腺肿瘤 | 2.12 |
正常乳腺GW00-235:238 | 27592-95 | 29.47 | 2243.69 | 2243.69 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 25.83 | 12385.23 | 12385.23 | 乳腺肿瘤 | 5.52 |
正常乳腺GW98-621 | 23656 | 26.05 | 11188.07 | 22376.14 | 正常乳腺 |
乳腺肿瘤GW98-620 | 23655 | 26.03 | 11303.95 | 22607.90 | 乳腺肿瘤 | 1.01 |
正常大脑BB99-542 | 25507 | 27.68 | 5198.79 | 10397.58 | 正常大脑 | |
正常大脑BB99-406 | 25509 | 29.81 | 1909.01 | 3818.02 | 正常大脑 | |
正常大脑BB99-904 | 25546 | 31.84 | 735.25 | 1470.50 | 正常大脑 | |
大脑期5ALZBB99-874 | 25502 | 28.43 | 3650.66 | 7301.32 | 大脑期5-ALZ | 1.40 |
大脑期5ALZBB99-887 | 25503 | 29.01 | 2785.56 | 5571.12 | 大脑期5-ALZ | 1.07 |
大脑期5ALZBB99-862 | 25504 | 29.65 | 2059.62 | 4119.24 | 大脑期5-ALZ | -1.27 |
大脑期5ALZBB99-927 | 25542 | 30.01 | 1742.3 | 3484.60 | 大脑期5-ALZ | -1.50 |
CT肺KC | normal | 25.49 | 14553.17 | 29106.34 | CT肺 | |
肺26KC | normal | 31.8 | 749.93 | 749.93 | 肺26 | |
肺27KC | normal | 33.35 | 362.66 | 362.66 | 肺27 | |
肺24KC | COPD | 30.67 | 1275.68 | 1275.68 | 肺24 | -6.03 |
肺28KC | COPD | 29.25 | 2490.39 | 2490.39 | 肺28 | -3.09 |
肺23KC | COPD | 30.11 | 1661.24 | 1661.24 | 肺23 | -4.63 |
肺25KC | normal | 32.45 | 553.75 | 553.75 | 肺25 | |
哮喘肺ODO3112 | 29321 | 27.3 | 6215.19 | 6215.19 | 哮喘肺 | -1.24 |
哮喘肺ODO3433 | 29323 | 26.66 | 8407.3 | 16814.60 | 哮喘肺 | 2.19 |
哮喘肺ODO3397 | 29322 | 24.06 | 28466.73 | 56933.46 | 哮喘肺 | 7.40 |
哮喘肺ODO4928 | 29325 | 26.22 | 10313.71 | 20627.42 | 哮喘肺 | 2.68 |
内皮细胞KC | control | 40 | 0 | 0.00 | 内皮细胞 | |
内皮细胞VEGF KC | 40 | 0 | 0.00 | 内皮细胞VEGF | 0.00 | |
内皮细胞bFGF KC | 40 | 0 | 0.00 | 内皮细胞bFGF | 0.00 | |
心脏Clontech | normal | 27.58 | 5449.78 | 10899.56 | 心脏 | |
心脏(T-1)缺血 | 29417 | 28.42 | 3670.86 | 7341.72 | 心脏T-1 | -1.48 |
心脏(T-14)非阻塞性DCM | 29422 | 27.18 | 6570.11 | 13140.22 | 心脏T-14 | 1.21 |
心脏(T-3399)DCM | 29426 | 26.23 | 10277.2 | 20554.40 | 心脏T-3399 | 1.89 |
腺样增殖体GW99-269 | 26162 | 31.98 | 688.86 | 1377.72 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 29.31 | 2421.67 | 4843.34 | 扁桃体 | |
T细胞PC00314 | 28453 | 29.53 | 2178.21 | 4356.42 | T细胞 | |
PBMNC | 33.23 | 383.88 | 383.88 | PBMNC | ||
单核细胞 | 31.07 | 1057.9 | 2115.80 | 单核细胞 | ||
B细胞PC00665 | 28455 | 35.97 | 106.01 | 212.02 | B细胞 | |
树突细胞28441 | 33.56 | 328.62 | 657.24 | 树突细胞 | ||
中性粒细胞 | 28440 | 22.32 | 64510.36 | 64510.36 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 24.18 | 26910.17 | 53820.34 | 嗜酸性粒细胞 | |
BM unstim | 30.35 | 1480.07 | 1480.07 | BM未刺激的 | ||
BM stim | 31.71 | 782.56 | 782.56 | BM刺激的 | -1.89 | |
osteo dif | 31.42 | 895.71 | 895.71 | 成骨细胞分化 | 2.03 | |
osteo undif | 32.93 | 440.66 | 440.66 | 成骨细胞未分化 | ||
软骨细胞 | 28.98 | 2820.8 | 7052.00 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 25.37 | 15383.84 | 15383.84 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 27.12 | 6763.44 | 13526.88 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 26.48 | 9130.81 | 18261.62 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 27.78 | 4967.23 | 9934.46 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 24.72 | 20923.66 | 41847.32 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 26.15 | 10658.82 | 21317.64 | RA滑膜 | |
OA骨(biobank) | 29217 | 28.68 | 3248.19 | 3248.19 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 27.19 | 6545.82 | 13091.64 | OA骨 | |
OA骨标本2 | J.Emory | 27.24 | 6384.92 | 12769.84 | OA骨 | |
软骨(库) | Normal | 26.28 | 10016.65 | 20033.30 | 软骨(库) | |
软骨(库) | OA | 26.67 | 8342.92 | 16685.84 | 软骨(库) | -1.20 |
PBL未感染的 | 28441 | 31.05 | 1069.84 | 2139.68 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 31.7 | 788.06 | 1576.12 | PBL HIV IIIB | -1.36 |
MRC5未感染的(100%) | 29158 | 26.37 | 9631.13 | 19262.26 | MRC5未感染的(100%) |
MRC5 HSV株F | 29178 | 28.38 | 3747.38 | 7494.76 | MRC5 HSV株F | -2.57 |
W12细胞 | 29179 | 35.15 | 155.25 | 310.50 | W12细胞 | |
角质细胞 | 29180 | 34.93 | 172.87 | 345.74 | 角质细胞 | |
B-肌动蛋白对照 | 28.06 | 4342.74 | ||||
基因组 | 30.54 | 1356.79 | ||||
1.00E+05 | 21.39 | 100000 | ||||
1.00E+05 | 21.64 | 100000 | ||||
1.00E+04 | 26.21 | 10000 | ||||
1.00E+04 | 26.24 | 10000 | ||||
1.00E+03 | 30.9 | 1000 | ||||
1.00E+03 | 30.97 | 1000 | ||||
1.00E+02 | 36.34 | 100 | ||||
1.00E+02 | 36.22 | 100 | ||||
1.00E+01 | 40 | 10 | ||||
1.00E+01 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
NTC | 40 | 0 |
基因名称sbg1002620TIa
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | 1.18 |
结肠肿瘤 | -1.87 |
结肠肿瘤 | -1.81 |
结肠肿瘤 | -2.72 |
肺肿瘤 | -4.91 |
肺肿瘤 | -1.22 |
肺肿瘤 | -1.62 |
肺肿瘤 | 2.23 |
乳腺肿瘤 | 1.38 |
乳腺肿瘤 | 2.12 |
乳腺肿瘤 | 5.52 |
乳腺肿瘤 | 1.01 |
大脑期5ALZ | 1.40 |
大脑期5ALZ | 1.07 |
大脑期5ALZ | -1.27 |
大脑期5ALZ | -1.50 |
肺24 | -6.03 |
肺28 | -3.09 |
肺23 | -4.63 |
哮喘肺 | -1.24 |
哮喘肺 | 2.19 |
哮喘肺 | 7.40 |
哮喘肺 | 2.68 |
内皮细胞VEGF | 0.00 |
内皮细胞bFGF | 0.00 |
心脏T-1 | -1.48 |
心脏T-14 | 1.21 |
心脏T-3399 | 1.89 |
BM刺激的 | -1.89 |
Osteo未分化的 | 2.03 |
软骨(库) | -1.20 |
PBL HIV IIIB | -1.36 |
MRC5 HSV株F | -2.57 |
基因名称sbg1002620TIb
中度到高度的总体表达。在全脑,子宫内膜,空肠,胎盘,胸腺和膀胱有最高的正常表达。在一份结肠正常/肿瘤对中,一份正常的肺标本中,一份哮喘肺标本中,中性粒细胞中和嗜酸性粒细胞中有最高的疾病表达。在所有胃肠道标本中的强表达提示该基因与IBS,IBD和Crohn’s病有关。在4份肺肿瘤标本的1份中下调可足以作出有关肺癌的疾病断言。在所有3份COPD肺标本中下调提示其参与慢性阻塞性肺病。在4份哮喘肺标本的1份中上调提示其在哮喘中的作用。在3份心脏标本的2份中上调该基因可能在非阻塞性和阻塞性扩张型心肌病中起作用。在RA和OA的滑膜标本中高表达,以及在软骨细胞和T细胞中高表达提示与骨关节炎和类风湿性关节炎有关。
标本sbg1002620TIb | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 31.35,31.44 | 58.54 | 55.11 | 56.83 | 3.06 | 16.34 | 928.51 |
皮下脂肪Zenbio | 35.12,34.21 | 5 | 9.05 | 7.03 | 0.96 | 52.36 | 367.80 |
肾上腺Clontech | 40,34.29 | 0 | 8.61 | 4.31 | 0.61 | 81.97 | 352.87 |
全脑Clontech | 26.02,26.06 | 1897.9 | 1849.19 | 1873.55 | 7.24 | 6.91 | 12938.85 |
胎脑clontech | 40,36.43 | 0 | 2.13 | 1.07 | 0.48 | 103.95 | 110.71 |
小脑Clontech | 40,36.05 | 0 | 2.74 | 1.37 | 2.17 | 23.04 | 31.57 |
子宫颈 | 32.23,33.04 | 33.11 | 19.47 | 26.29 | 2.42 | 20.66 | 543.18 |
结肠 | 30.44,30.45 | 105.93 | 105.29 | 105.61 | 2.71 | 18.45 | 1948.52 |
子宫内膜 | 30.86,30.56 | 80.75 | 97.92 | 89.34 | 0.73 | 68.21 | 6093.79 |
食管 | 33.03,32.34 | 19.62 | 30.66 | 25.14 | 1.37 | 36.50 | 917.52 |
心脏Clontech | 40,35.05 | 0 | 5.26 | 2.63 | 1.32 | 37.88 | 99.62 |
下丘脑 | 40,36.17 | 0 | 2.53 | 1.27 | 0.32 | 155.28 | 196.43 |
回肠 | 31.25,30.31 | 62.52 | 115.58 | 89.05 | 2.58 | 19.38 | 1725.78 |
空肠 | 27.75,27.93 | 612.01 | 543.46 | 577.74 | 6.60 | 7.58 | 4376.78 |
肾脏 | 32.59,31.86 | 26.03 | 42.14 | 34.09 | 2.12 | 23.58 | 803.89 |
肝脏 | 34.66,34.5 | 6.77 | 7.52 | 7.15 | 1.50 | 33.33 | 238.17 |
胚胎肝Clontech | 29.08,28.58 | 256.83 | 356.67 | 306.75 | 10.40 | 4.81 | 1474.76 |
肺 | 30.74,30.68 | 87.44 | 90.91 | 89.18 | 2.57 | 19.46 | 1734.92 |
乳腺Clontech | 27.49,26.81 | 725.02 | 1132.42 | 928.72 | 13.00 | 3.85 | 3572.00 |
子宫肌层 | 31.2,30.29 | 64.54 | 117.26 | 90.90 | 2.34 | 21.37 | 1942.31 |
网膜 | 31.19,30.12 | 65.05 | 130.86 | 97.96 | 3.94 | 12.69 | 1243.08 |
卵巢 | 30.24,30.54 | 120.95 | 99.3 | 110.13 | 4.34 | 11.52 | 1268.72 |
胰腺 | 36.01,36.55 | 2.81 | 1.97 | 2.39 | 0.81 | 61.80 | 147.71 |
胰头 | 33.95,35.73 | 10.72 | 3.36 | 7.04 | 1.57 | 31.85 | 224.20 |
腮腺 | 32.16,33.16 | 34.51 | 18.05 | 26.28 | 5.48 | 9.12 | 239.78 |
胎盘Clontech | 28.42,28.02 | 395.01 | 512.77 | 453.89 | 5.26 | 9.51 | 4314.54 |
前列腺 | 30.61,31.28 | 95.23 | 61.5 | 78.37 | 3.00 | 16.67 | 1306.08 |
直肠 | 30.5,30.93 | 101.73 | 76.9 | 89.32 | 1.23 | 40.65 | 3630.69 |
唾液腺Clontech | 31.17,31.07 | 65.95 | 70.23 | 68.09 | 7.31 | 6.84 | 465.73 |
骨骼肌Clontech | 40,40 | 0 | 0 | 0.00 | 1.26 | 39.68 | 0.00 |
皮肤 | 34.37,33.12 | 8.18 | 18.53 | 13.36 | 1.21 | 41.32 | 551.86 |
小肠Clontech | 36.71,34.96 | 1.78 | 5.55 | 3.67 | 0.98 | 51.07 | 187.18 |
脾脏 | 30.54,31.29 | 99.47 | 60.88 | 80.18 | 4.92 | 10.16 | 814.79 |
胃 | 32.4,31.53 | 29.49 | 52 | 40.75 | 2.73 | 18.32 | 746.25 |
睾丸Clontech | 34.4,35.19 | 8.03 | 4.79 | 6.41 | 0.57 | 87.87 | 563.27 |
胸腺Clontech | 27.18,27.12 | 888.84 | 924.29 | 906.57 | 9.89 | 5.06 | 4583.24 |
甲状腺 | 32.17,30.89 | 34.36 | 79.27 | 56.82 | 2.77 | 18.05 | 1025.54 |
气管Clontech | 30.01,29.25 | 140.31 | 230.28 | 185.30 | 9.71 | 5.15 | 954.15 |
膀胱 | 28.33,27.87 | 420.47 | 565.71 | 493.09 | 5.47 | 9.14 | 4507.22 |
子宫 | 29.09,28.81 | 255.27 | 308 | 281.64 | 5.34 | 9.36 | 2637.03 |
基因组 | 27.16 | 900.78 | |||||
b-肌动蛋白 | 27.4 | 769.87 | |||||
1.00E+05 | 19.87 | 100000 | |||||
1.00E+05 | 19.95 | 100000 | |||||
1.00E+04 | 23.4 | 10000 | |||||
1.00E+04 | 23.39 | 10000 | |||||
1.00E+03 | 26.94 | 1000 | |||||
1.00E+03 | 26.95 | 1000 | |||||
1.00E+02 | 31.02 | 100 |
1.00E+02 | 30.96 | 100 | |||||
1.00E+01 | 33.46 | 10 | |||||
1.00E+01 | 40 | 0 | |||||
1.00E-00 | 40 | 0 | |||||
1.00E-00 | 40 | 0 | |||||
NTC | 40 | 0 | |||||
NTC | 40 | 0 |
标本sbg1002620TIb | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 22.85 | 18631.2 | 37262.40 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 22.51 | 23090.96 | 46181.92 | 结肠肿瘤 | 1.24 |
正常结肠GW98-178 | 22080 | 25.49 | 3620.45 | 7240.90 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 26.88 | 1527.3 | 3054.60 | 结肠肿瘤 | -2.37 |
正常结肠GW98-561 | 23514 | 25.37 | 3901.36 | 7802.72 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 26.08 | 2512.21 | 5024.42 | 结肠肿瘤 | -1.55 |
正常结肠GW98-894 | 24691 | 23.78 | 10441.49 | 20882.98 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 25.54 | 3515.48 | 7030.96 | 结肠肿瘤 | -2.97 |
正常肺GW98-3 | 20742 | 22.6 | 21810.56 | 43621.12 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 26.19 | 2349.32 | 4698.64 | 肺肿瘤 | -9.28 |
正常肺GW97-179 | 20677 | 23.38 | 13423.28 | 26846.56 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 24.51 | 6653.03 | 13306.06 | 肺肿瘤 | -2.02 |
正常肺GW98-165 | 21922 | 23.68 | 11120.91 | 22241.82 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 24.37 | 7242.32 | 14484.64 | 肺肿瘤 | -1.54 |
正常肺GW98-282 | 22584 | 25.05 | 4745.83 | 9491.66 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 23.57 | 11943.28 | 23886.56 | 肺肿瘤 | 2.52 |
正常乳腺GW00-392 | 28750 | 24.84 | 5415.88 | 5415.88 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 24.98 | 4973.9 | 9947.80 | 乳腺肿瘤 | 1.84 |
正常乳腺GW00-413 | 28798 | 24.69 | 5954.77 | 5954.77 | 正常乳腺 |
乳腺肿瘤GW00-412 | 28797 | 26.38 | 2081.99 | 4163.98 | 乳腺肿瘤 | -1.43 |
正常乳腺GW00-235:238 | 27592-95 | 25.04 | 4792.18 | 4792.18 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 23.63 | 11520.86 | 11520.86 | 乳腺肿瘤 | 2.40 |
正常乳腺GW98-621 | 23656 | 23.22 | 14836.24 | 29672.48 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 24.24 | 7879 | 15758.00 | 乳腺肿瘤 | -1.88 |
正常大脑BB99-542 | 25507 | 25.16 | 4447.15 | 8894.30 | 正常大脑 | |
正常大脑BB99-406 | 25509 | 27.05 | 1377.71 | 2755.42 | 正常大脑 | |
正常大脑BB99-904 | 25546 | 29.35 | 330.53 | 661.06 | 正常大脑 | |
大脑期5ALZBB99-874 | 25502 | 27.64 | 956.16 | 1912.32 | 大脑期5-ALZ | -2.15 |
大脑期5ALZBB99-887 | 25503 | 27.02 | 1400.04 | 2800.08 | 大脑期5-ALZ | -1.47 |
大脑期5ALZBB99-862 | 25504 | 27.4 | 1105.21 | 2210.42 | 大脑期5-ALZ | -1.86 |
大脑期5ALZBB99-927 | 25542 | 27.1 | 1336.02 | 2672.04 | 大脑期5-ALZ | -1.54 |
CT肺KC | normal | 23.52 | 12295.29 | 24590.58 | CT肺 | |
肺26KC | normal | 31.42 | 91.19 | 91.19 | 肺26 | |
肺27KC | normal | 32.34 | 51.71 | 51.71 | 肺27 | |
肺24KC | COPD | 31.27 | 100.29 | 100.29 | 肺24 | -61.80 |
肺28KC | COPD | 28.64 | 511.37 | 511.37 | 肺28 | -12.12 |
肺23KC | COPD | 30.52 | 159.17 | 159.17 | 肺23 | -38.94 |
肺25KC | normal | 32.15 | 57.91 | 57.91 | 肺25 | |
哮喘肺ODO3112 | 29321 | 23.19 | 15086.65 | 15086.65 | 哮喘肺 | 2.43 |
哮喘肺ODO3433 | 29323 | 24.76 | 5706.9 | 11413.80 | 哮喘肺 | 1.84 |
哮喘肺ODO3397 | 29322 | 21.71 | 37760.01 | 75520.02 | 哮喘肺 | 12.18 |
哮喘肺ODO4928 | 29325 | 24.16 | 8255.16 | 16510.32 | 哮喘肺 | 2.66 |
内皮细胞KC | control | 37.31 | 2.36 | 2.36 | 内皮细胞 |
内皮细胞VEGFKC | 40 | 0 | 0.00 | 内皮细胞VEGF | -2.36 | |
内皮细胞bFGF KC | 35.67 | 6.54 | 6.54 | 内皮细胞bFGF | 2.77 | |
心脏Clontech | normal | 26.32 | 2170.24 | 4340.48 | 心脏 | |
心脏(T-1)缺血 | 29417 | 25.87 | 2863.04 | 5726.08 | 心脏T-1 | 1.32 |
心脏(T-14)非阻塞性DCM | 29422 | 24.62 | 6200.03 | 12400.06 | 心脏T-14 | 2.86 |
心脏(T-3399)DCM | 29426 | 24.06 | 8775.18 | 17550.36 | 心脏T-3399 | 4.04 |
腺样增殖体GW99-269 | 26162 | 29.2 | 362.88 | 725.76 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 27.24 | 1222.33 | 2444.66 | 扁桃体 | |
T细胞PC00314 | 28453 | 28.09 | 723.06 | 1446.12 | T细胞 | |
PBMNC | 30.67 | 145.75 | 145.75 | PBMNC | ||
单核细胞 | 28.42 | 587.16 | 1174.32 | 单核细胞 | ||
B细胞PC00665 | 28455 | 34.17 | 16.57 | 33.14 | B细胞 | |
树突细胞28441 | 31.78 | 72.95 | 145.90 | 树突细胞 | ||
中性粒细胞 | 28440 | 21.46 | 44297.23 | 44297.23 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 22.79 | 19332.21 | 38664.42 | 嗜酸性粒细胞 | |
BM unstim | 29.22 | 358.53 | 358.53 | BM未刺激的 | ||
BM stim | 31.27 | 100.39 | 100.39 | BM刺激的 | -3.57 | |
osteo dif | 30.14 | 202.25 | 202.25 | 成骨细胞分化 | 4.97 | |
osteo undif | 32.72 | 40.67 | 40.67 | 成骨细胞未分化 | ||
软骨细胞 | 27.3 | 1178.3 | 2945.75 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 23.33 | 13860.23 | 13860.23 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 25.3 | 4080.49 | 8160.98 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 25.23 | 4253.8 | 8507.60 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 25.46 | 3686.62 | 7373.24 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 23.31 | 14036.44 | 28072.88 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 24.28 | 7658.52 | 15317.04 | RA滑膜 |
OA骨(biobank) | 29217 | 26.48 | 1958.1 | 1958.10 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 25.28 | 4131.76 | 8263.52 | OA骨 | |
OA骨标本2 | J.Emory | 25.23 | 4242.9 | 8485.80 | OA骨 | |
软骨(库) | Normal | 24.05 | 8829.67 | 17659.34 | 软骨(库) | |
软骨(库) | OA | 24.28 | 7685.44 | 15370.88 | 软骨(库) | -1.15 |
PBL未感染的 | 28441 | 29.33 | 334.71 | 669.42 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 29.59 | 283.96 | 567.92 | PBL HIV IIIB | -1.18 |
MRC5未感染的(100%) | 29158 | 23.92 | 9595.12 | 19190.24 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 25.2 | 4341.36 | 8682.72 | MRC5 HSV株F | -2.21 |
W12细胞 | 29179 | 30.43 | 168.9 | 337.80 | W12细胞 | |
角质细胞 | 29180 | 29.66 | 272.9 | 545.80 | 角质细胞 | |
B-肌动蛋白对照 | 27.64 | 956.41 | ||||
基因组 | 27.35 | 1143.39 | ||||
1.00E+05 | 20.14 | 100000 | ||||
1.00E+05 | 20.26 | 100000 | ||||
1.00E+04 | 23.6 | 10000 | ||||
1.00E+04 | 24.02 | 10000 | ||||
1.00E+03 | 27.49 | 1000 | ||||
1.00E+03 | 27.5 | 1000 | ||||
1.00E+02 | 31.66 | 100 | ||||
1.00E+02 | 31.01 | 100 | ||||
1.00E+01 | 40 | 0 | ||||
1.00E+01 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
NTC | 40 | 0 |
基因名称sbg1002620TIb
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | 1.24 |
结肠肿瘤 | -2.37 |
结肠肿瘤 | -1.55 |
结肠肿瘤 | -2.97 |
肺肿瘤 | -9.28 |
肺肿瘤 | -2.02 |
肺肿瘤 | -1.54 |
肺肿瘤 | 2.52 |
乳腺肿瘤 | 1.84 |
乳腺肿瘤 | -1.43 |
乳腺肿瘤 | 2.40 |
乳腺肿瘤 | -1.88 |
大脑期5ALZ | -2.15 |
大脑期5ALZ | -1.47 |
大脑期5ALZ | -1.86 |
大脑期5ALZ | -1.54 |
肺24 | -61.80 |
肺28 | -12.12 |
肺23 | -38.94 |
哮喘肺 | 2.43 |
哮喘肺 | 1.84 |
哮喘肺 | 12.18 |
哮喘肺 | 2.66 |
内皮细胞VEGF | -2.36 |
内皮细胞bFGF | 2.77 |
心脏T-1 | 1.32 |
心脏T-14 | 2.86 |
心脏T-3399 | 4.04 |
BM刺激的 | -3.57 |
Osteo未分化的 | 4.97 |
软骨(库) | -1.15 |
PBL HIV IIIB | -1.18 |
MRC5 HSV株F | -2.21 |
基因名称sbg102200MCTa
中度到低度的总体表达。在皮下脂肪组织,全脑,胎脑,小脑和胚胎肝脏中有最高的正常表达。在4份肺肿瘤标本的2份中,一份正传肺标本,一份正常乳腺标本,和CT肺标本中有最高的疾病表达。在4份乳腺癌标本的1份中下调提示该基因与乳腺癌有关。在所有3份COPD肺标本中下调提示该基因参与慢性阻塞性肺病。在OA和RA滑膜中,以及在PBL,腺样增殖体,扁桃体,T细胞,B细胞和软骨细胞中中度表达提示其参与骨关节炎和类风湿性关节炎。
标本sbg102200MCTa | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 36.01,34.76 | 3.83 | 8.04 | 5.94 | 3.06 | 16.34 | 96.98 |
皮下脂肪Zenbio | 34.85,33.96 | 7.63 | 12.94 | 10.29 | 0.96 | 52.36 | 538.48 |
肾上腺Clontech | 40,40 | 0 | 0 | 0.00 | 0.61 | 81.97 | 0.00 |
全脑Clontech | 26.05,26.18 | 1434.25 | 1331.2 | 1382.73 | 7.24 | 6.91 | 9549.21 |
胎脑clontech | 40,34.46 | 0 | 9.63 | 4.82 | 0.48 | 103.95 | 500.52 |
小脑Clontech | 31.7,32.73 | 49.65 | 26.9 | 38.28 | 2.17 | 23.04 | 881.91 |
子宫颈 | 40,40 | 0 | 0 | 0.00 | 2.42 | 20.66 | 0.00 |
结肠 | 38.55,38.57 | 0.84 | 0.83 | 0.84 | 2.71 | 18.45 | 15.41 |
子宫内膜 | 40,40 | 0 | 0 | 0.00 | 0.73 | 68.21 | 0.00 |
食管 | 35.23,40 | 6.09 | 0 | 3.05 | 1.37 | 36.50 | 111.13 |
心脏Clontech | 40,40 | 0 | 0 | 0.00 | 1.32 | 37.88 | 0.00 |
下丘脑 | 39.8,40 | 0.4 | 0 | 0.20 | 0.32 | 155.28 | 31.06 |
回肠 | 34.16,40 | 11.53 | 0 | 5.77 | 2.58 | 19.38 | 111.72 |
空肠 | 32.82,33.18 | 25.46 | 20.6 | 23.03 | 6.60 | 7.58 | 174.47 |
肾脏 | 34.23,34.1 | 11.02 | 11.9 | 11.46 | 2.12 | 23.58 | 270.28 |
肝脏 | 35.35,37.28 | 5.65 | 1.79 | 3.72 | 1.50 | 33.33 | 124.00 |
胚胎肝Clontech | 29.45,28.98 | 189.89 | 250.96 | 220.43 | 10.40 | 4.81 | 1059.74 |
肺 | 34.99,33.43 | 7.04 | 17.81 | 12.43 | 2.57 | 19.46 | 241.73 |
乳腺Clontech | 31.76,31.05 | 48.02 | 73.18 | 60.60 | 13.00 | 3.85 | 233.08 |
子宫肌层 | 34.46,35.22 | 9.64 | 6.12 | 7.88 | 2.34 | 21.37 | 168.38 |
网膜 | 37.94,34.13 | 1.21 | 11.71 | 6.46 | 3.94 | 12.69 | 81.98 |
卵巢 | 34.03,33.43 | 12.44 | 17.77 | 15.11 | 4.34 | 11.52 | 174.02 |
胰腺 | 40,40 | 0 | 0 | 0.00 | 0.81 | 61.80 | 0.00 |
胰头 | 40,40 | 0 | 0 | 0.00 | 1.57 | 31.85 | 0.00 |
腮腺 | 32.56,31.81 | 29.88 | 46.65 | 38.27 | 5.48 | 9.12 | 349.13 |
胎盘Clontech | 40,40 | 0 | 0 | 0.00 | 5.26 | 9.51 | 0.00 |
前列腺 | 40,36.21 | 0 | 3.39 | 1.70 | 3.00 | 16.67 | 28.25 |
直肠 | 40,39.37 | 0 | 0.52 | 0.26 | 1.23 | 40.65 | 10.57 |
唾液腺Clontech | 30.6,31.77 | 95.89 | 47.76 | 71.83 | 7.31 | 6.84 | 491.28 |
骨骼肌Clontech | 40,40 | 0 | 0 | 0.00 | 1.26 | 39.68 | 0.00 |
皮肤 | 34.47,35.32 | 9.58 | 5.75 | 7.67 | 1.21 | 41.32 | 316.74 |
小肠Clontech | 40,40 | 0 | 0 | 0.00 | 0.98 | 51.07 | 0.00 |
脾脏 | 34.1,36.49 | 11.93 | 2.87 | 7.40 | 4.92 | 10.16 | 75.20 |
胃 | 35.17,36.07 | 6.3 | 3.68 | 4.99 | 2.73 | 18.32 | 91.39 |
睾丸Clontech | 37.98,40 | 1.19 | 0 | 0.60 | 0.57 | 87.87 | 52.28 |
胸腺Clontech | 31.28,30.4 | 63.69 | 108.05 | 85.87 | 9.89 | 5.06 | 434.13 |
甲状腺 | 33.08,32.96 | 21.88 | 23.47 | 22.68 | 2.77 | 18.05 | 409.30 |
气管Clontech | 32.54,31.34 | 30.14 | 61.71 | 45.93 | 9.71 | 5.15 | 236.48 |
膀胱 | 33.91,40 | 13.32 | 0 | 6.66 | 5.47 | 9.14 | 60.88 |
子宫 | 33.71,32.43 | 15.04 | 32.13 | 23.59 | 5.34 | 9.36 | 220.83 |
基因组 | 26.3 | 1237.42 | |||||
b-肌动蛋白 | 27.49 | 610.72 |
1.00E+05 | 19.18 | 100000 | |||||
1.00E+05 | 19.45 | 100000 | |||||
1.00E+04 | 22.6 | 10000 | |||||
1.00E+04 | 22.53 | 10000 | |||||
1.00E+03 | 26.17 | 1000 | |||||
1.00E+03 | 26.19 | 1000 | |||||
1.00E+02 | 30.61 | 100 | |||||
1.00E+02 | 30.53 | 100 | |||||
1.00E+01 | 40 | 0 | |||||
1.00E+01 | 34.91 | 10 | |||||
1.00E-00 | 40 | 0 | |||||
1.00E-00 | 40 | 0 | |||||
NTC | 40 | 0 | |||||
NTC | 40 | 0 |
标本sbg102200MCTa | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 28.58 | 519.72 | 1039.44 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 30.18 | 202.86 | 405.72 | 结肠肿瘤 | -2.56 |
正常结肠GW98-178 | 22080 | 31.39 | 100.15 | 200.30 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 29.62 | 282.42 | 564.84 | 结肠肿瘤 | 2.82 |
正常结肠GW98-561 | 23514 | 30.36 | 183.13 | 366.26 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 30.45 | 173.87 | 347.74 | 结肠肿瘤 | -1.05 |
正常结肠GW98-894 | 24691 | 30.23 | 196.98 | 393.96 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 30.35 | 183.76 | 367.52 | 结肠肿瘤 | -1.07 |
正常肺GW98-3 | 20742 | 26.68 | 1575.72 | 3151.44 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 28.8 | 456.47 | 912.94 | 肺肿瘤 | -3.45 |
正常肺GW97-179 | 20677 | 27.94 | 754.47 | 1508.94 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 26.27 | 2002.28 | 4004.56 | 肺肿瘤 | 2.65 |
正常肺GW98-165 | 21922 | 26.87 | 1411.09 | 2822.18 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 29.38 | 325.51 | 651.02 | 肺肿瘤 | -4.34 |
正常肺GW98-282 | 22584 | 30 | 225.32 | 450.64 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 28.64 | 502.02 | 1004.04 | 肺肿瘤 | 2.23 |
正常乳腺GW00-392 | 28750 | 28.32 | 602.59 | 602.59 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 28.05 | 709.37 | 1418.74 | 乳腺肿瘤 | 2.35 |
正常乳腺GW00-413 | 28798 | 29.56 | 292.43 | 292.43 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 30.05 | 218.89 | 437.78 | 乳腺肿瘤 | 1.50 |
正常乳腺GW00-235:238 | 27592-95 | 30.96 | 128.91 | 128.91 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 30.57 | 161.3 | 161.30 | 乳腺肿瘤 | 1.25 |
正常乳腺GW98-621 | 23656 | 27.04 | 1275.81 | 2551.62 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 31.35 | 102.26 | 204.52 | 乳腺肿瘤 | -12.48 |
正常大脑BB99-542 | 25507 | 28.44 | 564.32 | 1128.64 | 正常大脑 | |
正常大脑BB99-406 | 25509 | 29.01 | 402.37 | 804.74 | 正常大脑 | |
正常大脑BB99-904 | 25546 | 29.67 | 274.03 | 548.06 | 正常大脑 | |
大脑期5ALZ BB99-874 | 25502 | 29.6 | 284.82 | 569.64 | 大脑期5-ALZ | -1.45 |
大脑期5ALZ BB99-887 | 25503 | 27.92 | 765.16 | 1530.32 | 大脑期5-ALZ | 1.85 |
大脑期5ALZ BB99-862 | 25504 | 28.74 | 472.27 | 944.54 | 大脑期5-ALZ | 1.14 |
大脑期5ALZ BB99-927 | 25542 | 29.3 | 340.25 | 680.50 | 大脑期5-ALZ | -1.22 |
CT肺KC | normal | 26.69 | 1569.87 | 3139.74 | CT肺 | |
肺26KC | normal | 31.07 | 120.9 | 120.90 | 肺26 | |
肺27KC | normal | 31.17 | 113.69 | 113.69 | 肺27 | |
肺24KC | COPD | 31.8 | 78.78 | 78.78 | 肺24 | -10.98 |
肺28KC | COPD | 32.79 | 44.02 | 44.02 | 肺28 | -19.65 |
肺23KC | COPD | 31.35 | 102.33 | 102.33 | 肺23 | -8.45 |
肺25KC | normal | 31.66 | 85.57 | 85.57 | 肺25 | |
哮喘肺ODO3112 | 29321 | 28.76 | 467.45 | 467.45 | 哮喘肺 | -1.85 |
哮喘肺ODO3433 | 29323 | 27.73 | 851.21 | 1702.42 | 哮喘肺 | 1.97 |
哮喘肺ODO3397 | 29322 | 27.81 | 812.68 | 1625.36 | 哮喘肺 | 1.88 |
哮喘肺ODO4928 | 29325 | 29.42 | 317.12 | 634.24 | 哮喘肺 | -1.36 |
内皮细胞KC | control | 33.06 | 37.57 | 37.57 | 内皮细胞 | |
内皮细胞VEGF KC | 33.9 | 22.97 | 22.97 | 内皮细胞VEGF | -1.64 | |
内皮细胞bFGF KC | 33.13 | 36.03 | 36.03 | 内皮细胞bFGF | -1.04 | |
心脏Clontech | normal | 31.1 | 118.18 | 236.36 | 心脏 | |
心脏(T-1)缺血 | 29417 | 31.16 | 114.67 | 229.34 | 心脏T-1 | -1.03 |
心脏(T-14)非阻塞性DCM | 29422 | 30.52 | 166.47 | 332.94 | 心脏T-14 | 1.41 |
心脏(T-3399)DCM | 29426 | 30.14 | 208.3 | 416.60 | 心脏T-3399 | 1.76 |
腺样增殖体GW99-269 | 26162 | 29.07 | 388.9 | 777.80 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 28.29 | 614.82 | 1229.64 | 扁桃体 | |
T细胞PC00314 | 28453 | 29.78 | 256.1 | 512.20 | T细胞 | |
PBMNC | 33.73 | 25.44 | 25.44 | PBMNC | ||
单核细胞 | 33.52 | 28.71 | 57.42 | 单核细胞 | ||
B细胞PC00665 | 28455 | 28.66 | 495.36 | 990.72 | B细胞 | |
树突细胞28441 | 30.81 | 140.17 | 280.34 | 树突细胞 | ||
中性粒细胞 | 28440 | 30.17 | 204.92 | 204.92 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 34.19 | 19.39 | 38.78 | 嗜酸性粒细胞 | |
BM unstim | 35.9 | 7.11 | 7.11 | BM未刺激的 | ||
BM stim | 35.77 | 7.7 | 7.70 | BM刺激的 | 1.08 | |
osteo dif | 34.98 | 12.18 | 12.18 | 成骨细胞分化 | 2.55 | |
osteo undif | 36.59 | 4.77 | 4.77 | 成骨细胞未分化 | ||
软骨细胞 | 32.91 | 41.03 | 102.58 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 29.16 | 370.33 | 370.33 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 30.69 | 151.13 | 302.26 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 29.51 | 301.55 | 603.10 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 30.36 | 183.35 | 366.70 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 29.27 | 346.61 | 693.22 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 29.13 | 376.88 | 753.76 | RA滑膜 | |
OA骨(biobank) | 29217 | 30.47 | 171.6 | 171.60 | OA骨(biobank) |
OA骨标本1 | J.Emory | 30.05 | 219.19 | 438.38 | OA骨 | |
OA骨标本2 | J.Emory | 31.13 | 116.62 | 233.24 | OA骨 | |
软骨(库) | Normal | 30.65 | 154.56 | 309.12 | 软骨(库) | |
软骨(库) | OA | 32.01 | 69.39 | 138.78 | 软骨(库) | -2.23 |
PBL未感染的 | 28441 | 27.91 | 769.91 | 1539.82 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 28.14 | 672.12 | 1344.24 | PBL HIV IIIB | -1.15 |
MRC5未感染的(100%) | 29158 | 31.66 | 85.38 | 170.76 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 30.08 | 214.88 | 429.76 | MRC5 HSV株F | 2.52 |
W12细胞 | 29179 | 33.33 | 32.15 | 64.30 | W12细胞 | |
角质细胞 | 29180 | 30.64 | 155.16 | 310.32 | 角质细胞 | |
B-肌动蛋白对照 | 27.55 | 946.64 | ||||
基因组 | 26.82 | 1451.22 | ||||
1.00E+05 | 19.71 | 100000 | ||||
1.00E+05 | 19.95 | 100000 | ||||
1.00E+04 | 23.43 | 10000 | ||||
1.00E+04 | 23.38 | 10000 | ||||
1.00E+03 | 26.88 | 1000 | ||||
1.00E+03 | 26.8 | 1000 | ||||
1.00E+02 | 31.99 | 100 | ||||
1.00E+02 | 32.15 | 100 | ||||
1.00E+01 | 34.99 | 10 | ||||
1.00E+01 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
NTC | 40 | 0 |
基因名称sbg102200MCTa
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | -2.56 |
结肠肿瘤 | 2.82 |
结肠肿瘤 | -1.05 |
结肠肿瘤 | -1.07 |
肺肿瘤 | -3.45 |
肺肿瘤 | 2.65 |
肺肿瘤 | -4.34 |
肺肿瘤 | 2.23 |
乳腺肿瘤 | 2.35 |
乳腺肿瘤 | 1.50 |
乳腺肿瘤 | 1.25 |
乳腺肿瘤 | -12.48 |
大脑期5ALZ | -1.45 |
大脑期5ALZ | 1.85 |
大脑期5ALZ | 1.14 |
大脑期5ALZ | -1.22 |
肺24 | -10.98 |
肺28 | -19.65 |
肺23 | -8.45 |
哮喘肺 | -1.85 |
哮喘肺 | 1.97 |
哮喘肺 | 1.88 |
哮喘肺 | -1.36 |
内皮细胞VEGF | -1.64 |
内皮细胞bFGF | -1.04 |
心脏T-1 | -1.03 |
心脏T-14 | 1.41 |
心脏T-3399 | 1.76 |
BM stim | 1.08 |
Osteo undif | 2.55 |
软骨(库) | -2.23 |
PBL HIV IIIB | -1.15 |
MRC5 HSV株F | 2.52 |
基因名称sbg102200MCTb
高度到中度的总体表达。在全脑,肝脏,胚胎肝脏和胸腺有最高的正常表达。在一份结肠正常/肿瘤对,一份肺正常正常/肿瘤对,一份哮喘肺标本,树突细胞,未感染HIV和感染的HIV的PBL细胞中有最高的疾病表达。在4份乳腺肿瘤标本的2份中上调可足以作出有关乳腺癌的疾病断言。在4份AD脑标本的1份中上调提示其在阿尔茨海默氏病中潜在的作用。在所有3份COPD肺标本中下调提示其参与慢性阻塞性肺病。在4份哮喘肺标本的1份中上调提示该基因在肺癌中潜在的作用。在所有免疫细胞中高表达。在OA和RA滑膜标本中,OA骨标本中,和软骨细胞中也有高度到中度的表达,这提示其参与骨关节炎和类风湿性关节炎。
标本sbg102200MCTb | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 35.66,34.05 | 3.76 | 10.2 | 6.98 | 3.06 | 16.34 | 114.05 |
皮下脂肪Zenbio | 40,36 | 0.17 | 3.07 | 1.62 | 0.96 | 52.36 | 84.82 |
肾上腺Clontech | 40,40 | 0 | 0 | 0.00 | 0.61 | 81.97 | 0.00 |
全脑Clontech | 26.32,26.41 | 1192.66 | 1124.69 | 1158.68 | 7.24 | 6.91 | 8001.90 |
胎脑clontech | 40,35.84 | 0 | 3.38 | 1.69 | 0.48 | 103.95 | 175.68 |
小脑Clontech | 34.51,34.28 | 7.68 | 8.8 | 8.24 | 2.17 | 23.04 | 189.86 |
子宫颈 | 40,34.34 | 3.17 | 8.5 | 5.84 | 2.42 | 20.66 | 120.56 |
结肠 | 33.67,35.6 | 12.86 | 3.91 | 8.39 | 2.71 | 18.45 | 154.70 |
子宫内膜 | 35.32,34.43 | 4.66 | 8.05 | 6.36 | 0.73 | 68.21 | 433.49 |
食管 | 34.27,35.14 | 8.86 | 5.19 | 7.03 | 1.37 | 36.50 | 256.39 |
心脏Clontech | 40,35.05 | 0 | 5.5 | 2.75 | 1.32 | 37.88 | 104.17 |
下丘脑 | 40,40 | 0 | 0 | 0.00 | 0.32 | 155.28 | 0.00 |
回肠 | 35.29,33.68 | 4.74 | 12.8 | 8.77 | 2.58 | 19.38 | 169.96 |
空肠 | 31.23,30.98 | 57.65 | 67.22 | 62.44 | 6.60 | 7.58 | 472.99 |
肾脏 | 34.67,34.21 | 6.95 | 9.2 | 8.08 | 2.12 | 23.58 | 190.45 |
肝脏 | 30.76,30.65 | 77.12 | 82.56 | 79.84 | 1.50 | 33.33 | 2661.33 |
胚胎肝Clontech | 26.8,27.1 | 885.14 | 734.31 | 809.73 | 10.40 | 4.81 | 3892.91 |
肺 | 40,40 | 0 | 0.17 | 0.09 | 2.57 | 19.46 | 1.65 |
乳腺Clontech | 31.28,31.37 | 56.1 | 52.95 | 54.53 | 13.00 | 3.85 | 209.71 |
子宫肌层 | 34.16,36.28 | 9.48 | 2.57 | 6.03 | 2.34 | 21.37 | 128.74 |
网膜 | 34.18,33.42 | 9.38 | 15 | 12.19 | 3.94 | 12.69 | 154.70 |
卵巢 | 34.21,34.18 | 9.24 | 9.39 | 9.32 | 4.34 | 11.52 | 107.32 |
胰腺 | 40,40 | 0 | 0.14 | 0.07 | 0.81 | 61.80 | 4.33 |
胰头 | 40,35.02 | 0 | 5.59 | 2.80 | 1.57 | 31.85 | 89.01 |
腮腺 | 31.23,31.9 | 57.68 | 38.33 | 48.01 | 5.48 | 9.12 | 438.00 |
胎盘Clontech | 31.77,33.13 | 41.33 | 17.94 | 29.64 | 5.26 | 9.51 | 281.70 |
前列腺 | 39.72,35.03 | 0.31 | 5.56 | 2.94 | 3.00 | 16.67 | 48.92 |
直肠 | 35.36,34.34 | 4.53 | 8.5 | 6.52 | 1.23 | 40.65 | 264.84 |
唾液腺Clontech | 30.52,30.54 | 89.5 | 88.43 | 88.97 | 7.31 | 6.84 | 608.52 |
骨骼肌Clontech | 40,40 | 0 | 0 | 0.00 | 1.26 | 39.68 | 0.00 |
皮肤 | 40,40 | 0 | 0 | 0.00 | 1.21 | 41.32 | 0.00 |
小肠Clontech | 40,39.27 | 0 | 0.41 | 0.21 | 0.98 | 51.07 | 10.47 |
脾脏 | 34.21,33.54 | 9.2 | 13.91 | 11.56 | 4.92 | 10.16 | 117.43 |
胃 | 35.05,33.62 | 5.51 | 13.22 | 9.37 | 2.73 | 18.32 | 171.52 |
睾丸Clontech | 40,40 | 0 | 0 | 0.00 | 0.57 | 87.87 | 0.00 |
胸腺Clontech | 28.56,28.44 | 299.45 | 322.02 | 310.74 | 9.89 | 5.06 | 1570.96 |
甲状腺 | 31.65,32.3 | 44.76 | 29.81 | 37.29 | 2.77 | 18.05 | 673.01 |
气管Clontech | 32.3,31.9 | 29.9 | 38.28 | 34.09 | 9.71 | 5.15 | 175.54 |
膀胱 | 34.34,35.02 | 8.49 | 5.59 | 7.04 | 5.47 | 9.14 | 64.35 |
子宫 | 33.07,34.56 | 18.62 | 7.45 | 13.04 | 5.34 | 9.36 | 122.05 |
基因组 | 25.84 | 1597.08 |
b-肌动蛋白 | 27.32 | 643.56 | |||||
1.00E+05 | 19.22 | 100000 | |||||
1.00E+05 | 19.33 | 100000 | |||||
1.00E+04 | 22.48 | 10000 | |||||
1.00E+04 | 22.95 | 10000 | |||||
1.00E+03 | 26.19 | 1000 | |||||
1.00E+03 | 26.37 | 1000 | |||||
1.00E+02 | 31.23 | 100 | |||||
1.00E+02 | 30.48 | 100 | |||||
1.00E+01 | 32.76 | 10 | |||||
1.00E+01 | 35.02 | 10 | |||||
1.00E-00 | 40 | 0 | |||||
1.00E-00 | 40 | 0 | |||||
NTC | 40 | 0 | |||||
NTC | 40 | 0 |
标本sbg102200MCTb | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 26.48 | 1723.59 | 3447.18 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 26.06 | 2195.04 | 4390.08 | 结肠肿瘤 | 1.27 |
正常结肠GW98-178 | 22080 | 29.03 | 389.88 | 779.76 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 27.39 | 1015.65 | 2031.30 | 结肠肿瘤 | 2.61 |
正常结肠GW98-561 | 23514 | 26.74 | 1478.76 | 2957.52 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 26.37 | 1831.8 | 3663.60 | 结肠肿瘤 | 1.24 |
正常结肠GW98-894 | 24691 | 25.58 | 2918.02 | 5836.04 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 25 | 4089.75 | 8179.50 | 结肠肿瘤 | 1.40 |
正常肺GW98-3 | 20742 | 24.59 | 5183.31 | 10366.62 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 24.94 | 4232.23 | 8464.46 | 肺肿瘤 | -1.22 |
正常肺GW97-179 | 20677 | 25.73 | 2672.73 | 5345.46 | 正常肺 |
肺肿瘤GW97-178 | 20676 | 25.36 | 3307.37 | 6614.74 | 肺肿瘤 | 1.24 |
正常肺GW98-165 | 21922 | 26.13 | 2109.28 | 4218.56 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 25.54 | 2973.82 | 5947.64 | 肺肿瘤 | 1.41 |
正常肺GW98-282 | 22584 | 27.08 | 1212.64 | 2425.28 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 27.45 | 979.82 | 1959.64 | 肺肿瘤 | -1.24 |
正常乳腺GW00-392 | 28750 | 26.68 | 1536.57 | 1536.57 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 26.58 | 1626.58 | 3253.16 | 乳腺肿瘤 | 2.12 |
正常乳腺GW00-413 | 28798 | 31.71 | 81.9 | 81.90 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 26.57 | 1632 | 3264.00 | 乳腺肿瘤 | 39.85 |
正常乳腺GW00-235:238 | 27592-95 | 32.52 | 51.1 | 51.10 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 29.67 | 268.7 | 268.70 | 乳腺肿瘤 | 5.26 |
正常乳腺GW98-621 | 23656 | 26.48 | 1727.44 | 3454.88 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 25.65 | 2793.6 | 5587.20 | 乳腺肿瘤 | 1.62 |
正常大脑BB-99-542 | 25507 | 28.62 | 494 | 988.00 | 正常大脑 | |
正常大脑BB-99-406 | 25509 | 29.45 | 304.68 | 609.36 | 正常大脑 | |
正常大脑BB-99-904 | 25546 | 30.08 | 211.25 | 422.50 | 正常大脑 | |
大脑期5ALZ BB99-874 | 25502 | 28.75 | 458.64 | 917.28 | 大脑期5-ALZ | 1.36 |
大脑期5ALZ BB99-887 | 25503 | 26.86 | 1383.71 | 2767.42 | 大脑期5-ALZ | 4.11 |
大脑期5ALZ BB99-862 | 25504 | 28.02 | 702.59 | 1405.18 | 大脑期5-ALZ | 2.09 |
大脑期5ALZ BB99-927 | 25542 | 29.57 | 284.31 | 568.62 | 大脑期5-ALZ | -1.18 |
CT肺KC | normal | 26.58 | 1624.29 | 3248.58 | CT肺 | |
肺26KC | normal | 34.19 | 19.27 | 19.27 | 肺26 | |
肺27KC | normal | 32.45 | 53.23 | 53.23 | 肺27 | |
肺24KC | COPD | 33 | 38.6 | 38.60 | 肺24 | -21.75 |
肺28KC | COPD | 32.24 | 59.95 | 59.95 | 肺28 | -14.01 |
肺23KC | COPD | 32.87 | 41.63 | 41.63 | 肺23 | -20.17 |
肺25KC | normal | 33.04 | 37.52 | 37.52 | 肺25 | |
哮喘肺ODO3112 | 29321 | 30.13 | 205.46 | 205.46 | 哮喘肺 | -4.09 |
哮喘肺ODO3433 | 29323 | 27.82 | 788.82 | 1577.64 | 哮喘肺 | 1.88 |
哮喘肺ODO3397 | 29322 | 25.17 | 3695.43 | 7390.86 | 哮喘肺 | 8.80 |
哮喘肺ODO4928 | 29325 | 27.6 | 894.3 | 1788.60 | 哮喘肺 | 2.13 |
内皮细胞KC | control | 28.2 | 633.43 | 633.43 | 内皮细胞 | |
内皮细胞VEGF KC | 28.86 | 429.51 | 429.51 | 内皮细胞VEGF | -1.47 | |
内皮细胞bFGF KC | 28.97 | 403.08 | 403.08 | 内皮细胞bFGF | -1.57 | |
心脏Clontech | normal | 28.83 | 437.62 | 875.24 | 心脏 | |
心脏(T-1)缺血 | 29417 | 28.42 | 557.54 | 1115.08 | 心脏T-1 | 1.27 |
心脏(T-14)非阻塞性DCM | 29422 | 27.72 | 835.11 | 1670.22 | 心脏T-14 | 1.91 |
心脏(T-3399)DCM | 29426 | 28.63 | 493.01 | 986.02 | 心脏T-3399 | 1.13 |
腺样增殖体GW99-269 | 26162 | 27 | 1269.75 | 2539.50 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 26.33 | 1876.29 | 3752.58 | 扁桃体 | |
T细胞PC00314 | 28453 | 29.15 | 363.35 | 726.70 | T细胞 | |
PBMNC | 33.05 | 37.41 | 37.41 | PBMNC | ||
单核细胞 | 31.49 | 92.84 | 185.68 | 单核细胞 | ||
B细胞PC00665 | 28455 | 26.5 | 1700.87 | 3401.74 | B细胞 | |
树突细胞28441 | 24.2 | 6511.17 | 13022.34 | 树突细胞 | ||
中性粒细胞 | 28440 | 27.01 | 1262.74 | 1262.74 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 29.23 | 347.08 | 694.16 | 嗜酸性粒细胞 | |
BM unstim | 30.85 | 135.01 | 135.01 | BM未刺激的 | ||
BM stim | 28.68 | 478.5 | 478.50 | BM刺激的 | 3.54 | |
osteo dif | 31.03 | 121.2 | 121.20 | 成骨细胞分化 | 3.93 | |
osteo undif | 33.38 | 30.85 | 30.85 | 成骨细胞未分化 | ||
软骨细胞 | 26.63 | 1579.73 | 3949.33 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 29.11 | 371.98 | 371.98 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 29.45 | 304.55 | 609.10 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 27.83 | 784.87 | 1569.74 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 27.31 | 1063.77 | 2127.54 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 27.08 | 1217.21 | 2434.42 | RA滑膜 |
RA滑膜NP45/00 | 28475 | 26.6 | 1606.41 | 3212.82 | RA滑膜 | |
OA骨(biobank) | 29217 | 28.65 | 485.63 | 485.63 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 28.78 | 451.74 | 903.48 | OA骨 | |
OA骨标本2 | J.Emory | 28.27 | 607.15 | 1214.30 | OA骨 | |
软骨(库) | Normal | 29.42 | 310.76 | 621.52 | 软骨(库) | |
软骨(库) | OA | 30.09 | 209.7 | 419.40 | 软骨(库) | -1.48 |
PBL未感染的 | 28441 | 23.85 | 7997.03 | 15994.06 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 24.85 | 4447.34 | 8894.68 | PBL HIV IIIB | -1.80 |
MRC5未感染的(100%) | 29158 | 27.02 | 1258.46 | 2516.92 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 29.6 | 278.84 | 557.68 | MRC5 HSV株F | -4.51 |
W12细胞 | 29179 | 27.21 | 1122.77 | 2245.54 | W12细胞 | |
角质细胞 | 29180 | 25.64 | 2815.12 | 5630.24 | 角质细胞 | |
B-肌动蛋白对照 | 27.78 | 807.72 | ||||
基因组 | 27.04 | 1246.22 | ||||
1.00E+05 | 19.69 | 100000 | ||||
1.00E+05 | 20.01 | 100000 | ||||
1.00E+04 | 23.15 | 10000 | ||||
1.00E+04 | 23.2 | 10000 | ||||
1.00E+03 | 27.02 | 1000 | ||||
1.00E+03 | 26.76 | 1000 | ||||
1.00E+02 | 31.45 | 100 | ||||
1.00E+02 | 32.39 | 100 | ||||
1.00E+01 | 35.72 | 10 | ||||
1.00E+01 | 34.74 | 10 | ||||
1.00E-00 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
NTC | 40 | 0 |
基因名称sbg102200MCTb
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | 1.27 |
结肠肿瘤 | 2.61 |
结肠肿瘤 | 1.24 |
结肠肿瘤 | 1.40 |
肺肿瘤 | -1.22 |
肺肿瘤 | 1.24 |
肺肿瘤 | 1.41 |
肺肿瘤 | -1.24 |
乳腺肿瘤 | 2.12 |
乳腺肿瘤 | 39.85 |
乳腺肿瘤 | 5.26 |
乳腺肿瘤 | 1.62 |
大脑期5ALZ | 1.36 |
大脑期5ALZ | 4.11 |
大脑期5ALZ | 2.09 |
大脑期5ALZ | -1.18 |
肺24 | -21.75 |
肺28 | -14.01 |
肺23 | -20.17 |
哮喘肺 | -4.09 |
哮喘肺 | 1.88 |
哮喘肺 | 8.80 |
哮喘肺 | 2.13 |
内皮细胞VEGF | -1.47 |
内皮细胞bFGF | -1.57 |
心脏T-1 | 1.27 |
心脏T-14 | 1.91 |
心脏T-3399 | 1.13 |
BM stim | 3.54 |
Osteo undif | 3.93 |
软骨(库) | -1.48 |
PBL HIV IIIB | -1.80 |
MRC5 HSV株F | -4.51 |
基因名称sbg1020380LYG
失败
基因名称sbg1007026SGLT
良好到中度的总体表达。在全脑,小脑,下丘脑,空肠,胚胎肝脏,直肠和子宫中可见最高的正常表达。该基因在代表中枢神经系统,女性生殖器官和胃肠道的标本中显示系统特异性表达。在疾病标本中观察到的表达证实了在正常标本中观察到的表达,其中在正常和阿尔茨海默氏病脑标本中观察到最高水平的表达。在4份结肠肿瘤标本的1份中上调和在4份乳腺肿瘤标本的2份中上调,以及在4份肺肿瘤的一份中下调提示该基因在结肠癌和乳腺癌中有潜在作用。在4份阿尔茨海默氏病标本的2份中下调提示其参与阿尔茨海默氏病。在所有3份COPD标本中下调和在4份哮喘肺标本的2份中上调提示该基因在慢性阻塞性肺病中的潜在作用。在VEGF治疗的内皮细胞系中上调提示该基因在血管生成中可能的作用。在受到刺激的骨髓标本中下调。在RA和OA的滑膜标本中,OA的骨标本中,和软骨细胞中的高表达,以及在T细胞,B细胞,中性粒细胞和嗜酸性粒细胞中确定的高表达提示,该基因与骨关节炎和类风湿性关节炎有关。
标本sbg1007026SGLT | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 40,40 | 0 | 0 | 0.00 | 3.06 | 16.34 | 0.00 |
皮下脂肪Zenbio | 40,40 | 0 | 0.1 | 0.05 | 0.96 | 52.36 | 2.62 |
肾上腺Clontech | 40,38.76 | 0 | 0.31 | 0.16 | 0.61 | 81.97 | 12.70 |
全脑Clontech | 23.01,22.63 | 3438.45 | 4301.69 | 3870.07 | 7.24 | 6.91 | 26727.00 |
胎脑clontech | 35.91,39.16 | 1.66 | 0.24 | 0.95 | 0.48 | 103.95 | 98.75 |
小脑Clontech | 34.55,32.7 | 3.71 | 11.08 | 7.40 | 2.17 | 23.04 | 170.39 |
子宫颈 | 34.21,34.61 | 4.54 | 3.58 | 4.06 | 2.42 | 20.66 | 83.88 |
结肠 | 33.44,33.7 | 7.16 | 6.14 | 6.65 | 2.71 | 18.45 | 122.69 |
子宫内膜 | 34.88,40 | 3.05 | 0.1 | 1.58 | 0.73 | 68.21 | 107.44 |
食管 | 40,40 | 0 | 0.1 | 0.05 | 1.37 | 36.50 | 1.82 |
心脏Clontech | 39.63,39.53 | 0.18 | 0.19 | 0.19 | 1.32 | 37.88 | 7.01 |
下丘脑 | 40,35.34 | 0 | 2.33 | 1.17 | 0.32 | 155.28 | 180.90 |
回肠 | 40,40 | 0 | 0 | 0.00 | 2.58 | 19.38 | 0.00 |
空肠 | 30.1,30.34 | 51.59 | 44.92 | 48.26 | 6.60 | 7.58 | 365.57 |
肾脏 | 33.49,40 | 6.96 | 0 | 3.48 | 2.12 | 23.58 | 82.08 |
肝脏 | 40,33.7 | 0 | 6.15 | 3.08 | 1.50 | 33.33 | 102.50 |
胚胎肝Clontech | 29.58,29.41 | 70.26 | 77.58 | 73.92 | 10.40 | 4.81 | 355.38 |
肺 | 35.61,37.83 | 1.98 | 0.53 | 1.26 | 2.57 | 19.46 | 24.42 |
乳腺Clontech | 33.05,34.04 | 9.02 | 5.03 | 7.03 | 13.00 | 3.85 | 27.02 |
子宫肌层 | 33.63,34.13 | 6.38 | 4.77 | 5.58 | 2.34 | 21.37 | 119.12 |
网膜 | 40,40 | 0 | 0 | 0.00 | 3.94 | 12.69 | 0.00 |
卵巢 | 35.38,37.6 | 2.27 | 0.61 | 1.44 | 4.34 | 11.52 | 16.59 |
胰腺 | 40,37.1 | 0 | 0.82 | 0.41 | 0.81 | 61.80 | 25.34 |
胰头 | 35.45,36.72 | 2.18 | 1.03 | 1.61 | 1.57 | 31.85 | 51.11 |
腮腺 | 36.88,40 | 0.94 | 0 | 0.47 | 5.48 | 9.12 | 4.29 |
胎盘Clontech | 33.84,38.46 | 5.66 | 0.37 | 3.02 | 5.26 | 9.51 | 28.66 |
前列腺 | 38.76,37.12 | 0.31 | 0.81 | 0.56 | 3.00 | 16.67 | 9.33 |
直肠 | 36.18,33.82 | 1.42 | 5.7 | 3.56 | 1.23 | 40.65 | 144.72 |
唾液腺Clontech | 38.36,39.93 | 0.39 | 0.12 | 0.26 | 7.31 | 6.84 | 1.74 |
骨骼肌Clontech | 35.69,36.23 | 1.9 | 1.38 | 1.64 | 1.26 | 39.68 | 65.08 |
皮肤 | 39.51,40 | 0.2 | 0.09 | 0.15 | 1.21 | 41.32 | 5.99 |
小肠Clontech | 40,36.04 | 0.1 | 1.53 | 0.82 | 0.98 | 51.07 | 41.62 |
脾脏 | 33.51,38.51 | 6.87 | 0.36 | 3.62 | 4.92 | 10.16 | 36.74 |
胃 | 34.14,34.19 | 4.73 | 4.59 | 4.66 | 2.73 | 18.32 | 85.35 |
睾丸Clontech | 35.81,40 | 1.76 | 0.11 | 0.94 | 0.57 | 87.87 | 82.16 |
胸腺Clontech | 33.26,32.49 | 7.96 | 12.55 | 10.26 | 9.89 | 5.06 | 51.85 |
甲状腺 | 40,39.9 | 0.08 | 0.16 | 0.12 | 2.77 | 18.05 | 2.17 |
气管Clontech | 34.25,33.8 | 4.42 | 5.77 | 5.10 | 9.71 | 5.15 | 26.24 |
膀胱 | 39.95,36.54 | 0.1 | 1.14 | 0.62 | 5.47 | 9.14 | 5.67 |
子宫 | 33,31.23 | 9.3 | 26.52 | 17.91 | 5.34 | 9.36 | 167.70 |
基因组 | 24.72 | 1251.19 | |||||
b-肌动蛋白 | 25.89 | 625.04 | |||||
1.00E+05 | 17.54 | 100000 | |||||
1.00E+05 | 17.65 | 100000 | |||||
1.00E+04 | 21.03 | 10000 | |||||
1.00E+04 | 20.92 | 10000 | |||||
1.00E+03 | 24.87 | 1000 | |||||
1.00E+03 | 24.96 | 1000 | |||||
1.00E+02 | 29.1 | 100 | |||||
1.00E+02 | 29.04 | 100 | |||||
1.00E+01 | 32.05 | 10 | |||||
1.00E+01 | 33.51 | 10 | |||||
1.00E-00 | 36.41 | 1 | |||||
1.00E-00 | 37.41 | 1 | |||||
NTC | 40 | 0 | |||||
NTC | 40 | -1 |
标本bg1007026SGLT | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 29.22 | 127.1 | 254.20 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 31.07 | 44.11 | 88.22 | 结肠肿瘤 | -2.88 |
正常结肠GW98-178 | 22080 | 38.41 | 0.65 | 1.30 | 正常结肠 |
结肠肿瘤GW98-177 | 22060 | 31.17 | 41.5 | 83.00 | 结肠肿瘤 | 63.85 |
正常结肠GW98-561 | 23514 | 31.21 | 40.69 | 81.38 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 33.06 | 14.04 | 28.08 | 结肠肿瘤 | -2.90 |
正常结肠GW98-894 | 24691 | 29.63 | 100.41 | 200.82 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 32.22 | 22.7 | 45.40 | 结肠肿瘤 | -4.42 |
正常肺GW98-3 | 20742 | 29.8 | 91.46 | 182.92 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 34.26 | 7.02 | 14.04 | 肺肿瘤 | -13.03 |
正常肺GW97-179 | 20677 | 29.59 | 103.13 | 206.26 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 29.84 | 89.09 | 178.18 | 肺肿瘤 | -1.16 |
正常肺GW98-165 | 21922 | 29.6 | 102.46 | 204.92 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 30.8 | 51.53 | 103.06 | 肺肿瘤 | -1.99 |
正常肺GW98-282 | 22584 | 32.53 | 18.97 | 37.94 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 32.29 | 21.8 | 43.60 | 肺肿瘤 | 1.15 |
正常乳腺GW00-392 | 28750 | 28.77 | 164.85 | 164.85 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 30.64 | 56.21 | 112.42 | 乳腺肿瘤 | -1.47 |
正常乳腺GW00-413 | 28798 | 34.49 | 6.17 | 6.17 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 30.37 | 65.97 | 131.94 | 乳腺肿瘤 | 21.38 |
正常乳腺GW00-235:238 | 27592-95 | 32.87 | 15.66 | 15.66 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 29.8 | 91.07 | 91.07 | 乳腺肿瘤 | 5.82 |
正常乳腺GW98-621 | 23656 | 28.95 | 149.19 | 298.38 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 29.62 | 101.25 | 202.50 | 乳腺肿瘤 | -1.47 |
正常大脑BB99-542 | 25507 | 24.5 | 1917.28 | 3834.56 | 正常大脑 | |
正常大脑BB99-406 | 25509 | 21.35 | 11736.92 | 23473.84 | 正常大脑 | |
正常大脑BB99-904 | 25546 | 25.25 | 1248.68 | 2497.36 | 正常大脑 | |
大脑期5ALZ BB99-874 | 25502 | 27.29 | 386.81 | 773.62 | 大脑期5-ALZ | -12.84 |
大脑期5ALZ BB99-887 | 25503 | 23.61 | 3196.37 | 6392.74 | 大脑期5-ALZ | -1.55 |
大脑期5ALZ BB99-862 | 25504 | 25.56 | 1045.09 | 2090.18 | 大脑期5-ALZ | -4.75 |
大脑期5ALZ BB99-927 | 25542 | 24.45 | 1976.24 | 3952.48 | 大脑期5-ALZ | -2.51 |
CT肺KC | normal | 31.07 | 44.03 | 88.06 | CT肺 | |
肺26KC | normal | 24.93 | 1496.87 | 肺26 |
肺27KC | normal | 34.06 | 7.92 | 7.92 | 肺27 | |
肺24KC | COPD | 34.58 | 5.87 | 5.87 | 肺24 | -5.45 |
肺28KC | COPD | 40 | 0 | 0.00 | 肺28 | -31.99 |
肺23KC | COPD | 40 | 0 | 0.00 | 肺23 | -31.99 |
肺25KC | normal | 40 | 0 | 0.00 | 肺25 | |
哮喘肺ODO3112 | 29321 | 33.19 | 13.04 | 13.04 | 哮喘肺 | -2.45 |
哮喘肺ODO3433 | 29323 | 30.61 | 57.38 | 114.76 | 哮喘肺 | 3.59 |
哮喘肺ODO3397 | 29322 | 29.2 | 129.16 | 258.32 | 哮喘肺 | 8.07 |
哮喘肺ODO4928 | 29325 | 30.32 | 67.67 | 135.34 | 哮喘肺 | 4.23 |
内皮细胞KC | control | 35.09 | 4.37 | 4.37 | 内皮细胞 | |
内皮细胞VEGF KC | 32.22 | 22.7 | 22.70 | 内皮细胞VEGF | 5.19 | |
内皮细胞bFGF KC | 33.23 | 12.7 | 12.70 | 内皮细胞bFGF | 2.91 | |
心脏Clontech | normal | 33.53 | 10.71 | 21.42 | 心脏 | |
心脏(T-1)缺血 | 29417 | 33.43 | 11.37 | 22.74 | 心脏T-1 | 1.06 |
心脏(T-14)非阻塞性DCM | 29422 | 34.45 | 6.32 | 12.64 | 心脏T-14 | -1.69 |
心脏(T-3399)DCM | 29426 | 31.98 | 26.02 | 52.04 | 心脏T-3399 | 2.43 |
腺样增殖体GW99-269 | 26162 | 29.56 | 104.93 | 209.86 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 29 | 144.55 | 289.10 | 扁桃体 | |
T细胞PC00314 | 28453 | 32.03 | 25.34 | 50.68 | T细胞 | |
PBMNC | 37.71 | 0.97 | 0.97 | PBMNC | ||
单核细胞 | 37.49 | 1.1 | 2.20 | 单核细胞 | ||
B细胞PC00665 | 28455 | 27.18 | 410.49 | 820.98 | B细胞 | |
树突细胞28441 | 28441 | 33.7 | 9.73 | 19.46 | 树突细胞 | |
中性粒细胞 | 28440 | 32.48 | 19.6 | 19.60 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 32.44 | 20.08 | 40.16 | 嗜酸性粒细胞 | |
BM unstim | 33.8 | 9.17 | 9.17 | BM未刺激的 | ||
BM stim | treated | 38.89 | 0.49 | 0.49 | BM刺激的 | -18.71 |
osteo dif | treated | 37.26 | 1.26 | 1.26 | 成骨细胞分化 | 1.26 |
osteo undif | 40 | 0 | 0.00 | 成骨细胞未分 |
化 | ||||||
软骨细胞 | 32.07 | 24.82 | 62.05 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 30.31 | 68.26 | 68.26 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 30.74 | 53.26 | 106.52 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 31.3 | 38.48 | 76.96 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 31.08 | 43.89 | 87.78 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 31.35 | 37.58 | 75.16 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 30.74 | 53.21 | 106.42 | RA滑膜 | |
OA骨(biobank) | 29217 | 30.47 | 61.99 | 61.99 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 29.92 | 85.09 | 170.18 | OA骨 | |
OA骨标本2 | J.Emory | 30.91 | 48.27 | 96.54 | OA骨 | |
软骨(库) | Normal | 31.34 | 37.68 | 75.36 | 软骨(库) | |
软骨(库) | OA | 31.72 | 30.35 | 60.70 | 软骨(库) | -1.24 |
PBL未感染的 | 28441 | 30.8 | 51.54 | 103.08 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 32.03 | 25.38 | 50.76 | PBL HIV IIIB | -2.03 |
MRC5未感染的(100%) | 29158 | 32.29 | 21.85 | 43.70 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 31.21 | 40.73 | 81.46 | MRC5 HSV株F | 1.86 |
W12细胞 | 29179 | 33.12 | 13.52 | 27.04 | W12细胞 | |
角质细胞 | 29180 | 32.35 | 21.06 | 42.12 | 角质细胞 | |
B-肌动蛋白对照 | 25.63 | 1002.01 | ||||
基因组 | 25.19 | 1290.48 | ||||
1.00E+05 | 17.86 | 100000 | ||||
1.00E+05 | 17.85 | 100000 | ||||
1.00E+04 | 21.44 | 10000 | ||||
1.00E+04 | 21.51 | 10000 | ||||
1.00E+03 | 25.33 | 1000 | ||||
1.00E+03 | 25.26 | 1000 | ||||
1.00E+02 | 29.62 | 100 | ||||
1.00E+02 | 30.55 | 100 |
1.00E+01 | 32.93 | 10 | ||||
1.00E+01 | 33.46 | 10 | ||||
1.00E-00 | 38.18 | 1 | ||||
1.00E-00 | 40 | 0 | ||||
NTC | 38.28 | -1 | ||||
*肺26(正常标本)被忽略,因为对该标本进行的多重扩增失败 |
基因名称sbg1007026SGLT
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | -2.88 |
结肠肿瘤 | 63.85 |
结肠肿瘤 | -2.90 |
结肠肿瘤 | -4.42 |
肺肿瘤 | -13.03 |
肺肿瘤 | -1.16 |
肺肿瘤 | -1.99 |
肺肿瘤 | 1.15 |
乳腺肿瘤 | -1.47 |
乳腺肿瘤 | 21.38 |
乳腺肿瘤 | 5.82 |
乳腺肿瘤 | -1.47 |
大脑期5ALZ | -12.84 |
大脑期5ALZ | -1.55 |
大脑期5ALZ | -4.75 |
大脑期5ALZ | -2.51 |
肺24 | -5.45 |
肺28 | -31.99 |
肺23 | -31.99 |
哮喘肺 | -2.45 |
哮喘肺 | 3.59 |
哮喘肺 | 8.07 |
哮喘肺 | 4.23 |
内皮细胞VEGF | 5.19 |
内皮细胞bFGF | 2.91 |
心脏T-1 | 1.06 |
心脏T-14 | -1.69 |
心脏T-3399 | 2.43 |
BM stim | -18.71 |
Osteo undif | 1.26 |
软骨(库) | -1.24 |
PBL HIV IIIB | -2.03 |
MRC5 HSV株F | 1.86 |
基因名称sbg1012732GLUT
高度到中度的总体表达。该基因在所有参与分析的正常标本中的表达是相对普遍的,其中在全脑,胎脑,小脑,肾脏,胚胎肝脏和胎盘中表达水平最高。该基因在疾病标本中也有相当普遍的表达。在所有3份COPD标本中下调提示该基因在慢性阻塞性肺病中潜在的作用。在所有3份疾病心脏的标本中上调提示其参与心血管疾病,如非阻塞性和阻塞性DCM和缺血。在HSV感染的MRC5细胞中下调提示该基因在HSV中可能起作用。在分化的成骨细胞中上调。在RA和OA的滑膜标本中,在OA的骨标本中和软骨细胞中的高表达,和在T细胞,B细胞,树突细胞,中性粒细胞和嗜酸性粒细胞中确定的高表达提示,该基因与骨关节炎和类风湿性关节炎有关。
标本sbg1012732GLUT | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng |
总RNA | |||||||
皮下脂肪细胞Zenbio | 30.84,30.49 | 46.76 | 57.63 | 52.20 | 3.06 | 16.34 | 852.86 |
皮下脂肪Zenbio | 34.89,35.19 | 4.31 | 3.62 | 3.97 | 0.96 | 52.36 | 207.59 |
肾上腺Clontech | 33.79,32.74 | 8.27 | 15.31 | 11.79 | 0.61 | 81.97 | 966.39 |
全脑Clontech | 22.02,21.91 | 8374.61 | 8944.05 | 8659.33 | 7.24 | 6.91 | 59802.00 |
胎脑clontech | 32.03,32.85 | 23.23 | 14.34 | 18.79 | 0.48 | 103.95 | 1952.70 |
小脑Clontech | 28.2,28.26 | 221.12 | 213.07 | 217.10 | 2.17 | 23.04 | 5002.19 |
子宫颈 | 32.91,34.54 | 13.81 | 5.31 | 9.56 | 2.42 | 20.66 | 197.52 |
结肠 | 30.88,32.48 | 45.58 | 17.87 | 31.73 | 2.71 | 18.45 | 585.33 |
子宫内膜 | 36.13,32.5 | 2.08 | 17.6 | 9.84 | 0.73 | 68.21 | 671.21 |
食管 | 32.19,33.5 | 21.15 | 9.77 | 15.46 | 1.37 | 36.50 | 564.23 |
心脏Clontech | 31.93,31.73 | 24.67 | 27.76 | 26.22 | 1.32 | 37.88 | 992.99 |
下丘脑 | 40,32.77 | 0 | 15.04 | 7.52 | 0.32 | 155.28 | 1167.70 |
回肠 | 30.94,30.52 | 44.17 | 56.37 | 50.27 | 2.58 | 19.38 | 974.22 |
空肠 | 30.04,29.34 | 75.03 | 113.25 | 94.14 | 6.60 | 7.58 | 713.18 |
肾脏 | 29.72,29.18 | 90.58 | 124.19 | 107.39 | 2.12 | 23.58 | 2532.67 |
肝脏 | 34.81,32.2 | 4.52 | 21.05 | 12.79 | 1.50 | 33.33 | 426.17 |
胚胎肝Clontech | 26.6,26.85 | 567.46 | 488.36 | 527.91 | 10.40 | 4.81 | 2538.03 |
肺 | 31.61,30.52 | 29.69 | 56.54 | 43.12 | 2.57 | 19.46 | 838.81 |
乳腺Clontech | 28.06,27.59 | 239.58 | 316.2 | 277.89 | 13.00 | 3.85 | 1068.81 |
子宫肌层 | 30.44,29.88 | 59.31 | 82.52 | 70.92 | 2.34 | 21.37 | 1515.28 |
网膜 | 31.7,30.82 | 28.2 | 47.35 | 37.78 | 3.94 | 12.69 | 479.38 |
卵巢 | 30.92,31.56 | 44.74 | 30.55 | 37.65 | 4.34 | 11.52 | 433.70 |
胰腺 | 33.08,32.66 | 12.54 | 16.03 | 14.29 | 0.81 | 61.80 | 882.88 |
胰头 | 33.98,34.1 | 7.36 | 6.89 | 7.13 | 1.57 | 31.85 | 226.91 |
腮腺 | 29.5,30.55 | 102.86 | 55.41 | 79.14 | 5.48 | 9.12 | 722.03 |
胎盘Clontech | 25.63,25.87 | 1002.18 | 869.55 | 935.87 | 5.26 | 9.51 | 8896.06 |
前列腺 | 30.23,31.17 | 67.04 | 38.48 | 52.76 | 3.00 | 16.67 | 879.33 |
直肠 | 31.29,31.15 | 35.89 | 38.94 | 37.42 | 1.23 | 40.65 | 1520.93 |
唾液腺Clontech | 28.82,28.83 | 153.9 | 152.53 | 153.22 | 7.31 | 6.84 | 1047.98 |
骨骼肌Clontech | 33.23,32.66 | 11.48 | 16.02 | 13.75 | 1.26 | 39.68 | 545.63 |
皮肤 | 32.62,32.57 | 16.46 | 16.96 | 16.71 | 1.21 | 41.32 | 690.50 |
小肠Clontech | 34.63,32.82 | 5.03 | 14.62 | 9.83 | 0.98 | 51.07 | 501.79 |
脾脏 | 31.45,32.71 | 32.66 | 15.56 | 24.11 | 4.92 | 10.16 | 245.02 |
胃 | 32.38,32.43 | 18.93 | 18.41 | 18.67 | 2.73 | 18.32 | 341.94 |
睾丸Clontech | 32.32,32.27 | 19.58 | 20.17 | 19.88 | 0.57 | 87.87 | 1746.49 |
胸腺Clontech | 27.24,26.75 | 388.32 | 518.55 | 453.44 | 9.89 | 5.06 | 2292.39 |
甲状腺 | 30.48,29.44 | 57.86 | 106.5 | 82.18 | 2.77 | 18.05 | 1483.39 |
气管Clontech | 29.96,30.29 | 78.48 | 64.81 | 71.65 | 9.71 | 5.15 | 368.92 |
膀胱 | 30.59,30.1 | 54.25 | 72.45 | 63.35 | 5.47 | 9.14 | 579.07 |
子宫 | 30.62,29.73 | 53.18 | 89.72 | 71.45 | 5.34 | 9.36 | 669.01 |
基因组 | 25.15 | 1330.24 | |||||
b-肌动蛋白 | 26.01 | 800.58 | |||||
1.00E+05 | 18.01 | 100000 | |||||
1.00E+05 | 18.19 | 100000 | |||||
1.00E+04 | 21.35 | 10000 | |||||
1.00E+04 | 21.3 | 10000 | |||||
1.00E+03 | 25.59 | 1000 | |||||
1.00E+03 | 25.51 | 1000 | |||||
1.00E+02 | 29.95 | 100 | |||||
1.00E+02 | 29.37 | 100 | |||||
1.00E+01 | 34.05 | 10 | |||||
1.00E+01 | 33.22 | 10 | |||||
1.00E-00 | 37.19 | 1 | |||||
1.00E-00 | 40 | 0 | |||||
NTC | 40 | 0 | |||||
NTC | 40 | 0 |
标本sbg1012732GLUT | 登记号(GSK标 | Ct | GOI拷贝数的 | 检测到的mRNA拷贝数 | 标本 | 患病人群中的倍数 |
识符) | 均值 | /50ng总RNA | 变化 | |||
正常结肠GW98-167 | 21941 | 25.38 | 1695.47 | 3390.94 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 25.51 | 1576.91 | 3153.82 | 结肠肿瘤 | -1.08 |
正常结肠GW98-178 | 22080 | 26.8 | 765.5 | 1531.00 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 25.86 | 1297.34 | 2594.68 | 结肠肿瘤 | 1.69 |
正常结肠GW98-561 | 23514 | 26.12 | 1120.64 | 2241.28 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 26.12 | 1121.89 | 2243.78 | 结肠肿瘤 | 1.00 |
正常结肠GW98-894 | 24691 | 24.85 | 2283.56 | 4567.12 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 24.37 | 2989.5 | 5979.00 | 结肠肿瘤 | 1.31 |
正常肺GW98-3 | 20742 | 24.37 | 2984.11 | 5968.22 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 25.38 | 1691.06 | 3382.12 | 肺肿瘤 | -1.76 |
正常肺GW97-179 | 20677 | 25.07 | 2020.52 | 4041.04 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 24.61 | 2607.03 | 5214.06 | 肺肿瘤 | 1.29 |
正常肺GW98-165 | 21922 | 24.92 | 2195.85 | 4391.70 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 25.36 | 1712.62 | 3425.24 | 肺肿瘤 | -1.28 |
正常肺GW98-282 | 22584 | 26.24 | 1049.97 | 2099.94 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 25.94 | 1241.8 | 2483.60 | 肺肿瘤 | 1.18 |
正常乳腺GW00-392 | 28750 | 25.26 | 1813.7 | 1813.70 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 24.87 | 2259.54 | 4519.08 | 乳腺肿瘤 | 2.49 |
正常乳腺GW00-413 | 28798 | 25.4 | 1672.46 | 1672.46 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 25.21 | 1864.18 | 3728.36 | 乳腺肿瘤 | 2.23 |
正常乳腺GW00-235:238 | 27592-95 | 25.68 | 1435.2 | 1435.20 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 24.08 | 3510.78 | 3510.78 | 乳腺肿瘤 | 2.45 |
正常乳腺GW98-621 | 23656 | 24.16 | 3363.26 | 6726.52 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 24.19 | 3300.23 | 6600.46 | 乳腺肿瘤 | -1.02 |
正常大脑BB99-542 | 25507 | 22.64 | 7880.57 | 15761.14 | 正常大脑 | |
正常大脑BB99-406 | 25509 | 23.32 | 5357.05 | 10714.10 | 正常大脑 | |
正常大脑BB99-904 | 25546 | 23.66 | 4436.27 | 8872.54 | 正常大脑 | |
大脑期5ALZ BB99-874 | 25502 | 24.7 | 2474.23 | 4948.46 | 大脑期5-ALZ | -2.38 |
大脑期5ALZ BB99-887 | 25503 | 23.22 | 5674.88 | 11349.76 | 大脑期5-ALZ | -1.04 |
大脑期5ALZ BB99-862 | 25504 | 23.5 | 4868.6 | 9737.20 | 大脑期5-ALZ | -1.21 |
大脑期5ALZ BB99-927 | 25542 | 23.17 | 5843.2 | 11686.40 | 大脑期5-ALZ | -1.01 |
CT肺KC | normal | 25.61 | 1486.99 | 2973.98 | CT肺 | |
肺26KC | normal | 26.55 | 879.91 | 肺26 | ||
肺27KC | normal | 29.44 | 174.3 | 174.30 | 肺27 | |
肺24KC | COPD | 29.99 | 128.5 | 128.50 | 肺24 | -8.67 |
肺28KC | COPD | 29.56 | 163.34 | 163.34 | 肺28 | -6.82 |
肺23KC | COPD | 29.59 | 160.67 | 160.67 | 肺23 | -6.94 |
肺25KC | normal | 29.24 | 194.83 | 194.83 | 肺25 | |
哮喘肺ODO3112 | 29321 | 27.22 | 604.38 | 604.38 | 哮喘肺 | -1.84 |
哮喘肺ODO3433 | 29323 | 26.46 | 923.43 | 1846.86 | 哮喘肺 | 1.66 |
哮喘肺ODO3397 | 29322 | 26.16 | 1094.36 | 2188.72 | 哮喘肺 | 1.96 |
哮喘肺ODO4928 | 29325 | 25.51 | 1576.72 | 3153.44 | 哮喘肺 | 2.83 |
内皮细胞KC | control | 29.09 | 211.78 | 211.78 | 内皮细胞 | |
内皮细胞VEGF KC | 30.07 | 122.67 | 122.67 | 内皮细胞VEGF | -1.73 | |
内皮细胞bFGF KC | 29.93 | 132.63 | 132.63 | 内皮细胞bFGF | -1.60 | |
心脏Clontech | normal | 27.35 | 561.26 | 1122.52 | 心脏 | |
心脏(T-1)缺血 | 29417 | 23.82 | 4053.65 | 8107.30 | 心脏T-1 | 7.22 |
心脏(T-14)非阻塞性DCM | 29422 | 23.96 | 3746.25 | 7492.50 | 心脏T-14 | 6.67 |
心脏(T-3399)DCM | 29426 | 23.35 | 5282.35 | 10564.70 | 心脏T-3399 | 9.41 |
腺样增殖体GW99-269 | 26162 | 25.71 | 1405.41 | 2810.82 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 23.97 | 3725.77 | 7451.54 | 扁桃体 | |
T细胞PC00314 | 28453 | 25.03 | 2062.68 | 4125.36 | T细胞 | |
PBMNC | 30.16 | 116.69 | 116.69 | PBMNC | ||
单核细胞 | 30.15 | 117.05 | 234.10 | 单核细胞 | ||
B细胞PC00665 | 28455 | 23.22 | 5673.63 | 11347.26 | B细胞 | |
树突细胞28441 | 28441 | 25.74 | 1385.65 | 2771.30 | 树突细胞 | |
中性粒细胞 | 28440 | 27.14 | 631.86 | 631.86 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 28.27 | 335.66 | 671.32 | 嗜酸性粒细胞 |
BM unstim | 30.08 | 122.25 | 122.25 | BM未刺激的 | ||
BM stim | treated | 29.57 | 162.71 | 162.71 | BM刺激的 | 1.33 |
osteo dif | treated | 29.07 | 214.84 | 214.84 | 成骨细胞分化 | 2.91 |
osteo undif | 30.98 | 73.85 | 73.85 | 成骨细胞未分化 | ||
软骨细胞 | 25.41 | 1667.28 | 4168.20 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 24.65 | 2554.39 | 2554.39 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 25.72 | 1399 | 2798.00 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 25.24 | 1828.2 | 3656.40 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 25.69 | 1422.61 | 2845.22 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 25.25 | 1818.15 | 3636.30 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 25.22 | 1857.13 | 3714.26 | RA滑膜 | |
OA骨(biobank) | 29217 | 26.19 | 1074.74 | 1074.74 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 26.71 | 805.65 | 1611.30 | OA骨 | |
OA骨标本2 | J.Emory | 26.96 | 700.88 | 1401.76 | OA骨 | |
软骨(库) | Normal | 26.38 | 968.45 | 1936.90 | 软骨(库) | |
软骨(库) | OA | 28.07 | 376.23 | 752.46 | 软骨(库) | -2.57 |
PBL未感染的 | 28441 | 25.09 | 1997.75 | 3995.50 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 25.36 | 1710.81 | 3421.62 | PBL HIV IIIB | -1.17 |
MRC5未感染的(100%) | 29158 | 25.28 | 1788.71 | 3577.42 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 30.17 | 116.17 | 232.34 | MRC5 HSV株F | -15.40 |
W12细胞 | 29179 | 27.6 | 489.01 | 978.02 | W12细胞 | |
角质细胞 | 29180 | 26.4 | 959.61 | 1919.22 | 角质细胞 | |
B-肌动蛋白对照 | 25.62 | 1482.86 | ||||
基因组 | 25.42 | 1657.68 | ||||
1.00E+05 | 18.49 | 100000 | ||||
1.00E+05 | 18.49 | 100000 | ||||
1.00E+04 | 21.94 | 10000 | ||||
1.00E+04 | 21.98 | 10000 | ||||
1.00E+03 | 25.34 | 1000 |
1.00E+03 | 25.39 | 1000 | ||||
1.00E+02 | 30.59 | 100 | ||||
1.00E+02 | 30.9 | 100 | ||||
1.00E+01 | 32.51 | 10 | ||||
1.00E+01 | 39.12 | 10 | ||||
1.00E-00 | 39.07 | 1 | ||||
1.00E-00 | 36.71 | 1 | ||||
NTC | 39.63 | -1 | ||||
*肺26(正常标本)被忽略,因为对该标本进行的多重扩增失败 |
基因名称sbg1012732GLUT
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | -1.08 |
结肠肿瘤 | 1.69 |
结肠肿瘤 | 1.00 |
结肠肿瘤 | 1.31 |
肺肿瘤 | -1.76 |
肺肿瘤 | 1.29 |
肺肿瘤 | -1.28 |
肺肿瘤 | 1.18 |
乳腺肿瘤 | 2.49 |
乳腺肿瘤 | 2.23 |
乳腺肿瘤 | 2.45 |
乳腺肿瘤 | -1.02 |
大脑期5ALZ | -2.38 |
大脑期5ALZ | -1.04 |
大脑期5ALZ | -1.21 |
大脑期5ALZ | -1.01 |
肺24 | -8.67 |
肺28 | -6.82 |
肺23 | -6.94 |
哮喘肺 | -1.84 |
哮喘肺 | 1.66 |
哮喘肺 | 1.96 |
哮喘肺 | 2.83 |
内皮细胞VEGF | -1.73 |
内皮细胞bFGF | -1.60 |
心脏T-1 | 7.22 |
心脏T-14 | 6.67 |
心脏T-3399 | 9.41 |
BM stim | 1.33 |
Osteo undif | 2.91 |
软骨(库) | -2.57 |
PBL HIV IIIB | -1.17 |
MRC5 HSV株F | -15.40 |
基因名称sbg1012732GLUTb
与sbg1012732GLUT相同。
基因名称sbg1018172CSP
中度到低度的总体表达。在全脑,肾脏,甲状腺和子宫可见最高的正常表达。该基因在代表女性生殖系统的所有标本中表达。在许多正常/肿瘤肺标本中和哮喘肺标本中可见最高的疾病表达。在4份肺肿瘤标本的2份中下调,4份乳腺肿瘤标本的2份中上调提示其参与肺癌和乳腺癌。在所有3份COPD标本中下调提示该基因在慢性阻塞性肺病中潜在的作用。在4份哮喘肺标本的2份中上调提示其参与哮喘。在3份疾病心脏标本的1份中上调提示其参与心血管疾病,如阻塞性DCM。在OA的软骨库中下调和在免疫细胞(特别是T细胞和B细胞)中确定的低表达提示,该基因与骨关节炎和类风湿性关节炎有关。在HSV感染的MRC5细胞中的上调提示该基因可能是HSV中的宿主因子。
标本sbg1018172CSP | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 35.54,34.87 | 7.65 | 11.21 | 9.43 | 3.06 | 16.34 | 154.08 |
皮下脂肪Zenbio | 40,40 | 0.4 | 0 | 0.20 | 0.96 | 52.36 | 10.47 |
肾上腺Clontech | 40,40 | 0 | 0 | 0.00 | 0.61 | 81.97 | 0.00 |
全脑Clontech | 25.71,25.78 | 1950.98 | 1867.58 | 1909.28 | 7.24 | 6.91 | 13185.64 |
胎脑clontech | 40,40 | 0 | 0 | 0.00 | 0.48 | 103.95 | 0.00 |
小脑Clontech | 36.32,35.16 | 4.95 | 9.48 | 7.22 | 2.17 | 23.04 | 166.24 |
子宫颈 | 36.76,36.16 | 3.85 | 5.42 | 4.64 | 2.42 | 20.66 | 95.76 |
结肠 | 36.52,36.41 | 4.41 | 4.7 | 4.56 | 2.71 | 18.45 | 84.04 |
子宫内膜 | 36.4,35.92 | 4.73 | 6.19 | 5.46 | 0.73 | 68.21 | 372.44 |
食管 | 40,40 | 0 | 0 | 0.00 | 1.37 | 36.50 | 0.00 |
心脏Clontech | 40,40 | 0 | 0 | 0.00 | 1.32 | 37.88 | 0.00 |
下丘脑 | 40,40 | 0 | 0 | 0.00 | 0.32 | 155.28 | 0.00 |
回肠 | 40,40 | 0 | 0 | 0.00 | 2.58 | 19.38 | 0.00 |
空肠 | 36.53,33.22 | 4.38 | 28.28 | 16.33 | 6.60 | 7.58 | 123.71 |
肾脏 | 32.81,32.45 | 35.74 | 43.67 | 39.71 | 2.12 | 23.58 | 936.44 |
肝脏 | 35.92,36.2 | 6.19 | 5.29 | 5.74 | 1.50 | 33.33 | 191.33 |
胚胎肝Clontech | 31.57,30.46 | 71.69 | 134.34 | 103.02 | 10.40 | 4.81 | 495.26 |
肺 | 33.35,36.86 | 26.32 | 3.65 | 14.99 | 2.57 | 19.46 | 291.54 |
乳腺Clontech | 32.99,32.17 | 32.23 | 51.27 | 41.75 | 13.00 | 3.85 | 160.58 |
子宫肌层 | 34.99,40 | 10.44 | 0 | 5.22 | 2.34 | 21.37 | 111.54 |
网膜 | 35.61,40 | 7.37 | 0 | 3.69 | 3.94 | 12.69 | 46.76 |
卵巢 | 35.83,35.54 | 6.53 | 7.67 | 7.10 | 4.34 | 11.52 | 81.80 |
胰腺 | 35.86,40 | 6.39 | 0 | 3.20 | 0.81 | 61.80 | 197.47 |
胰头 | 40,40 | 0 | 0 | 0.00 | 1.57 | 31.85 | 0.00 |
腮腺 | 34.26,34.03 | 15.73 | 17.96 | 16.85 | 5.48 | 9.12 | 153.70 |
胎盘Clontech | 32.64,33.16 | 39.34 | 29.26 | 34.30 | 5.26 | 9.51 | 326.05 |
前列腺 | 35.71,40 | 6.95 | 0 | 3.48 | 3.00 | 16.67 | 57.92 |
直肠 | 33.84,34.42 | 19.99 | 14.41 | 17.20 | 1.23 | 40.65 | 699.19 |
唾液腺Clontech | 40,40 | 0 | 0 | 0.00 | 7.31 | 6.84 | 0.00 |
骨骼肌Clontech | 34.2,40 | 16.33 | 0 | 8.17 | 1.26 | 39.68 | 324.01 |
皮肤 | 35.02,40 | 10.31 | 0.48 | 5.40 | 1.21 | 41.32 | 222.93 |
小肠Clontech | 40,40 | 0 | 0 | 0.29 | 0.98 | 51.07 | 14.81 |
脾脏 | 40,35.31 | 0 | 8.71 | 4.36 | 4.92 | 10.16 | 44.26 |
胃 | 40,35.4 | 0 | 8.3 | 4.15 | 2.73 | 18.32 | 76.01 |
睾丸Clontech | 40,37.31 | 0 | 2.82 | 1.41 | 0.57 | 87.87 | 123.90 |
胸腺Clontech | 30.9,31.1 | 104.45 | 93.52 | 98.99 | 9.89 | 5.06 | 500.43 |
甲状腺 | 31.62,31.57 | 69.89 | 71.93 | 70.91 | 2.77 | 18.05 | 1279.96 |
气管Clontech | 34.19,34.08 | 16.41 | 17.49 | 16.95 | 9.71 | 5.15 | 87.28 |
膀胱 | 40,34.4 | 0 | 14.55 | 7.28 | 5.47 | 9.14 | 66.50 |
子宫 | 30.63,30.6 | 122.13 | 123.57 | 122.85 | 5.34 | 9.36 | 1150.28 |
基因组 | 26.58 | 1190.6 | |||||
b-肌动蛋白 | 27.38 | 758.43 | |||||
1.00E+05 | 19.07 | 100000 | |||||
1.00E+05 | 19.35 | 100000 | |||||
1.00E+04 | 22.57 | 10000 | |||||
1.00E+04 | 22.59 | 10000 | |||||
1.00E+03 | 26.24 | 1000 | |||||
1.00E+03 | 26.31 | 1000 | |||||
1.00E+02 | 30.18 | 100 | |||||
1.00E+02 | 31.64 | 100 | |||||
1.00E+01 | 35.9 | 10 | |||||
1.00E+01 | 40 | 0 |
1.00E-00 | 40 | 0 | |||||
1.00E-00 | 40 | 0 | |||||
NTC | 40 | 0 | |||||
NTC | 40 | 0 |
标本sbg1018172CSP | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 27.29 | 1064.89 | 2129.78 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 26.18 | 2023.11 | 4046.22 | 结肠肿瘤 | 1.90 |
正常结肠GW98-178 | 22080 | 30.45 | 168.68 | 337.36 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 29.33 | 324.49 | 648.98 | 结肠肿瘤 | 1.92 |
正常结肠GW98-561 | 23514 | 30.36 | 177.62 | 355.24 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 32.27 | 58.7 | 117.40 | 结肠肿瘤 | -3.03 |
正常结肠GW98-894 | 24691 | 30.71 | 145.57 | 291.14 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 32.3 | 57.43 | 114.86 | 结肠肿瘤 | -2.53 |
正常肺GW98-3 | 20742 | 24.82 | 4478.67 | 8957.34 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 33.61 | 26.86 | 53.72 | 肺肿瘤 | -166.74 |
正常肺GW97-179 | 20677 | 26.31 | 1874.25 | 3748.50 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 24.52 | 5311.72 | 10623.44 | 肺肿瘤 | 2.83 |
正常肺GW98-165 | 21922 | 24.99 | 4042.28 | 8084.56 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 27.19 | 1127.26 | 2254.52 | 肺肿瘤 | -3.59 |
正常肺GW98-282 | 22584 | 25.51 | 2990.53 | 5981.06 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 26.67 | 1522.51 | 3045.02 | 肺肿瘤 | -1.96 |
正常乳腺GW00-392 | 28750 | 32.25 | 59.17 | 59.17 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 30.48 | 165.82 | 331.64 | 乳腺肿瘤 | 5.60 |
正常乳腺GW00-413 | 28798 | 34.58 | 15.31 | 15.31 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 30.05 | 213.4 | 426.80 | 乳腺肿瘤 | 27.88 |
正常乳腺GW00-235:238 | 27592-95 | 34.41 | 16.85 | 16.85 | 正常乳腺 |
乳腺肿瘤GW00-231:234 | 27588-91 | 33.52 | 28.31 | 28.31 | 乳腺肿瘤 | 1.68 |
正常乳腺GW98-621 | 23656 | 28.22 | 618.19 | 1236.38 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 32.02 | 67.94 | 135.88 | 乳腺肿瘤 | -9.10 |
正常大脑BB99-542 | 25507 | 29.11 | 367.88 | 735.76 | 正常大脑 | |
正常大脑BB99-406 | 25509 | 28.05 | 682.39 | 1364.78 | 正常大脑 | |
正常大脑BB99-904 | 25546 | 29.06 | 379.07 | 758.14 | 正常大脑 | |
大脑期5ALZBB99-874 | 25502 | 30.06 | 211.81 | 423.62 | 大脑期5-ALZ | -2.25 |
大脑期5ALZBB99-887 | 25503 | 26.97 | 1280.13 | 2560.26 | 大脑期5-ALZ | 2.69 |
大脑期5ALZBB99-862 | 25504 | 29.85 | 239.03 | 478.06 | 大脑期5-ALZ | -1.99 |
大脑期5ALZBB99-927 | 25542 | 28.13 | 652.56 | 1305.12 | 大脑期5-ALZ | 1.37 |
CT肺KC | normal | 26.97 | 1280.81 | 2561.62 | CT肺 | |
肺26KC | normal | 32.21 | 60.75 | 肺26 | ||
肺27KC | normal | 34 | 21.39 | 21.39 | 肺27 | |
肺24KC | COPD | 32.11 | 64.11 | 64.11 | 肺24 | -13.87 |
肺28KC | COPD | 33.01 | 38.18 | 38.18 | 肺28 | -23.29 |
肺23KC | COPD | 32.84 | 42.15 | 42.15 | 肺23 | -21.10 |
肺25KC | normal | 31.63 | 84.78 | 84.78 | 肺25 | |
哮喘肺ODO3112 | 29321 | 29.4 | 310.75 | 310.75 | 哮喘肺 | -2.86 |
哮喘肺ODO3433 | 29323 | 27.02 | 1242.79 | 2485.58 | 哮喘肺 | 2.80 |
哮喘肺ODO3397 | 29322 | 25.97 | 2289.74 | 4579.48 | 哮喘肺 | 5.15 |
哮喘肺ODO4928 | 29325 | 26.84 | 1380.5 | 2761.00 | 哮喘肺 | 3.10 |
内皮细胞KC | control | 40 | 0 | 0.00 | 内皮细胞 | |
内皮细胞VEGF KC | 40 | 0 | 0.00 | 内皮细胞VEGF | 0.00 | |
内皮细胞bFGF KC | 40 | 1.01 | 1.01 | 内皮细胞bFGF | 1.01 | |
心脏Clontech | normal | 33.02 | 37.93 | 75.86 | 心脏 |
心脏(T-1)缺血 | 29417 | 34.34 | 17.51 | 35.02 | 心脏T-1 | -2.17 |
心脏(T-14)非阻塞性DCM | 29422 | 34.85 | 13.07 | 26.14 | 心脏T-14 | -2.90 |
心脏(T-3399)DCM | 29426 | 29.74 | 254.69 | 509.38 | 心脏T-3399 | 6.71 |
腺样增殖体GW99-269 | 26162 | 35.07 | 11.5 | 23.00 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 40 | 0 | 0.00 | 扁桃体 | |
T细胞PC00314 | 28453 | 36.12 | 6.22 | 12.44 | T细胞 | |
PBMNC | 40 | 0 | 0.00 | PBMNC | ||
单核细胞 | 40 | 0 | 0.00 | 单核细胞 | ||
B细胞PC00665 | 28455 | 40 | 0 | 0.00 | B细胞 | |
树突细胞28441 | 28441 | 40 | 0 | 0.00 | 树突细胞 | |
中性粒细胞 | 28440 | 35.43 | 9.3 | 9.30 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 40 | 1.32 | 2.64 | 嗜酸性粒细胞 | |
BM unstim | 40 | 0 | 0.00 | BM未刺激的 | ||
BM stim | treated | 40 | 0 | 0.00 | BM刺激的 | 0.00 |
osteo dif | treated | 40 | 0 | 0.00 | 成骨细胞分化 | 0.00 |
osteo undif | 40 | 0 | 0.00 | 成骨细胞未分化 | ||
软骨细胞 | 33.23 | 33.49 | 83.73 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 34.9 | 12.68 | 12.68 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 28.55 | 510.63 | 1021.26 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 34 | 21.41 | 42.82 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 40 | 0 | 0.00 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 36.2 | 5.96 | 11.92 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 36.38 | 5.34 | 10.68 | RA滑膜 | |
OA骨(biobank) | 29217 | 35.58 | 8.52 | 8.52 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 33.54 | 27.91 | 55.82 | OA骨 | |
OA骨标本2 | J.Emory | 34.92 | 12.54 | 25.08 | OA骨 | |
软骨(库) | Normal | 33.88 | 22.98 | 45.96 | 软骨(库) | |
软骨(库) | OA | 40 | 0 | 0.00 | 软骨(库) | -45.96 |
PBL未感染的 | 28441 | 30.74 | 142.65 | 285.30 | PBL未感染的 |
PBL HIV IIIB | 28442 | 32.47 | 52.13 | 104.26 | PBL HIV IIIB | -2.74 |
MRC5未感染的(100%) | 29158 | 40 | 0 | 0.00 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 30.06 | 211.88 | 423.76 | MRC5 HSV株F | 423.76 |
W12细胞 | 29179 | 39.65 | 0.8 | 1.60 | W12细胞 | |
角质细胞 | 29180 | 33.76 | 24.58 | 49.16 | 角质细胞 | |
B-肌动蛋白对照 | 27.17 | 1140.82 | ||||
基因组 | 26.81 | 1405.46 | ||||
1.00E+05 | 19.68 | 100000 | ||||
1.00E+05 | 19.63 | 100000 | ||||
1.00E+04 | 23.15 | 10000 | ||||
1.00E+04 | 23.27 | 10000 | ||||
1.00E+03 | 27.1 | 1000 | ||||
1.00E+03 | 27.33 | 1000 | ||||
1.00E+02 | 31.34 | 100 | ||||
1.00E+02 | 32.04 | 100 | ||||
1.00E+01 | 35.09 | 10 | ||||
1.00E+01 | 40 | 10 | ||||
1.00E-00 | 40 | 0 | ||||
1.00E-00 | 40 | 0 | ||||
NTC | 40 | 0 | ||||
*肺26(正常标本)被忽略,因为对该标本进行的多重扩增失败 |
基因名称sbg1018172CSP
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | 1.90 |
结肠肿瘤 | 1.92 |
结肠肿瘤 | -3.03 |
结肠肿瘤 | -2.53 |
肺肿瘤 | -166.74 |
肺肿瘤 | 2.83 |
肺肿瘤 | -3.59 |
肺肿瘤 | -1.96 |
乳腺肿瘤 | 5.60 |
乳腺肿瘤 | 27.88 |
乳腺肿瘤 | 1.68 |
乳腺肿瘤 | -9.10 |
大脑期5ALZ | -2.25 |
大脑期5ALZ | 2.69 |
大脑期5ALZ | -1.99 |
大脑期5ALZ | 1.37 |
肺24 | -13.87 |
肺28 | -23.29 |
肺23 | -21.10 |
哮喘肺 | -2.86 |
哮喘肺 | 2.80 |
哮喘肺 | 5.15 |
哮喘肺 | 3.10 |
内皮细胞VEGF | 0.00 |
内皮细胞bFGF | 1.01 |
心脏T-1 | -2.17 |
心脏T-14 | -2.90 |
心脏T-3399 | 6.71 |
BM stim | 0.00 |
Osteo undif | 0.00 |
软骨(库) | -45.96 |
PBL HIV IIIB | -2.74 |
MRC5 HSV株F | 423.76 |
基因名称sbg1004570ERGIC
中度到低度的总体表达。该基因在所有参与分析的正常标本中表达相当普遍,其中在全脑,下丘脑,胰腺和胰头有最高水平的表达。该表达模式提示该基因可能参与糖尿病和其它代谢性疾病。在结肠,乳腺和肺的正常/肿瘤对以及阿尔茨海默氏病脑标本,T细胞,B细胞,树突细胞和嗜酸性粒细胞中可见最高的疾病表达。在4份乳腺肿瘤标本的2份中上调提示该基因在乳腺癌中的作用。在4份阿尔茨海默氏病脑标本的2份中上调提示其参与阿尔茨海默氏病。在所有3份COPD标本中和所有4份哮喘肺标本中下调提示该基因在慢性阻塞性肺病和哮喘中潜在的作用。在受到刺激的骨髓中上调。
标本sbg1004570ERGIC | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 40,40 | 0 | 0 | 0.00 | 3.06 | 16.34 | 0.00 |
皮下脂肪Zenbio | 39.46,35.22 | 0.08 | 1.37 | 0.73 | 0.96 | 52.36 | 37.96 |
肾上腺Clontech | 36.91,36.21 | 0.43 | 0.7 | 0.57 | 0.61 | 81.97 | 46.31 |
全脑Clontech | 26.46,30.31 | 547.02 | 39.49 | 293.26 | 7.24 | 6.91 | 2025.24 |
胎脑clontech | 36.04,36.66 | 0.78 | 0.51 | 0.65 | 0.48 | 103.95 | 67.05 |
小脑Clontech | 35.46,34.63 | 1.16 | 2.06 | 1.61 | 2.17 | 23.04 | 37.10 |
子宫颈 | 35.63,36.28 | 1.04 | 0.67 | 0.86 | 2.42 | 20.66 | 17.67 |
结肠 | 35.38,34.57 | 1.23 | 2.13 | 1.68 | 2.71 | 18.45 | 31.00 |
子宫内膜 | 40,35.24 | 0.06 | 1.35 | 0.71 | 0.73 | 68.21 | 48.09 |
食管 | 35.02,36.31 | 1.57 | 0.65 | 1.11 | 1.37 | 36.50 | 40.51 |
心脏Clontech | 37.16,35.48 | 0.36 | 1.15 | 0.76 | 1.32 | 37.88 | 28.60 |
下丘脑 | 35.15,36.01 | 1.44 | 0.8 | 1.12 | 0.32 | 155.28 | 173.91 |
回肠 | 35.04,35.5 | 1.55 | 1.13 | 1.34 | 2.58 | 19.38 | 25.97 |
空肠 | 35.14,34.88 | 1.45 | 1.73 | 1.59 | 6.60 | 7.58 | 12.05 |
肾脏 | 35.81,37.16 | 0.91 | 0.36 | 0.64 | 2.12 | 23.58 | 14.98 |
肝脏 | 36.19,34.39 | 0.71 | 2.42 | 1.57 | 1.50 | 33.33 | 52.17 |
胚胎肝Clontech | 32.94,33.1 | 6.51 | 5.85 | 6.18 | 10.40 | 4.81 | 29.71 |
肺 | 34.54,35.16 | 2.18 | 1.43 | 1.81 | 2.57 | 19.46 | 35.12 |
乳腺Clontech | 34.45,34.76 | 2.33 | 1.88 | 2.11 | 13.00 | 3.85 | 8.10 |
子宫肌层 | 34.08,34.61 | 2.98 | 2.09 | 2.54 | 2.34 | 21.37 | 54.17 |
网膜 | 35.22,36.18 | 1.37 | 0.71 | 1.04 | 3.94 | 12.69 | 13.20 |
卵巢 | 34.52,34.83 | 2.21 | 1.78 | 2.00 | 4.34 | 11.52 | 22.98 |
胰腺 | 34.45,33.99 | 2.32 | 3.18 | 2.75 | 0.81 | 61.80 | 169.96 |
胰头 | 33.24,33.63 | 5.32 | 4.06 | 4.69 | 1.57 | 31.85 | 149.36 |
腮腺 | 33.22,33.08 | 5.38 | 5.9 | 5.64 | 5.48 | 9.12 | 51.46 |
胎盘Clontech | 36.02,35.39 | 0.79 | 1.22 | 1.01 | 5.26 | 9.51 | 9.55 |
前列腺 | 35.98,35.07 | 0.81 | 1.51 | 1.16 | 3.00 | 16.67 | 19.33 |
直肠 | 36.71,37.13 | 0.49 | 0.37 | 0.43 | 1.23 | 40.65 | 17.48 |
唾液腺Clontech | 33.51,34.22 | 4.41 | 2.71 | 3.56 | 7.31 | 6.84 | 24.35 |
骨骼肌Clontech | 35.53,34.52 | 1.11 | 2.21 | 1.66 | 1.26 | 39.68 | 65.87 |
皮肤 | 36.02,36.07 | 0.79 | 0.77 | 0.78 | 1.21 | 41.32 | 32.23 |
小肠Clontech | 35.02,37.21 | 1.57 | 0.35 | 0.96 | 0.98 | 51.07 | 49.03 |
脾脏 | 35.64,35.27 | 1.03 | 1.33 | 1.18 | 4.92 | 10.16 | 11.99 |
胃 | 35.08,35.41 | 1.51 | 1.2 | 1.36 | 2.73 | 18.32 | 24.82 |
睾丸Clontech | 35.48,38.1 | 1.15 | 0.19 | 0.67 | 0.57 | 87.87 | 58.88 |
胸腺Clontech | 32.15,31.72 | 11.16 | 14.98 | 13.07 | 9.89 | 5.06 | 66.08 |
甲状腺 | 35.61,35.09 | 1.05 | 1.49 | 1.27 | 2.77 | 18.05 | 22.92 |
气管Clontech | 35.04,34.75 | 1.55 | 1.89 | 1.72 | 9.71 | 5.15 | 8.86 |
膀胱 | 36.11,36.24 | 0.74 | 0.68 | 0.71 | 5.47 | 9.14 | 6.49 |
子宫 | 35.59,35.68 | 1.06 | 1 | 1.03 | 5.34 | 9.36 | 9.64 |
基因组 | 24.29 | 2416.83 | |||||
b-肌动蛋白 | 26.09 | 706.6 | |||||
1.00E+05 | 20.09 | 100000 | |||||
1.00E+05 | 19.53 | 100000 |
1.00E+04 | 21.72 | 10000 | |||||
1.00E+04 | 21.68 | 10000 | |||||
1.00E+03 | 24.13 | 1000 | |||||
1.00E+03 | 24.18 | 1000 | |||||
1.00E+02 | 29.13 | 100 | |||||
1.00E+02 | 30.16 | 100 | |||||
1.00E+01 | 31.7 | 10 | |||||
1.00E+01 | 33.16 | 10 | |||||
1.00E-00 | 36.93 | 1 | |||||
1.00E-00 | 34.75 | 1 | |||||
NTC | 36 | -1 | |||||
NTC | 35.85 | -1 |
标本sbg1004570ERGIC | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 30.51 | 38.25 | 76.50 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 31.28 | 23.13 | 46.26 | 结肠肿瘤 | -1.65 |
正常结肠GW98-178 | 22080 | 31.79 | 16.57 | 33.14 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 31.3 | 22.86 | 45.72 | 结肠肿瘤 | 1.38 |
正常结肠GW98-561 | 23514 | 30.71 | 33.5 | 67.00 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 31.18 | 24.73 | 49.46 | 结肠肿瘤 | -1.35 |
正常结肠GW98-894 | 24691 | 30.16 | 48.2 | 96.40 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 29.96 | 55 | 110.00 | 结肠肿瘤 | 1.14 |
正常肺GW98-3 | 20742 | 30.1 | 50.19 | 100.38 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 32.86 | 8.15 | 16.30 | 肺肿瘤 | -6.16 |
正常肺GW97-179 | 20677 | 31.65 | 18.14 | 36.28 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 31.05 | 26.89 | 53.78 | 肺肿瘤 | 1.48 |
正常肺GW98-165 | 21922 | 30.44 | 40.16 | 80.32 | 正常肺 |
肺肿瘤GW98-164 | 21921 | 30.72 | 33.36 | 66.72 | 肺肿瘤 | -1.20 |
正常肺GW98-282 | 22584 | 31.83 | 16.13 | 32.26 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 32.09 | 13.61 | 27.22 | 肺肿瘤 | -1.19 |
正常乳腺GW00-392 | 28750 | 32.76 | 8.73 | 8.73 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 30.68 | 34.38 | 68.76 | 乳腺肿瘤 | 7.88 |
正常乳腺GW00-413 | 28798 | 37.11 | 0.5 | 0.50 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 30.8 | 31.72 | 63.44 | 乳腺肿瘤 | 126.88 |
正常乳腺GW00-235:238 | 27592-95 | 38.8 | 0.17 | 0.17 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 37.36 | 0.43 | 0.43 | 乳腺肿瘤 | 2.53 |
正常乳腺GW98-621 | 23656 | 31.67 | 17.86 | 35.72 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 32.59 | 9.8 | 19.60 | 乳腺肿瘤 | -1.82 |
正常大脑BB99-542 | 25507 | 33.66 | 4.83 | 9.66 | 正常大脑 | |
正常大脑BB99-406 | 25509 | 33.24 | 6.37 | 12.74 | 正常大脑 | |
正常大脑BB99-904 | 25546 | 33.2 | 6.54 | 13.08 | 正常大脑 | |
大脑期5ALZBB99-874 | 25502 | 33.1 | 6.97 | 13.94 | 大脑期5-ALZ | 1.18 |
大脑期5ALZBB99-887 | 25503 | 30.93 | 29.17 | 58.34 | 大脑期5-ALZ | 4.93 |
大脑期5ALZBB99-862 | 25504 | 31.44 | 20.73 | 41.46 | 大脑期5-ALZ | 3.51 |
大脑期5ALZBB99-927 | 25542 | 32.93 | 7.83 | 15.66 | 大脑期5-ALZ | 1.32 |
CT肺KC | normal | 32.62 | 9.6 | 19.20 | CT肺 | |
肺26KC | normal | 肺26 | ||||
肺27KC | normal | 40 | 0 | 0.00 | 肺27 | |
肺24KC | COPD | 39.15 | 0.13 | 0.13 | 肺24 | -49.46 |
肺28KC | COPD | 40 | 0.08 | 0.08 | 肺28 | -80.38 |
肺23KC | COPD | 38.59 | 0.19 | 0.19 | 肺23 | -33.84 |
肺25KC | normal | 40 | 0.09 | 0.09 | 肺25 | |
哮喘肺ODO3112 | 29321 | 40 | 0 | 0.00 | 哮喘肺 | -6.43 |
哮喘肺ODO3433 | 29323 | 38.47 | 0.2 | 0.40 | 哮喘肺 | -16.08 |
哮喘肺ODO3397 | 29322 | 38.01 | 0.28 | 0.56 | 哮喘肺 | -11.48 |
哮喘肺ODO4928 | 29325 | 38.13 | 0.26 | 0.52 | 哮喘肺 | -12.37 |
内皮细胞KC | control | 36.24 | 0.89 | 0.89 | 内皮细胞 | |
内皮细胞VEGFKC | 39.8 | 0.09 | 0.09 | 内皮细胞VEGF | -9.89 | |
内皮细胞bFGF KC | 37.19 | 0.47 | 0.47 | 内皮细胞bFGF | -1.89 | |
心脏Clontech | normal | 35.52 | 1.43 | 2.86 | 心脏 | |
心脏(T-1)缺血 | 29417 | 33.79 | 4.43 | 8.86 | 心脏T-1 | 3.10 |
心脏(T-14)非阻塞性DCM | 29422 | 34.81 | 2.27 | 4.54 | 心脏T-14 | 1.59 |
心脏(T-3399)DCM | 29426 | 34.11 | 3.59 | 7.18 | 心脏T-3399 | 2.51 |
腺样增殖体GW99-269 | 26162 | 34.97 | 2.05 | 4.10 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 33.05 | 7.23 | 14.46 | 扁桃体 | |
T细胞PC00314 | 28453 | 31.09 | 26.2 | 52.40 | T细胞 | |
PBMNC | 38.01 | 0.28 | 0.28 | PBMNC | ||
单核细胞 | 36.29 | 0.86 | 1.72 | 单核细胞 | ||
B细胞PC00665 | 28455 | 32.13 | 13.23 | 26.46 | B细胞 | |
树突细胞28441 | 28441 | 31.94 | 14.96 | 29.92 | 树突细胞 | |
中性粒细胞 | 28440 | 34.08 | 3.66 | 3.66 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 32.23 | 12.37 | 24.74 | 嗜酸性粒细胞 | |
BM unstim | 39.73 | 0.09 | 0.09 | BM未刺激的 | ||
BM stim | treated | 37.03 | 0.53 | 0.53 | BM刺激的 | 5.89 |
osteo dif | treated | 36.8 | 0.61 | 0.61 | 成骨细胞分化 | 0.61 |
osteo undif | 40 | 0 | 0.00 | 成骨细胞未分化 | ||
软骨细胞 | 31.85 | 15.9 | 39.75 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 38.61 | 0.19 | 0.19 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 33.11 | 6.96 | 13.92 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 33.81 | 4.39 | 8.78 | OA滑膜 |
RA滑膜NP03/01 | 28466 | 33.11 | 6.96 | 13.92 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 32.03 | 14.14 | 28.28 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 32.47 | 10.55 | 21.10 | RA滑膜 | |
OA骨(biobank) | 29217 | 35.25 | 1.7 | 1.70 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 34.54 | 2.72 | 5.44 | OA骨 | |
OA骨标本2 | J.Emory | 36.28 | 0.87 | 1.74 | OA骨 | |
软骨(库) | Normal | 35.24 | 1.71 | 3.42 | 软骨(库) | |
软骨(库) | OA | 34.45 | 2.87 | 5.74 | 软骨(库) | 1.68 |
PBL未感染的 | 28441 | 32.53 | 10.19 | 20.38 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 31.77 | 16.79 | 33.58 | PBL HIV IIIB | 1.65 |
MRC5未感染的(100%) | 29158 | 33.12 | 6.87 | 13.74 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 33.76 | 4.54 | 9.08 | MRC5 HSV株F | -1.51 |
W12细胞 | 29179 | 33.1 | 6.96 | 13.92 | W12细胞 | |
角质细胞 | 29180 | 32.67 | 9.29 | 18.58 | 角质细胞 | |
B-肌动蛋白对照 | 26.03 | 726.55 | ||||
基因组 | 24.63 | 1825.58 | ||||
1.00E+05 | 19.96 | 100000 | ||||
1.00E+05 | 19.27 | 100000 | ||||
1.00E+04 | 21.83 | 10000 | ||||
1.00E+04 | 21.45 | 10000 | ||||
1.00E+03 | 23.86 | 1000 | ||||
1.00E+03 | 23.84 | 1000 | ||||
1.00E+02 | 28.42 | 100 | ||||
1.00E+02 | 29.35 | 100 | ||||
1.00E+01 | 33.3 | 10 | ||||
1.00E+01 | 35.09 | 10 | ||||
1.00E-00 | 35.16 | 1 | ||||
1.00E-00 | 36.05 | 1 | ||||
NTC | 38.24 | -1 |
*肺26(正常标本)被忽略,因为对该标本进行的多重扩增失败 |
基因名称sbg1004570ERGIC
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | -1.65 |
结肠肿瘤 | 1.38 |
结肠肿瘤 | -1.35 |
结肠肿瘤 | 1.14 |
肺肿瘤 | -6.16 |
肺肿瘤 | 1.48 |
肺肿瘤 | -1.20 |
肺肿瘤 | -1.19 |
乳腺肿瘤 | 7.88 |
乳腺肿瘤 | 126.88 |
乳腺肿瘤 | 2.53 |
乳腺肿瘤 | -1.82 |
大脑期5ALZ | 1.18 |
大脑期5ALZ | 4.93 |
大脑期5ALZ | 3.51 |
大脑期5ALZ | 1.32 |
肺24 | -49.46 |
肺28 | -80.38 |
肺23 | -33.84 |
哮喘肺 | -6.43 |
哮喘肺 | -16.08 |
哮喘肺 | -11.48 |
哮喘肺 | -12.37 |
内皮细胞VEGF | -9.89 |
内皮细胞bFGF | -1.89 |
心脏T-1 | 3.10 |
心脏T-14 | 1.59 |
心脏T-3399 | 2.51 |
BM stim | 5.89 |
Osteo undif | 0.61 |
软骨(库) | 1.68 |
PBL HIV IIIB | 1.65 |
MRC5 HSV株F | -1.51 |
基因名称sbg1016995IGBrecpt
中度到低度的总体表达。在全脑,肺中可见最高的正常表达,在子宫内膜,回肠,直肠和皮肤有略低水平的表达。在皮肤中的高水平表达可能提示该基因在牛皮癣和狼疮中可能的作用。在疾病板上的标本中的表达模式提示该基因对腺样增殖体和扁桃体的极高特异性。在4份肺肿瘤标本的2份中下调和在4份乳腺肿瘤标本的2份中上调提示其参与肺癌和乳腺癌。在所有3份COPD标本中下调提示该基因在慢性阻塞性肺病中的潜在作用。在受到刺激的骨髓中上调。在分化的成骨细胞中下调。在HIV感染的PBL细胞中上调提示该基因可能是HIV中的宿主因子。
标本sbg1016995IGBrecpt | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 40,40 | 0.61 | 0.61 | 0.61 | 3.06 | 16.34 | 9.97 |
皮下脂肪Zenbio | 40,40 | 0.59 | 0.56 | 0.58 | 0.96 | 52.36 | 30.10 |
肾上腺Clontech | 39.89,39.79 | 0.54 | 0.57 | 0.56 | 0.61 | 81.97 | 45.49 |
全脑Clontech | 30.69,30.76 | 108.67 | 104.35 | 106.51 | 7.24 | 6.91 | 735.57 |
胎脑clontech | 39.41,40 | 0.71 | 0.62 | 0.67 | 0.48 | 103.95 | 69.13 |
小脑Clontech | 39.33,37.82 | 0.74 | 1.78 | 1.26 | 2.17 | 23.04 | 29.03 |
子宫颈 | 36.12,36.58 | 4.73 | 3.62 | 4.18 | 2.42 | 20.66 | 86.26 |
结肠 | 35.23,38.35 | 7.9 | 1.31 | 4.61 | 2.71 | 18.45 | 84.96 |
子宫内膜 | 35.51,40 | 6.73 | 0 | 3.37 | 0.73 | 68.21 | 229.54 |
食管 | 37.22,38.18 | 2.5 | 1.45 | 1.98 | 1.37 | 36.50 | 72.08 |
心脏Clontech | 40,40 | 0 | 0 | 0.00 | 1.32 | 37.88 | 0.00 |
下丘脑 | 40,40 | 0 | 0 | 0.00 | 0.32 | 155.28 | 0.00 |
回肠 | 34.65,34.11 | 11.04 | 15.09 | 13.07 | 2.58 | 19.38 | 253.20 |
空肠 | 34.84,34.04 | 9.91 | 15.72 | 12.82 | 6.60 | 7.58 | 97.08 |
肾脏 | 38.2,39.11 | 1.43 | 0.84 | 1.14 | 2.12 | 23.58 | 26.77 |
肝脏 | 34.47,38.59 | 12.26 | 1.14 | 6.70 | 1.50 | 33.33 | 223.33 |
胚胎肝Clontech | 33.51,33.07 | 21.26 | 27.43 | 24.35 | 10.40 | 4.81 | 117.04 |
肺 | 27.32,37.11 | 755.31 | 2.68 | 379.00 | 2.57 | 19.46 | 7373.44 |
乳腺Clontech | 36.31,36.4 | 4.24 | 4.03 | 4.14 | 13.00 | 3.85 | 15.90 |
子宫肌层 | 40,38.7 | 0.7 | 1.07 | 0.89 | 2.34 | 21.37 | 18.91 |
网膜 | 35.44,36.14 | 6.98 | 4.68 | 5.83 | 3.94 | 12.69 | 73.98 |
卵巢 | 38.76,35.49 | 1.03 | 6.82 | 3.93 | 4.34 | 11.52 | 45.22 |
胰腺 | 40,38.56 | 0.48 | 1.16 | 0.82 | 0.81 | 61.80 | 50.68 |
胰头 | 40,40 | 0 | 0 | 0.00 | 1.57 | 31.85 | 0.00 |
腮腺 | 36.8,35.45 | 3.2 | 6.98 | 5.09 | 5.48 | 9.12 | 46.44 |
胎盘Clontech | 35.63,35.11 | 6.27 | 8.47 | 7.37 | 5.26 | 9.51 | 70.06 |
前列腺 | 37.4,37.5 | 2.26 | 2.14 | 2.20 | 3.00 | 16.67 | 36.67 |
直肠 | 35.45,35.25 | 6.94 | 7.81 | 7.38 | 1.23 | 40.65 | 299.80 |
唾液腺Clontech | 37.3,37.06 | 2.4 | 2.75 | 2.58 | 7.31 | 6.84 | 17.61 |
骨骼肌Clontech | 40,39.34 | 0 | 0.74 | 0.37 | 1.26 | 39.68 | 14.68 |
皮肤 | 38.84,34.56 | 0.98 | 11.63 | 6.31 | 1.21 | 41.32 | 260.54 |
小肠Clontech | 40,40 | 0 | 0.63 | 0.32 | 0.98 | 51.07 | 16.09 |
脾脏 | 34.37,34.89 | 13 | 9.6 | 11.30 | 4.92 | 10.16 | 114.84 |
胃 | 39.73,35.52 | 0.59 | 6.67 | 3.63 | 2.73 | 18.32 | 66.48 |
睾丸Clontech | 38.91,40 | 0.94 | 0 | 0.47 | 0.57 | 87.87 | 41.30 |
胸腺Clontech | 31.96,32.96 | 52.16 | 29.2 | 40.68 | 9.89 | 5.06 | 205.66 |
甲状腺 | 35.53,40 | 6.66 | 0 | 3.33 | 2.77 | 18.05 | 60.11 |
气管Clontech | 37.99,37.69 | 1.61 | 1.91 | 1.76 | 9.71 | 5.15 | 9.06 |
膀胱 | 39.69,39.02 | 0.6 | 0.89 | 0.75 | 5.47 | 9.14 | 6.81 |
子宫 | 34.41,33.56 | 12.67 | 20.75 | 16.71 | 5.34 | 9.36 | 156.46 |
基因组 | 26.31 | 1359.1 | |||||
b-a肌动蛋白 | 27.2 | 812.88 | |||||
1.00E+05 | 19.24 | 100000 | |||||
1.00E+05 | 19.38 | 100000 | |||||
1.00E+04 | 22.67 | 10000 | |||||
1.00E+04 | 22.67 | 10000 | |||||
1.00E+03 | 26.31 | 1000 | |||||
1.00E+03 | 26.28 | 1000 | |||||
1.00E+02 | 30.17 | 100 | |||||
1.00E+02 | 31.02 | 100 | |||||
1.00E+01 | 36.17 | 10 | |||||
1.00E+01 | 34.46 | 10 | |||||
1.00E-00 | 40 | 0 | |||||
1.00E-00 | 40 | 1 | |||||
NTC | 40 | -1 | |||||
NTC | 40 | -1 |
标本sbg1016995IGBrecpt | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 29.45 | 174.86 | 349.72 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 32.1 | 33.44 | 66.88 | 结肠肿瘤 | -5.23 |
正常结肠GW98-178 | 22080 | 31.77 | 41.07 | 82.14 | 正常结肠 |
结肠肿瘤GW98-177 | 22060 | 32.66 | 23.5 | 47.00 | 结肠肿瘤 | -1.75 |
正常结肠GW98-561 | 23514 | 29.15 | 211.24 | 422.48 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 31.25 | 56.95 | 113.90 | 结肠肿瘤 | -3.71 |
正常结肠GW98-894 | 24691 | 30.68 | 81.3 | 162.60 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 31.33 | 54.12 | 108.24 | 结肠肿瘤 | -1.50 |
正常肺GW98-3 | 20742 | 31.86 | 38.92 | 77.84 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 34.55 | 7.25 | 14.50 | 肺肿瘤 | -5.37 |
正常肺GW97-179 | 20677 | 28.38 | 342.07 | 684.14 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 32.1 | 33.52 | 67.04 | 肺肿瘤 | -10.20 |
正常肺GW98-165 | 21922 | 32.2 | 31.46 | 62.92 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 30.5 | 90.8 | 181.60 | 肺肿瘤 | 2.89 |
正常肺GW98-282 | 22584 | 29.82 | 138.8 | 277.60 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 32.72 | 22.64 | 45.28 | 肺肿瘤 | -6.13 |
正常乳腺GW00-392 | 28750 | 31.5 | 48.65 | 48.65 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 31.9 | 37.84 | 75.68 | 乳腺肿瘤 | 1.56 |
正常乳腺GW00-413 | 28798 | 34.37 | 8.07 | 8.07 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 29.97 | 126.73 | 253.46 | 乳腺肿瘤 | 31.41 |
正常乳腺GW00-235:238 | 27592-95 | 35.08 | 5.2 | 5.20 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 32.3 | 29.54 | 29.54 | 乳腺肿瘤 | 5.68 |
正常乳腺GW98-621 | 23656 | 31.11 | 61.96 | 123.92 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 31.27 | 56.22 | 112.44 | 乳腺肿瘤 | -1.10 |
正常大脑BB99-542 | 25507 | 33.3 | 15.82 | 31.64 | 正常大脑 | |
正常大脑BB99-406 | 25509 | 33.02 | 18.83 | 37.66 | 正常大脑 | |
正常大脑BB99-904 | 25546 | 33.93 | 10.62 | 21.24 | 正常大脑 | |
大脑期5ALZ BB99-874 | 25502 | 32.36 | 28.38 | 56.76 | 大脑期5-ALZ | 1.88 |
大脑期5ALZ BB99-887 | 25503 | 31.79 | 40.66 | 81.32 | 大脑期5-ALZ | 2.69 |
大脑期5ALZ BB99-862 | 25504 | 32.04 | 34.76 | 69.52 | 大脑期5-ALZ | 2.30 |
大脑期5ALZ BB99-927 | 25542 | 31.79 | 40.51 | 81.02 | 大脑期5-ALZ | 2.68 |
CT肺KC | normal | 33.32 | 15.63 | 31.26 | CT肺 | |
肺26KC | normal | 29.8 | 140.4 | 肺26 |
肺27KC | normal | 38.71 | 0.54 | 0.54 | 肺27 | |
肺24KC | COPD | 39.31 | 0.37 | 0.37 | 肺24 | -29.00 |
肺28KC | COPD | 37.09 | 1.48 | 1.48 | 肺28 | -7.25 |
肺23KC | COPD | 38.02 | 0.83 | 0.83 | 肺23 | -12.93 |
肺25KC | normal | 39.22 | 0.39 | 0.39 | 肺25 | |
哮喘肺ODO3112 | 29321 | 37.96 | 0.86 | 0.86 | 哮喘肺 | -12.48 |
哮喘肺ODO3433 | 29323 | 31.15 | 60.54 | 121.08 | 哮喘肺 | 11.28 |
哮喘肺ODO3397 | 29322 | 33.74 | 12.01 | 24.02 | 哮喘肺 | 2.24 |
哮喘肺ODO4928 | 29325 | 31.59 | 46.09 | 92.18 | 哮喘肺 | 8.59 |
内皮细胞KC | control | 36.98 | 1.58 | 1.58 | 内皮细胞 | |
内皮细胞VEGF KC | 39.28 | 0.38 | 0.38 | 内皮细胞VEGF | -4.16 | |
内皮细胞bFGF KC | 37.3 | 1.3 | 1.30 | 内皮细胞bFGF | -1.22 | |
心脏Clontech | normal | 35.73 | 3.45 | 6.90 | 心脏 | |
心脏(T-1)缺血 | 29417 | 34.7 | 6.58 | 13.16 | 心脏T-1 | 1.91 |
心脏(T-14)非阻塞性DCM | 29422 | 37.5 | 1.15 | 2.30 | 心脏T-14 | -3.00 |
心脏(T-3399)DCM | 29426 | 35.15 | 4.96 | 9.92 | 心脏T-3399 | 1.44 |
腺样增殖体GW99-269 | 26162 | 25.98 | 1528.07 | 3056.14 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 24.6 | 3626.43 | 7252.86 | 扁桃体 | |
T细胞PC00314 | 28453 | 34.49 | 7.5 | 15.00 | T细胞 | |
PBMNC | 37.58 | 1.09 | 1.09 | PBMNC | ||
单核细胞 | 37.4 | 1.22 | 2.44 | 单核细胞 | ||
B细胞PC00665 | 28455 | 31.68 | 43.59 | 87.18 | B细胞 | |
树突细胞28441 | 28441 | 35.05 | 5.28 | 10.56 | 树突细胞 | |
中性粒细胞 | 28440 | 35.68 | 3.57 | 3.57 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 35.07 | 5.23 | 10.46 | 嗜酸性粒细胞 | |
BM unstim | 38.19 | 0.75 | 0.75 | BM未刺激的 | ||
BM stim | treated | 34.27 | 8.61 | 8.61 | BM刺激的 | 11.48 |
osteo dif | treated | 40 | 0.09 | 0.09 | 成骨细胞分化 | -5.78 |
osteo undif | 40 | 0.52 | 0.52 | 成骨细胞未分化 |
软骨细胞 | 32.86 | 20.79 | 51.98 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 31.85 | 38.99 | 38.99 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 34.76 | 6.33 | 12.66 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 31.39 | 51.96 | 103.92 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 31.1 | 62.3 | 124.60 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 31.95 | 36.76 | 73.52 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 32.43 | 27.14 | 54.28 | RA滑膜 | |
OA骨(biobank) | 29217 | 35.84 | 3.22 | 3.22 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 35.43 | 4.18 | 8.36 | OA骨 | |
OA骨标本2 | J.Emory | 34.86 | 5.95 | 11.90 | OA骨 | |
软骨(库) | Normal | 34.79 | 6.21 | 12.42 | 软骨(库) | |
软骨(库) | OA | 36.55 | 2.07 | 4.14 | 软骨(库) | -3.00 |
PBL未感染的 | 28441 | 30.02 | 122.76 | 245.52 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 28.17 | 388.59 | 777.18 | PBL HIV IIIB | 3.17 |
MRC5未感染的(100%) | 29158 | 34.6 | 7.01 | 14.02 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 33.27 | 16.13 | 32.26 | MRC5 HSV株F | 2.30 |
W12细胞 | 29179 | 34.43 | 7.8 | 15.60 | W12细胞 | |
角质细胞 | 29180 | 35.04 | 5.31 | 10.62 | 角质细胞 | |
B-肌动蛋白对照 | 27 | 808.77 | ||||
基因组 | 26.18 | 1353.11 | ||||
1.00E+05 | 19.37 | 100000 | ||||
1.00E+05 | 19.59 | 100000 | ||||
1.00E+04 | 22.75 | 10000 | ||||
1.00E+04 | 22.8 | 10000 | ||||
1.00E+03 | 26.43 | 1000 | ||||
1.00E+03 | 26.17 | 1000 | ||||
1.00E+02 | 30.09 | 100 | ||||
1.00E+02 | 30.21 | 100 | ||||
1.00E+01 | 35.27 | 10 |
1.00E+01 | 35.55 | 10 | ||||
1.00E-00 | 39.31 | 1 | ||||
1.00E-00 | 34.53 | 1 | ||||
NTC | 40 | -1 | ||||
*肺26(正常标本)被忽略,因为对该标本进行的多重扩增失败 |
基因名称sbg1016995IGBrecpt
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | -5.23 |
结肠肿瘤 | -1.75 |
结肠肿瘤 | -3.71 |
结肠肿瘤 | -1.50 |
肺肿瘤 | -5.37 |
肺肿瘤 | -10.20 |
肺肿瘤 | 2.89 |
肺肿瘤 | -6.13 |
乳腺肿瘤 | 1.56 |
乳腺肿瘤 | 31.41 |
乳腺肿瘤 | 5.68 |
乳腺肿瘤 | -1.10 |
大脑期5ALZ | 1.88 |
大脑期5ALZ | 2.69 |
大脑期5ALZ | 2.30 |
大脑期5ALZ | 2.68 |
肺24 | -29.00 |
肺28 | -7.25 |
肺23 | -12.93 |
哮喘肺 | -12.48 |
哮喘肺 | 11.28 |
哮喘肺 | 2.24 |
哮喘肺 | 8.59 |
endo VEGF | -4.16 |
endo bFGF | -1.22 |
心脏T-1 | 1.91 |
心脏T-14 | -3.00 |
心脏T-3399 | 1.44 |
BM stim | 11.48 |
Osteo undif | -5.78 |
软骨(库) | -3.00 |
PBL HIV IIIB | 3.17 |
MRC5 HSV株F | 2.30 |
基因名称sbg1151bSREC
在正常和疾病标本中有最高的总体表达。其表达相当普遍,但在脂肪细胞,脂肪,全脑,胎脑和子宫内膜中最高的正常表达。在一份结肠肿瘤标本中,一份正常肺标本中,软骨细胞中和未感染的MRC5细胞中有最高的疾病表达。在阿尔茨海默氏病患者的脑中没有明显的变化。在4份肺肿瘤的1份中下调提示其可能参与肺癌。在4份乳腺肿瘤标本的1份中上调可足以断定其在乳腺癌中的作用。在4份哮喘肺的1份中上调提示其在哮喘中的作用。在HSV中下调提示其作为潜在的宿主因子与单纯疱疹病毒有关。在免疫细胞中高表达。在来自OA患者的软骨和骨标本中高表达以及在软骨细胞中的高表达提示其可能参与骨关节炎和类风湿性关节炎。另外,在免疫细胞中(尤其是B细胞和T细胞中)确定的表达为其在RA/OA中的作用提供了附加的证据。
标本sbg1151bSREC | Ct(标本1和标本2) | GOI拷贝数的 | GOI拷贝数的 | 平 均GOI拷 | 18SrRNA | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数 |
均值(标本1) | 均值(标本2) | 贝数 | (ng) | /50ng总RNA | |||
皮下脂肪细胞Zenbio | 28.31,28.35 | 477.04 | 466.02 | 471.53 | 3.06 | 16.34 | 7704.74 |
皮下脂肪Zenbio | 30.79,30.22 | 122.3 | 166.95 | 144.63 | 0.96 | 52.36 | 7571.99 |
肾上腺Clontech | 33.96,33.47 | 21.39 | 27.97 | 24.68 | 0.61 | 81.97 | 2022.95 |
全脑Clontech | 24.07,23.98 | 4889.28 | 5123.8 | 5006.54 | 7.24 | 6.91 | 34575.55 |
胎脑clontech | 31.1,32.29 | 103.16 | 53.55 | 78.36 | 0.48 | 103.95 | 8145.01 |
小脑Clontech | 31.03,31.99 | 107.02 | 63.18 | 85.10 | 2.17 | 23.04 | 1960.83 |
子宫颈 | 31.22,30.06 | 96.6 | 182.64 | 139.62 | 2.42 | 20.66 | 2884.71 |
结肠 | 30.68,30.53 | 129.52 | 140.99 | 135.26 | 2.71 | 18.45 | 2495.48 |
子宫内膜 | 30.59,30.44 | 136.06 | 147.8 | 141.93 | 0.73 | 68.21 | 9681.45 |
食管 | 33.11,32.17 | 34.08 | 57.32 | 45.70 | 1.37 | 36.50 | 1667.88 |
心脏Clontech | 33.19,32.41 | 32.68 | 50.11 | 41.40 | 1.32 | 37.88 | 1567.99 |
下丘脑 | 34.34,40 | 17.4 | 0 | 8.70 | 0.32 | 155.28 | 1350.93 |
回肠 | 31.29,30.13 | 92.84 | 174.99 | 133.92 | 2.58 | 19.38 | 2595.25 |
空肠 | 29.7,29.48 | 221.9 | 251.05 | 236.48 | 6.60 | 7.58 | 1791.48 |
肾脏 | 31.03,30.17 | 107.15 | 171.45 | 139.30 | 2.12 | 23.58 | 3285.38 |
肝脏 | 32.89,33.16 | 38.61 | 33.17 | 35.89 | 1.50 | 33.33 | 1196.33 |
胚胎肝Clontech | 28.05,28.15 | 550.64 | 518.95 | 534.80 | 10.40 | 4.81 | 2571.13 |
肺 | 29.39,28.63 | 263.85 | 398.99 | 331.42 | 2.57 | 19.46 | 6447.86 |
乳腺Clontech | 27.56,27.39 | 717.67 | 789.94 | 753.81 | 13.00 | 3.85 | 2899.25 |
子宫肌层 | 29.08,28.93 | 312.86 | 339.46 | 326.16 | 2.34 | 21.37 | 6969.23 |
网膜 | 30.72,29.32 | 126.7 | 273.04 | 199.87 | 3.94 | 12.69 | 2536.42 |
卵巢 | 28.89,28.68 | 346.91 | 388.02 | 367.47 | 4.34 | 11.52 | 4233.47 |
胰腺 | 35.24,35.75 | 10.59 | 8.02 | 9.31 | 0.81 | 61.80 | 575.09 |
胰头 | 35.25,33.21 | 10.57 | 32.34 | 21.46 | 1.57 | 31.85 | 683.28 |
腮腺 | 28.46,27.84 | 438.62 | 615.36 | 526.99 | 5.48 | 9.12 | 4808.30 |
胎盘Clontech | 28.67,28.66 | 391.9 | 393.15 | 392.53 | 5.26 | 9.51 | 3731.23 |
前列腺 | 30.55,31.46 | 139.05 | 84.64 | 111.85 | 3.00 | 16.67 | 1864.08 |
直肠 | 31.28,31.43 | 93.33 | 85.92 | 89.63 | 1.23 | 40.65 | 3643.29 |
唾液腺Clontech | 31.13,30.57 | 101.46 | 138.16 | 119.81 | 7.31 | 6.84 | 819.49 |
骨骼肌Clontech | 34.05,35.24 | 20.38 | 10.59 | 15.49 | 1.26 | 39.68 | 614.48 |
皮肤 | 31.53,31.2 | 81.49 | 97.36 | 89.43 | 1.21 | 41.32 | 3695.25 |
小肠Clontech | 34.81,33.82 | 13.41 | 23.18 | 18.30 | 0.98 | 51.07 | 934.37 |
脾脏 | 31.01,30.44 | 108.41 | 147.9 | 128.16 | 4.92 | 10.16 | 1302.39 |
胃 | 32.01,31.1 | 62.6 | 102.97 | 82.79 | 2.73 | 18.32 | 1516.21 |
睾丸Clontech | 31.74,32.29 | 72.49 | 53.45 | 62.97 | 0.57 | 87.87 | 5533.39 |
胸腺Clontech | 28.84,28.53 | 356.64 | 421.44 | 389.04 | 9.89 | 5.06 | 1966.84 |
甲状腺 | 30.12,30.04 | 176.76 | 184.5 | 180.63 | 2.77 | 18.05 | 3260.47 |
气管Clontech | 28.48,28.38 | 434.3 | 459.42 | 446.86 | 9.71 | 5.15 | 2301.03 |
膀胱 | 29.63,29.55 | 230.25 | 241.15 | 235.70 | 5.47 | 9.14 | 2154.48 |
子宫 | 28.69,28.37 | 387.47 | 461.07 | 424.27 | 5.34 | 9.36 | 3972.57 |
基因组 | 26.24 | 1487.44 | |||||
b-肌动蛋白 | 27.28 | 839.2 | |||||
1.00E+05 | 18.96 | 100000 | |||||
1.00E+05 | 19.34 | 100000 | |||||
1.00E+04 | 22.64 | 10000 | |||||
1.00E+04 | 22.84 | 10000 | |||||
1.00E+03 | 26.22 | 1000 | |||||
1.00E+03 | 26.04 | 1000 | |||||
1.00E+02 | 31.04 | 100 | |||||
1.00E+02 | 30.1 | 100 | |||||
1.00E+01 | 33.33 | 10 | |||||
1.00E+01 | 39.08 | 10 | |||||
1.00E-00 | 40 | 0 | |||||
1.00E-00 | 40 | 1 | |||||
NTC | 40 | 0 | |||||
NTC | 40 | 0 |
标本 | 登记号 | Ct | GOI拷贝 | 检测到的 | 标本 | 患病人群 |
sbg1151bSREC | (GSK标识符) | 数的均值 | mRNA拷贝数/50ng总RNA | 中的倍数变化 | ||
正常结肠GW98-167 | 21941 | 24.55 | 5357.25 | 10714.50 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 22.61 | 19769.94 | 39539.88 | 结肠肿瘤 | 3.69 |
正常结肠GW98-178 | 22080 | 26.71 | 1252.3 | 2504.60 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 26.13 | 1854.49 | 3708.98 | 结肠肿瘤 | 1.48 |
正常结肠GW98-561 | 23514 | 26.82 | 1165.06 | 2330.12 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 25.75 | 2390.26 | 4780.52 | 结肠肿瘤 | 2.05 |
正常结肠GW98-894 | 24691 | 26.06 | 1948.57 | 3897.14 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 26.59 | 1362.55 | 2725.10 | 结肠肿瘤 | -1.43 |
正常肺GW98-3 | 20742 | 22.77 | 17753 | 35506.00 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 26.17 | 1803.8 | 3607.60 | 肺肿瘤 | -9.84 |
正常肺GW97-179 | 20677 | 25.24 | 3370.88 | 6741.76 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 24.14 | 7057.92 | 14115.84 | 肺肿瘤 | 2.09 |
正常肺GW98-165 | 21922 | 23.87 | 8442.49 | 16884.98 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 24.08 | 7339.83 | 14679.66 | 肺肿瘤 | -1.15 |
正常肺GW98-282 | 22584 | 25.51 | 2804.42 | 5608.84 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 24.2 | 6787.31 | 13574.62 | 肺肿瘤 | 2.42 |
正常乳腺GW00-392 | 28750 | 25.7 | 2480.5 | 2480.50 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 25.77 | 2364.2 | 4728.40 | 乳腺肿瘤 | 1.91 |
正常乳腺GW00-413 | 28798 | 26.06 | 1948.1 | 1948.10 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 27.21 | 894.11 | 1788.22 | 乳腺肿瘤 | -1.09 |
正常乳腺GW00-235:238 | 27592-95 | 26.64 | 1317.83 | 1317.83 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 23.91 | 8225.11 | 8225.11 | 乳腺肿瘤 | 6.24 |
正常乳腺GW98-621 | 23656 | 24.46 | 5693.73 | 11387.46 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 23.91 | 8218.73 | 16437.46 | 乳腺肿瘤 | 1.44 |
正常大脑BB99-542 | 25507 | 26.39 | 1553.13 | 3106.26 | 正常大脑 | |
正常大脑BB99-406 | 25509 | 26.63 | 1325.63 | 2651.26 | 正常大脑 |
正常大脑BB99-904 | 25546 | 27.05 | 1001.6 | 2003.20 | 正常大脑 | |
大脑期5ALZBB99-874 | 25502 | 26.97 | 1052.15 | 2104.30 | 大脑期5-ALZ | -1.23 |
大脑期5ALZBB99-887 | 25503 | 25.28 | 3289.99 | 6579.98 | 大脑期5-ALZ | 2.54 |
大脑期5ALZBB99-862 | 25504 | 26.24 | 1725.06 | 3450.12 | 大脑期5-ALZ | 1.33 |
大脑期5ALZBB99-927 | 25542 | 26.12 | 1864.26 | 3728.52 | 大脑期5-ALZ | 1.44 |
CT肺KC | normal | 24.74 | 4711.99 | 9423.98 | CT肺 | |
肺26KC | normal | 27.78 | 611.36 | 611.36 | 肺26 | |
肺27KC | normal | 28.27 | 439.19 | 439.19 | 肺27 | |
肺24KC | COPD | 26.92 | 1091.11 | 1091.11 | 肺24 | -2.56 |
肺28KC | COPD | 26.93 | 1085.65 | 1085.65 | 肺28 | -2.57 |
肺23KC | COPD | 27.19 | 909.68 | 909.68 | 肺23 | -3.07 |
肺25KC | normal | 27.62 | 678.79 | 678.79 | 肺25 | |
哮喘肺ODO3112 | 29321 | 25.33 | 3173.52 | 3173.52 | 哮喘肺 | 1.14 |
哮喘肺ODO3433 | 29323 | 25.36 | 3106.89 | 6213.78 | 哮喘肺 | 2.23 |
哮喘肺ODO3397 | 29322 | 23.81 | 8809.42 | 17618.84 | 哮喘肺 | 6.32 |
哮喘肺ODO4928 | 29325 | 24.76 | 4649.98 | 9299.96 | 哮喘肺 | 3.34 |
内皮细胞KC | control | 26 | 2021.13 | 2021.13 | 内皮细胞 | |
内皮细胞VEGFKC | 25.78 | 2343.21 | 2343.21 | 内皮细胞VEGF | 1.16 | |
内皮细胞bFGFKC | 26.7 | 1264.03 | 1264.03 | 内皮细胞bFGF | -1.60 | |
心脏Clontech | normal | 26.62 | 1330.64 | 2661.28 | 心脏 | |
心脏(T-1)缺血 | 29417 | 27.07 | 984.33 | 1968.66 | 心脏T-1 | -1.35 |
心脏(T-14)非阻塞性DCM | 29422 | 26.11 | 1877.75 | 3755.50 | 心脏T-14 | 1.41 |
心脏(T-3399)DCM | 29426 | 26.34 | 1608.79 | 3217.58 | 心脏T-3399 | 1.21 |
腺样增殖体GW99-269 | 26162 | 27.64 | 670.25 | 1340.50 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 27.61 | 684.15 | 1368.30 | 扁桃体 |
T细胞PC00314 | 28453 | 25.95 | 2098.64 | 4197.28 | T细胞 | |
PBMNC | 31.16 | 63.19 | 63.19 | PBMNC | ||
单核细胞 | 31.32 | 56.63 | 113.26 | 单核细胞 | ||
B细胞PC00665 | 28455 | 26.34 | 1609.52 | 3219.04 | B细胞 | |
树突细胞28441 | 28.25 | 444.68 | 889.36 | 树突细胞 | ||
中性粒细胞 | 28440 | 26.11 | 1874.13 | 1874.13 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 26.39 | 1553.82 | 3107.64 | 嗜酸性粒细胞 | |
BM unstim | 31.45 | 51.76 | 51.76 | BM未刺激的 | ||
BM stim | 31.28 | 58.37 | 58.37 | BM刺激的 | 1.13 | |
osteo dif | 24.62 | 5118.74 | 5118.74 | 成骨细胞分化 | 1.70 | |
osteo undif | 25.41 | 3015.6 | 3015.60 | 成骨细胞未分化 | ||
软骨细胞 | 22.12 | 27351.89 | 68379.73 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 24.5 | 5551.61 | 5551.61 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 25.1 | 3711.29 | 7422.58 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 24.5 | 5537.1 | 11074.20 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 26.45 | 1492.95 | 2985.90 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 24.44 | 5783.96 | 11567.92 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 25.94 | 2112.54 | 4225.08 | RA滑膜 | |
OA骨(biobank) | 29217 | 26.16 | 1811.72 | 1811.72 | OA骨(biobank) | |
OA骨标本1 | J.Emory | 24.54 | 5399.31 | 10798.62 | OA骨 | |
OA骨标本2 | J.Emory | 26.07 | 1931.94 | 3863.88 | OA骨 | |
软骨(库) | Normal | 25.09 | 3730.42 | 7460.84 | 软骨(库) | |
软骨(库) | OA | 25.79 | 2328.66 | 4657.32 | 软骨(库) | -1.60 |
PBL未感染的 | 28441 | 26.95 | 1068.16 | 2136.32 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 28.41 | 401.86 | 803.72 | PBL HIV IIIB | -2.66 |
MRC5未感染的(100%) | 29158 | 22.28 | 24694.87 | 49389.74 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 29.07 | 256.64 | 513.28 | MRC5 HSV株F | -96.22 |
W12细胞 | 29179 | 28.37 | 410.68 | 821.36 | W12细胞 | |
角质细胞 | 29180 | 29.12 | 249.25 | 498.50 | 角质细胞 |
B-肌动蛋白对照 | 27.53 | 721.15 | ||||
基因组 | 26.92 | 1091.74 | ||||
1.00E+05 | 19.96 | 100000 | ||||
1.00E+05 | 20.19 | 100000 | ||||
1.00E+04 | 23.43 | 10000 | ||||
1.00E+04 | 23.34 | 10000 | ||||
1.00E+03 | 26.64 | 1000 | ||||
1.00E+03 | 26.8 | 1000 | ||||
1.00E+02 | 31.34 | 100 | ||||
1.00E+02 | 31.48 | 100 | ||||
1.00E+01 | 34.9 | 10 | ||||
1.00E+01 | 34.19 | 10 | ||||
1.00E-00 | 40 | 0 | ||||
1.00E-00 | 35.53 | 1 | ||||
NTC | 40 | 0 |
基因名称sbg1151bSREC
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | 3.69 |
结肠肿瘤 | 1.48 |
结肠肿瘤 | 2.05 |
结肠肿瘤 | -1.43 |
肺肿瘤 | -9.84 |
肺肿瘤 | 2.09 |
肺肿瘤 | -1.15 |
肺肿瘤 | 2.42 |
乳腺肿瘤 | 1.91 |
乳腺肿瘤 | -1.09 |
乳腺肿瘤 | 6.24 |
乳腺肿瘤 | 1.44 |
大脑期5ALZ | -1.23 |
大脑期5ALZ | 2.54 |
大脑期5ALZ | 1.33 |
大脑期5ALZ | 1.44 |
肺24 | -2.56 |
肺28 | -2.57 |
肺23 | -3.07 |
哮喘肺 | 1.14 |
哮喘肺 | 2.23 |
哮喘肺 | 6.32 |
哮喘肺 | 3.34 |
endo VEGF | 1.16 |
endo bFGF | -1.60 |
心脏T-1 | -1.35 |
心脏T-14 | 1.41 |
心脏T-3399 | 1.21 |
BM stim | 1.13 |
Osteo undif | 1.70 |
软骨(库) | -1.60 |
PBL HIV IIIB | -2.66 |
MRC5 HSV株F | -96.22 |
基因名称sbg1399854ANK
低度总体表达。在全脑,胎脑和肝脏可见最高的正常表达。在代表女性生殖系统的所有标本中可见良好的表达水平。在正常和阿尔茨海默氏病脑标本中以及在树突细胞中可见最高的疾病表达。在4份结肠肿瘤标本的2份中上调和在4份乳腺肿瘤标本的2份中上调,以及在4份肺肿瘤标本的2份中下调提示该基因与结肠癌,乳腺癌和肺癌有关。在所有3份COPD标本中下调和在4份哮喘标本的2份中下调提示该基因在慢性阻塞性肺病和哮喘中的潜在作用。在OA的软骨标本中下调和在正常软骨细胞和许多免疫细胞中的确定的低表达提示其参与骨关节炎。在HSV感染的HRC5细胞中上调提示该基因可能是HSV中的宿主因子。
标本sbg1399854ANK | Ct(标本1和标本2) | GOI拷贝数的均值(标本1) | GOI拷贝数的均值(标本2) | 平均GOI拷贝数 | 18SrRNA(ng) | 50ng/18SrRNA(ng) | 检测到的mRNA拷贝数/50ng总RNA |
皮下脂肪细胞Zenbio | 40,40 | 0 | 0 | 0.00 | 3.06 | 16.34 | 0.00 |
皮下脂肪Zenbio | 40,40 | 1.83 | 1.77 | 1.80 | 0.96 | 52.36 | 94.24 |
肾上腺Clontech | 40,40 | 1.75 | 0 | 0.88 | 0.61 | 81.97 | 71.72 |
全脑Clontech | 28.57,28.35 | 944.29 | 1058.09 | 1001.19 | 7.24 | 6.91 | 6914.30 |
胎脑clontech | 36.57,34.65 | 14.38 | 39.28 | 26.83 | 0.48 | 103.95 | 2788.98 |
小脑Clontech | 37.21,36.71 | 10.3 | 13.37 | 11.84 | 2.17 | 23.04 | 272.70 |
子宫颈 | 36.3,40 | 16.52 | 0 | 8.26 | 2.42 | 20.66 | 170.66 |
结肠 | 36.17,35.71 | 17.73 | 22.5 | 20.12 | 2.71 | 18.45 | 371.13 |
子宫内膜 | 40,36.1 | 0 | 18.41 | 9.21 | 0.73 | 68.21 | 627.90 |
食管 | 40,40 | 0 | 1.58 | 0.79 | 1.37 | 36.50 | 28.83 |
心脏Clontech | 40,40 | 0 | 0 | 0.00 | 1.32 | 37.88 | 0.00 |
下丘脑 | 40,40 | 0 | 0 | 0.00 | 0.32 | 155.28 | 0.00 |
回肠 | 40,40 | 0 | 0 | 0.00 | 2.58 | 19.38 | 0.00 |
空肠 | 34.07,34.37 | 53.18 | 45.33 | 49.26 | 6.60 | 7.58 | 373.14 |
肾脏 | 37.55,40 | 8.58 | 0 | 4.29 | 2.12 | 23.58 | 101.18 |
肝脏 | 36.53,35.62 | 14.69 | 23.59 | 19.14 | 1.50 | 33.33 | 638.00 |
胚胎肝Clontech | 34.56,34.61 | 41.04 | 40.04 | 40.54 | 10.40 | 4.81 | 194.90 |
肺 | 40,40 | 0 | 0 | 0.00 | 2.57 | 19.46 | 0.00 |
乳腺Clontech | 39.07,39.45 | 3.89 | 3.18 | 3.54 | 13.00 | 3.85 | 13.60 |
子宫肌层 | 39.5,35.37 | 3.1 | 26.93 | 15.02 | 2.34 | 21.37 | 320.83 |
网膜 | 40,36.18 | 0 | 17.61 | 8.81 | 3.94 | 12.69 | 111.74 |
卵巢 | 35.87,34.34 | 20.75 | 46.22 | 33.49 | 4.34 | 11.52 | 385.77 |
胰腺 | 40,40 | 0 | 0 | 0.00 | 0.81 | 61.80 | 0.00 |
胰头 | 40,39.79 | 0 | 2.66 | 1.33 | 1.57 | 31.85 | 42.36 |
腮腺 | 35.2,38.6 | 29.46 | 4.97 | 17.22 | 5.48 | 9.12 | 157.07 |
胎盘Clontech | 40,38.14 | 0 | 6.32 | 3.16 | 5.26 | 9.51 | 30.04 |
前列腺 | 40,40 | 0 | 0 | 0.00 | 3.00 | 16.67 | 0.00 |
直肠 | 40,39.2 | 0 | 3.63 | 1.82 | 1.23 | 40.65 | 73.78 |
唾液腺Clontech | 40,39.19 | 2.19 | 3.64 | 2.92 | 7.31 | 6.84 | 19.94 |
骨骼肌Clontech | 40,39.37 | 0 | 3.32 | 1.66 | 1.26 | 39.68 | 65.87 |
皮肤 | 40,40 | 0 | 2.09 | 1.05 | 1.21 | 41.32 | 43.18 |
小肠Clontech | 40,40 | 1.44 | 0 | 0.72 | 0.98 | 51.07 | 36.77 |
脾脏 | 35.36,40 | 27.05 | 1.84 | 14.45 | 4.92 | 10.16 | 146.80 |
胃 | 40,37.03 | 1.93 | 11.29 | 6.61 | 2.73 | 18.32 | 121.06 |
睾丸Clontech | 40,37.99 | 0 | 6.82 | 3.41 | 0.57 | 87.87 | 299.65 |
胸腺Clontech | 38.47,35.55 | 5.32 | 24.52 | 14.92 | 9.89 | 5.06 | 75.43 |
甲状腺 | 40,40 | 0 | 2.15 | 1.08 | 2.77 | 18.05 | 19.40 |
气管Clontech | 35.37,36.67 | 26.97 | 13.66 | 20.32 | 9.71 | 5.15 | 104.61 |
膀胱 | 39.07,40 | 3.89 | 1.42 | 2.66 | 5.47 | 9.14 | 24.27 |
子宫 | 36.01,33.41 | 19.29 | 75.06 | 47.18 | 5.34 | 9.36 | 441.71 |
基因组 | 29.57 | 558.84 | |||||
b-肌动蛋白 | 27.57 | 1592.66 | |||||
1.00E+05 | 19.91 | 100000 | |||||
1.00E+05 | 20.08 | 100000 | |||||
1.00E+04 | 23.79 | 10000 | |||||
1.00E+04 | 24.06 | 10000 | |||||
1.00E+03 | 27.72 | 1000 | |||||
1.00E+03 | 28.29 | 1000 | |||||
1.00E+02 | 31.95 | 100 | |||||
1.00E+02 | 33.62 | 100 | |||||
1.00E+01 | 39.75 | 10 | |||||
1.00E+01 | 35.41 | 10 |
1.00E-00 | 40 | 0 | |||||
1.00E-00 | 40 | 0 | |||||
NTC | 40 | -1 | |||||
NTC | 40 | -1 |
标本sbg1399854ANK | 登记号(GSK标识符) | Ct | GOI拷贝数的均值 | 检测到的mRNA拷贝数/50ng总RNA | 标本 | 患病人群中的倍数变化 |
正常结肠GW98-167 | 21941 | 35.32 | 22.34 | 44.68 | 正常结肠 | |
结肠肿瘤GW98-166 | 21940 | 34.14 | 47.5 | 95.00 | 结肠肿瘤 | 2.13 |
正常结肠GW98-178 | 22080 | 36.16 | 13.07 | 26.14 | 正常结肠 | |
结肠肿瘤GW98-177 | 22060 | 35.58 | 18.93 | 37.86 | 结肠肿瘤 | 1.45 |
正常结肠GW98-561 | 23514 | 36.58 | 10.03 | 20.06 | 正常结肠 | |
结肠肿瘤GW98-560 | 23513 | 32.61 | 126.48 | 252.96 | 结肠肿瘤 | 12.61 |
正常结肠GW98-894 | 24691 | 35.61 | 18.62 | 37.24 | 正常结肠 | |
结肠肿瘤GW98-893 | 24690 | 33.24 | 84.75 | 169.50 | 结肠肿瘤 | 4.55 |
正常肺GW98-3 | 20742 | 34.77 | 31.8 | 63.60 | 正常肺 | |
肺肿瘤GW98-2 | 20741 | 33.63 | 66.03 | 132.06 | 肺肿瘤 | 2.08 |
正常肺GW97-179 | 20677 | 34.76 | 32.04 | 64.08 | 正常肺 | |
肺肿瘤GW97-178 | 20676 | 34.44 | 39.23 | 78.46 | 肺肿瘤 | 1.22 |
正常肺GW98-165 | 21922 | 35.18 | 24.44 | 48.88 | 正常肺 | |
肺肿瘤GW98-164 | 21921 | 37.99 | 4.06 | 8.12 | 肺肿瘤 | -6.02 |
正常肺GW98-282 | 22584 | 33.64 | 65.37 | 130.74 | 正常肺 | |
肺肿瘤GW98-281 | 22583 | 37.3 | 6.34 | 12.68 | 肺肿瘤 | -10.31 |
正常乳腺GW00-392 | 28750 | 36.29 | 12.08 | 12.08 | 正常乳腺 | |
乳腺肿瘤GW00-391 | 28746 | 36.14 | 13.29 | 26.58 | 乳腺肿瘤 | 2.20 |
正常乳腺GW00-413 | 28798 | 37.08 | 7.29 | 7.29 | 正常乳腺 | |
乳腺肿瘤GW00-412 | 28797 | 33.26 | 83.58 | 167.16 | 乳腺肿瘤 | 22.93 |
正常乳腺GW00-235:238 | 27592-95 | 38.93 | 2.24 | 2.24 | 正常乳腺 | |
乳腺肿瘤GW00-231:234 | 27588-91 | 36.57 | 10.08 | 10.08 | 乳腺肿瘤 | 4.50 |
正常乳腺GW98-621 | 23656 | 34.9 | 29.32 | 58.64 | 正常乳腺 | |
乳腺肿瘤GW98-620 | 23655 | 36.11 | 13.51 | 27.02 | 乳腺肿瘤 | -2.17 |
正常大脑BB99-542 | 25507 | 29.6 | 866.9 | 1733.80 | 正常大脑 | |
正常大脑BB99-406 | 25509 | 31.93 | 194.87 | 389.74 | 正常大脑 | |
正常大脑BB99-904 | 25546 | 30.38 | 526.58 | 1053.16 | 正常大脑 | |
大脑期5ALZ BB99-874 | 25502 | 32.7 | 119.57 | 239.14 | 大脑期5-ALZ | -4.43 |
大脑期5ALZ BB99-887 | 25503 | 30.08 | 634.97 | 1269.94 | 大脑期5-ALZ | 1.20 |
大脑期5ALZ BB99-862 | 25504 | 29.7 | 809.22 | 1618.44 | 大脑期5-ALZ | 1.53 |
大脑期5ALZ BB99-927 | 25542 | 29.93 | 700.82 | 1401.64 | 大脑期5-ALZ | 1.32 |
CT肺KC | normal | 35.1 | 25.82 | 51.64 | CT肺 | |
肺26KC | normal | 36.74 | 9.07 | 肺26 | ||
肺27KC | normal | 40 | 0 | 0.00 | 肺27 | |
肺24KC | COPD | 40 | 2.5 | 2.50 | 肺24 | -7.11 |
肺28KC | COPD | 40 | 0 | 0.00 | 肺28 | -17.77 |
肺23KC | COPD | 40 | 0 | 0.00 | 肺23 | -17.77 |
肺25KC | normal | 39.39 | 1.67 | 1.67 | 肺25 | |
哮喘肺ODO3112 | 29321 | 40 | 0 | 0.00 | 哮喘肺 | -17.77 |
哮喘肺ODO3433 | 29323 | 37 | 7.68 | 15.36 | 哮喘肺 | -1.16 |
哮喘肺ODO3397 | 29322 | 36.08 | 13.8 | 27.60 | 哮喘肺 | 1.55 |
哮喘肺ODO4928 | 29325 | 40 | 0 | 0.00 | 哮喘肺 | -17.77 |
内皮细胞KC | control | 40 | 0 | 0.00 | 内皮细胞 | |
内皮细胞VEGF KC | 40 | 0 | 0.00 | 内皮细胞VEGF | 0.00 | |
内皮细胞bFGF KC | 35.68 | 17.77 | 17.77 | 内皮细胞bFGF | 17.77 | |
心脏Clontech | normal | 35.03 | 26.95 | 53.90 | 心脏 | |
心脏(T-1)缺血 | 29417 | 36.36 | 11.53 | 23.06 | 心脏T-1 | -2.34 |
心脏(T-14)非阻塞性DCM | 29422 | 34.57 | 36.11 | 72.22 | 心脏T-14 | 1.34 |
心脏(T-3399)DCM | 29426 | 36.25 | 12.37 | 24.74 | 心脏T-3399 | -2.18 |
腺样增殖体GW99-269 | 26162 | 38.51 | 2.92 | 5.84 | 腺样增殖体 | |
扁桃体GW98-280 | 22582 | 35.05 | 26.54 | 53.08 | 扁桃体 |
T细胞PC00314 | 28453 | 35.5 | 19.98 | 39.96 | T细胞 | |
PBMNC | 40 | 0 | 0.00 | PBMNC | ||
单核细胞 | 40 | 0 | 0.00 | 单核细胞 | ||
B细胞PC00665 | 28455 | 33.78 | 59.82 | 119.64 | B细胞 | |
树突细胞28441 | 28441 | 29.33 | 1026.14 | 2052.28 | 树突细胞 | |
中性粒细胞 | 28440 | 31.3 | 292.56 | 292.56 | 中性粒细胞 | |
嗜酸性粒细胞 | 28446 | 35.97 | 14.79 | 29.58 | 嗜酸性粒细胞 | |
BM unstim | 35.56 | 19.16 | 19.16 | BM未刺激的 | ||
BM stim | treated | 34.79 | 31.48 | 31.48 | BM刺激的 | 1.64 |
osteo dif | treated | 40 | 2.59 | 2.59 | 成骨细胞分化 | 2.59 |
osteo undif | 40 | 0 | 0.00 | 成骨细胞未分化 | ||
软骨细胞 | 37.11 | 7.15 | 17.88 | 软骨细胞 | ||
OA滑膜IP12/01 | 29462 | 35.95 | 14.93 | 14.93 | OA滑膜 | |
OA滑膜NP10/01 | 29461 | 35.74 | 17.17 | 34.34 | OA滑膜 | |
OA滑膜NP57/00 | 28464 | 39.09 | 2.02 | 4.04 | OA滑膜 | |
RA滑膜NP03/01 | 28466 | 38.03 | 3.97 | 7.94 | RA滑膜 | |
RA滑膜NP71/00 | 28467 | 35.08 | 26.03 | 52.06 | RA滑膜 | |
RA滑膜NP45/00 | 28475 | 37.11 | 7.13 | 14.26 | RA滑膜 | |
OA骨(biobank) | 29217 | 33.76 | 60.54 | 60.54 | OA骨(biobank) | |
OA骨标本1 | J.Emofy | 33.35 | 78.68 | 157.36 | OA骨 | |
OA骨标本2 | J.Emory | 34.15 | 47.2 | 94.40 | OA骨 | |
软骨(库) | Normal | 35.05 | 26.63 | 53.26 | 软骨(库) | |
软骨(库) | OA | 37.42 | 5.87 | 11.74 | 软骨(库) | -4.54 |
PBL未感染的 | 28441 | 33.95 | 53.63 | 107.26 | PBL未感染的 | |
PBL HIV IIIB | 28442 | 33.3 | 81.2 | 162.40 | PBL HIV IIIB | 1.51 |
MRC5未感染的(100%) | 29158 | 39.41 | 1.64 | 3.28 | MRC5未感染的(100%) | |
MRC5 HSV株F | 29178 | 35.73 | 17.22 | 34.44 | MRC5 HSV株F | 10.50 |
W12细胞 | 29179 | 35.08 | 26.08 | 52.16 | W12细胞 |
角质细胞 | 29180 | 36.69 | 9.33 | 18.66 | 角质细胞 | |
B-肌动蛋白对照 | 28.13 | 2213.67 | ||||
基因组 | 29.03 | 1240.79 | ||||
1.00E+05 | 22.03 | 100000 | ||||
1.00E+05 | 22.36 | 100000 | ||||
1.00E+04 | 25.68 | 10000 | ||||
1.00E+04 | 25.78 | 10000 | ||||
1.00E+03 | 29.01 | 1000 | ||||
1.00E+03 | 28.67 | 1000 | ||||
1.00E+02 | 33.46 | 100 | ||||
1.00E+02 | 40 | 100 | ||||
1.00E+01 | 38.75 | 10 | ||||
1.00E+01 | 40 | 10 | ||||
1.00E-00 | 40 | 0 | ||||
1.00E-00 | 38.6 | 1 | ||||
NTC | 40 | 0 | ||||
*肺26(正常标本)被忽略,因为对该标本进行的多重扩增失败 |
基因名称sbg1399854ANK
疾病组织 | 患病人群相对于正常人群的倍数变化 |
结肠肿瘤 | 2.13 |
结肠肿瘤 | 1.45 |
结肠肿瘤 | 12.61 |
结肠肿瘤 | 4.55 |
肺肿瘤 | 2.08 |
肺肿瘤 | 1.22 |
肺肿瘤 | -6.02 |
肺肿瘤 | -10.31 |
乳腺肿瘤 | 2.20 |
乳腺肿瘤 | 22.93 |
乳腺肿瘤 | 4.50 |
乳腺肿瘤 | -2.17 |
大脑期5ALZ | -4.43 |
大脑期5ALZ | 1.20 |
大脑期5ALZ | 1.53 |
大脑期5ALZ | 1.32 |
肺24 | -7.11 |
肺28 | -17.77 |
肺23 | -17.77 |
哮喘肺 | -17.77 |
哮喘肺 | -1.16 |
哮喘肺 | 1.55 |
哮喘肺 | -17.77 |
endo VEGF | 0.00 |
endo bFGF | 17.77 |
心脏T-1 | -2.34 |
心脏T-14 | 1.34 |
心脏T-3399 | -2.18 |
BM stim | 1.64 |
Osteo undif | 2.59 |
软骨(库) | -4.54 |
PBL HIV IIIB | 1.51 |
MRC5 HSV株F | 10.50 |
表V.基于特异性组织中mRNA表达的其它疾病
组织表达 | 其它疾病 |
脑 | 神经病和精神病,包括阿尔茨海默氏病、旁上核瘫痪(parasupranuclear palsey)、亨廷顿病、肌强直性营养不良、厌食、抑郁症、精神分裂症、头痛、健忘症、焦虑症、睡眠 |
机能紊乱、多发性硬化 | |
心脏 | 心血管病、包括充血性心力衰竭、扩张性心肌病(dilated cardiomyopathy)、心律不齐、Hodgson′s病、心肌梗塞、心律不齐 |
肺 | 呼吸道疾病,包括哮喘、慢性阻塞性肺病、囊性纤维化、急性支气管炎、成人呼吸窘迫综合征 |
肝脏 | 异常脂质血症、高胆固醇血症、高甘油三酯血症、肝硬化、肝性脑病、脂肪性肝硬化、病毒及非病毒性肝炎、II型糖尿病、葡萄糖耐量降低 |
肾脏 | 肾病,包括急性及慢性肾衰竭、急性肾小管坏死(acute tubular necrosis)、胱氨酸尿、范可尼综合征、肾小球肾炎、肾细胞癌、肾血管性高血压 |
骨胳肌 | Eulenburg’s病、低血糖、肥胖、腱炎、周期性麻痹、恶性高热、先天性副肌强直病、先天性肌强直病 |
肠道 | 胃肠道病,包括先天性肌强直、肠闭塞、肠梗阻、热带口炎性腹泻、假膜性小肠结肠炎 |
脾/淋巴结 | 淋巴管扩张、脾功能亢进、血管瘤、关节强直性脊椎炎、Hodgkin′s病、巨球蛋白血症、恶性淋巴瘤、类风湿性关节炎 |
胎盘 | 绒毛膜癌、葡萄胎、前置胚盘 |
睾丸 | 睾丸癌、男性生殖疾病,包括低睾丸激素和男性不育 |
胰腺 | 糖尿病酮症酸中毒,1型和2型糖尿病,肥胖、葡萄糖耐量降低 |
序列表
<110>史密斯克莱恩·比彻姆公司(SMITHKLINE BEECHAM CORPORATION)史密斯克莱·比奇曼生物公司(SMITHKLINE BEECHAM p.l.c.)葛兰素集团有限公司(GLAXO GROUP,LIMITED)
<120>新型化合物
<130>GP50034
<140>TO BE ASSIGNED
<141>2001-09-13
<150>60/232,463
<151>2000-09-13
<150>60/232,455
<151>2000-09-13
<150>60/237,293
<151>2000-10-02
<150>60/246,269
<151>2000-11-07
<150>60/252,049
<151>2000-11-20
<160>88
<170>FastSEQ for Windows Version 4.0
<210>1
<211>1707
<212>DNA
<213>人(Homo sapiens)
<400>1
atgaaggaag cagagatgga cggtgaggca gtccgcttct gcacagataa ccagtgtgtc 60
tccctgcacc cccaagaggt ggactctgtg gcaatggctc ctgcagcccc caagataccg 120
aggctcgttc aggctacccc ggcatttatg gctgtgacct tggtcttctc tcttgtgact 180
ctctttgtag tgggtaagcc cccagttcaa cagcagacaa gacctgttcc gaagcctgtg 240
caagccgtaa ttctgggaga caacattact gggcatttac cttttgaacc caacaatcat 300
caccactttg gcagggaggc agaaatgcga gagcttatcc agacatttaa aggccacatg 360
gagaattcca gtgcctgggt agtagaaatc cagatgttga agtgcagagt ggacaatgtc 420
aattcgcagc tccaggtgct cggtgatcat ctgggaaaca ccaatgctga catccagatg 480
gtaaaaggag ttctaaagga tgccactaca ttgagtttgc agacacagat gttaaggagt 540
tccctggagg gaaccaatgc tgagatccag aggctcaagg aagaccttga aaaggcagat 600
gctttaactt tccagacgct gaatttctta aaaagcagtt tagaaaacac cagcattgag 660
ctccacgtgc taagcagagg cttagaaaat gcaaactctg aaattcagat gttgaatgcc 720
agagccaatg ctgagatcca gggactaaag gaaaatttgc agaacacaaa tgctttaaac 780
tcccagaccc aggcctttat aaaaagcagt tttgacaaca ctagtgctga gatccagttc 840
ttaagaggtc atttggaaag agctggtgat gaaattcacg tgttaaaaag ggatttgaaa 900
atggtcacag cccagaccca aaaagcaaat ggccgtctgg accagacaga tactcagatt 960
caggtattca agtcagagat ggaaaatgtg aataccttaa atgcccagat tcaggtctta 1020
aatggtcata tgaaaaatgc cagcagagag atacagaccc taaaacaagg aatgaagaat 1080
gcttcagcct taacttccca gacccagatg ttagacagca atctgcagaa ggccagtgcc 1140
gagatccaga ggttaagagg ggatctagag aacaccaaag ctctaaccat ggaaatccag 1200
caggagcaga gtcgcctgaa gaccctccat gtggtcatta cttcacagga acagctacaa 1260
agaacccaaa gtcagcttct ccagatggtc ctgcaaggct ggaagttcaa tggtggaagc 1320
ttatattatt tttctagtgt caagaagtct tggcatgagg ctgagcagtt ctgcgtgtcc 1380
cagggagccc atctggcatc tgtggcctcc aaggaggagc aggcatttct ggtagagttc 1440
acaagtaaag tgtactactg gatcggtctc actgacaggg gcacagaggg ctcctggcgc 1500
tggacagatg ggacaccatt caacgccgcc cagaacaaag cccctgttgt cttcgggttt 1560
tgggaaaaga atcagtctga caactggcgg cacaagaatg ggcagactga agactgtgtc 1620
caaattcagc agaagtggaa tgacatgacc tgtgacaccc cctatcagtg ggtgtgcaag 1680
aagcccatgg gccagggtgt ggcctga
<210>2
<211>1095
<212>DNA
<213>人(Homo sapiens)
<400>2
atgtcgagac aaggaaaatt attttctgct tttggagtgg gttgttgtgt aacggcaggc 60
ttgccaaagg acgataacac tcctagcacc attgcggatg tgcacaatgg ttatacgatg 120
aatgttgtag agcaagttct aaaggatagt tttgtgttat ttttcccagg aacactttgt 180
gattttccaa aaatacacca tggatttctg tatgatgaag aagattataa ccctttttcc 240
caagttccta caggggaagt tttctattac tcctgtgaat ataattttgt gtctccttca 300
aaatcctttt ggactcgcat aacatgcaca gaagaaggat ggtcaccaac accgaagtgt 360
ctcagaatgt gttcctttcc ttttgtgaaa aatggtcatt ctgaatcttc aggactaata 420
catctggaag gtgatactgt acaaattatt tgcaacacag gatacagcct tcaaaacaat 480
gagaaaaaca tttcgtgtgt agaacggggc tggtccactc ctcccatatg cagcttcact 540
atgaaaacat gtggatacat acctgaactc gagtacggtt atgttcagcc gtctgtccct 600
ccctatcaac atggagtttc agtcgaggtg aattgcagaa atgaatatgc aatgattgga 660
aataacatga ttacctgtat taatggaata tggacagagc ttcctatgtg tgttgagtct 720
actgcatatt gtgggccccc tccatctatt aacaatggag ataccacctc attcccatta 780
tcagtatatc ctccagggtc aacagtgacg taccgttgcc agtccttcta taaactccag 840
ggctctgtaa ctgtaacatg cagaaataaa cagtggtcag aaccaccaag atgcctagat 900
ccatgtgtgg tatctgaaga aaacatgaac aaaaataaca tacagttaaa atggagaaac 960
gatggaaaac tctatgcaaa aacaggggat gctgttgaat tccagtgtaa attcccacat 1020
aaagcgatga tatcatcacc accatttcga gcaatctgtc aggaagggaa atttgaatat 1080
cctatatgtg aatga 1095
<210>3
<211>984
<212>DNA
<213>人(Homo sapiens)
<400>3
atgttgctct tattcagtgt aatcctaatc tcatgggtat ccactgttgg gggagaagga 60
acactttgtg attttccaaa aatacaccat ggatttctgt atgatgaaga agattataac 120
cctttttccc aagttcctac aggggaagtt ttctattact cctgtgaata taattttgtg 180
tctccttcaa aatccttttg gactcgcata acatgcacag aagaaggatg gtcaccaaca 240
ccgaagtgtc tcagaatgtg ttcctttcct tttgtgaaaa atggtcattc tgaatcttca 300
ggactaatac atctggaagg tgatactgta caaattattt gcaacacagg atacagcctt 360
caaaacaatg agaaaaacat ttcgtgtgta gaacggggct ggtccactcc tcccatatgc 420
agcttcacta tgaaaacatg tggatacata cctgaactcg agtacggtta tgttcagccg 480
tctgtccctc cctatcaaca tggagtttca gtcgaggtga attgcagaaa tgaatatgca 540
atgattggaa ataacatgat tacctgtatt aatggaatat ggacagagct tcctatgtgt 600
gttgagtcta ctgcatattg tgggccccct ccatctatta acaatggaga taccacctca 660
ttcccattat cagtatatcc tccagggtca acagtgacgt accgttgcca gtccttctat 720
aaactccagg gctctgtaac tgtaacatgc agaaataaac agtggtcaga accaccaaga 780
tgcctagatc catgtgtggt atctgaagaa aacatgaaca aaaataacat acagttaaaa 840
tggagaaacg atggaaaact ctatgcaaaa acaggggatg ctgttgaatt ccagtgtaaa 900
ttcccacata aagcgatgat atcatcacca ccatttcgag caatctgtca ggaagggaaa 960
tttgaatatc ctatatgtga atga 984
<210>4
<211>465
<212>DNA
<213>人(Homo sapiens)
<400>4
atggcaccgg ccagagcagg atgctgcccc ctgctgctgc tgcttctggg gctgtgggtg 60
gcagaggtcc tagtcagagc caagcccaag gacatgacat catctcagtg gtttaaaact 120
cagcatgtgc agcccagccc tcaagcatgc aactcagcca tgagcatcat caataagtac 180
acagaacggt gcaaagacct caacaccttc ctgcacgagc ccttctccag tgtggccatc 240
acctgccaga cccccaacat agcctgcaag aatagctgta aaaactgcca ccagagccac 300
gggcccatgt ccctgaccat gggtgagctc acctcaggga agtacccaaa ctgcaggtac 360
aaagagaagc acctgaacac accttacata gtggcctgtg accctccaca acagggtgac 420
ccagggtacc cacttgttcc tgtgcacttg gataaagttg tctaa 465
<210>5
<211>1509
<212>DNA
<213>人(Homo sapiens)
<400>5
atgcgccagc tgggagggtc tctccgcccc ccgcgcgcgg cccacggggc cgagcctctc 60
cccagtgcgc tggggccctg cgctgggggt gaccgggacc tgggtcgggg aacccccgga 120
tgggagccca ggcgcgccag ggtccccatc cacgagcagg tcgacccccc gcgagagggg 180
ccccacctct tccagaacct cctgctcttc ctgtgggccc tgctgaactg tggtttgggg 240
gtcagtgctc agggtccggg cgagtggacc ccgtgggtgt cctggacccg ctgctccagc 300
tcctgcgggc gtggcgtctc tgtgcgcagc cggcgctgcc tccggcttcc tggggaagaa 360
ccgtgctggg gagactccca tgagtaccgc ctctgccagt tgccagactg ccccccaggg 420
gctgtgccct tccgagacct acagtgtgcc ctgtacaatg gccgccctgt cctgggcacc 480
cagaagacct accagtgggt gcccttccat ggggcgccca accagtgcga cctcaactgc 540
ctggctgagg ggcacgcctt ctaccacagc ttcggccgcg tcctggacgg caccgcctgc 600
agcccgggtg cccagggggt ctgcgtggct ggccgctgcc ttagcgccgg ctgtgatggg 660
ttgttgggct cgggtgccct cgaggaccgc tgtggccgct gcggaggcgc caacgactcg 720
tgccttttcg tgcagcgcgt gtttcgtgac gccggtgcct tcgctgggta ctggaacgtg 780
accctgatcc ccgagggcgc cagacacatc cgcgtggaac acaggagccg caaccacctg 840
ggtatcctag gatcactgat ggggggcgat gggcgctacg tgcttaatgg gcactgggtg 900
gtcagcccac cagggaccta cgaggcggcc ggcacgcatg tggtctacac ccgagacaca 960
gggccccagg agacattgca agcagccggg cccacctccc atgacctgct cctacaggtc 1020
ctcctgcagg agcccaaccc tggcatcgag tttgagttct ggctccctcg ggagcgctac 1080
agccccttcc aggctcgtgt gcaggccctg ggctggcccc tgaggcagcc tcagccccgg 1140
ggggtggagc ctcagccccc cgcagcccct gctgtcaccc ctgcacagac cccaacgctg 1200
gccccagtgt tccaggcccg agtgctgggc caccaccacc aggcccagga gacccgctat 1260
gaggtgcgca tccagctcgt ctacaagaac cgctcgccac tgcgggcacg cgagtacgtg 1320
tgggcgccag gccactgccc ctgcccgatg ctggcacccc accgggacta cctgatggct 1380
gtccagcgtc ttgtcagccc cgacggcaca caggaccagc tgctgctgcc ccacgccggc 1440
tacgcccggc cctggagccc tgcggaggac agccgcatac gcctgactgc ccggcgctgt 1500
cctggctga 1509
<210>6
<211>1356
<212>DNA
<213>人(Homo sapiens)
<400>6
atggactcgg cccctctgtt ccccaggccc cacctcttcc agaacctcct gctcttcctg 60
tgggccctgc tgaactgtgg tttgggggtc agtgctcagg gtccgggcga gtggaccccg 120
tgggtgtcct ggacccgctg ctccagctcc tgcgggcgtg gcgtctctgt gcgcagccgg 180
cgctgcctcc ggcttcctgg ggaagaaccg tgctggggag actcccatga gtaccgcctc 240
tgccagttgc cagactgccc cccaggggct gtgcccttcc gagacctaca gtgtgccctg 300
tacaatggcc gccctgtcct gggcacccag aagacctacc agtgggtgcc cttccatggg 360
gcgcccaacc agtgcgacct caactgcctg gctgaggggc acgccttcta ccacagcttc 420
ggccgcgtcc tggacggcac cgcctgcagc ccgggtgccc agggggtctg cgtggctggc 480
cgctgcctta gcgccggctg tgatgggttg ttgggctcgg gtgccctcga ggaccgctgt 540
ggccgctgcg gaggcgccaa cgactcgtgc cttttcgtgc agcgcgtgtt tcgtgacgcc 600
ggtgccttcg ctgggtactg gaacgtgacc ctgatccccg agggcgccag acacatccgc 660
gtggaacaca ggagccgcaa ccacctgggt atcctaggat cactgatggg gggcgatggg 720
cgctacgtgc ttaatgggca ctgggtggtc agcccaccag ggacctacga ggcggccggc 780
acgcatgtgg tctacacccg agacacaggg ccccaggaga cattgcaagc agccgggccc 840
acctcccatg acctgctcct acaggtcctc ctgcaggagc ccaaccctgg catcgagttt 900
gagttctggc tccctcggga gcgctacagc cccttccagg ctcgtgtgca ggccctgggc 960
tggcccctga ggcagcctca gccccggggg gtggagcctc agccccccgc agcccctgct 1020
gtcacccctg cacagacccc aacgctggcc ccagtgttcc aggcccgagt gctgggccac 1080
caccaccagg cccaggagac ccgctatgag gtgcgcatcc agctcgtcta caagaaccgc 1140
tcgccactgc gggcacgcga gtacgtgtgg gcgccaggcc actgcccctg cccgatgctg 1200
gcaccccacc gggactacct gatggctgtc cagcgtcttg tcagccccga cggcacacag 1260
gaccagctgc tgctgcccca cgccggctac gcccggccct ggagccctgc ggaggacagc 1320
cgcatacgcc tgactgcccg gcgctgtcct ggctga 1356
<210>7
<211>1296
<212>DNA
<213>人(Homo sapiens)
<400>7
atgatccgga ccccattgtc ggcctctgcc catcgcctgc tcctcccagg ctcccgcggc 60
cgacccccgc gcaacatgca gcccacgggc cgcgagggtt cccgcgcgct cagccggcgg 120
tatctgcggc gtctgctgct cctgctactg ctgctgctgc tgcggcagcc cgtaacccgc 180
gcggagacca cgccgggcgc ccccagagcc ctctccacgc tgggctcccc cagcctcttc 240
accacgccgg gtgtccccag cgccctcact accccaggcc tcactacgcc aggcaccccc 300
aaaaccctgg accttcgggg tcgcgcgcag gccctgatgc ggagtttccc actcgtggac 360
gggtatgtag gtctgaacag ctctcaaaag ctggcctgcc tcattggcgt ggagggtggt 420
cactcactgg acagcagcct ctctgtgctg cgcagtttct atgtgctggg ggtgcgctac 480
ctgacactta ccttcacctg cagtacacca tgggcagaga gttccaccaa gttcagacac 540
cacatgtaca ccaacgtcag cggattgaca agctttggtg agaaagtagt agaggagttg 600
aaccgcctgg gcatgatgat agatttgtcc tatgcatcgg acaccttgat aagaagggtc 660
ctggaagtgt ctcaggctcc tgtgatcttc tcccactcag ctgccagagc tgtgtgtgac 720
aatttgttga atgttcccga tgatatcctg cagcttctga agaagaacgg tggcatcgtg 780
atggtgacac tgtccatggg ggtgctgcag tgcaacctgc ttgctaacgt gtccactgtg 840
gcagatgatt cgaatcgatg ctcggtaccc gtcattggat ctgagttcat cgggattggt 900
ggaaattatg acgggactgg ccggttccct caggggctgg aggatgtgtc cacataccca 960
gtcctgatag aggagttgct gagtcgtagc tggagcgagg aagagcttca aggtgtcctt 1020
cgtggaaacc tgctgcgggt cttcagacaa gtggaaaagg tgagagagga gagcagggcg 1080
cagagccccg tggaggctga gtttccatat gggcaactga gcacatcctg ccactcccac 1140
ctcgtgcctc agaatggaca ccaggctact catctggagg tgaccaagca gccaaccaat 1200
cgggtcccct ggaggtcctc aaatgcctcc ccataccttg ttccaggcct tgtggctgct 1260
gccaccatcc caaccttcac ccagtggctc tgctga 1296
<210>8
<211>1443
<212>DNA
<213>人(Homo sapiens)
<400>8
atgcagccct ccggcctcga gggtcccggc acgtttggtc ggtggcctct gctgagtctg 60
ctgctcctgc tgctgctgct ccagcctgta acctgtgcct acaccacgcc aggccccccc 120
agagccctca ccacgctggg cgcccccaga gcccacacca tgccgggcac ctacgctccc 180
tcgaccacac tcagtagtcc cagcacccag ggcctgcaag agcaggcacg ggccctgatg 240
cgggacttcc cgctcgtgga cggccacaac gacctgcccc tggtcctaag gcaggtttac 300
cagaaagggc tacaggatgt taacctgcgc aatttcagct acggccagac cagcctggac 360
aggcttagag atggcctcgt gggcgcccag ttctggtcag cctatgtgcc atgccagacc 420
caggaccggg atgccctgcg cctcaccctg gagcagattg acctcatacg ccgcatgtgt 480
gcctcctatt ctgagctgga gcttgtgacc tcggctaaag gtctgaacag ctctcaaaag 540
ctggcctgcc tcattggcgt ggagggtggt cactcactgg acagcagcct ctctgtgctg 600
cgcagtttct atgtgctggg ggtgcgctac ctgacactta ccttcacctg cagtacacca 660
tgggcagaga gttccaccaa gttcagacac cacatgtaca ccaacgtcag cggattgaca 720
agctttggtg agaaagtagt agaggagttg aaccgcctgg gcatgatgat agatttgtcc 780
tatgcatcgg acaccttgat aagaagggtc ctggaagtgt ctcaggctcc tgtgatcttc 840
tcccactcag ctgccagagc tgtgtgtgac aatttgttga atgttcccga tgatatcctg 900
cagcttctga agaagaacgg tggcatcgtg atggtgacac tgtccatggg ggtgctgcag 960
tgcaacctgc ttgctaacgt gtccactgtg gcagatcact ttgaccacat cagggcagtc 1020
attggatctg agttcatcgg gattggtgga aattatgacg ggactggccg gttccctcag 1080
gggctggagg atgtgtccac atacccagtc ctgatagagg agttgctgag tcgtagctgg 1140
agcgaggaag agcttcaagg tgtccttcgt ggaaacctgc tgcgggtctt cagacaagtg 1200
gaaaaggtga gagaggagag cagggcgcag agccccgtgg aggctgagtt tccatatggg 1260
caactgagca catcctgcca ctcccacctc gtgcctcaga atggacacca ggctactcat 1320
ctggaggtga ccaagcagcc aaccaatcgg gtcccctgga ggtcctcaaa tgcctcccca 1380
taccttgttc caggccttgt ggctgctgcc accatcccaa ccttcaccca gtggctctgc 1440
tga 1443
<210>9
<211>1116
<212>DNA
<213>人(Homo sapiens)
<400>9
atggatgcag ccacagctcc aaagcaagcc tggcccccat ggcccccgct ccttttcctc 60
ctcctcctac ctggagggag cggtggcagc tgccctgctg tgtgtgactg cacctcccag 120
ccccaggctg tgctctgtgg ccacaggcaa ctggaggctg tacctggagg actcccactg 180
gacactgagc tcctggacct gagtgggaac cgcctcccga aggctcagcc cctggtgcgg 240
ctccaggagc tacgcctgtc aggggcatgc ctcacctcca ttgctgccca tgccttccat 300
ggcttgactg ccttccacct cctggatgtg gcagataacg cccttcagac actagaggaa 360
acagctttcc cttctccaga caaactggtc accttgaggc tgtctggcaa ccccctaacc 420
tgtgactgcc gcctcctctg gctgctccgg ctccgccacc tggactttgg catgtccccc 480
cctgcctgtg ctggccccca tcatgtccag gggaagagcc tgaaggagtt ttcagacatc 540
ctgcctccag ggcacttcac ctgcaaacca gccctgatcc gaaagtcggg gcctcgatgg 600
gtcattgcag aggagggcgg gcatgcggtt ttctcctgct ctggagatgg agacccagcc 660
cccactgtct cctggatgag gcctcatggg gcttggctgg gcagggctgg gagagtaagg 720
gtcctagagg atgggacact ggagatccgc tcagtgcagc tacgggacag aggggcctat 780
gtctgtgtgg ttagcaatgt cgctgggaat gactccctga ggacctggct ggaagtcatc 840
caggtggaac caccaaacgg cacactttct gaccccaaca tcaccgtgcc agggatccca 900
gggccttttt ttctggatag cagaggtgtg gccatggtgc tggcagtcgg cttcctcccc 960
ttcctcacct cagtgaccct ctgctttggc ctgattgccc tttggagcaa gggcaaaggt 1020
cgggtcaaac atcacatgac ctttgacttt gtggcacctc ggccctctgg ggataaaaac 1080
tctgggggta accgggtcac tgccaagctc ttctga 1116
<210>10
<211>1779
<212>DNA
<213>人(Homo sapiens)
<400>10
atggatgcag ccacagctcc aaagcaagcc tggcccccat ggcccccgct ccttttcctc 60
ctcctcctac ctggagggag cggtggcagc tgccctgctg tgtgtgactg cacctcccag 120
ccccaggctg tgctctgtgg ccacaggcaa ctggaggctg tacctggagg actcccactg 180
gacactgagc tcctggacct gagtgggaac cgcctgtggg ggctccagca gggaatgctc 240
tcccgcctga gcctgctcca ggaattggac ctcagctaca accagctctc aacccttgag 300
cctggggcct tccatggcct acaaagccta ctcaccctga ggctgcaggg caatcggctc 360
agaatcatgg ggcctggggt cttctcaggc ctctctgctc tgaccctgct ggacctccgc 420
ctcaaccaga ttgttctctt cctagatgga gcttttgggg agctaggcag cctccagaag 480
ctggaggttg gggacaacca cctggtattt gtggctccgg gggcctttgc agggctagcc 540
aagttgagca ccctcaccct ggagcgctgc aacctcagca cagtgcctgg cctagccctt 600
gcccgtctcc cggcactagt ggccctaagg cttagagaac tggatattgg gaggctgcca 660
gctggggccc tgcgggggct ggggcagctc aaggagctgg agatccacct ctggccatct 720
ctggaggctc tggaccctgg gagcctggtt gggctcaatc tcagcagcct ggccatcact 780
cgctgcaatc tgagctcggt gcccttccaa gcactgtacc acctcagctt cctcagggtc 840
ctggatctgt cccagaatcc catctcagcc atcccagccc gaaggctcag ccccctggtg 900
cggctccagg agctacgcct gtcaggggca tgcctcacct ccattgctgc ccatgccttc 960
catggcttga ctgccttcca cctcctggat gtggcagata acgcccttca gacactagag 1020
gaaacagctt tcccttctcc agacaaactg gtcaccttga ggctgtctgg caacccccta 1080
acctgtgact gccgcctcct ctggctgctc cggctccgcc acctggactt tggcatgtcc 1140
ccccctgcct gtgctggccc ccatcatgtc caggggaaga gcctgaagga gttttcagac 1200
atcctgcctc cagggcactt cacctgcaaa ccagccctga tccgaaagtc ggggcctcga 1260
tgggtcattg cagaggaggg cgggcatgcg gttttctcct gctctggaga tggagaccca 1320
gcccccactg tctcctggat gaggcctcat ggggcttggc tgggcagggc tgggagagta 1380
agggtcctag aggatgggac actggagatc cgctcagtgc agctacggga cagaggggcc 1440
tatgtctgtg tggttagcaa tgtcgctggg aatgactccc tgaggacctg gctggaagtc 1500
atccaggtgg aaccaccaaa cggcacactt tctgacccca acatcaccgt gccagggatc 1560
ccagggcctt tttttctgga tagcagaggt gtggccatgg tgctggcagt cggcttcctc 1620
cccttcctca cctcagtgac cctctgcttt ggcctgattg ccctttggag caagggcaaa 1680
ggtcgggtca aacatcacat gacctttgac tttgtggcac ctcggccctc tggggataaa 1740
aactctgggg gtaaccgggt cactgccaag ctcttctga 1779
<210>11
<211>429
<212>DNA
<213>人(Homo sapiens)
<400>11
atggccaggt acatgctgct gctgctcctg gcggtatggg tgctgaccgg ggagctgtgg 60
ccgggagctg aggcccgggc agcgccttac ggggtcaggc tttgcggccg agaattcatc 120
cgagcagtca tcttcacctg cgggggctcc cggtggagac gatcagacat cctggcccac 180
gaggctatgg gagatacctt cccggatgca gatgctgatg aagacagtct ggcaggcgag 240
ctggatgagg ccatggggtc cagcgagtgg ctggccctga ccaagtcacc ccaggccttt 300
tacagggggc gacccagctg gcaaggaacc cctggggttc ttcggggcag ccgagatgtc 360
ctggctggcc tttccagcag ctgctgcaag tgggggtgta gcaaaagtga aatcagtagc 420
ctttgctag 429
<210>12
<211>692
<212>DNA
<213>人(Homo sapiens)
<400>12
atgtctgaag aagtgaccta cgcgacactc acatttcagg attctgctgg agcaaggaat 60
aaccgagatg gaaataacct aagaaaaaga gggcatccag ctccatctcc catttggcgt 120
catgctgctc tgggtctggt aactctttgc ctgatgttgc tgattgggct ggtgacgttg 180
gggatgatgt ttttgcagat atctaatgac attaactcag attcagagaa attgagtcaa 240
cttcagaaaa ccatccaaca gcagcaggat aacttatccc agcaactggg caactccaac 300
aacttgtcca tggaggagga atttctcaag tcacagatct ccagtctact gaagaggcag 360
gaacaaatgg ccatcaaact gtgccaagag ctaatcattc atacttcaga ccacagatgt 420
aatccatgtc ctaagatgtg gcaatggtac caaaatagtt gctactattt tacaacaaat 480
gaggagaaaa cctgggctaa cagtagaaag gactgcatag acaagaactc caccctagtg 540
aagatagaca gtttggaaga aaaggatttt cttatgtcac agccattact catgttttcg 600
ttcttttggc tgggattatc atgggactcc tctggcagaa gttggttctg ggaagatggc 660
tctgttccct ctccatcctt gtacgtctct aa 692
<210>13
<211>585
<212>DNA
<213>人(Homo sapiens)
<400>13
atgtggctgt ccccagctct gctgcttctc atcctcccag gttactccat tgccgctaaa 60
atcactggtc caacaacagt gaatggctcg gagcagggct cattgactgt gcagtgtgct 120
tatggctcag gctgggagac ctacttgaag tggcggtgtc aaggagctga ttggaattac 180
tgtaacatcc ttgttaaaac aaatggatca gagcaggagg taaagaagaa tcgagtttcc 240
atcagggaca atcagaaaaa ccacatgttc accgtgacca tggagaatct caaaagagat 300
gatgctgaca gttattggtg tgggactgag agacctggaa ttgatcttgg ggtcaaagtt 360
caagtgacca ttaacccagg cacacaaact gcagtctcag aatggacaac cacaacagca 420
agcctggctt tcacagctgc agccacccag aagaccagca gccccctcac caggtccccg 480
ctcaagagca cccacttcct gttcctgttc ctcctggagc tgcctctgct cctgagcatg 540
ctggggaccg tcctctgggt gaacagacca caaagaaggt cttga 585
<210>14
<211>1002
<212>DNA
<213>人(Homo sapiens)
<400>14
atgaggatct ggtggcttct gcttgccatt gaaatctgca cagggaacat aaactcacag 60
gacacctgca ggcaagggca ccctggaatc cctgggaacc ccggtcacaa tggtctgcct 120
ggaagagatg gacgagacgg agcgaagggt gacaaaggcg atgcaggaga accaggacgt 180
cctggcagcc cggggaagga tgggacgagt ggagagaagg gagaacgagg agcagatgga 240
aaagttgaag caaaaggcat caaaggtgat caaggctcaa gaggatcccc aggaaaacat 300
ggccccaagg ggcttgcagg gcccatggga gagaagggcc tccgaggaga gactgggcct 360
caggggcaga aggggaataa gggtgacgtg ggtcccactg gtcctgaggg gccaaggggc 420
aacattgggc ctttgggccc aactggttta ccgggcccca tgggccctat tggaaagcct 480
ggtcccaaag gagaagctgg acccacgggg ccccagggtg agccaggagt ccggggaata 540
agaggctgga aaggagatcg aggagagaaa gggaaaatcg gtgagactct agtcttgcca 600
aaaagtgctt tcactgtggg gctcacggtg ctgagcaagt ttccttcttc agatatgccc 660
attaaatttg ataagatcct gtataacgaa ttcaaccatt atgatacagc agcggggaaa 720
ttcacgtgcc acattgctgg ggtctattac ttcacctacc acatcactgt tttctccaga 780
aatgttcagg tgtctttggt caaaaatgga gtaaaaatac tgcacaccaa agatgcttac 840
atgagctctg aggaccaggc ctctggcggc attgtcctgc agctgaagct cggggatgag 900
gtgtggctgc aggtgacagg aggagagagg ttcaatggct tgtttgctga tgaggacgat 960
gacacaactt tcacagggtt ccttctgttc agcagcccgt ga 1002
<210>15
<211>678
<212>DNA
<213>人(Homo sapiens)
<400>15
atgaggatct ggtggcttct gcttgccatt gaaatctgca cagggaacat aaactcacag 60
gacacctgca ggcaagggca ccctggaatc cctgggaacc ccggtcacaa tggtctgcct 120
ggaagagatg gacgagacgg agcgaagggt gacaaaggcg atgcaggaga agctggaccc 180
acggggcccc agggtgagcc aggagtccgg ggaataagag gctggaaagg agatcgagga 240
gagaaaggga aaatcggtga gactctagtc ttgccaaaaa gtgctttcac tgtggggctc 300
acggtgctga gcaagtttcc ttcttcagat atgcccatta aatttgataa gatcctgtat 360
aacgaattca accattatga tacagcagcg gggaaattca cgtgccacat tgctggggtc 420
tattacttca cctaccacat cactgttttc tccagaaatg ttcaggtgtc tttggtcaaa 480
aatggagtaa aaatactgca caccaaagat gcttacatga gctctgagga ccaggcctct 540
ggcggcattg tcctgcagct gaagctcggg gatgaggtgt ggctgcaggt gacaggagga 600
gagaggttca atggcttgtt tgctgatgag gacgatgaca caactttcac agggttcctt 660
ctgttcagca gcccgtga 678
<210>16
<211>618
<212>DNA
<213>人(Homo sapiens)
<400>16
atgatgagaa ctctcatcac cacacaccca ctgcccctgc ttctattgcc gcagcagctg 60
ctgcagctgg tgcagtttca agaggtggat acagattttg atttcccaga agaagataaa 120
aaagaagaat ttgaagagtg tttggaaaaa ttttttagta cagggcccgc cagaccacct 180
accaaagaaa aagtcaaaag acgtgtcctt attgaacctg gaatgccact aaatcatata 240
gagtactgta accatgaaat catgggaaaa aatgtttact acaaacaccg ttgggtggca 300
gaacattact tccttcttat gcaatatgac gagctccaaa aaatctgtta caacagattt 360
gtgccatgta agaatggaat taggaaatgt aacaggagca aaggtcttgt agaaggagtg 420
tattgtaatt taacagaagc atttgaaata ccagcgtgta aatacgaatc actttatagg 480
aagggctacg tccttatcac ttgttcatgg caaaatgaaa tgcaaaaacg tattcctcat 540
actataaatg atctcgtgga gccacctgaa cacagaagtt tcctcagtga ggatggtgtc 600
tttgtcatat cgccctag 618
<210>17
<211>288
<212>DNA
<213>人(Homo sapiens)
<400>17
atggaggtgg tgctgatctt tctatgcagc ctgttggccc acattgtcct ggccgatgca 60
gttgagaggg agaagcaaat tgaccctttt cattatgact accagaccct gaggattagg 120
gggttggtat gtgctgtggt cctcttctcc attgggatcc tccttatcct aggttgcaga 180
tgcaagtgca gtttcaatca gaagcccagg accccaggag aggaggaagc ccaggtggag 240
aacctcatca ctgcaaatgc aacaaagctc cagaaagcag agagctga 288
<210>18
<211>1788
<212>DNA
<213>人(Homo sapiens)
<400>18
atggaggtgg gaatgggatg ctgggcccgg gaggtgctgg tccccgaggg gcccttgtac 60
cgcgtggctg gcacagctgt ctccatctcc tgcaatgtga ccggctatga gggccctgcc 120
cagcagaact tcgagtggtt cctgtatagg cccgaggccc cagatactgc actgggcatt 180
gtcagtacca aggataccca gttctcctat gctgtcttca agtcccgagt ggtggcgggt 240
gaggtgcagg tgcagcgcct acaaggtgat gccgtggtgc tcaagattgc ccgcctgcag 300
gcccaggatg ccggcattta tgagtgccac accccctcca ctgatacccg ctacctgggc 360
agctacagcg gcaaggtgga gctgagagtt cttccagatg tcctccaggt gtctgctgcc 420
cccccagggc cccgaggccg ccaggcccca acctcacccc cacgcatgac ggtgcatgag 480
gggcaggagc tggcactggg ctgcctggcg aggacaagca cacagaagca cacacacctg 540
gcagtgtcct ttgggcgatc tgtgcccgag gcaccagttg ggcggtcaac tctgcaggaa 600
gtggtgggaa tccggtcaga cttggccgtg gaggctggag ctccctatgc tgagcgattg 660
gctgcagggg agcttcgtct gggcaaggaa gggaccgatc ggtaccgcat ggtagtaggg 720
ggtgcccagg caggggacgc aggcacctac cactgcactg ccgctgagtg gattcaggat 780
cctgatggca gctgggccca gattgcagag aaaagggccg tcctggccca cgtggatgtg 840
cagacgctgt ccagccagct ggcagtgaca gtggggcctg gtgaacgtcg gatcggccca 900
ggggagccct tggaactgct gtgcaatgtg tcaggggcac ttcccccagc aggccgtcat 960
gctgcatact ctgtaggttg ggagatggca cctgcggggc acctggggcc cggccgcctg 1020
gtagcccagc tggacacaga gggtgtgggc agcctgggcc ctggctatga gggccgacac 1080
attgccatgg agaaggtggc atccagaaca taccggctac ggctagaggc tgccaggcct 1140
ggtgatgcgg gcacctaccg ctgcctcgcc aaagcctatg ttcgagggtc tgggacccgg 1200
cttcgtgaag cagccagtgc ccgttcccgg cctctccctg tacatgtgcg ggaggaaggt 1260
gtggtgctgg aggctgtggc atggctagca ggaggcacag tgtaccgcgg ggagactgcc 1320
tccctgctgt gcaacatctc tgtgcggggt ggccccccag gactgcggct ggccgccagc 1380
tggtgggtgg agcgaccaga ggacggagag ctcagctctg tccctgccca gctggtgggt 1440
ggcgtaggcc aggatggtgt ggcagagctg ggagtccggc ctggaggagg ccctgtcagc 1500
gtagagctgg tggggccccg aagccatcgg ctgagactac acagcttggg gcccgaggat 1560
gaaggcgtgt accactgtgc ccccagcgcc tgggtgcagc atgccgacta cagctggtac 1620
caggcgggca gtgcccgctc agggcctgtt acagtctacc cctacatgca tgccctggac 1680
accctatttg tgcctctgct ggtgggtaca ggggtggccc tagtcactgg tgccactgtc 1740
cttggtacca tcacttgctg cttcatgaag aggcttcgaa aacggtga 1788
<210>19
<211>1842
<212>DNA
<213>人(Homo sapiens)
<400>19
atgggcgccc tcaggcccac gctgctgccg ccttcgctgc cgctgctgct gctgctaatg 60
ctaggaatgg gatgctgggc ccgggaggtg ctggtccccg aggggccctt gtaccgcgtg 120
gctggcacag ctgtctccat ctcctgcaat gtgaccggct atgagggccc tgcccagcag 180
aacttcgagt ggttcctgta taggcccgag gccccagata ctgcactggg cattgtcagt 240
accaaggata cccagttctc ctatgctgtc ttcaagtccc gagtggtggc gggtgaggtg 300
caggtgcagc gcctacaagg tgatgccgtg gtgctcaaga ttgcccgcct gcaggcccag 360
gatgccggca tttatgagtg ccacaccccc tccactgata cccgctacct gggcagctac 420
agcggcaagg tggagctgag agttcttcca gatgtcctcc aggtgtctgc tgccccccca 480
gggccccgag gccgccaggc cccaacctca cccccacgca tgacggtgca tgaggggcag 540
gagctggcac tgggctgcct ggcgaggaca agcacacaga agcacacaca cctggcagtg 600
tcctttgggc gatctgtgcc cgaggcacca gttgggcggt caactctgca ggaagtggtg 660
ggaatccggt cagacttggc cgtggaggct ggagctccct atgctgagcg attggctgca 720
ggggagcttc gtctgggcaa ggaagggacc gatcggtacc gcatggtagt agggggtgcc 780
caggcagggg acgcaggcac ctaccactgc actgccgctg agtggattca ggatcctgat 840
ggcagctggg cccagattgc agagaaaagg gccgtcctgg cccacgtgga tgtgcagacg 900
ctgtccagcc agctggcagt gacagtgggg cctggtgaac gtcggatcgg cccaggggag 960
cccttggaac tgctgtgcaa tgtgtcaggg gcacttcccc cagcaggccg tcatgctgca 1020
tactctgtag gttgggagat ggcacctgcg ggggcacctg ggcccggccg cctggtagcc 1080
cagctggaca cagagggtgt gggcagcctg ggccctggct atgagggccg acacattgcc 1140
atggagaagg tggcatccag aacataccgg ctacggctag aggctgccag gcctggtgat 1200
gcgggcacct accgctgcct cgccaaagcc tatgttcgag ggtctgggac ccggcttcgt 1260
gaagcagcca gtgcccgttc ccggcctctc cctgtacatg tgcgggagga aggtgtggtg 1320
ctggaggctg tggcatggct agcaggaggc acagtgtacc gcggggagac tgcctccctg 1380
ctgtgcaaca tctctgtgcg gggtggcccc ccaggactgc ggctggccgc cagctggtgg 1440
gtggagcgac cagaggacgg agagctcagc tctgtccctg cccagctggt gggtggcgta 1500
ggccaggatg gtgtggcaga gctgggagtc cggcctggag gaggccctgt cagcgtagag 1560
ctggtggggc cccgaagcca tcggctgaga ctacacagct tggggcccga ggatgaaggc 1620
gtgtaccact gtgcccccag cgcctgggtg cagcatgccg actacagctg gtaccaggcg 1680
ggcagtgccc gctcagggcc tgttacagtc tacccctaca tgcatgccct ggacacccta 1740
tttgtgcctc tgctggtggg tacaggggtg gccctagtca ctggtgccac tgtccttggt 1800
accatcactt gctgcttcat gaagaggctt cgaaaacggt ga 1842
<210>20
<211>1791
<212>DNA
<213>人(Homo sapiens)
<400>20
atggccgcca actccaccag cgacctccac actcccggga cgcagctgag cgtggctgac 60
atcatcgtca tcactgtgta ttttgctctg aacgtggccg tgggcatatg gtcctcttgt 120
cgggccagta ggaacacggt gaatggctac ttcctggcag gccgggacat gacgtggtgg 180
ccgattggag cctccctctt cgccagcagc gagggctctg gcctcttcat tggactggcg 240
ggctcaggcg cggcaggagg tctggccgtg gcaggcttcg agtggaatgc cacgtacgtg 300
ctgctggcac tggcatgggt gttcgtgccc atctacatct cctcagagat cgtcacctta 360
cctgagtaca ttcagaagcg ctacgggggc cagcggatcc gcatgtacct gtctgtcctg 420
tccctgctac tgtctgtctt caccaagata tcgctggacc tgtacgcggg ggctctgttt 480
gtgcacatct gcctgggctg gaacttctac ctctccacca tcctcacgct cggcatcaca 540
gccctgtaca ccatcgcagg gggcctggct gctgtaatct acacggacgc cctgcagacg 600
ctcatcatgg tggtgggggc tgtcatcctg acaatcaaag cttttgacca gatcggtggt 660
tacgggcagc tggaggcagc ctacgcccag gccattccct ccaggaccat tgccaacacc 720
acctgccacc tgccacgtac agacgccatg cacatgtttc gagaccccca cacaggggac 780
ctgccgtgga ccgggatgac ctttggcctg accatcatgg ccacctggta ctggtgcacc 840
gaccaggtca tcgtgcagcg atcactgtca gcccgggacc tgaaccatgc caaggcgggc 900
tccatcctgg ccagctacct caagatgctc cccatgggcc tgatcataat gccgggcatg 960
atcagccgcg cattgttccc agatgatgtg ggctgcgtgg tgccgtccga gtgcctgcgg 1020
gcctgcgggg ccgaggtcgg ctgctccaac atcgcctacc ccaagctggt catggaactg 1080
atgcccatcg gtctgcgggg gctgatgatc gcagtgatgc tggcggcgct catgtcgtcg 1140
ctgacctcca tcttcaacag cagcagcacc ctcttcacta tggacatctg gaggcggctg 1200
cgtccccgct ccggcgagcg ggagctcctg ctggtgggac ggctggtcat agtggcactc 1260
atcggcgtga gtgtggcctg gatccccgtc ctgcaggact ccaacagcgg gcaactcttc 1320
atctacatgc agtcagtgac cagctccctg gccccaccag tgactgcagt ctttgtcctg 1380
ggcgtcttct ggcgacgtgc caacgagcag ggggccttct ggggcctgat agcagggctg 1440
gtggtggggg ccacgaggct ggtcctggaa ttcctgaacc cagccccacc gtgcggagag 1500
ccagacacgc ggccagccgt cctggggagc atccactacc tgcacttcgc tgtcgccctc 1560
tttgcactca gtggtgctgt tgtggtggct ggaagcctgc tgaccccacc cccacagagt 1620
gtccagattg agaaccttac ctggtggacc ctggctcagg atgtgccctt gggaactaaa 1680
gcaggtgatg gccaaacacc ccagaaacac gccttctggg cccgtgtctg tggcttcaat 1740
gccatcctcc tcatgtgtgt caacatattc ttttatgcct acttcgcctga 1791
<210>21
<211>1182
<212>DNA
<213>人(Homo sapiens)
<400>21
atggattcct taaagaatga gaactatgat ctggtatttg ttgaagcatt tgatttctgt 60
tctttcctga ttgctgagaa gcttgtgaaa ccatttgtgg ccattcttcc caccacattc 120
ggctctttgg attttgggct accaagcccc ttgtcttatg ttccagtatt cccttccttg 180
ctgactgatc acatggactt ctggggccga gtgaagaatt ttctgatgtt ctttagtttc 240
tccaggagcc aatgggacat gcagtctaca tttgacaaca ccatcaagga gcatttccca 300
gaaggctcta ggccagtttt gtctcatctt ctactgaaag cagagttgtg gtttgttaac 360
tctgattttg cctttgattt tgcccggccc ctgcttccca acactgttta tattggaggc 420
ttgatggaaa aacctattaa accagtacca caagacttgg acaacttcat tgccaacttt 480
ggggatgcag ggtttgtcct tgtggccttt ggctccatgt tgaacaccca tcagtcccag 540
gaagtcctca agaagatgca caatgccttt gcccacctcc ctcaaggagt gatatggaca 600
tgtcagagtt ctcattggcc cagagatgtt catttggcca caaatgtgaa aattgtggac 660
tggcttcctc agagtgacct cctggctcac cccagcatcc gtctttttgt cactcatggt 720
gggcagaaca gcgtaatgga ggccatccgt catggtgtgc ccatggtggg attaccagtc 780
aatggagacc agcatggaaa catggtccga gtagtagcca aaaattatgg tgtctctatc 840
cggttgaatc aggtcacagc cgacacactg acacttacaa tgaaacaagt catagaagac 900
aagaggtaca agtcggcagt ggtggcagcc agtgtcatcc tgcactctca gcccctgagc 960
cccgcacagc ggctggtggg ctggatcgac cacatcctcc agactggggg agcgacgcac 1020
ctcaagccct atgccttcca gcagccttgg catgagcagt acctcattga tgtctttgtg 1080
tttctgctgg ggctcactct gggcactatg tggctttgtg ggaagctgct gggtgtggtg 1140
gccaggtggc tgcgtggggc caggaaggtg aagaagacat ga 1182
<210>22
<211>1572
<212>DNA
<213>人(Homo sapiens)
<400>22
atggttgggc agcgggtgct gcttctagtg gccttccttc tttctggggt cctgctctca 60
gaggctgcca aaatcctgac aatatctaca ctgggtggaa gccattacct actgttggac 120
cgggtgtctc agattcttca agagcatggt cataatgtga ctatgcttca tcagagtgga 180
aagtttttga tcccagatat taaagaggag gaaaaatcat accaagttat caggtggttt 240
tcacctgaag atcatcaaaa aagaattaag aagcattttg atagctacat agaaacagca 300
ttggatggca gaaaagaatc tgaagccctt gtaaagctaa tggaaatatt tgggactcaa 360
tgtagttatt tgctaagcag aaaggatata atggattcct taaagaatga gaactatgat 420
ctggtatttg ttgaagcatt tgatttctgt tctttcctga ttgctgagaa gcttgtgaaa 480
ccatttgtgg ccattcttcc caccacattc ggctctttgg attttgggct accaagcccc 540
ttgtcttatg ttccagtatt cccttccttg ctgactgatc acatggactt ctggggccga 600
gtgaagaatt ttctgatgtt ctttagtttc tccaggagcc aatgggacat gcagtctaca 660
tttgacaaca ccatcaagga gcatttccca gaaggctcta ggccagtttt gtctcatctt 720
ctactgaaag cagagttgtg gtttgttaac tctgattttg cctttgattt tgcccggccc 780
ctgcttccca acactgttta tattggaggc ttgatggaaa aacctattaa accagtacca 840
caagacttgg acaacttcat tgccaacttt ggggatgcag ggtttgtcct tgtggccttt 900
ggctccatgt tgaacaccca tcagtcccag gaagtcctca agaagatgca caatgccttt 960
gcccacctcc ctcaaggagt gatatggaca tgtcagagtt ctcattggcc cagagatgtt 1020
catttggcca caaatgtgaa aattgtggac tggcttcctc agagtgacct cctggctcac 1080
cccagcatcc gtctttttgt cactcatggt gggcagaaca gcgtaatgga ggccatccgt 1140
catggtgtgc ccatggtggg attaccagtc aatggagacc agcatggaaa catggtccga 1200
gtagtagcca aaaattatgg tgtctctatc cggttgaatc aggtcacagc cgacacactg 1260
acacttacaa tgaaacaagt catagaagac aagaggtaca agtcggcagt ggtggcagcc 1320
agtgtcatcc tgcactctca gcccctgagc cccgcacagc ggctggtggg ctggatcgac 1380
cacatcctcc agactggggg agcgacgcac ctcaagccct atgccttcca gcagccttgg 1440
catgagcagt acctcattga tgtctttgtg tttctgctgg ggctcactct gggcactatg 1500
tggctttgtg ggaagctgct gggtgtggtg gccaggtggc tgcgtggggc caggaaggtg 1560
aagaagacat ga 1572
<210>23
<211>759
<212>DNA
<213>人(Homo sapiens)
<400>23
atgagctgcg tcctgggtgg tgtcatcccc ttggggctgc tgttcctggt ctgcggatcc 60
caaggctacc tcctgcccaa cgtcactctc ttagaggagc tgctcagcaa ataccagcac 120
aacgagtctc actcccgggt ccgcagagcc atccccaggg aggacaagga ggagatcctc 180
atgctgcaca acaagcttcg gggccaggtg cagcctcagg cctccaacat ggagtacatg 240
acctgggatg acgaactgga gaagtctgct gcagcgtggg ccagtcagtg catctgggag 300
cacgggccca ccagtctgct ggtgtccatc gggcagaacc tgggcgctca ctggggcagg 360
tatcgctctc cggggttcca tgtgcagtcc tggtatgacg aggtgaagga ctacacctac 420
ccctacccga gcgagtgcaa cccctggtgt ccagagaggt gctcggggcc catgtgcacg 480
cactacacac agatagtttg ggccaccacc aacaagatcg gttgtgctgt gaacacctgc 540
cggaagatga ctgtctgggg agaagtttgg gagaacgcgg tctactttgt ctgcaattat 600
tctccaaagg ggaactggat tggagaagcc ccctacaaga atggccggcc ctgctctgag 660
tgcccaccca gctatggagg cagctgcagg aacaacttgt gttaccgagg taggaaattt 720
actcccaaca cttttgcaat gaatttgccc tcagtctga 759
<210>24
<211>1494
<212>DNA
<213>人(Homo sapiens)
<400>24
atgagctgcg tcctgggtgg tgtcatcccc ttggggctgc tgttcctggt ctgcggatcc 60
caaggctacc tcctgcccaa cgtcactctc ttagaggagc tgctcagcaa ataccagcac 120
aacgagtctc actcccgggt ccgcagagcc atccccaggg aggacaagga ggagatcctc 180
atgctgcaca acaagcttcg gggccaggtg cagcctcagg cctccaacat ggagtacatg 240
acctgggatg acgaactgga gaagtctgct gcagcgtggg ccagtcagtg catctgggag 300
cacgggccca ccagtctgct ggtgtccatc gggcagaacc tgggcgctca ctggggcagg 360
tatcgctctc cggggttcca tgtgcagtcc tggtatgacg aggtgaagga ctacacctac 420
ccctacccga gcgagtgcaa cccctggtgt ccagagaggt gctcggggcc catgtgcacg 480
cactacacac agatagtttg ggccaccacc aacaagatcg gttgtgctgt gaacacctgc 540
cggaagatga ctgtctgggg agaagtttgg gagaacgcgg tctactttgt ctgcaattat 600
tctccaaagg ggaactggat tggagaagcc ccctacaaga atggccggcc ctgctctgag 660
tgcccaccca gctatggagg cagctgcagg aacaacttgt gttaccgaga agaaacctac 720
actccaaaac ctgaaacgga cgagatgaat gaggtggaaa cggctcccat tcctgaagaa 780
aaccatgttt ggctccaacc gagggtgatg agacccacca agcccaagaa aacctctgcg 840
gtcaactaca tgacccaagt cgtcagatgt gacaccaaga tgaaggacag gtgcaaaggg 900
tccacgtgta acaggtacca gtgcccagca ggctgcctga accacaaggc gaagatcttt 960
ggaactctgt tctatgaaag ctcgtctagc atatgccgcg ccgccatcca ctacgggatc 1020
ctggatgaca agggaggcct ggtggatatc accaggaacg ggaaggtccc cttcttcgtg 1080
aagtctgaga gacacggcgt gcagtccctc agcaaataca aaccttccag ctcattcatg 1140
gtgtcaaaag tgaaagtgca ggatttggac tgctacacga ccgttgctca gctgtgcccg 1200
tttgaaaagc cagcaactca ctgcccaaga atccattgtc cggcacactg caaagacgaa 1260
ccttcctact gggctccggt gtttggaacc aacatctatg cagatacctc aagcatctgc 1320
aagacagccg tgcacgcggg agtcatcagc aacgagagtg ggggtgacgt ggacgtgatg 1380
cccgtggata aaaagaagac ctacgtgggc tcgctcagga atggagttca gtctgaaagc 1440
ctggggactc ctcgggatgg aaaggccttc cggatctttg ctgtcaggca gtga 1494
<210>25
<211>1315
<212>DNA
<213>人(Homo sapiens)
<400>25
batgctgcac aacaagcttc ggggccaggt gcagcctcag gcctccaaca tggagtacat 60
gacctgggat gacgaactgg agaagtctgc tgcagcgtgg gccagtcagt gcatctggga 120
gcacgggccc accagtctgc tggtgtccat cgggcagaac ctgggcgctc actggggcag 180
gtatcgctct ccggggttcc atgtgcagtc ctggtatgac gaggtgaagg actacaccta 240
cccctacccg agcgagtgca acccctggtg tccagagagg tgctcggggc ccatgtgcac 300
gcactacaca cagatagttt gggccaccac caacaagatc ggttgtgctg tgaacacctg 360
ccggaagatg actgtctggg gagaagtttg ggagaacgcg gtctactttg tctgcaatta 420
ttctccaaag gggaactgga ttggagaagc cccctacaag aatggccggc cctgctctga 480
gtgcccaccc agctatggag gcagctgcag gaacaacttg tgttaccgag aagaaaccta 540
cactccaaaa cctgaaacgg acgagatgaa tgaggtggaa acggctccca ttcctgaaga 600
aaaccatgtt tggctccaac cgagggtgat gagacccacc aagcccaaga aaacctctgc 660
ggtcaactac atgacccaag tcgtcagatg tgacaccaag atgaaggaca ggtgcaaagg 720
gtccacgtgt aacaggtacc agtgcccagc aggctgcctg aaccacaagg cgaagatctt 780
tggaactctg ttctatgaaa gctcgtctag catatgccgc gccgccatcc actacgggat 840
cctggatgac aagggaggcc tggtggatat caccaggaac gggaaggtcc ccttcttcgt 900
gaagtctgag agacacggcg tgcagtccct cagcaaatac aaaccttcca gctcattcat 960
ggtgtcaaaa gtgaaagtgc aggatttgga ctgctacacg accgttgctc agctgtgccc 1020
gtttgaaaag ccagcaactc actgcccaag aatccattgt ccggcacact gcaaagacga 1080
accttcctac tgggctccgg tgtttggaac caacatctat gcagatacct caagcatctg 1140
caagacagcc gtgcacgcgg gagtcatcag caacgagagt gggggtgacg tggacgtgat 1200
gcccgtggat aaaaagaaga cctacgtggg ctcgctcagg aatggagttc agtctgaaag 1260
cctggggact cctcgggatg gaaaggcctt ccggatcttt gctgtcaggc agtga 1315
<210>26
<211>927
<212>DNA
<213>人(Homo sapiens)
<400>26
atggttgggg gcgtcctcgc ctcgctgggc ttcgtcttct cggctttcgc cagcgatctg 60
ctgcatctct acctcggcct gggcctcctc gctggctttg gttgggccct ggtgttcgcc 120
cccgccctag gcaccctctc gcgttacttc tcccgccgtc gagtcttggc ggtggggctg 180
gcgctcaccg gcaacggggc ctcctcgctg ctcctggcgc ccgccttgca gcttcttctc 240
gatactttcg gctggcgggg cgctctgctc ctcctcggcg cgatcaccct ccacctcacc 300
ccctgtggcg ccctgctgct acccctggtc cttcctggag accccccagc cccaccgcgt 360
agtcccctag ctgccctcgg cctgagtctg ttcacacgcc gggccttctc aatctttgct 420
ctaggcacag ccctggttgg gggcgggtac ttcgttcctt acgtgcactt ggctccccac 480
gctttagacc ggggcctggg gggatacgga gcagcgctgg tggtggccgt ggctgcgatg 540
ggggatgcgg gcgcccggct ggtctgcggg tggctggcag accaaggctg ggtgcccctc 600
ccgcggctgc tggccgtatt cggggctctg actgggctgg ggctgtgggt ggtggggctg 660
gtgcccgtgg tgggcggcga agagagctgg gggggtcccc tgctggccgc ggctgtggcc 720
tatgggctga gcgcggggag ttacgccccg ctggttttcg gtgtactccc cgggctggtg 780
ggcgtcggag gtgtggtgca ggccacaggg ctggtgatga tgctgatgag cctcgggggg 840
ctcctgggcc ctcccctgtc aggtaaggac ctgagctcac agatctgcct acaactatcc 900
tctgcccctg gggttcgagg cttctaa 927
<210>27
<211>1344
<212>DNA
<213>人(Homo sapiens)
<400>27
atgacccccc agcccgccgg acccccggat gggggctggg gctgggtggt ggcggccgca 60
gccttcgcga taaacgggct gtcctacggg ctgctgcgct cgctgggcct tgccttccct 120
gaccttgccg agcactttga ccgaagcgcc caggacactg cgtggatcag cgccctggcc 180
ctggccgtgc agcaggcagc cagccccgtg ggcagcgccc tgagcacgcg ctggggggcc 240
cgccccgtgg tgatggttgg gggcgtcctc gcctcgctgg gcttcgtctt ctcggctttc 300
gccagcgatc tgctgcatct ctacctcggc ctgggcctcc tcgctggctt tggttgggcc 360
ctggtgttcg cccccgccct aggcaccctc tcgcgttact tctcccgccg tcgagtcttg 420
gcggtggggc tggcgctcac cggcaacggg gcctcctcgc tgctcctggc gcccgccttg 480
cagcttcttc tcgatacttt cggctggcgg ggcgctctgc tcctcctcgg cgcgatcacc 540
ctccacctca ccccctgtgg cgccctgctg ctacccctgg tccttcctgg agacccccca 600
gccccaccgc gtagtcccct agctgccctc ggcctgagtc tgttcacacg ccgggccttc 660
tcaatctttg ctctaggcac agccctggtt gggggcgggt acttcgttcc ttacgtgcac 720
ttggctcccc acgctttaga ccggggcctg gggggatacg gagcagcgct ggtggtggcc 780
gtggctgcga tgggggatgc gggcgcccgg ctggtctgcg ggtggctggc agaccaaggc 840
tgggtgcccc tcccgcggct gctggccgta ttcggggctc tgactgggct ggggctgtgg 900
gtggtggggc tggtgcccgt ggtgggcggc gaagagagct gggggggtcc cctgctggcc 960
gcggctgtgg cctatgggct gagcgcgggg agttacgccc cgctggtttt cggtgtactc 1020
cccgggctgg tgggcgtcgg aggtgtggtg caggccacag ggctggtgat gatgctgatg 1080
agcctcgggg ggctcctggg ccctcccctg tcaggcttcc taagggatga gacaggagac 1140
ttcaccgcct ctttcctcct gtctggttct ttgatcctct ccggcagctt catctacata 1200
gggttgccca gggcgctgcc ctcctgtggt ccagcctccc ctccagccac gcctccccca 1260
gagacggggg agctgcttcc cgctccccag gcagtcttgc tgtccccagg aggccctggc 1320
tccactctgg acaccacttg ttga 1344
<210>28
<211>1375
<212>DNA
<213>人(Homo sapiens)
<400>28
batggcgcgc aggacagagc cccccgacgg gggctgggga tgggtggtgg tgctctcagc 60
gttcttccag tcggcgcttg tgtttggggt gctccgctcc tttggggtct tcttcgtgga 120
gtttgtggcg gcgtttgagg agcaggcagc gcgcgtctcc tggatcgcct ccataggaat 180
cgcggtgcag cagtttggga gcccggtagg cagtgccctg agcacgaagt tcgggcccag 240
gcccgtggtg atgactggag gcatcttggc tgcgctgggg atgctgctcg cctcttttgc 300
tacttccttg acccacctat acctgagtat tgggttgctg tcaggctctg gctgggcttt 360
gaccttcgct ccgaccctgg cctgcctgtc ctgttatttc tctcgccgac gatccctggc 420
caccgggctg gcactgacag gcgtgggcct ctcctccttc acatttgccc cctttttcca 480
gtggctgctc agccactacg cctggagggg gtccctgctg ctggtgtctg ccctctccct 540
ccacctagtg gcctgtggtg ctctcctccg cccaccctcc ctggctgagg accctgctgt 600
gggtggtccc agggcccaac tcacctctct cctccatcat ggccccttcc tccgttacac 660
tgttgccctc accctgatca acactggcta cttcattccc tacctccacc tggtggccca 720
tctccaggac ctggattggg acccactacc tgctgccttc ctactctcag ttgttgctat 780
ttctgacctc gtggggcgtg tggtctccgg atggctggga gatgcagtcc cagggcctgt 840
gacacgactc ctgatgctct ggaccacctt gactggggtg tcactagccc tgttccctgt 900
agctcaggct cccacagccc tggtggctct ggctgtggcc tacggcttca catcaggggc 960
tctggcccca ctggccttct ccgtgctgcc tgaactaata gggactagaa ggatttactg 1020
tggcctggga ctgttgcaga tgatagagag catcgggggg ctgctggggc ctcctctctc 1080
aggctacctc cgggatgtgt caggcaacta cacggcttct tttgtggtgg ctggggcctt 1140
ccttctttca gggagtggca ttctcctcac cctgccccac ttcttctgct tctcaactac 1200
tacctccggg cctcaggacc ttgtaacaga agcactagat actaaagttc ccctacccaa 1260
ggaggggctg gaaggaggac tgaactccac agagtcaggc ccagaaagcc aaagcttgac 1320
agctccaggt cttctcttgc cacgtcttgg tctccacaga accacagtgc cttaa 1375
<210>29
<211>510
<212>DNA
<213>人(Homo sapiens)
<400>29
atgaccatga agacctctgg ggccacttgt gatgcaaaca gtgtgatgaa ctgcgggatc 60
cgcgggtctg aaatgtttgc tgagatggat ttgagggcca taaaacctta ccagactctg 120
atcaaaaaag tcgggcagag acattgcgtg gaccctgctg tcatcgcagc catcatctcc 180
agggaaagcc atgggggatc tgtcctgcaa gacggctggg accacagggg acttaaattt 240
ggcttgatgc agcttgataa acaaacgtac caccctgtcg gtgcctggga tagcaaagag 300
cacctttcac aggctactgg gattctaaca gagagaatta aggcaatcca gaaaaaattc 360
cccacgtgga gtgttgctca gcacctcaaa ggtggtctct cagcttttaa gtcaggaatt 420
gaagcgattg ccaccccatc ggacatagac aatgacttcg tcaatgatat cattgctcga 480
gctaagttct ataaaagaca aagcttctag 510
<210>30
<211>561
<212>DNA
<213>人(Homo sapiens)
<400>30
atgaagcctc acctacatcc acgcctgtac cacggctgct atggggacat catgaccatg 60
aagacctctg gggccacttg tgatgcaaac agtgtgatga actgcgggat ccgcgggtct 120
gaaatgtttg ctgagatgga tttgagggcc ataaaacctt accagactct gatcaaaaaa 180
gtcgggcaga gacattgcgt ggaccctgct gtcatcgcag ccatcatctc cagggaaagc 240
catgggggat ctgtcctgca agacggctgg gaccacaggg gacttaaatt tggcttgatg 300
cagcttgata aacaaacgta ccaccctgtc ggtgcctggg atagcaaaga gcacctttca 360
caggctactg ggattctaac agagagaatt aaggcaatcc agaaaaaatt ccccacgtgg 420
agtgttgctc agcacctcaa aggtggtctc tcagctttta agtcaggaat tgaagcgatt 480
gccaccccat cggacataga caatgacttc gtcaatgata tcattgctcg agctaagttc 540
tataaaagac aaagcttcta g 561
<210>31
<211>2028
<212>DNA
<213>人(Homo sapiens)
<400>31
atggagagcg gcaccagcag ccctcagcct ccacagttag atcccctgga tgcgtttccc 60
cagaagggct tggagcctgg ggacatcgcg gtgctagttc tgtacttcct ctttgtcctg 120
gctgttggac tatggtccac agtgaagacc aaaagagaca cagtgaaagg ctacttcctg 180
gctggagggg acatggtgtg gtggccagtg ggtgcatcct tgtttgccag caatgttgga 240
agtggacatt tcattggcct ggcagggtca ggtgctgcta cgggcatttc tgtatcagct 300
tatgaactta atggcttgtt ttctgtgctg atgttggcct ggatcttcct acccatctac 360
attgctggtc aggtcaccac gatgccagaa tacctacgga agcgcttcgg tggcatcaga 420
atccccatca tcctggctgt actctaccta tttatctaca tcttcaccaa gatctcggta 480
gacatgtatg caggtgccat cttcatccag cagtctttgc acctggatct gtacctggcc 540
atagttgggc tactggccat cactgctgta tacacggttg ctggtggcct ggctgctgtg 600
atctacacgg atgccctgca gacgctgatc atgcttatag gagcgctcac cttgatgggc 660
tacagtttcg ccgcggttgg tgggatggaa ggactgaagg agaagtactt cttggccctg 720
gctagcaacc ggagtgagaa cagcagctgc gggctgcccc gggaagatgc cttccatatt 780
ttccgagatc cgctgacatc tgatctcccg tggccggggg tcctatttgg aatgtccatc 840
ccatccctct ggtactggtg cacggatcag gtgattgtcc agcggactct ggctgccaag 900
aacctgtccc atgccaaagg aggtgctctg atggctgcat acctgaaggt gctgcccctc 960
ttcataatgg tgttccctgg gatggtcagc cgcatcctct tcccagatca agtggcctgt 1020
gcagatccag agatctgcca gaagatctgc agcaacccct caggctgttc ggacatcgcg 1080
tatcccaaac tcgtgctgga actcctgccc acagggctcc gtgggctgat gatggctgtg 1140
atggtggcgg ctctcatgtc ctccctcacc tccatcttta acagtgccag caccatcttc 1200
accatggacc tctggaatca cctccggcct cgggcatctg agaaggagct catgattgtg 1260
ggcagggtgt ttgtgctgct gctggtcctg gtctccatcc tctggatccc tgtggtccag 1320
gccagccagg gcggccagct cttcatctat atccagtcca tcagctccta cctgcagccg 1380
cctgtggcgg tggtcttcat catgggatgt ttctggaaga ggaccaatga aaagggtgcc 1440
ttctggggcc tgatctcggg cctgctcctg ggcttggtta ggctggtcct ggactttatt 1500
tacgtgcagc ctcgatgcga ccagccagat gagcgcccgg tcctggtgaa gagcattcac 1560
tacctctact tctccatgat cctgtccacg gtcaccctca tcactgtctc caccgtgagc 1620
tggttcacag agccaccctc caaggagatg gtcagccacc tgacctggtt tactcgtcac 1680
gaccccgtgg tccagaagga acaagcacca ccagcagctc ccttgtctct taccctctct 1740
cagaacggga tgccagaggc cagcagcagc agcagcgtcc agttcgagat ggttcaagaa 1800
aacacgtcta aaacccacag ctgtgacatg accccaaagc agtccaaagt ggtgaaggcc 1860
atcctgtggc tctgtggaat acaggagaag ggcaaggaag agctcccggc cagagcagaa 1920
gccatcatag tttccctgga agaaaacccc ttggtgaaga ccctcctgga cgtcaacctc 1980
attttctgcg tgagctgcgc catctttatc tggggctatt ttgcttag 2028
<210>32
<211>1458
<212>DNA
<213>人(Homo sapiens)
<400>32
atggagccct gttggggaga aggcttgttt catctagcac ccccacgcca ccatccccag 60
aaggctgact ggcatttctg tccacagcac attcaggaat tcaccaatga gacatggcag 120
gcgcgtactg gagagccact gcccgatcac ctagtcctgc ttatgtggtc cctcatcgtg 180
tctctgtatc ccctgggagg cctctttgga gcactgcttg caggtccctt ggccatcacg 240
ctgggaagga agaagtccct cctggtgaat aacatctttg tggtgtcagc agcaatcctg 300
tttggattca gccgcaaagc aggctccttt gagatgatca tgctgggaag actgctcgtg 360
ggagtcaatg caggtgtgag catgaacatc cagcccatgt acctggggga gagcgcccct 420
aaggagctcc gaggagctgt ggccatgagc tcagccatct ttacggctct ggggatcgtg 480
atgggacagg tggtcggact cagggagctc ctaggtggcc ctcaggcctg gcccctgctg 540
ctggccagct gcctggtgcc cggggcgctc cagctcgcct ccctgcctct gctccctgaa 600
agcccgcgct acctcctcat tgactgtgga gacaccgagg cctgcctggc agcactacgg 660
cggctccggg gctccgggga cttggcaggg gagctggagg agctggagga ggagcgcgct 720
gcctgccagg gctgccgtgc ccggcgccca tgggagctgt tccagcatcg ggccctgagg 780
agacaggtga caagcctcgt ggttctgggc agtgccatgg agctctgcgg gaatgactcg 840
gtgtacgcct acgcctcctc cgtgttccgg aaggcaggag tgccggaagc gaagatccag 900
tacgcgatca tcgggactgg gagctgcgag ctgctcacgg cggttgttag ttgtgtggta 960
atcgagaggg tgggtcggcg cgtgctgctc atcggtgggt acagcctgat gacctgctgg 1020
gggagcatct tcactgtggc cctgtgcctg cagagctcct tcccctggac actctacctg 1080
gccatggcct gcatctttgc cttcatcctc agctttggca ttggccctgc cggagtgacg 1140
gggatcctgg ccacagagct gtttgaccag atggccaggc ctgctgcctg catggtctgc 1200
ggggcgctca tgtggatcat gctcatcctg gtcggcctgg gatttccctt tatcatggag 1260
gccttgtccc acttcctcta tgtccctttc cttggtgtct gtgtctgtgg ggccatctac 1320
actggcctgt tccttcctga gaccaaaggc aagaccttcc aagagatctc caaggaatta 1380
cacagactca acttccccag gcgggcccag ggccccacgt ggaggagcct ggaggttatc 1440
cagtcaacag aactctag 1458
<210>33
<211>1491
<212>DNA
<213>人(Homo sapiens)
<400>33
atgagagcgc tccgaagact gattcagggc aggatcctgc tcctgaccat ctgcgctgcc 60
ggcattggtg ggacttttca gtttggctat aacctctcta tcatcaatgc cccgaccttg 120
cacattcagg aattcaccaa tgagacatgg caggcgcgta ctggagagcc actgcccgat 180
cacctagtcc tgcttatgtg gtccctcatc gtgtctctgt atcccctggg aggcctcttt 240
ggagcactgc ttgcaggtcc cttggccatc acgctgggaa ggaagaagtc cctcctggtg 300
aataacatct ttgtggtgtc agcagcaatc ctgtttggat tcagccgcaa agcaggctcc 360
tttgagatga tcatgctggg aagactgctc gtgggagtca atgcaggtgt gagcatgaac 420
atccagccca tgtacctggg ggagagcgcc cctaaggagc tccgaggagc tgtggccatg 480
agctcagcca tctttacggc tctggggatc gtgatgggac aggtggtcgg actcagggag 540
ctcctaggtg gccctcaggc ctggcccctg ctgctggcca gctgcctggt gcccggggcg 600
ctccagctcg cctccctgcc tctgctccct gaaagcccgc gctacctcct cattgactgt 660
ggagacaccg aggcctgcct ggcagcacta cggcggctcc ggggctccgg ggacttggca 720
ggggagctgg aggagctgga ggaggagcgc gctgcctgcc agggctgccg tgcccggcgc 780
ccatgggagc tgttccagca tcgggccctg aggagacagg tgacaagcct cgtggttctg 840
ggcagtgcca tggagctctg cgggaatgac tcggtgtacg cctacgcctc ctccgtgttc 900
cggaaggcag gagtgccgga agcgaagatc cagtacgcga tcatcgggac tgggagctgc 960
gagctgctca cggcggttgt tagttgtgtg gtaatcgaga gggtgggtcg gcgcgtgctg 1020
ctcatcggtg ggtacagcct gatgacctgc tgggggagca tcttcactgt ggccctgtgc 1080
ctgcagagct ccttcccctg gacactctac ctggccatgg cctgcatctt tgccttcatc 1140
ctcagctttg gcattggccc tgccggagtg acggggatcc tggccacaga gctgtttgac 1200
cagatggcca ggcctgctgc ctgcatggtc tgcggggcgc tcatgtggat catgctcatc 1260
ctggtcggcc tgggatttcc ctttatcatg gaggccttgt cccacttcct ctatgtccct 1320
ttccttggtg tctgtgtctg tggggccatc tacactggcc tgttccttcc tgagaccaaa 1380
ggcaagacct tccaagagat ctccaaggaa ttacacagac tcaacttccc caggcgggcc 1440
cagggcccca cgtggaggag cctggaggtt atccagtcaa cagaactcta g 1491
<210>34
<211>1501
<212>DNA
<213>人(Homo sapiens)
<400>34
batgctccac gccctcctgc gatctagaat gattcagggc aggatcctgc tcctgaccat 60
ctgcgctgcc ggcattggtg ggacttttca gtttggctat aacctctcta tcatcaatgc 120
cccgaccttg cacattcagg aattcaccaa tgagacatgg caggcgcgta ctggagagcc 180
actgcccgat cacctagtcc tgcttatgtg gtccctcatc gtgtctctgt atcccctggg 240
aggcctcttt ggagcactgc ttgcaggtcc cttggccatc acgctgggaa ggaagaagtc 300
cctcctggtg aataacatct ttgtggtgtc agcagcaatc ctgtttggat tcagccgcaa 360
agcaggctcc tttgagatga tcatgctggg aagactgctc gtgggagtca atgcaggtgt 420
gagcatgaac atccagccca tgtacctggg ggagagcgcc cctaaggagc tccgaggagc 480
tgtggccatg agctcagcca tctttacggc tctggggatc gtgatgggac aggtggtcgg 540
actcagggag ctcctaggtg gccctcaggc ctggcccctg ctgctggcca gctgcctggt 600
gcccggggcg ctccagctcg cctccctgcc tctgctccct gaaagcccgc gctacctcct 660
cattgactgt ggagacaccg aggcctgcct ggcagcacta cggcggctcc ggggctccgg 720
ggacttggca ggggagctgg aggagctgga ggaggagcgc gctgcctgcc agggctgccg 780
tgcccggcgc ccatgggagc tgttccagca tcgggccctg aggagacagg tgacaagcct 840
cgtggttctg ggcagtgcca tggagctctg cgggaatgac tcggtgtacg cctacgcctc 900
ctccgtgttc cggaaggcag gagtgccgga agcgaagatc cagtacgcga tcatcgggac 960
tgggagctgc gagctgctca cggcggttgt tagttgtgtg gtaatcgaga gggtgggtcg 1020
gcgcgtgctg ctcatcggtg ggtacagcct gatgacctgc tgggggagca tcttcactgt 1080
ggccctgtgc ctgcagagct ccttcccctg gacactctac ctggccatgg cctgcatctt 1140
tgccttcatc ctcagctttg gcattggccc tgccggagtg acggggatcc tggccacaga 1200
gctgtttgac cagatggcca ggcctgctgc ctgcatggtc tgcggggcgc tcatgtggat 1260
catgctcatc ctggtcggcc tgggatttcc ctttatcatg gaggccttgt cccacttcct 1320
ctatgtccct ttccttggtg tctgtgtctg tggggccatc tacactggcc tgttccttcc 1380
tgagaccaaa ggcaagacct tccaagagat ctccaaggaa ttacacagac tcaacttccc 1440
caggcgggcc cagggcccca cgtggaggag cctggaggtt atccagtcaa cagaactcta 1500
g 1501
<210>35
<211>4077
<212>DNA
<213>人(Homo sapiens)
<400>35
atggtagtgg tgaagcccat gaacacaatg gctccggtgg tcacccggaa taccggtctt 60
attctctatg agggtcagtc tcggcccctc acaggccctg caggcagtgg tccgcaaaac 120
ttggtcatca gcgatgagga tgacctagaa gcagtgcggc tagaggtggt ggctgggctc 180
cggcatggtc accttgtcat tctgggtgct tccagtggca gctctgctcc caagagcttt 240
acagtggctg agctggcagc cggccaggtg gtctaccagc atgatgacag agacggctcg 300
ctgagcgaca acctggtgct tcgcatggtg gatggaggag gcaggcacca ggtacagttt 360
ctgttcccca tcaccttagt gcctgtggat gaccagccac ctgttctcaa tgccaacacg 420
gggctgacac tggcagaggg tgaaacagtg cccatcctgc ccctttccct gagtgcaact 480
gacatggatt cagatgattc tctgctgctt tttgtgctgg agtcaccctt cttaactacg 540
gggcatctgc ttctccgcca aactcaccct ccccatgaga agcaggaact tctcagaggc 600
ctttggagga aggagggggc attttatgag cgaacagtga cagagtggca gcagcaggac 660
ataacagagg gcaggctgtt ctatagacac tctgggcccc atagtcctgg gccagtcaca 720
gaccagttca catttagagt ccaggataac catgaccctc ctaatcagtc cgggctacag 780
cggtttgtga ttcgtatcca tcctgtggat cgcctccctc cggagctggg cagtggctgt 840
ccccttcgta tggtggtaca ggaatcccag ctcacaccac tgaggaagaa gtggctgcgc 900
tacactgacc tggacacaga tgaccgagaa ctacgttaca cagtgactca gtcccccaca 960
gacacagacg aaaatcacct gccagcccca ctgggtacct tggtcttgac tgacaacccc 1020
tcagtcgtgg tgacccattt tacccaagcc cagatcaacc atcataaaat tgcttacaga 1080
cccccgggtc aagaactggg cgtggctact cgagtggccc agttccagtt ccaggtggaa 1140
gaccgagctg ggaatgtggc tccaggtacc tttacccttt acttgcatcc cgtggacaac 1200
cagccacctg agatcctcaa caccggcttc actattcagg agaagggtca ccacatcctg 1260
agtgagacag agttgcacgt gaatgatgta gacactgatg ttgcccatat ctctttcact 1320
ctcactcagg cacccaaaca tggccacatg agagtgtctg gacagatcct gcatgtaggg 1380
ggtctcttcc acttggagga cataaaacag ggccgagttt cctatgccca taatggggac 1440
aagtccctga ctgatagctg ctccttggaa gtcagtgaca gacatcatgt ggtgcccatc 1500
actctcagag taaatgtccg gccagtggat gatgaagtgc ccatactgag ccatcctact 1560
ggcactctgg agtcctatct agatgtctta gaaaatgggg ctactgaaat cactgccaat 1620
gttattaagg ggaccaatga ggaaactgat gacttgatgt tgactttcct cttggaagat 1680
ccacctttgt atggggaaat cttggtcaat ggcattccag cagagcagtt tactcaaagg 1740
gacatcttgg agggctctgt tgtatatacc cacaccagtg gtgagatagg cctattgcct 1800
aaagcggatt cttttaacct gagtctgtca gatatgtctc aagaatggag aattggtggc 1860
aatactatcc aaggagttac tatatgggtg accatcctgc ctgttgatag ccaggcccca 1920
gaaatctttg taggtgaaca gttgatagta atggaaggtg ataaaagtgt tataacatca 1980
gtgcatataa gtgctgaaga tgtcgactcc ctgaatgatg acatcttgtg cactatagtt 2040
attcagccta cttcaggtta tgttgaaaac atttctccag caccaggctc tgagaaatca 2100
agagcaggga ttgccataag tgctttcaac ttgaaagatc tcaggcaggg ccacataaac 2160
tatgtccaga gtgtccataa aggggtggaa cctgtggagg accgatttgt atttcgttgt 2220
tctgatggca ttaacttttc agagagacag ttcttcccca ttgtaatcat tcccaccaat 2280
gatgaacagc cagagatgtt tatgagagaa tttatggtga tggaaggcat gagtctggta 2340
attgatacac ccattctcaa tgctgctgat gctgatgttc ccctggatga tttaactttc 2400
actattaccc aattccccac tcatggtcac atcatgaatc agctgataaa tggcacggtt 2460
ttggtcgaaa gcttcacctt ggatcagatc atagagagtt ccagcattat ttatgagcat 2520
gatgactccg agacccagga agacagtttt gtgattaaac taacagatgg gaagcactct 2580
gtggaaaaga cggtcctcat tatagttatc cctgttgatg atgagacgcc cagaatgact 2640
atcaataatg gactagaaat agaaattggg gataccaaga ttatcaacaa caaaatatta 2700
atggcaacag atttagattc agaagacaaa tctttggttt atattattcg ttatgggcca 2760
ggacatggct tattacagag acgaaaacct actggtgcct ttgaaaatat cacactgggc 2820
atgaatttta cccaggatga agtagacaga aacttaattc agtatgtcca tttggggcaa 2880
gagggcattc gggacctaat taaatttgat gtgactgatg gaataaatcc cctcatagat 2940
cgttactttt atgtgtccat cgggagcatt gacattgtct tccctgatgt gataagtaag 3000
ggagtgtcct tgaaagaagg tggcaaagtc actcttacaa cagacctact aagcactagt 3060
gacttgaaca gtcctgatga aaacttggtt tttaccatca ccagggctcc catgcgaggt 3120
cacctggaat gcacggatca gcctggtgtg tccatcacgt ctttcactca gctgcaactg 3180
gctggaaaca aaatctacta catccacaca gctgatgatg aagtgaaaat ggacagtttt 3240
gagtttcaag tcaccgatgg acgtaaccct gtctttcgga cattccgtat ctccattagc 3300
gatgtggaca ataaaaagcc agtggtcacc atccacaagc tggttgtcag tgaaagtgaa 3360
aacaagctga ttactccttt tgagctcact gtcgaagaca gagatactcc tgacaagctc 3420
ctgaaattca ctatcaccca ggtgcctatt catggccatc tcctattcaa caataccaga 3480
cctgtcatgg tttttaccaa gcaagacttg aatgaaaact taatcagcta caaacatgat 3540
ggcactgagt caagtgaaga tagcttctcc ttcacagtga ctgatggcac ccatacagac 3600
ttctatgttt ttcctgatac ggtgtttgaa acaaggagac cccaagtgat gaagatccag 3660
gtcttggctg ttgacaacag tgtcccccaa atcgcagtga ataagggggc ctctacactt 3720
cgcactctag ccactggcca cttggggttc atgatcacaa gcaaaatatt gaaagtggag 3780
gacagagaca gcttacacat ttctcttaga tttatcgtga cagaggcccc tcaacatgga 3840
tatcttctca acctggacaa aggcaaccac agcatcactc agttcacaca agctgacatt 3900
gatgacatga aaatatgcta tgtcttaaga gaaggggcta atgccacaag tgatatgttc 3960
tattttgcag ttgaagatgg tggtaagtat tcccctctcc tggtagtgac cgcaaggaga 4020
gacgcttttc ttggttgctc tctgatgaca ttattacaag aagtcttcat caagtaa 4077
<210>36
<211>9318
<212>DNA
<213>人(Homo sapiens)
<400>36
atggcacgat cttggctcac tgcaacctcc acctcccggc ccgctgcctt cggcagggcg 60
ttgctgtccc ctggtctcgc gggggctgca ggggtccctg ctgaggaggc catagtgctg 120
gcgaaccgcg gactccgggt gcctttcggc cgtgaagtct ggctggatcc cctgcatgac 180
ctggtgttgc aggtgcagcc cggggaccgc tgcgcggttt cggtactaga caacgacgca 240
ctggcccagc gaccgggccg cctgagtccc aagcgcttcc cgtgcgactt tggccctggc 300
gaggtgcgct actctcacct gggcgcgcgc agcccgtctc gggaccgcgt ccggctgcag 360
ctgcgctatg acgcgcccgg aggggcagta gtgctaccac tggtactgga ggtggaggtg 420
gtcttcaccc agctggaggt tgtgactcgg aacttgcctc tggtcgtgga agaactgctg 480
gggaccagca atgccctgga cgcgcggagc ctggagttcg ccttccagcc cgagacagag 540
gagtgccgcg tgggcatcct gtccggcttg ggcgcgctgc ctcgctatgg agaactcctc 600
cactacccgc aggtccctgg aggagccaga gagggaggcg ccccggagac tctcctgatg 660
gactgcaaag ctttccagga actaggcgtg cgctatcgcc acacagccgc cagtcgctca 720
ccaaacaggg actggatacc catggtggtg gagctgcgtt cacgaggggc tcctgtgggc 780
agccctgctt tgaaacgcga gcacttccag gttctggtga ggatccgagg aggggccgag 840
aacactgcac ccaagcccag tttcgtggcc atgatgatga tggaggtgga ccagtttgta 900
ctgacggccc tgaccccaga catgctggca gccgaggatg ctgagtctcc ctctgacctg 960
ttgatcttca accttacttc tccattccag cctggccagg gctacttggt gagcaccgat 1020
gatcgcagcc tgcccctttc ctccttcact cagagggatc tgcggctcct gaagattgcc 1080
taccagcccc cttctgaaga ctctgaccag gagcgcctct ttgaactgga attggaggta 1140
gtggatctag aaggagcagc ttcagaccct tttgccttca tggtagtggt gaagcccatg 1200
aacacaatgg ctccggtggt cacccggaat accggtctta ttctctatga gggtcagtct 1260
cggcccctca caggccctgc aggcagtggt ccgcaaaact tggtcatcag cgatgaggat 1320
gacctagaag cagtgcggct agaggtggtg gctgggctcc ggcatggtca ccttgtcatt 1380
ctgggtgctt ccagtggcag ctctgctccc aagagcttta cagtggctga gctggcagcc 1440
ggccaggtgg tctaccagca tgatgacaga gacggctcgc tgagcgacaa cctggtgctt 1500
cgcatggtgg atggaggagg caggcaccag gtacagtttc tgttccccat caccttagtg 1560
cctgtggatg accagccacc tgttctcaat gccaacacgg ggctgacact ggcagagggt 1620
gaaacagtgc ccatcctgcc cctttccctg agtgcaactg acatggattc agatgattct 1680
ctgctgcttt ttgtgctgga gtcacccttc ttaactacgg ggcatctgct tctccgccaa 1740
actcaccctc cccatgagaa gcaggaactt ctcagaggcc tttggaggaa ggagggggca 1800
ttttatgagc gaacagtgac agagtggcag cagcaggaca taacagaggg caggctgttc 1860
tatagacact ctgggcccca tagtcctggg ccagtcacag accagttcac atttagagtc 1920
caggataacc atgaccctcc taatcagtcc gggctacagc ggtttgtgat tcgtatccat 1980
cctgtggatc gcctccctcc ggagctgggc agtggctgtc cccttcgtat ggtggtacag 2040
gaatcccagc tcacaccact gaggaagaag tggctgcgct acactgacct ggacacagat 2100
gaccgagaac tacgttacac agtgactcag ccccccacag acacagacga aaatcacctg 2160
ccagccccac tgggtacctt ggtcttgact gacaacccct cagtcgtggt gacccatttt 2220
acccaagccc agatcaacca tcataaaatt gcttacagac ccccgggtca agaactgggc 2280
gtggctactc gagtggccca gttccagttc caggtggaag accgagctgg gaatgtggct 2340
ccaggtacct ttacccttta cttgcatccc gtggacaacc agccacctga gatcctcaac 2400
accggcttca ctattcagga gaagggtcac cacatcctga gtgagacaga gttgcacgtg 2460
aatgatgtag acactgatgt tgcccatatc tctttcactc tcactcaggc acccaaacat 2520
ggccacatga gagtgtctgg acagatcctg catgtagggg gtctcttcca cttggaggac 2580
ataaaacagg gccgagtttc ctatgcccat aatggggaca agtccctgac tgatagctgc 2640
tccttggaag tcagtgacag acatcatgtg gtgcccatca ctctcagagt aaatgtccgg 2700
ccagtggatg atgaagtgcc catactgagc catcctactg gcactctgga gtcctatcta 2760
gatgtcttag aaaatggggc tactgaaatc actgccaatg ttattaaggg gaccaatgag 2820
gaaactgatg acttgatgtt gactttcctc ttggaagatc cacctttgta tggggaaatc 2880
ttggtcaatg gcattccagc agagcagttt actcaaaggg acatcttgga gggctctgtt 2940
gtatataccc acaccagtgg tgagataggc ctattgccta aagcggattc ttttaacctg 3000
agtctgtcag ataagtctca agaatggaga attggtggca atactatcca aggagttact 3060
atatgggtga ccatcctgcc tgttgatagc caggccccag aaatctctgt aggtgaacag 3120
ttgatagtaa tggaaggtga taaaagtgtt ataacatcag tgcatataag tgctgaagat 3180
gtcgactccc tgaatgatga catcttgtgc actatagtta ttcagcctac ttcaggttat 3240
gttgaaaaca tttctccagc accaggctct gagaaatcaa gagcagggat tgccataagt 3300
gctttcaact tgaaagatct caggcagggc cacataaact atgtccagag tgtccataaa 3360
ggggtggaac ctgtggagga ccgatttgta tttcgttgtt ctgatggcat taacttttca 3420
gagagacagt tcttccccat tgtaatcatt cccaccaatg atgaacagcc agagatgttt 3480
atgagagaat ttatggtgat ggaaggcatg agtctggtaa ttgatacacc cattctcaat 3540
gctgctgatg ctgatgttcc cctggatgat ttaactttca ctattaccca attccccact 3600
catggtcaca tcatgaatca gctgataaat ggcacggttt tggtcgaaag cttcaccttg 3660
gatcagatca tagagagttc cagcattatt tatgagcatg atgactccga gacccaggaa 3720
gacagttttg tgattaaact aacagatggg aagcactctg tggaaaagac ggtcctcatt 3780
atagttatcc ctgttgatga tgagacgccc agaatgacta tcaataatgg actagaaata 3840
gaaattgggg ataccaagat tatcaacaac aaaatattaa tggcaacaga tttagattca 3900
gaagacaaat ctttggttta tattattcgt tatgggccag gacatggctt attacagaga 3960
cgaaaaccta ctggtgcctt tgaaaatatc acactgggca tgaattttac ccaggatgaa 4020
gtagacagaa acttaattca gtatgtccat ttggggcaag agggcattcg ggacctaatt 4080
aaatttgatg tgactgatgg aataaatccc ctcatagatc gttactttta tgtgtccatc 4140
gggagcattg acattgtctt ccctgatgtg ataagtaagg gagtgtcctt gaaagaaggt 4200
ggcaaagtca ctcttacaac agacctacta agcactagtg acttgaacag tcctgatgaa 4260
aacttggttt ttaccatcac cagggctccc atgcgaggtc acctggaatg cacggatcag 4320
cctggtgtgt ccatcacgtc tttcactcag ctgcaactgg ctggaaacaa aatctactac 4380
atccacacag ctgatgatga agtgaaaatg gacagttttg agtttcaagt caccgatgga 4440
cgtaaccctg tctttcggac attccgtatc tccattagcg atgtggacaa taaaaagcca 4500
gtggtcacca tccacaagct ggttgtcagt gaaagtgaaa acaagctgat tactcctttt 4560
gagctcactg tcgaagacag agatactcct gacaagctcc tgaaattcac tatcacccag 4620
gtgcctattc atggccatct cctattcaac aataccagac ctgtcatggt ttttaccaag 4680
caagacttga atgaaaactt aatcagctac aaacatgatg gcactgagtc aagtgaagat 4740
agcttctcct tcacagtgac tgatggcacc catacagact tctatgtttt tcctgatacg 4800
gtgtttgaaa caaggagacc ccaagtgatg aagatccagg tcttggctgt tgacaacagt 4860
gtcccccaaa tcgcagtgaa taagggggcc tctacacttc gcactctagc cactggccac 4920
ttggggttca tgatcacaag caaaatattg aaagtggagg acagagacag cttacacatt 4980
tctcttagat ttatcgtgac agaggcccct caacatggat atcttctcaa cctggacaaa 5040
ggcaaccaca gcatcactca gttcacacaa gctgacattg atgacatgaa aatatgctat 5100
gtcttaagag aaggggctaa tgccacaagt gatatgttct attttgcagt tgaagatggt 5160
ggtggaaaca agttaacgta ccagaatttt cgtctgaatt gggcatggat ctcctttgaa 5220
aaggaatatt acctggtcaa tgaggactcc aaatttctag atgttgttct taaacgtaga 5280
ggttacttgg gagaaacttc ttttataagt attggcacaa gagacagaac tgcagaaaaa 5340
gacaaagact tcaagggcaa agcacagaaa caagtgcagt tcaacccagg ccagaccagg 5400
gccacatggc gagtgcggat cctgagtgat ggggagcatg agcagtctga aacctttcag 5460
gtggtactct cagagcccgt gctggctgcc ttggaattcc ccacagtcgc cactgttgag 5520
atcgttgatc caggagatga gccaactgtg tttattcccc agtccaaata ctccgttgaa 5580
gaagatgttg gtgagctgtt cattcccatc aggaggagcg gagatgtgag ccaggagttg 5640
atggtggtct gttataccca acaaggaaca gcaactggaa ctgtgccgac ttccgtgttg 5700
tcttactctg attacatatc caggcctgag gaccacacca gtgttgtccg ctttgacaaa 5760
gatgaacggg agaaactgtg tcggatagtc ataattgatg actctttgta cgaggaggag 5820
gaaaccttcc atgtccttct gagcatgccc atggggggaa gaatcggatc agagttccca 5880
ggggctcaag ttacaatcgt tcctgacaaa gatgatggtc catctgattc caaatttaat 5940
gttgctgaga actacagttt actgcctttc acctgttttc aaggtagcat agccacggca 6000
gaggcagcca cccagggagg gggacgcagc accagacaag tagctgcagt caaaaaagac 6060
aaagacttca agggcaaagc acagaaacaa gtgcagttca acccaggcca gaccagggcc 6120
acatggcgag tgcggatcct gagtgatggg gagcatgagc agtctgaaac ctttcaggtg 6180
gtactctcag agcccgtgct ggctgccttg gaattcccca cagtcgccac tgttgagatc 6240
gttgatccag gagatgcatg cccatggggg gaagaatcgg atcagagttc ccaggggctc 6300
aagttacaat cgttcctgac aaagatgatg gtgagtacta atttacttga aaattctttt 6360
tcccgggaag atcaacatca ggaacaactt tctagacaga aaaaatggga atctaaaaca 6420
atgataatat acacatttat tttatgtgag acagaaaagc cctgcattct tgagctgatg 6480
gacgatgtgc tctatgagga ggtagaggag ctccgcctgg tactcggcac tccacaaagc 6540
aactctccct ttggggctgc agttggtgaa caaaatgaaa ctctcataag gatccgagat 6600
gatgctgata agactgttat taaatttgga gaaaccaaat ttagtgtcac tgaacccaaa 6660
gaacctggag agtcggtggt tataagaatt ccagtgattc gccaaggaga cacttcaaag 6720
gtttccattg tgagagtcca caccaaggat ggctcggcca cctctggaga agactaccac 6780
cctgtgtcag aagaaattga gtttaaggaa ggggaaaccc agcacgtggt tgaaatcgaa 6840
gttacctttg acggggtgag agagatgaga gaggccttca ctgttcacct aaaacctgat 6900
gaaaatatga tagcagagat gcagctttcc aactttgagc tcaccctcag ccctgatggc 6960
acaagagttg gaaaccacaa gtgctccaac ctcctggatt atactgaagt gaagactcat 7020
tatggtttct tgactgatgc taccaaaaat ccagaaataa ttggagagac atatccttac 7080
cagtacagct tgtccatcag aggttccact accttgcgct tctaccggaa cctgaaccta 7140
gaggcctgtt tatgggagtt cgttagctac tatgacatgt cagaactcct tgctgactgc 7200
agatcagtgt tgaatgcaag catatttcat gagatggcac ctgaaggaaa gcaaagtaaa 7260
tgcttggtaa attctacttt atactctatt ttggaatgtc atgagagcct tccaaacttt 7320
tgcatttcag cattaaggat gggaaaatgg agaaaaataa aaagcaaacc atcagcacag 7380
actccatgtg ctcagaggct tcgtggtttt attgaccacc ccaggaaaca gcccctgcag 7440
caagccagtg ctgacccagg catgctcccc gtgatctcca ctagagagct ttccaacttt 7500
gagctcaccc tcagccctga tggcacaaga gttggaaacc acaagtgctc caacctcctg 7560
gattatactg aagtgaagac tcattatggt ttcttgactg atgctaccaa aaatccagaa 7620
ataattggag agacatatcc ttaccagtac agcttgtcca tcagaggttc cactaccttg 7680
cgcttctacc ggaacctgaa cctagaggcc tgtttatggg agttcgttag ctactatgac 7740
atgtcagaac tccttgctga ctgtggtggc accattggaa cagatggaca ggtcctaaac 7800
ctagtgcagt cctatgtgac ccttcgagtc cctctgtatg tttcctacgt gttccattcc 7860
cccgtggggg taggaggctg gcagcatttt gacttgaagt cagagcttcg tctaactttt 7920
gtgtacgaca ccgccatctt gtggaatgat ggaattggca gccccccaga ggctgaactt 7980
caaggttctc tctatccaac cagcatgcgc atcggtgatg aggggcgctt ggccgtgcac 8040
ttcaagacag aggctcagtt ccatggctta tttgtgctgt cacatcccgc atcctttaca 8100
agctcagtga tcatgtcagc tgatcatcca ggcctgacat tttccctccg cctcataagg 8160
agtgaaccaa cctataacca gccagtacag cagtggagct ttgtctctga ctttgccgta 8220
cgtgactact cagggaccta tactgtgaag ctggtgccat gcactgcccc atcacatcag 8280
gaataccgcc tgccagtcac ctgcaacccc agagaacctg tcacctttga ccttgacatc 8340
cgattccaac aggtcagtga tccagtggct gctgagttta gcttgaacac ccaaatgtac 8400
ctgctctcta agaagagtct ctggttgtct gatggatcca tgggattcgg gcaagagagt 8460
gatgttgctt ttgcagaagg tgatataatt tatggtcgtg tcatggtgga tcctgtccag 8520
aatctgggtg actcctttta ctgcagcatt gagaaggtgt ttctatgcac tggagctgat 8580
ggctatgttc ccaagtatag tccaatgaat gcagaatatg gctgcttagc cgactctcct 8640
tcactcttat atagatttaa aattgtggac aaagctcagc cagagacaca agcgaccagt 8700
tttggaaatg tcctatttaa tgccaaacta gcagtggatg accctgaagc cattctctta 8760
gtgaatcagc ctggatctga tggatttaaa gtcgactcaa caccactctt tcaggtcgct 8820
ctaggccgag aatggtatat acatacgatc tatacagtga gatcgaaaga caatgccaat 8880
cgaggtattg gcaaaagaag tgtggagtac cattctctgg tgagtcaagg aaagccccaa 8940
tccaccacca agagccggaa gaagagagag atcaggagca caccctcact ggcatgggag 9000
attggtgctg aaaacagtcg aggaacaaac atccagcaca ttgccctgga ccgcaccaag 9060
aggcagatcc cccatgggag agcacctcca gatggcatcc tcccctggga gctcaacagc 9120
cccagctctg cagtcagcct ggtcactgtg gtgggaggca ccacggtagg gttactcacc 9180
atctgcctca ctgtcattgc agtgctgatg tgcaggggca aggaaagttt cagggggaag 9240
gatgccccga aaggctccag cagcagtgag cccatggtgc ccccacagag ccatcacaat 9300
gacagctcag aagtttga 9318
<210>37
<211>1374
<212>DNA
<213>人(Homo sapiens)
<400>37
atggggtgta gtggagcctg gggcttgagc tgcccttgtc cacagacgcc atcctgggcc 60
tggaggaaga tgcggacgcc atccatgagg aaccggagtg gcgccgtgtg gagcagggcc 120
tctgtcccct tctctgcctg ggaagtagag gtgcagatga gggtgacggg actggggcgc 180
cggggagccc agggcatggc cgtgtggtac acccggggca ggggccatgt aggctctgtc 240
cttggggggc tggcttcgtg ggacggcatc gggatcttct ttgactctcc ggcagaggat 300
actcaggaca gtcctgccat ccgtgtgctg gccagcgacg ggcacatccc ctctgagcag 360
cctggggatg gagctagcca agggctgggc tcctgtcatt gggacttccg gaaccggcca 420
caccccttca gagcacggat cacctactgg gggcagaggc tgcgcatgtc cttgaacagt 480
ggcctcactc ccagtgatcc aggtgagttc tgtgtggatg tggggcccct gcttttggtc 540
cctggaggtt tctttggggt ctcagcagcc accggcaccc tggcagatga tcatgatgtc 600
ctgtccttcc tgaccttcag cctgagtgag cccagcccag aggttccccc tcagcccttc 660
ctggagatgc agcacgtccg cctggcgagg cagctggaag ggctgtgggc aaggctgggc 720
ttgggcacca gggaggatgt aactccaaaa tcagactctg aagctcaagg agaaggggaa 780
aggctctttg acctggagga gacgctgggc agacaccgcc ggatcctgca ggctctgcgg 840
ggtctctcca agcagctggc ccaggctgag agacaatgga agaagcagct gggcccccag 900
gccaagccag gcctgacgga ggctggggat gcagctgtcc gcatggctgc agaagcccag 960
gtctcctacc tgcctgtggg cattgagcat catttcttag agctggacca catcctgggc 1020
ctcctgcagg aggagcttcg gggcccggcg aaggcagcag ccaaggcccc ccgcccacct 1080
ggccagcccc caagggcctc ctcgtgcctg cagcctggca tcttcctgtt ctacctcctc 1140
attcagactg taggcttctt cggctacgtg cacttcaggc gcccggtgcc ccggccggcg 1200
aagaccatgg cgttcatggt gaagaccatg gtgggcggcc agctgaagaa cctcactggg 1260
agcctgggag gcggcgagga taagggagat ggggacaagt cggcagccga agctcagggc 1320
atgagccggg aggagtacga ggagtatcag aagcaactcg tggaagagaa gtga 1374
<210>38
<211>1581
<212>DNA
<213>人(Homo sapiens)
<400>38
atgccggcgg tcagtggtcc aggtccctta ttctgccttc tcctcctgct cctggacccc 60
cacagccctg agacggggtg tcctcctcta cgcaggtttg agtacaagct cagcttcaaa 120
ggcccaaggc tggcattgcc tggggctgga atacccttct ggagccatca tggagacgcc 180
atcctgggcc tggaggaagt gcggctgacg ccatccatga ggaaccggag tggcgccgtg 240
tggagcaggg cctctgtccc cttctctgcc tgggaagtag aggtgcagat gagggtgacg 300
ggactggggc gccggggagc ccagggcatg gccgtgtggt acacccgggg caggggccat 360
gtaggctctg tccttggggg gctggcttcg tgggacggca tcgggatctt ctttgactct 420
ccggcagagg atactcagga cagtcctgcc atccgtgtgc tggccagcga cgggcacatc 480
ccctctgagc agcctgggga tggagctagc caagggctgg gctcctgtca ttgggacttc 540
cggaaccggc cacacccctt cagagcacgg atcacctact gggggcagag gctgcgcatg 600
tccttgaaca gtggcctcac tcccagtgat ccaggtgagt tctgtgtgga tgtggggccc 660
ctgcttttgg tccctggagg tttctttggg gtctcagcag ccaccggcac cctggcagat 720
gatcatgatg tcctgtcctt cctgaccttc agcctgagtg agcccagccc agaggttccc 780
cctcagccct tcctggagat gcagcacgtc cgcctggcga ggcagctgga agggctgtgg 840
gcaaggctgg gcttgggcac cagggaggat gtaactccaa aatcagactc tgaagctcaa 900
ggagaagggg aaaggctctt tgacctggag gagacgctgg gcagacaccg ccggatcctg 960
caggctctgc ggggtctctc caagcagctg gcccaggctg agagacaatg gaagaagcag 1020
ctggggcccc caggccaagc caggcctgac ggaggctggg ccctggatgc ttcctgccag 1080
attccatcca ccccagggag gggtggccac ctctccatgt cactcaataa ggactctgcc 1140
aaggtcggtg ccctgctcca tggacagtgg actctgctcc aggccctgca agagatgagg 1200
gatgcagctg tccgcatggc tgcagaagcc caggtctcct acctgcctgt gggcattgag 1260
catcatttct tagagctgga ccacatcctg ggcctcctgc aggaggagct tcggggcccg 1320
gcgaaggcag cagccaaggc cccccgccca cctggccagc ccccaagggc ctcctcgtgc 1380
ctgcagcctg gcatcttcct gttctacctc ctcattcaga ctgtaggctt cttcggctac 1440
gtgcacttca ggcaggagct gaacaagagc cttcaggagt gtctgtccac aggcagcctt 1500
cctctgggtc ctgcaccaca cacccccagg gccctgggga ttctgaggag gcagcctctc 1560
cctgccagca tgcctgcctg a 1581
<210>39
<211>2715
<212>DNA
<213>人(Homo sapiens)
<400>39
atgctcttgg ctctatgttc atctctggct cttatttttg cagctcctgt cagtggacag 60
cttgagcatt cagggaacta ctactgcaca gctgacaatg gctttggccc ccagcacagt 120
gaggtggtga gtctctctgt cactgtccct gtgtctcatc ctgtcctcac cctcagctct 180
gctgaggccc tgacttttga aggagccact gtgacacttc actcttcgct gatcctgcaa 240
gctccacttt ctgtgtttga aggagacttc gtggttctga ggtgccgggc aaaggcggaa 300
gtaacactga atactatgta caagaatggt aacgtcctga cattccttaa taaaagctct 360
gacttccata ttcatcacgc aagtctcaaa gacaatggtg catatcactt tactggattt 420
aacggaagta atttctctgt ttcttccaac atagtcaaaa tccaagtcca agagcatctc 480
ctgccccagt ggttcctgaa ggcacctgat cccactgtgg cccttagtga gatattctca 540
gtcaatagag gtccacttct gacaggcaca ggctcccgag ttatgactcc ctggatttac 600
ttccctactg aggactggaa cttcactctt attcccatta ctgtggacga tgcttgcaaa 660
aggccttgtg ctcctcgggc tccttgggaa gttggaagtc taacaccagg aaagagtttc 720
cagcagaagg ggaacccaga cctgctcatg ggcccttttg atgttcttca cttgtccctc 780
atcacacttt tttgcaacat ggcaggttct ttgttttatt atatggaact tggagaaaag 840
aaagatgcat tatttgttac aggaaatgaa agcagaagct atcattggtt ccagaagttc 900
agccttgctg gtgggcaaga agcagatcaa aagttgtggt ttccccctgg actgatgagt 960
caggatattt tcatatatat cagacaaggt gagagttgtc ttgtgattga gatgtttcat 1020
caggtctaca gacggcctgc tggaggtgtt ccagtagagc atatgagtgt atgggctctc 1080
agggtgaata gttcgggact cttcgcctac gctgatggct ggctctttac tctctttcag 1140
ctccagtctg tggacaatct gagcccatca actcagtctc aaacacacga aggccatgaa 1200
aagttatgtc ccttcctggc catagggcca cctgcacata gcaggggcag cttcctcaga 1260
gcaaagaaga gtctagttgc atacatcaaa ggaaatcaac tctccttccc tccagtagaa 1320
gacctattgc ctaagtccca atggccctgc atccaggtgc ttcccaggaa tatagctgca 1380
gctgcacaca aacctgtgat ttccgtccat cctccatgga ccacattctt caaaggagag 1440
agagtgactc tgacttgcaa tggatttcag ttctatgcaa cagagaaaac aacatggtat 1500
catcggcact actggggaga aaagttgacc ctgaccccag gaaacaccct cgaggttcgg 1560
gaatctggac tgtacagatg ccaggcccgg ggctccccac gaagtaaccc tgtgcgcttg 1620
ctcttttctt caggtgagaa agaagactgt gtctctgaca agaatcctgc tacaaatcac 1680
actccaatgt ccaggaagag atcctcatgt agttctctaa gtgccacttc tttcatagct 1740
cctgctctga gactcgactc cttaatcctg caggcaccat attctgtgtt tgaaggtgac 1800
acattggttc tgagatgcca cagaagaagg aaagagaaat tgactgctgt gaaatatact 1860
tggaatggaa acattctttc catttctaat aaaagctggg atcttcttat cccacaagca 1920
agttcaaata acaatggcaa ttatcgatgc attggatatg gagacgagaa tgatgtattt 1980
agatcaaatt tcaaaataat taaaattcaa gggatccctg tgtctggggt gctcctggag 2040
acccagccct cagggggcca ggctgttgaa ggggagatgc tggtccttgt ctgctccgtg 2100
gctgaaggca caggggatac cacattctcc tggcaccgag aggacatgca ggagagtctg 2160
gggaggaaaa ctcagcgttc cctgagagca gagctggagc tccctgccat cagacagagc 2220
catgcagggg gatactactg tacagcagac aacagctacg gccctgtcca gagcatggtg 2280
ctgaatgtca ctgtgagaga gaccccaggc aacagagatg gccttgtcgc cgcgggagcc 2340
actggagggc tgctcagtgc tcttctcctg gctgtggccc tgctgtttca ctgctggcgt 2400
cggaggaagt cagtacaccc caaaaaggga gatttggtat actctgagat ccagactact 2460
cagctgggag aagaagagga aggaaatcat ggcaataaaa atcaagaact agaacttgtt 2520
aatgtaggag agagtttttc tcacagggca tgcatatgga gtactctaat gggaacttgc 2580
caaacaatcg ggggtgctaa tacctccagg acacttctag aggataagga tgtctcagtt 2640
gtctactctg aggtaaagac acaacaccca gataactcag ctggaaagat cagctctaag 2700
gatgaagaaa gttaa 2715
<210>40
<211>1548
<212>DNA
<213>人(Homo sapiens)
<400>40
atgctgctgt gggcgtcctt gctggccttt gctccagtct gtggacaatc tgcagctgca 60
cacaaacctg tgatttccgt ccatcctcca tggaccacat tcttcaaagg agagagagtg 120
actctgactt gcaatggatt tcagttctat gcaacagaga aaacaacatg gtatcatcgg 180
cactactggg gagaaaagtt gaccctgacc ccaggaaaca ccctcgaggt tcgggaatct 240
ggactgtaca gatgccaggc ccggggctcc ccacgaagta accctgtgcg cttgctcttt 300
tcttcagact ccttaatcct gcaggcacca tattctgtgt ttgaaggtga cacattggtt 360
ctgagatgcc acagaagaag gaaagagaaa ttgactgctg tgaaatatac ttggaatgga 420
aacattcttt ccatttctaa taaaagctgg gatcttctta tcccacaagc aagttcaaat 480
aacaatggca attatcgatg cattggatat ggagatgaga atgatgtatt tagatcaaat 540
ttcaaaataa ttaaaattca agaactattt ccacatccag agctgaaagc tacagactct 600
cagcctacag aggggaattc tgtaaacctg agctgtgaaa cacagcttcc tccagagcgg 660
tcagacaccc cacttcactt caacttcttc agagatggcg aggtcatcct gtcagactgg 720
agcacgtacc cggaactcca gctcccaacc gtctggagag aaaactcagg atcctattgg 780
tgtggtgctg aaacagtgag gggtaacatc cacaagcaca gtccctcgct acagatccat 840
gtgcagcgga tccctgtgtc tggggtgctc ctggagaccc agccctcagg gggccaggct 900
gttgaagggg agatgctggt ccttgtctgc tccgtggctg aaggcacagg ggataccaca 960
ttctcctggc accgagagga catgcaggag agtctgggga ggaaaactca gcgttccctg 1020
agagcagagc tggagctccc tgccatcaga cagagccatg cagggggata ctactgtaca 1080
gcagacaaca gctacggccc tgtccagagc atggtgctga atgtcactgt gagagagacc 1140
ccaggcaaca gagatggcct tgtcgccgcg ggagccactg gagggctgct cagtgctctt 1200
ctcctggctg tggccctgct gtttcactgc tggcgtcgga ggaagtcagg agttggtttc 1260
ttgggagacg aaaccaggct ccctcccgct ccaggcccag gagagtcctc ccattccatc 1320
tgccctgccc aggtggagct tcagtcgttg tatgttgatg tacaccccaa aaagggagat 1380
ttggtatact ctgagatcca gactactcag ctgggagaag aagaggaagc taatacctcc 1440
aggacacttc tagaggataa ggatgtctca gttgtctact ctgaggtaaa gacacaacac 1500
ccagataact cagctggaaa gatcagctct aaggatgaag aaagttaa 1548
<210>41
<211>2494
<212>DNA
<213>人(Homo sapiens)
<400>41
batggctgtg ggaggaggac acaaaggagt tagatgtcct ccctctgctc gcagctccca 60
ggtgcccacg tgctgcgctg gctggaggca gcaaggggac gagtgtggga ttgcggtgtg 120
cgaaggcaac tccacgtgct cagagaacga ggtgtgcgtg aggcctggcg agtgccgctg 180
ccgccacggc tacttcggtg ccaactgcga caccaagtgc ccgcgccagt tctggggccc 240
cgactgcaag gagctgtgta gctgccaccc acacgggcag tgcgaggacg tgacaggcca 300
gtgtacttgt cacgcgcggc gctggggcgc gcgctgcgag catgcgtgcc agtgccagca 360
cggcacgtgc cacccccgga gcggcgcgtg ccgctgtgag tccggctggt ggggcgcgca 420
gtgcgccagc gcgtgctact gcagcgccac gtcgcgctgc gacccacaga ccggcgcctg 480
cctgtgccac gcaggctggt ggggccgcag ctgcaacaac cagtgcgcct gcaactcgtc 540
tccctgcgag cagcagagcg gccgctgtca gtgccgcgag cgtacgttcg gcgcgcgctg 600
cgatcgctac tgccagtgct tccgcggccg ctgccaccct gtggacggca cgtgtgcctg 660
cgagccgggc taccgcggca agtactgtcg cgagccgtgc cccgccggct tctacggctt 720
gggctgtcgc cgccggtgtg gccagtgcaa gggccagcag ccgtgcacgg tggccgaggg 780
ccgctgcttg acgtgcgagc ccggctggaa cggaaccaag tgcgaccagc cttgcgccac 840
cggtttctat ggcgagggct gcagccaccg ctgtccgcca tgccgcgacg ggcatgcctg 900
taaccatgtc accggcaagt gtacgcgctg caacgcgggc tggatcggcg accggtgcga 960
gaccaagtgt agcaatggca cttacggcga ggactgcgcc ttcgtgtgcg ccgactgcgg 1020
cagcggacac tgcgacttcc agtcggggcg ctgcctgtgc agccctggcg tccacgggcc 1080
ccactgtaac gtgacgtgcc cgcccggact ccacggcgcg gactgtgctc aggcctgcag 1140
ctgccacgag gacacgtgcg acccggtcac tggtgcctgc cacctagaaa ccaaccagcg 1200
caagggcgtg atgggcgcgg gcgcgctgct cgtcctgctc gtctgcctgc tgctctcgct 1260
gctcggctgc tgctgcgctt gccgcggcaa ggaccctacg cgccgacccc gcccccgcag 1320
ggagctttcg cttgggagga agaaggcgcc gcaccgacta tgcgggcgct tcagtcgcat 1380
cagcatgaag ctgccccgga tcccgctccg gaggcagaaa ctacccaaag tcgtagtggc 1440
ccaccacgac ctggataaca cactcaactg cagcttcctg gagccaccct cagggctgga 1500
gcagccctca ccatcctggt cctctcgggc ctccttctcc tcgtttgaca ccactgatga 1560
aggccctgtg tactgtgtac cccatgagga ggcaccagcg gagagccggg accccgaagt 1620
ccccactgtc cctgccgagg cgccggcgcc gtcccctgtg cccttgacca cgccagcctc 1680
cgccgaggag gcgatacccc tccccgcgtc ctccgacagc gagcggtcgg cgtccagcgt 1740
ggaggggccc ggaggggctc tgtacgcgcg cgtggcccga cgcgaggccc ggccggcccg 1800
ggcccggggc gagattgggg gcctgtcgct gtcgccatcg cccgagcgca ggaaaccgcc 1860
gccacctgac cccgccacca agcctaaggt gtcctggatc cacggcaagc acagcgccgc 1920
tgcagctggc cgtgcgccct caccaccgcc gccaggctcc gaggccgcgc ccagccccag 1980
caagaggaaa cggacgccca gcgacaaatc ggcgcatacg gtcgaacacg gcagcccccg 2040
gacccgcgac ccaacgccgc gccccccggg gctgcccgag gaggcgacag ccctcgctgc 2100
gccctcgccg cccagggccc gagcgcgcgc cgcgccccgg cctcttggag cccacggacg 2160
ccggcggtcc cccgcgaagc gcgccgaggc tgcctccatg ttggccgctg acgtgcgcgg 2220
caagactcgc agcctgggcc gcgccgaggt ggccctgggc gcgcagggcc ccagggaaaa 2280
gccggcgccc ccacagaaag ccaagcgctc cgtgccgcca gcctcgcccg cccgcgcgcc 2340
cccagcgacc gaaaccccgg ggcctgagaa ggcggcgacc gacttgcccg cgcctgagac 2400
cccccggaag aagaccccca tccagaagcc gccgcgcaag aagagccggg aggcggcggg 2460
cgagctgggc agggcgggcg cacccaccct gtag 2494
<210>42
<211>2614
<212>DNA
<213>人(Homo sapiens)
<400>42
batggagggc gcagggcccc ggggggccgg gccggcgcgg cgccggggag ccggggggcc 60
gccgtcaccg ctgctgccgt cgctgctgct gctgctgctg ctctggatgc tgccggacac 120
cgtggcgcct caggaactga accctcgcgg ccgcaacgtg tgccgtgctc ccggctccca 180
ggtgcccacg tgctgcgctg gctggaggca gcaaggggac gagtgtggga ttgcggtgtg 240
cgaaggcaac tccacgtgct cagagaacga ggtgtgcgtg aggcctggcg agtgccgctg 300
ccgccacggc tacttcggtg ccaactgcga caccaagtgc ccgcgccagt tctggggccc 360
cgactgcaag gagctgtgta gctgccaccc acacgggcag tgcgaggacg tgacaggcca 420
gtgtacttgt cacgcgcggc gctggggcgc gcgctgcgag catgcgtgcc agtgccagca 480
cggcacgtgc cacccccgga gcggcgcgtg ccgctgtgag tccggctggt ggggcgcgca 540
gtgcgccagc gcgtgctact gcagcgccac gtcgcgctgc gacccacaga ccggcgcctg 600
cctgtgccac gcaggctggt ggggccgcag ctgcaacaac cagtgcgcct gcaactcgtc 660
tccctgcgag cagcagagcg gccgctgtca gtgccgcgag cgtacgttcg gcgcgcgctg 720
cgatcgctac tgccagtgct tccgcggccg ctgccaccct gtggacggca cgtgtgcctg 780
cgagccgggc taccgcggca agtactgtcg cgagccgtgc cccgccggct tctacggctt 840
gggctgtcgc cgccggtgtg gccagtgcaa gggccagcag ccgtgcacgg tggccgaggg 900
ccgctgcttg acgtgcgagc ccggctggaa cggaaccaag tgcgaccagc cttgcgccac 960
cggtttctat ggcgagggct gcagccaccg ctgtccgcca tgccgcgacg ggcatgcctg 1020
taaccatgtc accggcaagt gtacgcgctg caacgcgggc tggatcggcg accggtgcga 1080
gaccaagtgt agcaatggca cttacggcga ggactgcgcc ttcgtgtgcg ccgactgcgg 1140
cagcggacac tgcgacttcc agtcggggcg ctgcctgtgc agccctggcg tccacgggcc 1200
ccactgtaac gtgacgtgcc cgcccggact ccacggcgcg gactgtgctc aggcctgcag 1260
ctgccacgag gacacgtgcg acccggtcac tggtgcctgc cacctagaaa ccaaccagcg 1320
caagggcgtg atgggcgcgg gcgcgctgct cgtcctgctc gtctgcctgc tgctctcgct 1380
gctcggctgc tgctgcgctt gccgcggcaa ggaccctacg cgccgacccc gcccccgcag 1440
ggagctttcg cttgggagga agaaggcgcc gcaccgacta tgcgggcgct tcagtcgcat 1500
cagcatgaag ctgccccgga tcccgctccg gaggcagaaa ctacccaaag tcgtagtggc 1560
ccaccacgac ctggataaca cactcaactg cagcttcctg gagccaccct cagggctgga 1620
gcagccctca ccatcctggt cctctcgggc ctccttctcc tcgtttgaca ccactgatga 1680
aggccctgtg tactgtgtac cccatgagga ggcaccagcg gagagccggg accccgaagt 1740
ccccactgtc cctgccgagg cgccggcgcc gtcccctgtg cccttgacca cgccagcctc 1800
cgccgaggag gcgatacccc tccccgcgtc ctccgacagc gagcggtcgg cgtccagcgt 1860
ggaggggccc ggaggggctc tgtacgcgcg cgtggcccga cgcgaggccc ggccggcccg 1920
ggcccggggc gagattgggg gcctgtcgct gtcgccatcg cccgagcgca ggaaaccgcc 1980
gccacctgac cccgccacca agcctaaggt gtcctggatc cacggcaagc acagcgccgc 2040
tgcagctggc cgtgcgccct caccaccgcc gccaggctcc gaggccgcgc ccagccccag 2100
caagaggaaa cggacgccca gcgacaaatc ggcgcatacg gtcgaacacg gcagcccccg 2160
gacccgcgac ccaacgccgc gccccccggg gctgcccgag gaggcgacag ccctcgctgc 2220
gccctcgccg cccagggccc gagcgcgcgc cgcgccccgg cctcttggag cccacggacg 2280
ccggcggtcc cccgcgaagc gcgccgaggc tgcctccatg ttggccgctg acgtgcgcgg 2340
caagactcgc agcctgggcc gcgccgaggt ggccctgggc gcgcagggcc ccagggaaaa 2400
gccggcgccc ccacagaaag ccaagcgctc cgtgccgcca gcctcgcccg cccgcgcgcc 2460
cccagcgacc gaaaccccgg ggcctgagaa ggcggcgacc gacttgcccg cgcctgagac 2520
cccccggaag aagaccccca tccagaagcc gccgcgcaag aagagccggg aggcggcggg 2580
cgagctgggc agggcgggcg cacccaccct gtag 2614
<210>43
<211>402
<212>DNA
<213>人(Homo sapiens)
<400>43
atcgactgcc gcgcggagca gggccgtacg ccgctcatgg tggccgtggg gctgccggac 60
cccgcgctgc gcgcgcgctt cgtgcggctg ctgctcgagc agggtgctgc agtgaacctg 120
cgagacgagc gcggccgcac cgcactcagc ctggcgtgcg agcgaggcca cctggacgcc 180
gtgcagctgc tggtgcagtt cagcggtgac cccgaggcgg ccgactctgc gggcaacagc 240
ccggtgatgt gggcggcggc ctgcggccac ggggcggtgc tcgagttcct ggtgcggtcc 300
ttccgccgcc taggcctgcg cctcgaccgc accaaccgtg cggggctcac cgcgctgcaa 360
ctggccgccg cccgcggcca cgggacctgt gtgcaggccc tc 402
<210>44
<211>975
<212>DNA
<213>人(Homo sapiens)
<400>44
atgctcaaac ccaaggacct gtgcccccga gcggggacgc gcaccttcct ggaggccatg 60
caggcgggca aagtgcactt ggcccgcttc gtgttggatg cgctggaccg cagcatcatc 120
gactgccgcg cggagcaggg ccgtacgccg ctcatggtgg ccgtggggct gccggacccc 180
gcgctgcgcg cgcgcttcgt gcggctgctg ctcgagcagg gtgctgcagt gaacctgcga 240
gacgagcgcg gccgcaccgc actcagcctg gcgtgcgagc gaggccacct ggacgccgtg 300
cagctgctgg tgcagttcag cggtgacccc gaggcggccg actctgcggg caacagcccg 360
gtgatgtggg cggcggcctg cggccacggg gcggtgctcg agttcctggt gcggtccttc 420
cgccgcctag gcctgcgcct cgaccgcacc aaccgtgcgg ggctcaccgc gctgcaactg 480
gccgccgccc gcggccacgg gacctcggcg ggcggccacg gcggcgaggc tggctcagcg 540
ggcaagaatt cgggccggca ccgggcgcag ggcagcgaac ggcccgagct gggtcggagc 600
atgagcctgg ctctaggtgc ggtaaccgag gaggaggctg cccgcctgcg ggctggggcc 660
ctgatggccc taccaaactc gccccagtct tcggggactg ggcggtggcg ctcacaggag 720
gtgctggagg gagcgccccc aaccttagcg caagccccca ttggcctcag tccccacccg 780
gagggcggcc ccggctctgg ccgcctgggt ttgcgccgac gctccacagc cccagatatc 840
cccagcctgg tcggggaggc gccagggccc gagagtggcc cggagttaga ggccaacgct 900
ctgtctgtct cggtgcctgg gccgaaccct tggcaggcgg gcaccgaggc tgtggtgctg 960
cgtgctcagc ggtaa 975
<210>45
<211>568
<212>PRT
<213>人(Homo sapiens)
<400>45
Met Lys Glu Ala Glu Met Asp Gly Glu Ala Val Arg Phe Cys Thr Asp
1 5 10 15
Asn Gln Cys Val Ser Leu His Pro Gln Glu Val Asp Ser Val Ala Met
20 25 30
Ala Pro Ala Ala Pro Lys Ile Pro Arg Leu Val Gln Ala Thr Pro Ala
35 40 45
Phe Met Ala Val Thr Leu Val Phe Ser Leu Val Thr Leu Phe Val Val
50 55 60
Gly Lys Pro Pro Val Gln Gln Gln Thr Arg Pro Val Pro Lys Pro Val
65 70 75 80
Gln Ala Val Ile Leu Gly Asp Asn Ile Thr Gly His Leu Pro Phe Glu
85 90 95
Pro Asn Asn His His His Phe Gly Arg Glu Ala Glu Met Arg Glu Leu
100 105 110
Ile Gln Thr Phe Lys Gly His Met Glu Asn Ser Ser Ala Trp Val Val
115 120 125
Glu Ile Gln Met Leu Lys Cys Arg Val Asp Asn Val Asn Ser Gln Leu
130 135 140
Gln Val Leu Gly Asp His Leu Gly Asn Thr Asn Ala Asp Ile Gln Met
145 150 155 160
Val Lys Gly Val Leu Lys Asp Ala Thr Thr Leu Ser Leu Gln Thr Gln
165 170 175
Met Leu Arg Ser Ser Leu Glu Gly Thr Asn Ala Glu Ile Gln Arg Leu
180 185 190
Lys Glu Asp Leu Glu Lys Ala Asp Ala Leu Thr Phe Gln Thr Leu Asn
195 200 205
Phe Leu Lys Ser Ser Leu Glu Asn Thr Ser Ile Glu Leu His Val Leu
210 215 220
Ser Arg Gly Leu Glu Asn Ala Asn Ser Glu Ile Gln Met Leu Asn Ala
225 230 235 240
Arg Ala Asn Ala Glu Ile Gln Gly Leu Lys Glu Asn Leu Gln Asn Thr
245 250 255
Asn Ala Leu Asn Ser Gln Thr Gln Ala Phe Ile Lys Ser Ser Phe Asp
260 265 270
Asn Thr Ser Ala Glu Ile Gln Phe Leu Arg Gly His Leu Glu Arg Ala
275 280 285
Gly Asp Glu Ile His Val Leu Lys Arg Asp Leu Lys Met Val Thr Ala
290 295 300
Gln Thr Gln Lys Ala Asn Gly Arg Leu Asp Gln Thr Asp Thr Gln Ile
305 310 315 320
Gln Val Phe Lys Ser Glu Met Glu Asn Val Asn Thr Leu Asn Ala Gln
325 330 335
Ile Gln Val Leu Asn Gly His Met Lys Asn Ala Ser Arg Glu Ile Gln
340 345 350
Thr Leu Lys Gln Gly Met Lys Asn Ala Ser Ala Leu Thr Ser Gln Thr
355 360 365
Gln Met Leu Asp Ser Asn Leu Gln Lys Ala Ser Ala Glu Ile Gln Arg
370 375 380
Leu Arg Gly Asp Leu Glu Asn Thr Lys Ala Leu Thr Met Glu Ile Gln
385 390 395 400
Gln Glu Gln Ser Arg Leu Lys Thr Leu His Val Val Ile Thr Ser Gln
405 410 415
Glu Gln Leu Gln Arg Thr Gln Ser Gln Leu Leu Gln Met Val Leu Gln
420 425 430
Gly Trp Lys Phe Asn Gly Gly Ser Leu Tyr Tyr Phe Ser Ser Val Lys
435 440 445
Lys Ser Trp His Glu Ala Glu Gln Phe Cys Val Ser Gln Gly Ala His
450 455 460
Leu Ala Ser Val Ala Ser Lys Glu Glu Gln Ala Phe Leu Val Glu Phe
465 470 475 480
Thr Ser Lys Val Tyr Tyr Trp Ile Gly Leu Thr Asp Arg Gly Thr Glu
485 490 495
Gly Ser Trp Arg Trp Thr Asp Gly Thr Pro Phe Asn Ala Ala Gln Asn
500 505 510
Lys Ala Pro Val Val Phe Gly Phe Trp Glu Lys Asn Gln Ser Asp Asn
515 520 525
Trp Arg His Lys Asn Gly Gln Thr Glu Asp Cys Val Gln Ile Gln Gln
530 535 540
Lys Trp Asn Asp Met Thr Cys Asp Thr Pro Tyr Gln Trp Val Cys Lys
545 550 555 560
Lys Pro Met Gly Gln Gly Val Ala
565
<210>46
<211>364
<212>PRT
<213>人(Homo sapiens)
<400>46
Met Ser Arg Gln Gly Lys Leu Phe Ser Ala Phe Gly Val Gly Cys Cys
1 5 10 15
Val Thr Ala Gly Leu Pro Lys Asp Asp Asn Thr Pro Ser Thr Ile Ala
20 25 30
Asp Val His Asn Gly Tyr Thr Met Asn Val Val Glu Gln Val Leu Lys
35 40 45
Asp Ser Phe Val Leu Phe Phe Pro Gly Thr Leu Cys Asp Phe Pro Lys
50 55 60
Ile His His Gly Phe Leu Tyr Asp Glu Glu Asp Tyr Asn Pro Phe Ser
65 70 75 80
Gln Val Pro Thr Gly Glu Val Phe Tyr Tyr Ser Cys Glu Tyr Asn Phe
85 90 95
Val Ser Pro Ser Lys Ser Phe Trp Thr Arg Ile Thr Cys Thr Glu Glu
100 105 110
Gly Trp Ser Pro Thr Pro Lys Cys Leu Arg Met Cys Ser Phe Pro Phe
115 120 125
Val Lys Asn Gly His Ser Glu Ser Ser Gly Leu Ile His Leu Glu Gly
130 135 140
Asp Thr Val Gln Ile Ile Cys Asn Thr Gly Tyr Ser Leu Gln Asn Asn
145 150 155 160
Glu Lys Asn Ile Ser Cys Val Glu Arg Gly Trp Ser Thr Pro Pro Ile
165 170 175
Cys Ser Phe Thr Met Lys Thr Cys Gly Tyr Ile Pro Glu Leu Glu Tyr
180 185 190
Gly Tyr Val Gln Pro Ser Val Pro Pro Tyr Gln His Gly Val Ser Val
195 200 205
Glu Val Asn Cys Arg Asn Glu Tyr Ala Met Ile Gly Asn Asn Met Ile
210 215 220
Thr Cys Ile Asn Gly Ile Trp Thr Glu Leu Pro Met Cys Val Glu Ser
225 230 235 240
Thr Ala Tyr Cys Gly Pro Pro Pro Ser Ile Asn Asn Gly Asp Thr Thr
245 250 255
Ser Phe Pro Leu Ser Val Tyr Pro Pro Gly Ser Thr Val Thr Tyr Arg
260 265 270
Cys Gln Ser Phe Tyr Lys Leu Gln Gly Ser Val Thr Val Thr Cys Arg
275 280 285
Asn Lys Gln Trp Ser Glu Pro Pro Arg Cys Leu Asp Pro Cys Val Val
290 295 300
Ser Glu Glu Asn Met Asn Lys Asn Asn Ile Gln Leu Lys Trp Arg Asn
305 310 315 320
Asp Gly Lys Leu Tyr Ala Lys Thr Gly Asp Ala Val Glu Phe Gln Cys
325 330 335
Lys Phe Pro His Lys Ala Met Ile Ser Ser Pro Pro Phe Arg Ala Ile
340 345 350
Cys Gln Glu Gly Lys Phe Glu Tyr Pro Ile Cys Glu
355 360
<210>47
<211>327
<212>PRT
<213>人(Homo sapiens)
<400>47
Met Leu Leu Leu Phe Ser Val Ile Leu Ile Ser Trp Val Ser Thr Val
1 5 10 15
Gly Gly Glu Gly Thr Leu Cys Asp Phe Pro Lys Ile His His Gly Phe
20 25 30
Leu Tyr Asp Glu Glu Asp Tyr Asn Pro Phe Ser Gln Val Pro Thr Gly
35 40 45
Glu Val Phe Tyr Tyr Ser Cys Glu Tyr Asn Phe Val Ser Pro Ser Lys
50 55 60
Ser Phe Trp Thr Arg Ile Thr Cys Thr Glu Glu Gly Trp Ser Pro Thr
65 70 75 80
Pro Lys Cys Leu Arg Met Cys Ser Phe Pro Phe Val Lys Asn Gly His
85 90 95
Ser Glu Ser Ser Gly Leu Ile His Leu Glu Gly Asp Thr Val Gln Ile
100 105 110
Ile Cys Asn Thr Gly Tyr Ser Leu Gln Asn Asn Glu Lys Asn Ile Ser
115 120 125
Cys Val Glu Arg Gly Trp Ser Thr Pro Pro Ile Cys Ser Phe Thr Met
130 135 140
Lys Thr Cys Gly Tyr Ile Pro Glu Leu Glu Tyr Gly Tyr Val Gln Pro
145 150 155 160
Ser Val Pro Pro Tyr Gln His Gly Val Ser Val Glu Val Asn Cys Arg
165 170 175
Asn Glu Tyr Ala Met Ile Gly Asn Asn Met Ile Thr Cys Ile Asn Gly
180 185 190
Ile Trp Thr Glu Leu Pro Met Cys Val Glu Ser Thr Ala Tyr Cys Gly
195 200 205
Pro Pro Pro Ser Ile Asn Asn Gly Asp Thr Thr Ser Phe Pro Leu Ser
210 215 220
Val Tyr Pro Pro Gly Ser Thr Val Thr Tyr Arg Cys Gln Ser Phe Tyr
225 230 235 240
Lys Leu Gln Gly Ser Val Thr Val Thr Cys Arg Asn Lys Gln Trp Ser
245 250 255
Glu Pro Pro Arg Cys Leu Asp Pro Cys Val Val Ser Glu Glu Asn Met
260 265 270
Asn Lys Asn Asn Ile Gln Leu Lys Trp Arg Asn Asp Gly Lys Leu Tyr
275 280 285
Ala Lys Thr Gly Asp Ala Val Glu Phe Gln Cys Lys Phe Pro His Lys
290 295 300
Ala Met Ile Ser Ser Pro Pro Phe Arg Ala Ile Cys Gln Glu Gly Lys
305 310 315 320
Phe Glu Tyr Pro Ile Cys Glu
325
<210>48
<211>154
<212>PRT
<213>人(Homo sapiens)
<400>48
Met Ala Pro Ala Arg Ala Gly Cys Cys Pro Leu Leu Leu Leu Leu Leu
1 5 10 15
Gly Leu Trp Val Ala Glu Val Leu Val Arg Ala Lys Pro Lys Asp Met
20 25 30
Thr Ser Ser Gln Trp Phe Lys Thr Gln His Val Gln Pro Ser Pro Gln
35 40 45
Ala Cys Asn Ser Ala Met Ser Ile Ile Asn Lys Tyr Thr Glu Arg Cys
50 55 60
Lys Asp Leu Asn Thr Phe Leu His Glu Pro Phe Ser Ser Val Ala Ile
65 70 75 80
Thr Cys Gln Thr Pro Asn Ile Ala Cys Lys Asn Ser Cys Lys Asn Cys
85 90 95
His Gln Ser His Gly Pro Met Ser Leu Thr Met Gly Glu Leu Thr Ser
100 105 110
Gly Lys Tyr Pro Asn Cys Arg Tyr Lys Glu Lys His Leu Asn Thr Pro
115 120 125
Tyr Ile Val Ala Cys Asp Pro Pro Gln Gln Gly Asp Pro Gly Tyr Pro
130 135 140
Leu Val Pro Val His Leu Asp Lys Val Val
145 150
<210>49
<211>502
<212>PRT
<213>人(Homo sapiens)
<400>49
Met Arg Gln Leu Gly Gly Ser Leu Arg Pro Pro Arg Ala Ala His Gly
1 5 10 15
Ala Glu Pro Leu Pro Ser Ala Leu Gly Pro Cys Ala Gly Gly Asp Arg
20 25 30
Asp Leu Gly Arg Gly Thr Pro Gly Trp Glu Pro Arg Arg Ala Arg Val
35 40 45
Pro Ile His Glu Gln Val Asp Pro Pro Arg Glu Gly Pro His Leu Phe
50 55 60
Gln Asn Leu Leu Leu Phe Leu Trp Ala Leu Leu Asn Cys Gly Leu Gly
65 70 75 80
Val Ser Ala Gln Gly Pro Gly Glu Trp Thr Pro Trp Val Ser Trp Thr
85 90 95
Arg Cys Ser Ser Ser Cys Gly Arg Gly Val Ser Val Arg Ser Arg Arg
100 105 110
Cys Leu Arg Leu Pro Gly Glu Glu Pro Cys Trp Gly Asp Ser His Glu
115 120 125
Tyr Arg Leu Cys Gln Leu Pro Asp Cys Pro Pro Gly Ala Val Pro Phe
130 135 140
Arg Asp Leu Gln Cys Ala Leu Tyr Asn Gly Arg Pro Val Leu Gly Thr
145 150 155 160
Gln Lys Thr Tyr Gln Trp Val Pro Phe His Gly Ala Pro Asn Gln Cys
165 170 175
Asp Leu Asn Cys Leu Ala Glu Gly His Ala Phe Tyr His Ser Phe Gly
180 185 190
Arg Val Leu Asp Gly Thr Ala Cys Ser Pro Gly Ala Gln Gly Val Cys
195 200 205
Val Ala Gly Arg Cys Leu Ser Ala Gly Cys Asp Gly Leu Leu Gly Ser
210 215 220
Gly Ala Leu Glu Asp Arg Cys Gly Arg Cys Gly Gly Ala Asn Asp Ser
225 230 235 240
Cys Leu Phe Val Gln Arg Val Phe Arg Asp Ala Gly Ala Phe Ala Gly
245 250 255
Tyr Trp Asn Val Thr Leu Ile Pro Glu Gly Ala Arg His Ile Arg Val
260 265 270
Glu His Arg Ser Arg Asn His Leu Gly Ile Leu Gly Ser Leu Met Gly
275 280 285
Gly Asp Gly Arg Tyr Val Leu Asn Gly His Trp Val Val Ser Pro Pro
290 295 300
Gly Thr Tyr Glu Ala Ala Gly Thr His Val Val Tyr Thr Arg Asp Thr
305 310 315 320
Gly Pro Gln Glu Thr Leu Gln Ala Ala Gly Pro Thr Ser His Asp Leu
325 330 335
Leu Leu Gln Val Leu Leu Gln Glu Pro Asn Pro Gly Ile Glu Phe Glu
340 345 350
Phe Trp Leu Pro Arg Glu Arg Tyr Ser Pro Phe Gln Ala Arg Val Gln
355 360 365
Ala Leu Gly Trp Pro Leu Arg Gln Pro Gln Pro Arg Gly Val Glu Pro
370 375 380
Gln Pro Pro Ala Ala Pro Ala Val Thr Pro Ala Gln Thr Pro Thr Leu
385 390 395 400
Ala Pro Val Phe Gln Ala Arg Val Leu Gly His His His Gln Ala Gln
405 410 415
Glu Thr Arg Tyr Glu Val Arg Ile Gln Leu Val Tyr Lys Asn Arg Ser
420 425 430
Pro Leu Arg Ala Arg Glu Tyr Val Trp Ala Pro Gly His Cys Pro Cys
435 440 445
Pro Met Leu Ala Pro His Arg Asp Tyr Leu Met Ala Val Gln Arg Leu
450 455 460
Val Ser Pro Asp Gly Thr Gln Asp Gln Leu Leu Leu Pro His Ala Gly
465 470 475 480
Tyr Ala Arg Pro Trp Ser Pro Ala Glu Asp Ser Arg Ile Arg Leu Thr
485 490 495
Ala Arg Arg Cys Pro Gly
500
<210>50
<211>451
<212>PRT
<213>人(Homo sapiens)
<400>50
Met Asp Ser Ala Pro Leu Phe Pro Arg Pro His Leu Phe Gln Asn Leu
1 5 10 15
Leu Leu Phe Leu Trp Ala Leu Leu Asn Cys Gly Leu Gly Val Ser Ala
20 25 30
Gln Gly Pro Gly Glu Trp Thr Pro Trp Val Ser Trp Thr Arg Cys Ser
35 40 45
Ser Ser Cys Gly Arg Gly Val Ser Val Arg Ser Arg Arg Cys Leu Arg
50 55 60
Leu Pro Gly Glu Glu Pro Cys Trp Gly Asp Ser His Glu Tyr Arg Leu
65 70 75 80
Cys Gln Leu Pro Asp Cys Pro Pro Gly Ala Val Pro Phe Arg Asp Leu
85 90 95
Gln Cys Ala Leu Tyr Asn Gly Arg Pro Val Leu Gly Thr Gln Lys Thr
100 105 110
Tyr Gln Trp Val Pro Phe His Gly Ala Pro Asn Gln Cys Asp Leu Asn
115 120 125
Cys Leu Ala Glu Gly His Ala Phe Tyr His Ser Phe Gly Arg Val Leu
130 135 140
Asp Gly Thr Ala Cys Ser Pro Gly Ala Gln Gly Val Cys Val Ala Gly
145 150 155 160
Arg Cys Leu Ser Ala Gly Cys Asp Gly Leu Leu Gly Ser Gly Ala Leu
165 170 175
Glu Asp Arg Cys Gly Arg Cys Gly Gly Ala Asn Asp Ser Cys Leu Phe
180 185 190
Val Gln Arg Val Phe Arg Asp Ala Gly Ala Phe Ala Gly Tyr Trp Asn
195 200 205
Val Thr Leu Ile Pro Glu Gly Ala Arg His Ile Arg Val Glu His Arg
210 215 220
Ser Arg Asn His Leu Gly Ile Leu Gly Ser Leu Met Gly Gly Asp Gly
225 230 235 240
Arg Tyr Val Leu Asn Gly His Trp Val Val Ser Pro Pro Gly Thr Tyr
245 250 255
Glu Ala Ala Gly Thr His Val Val Tyr Thr Arg Asp Thr Gly Pro Gln
260 265 270
Glu Thr Leu Gln Ala Ala Gly Pro Thr Ser His Asp Leu Leu Leu Gln
275 280 285
Val Leu Leu Gln Glu Pro Asn Pro Gly Ile Glu Phe Glu Phe Trp Leu
290 295 300
Pro Arg Glu Arg Tyr Ser Pro Phe Gln Ala Arg Val Gln Ala Leu Gly
305 310 315 320
Trp Pro Leu Arg Gln Pro Gln Pro Arg Gly Val Glu Pro Gln Pro Pro
325 330 335
Ala Ala Pro Ala Val Thr Pro Ala Gln Thr Pro Thr Leu Ala Pro Val
340 345 350
Phe Gln Ala Arg Val Leu Gly His His His Gln Ala Gln Glu Thr Arg
355 360 365
Tyr Glu Val Arg Ile Gln Leu Val Tyr Lys Asn Arg Ser Pro Leu Arg
370 375 380
Ala Arg Glu Tyr Val Trp Ala Pro Gly His Cys Pro Cys Pro Met Leu
385 390 395 400
Ala Pro His Arg Asp Tyr Leu Met Ala Val Gln Arg Leu Val Ser Pro
405 410 415
Asp Gly Thr Gln Asp Gln Leu Leu Leu Pro His Ala Gly Tyr Ala Arg
420 425 430
Pro Trp Ser Pro Ala Glu Asp Ser Arg Ile Arg Leu Thr Ala Arg Arg
435 440 445
Cys Pro Gly
450
<210>51
<211>431
<212>PRT
<213>人(Homo sapiens)
<400>51
Met Ile Arg Thr Pro Leu Ser Ala Ser Ala His Arg Leu Leu Leu Pro
1 5 10 15
Gly Ser Arg Gly Arg Pro Pro Arg Asn Met Gln Pro Thr Gly Arg Glu
20 25 30
Gly Ser Arg Ala Leu Ser Arg Arg Tyr Leu Arg Arg Leu Leu Leu Leu
35 40 45
Leu Leu Leu Leu Leu Leu Arg Gln Pro Val Thr Arg Ala Glu Thr Thr
50 55 60
Pro Gly Ala Pro Arg Ala Leu Ser Thr Leu Gly Ser Pro Ser Leu Phe
65 70 75 80
Thr Thr Pro Gly Val Pro Ser Ala Leu Thr Thr Pro Gly Leu Thr Thr
85 90 95
Pro Gly Thr Pro Lys Thr Leu Asp Leu Arg Gly Arg Ala Gln Ala Leu
100 105 110
Met Arg Ser Phe Pro Leu Val Asp Gly Tyr Val Gly Leu Asn Ser Ser
115 120 125
Gln Lys Leu Ala Cys Leu Ile Gly Val Glu Gly Gly His Ser Leu Asp
130 135 140
Ser Ser Leu Ser Val Leu Arg Ser Phe Tyr Val Leu Gly Val Arg Tyr
145 150 155 160
Leu Thr Leu Thr Phe Thr Cys Ser Thr Pro Trp Ala Glu Ser Ser Thr
165 170 175
Lys Phe Arg His His Met Tyr Thr Asn Val Ser Gly Leu Thr Ser Phe
180 185 190
Gly Glu Lys Val Val Glu Glu Leu Asn Arg Leu Gly Met Met Ile Asp
195 200 205
Leu Ser Tyr Ala Ser Asp Thr Leu Ile Arg Arg Val Leu Glu Val Ser
210 215 220
Gln Ala Pro Val Ile Phe Ser His Ser Ala Ala Arg Ala Val Cys Asp
225 230 235 240
Asn Leu Leu Asn Val Pro Asp Asp Ile Leu Gln Leu Leu Lys Lys Asn
245 250 255
Gly Gly Ile Val Met Val Thr Leu Ser Met Gly Val Leu Gln Cys Asn
260 265 270
Leu Leu Ala Asn Val Ser Thr Val Ala Asp Asp Ser Asn Arg Cys Ser
275 280 285
Val Pro Val Ile Gly Ser Glu Phe Ile Gly Ile Gly Gly Asn Tyr Asp
290 295 300
Gly Thr Gly Arg Phe Pro Gln Gly Leu Glu Asp Val Ser Thr Tyr Pro
305 310 315 320
Val Leu Ile Glu Glu Leu Leu Ser Arg Ser Trp Ser Glu Glu Glu Leu
325 330 335
Gln Gly Val Leu Arg Gly Asn Leu Leu Arg Val Phe Arg Gln Val Glu
340 345 350
Lys Val Arg Glu Glu Ser Arg Ala Gln Ser Pro Val Glu Ala Glu Phe
355 360 365
Pro Tyr Gly Gln Leu Ser Thr Ser Cys His Ser His Leu Val Pro Gln
370 375 380
Asn Gly His Gln Ala Thr His Leu Glu Val Thr Lys Gln Pro Thr Asn
385 390 395 400
Arg Val Pro Trp Arg Ser Ser Asn Ala Ser Pro Tyr Leu Val Pro Gly
405 410 415
Leu Val Ala Ala Ala Thr Ile Pro Thr Phe Thr Gln Trp Leu Cys
420 425 430
<210>52
<211>480
<212>PRT
<213>人(Homo sapiens)
<400>52
Met Gln Pro Ser Gly Leu Glu Gly Pro Gly Thr Phe Gly Arg Trp Pro
1 5 10 15
Leu Leu Ser Leu Leu Leu Leu Leu Leu Leu Leu Gln Pro Val Thr Cys
20 25 30
Ala Tyr Thr Thr Pro Gly Pro Pro Arg Ala Leu Thr Thr Leu Gly Ala
35 40 45
Pro Arg Ala His Thr Met Pro Gly Thr Tyr Ala Pro Ser Thr Thr Leu
50 55 60
Ser Ser Pro Ser Thr Gln Gly Leu Gln Glu Gln Ala Arg Ala Leu Met
65 70 75 80
Arg Asp Phe Pro Leu Val Asp Gly His Asn Asp Leu Pro Leu Val Leu
85 90 95
Arg Gln Val Tyr Gln Lys Gly Leu Gln Asp Val Asn Leu Arg Asn Phe
100 105 110
Ser Tyr Gly Gln Thr Ser Leu Asp Arg Leu Arg Asp Gly Leu Val Gly
115 120 125
Ala Gln Phe Trp Ser Ala Tyr Val Pro Cys Gln Thr Gln Asp Arg Asp
130 135 140
Ala Leu Arg Leu Thr Leu Glu Gln Ile Asp Leu Ile Arg Arg Met Cys
145 150 155 160
Ala Ser Tyr Ser Glu Leu Glu Leu Val Thr Ser Ala Lys Gly Leu Asn
165 170 175
Ser Ser Gln Lys Leu Ala Cys Leu Ile Gly Val Glu Gly Gly His Ser
180 185 190
Leu Asp Ser Ser Leu Ser Val Leu Arg Ser Phe Tyr Val Leu Gly Val
195 200 205
Arg Tyr Leu Thr Leu Thr Phe Thr Cys Ser Thr Pro Trp Ala Glu Ser
210 215 220
Ser Thr Lys Phe Arg His His Met Tyr Thr Asn Val Ser Gly Leu Thr
225 230 235 240
Ser Phe Gly Glu Lys Val Val Glu Glu Leu Asn Arg Leu Gly Met Met
245 250 255
Ile Asp Leu Ser Tyr Ala Ser Asp Thr Leu Ile Arg Arg Val Leu Glu
260 265 270
Val Ser Gln Ala Pro Val Ile Phe Ser His Ser Ala Ala Arg Ala Val
275 280 285
Cys Asp Asn Leu Leu Asn Val Pro Asp Asp Ile Leu Gln Leu Leu Lys
290 295 300
Lys Asn Gly Gly Ile Val Met Val Thr Leu Ser Met Gly Val Leu Gln
305 310 315 320
Cys Asn Leu Leu Ala Asn Val Ser Thr Val Ala Asp His Phe Asp His
325 330 335
Ile Arg Ala Val Ile Gly Ser Glu Phe Ile Gly Ile Gly Gly Asn Tyr
340 345 350
Asp Gly Thr Gly Arg Phe Pro Gln Gly Leu Glu Asp Val Ser Thr Tyr
355 360 365
Pro Val Leu Ile Glu Glu Leu Leu Ser Arg Ser Trp Ser Glu Glu Glu
370 375 380
Leu Gln Gly Val Leu Arg Gly Asn Leu Leu Arg Val Phe Arg Gln Val
385 390 395 400
Glu Lys Val Arg Glu Glu Ser Arg Ala Gln Ser Pro Val Glu Ala Glu
405 410 415
Phe Pro Tyr Gly Gln Leu Ser Thr Ser Cys His Ser His Leu Val Pro
420 425 430
Gln Asn Gly His Gln Ala Thr His Leu Glu Val Thr Lys Gln Pro Thr
435 440 445
Asn Arg Val Pro Trp Arg Ser Ser Asn Ala Ser Pro Tyr Leu Val Pro
450 455 460
Gly Leu Val Ala Ala Ala Thr Ile Pro Thr Phe Thr Gln Trp Leu Cys
465 470 475 480
<210>53
<211>371
<212>PRT
<213>人(Homo sapiens)
<400>53
Met Asp Ala Ala Thr Ala Pro Lys Gln Ala Trp Pro Pro Trp Pro Pro
1 5 10 15
Leu Leu Phe Leu Leu Leu Leu Pro Gly Gly Ser Gly Gly Ser Cys Pro
20 25 30
Ala Val Cys Asp Cys Thr Ser Gln Pro Gln Ala Val Leu Cys Gly His
35 40 45
Arg Gln Leu Glu Ala Val Pro Gly Gly Leu Pro Leu Asp Thr Glu Leu
50 55 60
Leu Asp Leu Ser Gly Asn Arg Leu Pro Lys Ala Gln Pro Leu Val Arg
65 70 75 80
Leu Gln Glu Leu Arg Leu Ser Gly Ala Cys Leu Thr Ser Ile Ala Ala
85 90 95
His Ala Phe His Gly Leu Thr Ala Phe His Leu Leu Asp Val Ala Asp
100 105 110
Asn Ala Leu Gln Thr Leu Glu Glu Thr Ala Phe Pro Ser Pro Asp Lys
115 120 125
Leu Val Thr Leu Arg Leu Ser Gly Asn Pro Leu Thr Cys Asp Cys Arg
130 135 140
Leu Leu Trp Leu Leu Arg Leu Arg His Leu Asp Phe Gly Met Ser Pro
145 150 155 160
Pro Ala Cys Ala Gly Pro His His Val Gln Gly Lys Ser Leu Lys Glu
165 170 175
Phe Ser Asp Ile Leu Pro Pro Gly His Phe Thr Cys Lys Pro Ala Leu
180 185 190
Ile Arg Lys Ser Gly Pro Arg Trp Val Ile Ala Glu Glu Gly Gly His
195 200 205
Ala Val Phe Ser Cys Ser Gly Asp Gly Asp Pro Ala Pro Thr Val Ser
210 215 220
Trp Met Arg Pro His Gly Ala Trp Leu Gly Arg Ala Gly Arg Val Arg
225 230 235 240
Val Leu Glu Asp Gly Thr Leu Glu Ile Arg Ser Val Gln Leu Arg Asp
245 250 255
Arg Gly Ala Tyr Val Cys Val Val Ser Asn Val Ala Gly Asn Asp Ser
260 265 270
Leu Arg Thr Trp Leu Glu Val Ile Gln Val Glu Pro Pro Asn Gly Thr
275 280 285
Leu Ser Asp Pro Asn Ile Thr Val Pro Gly Ile Pro Gly Pro Phe Phe
290 295 300
Leu Asp Ser Arg Gly Val Ala Met Val Leu Ala Val Gly Phe Leu Pro
305 310 315 320
Phe Leu Thr Ser Val Thr Leu Cys Phe Gly Leu Ile Ala Leu Trp Ser
325 330 335
Lys Gly Lys Gly Arg Val Lys His His Met Thr Phe Asp Phe Val Ala
340 345 350
Pro Arg Pro Ser Gly Asp Lys Asn Ser Gly Gly Asn Arg Val Thr Ala
355 360 365
Lys Leu Phe
370
<210>54
<211>592
<212>PRT
<213>人(Homo sapiens)
<400>54
Met Asp Ala Ala Thr Ala Pro Lys Gln Ala Trp Pro Pro Trp Pro Pro
1 5 10 15
Leu Leu Phe Leu Leu Leu Leu Pro Gly Gly Ser Gly Gly Ser Cys Pro
20 25 30
Ala Val Cys Asp Cys Thr Ser Gln Pro Gln Ala Val Leu Cys Gly His
35 40 45
Arg Gln Leu Glu Ala Val Pro Gly Gly Leu Pro Leu Asp Thr Glu Leu
50 55 60
Leu Asp Leu Ser Gly Asn Arg Leu Trp Gly Leu Gln Gln Gly Met Leu
65 70 75 80
Ser Arg Leu Ser Leu Leu Gln Glu Leu Asp Leu Ser Tyr Asn Gln Leu
85 90 95
Ser Thr Leu Glu Pro Gly Ala Phe His Gly Leu Gln Ser Leu Leu Thr
100 105 110
Leu Arg Leu Gln Gly Asn Arg Leu Arg Ile Met Gly Pro Gly Val Phe
115 120 125
Ser Gly Leu Ser Ala Leu Thr Leu Leu Asp Leu Arg Leu Asn Gln Ile
130 135 140
Val Leu Phe Leu Asp Gly Ala Phe Gly Glu Leu Gly Ser Leu Gln Lys
145 150 155 160
Leu Glu Val Gly Asp Asn His Leu Val Phe Val Ala Pro Gly Ala Phe
165 170 175
Ala Gly Leu Ala Lys Leu Ser Thr Leu Thr Leu Glu Arg Cys Asn Leu
180 185 190
Ser Thr Val Pro Gly Leu Ala Leu Ala Arg Leu Pro Ala Leu Val Ala
195 200 205
Leu Arg Leu Arg Glu Leu Asp Ile Gly Arg Leu Pro Ala Gly Ala Leu
210 215 220
Arg Gly Leu Gly Gln Leu Lys Glu Leu Glu Ile His Leu Trp Pro Ser
225 230 235 240
Leu Glu Ala Leu Asp Pro Gly Ser Leu Val Gly Leu Asn Leu Ser Ser
245 250 255
Leu Ala Ile Thr Arg Cys Asn Leu Ser Ser Val Pro Phe Gln Ala Leu
260 265 270
Tyr His Leu Ser Phe Leu Arg Val Leu Asp Leu Ser Gln Asn Pro Ile
275 280 285
Ser Ala Ile Pro Ala Arg Arg Leu Ser Pro Leu Val Arg Leu Gln Glu
290 295 300
Leu Arg Leu Ser Gly Ala Cys Leu Thr Ser Ile Ala Ala His Ala Phe
305 310 315 320
His Gly Leu Thr Ala Phe His Leu Leu Asp Val Ala Asp Asn Ala Leu
325 330 335
Gln Thr Leu Glu Glu Thr Ala Phe Pro Ser Pro Asp Lys Leu Val Thr
340 345 350
Leu Arg Leu Ser Gly Asn Pro Leu Thr Cys Asp Cys Arg Leu Leu Trp
355 360 365
Leu Leu Arg Leu Arg His Leu Asp Phe Gly Met Ser Pro Pro Ala Cys
370 375 380
Ala Gly Pro His His Val Gln Gly Lys Ser Leu Lys Glu Phe Ser Asp
385 390 395 400
Ile Leu Pro Pro Gly His Phe Thr Cys Lys Pro Ala Leu Ile Arg Lys
405 410 415
Ser Gly Pro Arg Trp Val Ile Ala Glu Glu Gly Gly His Ala Val Phe
420 425 430
Ser Cys Ser Gly Asp Gly Asp Pro Ala Pro Thr Val Ser Trp Met Arg
435 440 445
Pro His Gly Ala Trp Leu Gly Arg Ala Gly Arg Val Arg Val Leu Glu
450 455 460
Asp Gly Thr Leu Glu Ile Arg Ser Val Gln Leu Arg Asp Arg Gly Ala
465 470 475 480
Tyr Val Cys Val Val Ser Asn Val Ala Gly Asn Asp Ser Leu Arg Thr
485 490 495
Trp Leu Glu Val Ile Gln Val Glu Pro Pro Asn Gly Thr Leu Ser Asp
500 505 510
Pro Asn Ile Thr Val Pro Gly Ile Pro Gly Pro Phe Phe Leu Asp Ser
515 520 525
Arg Gly Val Ala Met Val Leu Ala Val Gly Phe Leu Pro Phe Leu Thr
530 535 540
Ser Val Thr Leu Cys Phe Gly Leu Ile Ala Leu Trp Ser Lys Gly Lys
545 550 555 560
Gly Arg Val Lys His His Met Thr Phe Asp Phe Val Ala Pro Arg Pro
565 570 575
Ser Gly Asp Lys Asn Ser Gly Gly Asn Arg Val Thr Ala Lys Leu Phe
580 585 590
<210>55
<211>142
<212>PRT
<213>人(Homo sapiens)
<400>55
Met Ala Arg Tyr Met Leu Leu Leu Leu Leu Ala Val Trp Val Leu Thr
1 5 10 15
Gly Glu Leu Trp Pro Gly Ala Glu Ala Arg Ala Ala Pro Tyr Gly Val
20 25 30
Arg Leu Cys Gly Arg Glu Phe Ile Arg Ala Val Ile Phe Thr Cys Gly
35 40 45
Gly Ser Arg Trp Arg Arg Ser Asp Ile Leu Ala His Glu Ala Met Gly
50 55 60
Asp Thr Phe Pro Asp Ala Asp Ala Asp Glu Asp Ser Leu Ala Gly Glu
65 70 75 80
Leu Asp Glu Ala Met Gly Ser Ser Glu Trp Leu Ala Leu Thr Lys Ser
85 90 95
Pro Gln Ala Phe Tyr Arg Gly Arg Pro Ser Trp Gln Gly Thr Pro Gly
100 105 110
Val Leu Arg Gly Ser Arg Asp Val Leu Ala Gly Leu Ser Ser Ser Cys
115 120 125
Cys Lys Trp Gly Cys Ser Lys Ser Glu Ile Ser Ser Leu Cys
130 135 140
<210>56
<211>230
<212>PRT
<213>人(Homo sapiens)
<400>56
Met Ser Glu Glu Val Thr Tyr Ala Thr Leu Thr Phe Gln Asp Ser Ala
1 5 10 15
Gly Ala Arg Asn Asn Arg Asp Gly Asn Asn Leu Arg Lys Arg Gly His
20 25 30
Pro Ala Pro Ser Pro Ile Trp Arg His Ala Ala Leu Gly Leu Val Thr
35 40 45
Leu Cys Leu Met Leu Leu Ile Gly Leu Val Thr Leu Gly Met Met Phe
50 55 60
Leu Gln Ile Ser Asn Asp Ile Asn Ser Asp Ser Glu Lys Leu Ser Gln
65 70 75 80
Leu Gln Lys Thr Ile Gln Gln Gln Gln Asp Asn Leu Ser Gln Gln Leu
85 90 95
Gly Asn Ser Asn Asn Leu Ser Met Glu Glu Glu Phe Leu Lys Ser Gln
100 105 110
Ile Ser Ser Leu Leu Lys Arg Gln Glu Gln Met Ala Ile Lys Leu Cys
115 120 125
Gln Glu Leu Ile Ile His Thr Ser Asp His Arg Cys Asn Pro Cys Pro
130 135 140
Lys Met Trp Gln Trp Tyr Gln Asn Ser Cys Tyr Tyr Phe Thr Thr Asn
145 150 155 160
Glu Glu Lys Thr Trp Ala Asn Ser Arg Lys Asp Cys Ile Asp Lys Asn
165 170 175
Ser Thr Leu Val Lys Ile Asp Ser Leu Glu Glu Lys Asp Phe Leu Met
180 185 190
Ser Gln Pro Leu Leu Met Phe Ser Phe Phe Trp Leu Gly Leu Ser Trp
195 200 205
Asp Ser Ser Gly Arg Ser Trp Phe Trp Glu Asp Gly Ser Val Pro Ser
210 215 220
Pro Ser Leu Tyr Val Ser
225 230
<210>57
<211>194
<212>PRT
<213>人(Homo sapiens)
<400>57
Met Trp Leu Ser Pro Ala Leu Leu Leu Leu Ile Leu Pro Gly Tyr Ser
1 5 10 15
Ile Ala Ala Lys Ile Thr Gly Pro Thr Thr Val Asn Gly Ser Glu Gln
20 25 30
Gly Ser Leu Thr Val Gln Cys Ala Tyr Gly Ser Gly Trp Glu Thr Tyr
35 40 45
Leu Lys Trp Arg Cys Gln Gly Ala Asp Trp Asn Tyr Cys Asn Ile Leu
50 55 60
Val Lys Thr Asn Gly Ser Glu Gln Glu Val Lys Lys Asn Arg Val Ser
65 70 75 80
Ile Arg Asp Asn Gln Lys Asn His Met Phe Thr Val Thr Met Glu Asn
85 90 95
Leu Lys Arg Asp Asp Ala Asp Ser Tyr Trp Cys Gly Thr Glu Arg Pro
100 105 110
Gly Ile Asp Leu Gly Val Lys Val Gln Val Thr Ile Asn Pro Gly Thr
115 120 125
Gln Thr Ala Val Ser Glu Trp Thr Thr Thr Thr Ala Ser Leu Ala Phe
130 135 140
Thr Ala Ala Ala Thr Gln Lys Thr Ser Ser Pro Leu Thr Arg Ser Pro
145 150 155 160
Leu Lys Ser Thr His Phe Leu Phe Leu Phe Leu Leu Glu Leu Pro Leu
165 170 175
Leu Leu Ser Met Leu Gly Thr Val Leu Trp Val Asn Arg Pro Gln Arg
180 185 190
Arg Ser
<210>58
<211>333
<212>PRT
<213>人(Homo sapiens)
<400>58
Met Arg Ile Trp Trp Leu Leu Leu Ala Ile Glu Ile Cys Thr Gly Asn
1 5 10 15
Ile Asn Ser Gln Asp Thr Cys Arg Gln Gly His Pro Gly Ile Pro Gly
20 25 30
Asn Pro Gly His Asn Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Ala
35 40 45
Lys Gly Asp Lys Gly Asp Ala Gly Glu Pro Gly Arg Pro Gly Ser Pro
50 55 60
Gly Lys Asp Gly Thr Ser Gly Glu Lys Gly Glu Arg Gly Ala Asp Gly
65 70 75 80
Lys Val Glu Ala Lys Gly Ile Lys Gly Asp Gln Gly Ser Arg Gly Ser
85 90 95
Pro Gly Lys His Gly Pro Lys Gly Leu Ala Gly Pro Met Gly Glu Lys
100 105 110
Gly Leu Arg Gly Glu Thr Gly Pro Gln Gly Gln Lys Gly Asn Lys Gly
115 120 125
Asp Val Gly Pro Thr Gly Pro Glu Gly Pro Arg Gly Asn Ile Gly Pro
130 135 140
Leu Gly Pro Thr Gly Leu Pro Gly Pro Met Gly Pro Ile Gly Lys Pro
145 150 155 160
Gly Pro Lys Gly Glu Ala Gly Pro Thr Gly Pro Gln Gly Glu Pro Gly
165 170 175
Val Arg Gly Ile Arg Gly Trp Lys Gly Asp Arg Gly Glu Lys Gly Lys
180 185 190
Ile Gly Glu Thr Leu Val Leu Pro Lys Ser Ala Phe Thr Val Gly Leu
195 200 205
Thr Val Leu Ser Lys Phe Pro Ser Ser Asp Met Pro Ile Lys Phe Asp
210 215 220
Lys Ile Leu Tyr Asn Glu Phe Asn His Tyr Asp Thr Ala Ala Gly Lys
225 230 235 240
Phe Thr Cys His Ile Ala Gly Val Tyr Tyr Phe Thr Tyr His Ile Thr
245 250 255
Val Phe Ser Arg Asn Val Gln Val Ser Leu Val Lys Asn Gly Val Lys
260 265 270
Ile Leu His Thr Lys Asp Ala Tyr Met Ser Ser Glu Asp Gln Ala Ser
275 280 285
Gly Gly Ile Val Leu Gln Leu Lys Leu Gly Asp Glu Val Trp Leu Gln
290 295 300
Val Thr Gly Gly Glu Arg Phe Asn Gly Leu Phe Ala Asp Glu Asp Asp
305 310 315 320
Asp Thr Thr Phe Thr Gly Phe Leu Leu Phe Ser Ser Pro
325 330
<210>59
<211>225
<212>PRT
<213>人(Homo sapiens)
<400>59
Met Arg Ile Trp Trp Leu Leu Leu Ala Ile Glu Ile Cys Thr Gly Asn
1 5 10 15
Ile Asn Ser Gln Asp Thr Cys Arg Gln Gly His Pro Gly Ile Pro Gly
20 25 30
Asn Pro Gly His Asn Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Ala
35 40 45
Lys Gly Asp Lys Gly Asp Ala Gly Glu Ala Gly Pro Thr Gly Pro Gln
50 55 60
Gly Glu Pro Gly Val Arg Gly Ile Arg Gly Trp Lys Gly Asp Arg Gly
65 70 75 80
Glu Lys Gly Lys Ile Gly Glu Thr Leu Val Leu Pro Lys Ser Ala Phe
85 90 95
Thr Val Gly Leu Thr Val Leu Ser Lys Phe Pro Ser Ser Asp Met Pro
100 105 110
Ile Lys Phe Asp Lys Ile Leu Tyr Asn Glu Phe Asn His Tyr Asp Thr
115 120 125
Ala Ala Gly Lys Phe Thr Cys His Ile Ala Gly Val Tyr Tyr Phe Thr
130 135 140
Tyr His Ile Thr Val Phe Ser Arg Asn Val Gln Val Ser Leu Val Lys
145 150 155 160
Asn Gly Val Lys Ile Leu His Thr Lys Asp Ala Tyr Met Ser Ser Glu
165 170 175
Asp Gln Ala Ser Gly Gly Ile Val Leu Gln Leu Lys Leu Gly Asp Glu
180 185 190
Val Trp Leu Gln Val Thr Gly Gly Glu Arg Phe Asn Gly Leu Phe Ala
195 200 205
Asp Glu Asp Asp Asp Thr Thr Phe Thr Gly Phe Leu Leu Phe Ser Ser
210 215 220
Pro
225
<210>60
<211>205
<212>PRT
<213>人(Homo sapiens)
<400>60
Met Met Arg Thr Leu Ile Thr Thr His Pro Leu Pro Leu Leu Leu Leu
1 5 10 15
Pro Gln Gln Leu Leu Gln Leu Val Gln Phe Gln Glu Val Asp Thr Asp
20 25 30
Phe Asp Phe Pro Glu Glu Asp Lys Lys Glu Glu Phe Glu Glu Cys Leu
35 40 45
Glu Lys Phe Phe Ser Thr Gly Pro Ala Arg Pro Pro Thr Lys Glu Lys
50 55 60
Val Lys Arg Arg Val Leu Ile Glu Pro Gly Met Pro Leu Asn His Ile
65 70 75 80
Glu Tyr Cys Asn His Glu Ile Met Gly Lys Asn Val Tyr Tyr Lys His
85 90 95
Arg Trp Val Ala Glu His Tyr Phe Leu Leu Met Gln Tyr Asp Glu Leu
100 105 110
Gln Lys Ile Cys Tyr Asn Arg Phe Val Pro Cys Lys Asn Gly Ile Arg
115 120 125
Lys Cys Asn Arg Ser Lys Gly Leu Val Glu Gly Val Tyr Cys Asn Leu
130 135 140
Thr Glu Ala Phe Glu Ile Pro Ala Cys Lys Tyr Glu Ser Leu Tyr Arg
145 150 155 160
Lys Gly Tyr Val Leu Ile Thr Cys Ser Trp Gln Asn Glu Met Gln Lys
165 170 175
Arg Ile Pro His Thr Ile Asn Asp Leu Val Glu Pro Pro Glu His Arg
180 185 190
Ser Phe Leu Ser Glu Asp Gly Val Phe Val Ile Ser Pro
195 200 205
<210>61
<211>95
<212>PRT
<213>人(Homo sapiens)
<400>61
Met Glu Val Val Leu Ile Phe Leu Cys Ser Leu Leu Ala His Ile Val
1 5 10 15
Leu Ala Asp Ala Val Glu Arg Glu Lys Gln Ile Asp Pro Phe His Tyr
20 25 30
Asp Tyr Gln Thr Leu Arg Ile Arg Gly Leu Val Cys Ala Val Val Leu
35 40 45
Phe Ser Ile Gly Ile Leu Leu Ile Leu Gly Cys Arg Cys Lys Cys Ser
50 55 60
Phe Asn Gln Lys Pro Arg Thr Pro Gly Glu Glu Glu Ala Gln Val Glu
65 70 75 80
Asn Leu Ile Thr Ala Asn Ala Thr Lys Leu Gln Lys Ala Glu Ser
85 90 95
<210>62
<211>595
<212>PRT
<213>人(Homo sapiens)
<400>62
Met Glu Val Gly Met Gly Cys Trp Ala Arg Glu Val Leu Val Pro Glu
1 5 10 15
Gly Pro Leu Tyr Arg Val Ala Gly Thr Ala Val Ser Ile Ser Cys Asn
20 25 30
Val Thr Gly Tyr Glu Gly Pro Ala Gln Gln Asn Phe Glu Trp Phe Leu
35 40 45
Tyr Arg Pro Glu Ala Pro Asp Thr Ala Leu Gly Ile Val Ser Thr Lys
50 55 60
Asp Thr Gln Phe Ser Tyr Ala Val Phe Lys Ser Arg Val Val Ala Gly
65 70 75 80
Glu Val Gln Val Gln Arg Leu Gln Gly Asp Ala Val Val Leu Lys Ile
85 90 95
Ala Arg Leu Gln Ala Gln Asp Ala Gly Ile Tyr Glu Cys His Thr Pro
100 105 110
Ser Thr Asp Thr Arg Tyr Leu Gly Ser Tyr Ser Gly Lys Val Glu Leu
115 120 125
Arg Val Leu Pro Asp Val Leu Gln Val Ser Ala Ala Pro Pro Gly Pro
130 135 140
Arg Gly Arg Gln Ala Pro Thr Ser Pro Pro Arg Met Thr Val His Glu
145 150 155 160
Gly Gln Glu Leu Ala Leu Gly Cys Leu Ala Arg Thr Ser Thr Gln Lys
165 170 175
His Thr His Leu Ala Val Ser Phe Gly Arg Ser Val Pro Glu Ala Pro
180 185 190
Val Gly Arg Ser Thr Leu Gln Glu Val Val Gly Ile Arg Ser Asp Leu
195 200 205
Ala Val Glu Ala Gly Ala Pro Tyr Ala Glu Arg Leu Ala Ala Gly Glu
210 215 220
Leu Arg Leu Gly Lys Glu Gly Thr Asp Arg Tyr Arg Met Val Val Gly
225 230 235 240
Gly Ala Gln Ala Gly Asp Ala Gly Thr Tyr His Cys Thr Ala Ala Glu
245 250 255
Trp Ile Gln Asp Pro Asp Gly Ser Trp Ala Gln Ile Ala Glu Lys Arg
260 265 270
Ala Val Leu Ala His Val Asp Val Gln Thr Leu Ser Ser Gln Leu Ala
275 280 285
Val Thr Val Gly Pro Gly Glu Arg Arg Ile Gly Pro Gly Glu Pro Leu
290 295 300
Glu Leu Leu Cys Asn Val Ser Gly Ala Leu Pro Pro Ala Gly Arg His
305 310 315 320
Ala Ala Tyr Ser Val Gly Trp Glu Met Ala Pro Ala Gly His Leu Gly
325 330 335
Pro Gly Arg Leu Val Ala Gln Leu Asp Thr Glu Gly Val Gly Ser Leu
340 345 350
Gly Pro Gly Tyr Glu Gly Arg His Ile Ala Met Glu Lys Val Ala Ser
355 360 365
Arg Thr Tyr Arg Leu Arg Leu Glu Ala Ala Arg Pro Gly Asp Ala Gly
370 375 380
Thr Tyr Arg Cys Leu Ala Lys Ala Tyr Val Arg Gly Ser Gly Thr Arg
385 390 395 400
Leu Arg Glu Ala Ala Ser Ala Arg Ser Arg Pro Leu Pro Val His Val
405 410 415
Arg Glu Glu Gly Val Val Leu Glu Ala Val Ala Trp Leu Ala Gly Gly
420 425 430
Thr Val Tyr Arg Gly Glu Thr Ala Ser Leu Leu Cys Asn Ile Ser Val
435 440 445
Arg Gly Gly Pro Pro Gly Leu Arg Leu Ala Ala Ser Trp Trp Val Glu
450 455 460
Arg Pro Glu Asp Gly Glu Leu Ser Ser Val Pro Ala Gln Leu Val Gly
465 470 475 480
Gly Val Gly Gln Asp Gly Val Ala Glu Leu Gly Val Arg Pro Gly Gly
485 490 495
Gly Pro Val Ser Val Glu Leu Val Gly Pro Arg Ser His Arg Leu Arg
500 505 510
Leu His Ser Leu Gly Pro Glu Asp Glu Gly Val Tyr His Cys Ala Pro
515 520 525
Ser Ala Trp Val Gln His Ala Asp Tyr Ser Trp Tyr Gln Ala Gly Ser
530 535 540
Ala Arg Ser Gly Pro Val Thr Val Tyr Pro Tyr Met His Ala Leu Asp
545 550 555 560
Thr Leu Phe Val Pro Leu Leu Val Gly Thr Gly Val Ala Leu Val Thr
565 570 575
Gly Ala Thr Val Leu Gly Thr Ile Thr Cys Cys Phe Met Lys Arg Leu
580 585 590
Arg Lys Arg
595
<210>63
<211>613
<212>PRT
<213>人(Homo sapiens)
<400>63
Met Gly Ala Leu Arg Pro Thr Leu Leu Pro Pro Ser Leu Pro Leu Leu
1 5 10 15
Leu Leu Leu Met Leu Gly Met Gly Cys Trp Ala Arg Glu Val Leu Val
20 25 30
Pro Glu Gly Pro Leu Tyr Arg Val Ala Gly Thr Ala Val Ser Ile Ser
35 40 45
Cys Asn Val Thr Gly Tyr Glu Gly Pro Ala Gln Gln Asn Phe Glu Trp
50 55 60
Phe Leu Tyr Arg Pro Glu Ala Pro Asp Thr Ala Leu Gly Ile Val Ser
65 70 75 80
Thr Lys Asp Thr Gln Phe Ser Tyr Ala Val Phe Lys Ser Arg Val Val
85 90 95
Ala Gly Glu Val Gln Val Gln Arg Leu Gln Gly Asp Ala Val Val Leu
100 105 110
Lys Ile Ala Arg Leu Gln Ala Gln Asp Ala Gly Ile Tyr Glu Cys His
115 120 125
Thr Pro Ser Thr Asp Thr Arg Tyr Leu Gly Ser Tyr Ser Gly Lys Val
130 135 140
Glu Leu Arg Val Leu Pro Asp Val Leu Gln Val Ser Ala Ala Pro Pro
145 150 155 160
Gly Pro Arg Gly Arg Gln Ala Pro Thr Ser Pro Pro Arg Met Thr Val
165 170 175
His Glu Gly Gln Glu Leu Ala Leu Gly Cys Leu Ala Arg Thr Ser Thr
180 185 190
Gln Lys His Thr His Leu Ala Val Ser Phe Gly Arg Ser Val Pro Glu
195 200 205
Ala Pro Val Gly Arg Ser Thr Leu Gln Glu Val Val Gly Ile Arg Ser
210 215 220
Asp Leu Ala Val Glu Ala Gly Ala Pro Tyr Ala Glu Arg Leu Ala Ala
225 230 235 240
Gly Glu Leu Arg Leu Gly Lys Glu Gly Thr Asp Arg Tyr Arg Met Val
245 250 255
Val Gly Gly Ala Gln Ala Gly Asp Ala Gly Thr Tyr His Cys Thr Ala
260 265 270
Ala Glu Trp Ile Gln Asp Pro Asp Gly Ser Trp Ala Gln Ile Ala Glu
275 280 285
Lys Arg Ala Val Leu Ala His Val Asp Val Gln Thr Leu Ser Ser Gln
290 295 300
Leu Ala Val Thr Val Gly Pro Gly Glu Arg Arg Ile Gly Pro Gly Glu
305 310 315 320
Pro Leu Glu Leu Leu Cys Asn Val Ser Gly Ala Leu Pro Pro Ala Gly
325 330 335
Arg His Ala Ala Tyr Ser Val Gly Trp Glu Met Ala Pro Ala Gly Ala
340 345 350
Pro Gly Pro Gly Arg Leu Val Ala Gln Leu Asp Thr Glu Gly Val Gly
355 360 365
Ser Leu Gly Pro Gly Tyr Glu Gly Arg His Ile Ala Met Glu Lys Val
370 375 380
Ala Ser Arg Thr Tyr Arg Leu Arg Leu Glu Ala Ala Arg Pro Gly Asp
385 390 395 400
Ala Gly Thr Tyr Arg Cys Leu Ala Lys Ala Tyr Val Arg Gly Ser Gly
405 410 415
Thr Arg Leu Arg Glu Ala Ala Ser Ala Arg Ser Arg Pro Leu Pro Val
420 425 430
His Val Arg Glu Glu Gly Val Val Leu Glu Ala Val Ala Trp Leu Ala
435 440 445
Gly Gly Thr Val Tyr Arg Gly Glu Thr Ala Ser Leu Leu Cys Asn Ile
450 455 460
Ser Val Arg Gly Gly Pro Pro Gly Leu Arg Leu Ala Ala Ser Trp Trp
465 470 475 480
Val Glu Arg Pro Glu Asp Gly Glu Leu Ser Ser Val Pro Ala Gln Leu
485 490 495
Val Gly Gly Val Gly Gln Asp Gly Val Ala Glu Leu Gly Val Arg Pro
500 505 510
Gly Gly Gly Pro Val Ser Val Glu Leu Val Gly Pro Arg Ser His Arg
515 520 525
Leu Arg Leu His Ser Leu Gly Pro Glu Asp Glu Gly Val Tyr His Cys
530 535 540
Ala Pro Ser Ala Trp Val Gln His Ala Asp Tyr Ser Trp Tyr Gln Ala
545 550 555 560
Gly Ser Ala Arg Ser Gly Pro Val Thr Val Tyr Pro Tyr Met His Ala
565 570 575
Leu Asp Thr Leu Phe Val Pro Leu Leu Val Gly Thr Gly Val Ala Leu
580 585 590
Val Thr Gly Ala Thr Val Leu Gly Thr Ile Thr Cys Cys Phe Met Lys
595 600 605
Arg Leu Arg Lys Arg
610
<210>64
<211>596
<212>PRT
<213>人(Homo sapiens)
<400>64
Met Ala Ala Asn Ser Thr Ser Asp Leu His Thr Pro Gly Thr Gln Leu
1 5 10 15
Ser Val Ala Asp Ile Ile Val Ile Thr Val Tyr Phe Ala Leu Asn Val
20 25 30
Ala Val Gly Ile Trp Ser Ser Cys Arg Ala Ser Arg Asn Thr Val Asn
35 40 45
Gly Tyr Phe Leu Ala Gly Arg Asp Met Thr Trp Trp Pro Ile Gly Ala
50 55 60
Ser Leu Phe Ala Ser Ser Glu Gly Ser Gly Leu Phe Ile Gly Leu Ala
65 70 75 80
Gly Ser Gly Ala Ala Gly Gly Leu Ala Val Ala Gly Phe Glu Trp Asn
85 90 95
Ala Thr Tyr Val Leu Leu Ala Leu Ala Trp Val Phe Val Pro Ile Tyr
100 105 110
Ile Ser Ser Glu Ile Val Thr Leu Pro Glu Tyr Ile Gln Lys Arg Tyr
115 120 125
Gly Gly Gln Arg Ile Arg Met Tyr Leu Ser Val Leu Ser Leu Leu Leu
130 135 140
Ser Val Phe Thr Lys Ile Ser Leu Asp Leu Tyr Ala Gly Ala Leu Phe
145 150 155 160
Val His Ile Cys Leu Gly Trp Asn Phe Tyr Leu Ser Thr Ile Leu Thr
165 170 175
Leu Gly Ile Thr Ala Leu Tyr Thr Ile Ala Gly Gly Leu Ala Ala Val
180 185 190
Ile Tyr Thr Asp Ala Leu Gln Thr Leu Ile Met Val Val Gly Ala Val
195 200 205
Ile Leu Thr Ile Lys Ala Phe Asp Gln Ile Gly Gly Tyr Gly Gln Leu
210 215 220
Glu Ala Ala Tyr Ala Gln Ala Ile Pro Ser Arg Thr Ile Ala Asn Thr
225 230 235 240
Thr Cys His Leu Pro Arg Thr Asp Ala Met His Met Phe Arg Asp Pro
245 250 255
His Thr Gly Asp Leu Pro Trp Thr Gly Met Thr Phe Gly Leu Thr Ile
260 265 270
Met Ala Thr Trp Tyr Trp Cys Thr Asp Gln Val Ile Val Gln Arg Ser
275 280 285
Leu Ser Ala Arg Asp Leu Asn His Ala Lys Ala Gly Ser Ile Leu Ala
290 295 300
Ser Tyr Leu Lys Met Leu Pro Met Gly Leu Ile Ile Met Pro Gly Met
305 310 315 320
Ile Ser Arg Ala Leu Phe Pro Asp Asp Val Gly Cys Val Val Pro Ser
325 330 335
Glu Cys Leu Arg Ala Cys Gly Ala Glu Val Gly Cys Ser Asn Ile Ala
340 345 350
Tyr Pro Lys Leu Val Met Glu Leu Met Pro Ile Gly Leu Arg Gly Leu
355 360 365
Met Ile Ala Val Met Leu Ala Ala Leu Met Ser Ser Leu Thr Ser Ile
370 375 380
Phe Asn Ser Ser Ser Thr Leu Phe Thr Met Asp Ile Trp Arg Arg Leu
385 390 395 400
Arg Pro Arg Ser Gly Glu Arg Glu Leu Leu Leu Val Gly Arg Leu Val
405 410 415
Ile Val Ala Leu Ile Gly Val Ser Val Ala Trp Ile Pro Val Leu Gln
420 425 430
Asp Ser Asn Ser Gly Gln Leu Phe Ile Tyr Met Gln Ser Val Thr Ser
435 440 445
Ser Leu Ala Pro Pro Val Thr Ala Val Phe Val Leu Gly Val Phe Trp
450 455 460
Arg Arg Ala Asn Glu Gln Gly Ala Phe Trp Gly Leu Ile Ala Gly Leu
465 470 475 480
Val Val Gly Ala Thr Arg Leu Val Leu Glu Phe Leu Asn Pro Ala Pro
485 490 495
Pro Cys Gly Glu Pro Asp Thr Arg Pro Ala Val Leu Gly Ser Ile His
500 505 510
Tyr Leu His Phe Ala Val Ala Leu Phe Ala Leu Ser Gly Ala Val Val
515 520 525
Val Ala Gly Ser Leu Leu Thr Pro Pro Pro Gln Ser Val Gln Ile Glu
530 535 540
Asn Leu Thr Trp Trp Thr Leu Ala Gln Asp Val Pro Leu Gly Thr Lys
545 550 555 560
Ala Gly Asp Gly Gln Thr Pro Gln Lys His Ala Phe Trp Ala Arg Val
565 570 575
Cys Gly Phe Asn Ala Ile Leu Leu Met Cys Val Asn Ile Phe Phe Tyr
580 585 590
Ala Tyr Phe Ala
595
<210>65
<211>393
<212>PRT
<213>人(Homo sapiens)
<400>65
Met Asp Ser Leu Lys Asn Glu Asn Tyr Asp Leu Val Phe Val Glu Ala
1 5 10 15
Phe Asp Phe Cys Ser Phe Leu Ile Ala Glu Lys Leu Val Lys Pro Phe
20 25 30
Val Ala Ile Leu Pro Thr Thr Phe Gly Ser Leu Asp Phe Gly Leu Pro
35 40 45
Ser Pro Leu Ser Tyr Val Pro Val Phe Pro Ser Leu Leu Thr Asp His
50 55 60
Met Asp Phe Trp Gly Arg Val Lys Asn Phe Leu Met Phe Phe Ser Phe
65 70 75 80
Ser Arg Ser Gln Trp Asp Met Gln Ser Thr Phe Asp Asn Thr Ile Lys
85 90 95
Glu His Phe Pro Glu Gly Ser Arg Pro Val Leu Ser His Leu Leu Leu
100 105 110
Lys Ala Glu Leu Trp Phe Val Asn Ser Asp Phe Ala Phe Asp Phe Ala
115 120 125
Arg Pro Leu Leu Pro Asn Thr Val Tyr Ile Gly Gly Leu Met Glu Lys
130 135 140
Pro Ile Lys Pro Val Pro Gln Asp Leu Asp Asn Phe Ile Ala Asn Phe
145 150 155 160
Gly Asp Ala Gly Phe Val Leu Val Ala Phe Gly Ser Met Leu Asn Thr
165 170 175
His Gln Ser Gln Glu Val Leu Lys Lys Met His Asn Ala Phe Ala His
180 185 190
Leu Pro Gln Gly Val Ile Trp Thr Cys Gln Ser Ser His Trp Pro Arg
195 200 205
Asp Val His Leu Ala Thr Asn Val Lys Ile Val Asp Trp Leu Pro Gln
210 215 220
Ser Asp Leu Leu Ala His Pro Ser Ile Arg Leu Phe Val Thr His Gly
225 230 235 240
Gly Gln Asn Ser Val Met Glu Ala Ile Arg His Gly Val Pro Met Val
245 250 255
Gly Leu Pro Val Asn Gly Asp Gln His Gly Asn Met Val Arg Val Val
260 265 270
Ala Lys Asn Tyr Gly Val Ser Ile Arg Leu Asn Gln Val Thr Ala Asp
275 280 285
Thr Leu Thr Leu Thr Met Lys Gln Val Ile Glu Asp Lys Arg Tyr Lys
290 295 300
Ser Ala Val Val Ala Ala Ser Val Ile Leu His Ser Gln Pro Leu Ser
305 310 315 320
Pro Ala Gln Arg Leu Val Gly Trp Ile Asp His Ile Leu Gln Thr Gly
325 330 335
Gly Ala Thr His Leu Lys Pro Tyr Ala Phe Gln Gln Pro Trp His Glu
340 345 350
Gln Tyr Leu Ile Asp Val Phe Val Phe Leu Leu Gly Leu Thr Leu Gly
355 360 365
Thr Met Trp Leu Cys Gly Lys Leu Leu Gly Val Val Ala Arg Trp Leu
370 375 380
Arg Gly Ala Arg Lys Val Lys Lys Thr
385 390
<210>66
<211>523
<212>PRT
<213>人(Homo sapiens)
<400>66
Met Val Gly Gln Arg Val Leu Leu Leu Val Ala Phe Leu Leu Ser Gly
1 5 10 15
Val Leu Leu Ser Glu Ala Ala Lys Ile Leu Thr Ile Ser Thr Leu Gly
20 25 30
Gly Ser His Tyr Leu Leu Leu Asp Arg Val Ser Gln Ile Leu Gln Glu
35 40 45
His Gly His Asn Val Thr Met Leu His Gln Ser Gly Lys Phe Leu Ile
50 55 60
Pro Asp Ile Lys Glu Glu Glu Lys Ser Tyr Gln Val Ile Arg Trp Phe
65 70 75 80
Ser Pro Glu Asp His Gln Lys Arg Ile Lys Lys His Phe Asp Ser Tyr
85 90 95
Ile Glu Thr Ala Leu Asp Gly Arg Lys Glu Ser Glu Ala Leu Val Lys
100 105 110
Leu Met Glu Ile Phe Gly Thr Gln Cys Ser Tyr Leu Leu Ser Arg Lys
115 120 125
Asp Ile Met Asp Ser Leu Lys Asn Glu Asn Tyr Asp Leu Val Phe Val
130 135 140
Glu Ala Phe Asp Phe Cys Ser Phe Leu Ile Ala Glu Lys Leu Val Lys
145 150 155 160
Pro Phe Val Ala Ile Leu Pro Thr Thr Phe Gly Ser Leu Asp Phe Gly
165 170 175
Leu Pro Ser Pro Leu Ser Tyr Val Pro Val Phe Pro Ser Leu Leu Thr
180 185 190
Asp His Met Asp Phe Trp Gly Arg Val Lys Asn Phe Leu Met Phe Phe
195 200 205
Ser Phe Ser Arg Ser Gln Trp Asp Met Gln Ser Thr Phe Asp Asn Thr
210 215 220
Ile Lys Glu His Phe Pro Glu Gly Ser Arg Pro Val Leu Ser His Leu
225 230 235 240
Leu Leu Lys Ala Glu Leu Trp Phe Val Asn Ser Asp Phe Ala Phe Asp
245 250 255
Phe Ala Arg Pro Leu Leu Pro Asn Thr Val Tyr Ile Gly Gly Leu Met
260 265 270
Glu Lys Pro Ile Lys Pro Val Pro Gln Asp Leu Asp Asn Phe Ile Ala
275 280 285
Asn Phe Gly Asp Ala Gly Phe Val Leu Val Ala Phe Gly Ser Met Leu
290 295 300
Asn Thr His Gln Ser Gln Glu Val Leu Lys Lys Met His Asn Ala Phe
305 310 315 320
Ala His Leu Pro Gln Gly Val Ile Trp Thr Cys Gln Ser Ser His Trp
325 330 335
Pro Arg Asp Val His Leu Ala Thr Asn Val Lys Ile Val Asp Trp Leu
340 345 350
Pro Gln Ser Asp Leu Leu Ala His Pro Ser Ile Arg Leu Phe Val Thr
355 360 365
His Gly Gly Gln Asn Ser Val Met Glu Ala Ile Arg His Gly Val Pro
370 375 380
Met Val Gly Leu Pro Val Asn Gly Asp Gln His Gly Asn Met Val Arg
385 390 395 400
Val Val Ala Lys Asn Tyr Gly Val Ser Ile Arg Leu Asn Gln Val Thr
405 410 415
Ala Asp Thr Leu Thr Leu Thr Met Lys Gln Val Ile Glu Asp Lys Arg
420 425 430
Tyr Lys Ser Ala Val Val Ala Ala Ser Val Ile Leu His Ser Gln Pro
435 440 445
Leu Ser Pro Ala Gln Arg Leu Val Gly Trp Ile Asp His Ile Leu Gln
450 455 460
Thr Gly Gly Ala Thr His Leu Lys Pro Tyr Ala Phe Gln Gln Pro Trp
465 470 475 480
His Glu Gln Tyr Leu Ile Asp Val Phe Val Phe Leu Leu Gly Leu Thr
485 490 495
Leu Gly Thr Met Trp Leu Cys Gly Lys Leu Leu Gly Val Val Ala Arg
500 505 510
Trp Leu Arg Gly Ala Arg Lys Val Lys Lys Thr
515 520
<210>67
<211>252
<212>PRT
<213>人(Homo sapiens)
<400>67
Met Ser Cys Val Leu Gly Gly Val Ile Pro Leu Gly Leu Leu Phe Leu
1 5 10 15
Val Cys Gly Ser Gln Gly Tyr Leu Leu Pro Asn Val Thr Leu Leu Glu
20 25 30
Glu Leu Leu Ser Lys Tyr Gln His Asn Glu Ser His Ser Arg Val Arg
35 40 45
Arg Ala Ile Pro Arg Glu Asp Lys Glu Glu Ile Leu Met Leu His Asn
50 55 60
Lys Leu Arg Gly Gln Val Gln Pro Gln Ala Ser Asn Met Glu Tyr Met
65 70 75 80
Thr Trp Asp Asp Glu Leu Glu Lys Ser Ala Ala Ala Trp Ala Ser Gln
85 90 95
Cys Ile Trp Glu His Gly Pro Thr Ser Leu Leu Val Ser Ile Gly Gln
100 105 110
Asn Leu Gly Ala His Trp Gly Arg Tyr Arg Ser Pro Gly Phe His Val
115 120 125
Gln Ser Trp Tyr Asp Glu Val Lys Asp Tyr Thr Tyr Pro Tyr Pro Ser
130 135 140
Glu Cys Asn Pro Trp Cys Pro Glu Arg Cys Ser Gly Pro Met Cys Thr
145 150 155 160
His Tyr Thr Gln Ile Val Trp Ala Thr Thr Asn Lys Ile Gly Cys Ala
165 170 175
Val Asn Thr Cys Arg Lys Met Thr Val Trp Gly Glu Val Trp Glu Asn
180 185 190
Ala Val Tyr Phe Val Cys Asn Tyr Ser Pro Lys Gly Asn Trp Ile Gly
195 200 205
Glu Ala Pro Tyr Lys Asn Gly Arg Pro Cys Ser Glu Cys Pro Pro Ser
210 215 220
Tyr Gly Gly Ser Cys Arg Asn Asn Leu Cys Tyr Arg Gly Arg Lys Phe
225 230 235 240
Thr Pro Asn Thr Phe Ala Met Asn Leu Pro Ser Val
245 250
<210>68
<211>497
<212>PRT
<213>人(Homo sapiens)
<400>68
Met Ser Cys Val Leu Gly Gly Val Ile Pro Leu Gly Leu Leu Phe Leu
1 5 10 15
Val Cys Gly Ser Gln Gly Tyr Leu Leu Pro Asn Val Thr Leu Leu Glu
20 25 30
Glu Leu Leu Ser Lys Tyr Gln His Asn Glu Ser His Ser Arg Val Arg
35 40 45
Arg Ala Ile Pro Arg Glu Asp Lys Glu Glu Ile Leu Met Leu His Asn
50 55 60
Lys Leu Arg Gly Gln Val Gln Pro Gln Ala Ser Asn Met Glu Tyr Met
65 70 75 80
Thr Trp Asp Asp Glu Leu Glu Lys Ser Ala Ala Ala Trp Ala Ser Gln
85 90 95
Cys Ile Trp Glu His Gly Pro Thr Ser Leu Leu Val Ser Ile Gly Gln
100 105 110
Asn Leu Gly Ala His Trp Gly Arg Tyr Arg Ser Pro Gly Phe His Val
115 120 125
Gln Ser Trp Tyr Asp Glu Val Lys Asp Tyr Thr Tyr Pro Tyr Pro Ser
130 135 140
Glu Cys Asn Pro Trp Cys Pro Glu Arg Cys Ser Gly Pro Met Cys Thr
145 150 155 160
His Tyr Thr Gln Ile Val Trp Ala Thr Thr Asn Lys Ile Gly Cys Ala
165 170 175
Val Asn Thr Cys Arg Lys Met Thr Val Trp Gly Glu Val Trp Glu Asn
180 185 190
Ala Val Tyr Phe Val Cys Asn Tyr Ser Pro Lys Gly Asn Trp Ile Gly
195 200 205
Glu Ala Pro Tyr Lys Asn Gly Arg Pro Cys Ser Glu Cys Pro Pro Ser
210 215 220
Tyr Gly Gly Ser Cys Arg Asn Asn Leu Cys Tyr Arg Glu Glu Thr Tyr
225 230 235 240
Thr Pro Lys Pro Glu Thr Asp Glu Met Asn Glu Val Glu Thr Ala Pro
245 250 255
Ile Pro Glu Glu Asn His Val Trp Leu Gln Pro Arg Val Met Arg Pro
260 265 270
Thr Lys Pro Lys Lys Thr Ser Ala Val Asn Tyr Met Thr Gln Val Val
275 280 285
Arg Cys Asp Thr Lys Met Lys Asp Arg Cys Lys Gly Ser Thr Cys Asn
290 295 300
Arg Tyr Gln Cys Pro Ala Gly Cys Leu Asn His Lys Ala Lys Ile Phe
305 310 315 320
Gly Thr Leu Phe Tyr Glu Ser Ser Ser Ser Ile Cys Arg Ala Ala Ile
325 330 335
His Tyr Gly Ile Leu Asp Asp Lys Gly Gly Leu Val Asp Ile Thr Arg
340 345 350
Asn Gly Lys Val Pro Phe Phe Val Lys Ser Glu Arg His Gly Val Gln
355 360 365
Ser Leu Ser Lys Tyr Lys Pro Ser Ser Ser Phe Met Val Ser Lys Val
370 375 380
Lys Val Gln Asp Leu Asp Cys Tyr Thr Thr Val Ala Gln Leu Cys Pro
385 390 395 400
Phe Glu Lys Pro Ala Thr His Cys Pro Arg Ile His Cys Pro Ala His
405 410 415
Cys Lys Asp Glu Pro Ser Tyr Trp Ala Pro Val Phe Gly Thr Asn Ile
420 425 430
Tyr Ala Asp Thr Ser Ser Ile Cys Lys Thr Ala Val His Ala Gly Val
435 440 445
Ile Ser Asn Glu Ser Gly Gly Asp Val Asp Val Met Pro Val Asp Lys
450 455 460
Lys Lys Thr Tyr Val Gly Ser Leu Arg Asn Gly Val Gln Ser Glu Ser
465 470 475 480
Leu Gly Thr Pro Arg Asp Gly Lys Ala Phe Arg Ile Phe Ala Val Arg
485 490 495
Gln
<210>69
<211>438
<212>PRT
<213>人(Homo sapiens)
<400>69
Asx Met Leu His Asn Lys Leu Arg Gly Gln Val Gln Pro Gln Ala Ser
1 5 10 15
Asn Met Glu Tyr Met Thr Trp Asp Asp Glu Leu Glu Lys Ser Ala Ala
20 25 30
Ala Trp Ala Ser Gln Cys Ile Trp Glu His Gly Pro Thr Ser Leu Leu
35 40 45
Val Ser Ile Gly Gln Asn Leu Gly Ala His Trp Gly Arg Tyr Arg Ser
50 55 60
Pro Gly Phe His Val Gln Ser Trp Tyr Asp Glu Val Lys Asp Tyr Thr
65 70 75 80
Tyr Pro Tyr Pro Ser Glu Cys Asn Pro Trp Cys Pro Glu Arg Cys Ser
85 90 95
Gly Pro Met Cys Thr His Tyr Thr Gln Ile Val Trp Ala Thr Thr Asn
100 105 110
Lys Ile Gly Cys Ala Val Asn Thr Cys Arg Lys Met Thr Val Trp Gly
115 120 125
Glu Val Trp Glu Asn Ala Val Tyr Phe Val Cys Asn Tyr Ser Pro Lys
130 135 140
Gly Asn Trp Ile Gly Glu Ala Pro Tyr Lys Asn Gly Arg Pro Cys Ser
145 150 155 160
Glu Cys Pro Pro Ser Tyr Gly Gly Ser Cys Arg Asn Asn Leu Cys Tyr
165 170 175
Arg Glu Glu Thr Tyr Thr Pro Lys Pro Glu Thr Asp Glu Met Asn Glu
180 185 190
Val Glu Thr Ala Pro Ile Pro Glu Glu Asn His Val Trp Leu Gln Pro
195 200 205
Arg Val Met Arg Pro Thr Lys Pro Lys Lys Thr Ser Ala Val Asn Tyr
210 215 220
Met Thr Gln Val Val Arg Cys Asp Thr Lys Met Lys Asp Arg Cys Lys
225 230 235 240
Gly Ser Thr Cys Asn Arg Tyr Gln Cys Pro Ala Gly Cys Leu Asn His
245 250 255
Lys Ala Lys Ile Phe Gly Thr Leu Phe Tyr Glu Ser Ser Ser Ser Ile
260 265 270
Cys Arg Ala Ala Ile His Tyr Gly Ile Leu Asp Asp Lys Gly Gly Leu
275 280 285
Val Asp Ile Thr Arg Asn Gly Lys Val Pro Phe Phe Val Lys Ser Glu
290 295 300
Arg His Gly Val Gln Ser Leu Ser Lys Tyr Lys Pro Ser Ser Ser Phe
305 310 315 320
Met Val Ser Lys Val Lys Val Gln Asp Leu Asp Cys Tyr Thr Thr Val
325 330 335
Ala Gln Leu Cys Pro Phe Glu Lys Pro Ala Thr His Cys Pro Arg Ile
340 345 350
His Cys Pro Ala His Cys Lys Asp Glu Pro Ser Tyr Trp Ala Pro Val
355 360 365
Phe Gly Thr Asn Ile Tyr Ala Asp Thr Ser Ser Ile Cys Lys Thr Ala
370 375 380
Val His Ala Gly Val Ile Ser Asn Glu Ser Gly Gly Asp Val Asp Val
385 390 395 400
Met Pro Val Asp Lys Lys Lys Thr Tyr Val Gly Ser Leu Arg Asn Gly
405 410 415
Val Gln Ser Glu Ser Leu Gly Thr Pro Arg Asp Gly Lys Ala Phe Arg
420 425 430
Ile Phe Ala Val Arg Gln
435
<210>70
<211>308
<212>PRT
<213>人(Homo sapiens)
<400>70
Met Val Gly Gly Val Leu Ala Ser Leu Gly Phe Val Phe Ser Ala Phe
1 5 10 15
Ala Ser Asp Leu Leu His Leu Tyr Leu Gly Leu Gly Leu Leu Ala Gly
20 25 30
Phe Gly Trp Ala Leu Val Phe Ala Pro Ala Leu Gly Thr Leu Ser Arg
35 40 45
Tyr Phe Ser Arg Arg Arg Val Leu Ala Val Gly Leu Ala Leu Thr Gly
50 55 60
Asn Gly Ala Ser Ser Leu Leu Leu Ala Pro Ala Leu Gln Leu Leu Leu
65 70 75 80
Asp Thr Phe Gly Trp Arg Gly Ala Leu Leu Leu Leu Gly Ala Ile Thr
85 90 95
Leu His Leu Thr Pro Cys Gly Ala Leu Leu Leu Pro Leu Val Leu Pro
100 105 110
Gly Asp Pro Pro Ala Pro Pro Arg Ser Pro Leu Ala Ala Leu Gly Leu
115 120 125
Ser Leu Phe Thr Arg Arg Ala Phe Ser Ile Phe Ala Leu Gly Thr Ala
130 135 140
Leu Val Gly Gly Gly Tyr Phe Val Pro Tyr Val His Leu Ala Pro His
145 150 155 160
Ala Leu Asp Arg Gly Leu Gly Gly Tyr Gly Ala Ala Leu Val Val Ala
165 170 175
Val Ala Ala Met Gly Asp Ala Gly Ala Arg Leu Val Cys Gly Trp Leu
180 185 190
Ala Asp Gln Gly Trp Val Pro Leu Pro Arg Leu Leu Ala Val Phe Gly
195 200 205
Ala Leu Thr Gly Leu Gly Leu Trp Val Val Gly Leu Val Pro Val Val
210 215 220
Gly Gly Glu Glu Ser Trp Gly Gly Pro Leu Leu Ala Ala Ala Val Ala
225 230 235 240
Tyr Gly Leu Ser Ala Gly Ser Tyr Ala Pro Leu Val Phe Gly Val Leu
245 250 255
Pro Gly Leu Val Gly Val Gly Gly Val Val Gln Ala Thr Gly Leu Val
260 265 270
Met Met Leu Met Ser Leu Gly Gly Leu Leu Gly Pro Pro Leu Ser Gly
275 280 285
Lys Asp Leu Ser Ser Gln Ile Cys Leu Gln Leu Ser Ser Ala Pro Gly
290 295 300
Val Arg Gly Phe
305
<210>71
<211>447
<212>PRT
<213>人(Homo sapiens)
<400>71
Met Thr Pro Gln Pro Ala Gly Pro Pro Asp Gly Gly Trp Gly Trp Val
1 5 10 15
Val Ala Ala Ala Ala Phe Ala Ile Asn Gly Leu Ser Tyr Gly Leu Leu
20 25 30
Arg Ser Leu Gly Leu Ala Phe Pro Asp Leu Ala Glu His Phe Asp Arg
35 40 45
Ser Ala Gln Asp Thr Ala Trp Ile Ser Ala Leu Ala Leu Ala Val Gln
50 55 60
Gln Ala Ala Ser Pro Val Gly Ser Ala Leu Ser Thr Arg Trp Gly Ala
65 70 75 80
Arg Pro Val Val Met Val Gly Gly Val Leu Ala Ser Leu Gly Phe Val
85 90 95
Phe Ser Ala Phe Ala Ser Asp Leu Leu His Leu Tyr Leu Gly Leu Gly
100 105 110
Leu Leu Ala Gly Phe Gly Trp Ala Leu Val Phe Ala Pro Ala Leu Gly
115 120 125
Thr Leu Ser Arg Tyr Phe Ser Arg Arg Arg Val Leu Ala Val Gly Leu
130 135 140
Ala Leu Thr Gly Asn Gly Ala Ser Ser Leu Leu Leu Ala Pro Ala Leu
145 150 155 160
Gln Leu Leu Leu Asp Thr Phe Gly Trp Arg Gly Ala Leu Leu Leu Leu
165 170 175
Gly Ala Ile Thr Leu His Leu Thr Pro Cys Gly Ala Leu Leu Leu Pro
180 185 190
Leu Val Leu Pro Gly Asp Pro Pro Ala Pro Pro Arg Ser Pro Leu Ala
195 200 205
Ala Leu Gly Leu Ser Leu Phe Thr Arg Arg Ala Phe Ser Ile Phe Ala
210 215 220
Leu Gly Thr Ala Leu Val Gly Gly Gly Tyr Phe Val Pro Tyr Val His
225 230 235 240
Leu Ala Pro His Ala Leu Asp Arg Gly Leu Gly Gly Tyr Gly Ala Ala
245 250 255
Leu Val Val Ala Val Ala Ala Met Gly Asp Ala Gly Ala Arg Leu Val
260 265 270
Cys Gly Trp Leu Ala Asp Gln Gly Trp Val Pro Leu Pro Arg Leu Leu
275 280 285
Ala Val Phe Gly Ala Leu Thr Gly Leu Gly Leu Trp Val Val Gly Leu
290 295 300
Val Pro Val Val Gly Gly Glu Glu Ser Trp Gly Gly Pro Leu Leu Ala
305 310 315 320
Ala Ala Val Ala Tyr Gly Leu Ser Ala Gly Ser Tyr Ala Pro Leu Val
325 330 335
Phe Gly Val Leu Pro Gly Leu Val Gly Val Gly Gly Val Val Gln Ala
340 345 350
Thr Gly Leu Val Met Met Leu Met Ser Leu Gly Gly Leu Leu Gly Pro
355 360 365
Pro Leu Ser Gly Phe Leu Arg Asp Glu Thr Gly Asp Phe Thr Ala Ser
370 375 380
Phe Leu Leu Ser Gly Ser Leu Ile Leu Ser Gly Ser Phe Ile Tyr Ile
385 390 395 400
Gly Leu Pro Arg Ala Leu Pro Ser Cys Gly Pro Ala Ser Pro Pro Ala
405 410 415
Thr Pro Pro Pro Glu Thr Gly Glu Leu Leu Pro Ala Pro Gln Ala Val
420 425 430
Leu Leu Ser Pro Gly Gly Pro Gly Ser Thr Leu Asp Thr Thr Cys
435 440 445
<210>72
<211>458
<212>PRT
<213>人(Homo sapiens)
<400>72
Asx Met Ala Arg Arg Thr Glu Pro Pro Asp Gly Gly Trp Gly Trp Val
1 5 10 15
Val Val Leu Ser Ala Phe Phe Gln Ser Ala Leu Val Phe Gly Val Leu
20 25 30
Arg Ser Phe Gly Val Phe Phe Val Glu Phe Val Ala Ala Phe Glu Glu
35 40 45
Gln Ala Ala Arg Val Ser Trp Ile Ala Ser Ile Gly Ile Ala Val Gln
50 55 60
Gln Phe Gly Ser Pro Val Gly Ser Ala Leu Ser Thr Lys Phe Gly Pro
65 70 75 80
Arg Pro Val Val Met Thr Gly Gly Ile Leu Ala Ala Leu Gly Met Leu
85 90 95
Leu Ala Ser Phe Ala Thr Ser Leu Thr His Leu Tyr Leu Ser Ile Gly
100 105 110
Leu Leu Ser Gly Ser Gly Trp Ala Leu Thr Phe Ala Pro Thr Leu Ala
115 120 125
Cys Leu Ser Cys Tyr Phe Ser Arg Arg Arg Ser Leu Ala Thr Gly Leu
130 135 140
Ala Leu Thr Gly Val Gly Leu Ser Ser Phe Thr Phe Ala Pro Phe Phe
145 150 155 160
Gln Trp Leu Leu Ser His Tyr Ala Trp Arg Gly Ser Leu Leu Leu Val
165 170 175
Ser Ala Leu Ser Leu His Leu Val Ala Cys Gly Ala Leu Leu Arg Pro
180 185 190
Pro Ser Leu Ala Glu Asp Pro Ala Val Gly Gly Pro Arg Ala Gln Leu
195 200 205
Thr Ser Leu Leu His His Gly Pro Phe Leu Arg Tyr Thr Val Ala Leu
210 215 220
Thr Leu Ile Asn Thr Gly Tyr Phe Ile Pro Tyr Leu His Leu Val Ala
225 230 235 240
His Leu Gln Asp Leu Asp Trp Asp Pro Leu Pro Ala Ala Phe Leu Leu
245 250 255
Ser Val Val Ala Ile Ser Asp Leu Val Gly Arg Val Val Ser Gly Trp
260 265 270
Leu Gly Asp Ala Val Pro Gly Pro Val Thr Arg Leu Leu Met Leu Trp
275 280 285
Thr Thr Leu Thr Gly Val Ser Leu Ala Leu Phe Pro Val Ala Gln Ala
290 295 300
Pro Thr Ala Leu Val Ala Leu Ala Val Ala Tyr Gly Phe Thr Ser Gly
305 310 315 320
Ala Leu Ala Pro Leu Ala Phe Ser Val Leu Pro Glu Leu Ile Gly Thr
325 330 335
Arg Arg Ile Tyr Cys Gly Leu Gly Leu Leu Gln Met Ile Glu Ser Ile
340 345 350
Gly Gly Leu Leu Gly Pro Pro Leu Ser Gly Tyr Leu Arg Asp Val Ser
355 360 365
Gly Asn Tyr Thr Ala Ser Phe Val Val Ala Gly Ala Phe Leu Leu Ser
370 375 380
Gly Ser Gly Ile Leu Leu Thr Leu Pro His Phe Phe Cys Phe Ser Thr
385 390 395 400
Thr Thr Ser Gly Pro Gln Asp Leu Val Thr Glu Ala Leu Asp Thr Lys
405 410 415
Val Pro Leu Pro Lys Glu Gly Leu Glu Gly Gly Leu Asn Ser Thr Glu
420 425 430
Ser Gly Pro Glu Ser Gln Ser Leu Thr Ala Pro Gly Leu Leu Leu Pro
435 440 445
Arg Leu Gly Leu His Arg Thr Thr Val Pro
450 455
<210>73
<211>169
<212>PRT
<213>人(Homo sapiens)
<400>73
Met Thr Met Lys Thr Ser Gly Ala Thr Cys Asp Ala Asn Ser Val Met
1 5 10 15
Asn Cys Gly Ile Arg Gly Ser Glu Met Phe Ala Glu Met Asp Leu Arg
20 25 30
Ala Ile Lys Pro Tyr Gln Thr Leu Ile Lys Lys Val Gly Gln Arg His
35 40 45
Cys Val Asp Pro Ala Val Ile Ala Ala Ile Ile Ser Arg Glu Ser His
50 55 60
Gly Gly Ser Val Leu Gln Asp Gly Trp Asp His Arg Gly Leu Lys Phe
65 70 75 80
Gly Leu Met Gln Leu Asp Lys Gln Thr Tyr His Pro Val Gly Ala Trp
85 90 95
Asp Ser Lys Glu His Leu Ser Gln Ala Thr Gly Ile Leu Thr Glu Arg
100 105 110
Ile Lys Ala Ile Gln Lys Lys Phe Pro Thr Trp Ser Val Ala Gln His
115 120 125
Leu Lys Gly Gly Leu Ser Ala Phe Lys Ser Gly Ile Glu Ala Ile Ala
130 135 140
Thr Pro Ser Asp Ile Asp Asn Asp Phe Val Asn Asp Ile Ile Ala Arg
145 150 155 160
Ala Lys Phe Tyr Lys Arg Gln Ser Phe
165
<210>74
<211>186
<212>PRT
<213>人(Homo sapiens)
<400>74
Met Lys Pro His Leu His Pro Arg Leu Tyr His Gly Cys Tyr Gly Asp
1 5 10 15
Ile Met Thr Met Lys Thr Ser Gly Ala Thr Cys Asp Ala Asn Ser Val
20 25 30
Met Asn Cys Gly Ile Arg Gly Ser Glu Met Phe Ala Glu Met Asp Leu
35 40 45
Arg Ala Ile Lys Pro Tyr Gln Thr Leu Ile Lys Lys Val Gly Gln Arg
50 55 60
His Cys Val Asp Pro Ala Val Ile Ala Ala Ile Ile Ser Arg Glu Ser
65 70 75 80
His Gly Gly Ser Val Leu Gln Asp Gly Trp Asp His Arg Gly Leu Lys
85 90 95
Phe Gly Leu Met Gln Leu Asp Lys Gln Thr Tyr His Pro Val Gly Ala
100 105 110
Trp Asp Ser Lys Glu His Leu Ser Gln Ala Thr Gly Ile Leu Thr Glu
115 120 125
Arg Ile Lys Ala Ile Gln Lys Lys Phe Pro Thr Trp Ser Val Ala Gln
130 135 140
His Leu Lys Gly Gly Leu Ser Ala Phe Lys Ser Gly Ile Glu Ala Ile
145 150 155 160
Ala Thr Pro Ser Asp Ile Asp Asn Asp Phe Val Asn Asp Ile Ile Ala
165 170 175
Arg Ala Lys Phe Tyr Lys Arg Gln Ser Phe
180 185
<210>75
<211>675
<212>PRT
<213>人(Homo sapiens)
<400>75
Met Glu Ser Gly Thr Ser Ser Pro Gln Pro Pro Gln Leu Asp Pro Leu
1 5 10 15
Asp Ala Phe Pro Gln Lys Gly Leu Glu Pro Gly Asp Ile Ala Val Leu
20 25 30
Val Leu Tyr Phe Leu Phe Val Leu Ala Val Gly Leu Trp Ser Thr Val
35 40 45
Lys Thr Lys Arg Asp Thr Val Lys Gly Tyr Phe Leu Ala Gly Gly Asp
50 55 60
Met Val Trp Trp Pro Val Gly Ala Ser Leu Phe Ala Ser Asn Val Gly
65 70 75 80
Ser Gly His Phe Ile Gly Leu Ala Gly Ser Gly Ala Ala Thr Gly Ile
85 90 95
Ser Val Ser Ala Tyr Glu Leu Asn Gly Leu Phe Ser Val Leu Met Leu
100 105 110
Ala Trp Ile Phe Leu Pro Ile Tyr Ile Ala Gly Gln Val Thr Thr Met
115 120 125
Pro Glu Tyr Leu Arg Lys Arg Phe Gly Gly Ile Arg Ile Pro Ile Ile
130 135 140
Leu Ala Val Leu Tyr Leu Phe Ile Tyr Ile Phe Thr Lys Ile Ser Val
145 150 155 160
Asp Met Tyr Ala Gly Ala Ile Phe Ile Gln Gln Ser Leu His Leu Asp
165 170 175
Leu Tyr Leu Ala Ile Val Gly Leu Leu Ala Ile Thr Ala Val Tyr Thr
180 185 190
Val Ala Gly Gly Leu Ala Ala Val Ile Tyr Thr Asp Ala Leu Gln Thr
195 200 205
Leu Ile Met Leu Ile Gly Ala Leu Thr Leu Met Gly Tyr Ser Phe Ala
210 215 220
Ala Val Gly Gly Met Glu Gly Leu Lys Glu Lys Tyr Phe Leu Ala Leu
225 230 235 240
Ala Ser Asn Arg Ser Glu Asn Ser Ser Cys Gly Leu Pro Arg Glu Asp
245 250 255
Ala Phe His Ile Phe Arg Asp Pro Leu Thr Ser Asp Leu Pro Trp Pro
260 265 270
Gly Val Leu Phe Gly Met Ser Ile Pro Ser Leu Trp Tyr Trp Cys Thr
275 280 285
Asp Gln Val Ile Val Gln Arg Thr Leu Ala Ala Lys Asn Leu Ser His
290 295 300
Ala Lys Gly Gly Ala Leu Met Ala Ala Tyr Leu Lys Val Leu Pro Leu
305 310 315 320
Phe Ile Met Val Phe Pro Gly Met Val Ser Arg Ile Leu Phe Pro Asp
325 330 335
Gln Val Ala Cys Ala Asp Pro Glu Ile Cys Gln Lys Ile Cys Ser Asn
340 345 350
Pro Ser Gly Cys Ser Asp Ile Ala Tyr Pro Lys Leu Val Leu Glu Leu
355 360 365
Leu Pro Thr Gly Leu Arg Gly Leu Met Met Ala Val Met Val Ala Ala
370 375 380
Leu Met Ser Ser Leu Thr Ser Ile Phe Asn Ser Ala Ser Thr Ile Phe
385 390 395 400
Thr Met Asp Leu Trp Asn His Leu Arg Pro Arg Ala Ser Glu Lys Glu
405 410 415
Leu Met Ile Val Gly Arg Val Phe Val Leu Leu Leu Val Leu Val Ser
420 425 430
Ile Leu Trp Ile Pro Val Val Gln Ala Ser Gln Gly Gly Gln Leu Phe
435 440 445
Ile Tyr Ile Gln Ser Ile Ser Ser Tyr Leu Gln Pro Pro Val Ala Val
450 455 460
Val Phe Ile Met Gly Cys Phe Trp Lys Arg Thr Asn Glu Lys Gly Ala
465 470 475 480
Phe Trp Gly Leu Ile Ser Gly Leu Leu Leu Gly Leu Val Arg Leu Val
485 490 495
Leu Asp Phe Ile Tyr Val Gln Pro Arg Cys Asp Gln Pro Asp Glu Arg
500 505 510
Pro Val Leu Val Lys Ser Ile His Tyr Leu Tyr Phe Ser Met Ile Leu
515 520 525
Ser Thr Val Thr Leu Ile Thr Val Ser Thr Val Ser Trp Phe Thr Glu
530 535 540
Pro Pro Ser Lys Glu Met Val Ser His Leu Thr Trp Phe Thr Arg His
545 550 555 560
Asp Pro Val Val Gln Lys Glu Gln Ala Pro Pro Ala Ala Pro Leu Ser
565 570 575
Leu Thr Leu Ser Gln Asn Gly Met Pro Glu Ala Ser Ser Ser Ser Ser
580 585 590
Val Gln Phe Glu Met Val Gln Glu Asn Thr Ser Lys Thr His Ser Cys
595 600 605
Asp Met Thr Pro Lys Gln Ser Lys Val Val Lys Ala Ile Leu Trp Leu
610 615 620
Cys Gly Ile Gln Glu Lys Gly Lys Glu Glu Leu Pro Ala Arg Ala Glu
625 630 635 640
Ala Ile Ile Val Ser Leu Glu Glu Asn Pro Leu Val Lys Thr Leu Leu
645 650 655
Asp Val Asn Leu Ile Phe Cys Val Ser Cys Ala Ile Phe Ile Trp Gly
660 665 670
Tyr Phe Ala
675
<210>76
<211>485
<212>PRT
<213>人(Homo sapiens)
<400>76
Met Glu Pro Cys Trp Gly Glu Gly Leu Phe His Leu Ala Pro Pro Arg
1 5 10 15
His His Pro Gln Lys Ala Asp Trp His Phe Cys Pro Gln His Ile Gln
20 25 30
Glu Phe Thr Asn Glu Thr Trp Gln Ala Arg Thr Gly Glu Pro Leu Pro
35 40 45
Asp His Leu Val Leu Leu Met Trp Ser Leu Ile Val Ser Leu Tyr Pro
50 55 60
Leu Gly Gly Leu Phe Gly Ala Leu Leu Ala Gly Pro Leu Ala Ile Thr
65 70 75 80
Leu Gly Arg Lys Lys Ser Leu Leu Val Asn Asn Ile Phe Val Val Ser
85 90 95
Ala Ala Ile Leu Phe Gly Phe Ser Arg Lys Ala Gly Ser Phe Glu Met
100 105 110
Ile Met Leu Gly Arg Leu Leu Val Gly Val Asn Ala Gly Val Ser Met
115 120 125
Asn Ile Gln Pro Met Tyr Leu Gly Glu Ser Ala Pro Lys Glu Leu Arg
130 135 140
Gly Ala Val Ala Met Ser Ser Ala Ile Phe Thr Ala Leu Gly Ile Val
145 150 155 160
Met Gly Gln Val Val Gly Leu Arg Glu Leu Leu Gly Gly Pro Gln Ala
165 170 175
Trp Pro Leu Leu Leu Ala Ser Cys Leu Val Pro Gly Ala Leu Gln Leu
180 185 190
Ala Ser Leu Pro Leu Leu Pro Glu Ser Pro Arg Tyr Leu Leu Ile Asp
195 200 205
Cys Gly Asp Thr Glu Ala Cys Leu Ala Ala Leu Arg Arg Leu Arg Gly
210 215 220
Ser Gly Asp Leu Ala Gly Glu Leu Glu Glu Leu Glu Glu Glu Arg Ala
225 230 235 240
Ala Cys Gln Gly Cys Arg Ala Arg Arg Pro Trp Glu Leu Phe Gln His
245 250 255
Arg Ala Leu Arg Arg Gln Val Thr Ser Leu Val Val Leu Gly Ser Ala
260 265 270
Met Glu Leu Cys Gly Asn Asp Ser Val Tyr Ala Tyr Ala Ser Ser Val
275 280 285
Phe Arg Lys Ala Gly Val Pro Glu Ala Lys Ile Gln Tyr Ala Ile Ile
290 295 300
Gly Thr Gly Ser Cys Glu Leu Leu Thr Ala Val Val Ser Cys Val Val
305 310 315 320
Ile Glu Arg Val Gly Arg Arg Val Leu Leu Ile Gly Gly Tyr Ser Leu
325 330 335
Met Thr Cys Trp Gly Ser Ile Phe Thr Val Ala Leu Cys Leu Gln Ser
340 345 350
Ser Phe Pro Trp Thr Leu Tyr Leu Ala Met Ala Cys Ile Phe Ala Phe
355 360 365
Ile Leu Ser Phe Gly Ile Gly Pro Ala Gly Val Thr Gly Ile Leu Ala
370 375 380
Thr Glu Leu Phe Asp Gln Met Ala Arg Pro Ala Ala Cys Met Val Cys
385 390 395 400
Gly Ala Leu Met Trp Ile Met Leu Ile Leu Val Gly Leu Gly Phe Pro
405 410 415
Phe Ile Met Glu Ala Leu Ser His Phe Leu Tyr Val Pro Phe Leu Gly
420 425 430
Val Cys Val Cys Gly Ala Ile Tyr Thr Gly Leu Phe Leu Pro Glu Thr
435 440 445
Lys Gly Lys Thr Phe Gln Glu Ile Ser Lys Glu Leu His Arg Leu Asn
450 455 460
Phe Pro Arg Arg Ala Gln Gly Pro Thr Trp Arg Ser Leu Glu Val Ile
465 470 475 480
Gln Ser Thr Glu Leu
485
<210>77
<211>496
<212>PRT
<213>人(Homo sapiens)
<400>77
Met Arg Ala Leu Arg Arg Leu Ile Gln Gly Arg Ile Leu Leu Leu Thr
1 5 10 15
Ile Cys Ala Ala Gly Ile Gly Gly Thr Phe Gln Phe Gly Tyr Asn Leu
20 25 30
Ser Ile Ile Asn Ala Pro Thr Leu His Ile Gln Glu Phe Thr Asn Glu
35 40 45
Thr Trp Gln Ala Arg Thr Gly Glu Pro Leu Pro Asp His Leu Val Leu
50 55 60
Leu Met Trp Ser Leu Ile Val Ser Leu Tyr Pro Leu Gly Gly Leu Phe
65 70 75 80
Gly Ala Leu Leu Ala Gly Pro Leu Ala Ile Thr Leu Gly Arg Lys Lys
85 90 95
Ser Leu Leu Val Asn Asn Ile Phe Val Val Ser Ala Ala Ile Leu Phe
100 105 110
Gly Phe Ser Arg Lys Ala Gly Ser Phe Glu Met Ile Met Leu Gly Arg
115 120 125
Leu Leu Val Gly Val Asn Ala Gly Val Ser Met Asn Ile Gln Pro Met
130 135 140
Tyr Leu Gly Glu Ser Ala Pro Lys Glu Leu Arg Gly Ala Val Ala Met
145 150 155 160
Ser Ser Ala Ile Phe Thr Ala Leu Gly Ile Val Met Gly Gln Val Val
165 170 175
Gly Leu Arg Glu Leu Leu Gly Gly Pro Gln Ala Trp Pro Leu Leu Leu
180 185 190
Ala Ser Cys Leu Val Pro Gly Ala Leu Gln Leu Ala Ser Leu Pro Leu
195 200 205
Leu Pro Glu Ser Pro Arg Tyr Leu Leu Ile Asp Cys Gly Asp Thr Glu
210 215 220
Ala Cys Leu Ala Ala Leu Arg Arg Leu Arg Gly Ser Gly Asp Leu Ala
225 230 235 240
Gly Glu Leu Glu Glu Leu Glu Glu Glu Arg Ala Ala Cys Gln Gly Cys
245 250 255
Arg Ala Arg Arg Pro Trp Glu Leu Phe Gln His Arg Ala Leu Arg Arg
260 265 270
Gln Val Thr Ser Leu Val Val Leu Gly Ser Ala Met Glu Leu Cys Gly
275 280 285
Asn Asp Ser Val Tyr Ala Tyr Ala Ser Ser Val Phe Arg Lys Ala Gly
290 295 300
Val Pro Glu Ala Lys Ile Gln Tyr Ala Ile Ile Gly Thr Gly Ser Cys
305 310 315 320
Glu Leu Leu Thr Ala Val Val Ser Cys Val Val Ile Glu Arg Val Gly
325 330 335
Arg Arg Val Leu Leu Ile Gly Gly Tyr Ser Leu Met Thr Cys Trp Gly
340 345 350
Ser Ile Phe Thr Val Ala Leu Cys Leu Gln Ser Ser Phe Pro Trp Thr
355 360 365
Leu Tyr Leu Ala Met Ala Cys Ile Phe Ala Phe Ile Leu Ser Phe Gly
370 375 380
Ile Gly Pro Ala Gly Val Thr Gly Ile Leu Ala Thr Glu Leu Phe Asp
385 390 395 400
Gln Met Ala Arg Pro Ala Ala Cys Met Val Cys Gly Ala Leu Met Trp
405 410 415
Ile Met Leu Ile Leu Val Gly Leu Gly Phe Pro Phe Ile Met Glu Ala
420 425 430
Leu Ser His Phe Leu Tyr Val Pro Phe Leu Gly Val Cys Val Cys Gly
435 440 445
Ala Ile Tyr Thr Gly Leu Phe Leu Pro Glu Thr Lys Gly Lys Thr Phe
450 455 460
Gln Glu Ile Ser Lys Glu Leu His Arg Leu Asn Phe Pro Arg Arg Ala
465 470 475 480
Gln Gly Pro Thr Trp Arg Ser Leu Glu Val Ile Gln Ser Thr Glu Leu
485 490 495
<210>78
<211>500
<212>PRT
<213>人(Homo sapiens)
<400>78
Asx Met Leu His Ala Leu Leu Arg Ser Arg Met Ile Gln Gly Arg Ile
1 5 10 15
Leu Leu Leu Thr Ile Cys Ala Ala Gly Ile Gly Gly Thr Phe Gln Phe
20 25 30
Gly Tyr Asn Leu Ser Ile Ile Asn Ala Pro Thr Leu His Ile Gln Glu
35 40 45
Phe Thr Asn Glu Thr Trp Gln Ala Arg Thr Gly Glu Pro Leu Pro Asp
50 55 60
His Leu Val Leu Leu Met Trp Ser Leu Ile Val Ser Leu Tyr Pro Leu
65 70 75 80
Gly Gly Leu Phe Gly Ala Leu Leu Ala Gly Pro Leu Ala Ile Thr Leu
85 90 95
Gly Arg Lys Lys Ser Leu Leu Val Asn Asn Ile Phe Val Val Ser Ala
100 105 110
Ala Ile Leu Phe Gly Phe Ser Arg Lys Ala Gly Ser Phe Glu Met Ile
115 120 125
Met Leu Gly Arg Leu Leu Val Gly Val Asn Ala Gly Val Ser Met Asn
130 135 140
Ile Gln Pro Met Tyr Leu Gly Glu Ser Ala Pro Lys Glu Leu Arg Gly
145 150 155 160
Ala Val Ala Met Ser Ser Ala Ile Phe Thr Ala Leu Gly Ile Val Met
165 170 175
Gly Gln Val Val Gly Leu Arg Glu Leu Leu Gly Gly Pro Gln Ala Trp
180 185 190
Pro Leu Leu Leu Ala Ser Cys Leu Val Pro Gly Ala Leu Gln Leu Ala
195 200 205
Ser Leu Pro Leu Leu Pro Glu Ser Pro Arg Tyr Leu Leu Ile Asp Cys
210 215 220
Gly Asp Thr Glu Ala Cys Leu Ala Ala Leu Arg Arg Leu Arg Gly Ser
225 230 235 240
Gly Asp Leu Ala Gly Glu Leu Glu Glu Leu Glu Glu Glu Arg Ala Ala
245 250 255
Cys Gln Gly Cys Arg Ala Arg Arg Pro Trp Glu Leu Phe Gln His Arg
260 265 270
Ala Leu Arg Arg Gln Val Thr Ser Leu Val Val Leu Gly Ser Ala Met
275 280 285
Glu Leu Cys Gly Asn Asp Ser Val Tyr Ala Tyr Ala Ser Ser Val Phe
290 295 300
Arg Lys Ala Gly Val Pro Glu Ala Lys Ile Gln TyrAla Ile Ile Gly
305 310 315 320
Thr Gly Ser Cys Glu Leu Leu Thr Ala Val Val Ser Cys Val Val Ile
325 330 335
Glu Arg Val Gly Arg Arg Val Leu Leu Ile Gly Gly Tyr Ser Leu Met
340 345 350
Thr Cys Trp Gly Ser Ile Phe Thr Val Ala Leu Cys Leu Gln Ser Ser
355 360 365
Phe Pro Trp Thr Leu Tyr Leu Ala Met Ala Cys Ile Phe Ala Phe Ile
370 375 380
Leu Ser Phe Gly Ile Gly Pro Ala Gly Val Thr Gly Ile Leu Ala Thr
385 390 395 400
Glu Leu Phe Asp Gln Met Ala Arg Pro Ala Ala Cys Met Val Cys Gly
405 410 415
Ala Leu Met Trp Ile Met Leu Ile Leu Val Gly Leu Gly Phe Pro Phe
420 425 430
Ile Met Glu Ala Leu Ser His Phe Leu Tyr Val Pro Phe Leu Gly Val
435 440 445
Cys Val Cys Gly Ala Ile Tyr Thr Gly Leu Phe Leu Pro Glu Thr Lys
450 455 460
Gly Lys Thr Phe Gln Glu Ile Ser Lys Glu Leu His Arg Leu Asn Phe
465 470 475 480
Pro Arg Arg Ala Gln Gly Pro Thr Trp Arg Ser Leu Glu Val Ile Gln
485 490 495
Ser Thr Glu Leu
500
<210>79
<211>1358
<212>PRT
<213>人(Homo sapiens)
<400>79
Met Val Val Val Lys Pro Met Asn Thr Met Ala Pro Val Val Thr Arg
1 5 10 15
Asn Thr Gly Leu Ile Leu Tyr Glu Gly Gln Ser Arg Pro Leu Thr Gly
20 25 30
Pro Ala Gly Ser Gly Pro Gln Asn Leu Val Ile Ser Asp Glu Asp Asp
35 40 45
Leu Glu Ala Val Arg Leu Glu Val Val Ala Gly Leu Arg His Gly His
50 55 60
Leu Val Ile Leu Gly Ala Ser Ser Gly Ser Ser Ala Pro Lys Ser Phe
65 70 75 80
Thr Val Ala Glu Leu Ala Ala Gly Gln Val Val Tyr Gln His Asp Asp
85 90 95
Arg Asp Gly Ser Leu Ser Asp Asn Leu Val Leu Arg Met Val Asp Gly
100 105 110
Gly Gly Arg His Gln Val Gln Phe Leu Phe Pro Ile Thr Leu Val Pro
115 120 125
Val Asp Asp Gln Pro Pro Val Leu Asn Ala Asn Thr Gly Leu Thr Leu
130 135 140
Ala Glu Gly Glu Thr Val Pro Ile Leu Pro Leu Ser Leu Ser Ala Thr
145 150 155 160
Asp Met Asp Ser Asp Asp Ser Leu Leu Leu Phe Val Leu Glu Ser Pro
165 170 175
Phe Leu Thr Thr Gly His Leu Leu Leu Arg Gln Thr His Pro Pro His
180 185 190
Glu Lys Gln Glu Leu Leu Arg Gly Leu Trp Arg Lys Glu Gly Ala Phe
195 200 205
Tyr Glu Arg Thr Val Thr Glu Trp Gln Gln Gln Asp Ile Thr Glu Gly
210 215 220
Arg Leu Phe Tyr Arg His Ser Gly Pro His Ser Pro Gly Pro Val Thr
225 230 235 240
Asp Gln Phe Thr Phe Arg Val Gln Asp Asn His Asp Pro Pro Asn Gln
245 250 255
Ser Gly Leu Gln Arg Phe Val Ile Arg Ile His Pro Val Asp Arg Leu
260 265 270
Pro Pro Glu Leu Gly Ser Gly Cys Pro Leu Arg Met Val Val Gln Glu
275 280 285
Ser Gln Leu Thr Pro Leu Arg Lys Lys Trp Leu Arg Tyr Thr Asp Leu
290 295 300
Asp Thr Asp Asp Arg Glu Leu Arg Tyr Thr Val Thr Gln Ser Pro Thr
305 310 315 320
Asp Thr Asp Glu Asn His Leu Pro Ala Pro Leu Gly Thr Leu Val Leu
325 330 335
Thr Asp Asn Pro Ser Val Val Val Thr His Phe Thr Gln Ala Gln Ile
340 345 350
Asn His His Lys Ile Ala Tyr Arg Pro Pro Gly Gln Glu Leu Gly Val
355 360 365
Ala Thr Arg Val Ala Gln Phe Gln Phe Gln Val Glu Asp Arg Ala Gly
370 375 380
Asn Val Ala Pro Gly Thr Phe Thr Leu Tyr Leu His Pro Val Asp Asn
385 390 395 400
Gln Pro Pro Glu Ile Leu Asn Thr Gly Phe Thr Ile Gln Glu Lys Gly
405 410 415
His His Ile Leu Ser Glu Thr Glu Leu His Val Asn Asp Val Asp Thr
420 425 430
Asp Val Ala His Ile Ser Phe Thr Leu Thr Gln Ala Pro Lys His Gly
435 440 445
His Met Arg Val Ser Gly Gln Ile Leu His Val Gly Gly Leu Phe His
450 455 460
Leu Glu Asp Ile Lys Gln Gly Arg Val Ser Tyr Ala His Asn Gly Asp
465 470 475 480
Lys Ser Leu Thr Asp Ser Cys Ser Leu Glu Val Ser Asp Arg His His
485 490 495
Val Val Pro Ile Thr Leu Arg Val Asn Val Arg Pro Val Asp Asp Glu
500 505 510
Val Pro Ile Leu Ser His Pro Thr Gly Thr Leu Glu Ser Tyr Leu Asp
515 520 525
Val Leu Glu Asn Gly Ala Thr Glu Ile Thr Ala Asn Val Ile Lys Gly
530 535 540
Thr Asn Glu Glu Thr Asp Asp Leu Met Leu Thr Phe Leu Leu Glu Asp
545 550 555 560
Pro Pro Leu Tyr Gly Glu Ile Leu Val Asn Gly Ile Pro Ala Glu Gln
565 570 575
Phe Thr Gln Arg Asp Ile Leu Glu Gly Ser Val Val Tyr Thr His Thr
580 585 590
Ser Gly Glu Ile Gly Leu Leu Pro Lys Ala Asp Ser Phe Asn Leu Ser
595 600 605
Leu Ser Asp Met Ser Gln Glu Trp Arg Ile Gly Gly Asn Thr Ile Gln
610 615 620
Gly Val Thr Ile Trp Val Thr Ile Leu Pro Val Asp Ser Gln Ala Pro
625 630 635 640
Glu Ile Phe Val Gly Glu Gln Leu Ile Val Met Glu Gly Asp Lys Ser
645 650 655
Val Ile Thr Ser Val His Ile Ser Ala Glu Asp Val Asp Ser Leu Asn
660 665 670
Asp Asp Ile Leu Cys Thr Ile Val Ile Gln Pro Thr Ser Gly Tyr Val
675 680 685
Glu Asn Ile Ser Pro Ala Pro Gly Ser Glu Lys Ser Arg Ala Gly Ile
690 695 700
Ala Ile Ser Ala Phe Asn Leu Lys Asp Leu Arg Gln Gly His Ile Asn
705 710 715 720
Tyr Val Gln Ser Val His Lys Gly Val Glu Pro Val Glu Asp Arg Phe
725 730 735
Val Phe Arg Cys Ser Asp Gly Ile Asn Phe Ser Glu Arg Gln Phe Phe
740 745 750
Pro Ile Val Ile Ile Pro Thr Asn Asp Glu Gln Pro Glu Met Phe Met
755 760 765
Arg Glu Phe Met Val Met Glu Gly Met Ser Leu Val Ile Asp Thr Pro
770 775 780
Ile Leu Asn Ala Ala Asp Ala Asp Val Pro Leu Asp Asp Leu Thr Phe
785 790 795 800
Thr Ile Thr Gln Phe Pro Thr His Gly His Ile Met Asn Gln Leu Ile
805 810 815
Asn Gly Thr Val Leu Val Glu Ser Phe Thr Leu Asp Gln Ile Ile Glu
820 825 830
Ser Ser Ser Ile Ile Tyr Glu His Asp Asp Ser Glu Thr Gln Glu Asp
835 840 845
Ser Phe Val Ile Lys Leu Thr Asp Gly Lys His Ser Val Glu Lys Thr
850 855 860
Val Leu Ile Ile Val Ile Pro Val Asp Asp Glu Thr Pro Arg Met Thr
865 870 875 880
Ile Asn Asn Gly Leu Glu Ile Glu Ile Gly Asp Thr Lys Ile Ile Asn
885 890 895
Asn Lys Ile Leu Met Ala Thr Asp Leu Asp Ser Glu Asp Lys Ser Leu
900 905 910
Val Tyr Ile Ile Arg Tyr Gly Pro Gly His Gly Leu Leu Gln Arg Arg
915 920 925
Lys Pro Thr Gly Ala Phe Glu Asn Ile Thr Leu Gly Met Asn Phe Thr
930 935 940
Gln Asp Glu Val Asp Arg Asn Leu Ile Gln Tyr Val His Leu Gly Gln
945 950 955 960
Glu Gly Ile Arg Asp Leu Ile Lys Phe Asp Val Thr Asp Gly Ile Asn
965 970 975
Pro Leu Ile Asp Arg Tyr Phe Tyr Val Ser Ile Gly Ser Ile Asp Ile
980 985 990
Val Phe Pro Asp Val Ile Ser Lys Gly Val Ser Leu Lys Glu Gly Gly
995 1000 1005
Lys Val Thr Leu Thr Thr Asp Leu Leu Ser Thr Ser Asp Leu Asn Ser
1010 1015 1020
Pro Asp Glu Asn Leu Val Phe Thr Ile Thr Arg Ala Pro Met Arg Gly
1025 1030 1035 1040
His Leu Glu Cys Thr Asp Gln Pro Gly Val Ser Ile Thr Ser Phe Thr
1045 1050 1055
Gln Leu Gln Leu Ala Gly Asn Lys Ile Tyr Tyr Ile His Thr Ala Asp
1060 1065 1070
Asp Glu Val Lys Met Asp Ser Phe Glu Phe Gln Val Thr Asp Gly Arg
1075 1080 1085
Asn Pro Val Phe Arg Thr Phe Arg Ile Ser Ile Ser Asp Val Asp Asn
1090 1095 1100
Lys Lys Pro Val Val Thr Ile His Lys Leu Val Val Ser Glu Ser Glu
1105 1110 1115 1120
Asn Lys Leu Ile Thr Pro Phe Glu Leu Thr Val Glu Asp Arg Asp Thr
1125 1130 1135
Pro Asp Lys Leu Leu Lys Phe Thr Ile Thr Gln Val Pro Ile His Gly
1140 1145 1150
His Leu Leu Phe Asn Asn Thr Arg Pro Val Met Val Phe Thr Lys Gln
1155 1160 1165
Asp Leu Asn Glu AsnLeu Ile Ser Tyr Lys His Asp Gly Thr Glu Ser
1170 1175 1180
Ser Glu Asp Ser Phe Ser Phe Thr Val Thr Asp Gly Thr His Thr Asp
1l85 1190 1195 1200
Phe Tyr Val Phe Pro Asp Thr Val Phe Glu Thr Arg Arg Pro Gln Val
1205 1210 1215
Met Lys Ile Gln Val Leu Ala Val Asp Asn Ser Val Pro Gln Ile Ala
1220 1225 1230
Val Asn Lys Gly Ala Ser Thr Leu Arg Thr Leu Ala Thr Gly His Leu
1235 1240 1245
Gly Phe Met Ile Thr Ser Lys Ile Leu Lys Val Glu Asp Arg Asp Ser
1250 1255 1260
Leu His Ile Ser Leu Arg Phe Ile Val Thr Glu Ala Pro Gln His Gly
1265 1270 1275 1280
Tyr Leu Leu Asn Leu Asp Lys Gly Asn His Ser Ile Thr Gln Phe Thr
1285 1290 1295
Gln Ala Asp Ile Asp Asp Met Lys Ile Cys Tyr Val Leu Arg Glu Gly
1300 1305 1310
Ala Asn Ala Thr Ser Asp Met Phe Tyr Phe Ala Val Glu Asp Gly Gly
1315 1320 1325
Lys Tyr Ser Pro Leu Leu Val Val Thr Ala Arg Arg Asp Ala Phe Leu
1330 1335 1340
Gly Cys Ser Leu Met Thr Leu Leu Gln Glu Val Phe Ile Lys
1345 1350 1355
<210>80
<211>3105
<212>PRT
<213>人(Homo sapiens)
<400>80
Met Ala Arg Ser Trp Leu Thr Ala Thr Ser Thr Ser Arg Pro Ala Ala
1 5 10 15
Phe Gly Arg Ala Leu Leu Ser Pro Gly Leu Ala Gly Ala Ala Gly Val
20 25 30
Pro Ala Glu Glu Ala Ile Val Leu Ala Asn Arg Gly Leu Arg Val Pro
35 40 45
Phe Gly Arg Glu Val Trp Leu Asp Pro Leu His Asp Leu Val Leu Gln
50 55 60
Val Gln Pro Gly Asp Arg Cys Ala Val Ser Val Leu Asp Asn Asp Ala
65 70 75 80
Leu Ala Gln Arg Pro Gly Arg Leu Ser Pro Lys Arg Phe Pro Cys Asp
85 90 95
Phe Gly Pro Gly Glu Val Arg Tyr Ser His Leu Gly Ala Arg Ser Pro
100 105 110
Ser Arg Asp Arg Val Arg Leu Gln Leu Arg Tyr Asp Ala Pro Gly Gly
115 120 125
Ala Val Val Leu Pro Leu Val Leu Glu Val Glu Val Val Phe Thr Gln
130 135 140
Leu Glu Val Val Thr Arg Asn Leu Pro Leu Val Val Glu Glu Leu Leu
145 150 155 160
Gly Thr Ser Asn Ala Leu Asp Ala Arg Ser Leu Glu Phe Ala Phe Gln
165 170 175
Pro Glu Thr Glu Glu Cys Arg Val Gly Ile Leu Ser Gly Leu Gly Ala
180 185 190
Leu Pro Arg Tyr Gly Glu Leu Leu His Tyr Pro Gln Val Pro Gly Gly
195 200 205
Ala Arg Glu Gly Gly Ala Pro Glu Thr Leu Leu Met Asp Cys Lys Ala
210 215 220
Phe Gln Glu Leu Gly Val Arg Tyr Arg His Thr Ala Ala Ser Arg Ser
225 230 235 240
Pro Asn Arg Asp Trp Ile Pro Met Val Val Glu Leu Arg Ser Arg Gly
245 250 255
Ala Pro Val Gly Ser Pro Ala Leu Lys Arg Glu His Phe Gln Val Leu
260 265 270
Val Arg Ile Arg Gly Gly Ala Glu Asn Thr Ala Pro Lys Pro Ser Phe
275 280 285
Val Ala Met Met Met Met Glu Val Asp Gln Phe Val Leu Thr Ala Leu
290 295 300
Thr Pro Asp Met Leu Ala Ala Glu Asp Ala Glu Ser Pro Ser Asp Leu
305 310 315 320
Leu Ile Phe Asn Leu Thr Ser Pro Phe Gln Pro Gly Gln Gly Tyr Leu
325 330 335
Val Ser Thr Asp Asp Arg Ser Leu Pro Leu Ser Ser Phe Thr Gln Arg
340 345 350
Asp Leu Arg Leu Leu Lys Ile Ala Tyr Gln Pro Pro Ser Glu Asp Ser
355 360 365
Asp Gln Glu Arg Leu Phe Glu Leu Glu Leu Glu Val Val Asp Leu Glu
370 375 380
Gly Ala Ala Ser Asp Pro Phe Ala Phe Met Val Val Val Lys Pro Met
385 390 395 400
Asn Thr Met Ala Pro Val Val Thr Arg Asn Thr Gly Leu Ile Leu Tyr
405 410 415
Glu Gly Gln Ser Arg Pro Leu Thr Gly Pro Ala Gly Ser Gly Pro Gln
420 425 430
Asn Leu Val Ile Ser Asp Glu Asp Asp Leu Glu Ala Val Arg Leu Glu
435 440 445
Val Val Ala Gly Leu Arg His Gly His Leu Val Ile Leu Gly Ala Ser
450 455 460
Ser Gly Ser Ser Ala Pro Lys Ser Phe Thr Val Ala Glu Leu Ala Ala
465 470 475 480
Gly Gln Val Val Tyr Gln His Asp Asp Arg Asp Gly Ser Leu Ser Asp
485 490 495
Asn Leu Val Leu Arg Met Val Asp Gly Gly Gly Arg His Gln Val Gln
500 505 510
Phe Leu Phe Pro Ile Thr Leu Val Pro Val Asp Asp Gln Pro Pro Val
515 520 525
Leu Asn Ala Asn Thr Gly Leu Thr Leu Ala Glu Gly Glu Thr Val Pro
530 535 540
Ile Leu Pro Leu Ser Leu Ser Ala Thr Asp Met Asp Ser Asp Asp Ser
545 550 555 560
Leu Leu Leu Phe Val Leu Glu Ser Pro Phe Leu Thr Thr Gly His Leu
565 570 575
Leu Leu Arg Gln Thr His Pro Pro His Glu Lys Gln Glu Leu Leu Arg
580 585 590
Gly Leu Trp Arg Lys Glu Gly Ala Phe Tyr Glu Arg Thr Val Thr Glu
595 600 605
Trp Gln Gln Gln Asp Ile Thr Glu Gly Arg Leu Phe Tyr Arg His Ser
610 615 620
Gly Pro His Ser Pro Gly Pro Val Thr Asp Gln Phe Thr Phe Arg Val
625 630 635 640
Gln Asp Asn His Asp Pro Pro Asn Gln Ser Gly Leu Gln Arg Phe Val
645 650 655
Ile Arg Ile His Pro Val Asp Arg Leu Pro Pro Glu Leu Gly Ser Gly
660 665 670
Cys Pro Leu Arg Met Val Val Gln Glu Ser Gln Leu Thr Pro Leu Arg
675 680 685
Lys Lys Trp Leu Arg Tyr Thr Asp Leu Asp Thr Asp Asp Arg Glu Leu
690 695 700
Arg Tyr Thr Val Thr Gln Pro Pro Thr Asp Thr Asp Glu Asn His Leu
705 710 715 720
Pro Ala Pro Leu Gly Thr Leu Val Leu Thr Asp Asn Pro Ser Val Val
725 730 735
Val Thr His Phe Thr Gln Ala Gln Ile Asn His His Lys Ile Ala Tyr
740 745 750
Arg Pro Pro Gly Gln Glu Leu Gly Val Ala Thr Arg Val Ala Gln Phe
755 760 765
Gln Phe Gln Val Glu Asp Arg Ala Gly Asn Val Ala Pro Gly Thr Phe
770 775 780
Thr Leu Tyr Leu His Pro Val Asp Asn Gln Pro Pro Glu Ile Leu Asn
785 790 795 800
Thr Gly Phe Thr Ile Gln Glu Lys Gly His His Ile Leu Ser Glu Thr
805 810 815
Glu Leu His Val Asn Asp Val Asp Thr Asp Val Ala His Ile Ser Phe
820 825 830
Thr Leu Thr Gln Ala Pro Lys His Gly His Met Arg Val Ser Gly Gln
835 840 845
Ile Leu His Val Gly Gly Leu Phe His Leu Glu Asp Ile Lys Gln Gly
850 855 860
Arg Val Ser Tyr Ala His Asn Gly Asp Lys Ser Leu Thr Asp Ser Cys
865 870 875 880
Ser Leu Glu Val Ser Asp Arg His His Val Val Pro Ile Thr Leu Arg
885 890 895
Val Asn Val Arg Pro Val Asp Asp Glu Val Pro Ile Leu Ser His Pro
900 905 910
Thr Gly Thr Leu Glu Ser Tyr Leu Asp Val Leu Glu Asn Gly Ala Thr
915 920 925
Glu Ile Thr Ala Asn Val Ile Lys Gly Thr Asn Glu Glu Thr Asp Asp
930 935 940
Leu Met Leu Thr Phe Leu Leu Glu Asp Pro Pro Leu Tyr Gly Glu Ile
945 950 955 960
Leu Val Asn Gly Ile Pro Ala Glu Gln Phe Thr Gln Arg Asp Ile Leu
965 970 975
Glu Gly Ser Val Val Tyr Thr His Thr Ser Gly Glu Ile Gly Leu Leu
980 985 990
Pro Lys Ala Asp Ser Phe Asn Leu Ser Leu Ser Asp Lys Ser Gln Glu
995 1000 1005
Trp Arg Ile Gly Gly Asn Thr Ile Gln Gly Val Thr Ile Trp Val Thr
1010 1015 1020
Ile Leu Pro Val Asp Ser Gln Ala Pro Glu Ile Ser Val Gly Glu Gln
1025 1030 1035 1040
Leu Ile Val Met Glu Gly Asp Lys Ser Val Ile Thr Ser Val His Ile
1045 1050 1055
Ser Ala Glu Asp Val Asp Ser Leu Asn Asp Asp Ile Leu Cys Thr Ile
1060 1065 1070
Val Ile Gln Pro Thr Ser Gly Tyr Val Glu Asn Ile Ser Pro Ala Pro
1075 1080 1085
Gly Ser Glu Lys Ser Arg Ala Gly Ile Ala Ile Ser Ala Phe Asn Leu
1090 1095 1100
Lys Asp Leu Arg Gln Gly His Ile Asn Tyr Val Gln Ser Val His Lys
1105 1110 1115 1120
Gly Val Glu Pro Val Glu Asp Arg Phe Val Phe Arg Cys Ser Asp Gly
1125 1130 1135
Ile Asn Phe Ser Glu Arg Gln Phe Phe Pro Ile Val Ile Ile Pro Thr
1140 1145 1150
Asn Asp Glu Gln Pro Glu Met Phe Met Arg Glu Phe Met Val Met Glu
1155 1160 1165
Gly Met Ser Leu Val Ile Asp Thr Pro Ile Leu Asn Ala Ala Asp Ala
1170 1175 1180
Asp Val Pro Leu Asp Asp Leu Thr Phe Thr Ile Thr Gln Phe Pro Thr
1185 1190 1195 1200
His Gly His Ile Met Asn Gln Leu Ile Asn Gly Thr Val Leu Val Glu
1205 1210 1215
Ser Phe Thr Leu Asp Gln Ile Ile Glu Ser Ser Ser Ile Ile Tyr Glu
1220 1225 1230
His Asp Asp Ser Glu Thr Gln Glu Asp Ser Phe Val Ile Lys Leu Thr
1235 1240 1245
Asp Gly Lys His Ser Val Glu Lys Thr Val Leu Ile Ile Val Ile Pro
1250 1255 1260
Val Asp Asp Glu Thr Pro Arg Met Thr Ile Asn Asn Gly Leu Glu Ile
1265 1270 1275 1280
Glu Ile Gly Asp Thr Lys Ile Ile Asn Asn Lys Ile Leu Met Ala Thr
1285 1290 1295
Asp Leu Asp Ser Glu Asp Lys Ser Leu Val Tyr Ile Ile Arg Tyr Gly
1300 1305 1310
Pro Gly His Gly Leu Leu Gln Arg Arg Lys Pro Thr Gly Ala Phe Glu
1315 1320 1325
Asn Ile Thr Leu Gly Met Asn Phe Thr Gln Asp Glu Val Asp Arg Asn
1330 1335 1340
Leu Ile Gln Tyr Val His Leu Gly Gln Glu Gly Ile Arg Asp Leu Ile
1345 1350 1355 1360
Lys Phe Asp Val Thr Asp Gly Ile Asn Pro Leu Ile Asp Arg Tyr Phe
1365 1370 1375
Tyr Val Ser Ile Gly Ser Ile Asp Ile Val Phe Pro Asp Val Ile Ser
1380 1385 1390
Lys Gly Val Ser Leu Lys Glu Gly Gly Lys Val Thr Leu Thr Thr Asp
1395 1400 1405
Leu Leu Ser Thr Ser Asp Leu Asn Ser Pro Asp Glu Asn Leu Val Phe
1410 1415 1420
Thr Ile Thr Arg Ala Pro Met Arg Gly His Leu Glu Cys Thr Asp Gln
1425 1430 1435 1440
Pro Gly Val Ser Ile Thr Ser Phe Thr Gln Leu Gln Leu Ala Gly Asn
1445 1450 1455
Lys Ile Tyr Tyr Ile His Thr Ala Asp Asp Glu Val Lys Met Asp Ser
1460 1465 1470
Phe Glu Phe Gln Val Thr Asp Gly Arg Asn Pro Val Phe Arg Thr Phe
1475 1480 1485
Arg Ile Ser Ile Ser Asp Val Asp Asn Lys Lys Pro Val Val Thr Ile
1490 1495 1500
His Lys Leu Val Val Ser Glu Ser Glu Asn Lys Leu Ile Thr Pro Phe
1505 1510 1515 1520
Glu Leu Thr Val Glu Asp Arg Asp Thr Pro Asp Lys Leu Leu Lys Phe
1525 1530 1535
Thr Ile Thr Gln Val Pro Ile His Gly His Leu Leu Phe Asn Asn Thr
1540 1545 1550
Arg Pro Val Met Val Phe Thr Lys Gln Asp Leu Asn Glu Asn Leu Ile
1555 1560 1565
Ser Tyr Lys His Asp Gly Thr Glu Ser Ser Glu Asp Ser Phe Ser Phe
1570 1575 1580
Thr Val Thr Asp Gly Thr His Thr Asp Phe Tyr Val Phe Pro Asp Thr
1585 1590 1595 1600
Val Phe Glu Thr Arg Arg Pro Gln Val Met Lys Ile Gln Val Leu Ala
1605 1610 1615
Val Asp Asn Ser Val Pro Gln Ile Ala Val Asn Lys Gly Ala Ser Thr
1620 1625 1630
Leu Arg Thr Leu Ala Thr Gly His Leu Gly Phe Met Ile Thr Ser Lys
1635 1640 1645
Ile Leu Lys Val Glu Asp Arg Asp Ser Leu His Ile Ser Leu Arg Phe
1650 1655 1660
Ile Val Thr Glu Ala Pro Gln His Gly Tyr Leu Leu Asn Leu Asp Lys
1665 1670 1675 1680
Gly Asn His Ser Ile Thr Gln Phe Thr Gln Ala Asp Ile Asp Asp Met
1685 1690 1695
Lys Ile Cys Tyr Val Leu Arg Glu Gly Ala Asn Ala Thr Ser Asp Met
1700 1705 1710
Phe Tyr Phe Ala Val Glu Asp Gly Gly Gly Asn Lys Leu Thr Tyr Gln
1715 1720 1725
Asn Phe Arg Leu Asn Trp Ala Trp Ile Ser Phe Glu Lys Glu Tyr Tyr
1730 1735 1740
Leu Val Asn Glu Asp Ser Lys Phe Leu Asp Val Val Leu Lys Arg Arg
1745 1750 1755 1760
Gly Tyr Leu Gly Glu Thr Ser Phe Ile Ser Ile Gly Thr Arg Asp Arg
1765 1770 1775
Thr Ala Glu Lys Asp Lys Asp Phe Lys Gly Lys Ala Gln Lys Gln Val
1780 1785 1790
Gln Phe Asn Pro Gly Gln Thr Arg Ala Thr Trp Arg Val Arg Ile Leu
1795 1800 1805
Ser Asp Gly Glu His Glu Gln Ser Glu Thr Phe Gln Val Val Leu Ser
1810 1815 1820
Glu Pro Val Leu Ala Ala Leu Glu Phe Pro Thr Val Ala Thr Val Glu
1825 1830 1835 1840
Ile Val Asp Pro Gly Asp Glu Pro Thr Val Phe Ile Pro Gln Ser Lys
1845 1850 1855
Tyr Ser Val Glu Glu Asp Val Gly Glu Leu Phe Ile Pro Ile Arg Arg
1860 1865 1870
Ser Gly Asp Val Ser Gln Glu Leu Met Val Val Cys Tyr Thr Gln Gln
1875 1880 1885
Gly Thr Ala Thr Gly Thr Val Pro Thr Ser Val Leu Ser Tyr Ser Asp
1890 1895 1900
Tyr Ile Ser Arg Pro Glu Asp His Thr Ser Val Val Arg Phe Asp Lys
1905 1910 1915 1920
Asp Glu Arg Glu Lys Leu Cys Arg Ile Val Ile Ile Asp Asp Ser Leu
1925 1930 1935
Tyr Glu Glu Glu Glu Thr Phe His Val Leu Leu Ser Met Pro Met Gly
1940 1945 1950
Gly Arg Ile Gly Ser Glu Phe Pro Gly Ala Gln Val Thr Ile Val Pro
1955 1960 1965
Asp Lys Asp Asp Gly Pro Ser Asp Ser Lys Phe Asn Val Ala Glu Asn
1970 1975 1980
Tyr Ser Leu Leu Pro Phe Thr Cys Phe Gln Gly Ser Ile Ala Thr Ala
1985 1990 1995 2000
Glu Ala Ala Thr Gln Gly Gly Gly Arg Ser Thr Arg Gln Val Ala Ala
2005 2010 2015
Val Lys Lys Asp Lys Asp Phe Lys Gly Lys Ala Gln Lys Gln Val Gln
2020 2025 2030
Phe Asn Pro Gly Gln Thr Arg Ala Thr Trp Arg Val Arg Ile Leu Ser
2035 2040 2045
Asp Gly Glu His Glu Gln Ser Glu Thr Phe Gln Val Val Leu Ser Glu
2050 2055 2060
Pro Val Leu Ala Ala Leu Glu Phe Pro Thr Val Ala Thr Val Glu Ile
2065 2070 2075 2080
Val Asp Pro Gly Asp Ala Cys Pro Trp Gly Glu Glu Ser Asp Gln Ser
2085 2090 2095
Ser Gln Gly Leu Lys Leu Gln Ser Phe Leu Thr Lys Met Met Val Ser
2100 2105 2110
Thr Asn Leu Leu Glu Asn Ser Phe Ser Arg Glu Asp Gln His Gln Glu
2115 2120 2125
Gln Leu Ser Arg Gln Lys Lys Trp Glu Ser Lys Thr Met Ile Ile Tyr
2130 2135 2140
Thr Phe Ile Leu Cys Glu Thr Glu Lys Pro Cys Ile Leu Glu Leu Met
2145 2150 2155 2160
Asp Asp Val Leu Tyr Glu Glu Val Glu Glu Leu Arg Leu Val Leu Gly
2165 2170 2175
Thr Pro Gln Ser Asn Ser Pro Phe Gly Ala Ala Val Gly Glu Gln Asn
2180 2185 2190
Glu Thr Leu Ile Arg Ile Arg Asp Asp Ala Asp Lys Thr Val Ile Lys
2195 2200 2205
Phe Gly Glu Thr Lys Phe Ser Val Thr Glu Pro Lys Glu Pro Gly Glu
2210 2215 2220
Ser Val Val Ile Arg Ile Pro Val Ile Arg Gln Gly Asp Thr Ser Lys
2225 2230 2235 2240
Val Ser Ile Val Arg Val His Thr Lys Asp Gly Ser Ala Thr Ser Gly
2245 2250 2255
Glu Asp Tyr His Pro Val Ser Glu Glu Ile Glu Phe Lys Glu Gly Glu
2260 2265 2270
Thr Gln His Val Val Glu Ile Glu Val Thr Phe Asp Gly Val Arg Glu
2275 2280 2285
Met Arg Glu Ala Phe Thr Val His Leu Lys Pro Asp Glu Asn Met Ile
2290 2295 2300
Ala Glu Met Gln Leu Ser Asn Phe Glu Leu Thr Leu Ser Pro Asp Gly
2305 2310 2315 2320
Thr Arg Val Gly Asn His Lys Cys Ser Asn Leu Leu Asp Tyr Thr Glu
2325 2330 2335
Val Lys Thr His Tyr Gly Phe Leu Thr Asp Ala Thr Lys Asn Pro Glu
2340 2345 2350
Ile Ile Gly Glu Thr Tyr Pro Tyr Gln Tyr Ser Leu Ser Ile Arg Gly
2355 2360 2365
Ser Thr Thr Leu Arg Phe Tyr Arg Asn Leu Asn Leu Glu Ala Cys Leu
2370 2375 2380
Trp Glu Phe Val Ser Tyr Tyr Asp Met Ser Glu Leu Leu Ala Asp Cys
2385 2390 2395 2400
Arg Ser Val Leu Asn Ala Ser Ile Phe His Glu Met Ala Pro Glu Gly
2405 2410 2415
Lys Gln Ser Lys Cys Leu Val Asn Ser Thr Leu Tyr Ser Ile Leu Glu
2420 2425 2430
Cys His Glu Ser Leu Pro Asn Phe Cys Ile Ser Ala Leu Arg Met Gly
2435 2440 2445
Lys Trp Arg Lys Ile Lys Ser Lys Pro Ser Ala Gln Thr Pro Cys Ala
2450 2455 2460
Gln Arg Leu Arg Gly Phe Ile Asp His Pro Arg Lys Gln Pro Leu Gln
2465 2470 2475 2480
Gln Ala Ser Ala Asp Pro Gly Met Leu Pro Val Ile Ser Thr Arg Glu
2485 2490 2495
Leu Ser Asn Phe Glu Leu Thr Leu Ser Pro Asp Gly Thr Arg Val Gly
2500 2505 2510
Asn His Lys Cys Ser Asn Leu Leu Asp Tyr Thr Glu Val Lys Thr His
2515 2520 2525
Tyr Gly Phe Leu Thr Asp Ala Thr Lys Asn Pro Glu Ile Ile Gly Glu
2530 2535 2540
Thr Tyr Pro Tyr Gln Tyr Ser Leu Ser Ile Arg Gly Ser Thr Thr Leu
2545 2550 2555 2560
Arg Phe Tyr Arg Asn Leu Asn Leu Glu Ala Cys Leu Trp Glu Phe Val
2565 2570 2575
Ser Tyr Tyr Asp Met Ser Glu Leu Leu Ala Asp Cys Gly Gly Thr Ile
2580 2585 2590
Gly Thr Asp Gly Gln Val Leu Asn Leu Val Gln Ser Tyr Val Thr Leu
2595 2600 2605
Arg Val Pro Leu Tyr Val Ser Tyr Val Phe His Ser Pro Val Gly Val
2610 2615 2620
Gly Gly Trp Gln His Phe Asp Leu Lys Ser Glu Leu Arg Leu Thr Phe
2625 2630 2635 2640
Val Tyr Asp Thr Ala Ile Leu Trp Asn Asp Gly Ile Gly Ser Pro Pro
2645 2650 2655
Glu Ala Glu Leu Gln Gly Ser Leu Tyr Pro Thr Ser Met Arg Ile Gly
2660 2665 2670
Asp Glu Gly Arg Leu Ala Val His Phe Lys Thr Glu Ala Gln Phe His
2675 2680 2685
Gly Leu Phe Val Leu Ser His Pro Ala Ser Phe Thr Ser Ser Val Ile
2690 2695 2700
Met Ser Ala Asp His Pro Gly Leu Thr Phe Ser Leu Arg Leu Ile Arg
2705 2710 2715 2720
Ser Glu Pro Thr Tyr Asn Gln Pro Val Gln Gln Trp Ser Phe Val Ser
2725 2730 2735
Asp Phe Ala Val Arg Asp Tyr Ser Gly Thr Tyr Thr Val Lys Leu Val
2740 2745 2750
Pro Cys Thr Ala Pro Ser His Gln Glu Tyr Arg Leu Pro Val Thr Cys
2755 2760 2765
Asn Pro Arg Glu Pro Val Thr Phe Asp Leu Asp Ile Arg Phe Gln Gln
2770 2775 2780
Val Ser Asp Pro Val Ala Ala Glu Phe Ser Leu Asn Thr Gln Met Tyr
2785 2790 2795 2800
Leu Leu Ser Lys Lys Ser Leu Trp Leu Ser Asp Gly Ser Met Gly Phe
2805 2810 2815
Gly Gln Glu Ser Asp Val Ala Phe Ala Glu Gly Asp Ile Ile Tyr Gly
2820 2825 2830
Arg Val Met Val Asp Pro Val Gln Asn Leu Gly Asp Ser Phe Tyr Cys
2835 2840 2845
Ser Ile Glu Lys Val Phe Leu Cys Thr Gly Ala Asp Gly Tyr Val Pro
2850 2855 2860
Lys Tyr Ser Pro Met Asn Ala Glu Tyr Gly Cys Leu Ala Asp Ser Pro
2865 2870 2875 2880
Ser Leu Leu Tyr Arg Phe Lys Ile Val Asp Lys Ala Gln Pro Glu Thr
2885 2890 2895
Gln Ala Thr Ser Phe Gly Asn Val Leu Phe Asn Ala Lys Leu Ala Val
2900 2905 2910
Asp Asp Pro Glu Ala Ile Leu Leu Val Asn Gln Pro Gly Ser Asp Gly
2915 2920 2925
Phe Lys Val Asp Ser Thr Pro Leu Phe Gln Val Ala Leu Gly Arg Glu
2930 2935 2940
Trp Tyr Ile His Thr Ile Tyr Thr Val Arg Ser Lys Asp Asn Ala Asn
2945 2950 2955 2960
Arg Gly Ile Gly Lys Arg Ser Val Glu Tyr His Ser Leu Val Ser Gln
2965 2970 2975
Gly Lys Pro Gln Ser Thr Thr Lys Ser Arg Lys Lys Arg Glu Ile Arg
2980 2985 2990
Ser Thr Pro Ser Leu Ala Trp Glu Ile Gly Ala Glu Asn Ser Arg Gly
2995 3000 3005
Thr Asn Ile Gln His Ile Ala Leu Asp Arg Thr Lys Arg Gln Ile Pro
3010 3015 3020
His Gly Arg Ala Pro Pro Asp Gly Ile Leu Pro Trp Glu Leu Asn Ser
3025 3030 3035 3040
Pro Ser Ser Ala Val Ser Leu Val Thr Val Val Gly Gly Thr Thr Val
3045 3050 3055
Gly Leu Leu Thr Ile Cys Leu Thr Val Ile Ala Val Leu Met Cys Arg
3060 3065 3070
Gly Lys Glu Ser Phe Arg Gly Lys Asp Ala Pro Lys Gly Ser Ser Ser
3075 3080 3085
Ser Glu Pro Met Val Pro Pro Gln Ser His His Asn Asp Ser Ser Glu
3090 3095 3100
Val
3105
<210>81
<211>457
<212>PRT
<213>人(Homo sapiens)
<400>81
Met Gly Cys Ser Gly Ala Trp Gly Leu Ser Cys Pro Cys Pro Gln Thr
1 5 10 15
Pro Ser Trp Ala Trp Arg Lys Met Arg Thr Pro Ser Met Arg Asn Arg
20 25 30
Ser Gly Ala Val Trp Ser Arg Ala Ser Val Pro Phe Ser Ala Trp Glu
35 40 45
Val Glu Val Gln Met Arg Val Thr Gly Leu Gly Arg Arg Gly Ala Gln
50 55 60
Gly Met Ala Val Trp Tyr Thr Arg Gly Arg Gly His Val Gly Ser Val
65 70 75 80
Leu Gly Gly Leu Ala Ser Trp Asp Gly Ile Gly Ile Phe Phe Asp Ser
85 90 95
Pro Ala Glu Asp Thr Gln Asp Ser Pro Ala Ile Arg Val Leu Ala Ser
100 105 110
Asp Gly His Ile Pro Ser Glu Gln Pro Gly Asp Gly Ala Ser Gln Gly
115 120 125
Leu Gly Ser Cys His Trp Asp Phe Arg Asn Arg Pro His Pro Phe Arg
130 135 140
Ala Arg Ile Thr Tyr Trp Gly Gln Arg Leu Arg Met Ser Leu Asn Ser
145 150 155 160
Gly Leu Thr Pro Ser Asp Pro Gly Glu Phe Cys Val Asp Val Gly Pro
165 170 175
Leu Leu Leu Val Pro Gly Gly Phe Phe Gly Val Ser Ala Ala Thr Gly
180 185 190
Thr Leu Ala Asp Asp His Asp Val Leu Ser Phe Leu Thr Phe Ser Leu
195 200 205
Ser Glu Pro Ser Pro Glu Val Pro Pro Gln Pro Phe Leu Glu Met Gln
210 215 220
His Val Arg Leu Ala Arg Gln Leu Glu Gly Leu Trp Ala Arg Leu Gly
225 230 235 240
Leu Gly Thr Arg Glu Asp Val Thr Pro Lys Ser Asp Ser Glu Ala Gln
245 250 255
Gly Glu Gly Glu Arg Leu Phe Asp Leu Glu Glu Thr Leu Gly Arg His
260 265 270
Arg Arg Ile Leu Gln Ala Leu Arg Gly Leu Ser Lys Gln Leu Ala Gln
275 280 285
Ala Glu Arg Gln Trp Lys Lys Gln Leu Gly Pro Gln Ala Lys Pro Gly
290 295 300
Leu Thr Glu Ala Gly Asp Ala Ala Val Arg Met Ala Ala Glu Ala Gln
305 310 315 320
Val Ser Tyr Leu Pro Val Gly Ile Glu His His Phe Leu Glu Leu Asp
325 330 335
His Ile Leu Gly Leu Leu Gln Glu Glu Leu Arg Gly Pro Ala Lys Ala
340 345 350
Ala Ala Lys Ala Pro Arg Pro Pro Gly Gln Pro Pro Arg Ala Ser Ser
355 360 365
Cys Leu Gln Pro Gly Ile Phe Leu Phe Tyr Leu Leu Ile Gln Thr Val
370 375 380
Gly Phe Phe Gly Tyr Val His Phe Arg Arg Pro Val Pro Arg Pro Ala
385 390 395 400
Lys Thr Met Ala Phe Met Val Lys Thr Met Val Gly Gly Gln Leu Lys
405 410 415
Asn Leu Thr Gly Ser Leu Gly Gly Gly Glu Asp Lys Gly Asp Gly Asp
420 425 430
Lys Ser Ala Ala Glu Ala Gln Gly Met Ser Arg Glu Glu Tyr Glu Glu
435 440 445
Tyr Gln Lys Gln Leu Val Glu Glu Lys
450 455
<210>82
<211>526
<212>PRT
<213>人(Homo sapiens)
<400>82
Met Pro Ala Val Ser Gly Pro Gly Pro Leu Phe Cys Leu Leu Leu Leu
1 5 10 15
Leu Leu Asp Pro His Ser Pro Glu Thr Gly Cys Pro Pro Leu Arg Arg
20 25 30
Phe Glu Tyr Lys Leu Ser Phe Lys Gly Pro Arg Leu Ala Leu Pro Gly
35 40 45
Ala Gly Ile Pro Phe Trp Ser His His Gly Asp Ala Ile Leu Gly Leu
50 55 60
Glu Glu Val Arg Leu Thr Pro Ser Met Arg Asn Arg Ser Gly Ala Val
65 70 75 80
Trp Ser Arg Ala Ser Val Pro Phe Ser Ala Trp Glu Val Glu Val Gln
85 90 95
Met Arg Val Thr Gly Leu Gly Arg Arg Gly Ala Gln Gly Met Ala Val
100 105 110
Trp Tyr Thr Arg Gly Arg Gly His Val Gly Ser Val Leu Gly Gly Leu
115 120 125
Ala Ser Trp Asp Gly Ile Gly Ile Phe Phe Asp Ser Pro Ala Glu Asp
130 135 140
Thr Gln Asp Ser Pro Ala Ile Arg Val Leu Ala Ser Asp Gly His Ile
145 150 155 160
Pro Ser Glu Gln Pro Gly Asp Gly Ala Ser Gln Gly Leu Gly Ser Cys
165 170 175
His Trp Asp Phe Arg Asn Arg Pro His Pro Phe Arg Ala Arg Ile Thr
180 185 190
Tyr Trp Gly Gln Arg LeuArg Met Ser Leu Asn Ser Gly Leu Thr Pro
195 200 205
Ser Asp Pro Gly Glu Phe Cys Val Asp Val Gly Pro Leu Leu Leu Val
210 215 220
Pro Gly Gly Phe Phe Gly Val Ser Ala Ala Thr Gly Thr Leu Ala Asp
225 230 235 240
Asp His Asp Val Leu Ser Phe Leu Thr Phe Ser Leu Ser Glu Pro Ser
245 250 255
Pro Glu Val Pro Pro Gln Pro Phe Leu Glu Met Gln His Val Arg Leu
260 265 270
Ala Arg Gln Leu Glu Gly Leu Trp Ala Arg Leu Gly Leu Gly Thr Arg
275 280 285
Glu Asp Val Thr Pro Lys Ser Asp Ser Glu Ala Gln Gly Glu Gly Glu
290 295 300
Arg Leu Phe Asp Leu Glu Glu Thr Leu Gly Arg His Arg Arg Ile Leu
305 310 315 320
Gln Ala Leu Arg Gly Leu Ser Lys Gln Leu Ala Gln Ala Glu Arg Gln
325 330 335
Trp Lys Lys Gln Leu Gly Pro Pro Gly Gln Ala Arg Pro Asp Gly Gly
340 345 350
Trp Ala Leu Asp Ala Ser Cys Gln Ile Pro Ser Thr Pro Gly Arg Gly
355 360 365
Gly His Leu Ser Met Ser Leu Asn Lys Asp Ser Ala Lys Val Gly Ala
370 375 380
Leu Leu His Gly Gln Trp Thr Leu Leu Gln Ala Leu Gln Glu Met Arg
385 390 395 400
Asp Ala Ala Val Arg Met Ala Ala Glu Ala Gln Val Ser Tyr Leu Pro
405 410 415
Val Gly Ile Glu His His Phe Leu Glu Leu Asp His Ile Leu Gly Leu
420 425 430
Leu Gln Glu Glu Leu Arg Gly Pro Ala LysAla Ala Ala Lys Ala Pro
435 440 445
Arg Pro Pro Gly Gln Pro Pro Arg Ala Ser Ser Cys Leu Gln Pro Gly
450 455 460
Ile Phe Leu Phe Tyr Leu Leu Ile Gln Thr Val Gly Phe Phe Gly Tyr
465 470 475 480
Val His Phe Arg Gln Glu Leu Asn Lys Ser Leu Gln Glu Cys Leu Ser
485 490 495
Thr Gly Ser Leu Pro Leu Gly Pro Ala Pro His Thr Pro Arg Ala Leu
500 505 510
Gly Ile Leu Arg Arg Gln Pro Leu Pro Ala Ser Met Pro Ala
515 520 525
<210>83
<211>904
<212>PRT
<213>人(Homo sapiens)
<400>83
Met Leu Leu Ala Leu Cys Ser Ser Leu Ala Leu Ile Phe Ala Ala Pro
1 5 10 15
Val Ser Gly Gln Leu Glu His Ser Gly Asn Tyr Tyr Cys Thr Ala Asp
20 25 30
Asn Gly Phe Gly Pro Gln His Ser Glu Val Val Ser Leu Ser Val Thr
35 40 45
Val Pro Val Ser His Pro Val Leu Thr Leu Ser Ser Ala Glu Ala Leu
50 55 60
Thr Phe Glu Gly Ala Thr Val Thr Leu His Ser Ser Leu Ile Leu Gln
65 70 75 80
Ala Pro Leu Ser Val Phe Glu Gly Asp Phe Val Val Leu Arg Cys Arg
85 90 95
Ala Lys Ala Glu Val Thr Leu Asn Thr Met Tyr Lys Asn Gly Asn Val
100 105 110
Leu Thr Phe Leu Asn Lys Ser Ser Asp Phe His Ile His His Ala Ser
115 120 125
Leu Lys Asp Asn Gly Ala Tyr His Phe Thr Gly Phe Asn Gly Ser Asn
130 135 140
Phe Ser Val Ser Ser Asn Ile Val Lys Ile Gln Val Gln Glu His Leu
145 150 155 160
Leu Pro Gln Trp Phe Leu Lys Ala Pro Asp Pro Thr Val Ala Leu Ser
165 170 175
Glu Ile Phe Ser Val Asn Arg Gly Pro Leu Leu Thr Gly Thr Gly Ser
180 185 190
Arg Val Met Thr Pro Trp Ile Tyr Phe Pro Thr Glu Asp Trp Asn Phe
195 200 205
Thr Leu Ile Pro Ile Thr Val Asp Asp Ala Cys Lys Arg Pro Cys Ala
210 215 220
Pro Arg Ala Pro Trp Glu Val Gly Ser Leu Thr Pro Gly Lys Ser Phe
225 230 235 240
Gln Gln Lys Gly Asn Pro Asp Leu Leu Met Gly Pro Phe Asp Val Leu
245 250 255
His Leu Ser Leu Ile Thr Leu Phe Cys Asn Met Ala Gly Ser Leu Phe
260 265 270
Tyr Tyr Met Glu Leu Gly Glu Lys Lys Asp Ala Leu Phe Val Thr Gly
275 280 285
Asn Glu Ser Arg Ser Tyr His Trp Phe Gln Lys Phe Ser Leu Ala Gly
290 295 300
Gly Gln Glu Ala Asp Gln Lys Leu Trp Phe Pro Pro Gly Leu Met Ser
305 310 315 320
Gln Asp Ile Phe Ile Tyr Ile Arg Gln Gly Glu Ser Cys Leu Val Ile
325 330 335
Glu Met Phe His Gln Val Tyr Arg Arg Pro Ala Gly Gly Val Pro Val
340 345 350
Glu His Met Ser Val Trp Ala Leu Arg Val Asn Ser Ser Gly Leu Phe
355 360 365
Ala Tyr Ala Asp Gly Trp Leu Phe Thr Leu Phe Gln Leu Gln Ser Val
370 375 380
Asp Asn Leu Ser Pro Ser Thr Gln Ser Gln Thr His Glu Gly His Glu
385 390 395 400
Lys Leu Cys Pro Phe Leu Ala Ile Gly Pro Pro Ala His Ser Arg Gly
405 410 415
Ser Phe Leu Arg Ala Lys Lys Ser Leu ValAla Tyr Ile Lys Gly Asn
420 425 430
Gln Leu Ser Phe Pro Pro Val Glu Asp Leu Leu Pro Lys Ser Gln Trp
435 440 445
Pro Cys Ile Gln Val Leu Pro Arg Asn Ile Ala Ala Ala Ala His Lys
450 455 460
Pro Val Ile Ser Val His Pro Pro Trp Thr Thr Phe Phe Lys Gly Glu
465 470 475 480
Arg Val Thr Leu Thr Cys Asn Gly Phe Gln Phe Tyr Ala Thr Glu Lys
485 490 495
Thr Thr Trp Tyr His Arg His Tyr Trp Gly Glu Lys Leu Thr Leu Thr
500 505 510
Pro Gly Asn Thr Leu Glu Val Arg Glu Ser Gly Leu Tyr Arg Cys Gln
515 520 525
Ala Arg Gly Ser Pro Arg Ser Asn Pro Val Arg Leu Leu Phe Ser Ser
530 535 540
Gly Glu Lys Glu Asp Cys Val Ser Asp Lys Asn Pro Ala Thr Asn His
545 550 555 560
Thr Pro Met Ser Arg Lys Arg Ser Ser Cys Ser Ser Leu Ser Ala Thr
565 570 575
Ser Phe Ile Ala Pro Ala Leu Arg Leu Asp Ser Leu Ile Leu Gln Ala
580 585 590
Pro Tyr Ser Val Phe Glu Gly Asp Thr Leu Val Leu Arg Cys His Arg
595 600 605
Arg Arg Lys Glu Lys Leu Thr Ala Val Lys Tyr Thr Trp Asn Gly Asn
610 615 620
Ile Leu Ser Ile Ser Asn Lys Ser Trp Asp Leu Leu Ile Pro Gln Ala
625 630 635 640
Ser Ser Asn Asn Asn Gly Asn Tyr Arg Cys Ile Gly Tyr Gly Asp Glu
645 650 655
Asn Asp Val Phe Arg Ser Asn Phe Lys Ile Ile Lys Ile Gln Gly Ile
660 665 670
Pro Val Ser Gly Val Leu Leu Glu Thr Gln Pro Ser Gly Gly Gln Ala
675 680 685
Val Glu Gly Glu Met Leu Val Leu Val Cys Ser Val Ala Glu Gly Thr
690 695 700
Gly Asp Thr Thr Phe Ser Trp His Arg Glu Asp Met Gln Glu Ser Leu
705 710 715 720
Gly Arg Lys Thr Gln Arg Ser Leu Arg Ala Glu Leu Glu Leu Pro Ala
725 730 735
Ile Arg Gln Ser His Ala Gly Gly Tyr Tyr Cys Thr Ala Asp Asn Ser
740 745 750
Tyr Gly Pro Val Gln Ser Met Val Leu Asn Val Thr Val Arg Glu Thr
755 760 765
Pro Gly Asn Arg Asp Gly Leu Val Ala Ala Gly Ala Thr Gly Gly Leu
770 775 780
Leu Ser Ala Leu Leu Leu Ala Val Ala Leu Leu Phe His Cys Trp Arg
785 790 795 800
Arg Arg Lys Ser Val His Pro Lys Lys Gly Asp Leu Val Tyr Ser Glu
805 810 815
Ile Gln Thr Thr Gln Leu Gly Glu Glu Glu Glu Gly Asn His Gly Asn
820 825 830
Lys Asn Gln Glu Leu Glu Leu Val Asn Val Gly Glu Ser Phe Ser His
835 840 845
Arg Ala Cys Ile Trp Ser Thr Leu Met Gly Thr Cys Gln Thr Ile Gly
850 855 860
Gly Ala Asn Thr Ser Arg Thr Leu Leu Glu Asp Lys Asp Val Ser Val
865 870 875 880
Val Tyr Ser Glu Val Lys Thr Gln His Pro Asp Asn Ser Ala Gly Lys
885 890 895
Ile Ser Ser Lys Asp Glu Glu Ser
900
<210>84
<211>515
<212>PRT
<213>人(Homo sapiens)
<400>84
Met Leu Leu Trp Ala Ser Leu Leu Ala Phe Ala Pro Val Cys Gly Gln
1 5 10 15
Ser Ala Ala Ala His Lys Pro Val Ile Ser Val His Pro Pro Trp Thr
20 25 30
Thr Phe Phe Lys Gly Glu Arg Val Thr Leu Thr Cys Asn Gly Phe Gln
35 40 45
Phe Tyr Ala Thr Glu Lys Thr Thr Trp Tyr His Arg His Tyr Trp Gly
50 55 60
Glu Lys Leu Thr Leu Thr Pro Gly Asn Thr Leu Glu Val Arg Glu Ser
65 70 75 80
Gly Leu Tyr Arg Cys Gln Ala Arg Gly Ser Pro Arg Ser Asn Pro Val
85 90 95
Arg Leu Leu Phe Ser Ser Asp Ser Leu Ile Leu Gln Ala Pro Tyr Ser
100 105 110
Val Phe Glu Gly Asp Thr Leu Val Leu Arg Cys His Arg Arg Arg Lys
115 120 125
Glu Lys Leu Thr Ala Val Lys Tyr Thr Trp Asn Gly Asn Ile Leu Ser
130 135 140
Ile Ser Asn Lys Ser Trp Asp Leu Leu Ile Pro Gln Ala Ser Ser Asn
145 150 155 160
Asn Asn Gly Asn Tyr Arg Cys Ile Gly Tyr Gly Asp Glu Asn Asp Val
165 170 175
Phe Arg Ser Asn Phe Lys Ile Ile Lys Ile Gln Glu Leu Phe Pro His
180 185 190
Pro Glu Leu Lys Ala Thr Asp Ser Gln Pro Thr Glu Gly Asn Ser Val
195 200 205
Asn Leu Ser Cys Glu Thr Gln Leu Pro Pro Glu Arg Ser Asp Thr Pro
210 215 220
Leu His Phe Asn Phe Phe Arg Asp Gly Glu Val Ile Leu Ser Asp Trp
225 230 235 240
Ser Thr Tyr Pro Glu Leu Gln Leu Pro Thr Val Trp Arg Glu Asn Ser
245 250 255
Gly Ser Tyr Trp Cys Gly Ala Glu Thr Val Arg Gly Asn Ile His Lys
260 265 270
His Ser Pro Ser Leu Gln Ile His Val Gln Arg Ile Pro Val Ser Gly
275 280 285
Val Leu Leu Glu Thr Gln Pro Ser Gly Gly Gln Ala Val Glu Gly Glu
290 295 300
Met Leu Val Leu Val Cys Ser Val Ala Glu Gly Thr Gly Asp Thr Thr
305 310 315 320
Phe Ser Trp His Arg Glu Asp Met Gln Glu Ser Leu Gly Arg Lys Thr
325 330 335
Gln Arg Ser Leu Arg Ala Glu Leu Glu Leu Pro Ala Ile Arg Gln Ser
340 345 350
His Ala Gly Gly Tyr Tyr Cys Thr Ala Asp Asn Ser Tyr Gly Pro Val
355 360 365
Gln Ser Met Val Leu Asn Val Thr Val Arg Glu Thr Pro Gly Asn Arg
370 375 380
Asp Gly Leu Val Ala Ala Gly Ala Thr Gly Gly Leu Leu Ser Ala Leu
385 390 395 400
Leu Leu Ala Val Ala Leu Leu Phe His Cys Trp Arg Arg Arg Lys Ser
405 410 415
Gly Val Gly Phe Leu Gly Asp Glu Thr Arg Leu Pro Pro Ala Pro Gly
420 425 430
Pro Gly Glu Ser Ser His Ser Ile Cys Pro Ala Gln Val Glu Leu Gln
435 440 445
Ser Leu Tyr Val Asp Val His Pro Lys Lys Gly Asp Leu Val Tyr Ser
450 455 460
Glu Ile Gln Thr Thr Gln Leu Gly Glu Glu Glu Glu Ala Asn Thr Ser
465 470 475 480
Arg Thr Leu Leu Glu Asp Lys Asp Val Ser Val Val Tyr Ser Glu Val
485 490 495
Lys Thr Gln His Pro Asp Asn Ser Ala Gly Lys Ile Ser Ser Lys Asp
500 505 510
Glu Glu Ser
515
<210>85
<211>831
<212>PRT
<213>人(Homo sapiens)
<400>85
Asx Met Ala Val Gly Gly Gly His Lys Gly Val Arg Cys Pro Pro Ser
1 5 10 15
Ala Arg Ser Ser Gln Val Pro Thr Cys Cys Ala Gly Trp Arg Gln Gln
20 25 30
Gly Asp Glu Cys Gly Ile Ala Val Cys Glu Gly Asn Ser Thr Cys Ser
35 40 45
Glu Asn Glu Val Cys Val Arg Pro Gly Glu Cys Arg Cys Arg His Gly
50 55 60
Tyr Phe Gly Ala Asn Cys A sp Thr Lys Cys Pro Arg Gln Phe Trp Gly
65 70 75 80
Pro Asp Cys Lys Glu Leu Cys Ser Cys His Pro His Gly Gln Cys Glu
85 90 95
Asp Val Thr Gly Gln Cys Thr Cys His Ala Arg Arg Trp Gly Ala Arg
100 105 110
Cys Glu His Ala Cys Gln Cys Gln His Gly Thr Cys His Pro Arg Ser
115 120 125
Gly Ala Cys Arg Cys Glu Ser Gly Trp Trp Gly Ala Gln Cys Ala Ser
130 135 140
Ala Cys Tyr Cys Ser Ala Thr Ser Arg Cys Asp Pro Gln Thr Gly Ala
145 150 155 160
Cys Leu Cys His Ala Gly Trp Trp Gly Arg Ser Cys Asn Asn Gln Cys
165 170 175
Ala Cys Asn Ser Ser Pro Cys Glu Gln Gln Ser Gly Arg Cys Gln Cys
180 185 190
Arg Glu Arg Thr Phe Gly Ala Arg Cys Asp Arg Tyr Cys Gln Cys Phe
195 200 205
Arg Gly Arg Cys His Pro Val Asp Gly Thr Cys Ala Cys Glu Pro Gly
210 215 220
Tyr Arg Gly Lys Tyr Cys Arg Glu Pro Cys Pro Ala Gly Phe Tyr Gly
225 230 235 240
Leu Gly Cys Arg Arg Arg Cys Gly Gln Cys Lys Gly Gln Gln Pro Cys
245 250 255
Thr Val Ala Glu Gly Arg Cys Leu Thr Cys Glu Pro Gly Trp Asn Gly
260 265 270
Thr Lys Cys Asp Gln Pro Cys Ala Thr Gly Phe Tyr Gly Glu Gly Cys
275 280 285
Ser His Arg Cys Pro Pro Cys Arg Asp Gly His Ala Cys Asn His Val
290 295 300
Thr Gly Lys Cys Thr Arg Cys Asn Ala Gly Trp Ile Gly Asp Arg Cys
305 310 315 320
Glu Thr Lys Cys Ser Asn Gly Thr Tyr Gly Glu Asp Cys Ala Phe Val
325 330 335
Cys Ala Asp Cys Gly Ser Gly His Cys Asp Phe Gln Ser Gly Arg Cys
340 345 350
Leu Cys Ser Pro Gly Val His Gly Pro His Cys Asn Val Thr Cys Pro
355 360 365
Pro Gly Leu His Gly Ala Asp Cys Ala Gln Ala Cys Ser Cys His Glu
370 375 380
Asp Thr Cys Asp Pro Val Thr Gly Ala Cys His Leu Glu Thr Asn Gln
385 390 395 400
Arg Lys Gly Val Met Gly Ala Gly Ala Leu Leu Val Leu Leu Val Cys
405 410 415
Leu Leu Leu Ser Leu Leu Gly Cys Cys Cys Ala Cys Arg Gly Lys Asp
420 425 430
Pro Thr Arg Arg Pro Arg Pro Arg Arg Glu Leu Ser Leu Gly Arg Lys
435 440 445
Lys Ala Pro His Arg Leu Cys Gly Arg Phe Ser Arg Ile Ser Met Lys
450 455 460
Leu Pro Arg Ile Pro Leu Arg Arg Gln Lys Leu Pro Lys Val Val Val
465 470 475 480
Ala His His Asp Leu Asp Asn Thr Leu Asn Cys Ser Phe Leu Glu Pro
485 490 495
Pro Ser Gly Leu Glu Gln Pro Ser Pro Ser Trp Ser Ser Arg Ala Ser
500 505 510
Phe Ser Ser Phe Asp Thr Thr Asp Glu Gly Pro Val Tyr Cys Val Pro
515 520 525
His Glu Glu Ala Pro Ala Glu Ser Arg Asp Pro Glu Val Pro Thr Val
530 535 540
Pro Ala Glu Ala Pro Ala Pro Ser Pro Val Pro Leu Thr Thr Pro Ala
545 550 555 560
Ser Ala Glu Glu Ala Ile Pro Leu Pro Ala Ser Ser Asp Ser Glu Arg
565 570 575
Ser Ala Ser Ser Val Glu Gly Pro Gly Gly Ala Leu Tyr Ala Arg Val
580 585 590
Ala Arg Arg Glu Ala Arg Pro Ala Arg Ala Arg Gly Glu Ile Gly Gly
595 600 605
Leu Ser Leu Ser Pro Ser Pro Glu Arg Arg Lys Pro Pro Pro Pro Asp
610 615 620
Pro Ala Thr Lys Pro Lys Val Ser Trp Ile His Gly Lys His Ser Ala
625 630 635 640
Ala Ala Ala Gly Arg Ala Pro Ser Pro Pro Pro Pro Gly Ser Glu Ala
645 650 655
Ala Pro Ser Pro Ser Lys Arg Lys Arg Thr Pro Ser Asp Lys Ser Ala
660 665 670
His Thr Val Glu His Gly Ser Pro Arg Thr Arg Asp Pro Thr Pro Arg
675 680 685
Pro Pro Gly Leu Pro Glu Glu Ala Thr Ala Leu Ala Ala Pro Ser Pro
690 695 700
Pro Arg Ala Arg Ala Arg Ala Ala Pro Arg Pro Leu Gly Ala His Gly
705 710 715 720
Arg Arg Arg Ser Pro Ala Lys Arg Ala Glu Ala Ala Ser Met Leu Ala
725 730 735
Ala Asp Val Arg Gly Lys Thr Arg Ser Leu Gly Arg Ala Glu Val Ala
740 745 750
Leu Gly Ala Gln Gly Pro Arg Glu Lys Pro Ala Pro Pro Gln Lys Ala
755 760 765
Lys Arg Ser Val Pro Pro Ala Ser Pro Ala Arg Ala Pro Pro Ala Thr
770 775 780
Glu Thr Pro Gly Pro Glu Lys Ala Ala Thr Asp Leu Pro Ala Pro Glu
785 790 795 800
Thr Pro Arg Lys Lys Thr Pro Ile Gln Lys Pro Pro Arg Lys Lys Ser
805 810 815
Arg Glu Ala Ala Gly Glu Leu Gly Arg Ala Gly Ala Pro Thr Leu
820 825 830
<210>86
<211>871
<212>PRT
<213>人(Homo sapiens)
<400>86
Asx Met Glu Gly Ala Gly Pro Arg Gly Ala Gly Pro Ala Arg Arg Arg
1 5 10 15
Gly Ala Gly Gly Pro Pro Ser Pro Leu Leu Pro Ser Leu Leu Leu Leu
20 25 30
Leu Leu Leu Trp Met Leu Pro Asp Thr Val Ala Pro Gln Glu Leu Asn
35 40 45
Pro Arg Gly Arg Asn Val Cys Arg Ala Pro Gly Ser Gln Val Pro Thr
50 55 60
Cys Cys Ala Gly Trp Arg Gln Gln Gly Asp Glu Cys Gly Ile Ala Val
65 70 75 80
Cys Glu Gly Asn Ser Thr Cys Ser Glu Asn Glu Val Cys Val Arg Pro
85 90 95
Gly Glu Cys Arg Cys Arg His Gly Tyr Phe Gly Ala Asn Cys Asp Thr
100 105 110
Lys Cys Pro Arg Gln Phe Trp Gly Pro Asp Cys Lys Glu Leu Cys Ser
115 120 125
Cys His Pro His Gly Gln Cys Glu Asp Val Thr Gly Gln Cys Thr Cys
130 135 140
His Ala Arg Arg Trp Gly Ala Arg Cys Glu His Ala Cys Gln Cys Gln
145 150 155 160
His Gly Thr Cys His Pro Arg Ser Gly Ala Cys Arg Cys Glu Ser Gly
165 170 175
Trp Trp Gly Ala Gln Cys Ala Ser Ala Cys Tyr Cys Ser Ala Thr Ser
180 185 190
Arg Cys Asp Pro Gln Thr Gly Ala Cys Leu Cys His Ala Gly Trp Trp
195 200 205
Gly Arg Ser Cys Asn Asn Gln Cys Ala Cys Asn Ser Ser Pro Cys Glu
210 215 220
Gln Gln Ser Gly Arg Cys Gln Cys Arg Glu Arg Thr Phe Gly Ala Arg
225 230 235 240
Cys Asp Arg Tyr Cys Gln Cys Phe Arg Gly Arg Cys His Pro Val Asp
245 250 255
Gly Thr Cys Ala Cys Glu Pro Gly Tyr Arg Gly Lys Tyr Cys Arg Glu
260 265 270
Pro Cys Pro Ala Gly Phe Tyr Gly Leu Gly Cys Arg Arg Arg Cys Gly
275 280 285
Gln Cys Lys Gly Gln Gln Pro Cys Thr Val Ala Glu Gly Arg Cys Leu
290 295 300
Thr Cys Glu Pro Gly Trp Asn Gly Thr Lys Cys Asp Gln Pro Cys Ala
305 310 315 320
Thr Gly Phe Tyr Gly Glu Gly Cys Ser His Arg Cys Pro Pro Cys Arg
325 330 335
Asp Gly His Ala Cys Asn His Val Thr Gly Lys Cys Thr Arg Cys Asn
340 345 350
Ala Gly Trp Ile Gly Asp Arg Cys Glu Thr Lys Cys Ser Asn Gly Thr
355 360 365
Tyr Gly Glu Asp Cys Ala Phe Val Cys Ala Asp Cys Gly Ser Gly His
370 375 380
Cys Asp Phe Gln Ser Gly Arg Cys Leu Cys Ser Pro Gly Val His Gly
385 390 395 400
Pro His Cys Asn Val Thr Cys Pro Pro Gly Leu His Gly Ala Asp Cys
405 410 415
Ala Gln Ala Cys Ser Cys His Glu Asp Thr Cys Asp Pro Val Thr Gly
420 425 430
Ala Cys His Leu Glu Thr Asn Gln Arg Lys Gly Val Met Gly Ala Gly
435 440 445
Ala Leu Leu Val Leu Leu Val Cys Leu Leu Leu Ser Leu Leu Gly Cys
450 455 460
Cys Cys Ala Cys Arg Gly Lys Asp Pro Thr Arg Arg Pro Arg Pro Arg
465 470 475 480
Arg Glu Leu Ser Leu Gly Arg Lys Lys Ala Pro His Arg Leu Cys Gly
485 490 495
Arg Phe Ser Arg Ile Ser Met Lys Leu Pro Arg Ile Pro Leu Arg Arg
500 505 510
Gln Lys Leu Pro Lys Val Val Val Ala His His Asp Leu Asp Asn Thr
515 520 525
Leu Asn Cys Ser Phe Leu Glu Pro Pro Ser Gly Leu Glu Gln Pro Ser
530 535 540
Pro Ser Trp Ser Ser Arg Ala Ser Phe Ser Ser Phe Asp Thr Thr Asp
545 550 555 560
Glu Gly Pro Val Tyr Cys Val Pro His Glu Glu Ala Pro Ala Glu Ser
565 570 575
Arg Asp Pro Glu Val Pro Thr Val Pro Ala Glu Ala Pro Ala Pro Ser
580 585 590
Pro Val Pro Leu Thr Thr Pro Ala SerAla Glu Glu Ala Ile Pro Leu
595 600 605
Pro Ala Ser Ser Asp Ser Glu Arg Ser Ala Ser Ser Val Glu Gly Pro
610 615 620
Gly Gly Ala Leu Tyr Ala Arg Val Ala Arg Arg Glu Ala Arg Pro Ala
625 630 635 640
Arg Ala Arg Gly Glu Ile Gly Gly Leu Ser Leu Ser Pro Ser Pro Glu
645 650 655
Arg Arg Lys Pro Pro Pro Pro Asp Pro Ala Thr Lys Pro Lys Val Ser
660 665 670
Trp Ile His Gly Lys His Ser Ala Ala Ala Ala Gly Arg Ala Pro Ser
675 680 685
Pro Pro Pro Pro Gly Ser Glu Ala Ala Pro Ser Pro Ser Lys Arg Lys
690 695 700
Arg Thr Pro Ser Asp Lys Ser Ala His Thr Val Glu His Gly Ser Pro
705 710 715 720
Arg Thr Arg Asp Pro Thr Pro Arg Pro Pro Gly Leu Pro Glu Glu Ala
725 730 735
Thr Ala Leu Ala Ala Pro Ser Pro Pro Arg Ala Arg Ala Arg Ala Ala
740 745 750
Pro Arg Pro Leu Gly Ala His Gly Arg Arg Arg Ser Pro Ala Lys Arg
755 760 765
Ala Glu Ala Ala Ser Met Leu Ala Ala Asp Val Arg Gly Lys Thr Arg
770 775 780
Ser Leu Gly Arg Ala Glu Val Ala Leu Gly Ala Gln Gly Pro Arg Glu
785 790 795 800
Lys Pro Ala Pro Pro Gln Lys Ala Lys Arg Ser Val Pro Pro Ala Ser
805 810 815
Pro Ala Arg Ala Pro Pro Ala Thr Glu Thr Pro Gly Pro Glu Lys Ala
820 825 830
Ala Thr Asp Leu Pro Ala Pro Glu Thr Pro Arg Lys Lys Thr Pro Ile
835 840 845
Gln Lys Pro Pro Arg Lys Lys Ser Arg Glu Ala Ala Gly Glu Leu Gly
850 855 860
Arg Ala Gly Ala Pro Thr Leu
865 870
<210>87
<211>134
<212>PRT
<213>人(Homo sapiens)
<400>87
Ile Asp Cys Arg Ala Glu Gln Gly Arg Thr Pro Leu Met Val Ala Val
1 5 10 15
Gly Leu Pro Asp Pro Ala Leu Arg Ala Arg Phe Val Arg Leu Leu Leu
20 25 30
Glu Gln Gly Ala Ala Val Asn Leu Arg Asp Glu Arg Gly Arg Thr Ala
35 40 45
Leu Ser Leu Ala Cys Glu Arg Gly His Leu Asp Ala Val Gln Leu Leu
50 55 60
Val Gln Phe Ser Gly Asp Pro Glu Ala Ala Asp Ser Ala Gly Asn Ser
65 70 75 80
Pro Val Met Trp Ala Ala Ala Cys Gly His Gly Ala Val Leu Glu Phe
85 90 95
Leu Val Arg Ser Phe Arg Arg Leu Gly Leu Arg Leu Asp Arg Thr Asn
100 105 110
Arg Ala Gly Leu Thr Ala Leu Gln Leu Ala Ala Ala Arg Gly His Gly
115 120 125
Thr Cys Val Gln Ala Leu
130
<210>88
<211>324
<212>PRT
<213>人(Homo sapiens)
<400>88
Met Leu Lys Pro Lys Asp Leu Cys Pro Arg Ala Gly Thr Arg Thr Phe
1 5 10 15
Leu Glu Ala Met Gln Ala Gly Lys Val His Leu Ala Arg Phe Val Leu
20 25 30
Asp Ala Leu Asp Arg Ser Ile Ile Asp Cys Arg Ala Glu Gln Gly Arg
35 40 45
Thr Pro Leu Met Val Ala Val Gly Leu Pro Asp Pro Ala Leu ArgAla
50 55 60
Arg Phe Val Arg Leu Leu Leu Glu Gln Gly Ala Ala Val Asn Leu Arg
65 70 75 80
Asp Glu Arg Gly Arg Thr Ala Leu Ser Leu Ala Cys Glu Arg Gly His
85 90 95
Leu Asp Ala Val Gln Leu Leu Val Gln Phe Ser Gly Asp Pro Glu Ala
100 105 110
Ala Asp Ser Ala Gly Asn Ser Pro Val Met Trp Ala Ala Ala Cys Gly
115 120 125
His Gly Ala Val Leu Glu Phe Leu Val Arg Ser Phe Arg Arg Leu Gly
130 135 140
Leu Arg Leu Asp Arg Thr Asn Arg Ala Gly Leu Thr Ala Leu Gln Leu
145 150 155 160
Ala Ala Ala Arg Gly His Gly Thr Ser Ala Gly Gly His Gly Gly Glu
165 170 175
Ala Gly Ser Ala Gly Lys Asn Ser Gly Arg His Arg Ala Gln Gly Ser
180 185 190
Glu Arg Pro Glu Leu Gly Arg Ser Met Ser Leu Ala Leu Gly Ala Val
195 200 205
Thr Glu Glu Glu Ala Ala Arg Leu Arg Ala Gly Ala Leu Met Ala Leu
210 215 220
Pro Asn Ser Pro Gln Ser Ser Gly Thr Gly Arg Trp Arg Ser Gln Glu
225 230 235 240
Val Leu Glu Gly Ala Pro Pro Thr Leu Ala Gln Ala Pro Ile Gly Leu
245 250 255
Ser Pro His Pro Glu Gly Gly Pro Gly Ser Gly Arg Leu Gly Leu Arg
260 265 270
Arg Arg Ser Thr Ala Pro Asp Ile Pro Ser Leu Val Gly Glu Ala Pro
275 280 285
Gly Pro Glu Ser Gly Pro Glu Leu Glu Ala Asn Ala Leu Ser Val Ser
290 295 300
Val Pro Gly Pro Asn Pro Trp Gln Ala Gly Thr Glu Ala Val Val Leu
305 310 315 320
Arg Ala Gln Arg
Claims (7)
1.一种分离的多肽,该多肽选自:
(a)一种分离的多肽,由包含SEQ ID NO:23-25之一所示序列的多核苷酸编码;
(b)一种分离的多肽,包含SEQ ID NO:67-69之一所示的多肽序列;和
(c)基因sbg1002620TIa或sbg1002620TIb编码的多肽序列。
2.一种分离的多核苷酸,该多核苷酸选自:
(a)一种分离的多核苷酸,其包含SEQ ID NO:23-25之一所示的多核苷酸序列;
(b)基因sbg1002620TIa或sbg1002620TIb的分离的多核苷酸;
(c)一种分离的多核苷酸,其包含编码SEQ ID NO:67-69之一所示多肽的多核苷酸序列;
(d)一种分离的多核苷酸,其编码SEQ ID NO:67-69之一所示的多肽;
(e)一种多核苷酸,该多核苷酸是(a)到(d)的多核苷酸的RNA等价物;
或者是与所述分离的多核苷酸互补的多核苷酸序列。
3.一种表达载体,其包含多核苷酸,当所述表达载体出现在相容性宿主细胞中时,该多核苷酸能够产生权利要求1的多肽。
4.一种制备重组宿主细胞的方法,其中包括下述步骤:将包含能产生权利要求1中所述多肽的多核苷酸的表达载体导入细胞,从而使得所述宿主细胞在合适的培养条件下产生所述的多肽。
5.一种用权利要求4所述方法制备而成的重组宿主细胞。
6.一种膜,其为表达所述多肽的权利要求5所述重组宿主细胞的膜。
7.一种制备多肽的方法,其中包括:将权利要求5中所述宿主细胞培养在足以制备出所述多肽的条件下,然后从所述培养中回收所述多肽。
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23246300P | 2000-09-13 | 2000-09-13 | |
US23245500P | 2000-09-13 | 2000-09-13 | |
US60/232,455 | 2000-09-13 | ||
US60/232,463 | 2000-09-13 | ||
US23729300P | 2000-10-02 | 2000-10-02 | |
US60/237,293 | 2000-10-02 | ||
US24626900P | 2000-11-07 | 2000-11-07 | |
US60/246,269 | 2000-11-07 | ||
US25204900P | 2000-11-20 | 2000-11-20 | |
US60/252,049 | 2000-11-20 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA018188303A Division CN1474869A (zh) | 2000-09-13 | 2001-09-13 | 新型化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1680441A true CN1680441A (zh) | 2005-10-12 |
Family
ID=27540000
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005100624133A Pending CN1680441A (zh) | 2000-09-13 | 2001-09-13 | 新型化合物 |
CNA018188303A Pending CN1474869A (zh) | 2000-09-13 | 2001-09-13 | 新型化合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA018188303A Pending CN1474869A (zh) | 2000-09-13 | 2001-09-13 | 新型化合物 |
Country Status (16)
Country | Link |
---|---|
US (1) | US20070238151A1 (zh) |
EP (1) | EP1317538A4 (zh) |
JP (1) | JP2004508825A (zh) |
KR (1) | KR20030033055A (zh) |
CN (2) | CN1680441A (zh) |
AU (2) | AU2001292619B2 (zh) |
BR (1) | BR0113820A (zh) |
CA (1) | CA2421303A1 (zh) |
CZ (1) | CZ2003722A3 (zh) |
HU (1) | HUP0400016A3 (zh) |
IL (1) | IL154725A (zh) |
MX (1) | MXPA03002180A (zh) |
NO (1) | NO20031141L (zh) |
NZ (2) | NZ534259A (zh) |
PL (1) | PL361691A1 (zh) |
WO (1) | WO2002022802A1 (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7339033B2 (en) * | 1998-06-26 | 2008-03-04 | Genentech, Inc. | Pro1481 |
CA2406855A1 (en) * | 2000-04-21 | 2001-11-01 | Takeda Chemical Industries, Ltd. | Novel insulin/igf/relaxin family polypeptides and dnas thereof |
US20030166522A1 (en) * | 2000-12-12 | 2003-09-04 | Ketchum Karen A. | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
CN1252257C (zh) * | 2001-03-02 | 2006-04-19 | 复旦大学 | 人类g型溶菌酶、其编码序列、制法及用途 |
US7223558B2 (en) | 2001-07-11 | 2007-05-29 | Bristol-Myers Squibb Company | Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof |
AU2002359815A1 (en) * | 2001-12-19 | 2003-07-09 | Immunex Corporation | C-type lectin polypeptide, polynucleotide and methods of making and use thereof |
WO2003091414A2 (en) * | 2002-04-26 | 2003-11-06 | Zymogenetics, Inc. | Adipocyte complement related protein zacrp8 |
AU2002952993A0 (en) * | 2002-11-29 | 2002-12-12 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | Therapeutic and diagnostic agents |
PL1606409T3 (pl) | 2003-03-19 | 2011-02-28 | Biogen Ma Inc | Białko wiążące receptor Nogo |
WO2004087194A2 (en) * | 2003-03-31 | 2004-10-14 | Develogen Aktiengesellschaft | Use of a dg931 protein for treating diabetes, obesity and metabolic syndrome |
BR0318307A (pt) * | 2003-05-21 | 2006-07-11 | Ares Trading Sa | polipeptìdeo, molécula de ácido nucleico purificado, vetor, célula hospedeira, ligante, composto, método para diagnosticar uma doença em um paciente, uso de um polipeptìdeo, composição farmacêutica, composição de vacina, métodos para tratar uma doença para monitorar o tratamento terapêutico de doença em um paciente, método para a identificação de um composto que é efetivo no tratamento e/ou diagnóstico de doença, kit, e, animal não-humano transgênico ou knockout |
CA2528529A1 (en) * | 2003-06-20 | 2004-12-29 | Amgen Inc. | Gene amplification and overexpression in cancer |
JP4960865B2 (ja) | 2004-06-24 | 2012-06-27 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 脱髄に関連する状態の処置 |
US10003762B2 (en) | 2005-04-26 | 2018-06-19 | Invention Science Fund I, Llc | Shared image devices |
US9093121B2 (en) | 2006-02-28 | 2015-07-28 | The Invention Science Fund I, Llc | Data management of an audio data stream |
SI1904104T1 (sl) | 2005-07-08 | 2013-12-31 | Biogen Idec Ma Inc. | Protitelesa SP35 in njihova uporaba |
CA2729961C (en) | 2008-07-09 | 2018-05-01 | Biogen Idec Ma Inc. | Li113, li62 variant co2, anti-lingo antibodies |
EP2501716B1 (en) | 2009-11-19 | 2015-01-21 | Solis Biodyne | Compositions for increasing polypeptide stability and activity, and related methods |
MX2014013950A (es) | 2012-05-14 | 2015-02-17 | Biogen Idec Inc | Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras. |
CA2973266A1 (en) | 2015-01-08 | 2016-07-14 | Biogen Ma Inc. | Lingo-1 antagonists and uses for treatment of demyelinating disorders |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0997476A3 (en) * | 1998-09-25 | 2000-07-19 | Schering-Plough | Antibodies to a mammalian Langerhans cell antigen and their uses |
AU2001243142A1 (en) * | 2000-02-03 | 2001-08-14 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
US20020012967A1 (en) * | 2000-03-10 | 2002-01-31 | Holloway James L. | Insulin homolog polypeptide zins4 |
CA2406855A1 (en) * | 2000-04-21 | 2001-11-01 | Takeda Chemical Industries, Ltd. | Novel insulin/igf/relaxin family polypeptides and dnas thereof |
JP3785029B2 (ja) * | 2000-08-04 | 2006-06-14 | 株式会社山武 | 制御装置および制御方法 |
WO2002059312A2 (en) * | 2000-12-18 | 2002-08-01 | Incyte Genomics, Inc. | Cell adhesion proteins |
WO2002068649A2 (en) * | 2001-01-31 | 2002-09-06 | Curagen Corporation | Proteins and nucleic acids encoding same |
US6783969B1 (en) * | 2001-03-05 | 2004-08-31 | Nuvelo, Inc. | Cathepsin V-like polypeptides |
-
2001
- 2001-09-13 WO PCT/US2001/028462 patent/WO2002022802A1/en active IP Right Grant
- 2001-09-13 HU HU0400016A patent/HUP0400016A3/hu unknown
- 2001-09-13 CA CA002421303A patent/CA2421303A1/en not_active Abandoned
- 2001-09-13 AU AU2001292619A patent/AU2001292619B2/en not_active Ceased
- 2001-09-13 AU AU9261901A patent/AU9261901A/xx active Pending
- 2001-09-13 CN CNA2005100624133A patent/CN1680441A/zh active Pending
- 2001-09-13 PL PL01361691A patent/PL361691A1/xx not_active Application Discontinuation
- 2001-09-13 CN CNA018188303A patent/CN1474869A/zh active Pending
- 2001-09-13 BR BR0113820-0A patent/BR0113820A/pt not_active IP Right Cessation
- 2001-09-13 JP JP2002527244A patent/JP2004508825A/ja not_active Withdrawn
- 2001-09-13 CZ CZ2003722A patent/CZ2003722A3/cs unknown
- 2001-09-13 NZ NZ534259A patent/NZ534259A/xx unknown
- 2001-09-13 IL IL15472501A patent/IL154725A/xx unknown
- 2001-09-13 MX MXPA03002180A patent/MXPA03002180A/es unknown
- 2001-09-13 KR KR10-2003-7003613A patent/KR20030033055A/ko not_active Application Discontinuation
- 2001-09-13 EP EP01972996A patent/EP1317538A4/en not_active Withdrawn
- 2001-09-13 NZ NZ524328A patent/NZ524328A/en unknown
-
2003
- 2003-03-12 NO NO20031141A patent/NO20031141L/no not_active Application Discontinuation
-
2006
- 2006-06-01 US US11/445,001 patent/US20070238151A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20070238151A1 (en) | 2007-10-11 |
IL154725A0 (en) | 2003-10-31 |
PL361691A1 (en) | 2004-10-04 |
IL154725A (en) | 2003-12-23 |
NO20031141D0 (no) | 2003-03-12 |
CA2421303A1 (en) | 2002-03-21 |
NO20031141L (no) | 2003-05-09 |
NZ534259A (en) | 2006-05-26 |
CZ2003722A3 (en) | 2004-03-17 |
KR20030033055A (ko) | 2003-04-26 |
EP1317538A4 (en) | 2005-04-06 |
BR0113820A (pt) | 2003-06-24 |
MXPA03002180A (es) | 2004-12-13 |
HUP0400016A2 (hu) | 2004-04-28 |
JP2004508825A (ja) | 2004-03-25 |
AU2001292619B2 (en) | 2006-01-12 |
CN1474869A (zh) | 2004-02-11 |
WO2002022802A1 (en) | 2002-03-21 |
AU9261901A (en) | 2002-03-26 |
NZ524328A (en) | 2004-09-24 |
HUP0400016A3 (en) | 2006-01-30 |
EP1317538A1 (en) | 2003-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1680441A (zh) | 新型化合物 | |
CN1310942C (zh) | 校正基因 | |
CN1439017A (zh) | 新型化合物 | |
CN1253565A (zh) | 能调节对细胞因子的细胞反应性的治疗和诊断制剂 | |
CN101044247A (zh) | 用于鉴定,评估,预防和治疗子宫颈癌的组合物,试剂盒及方法 | |
CN1839205A (zh) | 用于鉴定、评估、预防和治疗乳腺癌的组合物、试剂盒及方法 | |
CN1444599A (zh) | 新型化合物 | |
CN1646692A (zh) | 在肿瘤中差异表达的基因产物及其用途 | |
CN1741741A (zh) | 用于治疗狼疮肾炎的组合物和方法 | |
US6764677B1 (en) | Tango 294, a lipase-like protein | |
CN1468306A (zh) | 与精神分裂症相关的基因及蛋白质 | |
CN101039956A (zh) | 细胞表面糖蛋白 | |
CN1615439A (zh) | 编码g蛋白偶联受体的基因及其使用方法 | |
CN1249087C (zh) | 新的人g蛋白偶联受体 | |
CN1289670C (zh) | 用于调节癌细胞增生的多核苷酸 | |
CN1865440A (zh) | 肥厚型心肌病致病基因的新突变及其用途 | |
CN1649897A (zh) | Falp蛋白 | |
CN1382156A (zh) | 与bcl-xl相互作用的多肽pablo及其有关用途 | |
CN1346368A (zh) | 钾通道互作剂及其用途 | |
CN1177864C (zh) | 在肝癌组织中具有表达差异的新的人蛋白及其编码序列 | |
CN1246457C (zh) | 人tsc403基因和人ing1l基因 | |
CN1717413A (zh) | 新的pth应答基因 | |
CN1780853A (zh) | 分泌性蛋白质家族 | |
CN1708511A (zh) | 对促肾上腺皮质激素释放激素刺激的应答而表达增加的基因 | |
CN1900279A (zh) | 诱导细胞凋亡的多核苷酸及其编码的多肽和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |